{"generated":"2026-09-09T23:35:12.961Z","today":"2026-09-09","total":4455,"findings":[{"check":"approvals-vs-regional","severity":"high","id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","detail":"approvals list US 2026 but regional-approvals.ts says under-review (RASolute 302 positive; NDA expected late 2026)"},{"check":"soc-cites-dead","severity":"high","id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","detail":"standard-of-care row \"Fit, adverse risk (TP53, complex karyotype, MDS-related)\" cites Magrolimab (status withdrawn)"},{"check":"soc-cites-dead","severity":"high","id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/","detail":"standard-of-care row \"Second-line, no target\" cites NALIRICC (AIO) (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","detail":"standard-of-care row \"Stage IB2-IIA (surgical candidates)\" cites LACC (Laparoscopic Approach to Cervical Cancer) (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","detail":"standard-of-care row \"Locally advanced, high risk (node-positive IB2-IIB, III-IVA)\" cites OUTBACK / ANZGOG 0902 / GOG-0274 (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"hairy-cell-leukemia","kind":"cancer","name":"Hairy cell leukaemia","route":"/cancers/hairy-cell-leukemia/","detail":"standard-of-care row \"Early relapse or refractory\" cites Moxetumomab pasudotox (status withdrawn)"},{"check":"soc-cites-dead","severity":"high","id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/","detail":"standard-of-care row \"Locally advanced, unresectable or organ preservation\" cites JAVELIN Head and Neck 100 (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/","detail":"standard-of-care row \"Locally advanced, unresectable or organ preservation\" cites TrilynX (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","detail":"standard-of-care row \"Adjuvant after resection/ablation\" cites IMbrave050 (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","detail":"standard-of-care row \"Early stage, high risk: adjuvant CDK4/6\" cites PALLAS & PENELOPE-B (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","detail":"standard-of-care row \"Stage III after surgery (adjuvant)\" cites RELATIVITY-098 (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","detail":"standard-of-care row \"Surgery\" cites Extended pleurectomy/decortication & radical mesothelioma surgery (status historic)"},{"check":"soc-cites-dead","severity":"high","id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","detail":"standard-of-care row \"Surgery\" cites MARS 2 (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","detail":"standard-of-care row \"Prevention and risk\" cites UKCTOCS (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","detail":"standard-of-care row \"Second line after IO-based therapy\" cites CONTACT-03 (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","detail":"standard-of-care row \"Second line after IO-based therapy\" cites TiNivo-2 (status negative)"},{"check":"soc-cites-dead","severity":"high","id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/","detail":"standard-of-care row \"Advanced soft-tissue sarcoma, first line\" cites ANNOUNCE (status negative)"},{"check":"status-vs-approvals","severity":"high","id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/","detail":"status \"standard-of-care\" but no approvals recorded"},{"check":"status-vs-approvals","severity":"high","id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/","detail":"status \"standard-of-care\" but no approvals recorded"},{"check":"status-vs-approvals","severity":"high","id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/","detail":"status \"standard-of-care\" but no approvals recorded"},{"check":"status-vs-approvals","severity":"high","id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/","detail":"status \"standard-of-care\" but no approvals recorded"},{"check":"approvals-vs-regional","severity":"medium","id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","detail":"US first approval year 2017 in approvals but 2013 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","detail":"US first approval year 2004 in approvals but 1996 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","detail":"US first approval year 2018 in approvals but 2017 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/","detail":"US first approval year 2014 in approvals but 2013 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/","detail":"EU first approval year 2022 in approvals but 2014 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/","detail":"US first approval year 2006 in approvals but 2005 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","detail":"US first approval year 1999 in approvals but 1995 in regional-approvals.ts"},{"check":"duplicate-name","severity":"medium","id":"american-cancer-society","kind":"collection","name":"American Cancer Society (ACS)","route":"/collections/american-cancer-society/","detail":"same normalised name as src-cancer-org-asco (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-cancer-org-asco","kind":"collection","name":"American Cancer Society (cancer.org, incl. former Cancer.Net)","route":"/collections/src-cancer-org-asco/","detail":"same normalised name as american-cancer-society (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-annals-oncology","kind":"collection","name":"Annals of Oncology","route":"/collections/src-annals-oncology/","detail":"same normalised name as annals-of-oncology (journal)"},{"check":"duplicate-name","severity":"medium","id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/","detail":"same normalised name as src-annals-oncology (collection)"},{"check":"duplicate-name","severity":"medium","id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","detail":"same normalised name as bevacizumab-glioma (drug)"},{"check":"duplicate-name","severity":"medium","id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/","detail":"same normalised name as bevacizumab (drug)"},{"check":"duplicate-name","severity":"medium","id":"src-biorxiv","kind":"collection","name":"bioRxiv","route":"/collections/src-biorxiv/","detail":"same normalised name as biorxiv (journal)"},{"check":"duplicate-name","severity":"medium","id":"biorxiv","kind":"journal","name":"bioRxiv","route":"/journals/biorxiv/","detail":"same normalised name as src-biorxiv (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-blood","kind":"collection","name":"Blood","route":"/collections/src-blood/","detail":"same normalised name as blood (journal)"},{"check":"duplicate-name","severity":"medium","id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/","detail":"same normalised name as src-blood (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-bcrf","kind":"collection","name":"Breast Cancer Research Foundation","route":"/collections/src-bcrf/","detail":"same normalised name as bcrf (institution)"},{"check":"duplicate-name","severity":"medium","id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/","detail":"same normalised name as src-bcrf (collection)"},{"check":"duplicate-name","severity":"medium","id":"cachexia-biology","kind":"pathway","name":"Cancer cachexia","route":"/pathways/cachexia-biology/","detail":"same normalised name as cachexia (term)"},{"check":"duplicate-name","severity":"medium","id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","detail":"same normalised name as cachexia-biology (pathway)"},{"check":"duplicate-name","severity":"medium","id":"src-cancer-cell","kind":"collection","name":"Cancer Cell","route":"/collections/src-cancer-cell/","detail":"same normalised name as cancer-cell (journal)"},{"check":"duplicate-name","severity":"medium","id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/","detail":"same normalised name as src-cancer-cell (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-cancer-discovery","kind":"collection","name":"Cancer Discovery","route":"/collections/src-cancer-discovery/","detail":"same normalised name as cancer-discovery (journal)"},{"check":"duplicate-name","severity":"medium","id":"cancer-discovery","kind":"journal","name":"Cancer Discovery","route":"/journals/cancer-discovery/","detail":"same normalised name as src-cancer-discovery (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-cancer-research","kind":"collection","name":"Cancer Research","route":"/collections/src-cancer-research/","detail":"same normalised name as cancer-research (journal)"},{"check":"duplicate-name","severity":"medium","id":"cancer-research","kind":"journal","name":"Cancer Research","route":"/journals/cancer-research/","detail":"same normalised name as src-cancer-research (collection)"},{"check":"duplicate-name","severity":"medium","id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","detail":"same normalised name as cell-term (term)"},{"check":"duplicate-name","severity":"medium","id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","detail":"same normalised name as cell (journal)"},{"check":"duplicate-name","severity":"medium","id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/","detail":"same normalised name as chemotherapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"chemotherapy-term","kind":"term","name":"Chemotherapy","route":"/terms/chemotherapy-term/","detail":"same normalised name as chemotherapy (section)"},{"check":"duplicate-name","severity":"medium","id":"src-clinical-cancer-research","kind":"collection","name":"Clinical Cancer Research","route":"/collections/src-clinical-cancer-research/","detail":"same normalised name as clinical-cancer-research (journal)"},{"check":"duplicate-name","severity":"medium","id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/","detail":"same normalised name as src-clinical-cancer-research (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-esmo-open","kind":"collection","name":"ESMO Open","route":"/collections/src-esmo-open/","detail":"same normalised name as esmo-open (journal)"},{"check":"duplicate-name","severity":"medium","id":"esmo-open","kind":"journal","name":"ESMO Open","route":"/journals/esmo-open/","detail":"same normalised name as src-esmo-open (collection)"},{"check":"duplicate-name","severity":"medium","id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/","detail":"same normalised name as immunotherapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"immunotherapy-term","kind":"term","name":"Immunotherapy","route":"/terms/immunotherapy-term/","detail":"same normalised name as immunotherapy (section)"},{"check":"duplicate-name","severity":"medium","id":"inc-colombia","kind":"institution","name":"Instituto Nacional de Cancerología (Colombia)","route":"/institutions/inc-colombia/","detail":"same normalised name as incan-mexico (institution)"},{"check":"duplicate-name","severity":"medium","id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","route":"/institutions/incan-mexico/","detail":"same normalised name as inc-colombia (institution)"},{"check":"duplicate-name","severity":"medium","id":"src-jama-oncology","kind":"collection","name":"JAMA Oncology","route":"/collections/src-jama-oncology/","detail":"same normalised name as jama-oncology (journal)"},{"check":"duplicate-name","severity":"medium","id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/","detail":"same normalised name as src-jama-oncology (collection)"},{"check":"duplicate-name","severity":"medium","id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/","detail":"same normalised name as jiangsu-hengrui (company)"},{"check":"duplicate-name","severity":"medium","id":"jiangsu-hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/jiangsu-hengrui/","detail":"same normalised name as hengrui (company)"},{"check":"duplicate-name","severity":"medium","id":"src-jnci","kind":"collection","name":"JNCI: Journal of the National Cancer Institute","route":"/collections/src-jnci/","detail":"same normalised name as jnci (journal)"},{"check":"duplicate-name","severity":"medium","id":"jnci","kind":"journal","name":"JNCI: Journal of the National Cancer Institute","route":"/journals/jnci/","detail":"same normalised name as src-jnci (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-jco","kind":"collection","name":"Journal of Clinical Oncology","route":"/collections/src-jco/","detail":"same normalised name as jco (journal)"},{"check":"duplicate-name","severity":"medium","id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","detail":"same normalised name as src-jco (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-macmillan","kind":"collection","name":"Macmillan Cancer Support","route":"/collections/src-macmillan/","detail":"same normalised name as macmillan-cancer-support (institution)"},{"check":"duplicate-name","severity":"medium","id":"macmillan-cancer-support","kind":"institution","name":"Macmillan Cancer Support","route":"/institutions/macmillan-cancer-support/","detail":"same normalised name as src-macmillan (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-medrxiv","kind":"collection","name":"medRxiv","route":"/collections/src-medrxiv/","detail":"same normalised name as medrxiv (journal)"},{"check":"duplicate-name","severity":"medium","id":"medrxiv","kind":"journal","name":"medRxiv","route":"/journals/medrxiv/","detail":"same normalised name as src-medrxiv (collection)"},{"check":"duplicate-name","severity":"medium","id":"microsoft","kind":"company","name":"Microsoft (Health & Life Sciences)","route":"/companies/microsoft/","detail":"same normalised name as microsoft-research (company)"},{"check":"duplicate-name","severity":"medium","id":"microsoft-research","kind":"company","name":"Microsoft (Research and Health AI)","route":"/companies/microsoft-research/","detail":"same normalised name as microsoft (company)"},{"check":"duplicate-name","severity":"medium","id":"src-nature-cancer","kind":"collection","name":"Nature Cancer","route":"/collections/src-nature-cancer/","detail":"same normalised name as nature-cancer (journal)"},{"check":"duplicate-name","severity":"medium","id":"nature-cancer","kind":"journal","name":"Nature Cancer","route":"/journals/nature-cancer/","detail":"same normalised name as src-nature-cancer (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-nature-medicine","kind":"collection","name":"Nature Medicine","route":"/collections/src-nature-medicine/","detail":"same normalised name as nature-medicine (journal)"},{"check":"duplicate-name","severity":"medium","id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","detail":"same normalised name as src-nature-medicine (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-nejm","kind":"collection","name":"New England Journal of Medicine","route":"/collections/src-nejm/","detail":"same normalised name as nejm (journal)"},{"check":"duplicate-name","severity":"medium","id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","detail":"same normalised name as src-nejm (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","route":"/collections/src-pancan/","detail":"same normalised name as pancan (collection)"},{"check":"duplicate-name","severity":"medium","id":"pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","route":"/collections/pancan/","detail":"same normalised name as src-pancan (collection)"},{"check":"duplicate-name","severity":"medium","id":"targeted-therapy-term","kind":"term","name":"Targeted therapy","route":"/terms/targeted-therapy-term/","detail":"same normalised name as targeted-therapy (section)"},{"check":"duplicate-name","severity":"medium","id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/","detail":"same normalised name as targeted-therapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"src-lancet-oncology","kind":"collection","name":"The Lancet Oncology","route":"/collections/src-lancet-oncology/","detail":"same normalised name as lancet-oncology (journal)"},{"check":"duplicate-name","severity":"medium","id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","detail":"same normalised name as src-lancet-oncology (collection)"},{"check":"future-year-in-text","severity":"medium","id":"alcohol-reduction-labelling","kind":"technology","name":"Alcohol reduction, pricing and cancer warning labels","route":"/technologies/alcohol-reduction-labelling/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"idea-acc-open-oncology-workforce-model","kind":"idea","name":"An open global model of cancer workforce supply and demand by country","route":"/ideas/idea-acc-open-oncology-workforce-model/","detail":"mentions 2040"},{"check":"future-year-in-text","severity":"medium","id":"idea-reg-biosimilar-no-efficacy-trial","kind":"idea","name":"Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials","route":"/ideas/idea-reg-biosimilar-no-efficacy-trial/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"fortifi-hn01","kind":"trial","name":"FORTIFI-HN01","route":"/trials/fortifi-hn01/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","detail":"mentions 2068"},{"check":"future-year-in-text","severity":"medium","id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/","detail":"mentions 2056"},{"check":"future-year-in-text","severity":"medium","id":"mevrometostat","kind":"drug","name":"Mevrometostat","route":"/drugs/mevrometostat/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/","detail":"mentions 2056"},{"check":"future-year-in-text","severity":"medium","id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/","detail":"mentions 2027"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","detail":"\"CheckMate 9DW\" and \"CheckMate 9ER\" (checkmate-9er) differ by at most two characters; if they are one thing, keep checkmate-9dw, move \"CheckMate 9ER\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","detail":"\"Feng Zhang\" and \"Feng Wang\" (wang-feng-sysucc) differ by at most two characters; if they are one thing, keep feng-zhang, move \"Feng Wang\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","detail":"\"Tae Won Kim\" and \"Tae-You Kim\" (kim-tae-you) differ by at most two characters; if they are one thing, keep kim-tae-won, move \"Tae-You Kim\" into its aka and repoint links"},{"check":"outcome-no-source","severity":"medium","id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"admiral","kind":"trial","name":"ADMIRAL","route":"/trials/admiral/","detail":"1 of 2 structured outcomes carry numbers without a source: CR/CRh"},{"check":"outcome-no-source","severity":"medium","id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"agile","kind":"trial","name":"AGILE","route":"/trials/agile/","detail":"2 of 3 structured outcomes carry numbers without a source: Overall survival (median); Complete remission"},{"check":"outcome-no-source","severity":"medium","id":"alfa-0701","kind":"trial","name":"ALFA-0701","route":"/trials/alfa-0701/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival (median)"},{"check":"outcome-no-source","severity":"medium","id":"alpine","kind":"trial","name":"ALPINE","route":"/trials/alpine/","detail":"2 of 3 structured outcomes carry numbers without a source: Overall response rate; Atrial fibrillation/flutter"},{"check":"outcome-no-source","severity":"medium","id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival (AV vs CIT)"},{"check":"outcome-no-source","severity":"medium","id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","detail":"1 of 3 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","detail":"1 of 3 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"augment-101","kind":"trial","name":"AUGMENT-101","route":"/trials/augment-101/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall response rate"},{"check":"outcome-no-source","severity":"medium","id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival (ITT)"},{"check":"outcome-no-source","severity":"medium","id":"bl-b01d1-307","kind":"trial","name":"BL-B01D1-307","route":"/trials/bl-b01d1-307/","detail":"1 of 3 structured outcomes carry numbers without a source: Confirmed objective response rate (BICR)"},{"check":"outcome-no-source","severity":"medium","id":"bond-003","kind":"trial","name":"BOND-003","route":"/trials/bond-003/","detail":"1 of 2 structured outcomes carry numbers without a source: Complete response at 24 months"},{"check":"outcome-no-source","severity":"medium","id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival (pancreatic NET); Progression-free survival (extra-pancreatic NET)"},{"check":"outcome-no-source","severity":"medium","id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival (AKT-pathway-altered)"},{"check":"outcome-no-source","severity":"medium","id":"captivate","kind":"trial","name":"CAPTIVATE","route":"/trials/captivate/","detail":"1 of 2 structured outcomes carry numbers without a source: Undetectable MRD in peripheral blood"},{"check":"outcome-no-source","severity":"medium","id":"cares-310","kind":"trial","name":"CARES-310","route":"/trials/cares-310/","detail":"2 of 2 structured outcomes carry numbers without a source: Overall survival; Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/","detail":"1 of 2 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/","detail":"1 of 2 structured outcomes carry numbers without a source: 3-year overall survival rate"},{"check":"outcome-no-source","severity":"medium","id":"celestial","kind":"trial","name":"CELESTIAL","route":"/trials/celestial/","detail":"2 of 2 structured outcomes carry numbers without a source: Overall survival; Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"cepheus","kind":"trial","name":"CEPHEUS","route":"/trials/cepheus/","detail":"2 of 2 structured outcomes carry numbers without a source: MRD negativity (10⁻⁵); Progression-free survival at 54 months"},{"check":"outcome-no-source","severity":"medium","id":"checkmate-205","kind":"trial","name":"CheckMate 205","route":"/trials/checkmate-205/","detail":"1 of 1 structured outcome carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival, ITT (8-year follow-up)"},{"check":"outcome-no-source","severity":"medium","id":"checkmate-274","kind":"trial","name":"CheckMate 274","route":"/trials/checkmate-274/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival (ITT)"},{"check":"outcome-no-source","severity":"medium","id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","detail":"2 of 2 structured outcomes carry numbers without a source: Overall survival; Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"checkmate-9er","kind":"trial","name":"CheckMate 9ER","route":"/trials/checkmate-9er/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival (final)"},{"check":"outcome-no-source","severity":"medium","id":"claridhy","kind":"trial","name":"ClarIDHy","route":"/trials/claridhy/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival; Overall survival (crossover-adjusted)"},{"check":"outcome-no-source","severity":"medium","id":"clarinet","kind":"trial","name":"CLARINET","route":"/trials/clarinet/","detail":"1 of 1 structured outcome carry numbers without a source: Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/","detail":"2 of 3 structured outcomes carry numbers without a source: Progression-free survival at 6 years; Undetectable MRD in blood at end of treatment"},{"check":"outcome-no-source","severity":"medium","id":"codebreak-200","kind":"trial","name":"CodeBreaK 200","route":"/trials/codebreak-200/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival at 2 years"},{"check":"outcome-no-source","severity":"medium","id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival; Overall survival (interim)"},{"check":"outcome-no-source","severity":"medium","id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","route":"/trials/d-alba/","detail":"1 of 2 structured outcomes carry numbers without a source: Disease-free survival at 18 months"},{"check":"outcome-no-source","severity":"medium","id":"defi","kind":"trial","name":"DeFi","route":"/trials/defi/","detail":"1 of 2 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/","detail":"1 of 3 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/","detail":"1 of 3 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"dreamm-7","kind":"trial","name":"DREAMM-7","route":"/trials/dreamm-7/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/","detail":"1 of 2 structured outcomes carry numbers without a source: Relapse-free survival at 3 years"},{"check":"outcome-no-source","severity":"medium","id":"elevate-tn","kind":"trial","name":"ELEVATE-TN","route":"/trials/elevate-tn/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival (A+O vs O+Clb)"},{"check":"outcome-no-source","severity":"medium","id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/","detail":"1 of 3 structured outcomes carry numbers without a source: Overall survival at 12 months"},{"check":"outcome-no-source","severity":"medium","id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival (all patients)"},{"check":"outcome-no-source","severity":"medium","id":"emerald-1","kind":"trial","name":"EMERALD-1","route":"/trials/emerald-1/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival; Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/","detail":"1 of 2 structured outcomes carry numbers without a source: Complete response rate"},{"check":"outcome-no-source","severity":"medium","id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","detail":"2 of 3 structured outcomes carry numbers without a source: Overall survival; Pathologic complete response"},{"check":"outcome-no-source","severity":"medium","id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival (ESR1-mutant)"},{"check":"outcome-no-source","severity":"medium","id":"felix","kind":"trial","name":"FELIX","route":"/trials/felix/","detail":"2 of 3 structured outcomes carry numbers without a source: Complete remission; Event-free survival (median)"},{"check":"outcome-no-source","severity":"medium","id":"fight-202","kind":"trial","name":"FIGHT-202","route":"/trials/fight-202/","detail":"2 of 2 structured outcomes carry numbers without a source: Objective response rate; Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","detail":"3 of 3 structured outcomes carry numbers without a source: Objective response rate; Progression-free survival; Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"gd2-cart01","kind":"trial","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival at 3 years"},{"check":"outcome-no-source","severity":"medium","id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","detail":"1 of 2 structured outcomes carry numbers without a source: Treatment-related morbidity"},{"check":"outcome-no-source","severity":"medium","id":"glow","kind":"trial","name":"GLOW","route":"/trials/glow/","detail":"1 of 2 structured outcomes carry numbers without a source: Undetectable MRD in bone marrow at 3 months post-treatment"},{"check":"outcome-no-source","severity":"medium","id":"her2climb","kind":"trial","name":"HER2CLIMB","route":"/trials/her2climb/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/","detail":"1 of 2 structured outcomes carry numbers without a source: Disease-free survival (B-31/N9831)"},{"check":"outcome-no-source","severity":"medium","id":"himalaya","kind":"trial","name":"HIMALAYA","route":"/trials/himalaya/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"imbrave050","kind":"trial","name":"IMbrave050","route":"/trials/imbrave050/","detail":"1 of 1 structured outcome carry numbers without a source: Recurrence-free survival (interim)"},{"check":"outcome-no-source","severity":"medium","id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","detail":"3 of 3 structured outcomes carry numbers without a source: Overall survival (updated); Progression-free survival; Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival (IRF)"},{"check":"outcome-no-source","severity":"medium","id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/","detail":"1 of 1 structured outcome carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","detail":"1 of 3 structured outcomes carry numbers without a source: Overall survival, ITT"},{"check":"outcome-no-source","severity":"medium","id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"inavo120","kind":"trial","name":"INAVO120","route":"/trials/inavo120/","detail":"1 of 3 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"keynote-483","kind":"trial","name":"IND.227 / KEYNOTE-483","route":"/trials/keynote-483/","detail":"1 of 2 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"ino-vate","kind":"trial","name":"INO-VATE ALL","route":"/trials/ino-vate/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival (median)"},{"check":"outcome-no-source","severity":"medium","id":"invictus","kind":"trial","name":"INVICTUS","route":"/trials/invictus/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival (median)"},{"check":"outcome-no-source","severity":"medium","id":"keynote-426","kind":"trial","name":"KEYNOTE-426","route":"/trials/keynote-426/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"keynote-966","kind":"trial","name":"KEYNOTE-966","route":"/trials/keynote-966/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"komet-001","kind":"trial","name":"KOMET-001","route":"/trials/komet-001/","detail":"2 of 3 structured outcomes carry numbers without a source: Overall response rate; Overall survival (median)"},{"check":"outcome-no-source","severity":"medium","id":"l-mind","kind":"trial","name":"L-MIND","route":"/trials/l-mind/","detail":"1 of 1 structured outcome carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"leap-002","kind":"trial","name":"LEAP-002","route":"/trials/leap-002/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"leap-012","kind":"trial","name":"LEAP-012","route":"/trials/leap-012/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival; Overall survival (final)"},{"check":"outcome-no-source","severity":"medium","id":"linker-mm1","kind":"trial","name":"LINKER-MM1","route":"/trials/linker-mm1/","detail":"1 of 1 structured outcome carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"litespark-005","kind":"trial","name":"LITESPARK-005","route":"/trials/litespark-005/","detail":"1 of 2 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"lotis-2","kind":"trial","name":"LOTIS-2","route":"/trials/lotis-2/","detail":"1 of 1 structured outcome carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"magnetismm-3","kind":"trial","name":"MagnetisMM-3","route":"/trials/magnetismm-3/","detail":"1 of 1 structured outcome carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"monarch-3","kind":"trial","name":"MONARCH 3","route":"/trials/monarch-3/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"monumental-1","kind":"trial","name":"MonumenTAL-1","route":"/trials/monumental-1/","detail":"1 of 1 structured outcome carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"naliricc","kind":"trial","name":"NALIRICC (AIO)","route":"/trials/naliricc/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"niagara","kind":"trial","name":"NIAGARA","route":"/trials/niagara/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"paloma-2","kind":"trial","name":"PALOMA-2","route":"/trials/paloma-2/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"perseus","kind":"trial","name":"PERSEUS","route":"/trials/perseus/","detail":"1 of 2 structured outcomes carry numbers without a source: MRD negativity (10⁻⁵)"},{"check":"outcome-no-source","severity":"medium","id":"promid","kind":"trial","name":"PROMID","route":"/trials/promid/","detail":"1 of 1 structured outcome carry numbers without a source: Time to tumour progression"},{"check":"outcome-no-source","severity":"medium","id":"quilt-3-032","kind":"trial","name":"QUILT 3.032","route":"/trials/quilt-3-032/","detail":"1 of 1 structured outcome carry numbers without a source: Complete response rate (CIS)"},{"check":"outcome-no-source","severity":"medium","id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival (RADIANT-3); Progression-free survival (RADIANT-4)"},{"check":"outcome-no-source","severity":"medium","id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/","detail":"1 of 2 structured outcomes carry numbers without a source: 4-year overall survival"},{"check":"outcome-no-source","severity":"medium","id":"reflect","kind":"trial","name":"REFLECT","route":"/trials/reflect/","detail":"2 of 2 structured outcomes carry numbers without a source: Overall survival; Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"resonate","kind":"trial","name":"RESONATE","route":"/trials/resonate/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival (median, 6-year follow-up)"},{"check":"outcome-no-source","severity":"medium","id":"resorce","kind":"trial","name":"RESORCE","route":"/trials/resorce/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/","detail":"1 of 2 structured outcomes carry numbers without a source: 5-year iDFS, premenopausal"},{"check":"outcome-no-source","severity":"medium","id":"sanet","kind":"trial","name":"SANET-ep and SANET-p","route":"/trials/sanet/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival (SANET-ep); Progression-free survival (SANET-p)"},{"check":"outcome-no-source","severity":"medium","id":"sarah-sirvenib","kind":"trial","name":"SARAH and SIRveNIB","route":"/trials/sarah-sirvenib/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival (SARAH)"},{"check":"outcome-no-source","severity":"medium","id":"sharp","kind":"trial","name":"SHARP","route":"/trials/sharp/","detail":"2 of 2 structured outcomes carry numbers without a source: Overall survival; Time to radiologic progression"},{"check":"outcome-no-source","severity":"medium","id":"ssgxviii","kind":"trial","name":"SSGXVIII/AIO (adjuvant imatinib in GIST)","route":"/trials/ssgxviii/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"stellar","kind":"trial","name":"STELLAR","route":"/trials/stellar/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival (single arm vs historical)"},{"check":"outcome-no-source","severity":"medium","id":"sunrise-1","kind":"trial","name":"SunRISe-1","route":"/trials/sunrise-1/","detail":"2 of 2 structured outcomes carry numbers without a source: Complete response rate (CIS); Duration of CR ≥12 months"},{"check":"outcome-no-source","severity":"medium","id":"swog-s1826","kind":"trial","name":"SWOG S1826","route":"/trials/swog-s1826/","detail":"1 of 2 structured outcomes carry numbers without a source: Any-grade peripheral neuropathy"},{"check":"outcome-no-source","severity":"medium","id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","detail":"2 of 2 structured outcomes carry numbers without a source: Overall survival (updated); 24-month overall survival"},{"check":"outcome-no-source","severity":"medium","id":"tower","kind":"trial","name":"TOWER","route":"/trials/tower/","detail":"1 of 2 structured outcomes carry numbers without a source: Complete remission within 12 weeks"},{"check":"outcome-no-source","severity":"medium","id":"transcend-cll-004","kind":"trial","name":"TRANSCEND CLL 004","route":"/trials/transcend-cll-004/","detail":"2 of 3 structured outcomes carry numbers without a source: Overall response rate; Undetectable MRD in blood"},{"check":"outcome-no-source","severity":"medium","id":"tropics-02","kind":"trial","name":"TROPiCS-02","route":"/trials/tropics-02/","detail":"1 of 2 structured outcomes carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/","detail":"1 of 3 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"viale-a","kind":"trial","name":"VIALE-A","route":"/trials/viale-a/","detail":"2 of 3 structured outcomes carry numbers without a source: Complete remission; Composite CR (CR + CRi)"},{"check":"pipeline-cites-dead","severity":"medium","id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/","detail":"pipeline lists Magrolimab (status withdrawn)"},{"check":"positive-hr-ge-1","severity":"medium","id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/","detail":"status positive but primary endpoint hazard ratio 1.02 (5-year iDFS, postmenopausal); not described as a non-inferiority or de-escalation trial"},{"check":"spike-scalar-divergence","severity":"medium","id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","detail":"defined in the colorectal and ovarian spikes with different values; the first wins and hides the rest: modality: \"Monoclonal antibody (anti-VEGF)\" vs \"Monoclonal antibody (anti-VEGF-A)\"; tldr: \"The first drug to starve tumours of blood vessels. Approv...\" vs \"The first drug to starve tumours of their blood supply, n...\"; summary: \"Humanised anti-VEGF-A IgG1. Standard with first- and seco...\" vs \"Approved 2004 (colorectal). In gynaecologic oncology: fir...\"; mechanism: \"Neutralises circulating VEGF-A, reducing angiogenesis and...\" vs \"Humanised IgG1 that binds VEGF-A, preventing VEGFR activa...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","detail":"defined in the hcc and rcc spikes with different values; the first wins and hides the rest: modality: \"Small-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, ...\" vs \"Small-molecule kinase inhibitor (VEGFR/MET/AXL)\"; tldr: \"A pill that blocks both blood-vessel growth and the MET e...\" vs \"A multi-kinase pill that also blocks the MET and AXL esca...\"; summary: \"CELESTIAL: OS 10.2 vs 8.0 months after sorafenib in HCC (...\" vs \"CABOSUN (first line vs sunitinib, PFS benefit), METEOR (s...\"; mechanism: \"Oral inhibitor of MET, VEGFR2, AXL, RET, KIT and FLT3; ME...\" vs \"Inhibits VEGFR2, MET, AXL, RET, KIT, FLT3.\""},{"check":"spike-scalar-divergence","severity":"medium","id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","detail":"defined in the hcc and rcc and endometrial spikes with different values; the first wins and hides the rest: tldr: \"Japanese pharma that makes lenvatinib (Lenvima), a first-...\" vs \"Japanese pharma that discovered lenvatinib and partners w...\"; summary: \"Lenvatinib is approved in HCC (REFLECT), thyroid cancer, ...\" vs \"Lenvatinib (Lenvima) across RCC, HCC, thyroid, endometria...\"; tldr: \"Japanese pharma that makes lenvatinib (Lenvima), a first-...\" vs \"Japanese pharma that discovered lenvatinib and eribulin a...\"; summary: \"Lenvatinib is approved in HCC (REFLECT), thyroid cancer, ...\" vs \"Lenvatinib (Lenvima) across thyroid, liver, kidney, and e...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","detail":"defined in the breast-hr-positive and neuroendocrine and rcc spikes with different values; the first wins and hides the rest: tldr: \"An mTOR-blocking pill that doubled progression-free time ...\" vs \"A pill that blocks the mTOR growth switch, approved for p...\"; summary: \"BOLERO-2: PFS 7.8 vs 3.2 months (everolimus + exemestane ...\" vs \"RADIANT-3 (2011): PFS 11.0 vs 4.6 months in pancreatic NE...\"; mechanism: \"Allosteric mTORC1 inhibitor (rapalog) via FKBP12.\" vs \"Allosteric mTORC1 inhibitor (rapalog) via FKBP12 binding.\"; tldr: \"An mTOR-blocking pill that doubled progression-free time ...\" vs \"An mTOR-blocking pill that was kidney cancer's second-lin...\"; summary: \"BOLERO-2: PFS 7.8 vs 3.2 months (everolimus + exemestane ...\" vs \"RECORD-1 (2008): PFS 4.9 vs 1.9 months vs placebo after V...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","detail":"defined in the hcc and rcc spikes with different values; the first wins and hides the rest: tldr: \"Exelixis makes cabozantinib (Cabometyx), used in kidney, ...\" vs \"Maker of cabozantinib, the most-prescribed kidney cancer ...\"; summary: \"Cabozantinib is approved in RCC (alone and with nivolumab...\" vs \"Cabometyx (RCC, HCC, thyroid, NET), zanzalintinib (XL092)...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","detail":"defined in the cholangiocarcinoma and dlbcl spikes with different values; the first wins and hides the rest: name: \"Incyte\" vs \"Incyte (incl. MorphoSys US rights)\"; tldr: \"Incyte makes pemigatinib, the first targeted drug approve...\" vs \"Maker of tafasitamab, whose frontMIND trial gave the firs...\"; summary: \"Pemigatinib (Pemazyre) approved for FGFR2-fusion cholangi...\" vs \"Incyte holds US rights to tafasitamab (Monjuvi) and world...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","detail":"defined in the cholangiocarcinoma and aml spikes with different values; the first wins and hides the rest: tldr: \"Ivosidenib is a pill that blocks the mutant IDH1 enzyme, ...\" vs \"The first drug to block a mutant metabolic enzyme in canc...\"; summary: \"ClarIDHy: PFS 2.7 vs 1.4 months (HR 0.37) and crossover-a...\" vs \"Approved 2018 (relapsed/refractory IDH1 AML), 2019 (newly...\"; mechanism: \"Allosteric inhibitor of mutant IDH1, lowering the oncomet...\" vs \"Allosteric inhibitor of mutant IDH1; blocks 2-hydroxyglut...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","detail":"defined in the hcc and rcc and endometrial spikes with different values; the first wins and hides the rest: modality: \"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR...\" vs \"Small-molecule kinase inhibitor (VEGFR/FGFR/PDGFR/RET/KIT)\"; tldr: \"An oral anti-angiogenic pill that matched sorafenib in li...\" vs \"A broad anti-angiogenic pill that, with pembrolizumab, pr...\"; summary: \"REFLECT (2018): non-inferior OS (13.6 vs 12.3 months) wit...\" vs \"CLEAR (with pembrolizumab, PFS 23.9 months, OS HR 0.79); ...\"; mechanism: \"Oral inhibitor of VEGFR1-3, FGFR1-4, PDGFR-α, RET and KIT.\" vs \"Inhibits VEGFR1-3, FGFR1-4, PDGFRα, RET, KIT.\"; modality: \"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR...\" vs \"Small-molecule multikinase inhibitor (VEGFR, FGFR, RET, K...\"; tldr: \"An oral anti-angiogenic pill that matched sorafenib in li...\" vs \"A blood-vessel-blocking pill used with pembrolizumab in e...\"; summary: \"REFLECT (2018): non-inferior OS (13.6 vs 12.3 months) wit...\" vs \"Approved for radioiodine-refractory thyroid cancer (2015)...\"; mechanism: \"Oral inhibitor of VEGFR1-3, FGFR1-4, PDGFR-α, RET and KIT.\" vs \"ATP-competitive inhibitor of VEGFR1-3, FGFR1-4, PDGFRα, R...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","detail":"defined in the breast-hr-positive and ovarian spikes with different values; the first wins and hides the rest: name: \"Letrozole (and other aromatase inhibitors)\" vs \"Letrozole\"; brand: \"Femara; anastrozole (Arimidex); exemestane (Aromasin)\" vs \"Femara\"; tldr: \"Daily pills that stop the body making oestrogen after men...\" vs \"A hormone-blocking pill, standard in breast cancer, that ...\"; summary: \"Non-steroidal (letrozole, anastrozole) and steroidal (exe...\" vs \"Approved 1997 for breast cancer. In LGSOC, retrospective ...\"; mechanism: \"Competitive (letrozole, anastrozole) or irreversible (exe...\" vs \"Non-steroidal aromatase inhibitor; blocks conversion of a...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/","detail":"defined in the hcc and gastric spikes with different values; the first wins and hides the rest: tldr: \"An antibody that blocks the VEGF receptor, approved in li...\" vs \"An antibody that blocks the blood-vessel receptor VEGFR2;...\"; summary: \"REACH-2: OS 8.5 vs 7.3 months in sorafenib-pretreated HCC...\" vs \"Fully human IgG1 against VEGFR2. RAINBOW (with paclitaxel...\"; mechanism: \"Fully human IgG1 binding VEGFR2 ectodomain, blocking VEGF...\" vs \"Blocks VEGF-A, -C, -D binding to VEGFR2 on endothelium.\""},{"check":"spike-scalar-divergence","severity":"medium","id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/","detail":"defined in the hcc and colorectal spikes with different values; the first wins and hides the rest: tldr: \"A sorafenib successor that became the first second-line d...\" vs \"A multi-target pill for refractory bowel cancer, liver ca...\"; summary: \"RESORCE: OS 10.6 vs 7.8 months versus placebo after soraf...\" vs \"Inhibits VEGFR1-3, TIE2, KIT, RET, RAF, PDGFR. CORRECT (2...\"; mechanism: \"Oral inhibitor of VEGFR1-3, TIE2, PDGFR, FGFR, KIT, RET a...\" vs \"Multi-kinase inhibition of angiogenic, stromal, and oncog...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","detail":"defined in the neuroendocrine and rcc spikes with different values; the first wins and hides the rest: modality: \"Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, KIT)\" vs \"Small-molecule kinase inhibitor (VEGFR/PDGFR/KIT)\"; tldr: \"Sunitinib is an anti-angiogenic pill approved for pancrea...\" vs \"The pill that replaced interferon as kidney cancer's stan...\"; summary: \"Phase 3 in pancreatic NETs (Raymond 2011): PFS 11.4 vs 5....\" vs \"Motzer 2007: PFS 11 vs 5 months vs interferon-α; OS 26.4 ...\"; mechanism: \"Oral inhibitor of VEGFR1-3, PDGFR, KIT, FLT3, RET.\" vs \"Multi-targeted TKI of VEGFR1-3, PDGFRα/β, KIT, FLT3, RET.\""},{"check":"spike-scalar-divergence","severity":"medium","id":"trabectedin","kind":"drug","name":"Trabectedin","route":"/drugs/trabectedin/","detail":"defined in the ovarian and sarcoma spikes with different values; the first wins and hides the rest: modality: \"Cytotoxic (DNA minor-groove binder)\" vs \"Cytotoxic chemotherapy (marine-derived DNA binder)\"; tldr: \"A chemotherapy derived from a sea squirt, used with lipos...\" vs \"A sea-squirt-derived chemotherapy approved for liposarcom...\"; summary: \"OVA-301 showed a PFS benefit with pegylated liposomal dox...\" vs \"ET743 (SAR-3007): PFS 4.2 vs 1.5 months vs dacarbazine (H...\"; mechanism: \"Binds the DNA minor groove, bends DNA, blocks transcripti...\" vs \"Binds the DNA minor groove, blocks transcription-coupled ...\""},{"check":"status-vs-approvals","severity":"medium","id":"interferon-alfa","kind":"drug","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/","detail":"US/EU approvals recorded (US 1986, US 1988, US 1995) but status is \"historic\""},{"check":"status-vs-approvals","severity":"medium","id":"mammaprint","kind":"drug","name":"MammaPrint (70-gene signature)","route":"/drugs/mammaprint/","detail":"US/EU approvals recorded (US 2007) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"nintedanib","kind":"drug","name":"Nintedanib","route":"/drugs/nintedanib/","detail":"US/EU approvals recorded (EU 2014, US 2014) but status is \"negative\""},{"check":"unsourced-numbers","severity":"medium","id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","detail":"4 numbers in the text (HR 0.67, HR 0.78, 14.1 months, 58.7 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-breath-voc-symptomatic-ruleout","kind":"idea","name":"A breath test to rule out cancer in people with vague symptoms","route":"/ideas/idea-prev-breath-voc-symptomatic-ruleout/","detail":"1 number in the text (99%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-reg-delinked-market-entry-reward","kind":"idea","name":"A delinked market-entry reward paid by payers when a repurposed generic wins approval","route":"/ideas/idea-reg-delinked-market-entry-reward/","detail":"2 numbers in the text ($30, 100 million) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-fund-implementation-quota","kind":"idea","name":"A fixed share of trial-group funding for getting proven care to patients","route":"/ideas/idea-fund-implementation-quota/","detail":"1 number in the text (10%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-moon-adult-late-effects-registry","kind":"idea","name":"A lifelong late-effects registry linked to every treatment for adult survivors","route":"/ideas/idea-moon-adult-late-effects-registry/","detail":"1 number in the text (18 million) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-data-evidence-to-adoption-tracker","kind":"idea","name":"A public tracker of how long each country takes to adopt new evidence","route":"/ideas/idea-data-evidence-to-adoption-tracker/","detail":"1 number in the text (50 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-data-sequencing-analysis-per-approval","kind":"idea","name":"A real-world sequencing analysis within a year of every new approval","route":"/ideas/idea-data-sequencing-analysis-per-approval/","detail":"1 number in the text (12 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-fund-non-drug-trial-quota","kind":"idea","name":"A statutory minimum share of public trial money for surgery and radiotherapy","route":"/ideas/idea-fund-non-drug-trial-quota/","detail":"1 number in the text (25%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-fund-survivorship-endowment-levy","kind":"idea","name":"A survivorship research endowment funded by a levy on curative therapy prices","route":"/ideas/idea-fund-survivorship-endowment-levy/","detail":"1 number in the text (0.5%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-lmic-five-cancer-methylation-test","kind":"idea","name":"A ten-dollar blood test for the five cancers that kill most people in poorer countries","route":"/ideas/idea-prev-lmic-five-cancer-methylation-test/","detail":"1 number in the text ($950) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-hpylori-childhood-vaccine","kind":"idea","name":"A vaccine against H. pylori for children in high-risk regions","route":"/ideas/idea-prev-hpylori-childhood-vaccine/","detail":"1 number in the text (72%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/","detail":"1 number in the text ($2) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","detail":"1 number in the text ($4) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-ptmc-active-surveillance-default","kind":"idea","name":"Active surveillance as the default for tiny papillary thyroid cancers","route":"/ideas/idea-prev-ptmc-active-surveillance-default/","detail":"1 number in the text (1%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"active-surveillance-thyroid","kind":"technology","name":"Active surveillance of papillary microcarcinoma","route":"/technologies/active-surveillance-thyroid/","detail":"1 number in the text (90%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"adc-plus-io","kind":"pairing","name":"ADC + checkpoint inhibitor","route":"/pairings/adc-plus-io/","detail":"2 numbers in the text (HR 0.47, HR 0.65) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-ldct-ai-negative-triage","kind":"idea","name":"AI clears the normal lung screening scans so radiologists read only the suspicious ones","route":"/ideas/idea-prev-ldct-ai-negative-triage/","detail":"1 number in the text (10%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-lung-nodule-ai-discharge","kind":"idea","name":"AI malignancy scores to end repeat scans and biopsies for benign lung nodules","route":"/ideas/idea-prev-lung-nodule-ai-discharge/","detail":"1 number in the text (1%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-ai-her2-low-scoring","kind":"idea","name":"AI quantification of HER2-low and HER2-ultralow","route":"/ideas/idea-ai-her2-low-scoring/","detail":"1 number in the text (50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-pancreas-ai-prediagnostic-ct","kind":"idea","name":"AI that spots pancreatic cancer on scans taken a year before diagnosis","route":"/ideas/idea-prev-pancreas-ai-prediagnostic-ct/","detail":"1 number in the text (36 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/","detail":"1 number in the text (8%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"aignostics","kind":"company","name":"Aignostics","route":"/companies/aignostics/","detail":"1 number in the text (1.2 million) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"aldevron","kind":"company","name":"Aldevron (Danaher)","route":"/companies/aldevron/","detail":"1 number in the text ($9) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-alpha-first-mhspc","kind":"idea","name":"Alpha-emitting PSMA therapy at first metastatic diagnosis","route":"/ideas/idea-alpha-first-mhspc/","detail":"1 number in the text (HR 0.72) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"amivantamab-plus-lazertinib","kind":"pairing","name":"Amivantamab + lazertinib (first-line EGFR NSCLC)","route":"/pairings/amivantamab-plus-lazertinib/","detail":"4 numbers in the text (HR 0.70, HR 0.75, 16.6 months, 12 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-reg-pd1-biosimilar-advance-commitment","kind":"idea","name":"An advance market commitment for PD-1 biosimilars for lower-income countries","route":"/ideas/idea-reg-pd1-biosimilar-advance-commitment/","detail":"1 number in the text ($500) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-indolent-lesion-nomenclature-body","kind":"idea","name":"An international body to rename indolent lesions so 'cancer' means something","route":"/ideas/idea-prev-indolent-lesion-nomenclature-body/","detail":"1 number in the text (1%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/","detail":"1 number in the text (100%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"anitocabtagene-autoleucel","kind":"drug","name":"Anitocabtagene autoleucel","route":"/drugs/anitocabtagene-autoleucel/","detail":"2 numbers in the text (97%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"anti-egfr-left-sided","kind":"pairing","name":"Anti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC","route":"/pairings/anti-egfr-left-sided/","detail":"1 number in the text (37.9 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"anti-gd2-plus-chemo-relapse","kind":"pairing","name":"Anti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)","route":"/pairings/anti-gd2-plus-chemo-relapse/","detail":"2 numbers in the text (53%, 18%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-hpylori-stool-resistance-guided","kind":"idea","name":"Antibiotic-resistance testing from a stool sample before treating H. pylori","route":"/ideas/idea-prev-hpylori-stool-resistance-guided/","detail":"1 number in the text (30%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"arx788","kind":"drug","name":"ARX788","route":"/drugs/arx788/","detail":"2 numbers in the text (HR 0.64, 8.2 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-reflex-germline-testing","kind":"idea","name":"Automatic germline testing for every cancer type where it changes care","route":"/ideas/idea-prev-reflex-germline-testing/","detail":"1 number in the text (50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/","detail":"2 numbers in the text (44%, 31.1 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"bcg-unresponsive","kind":"term","name":"BCG-unresponsive","route":"/terms/bcg-unresponsive/","detail":"3 numbers in the text (80%, 12 months, 6 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"bcma-then-gprc5d","kind":"pairing","name":"BCMA-directed therapy → GPRC5D-directed therapy","route":"/pairings/bcma-then-gprc5d/","detail":"2 numbers in the text (65%, 80%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/","detail":"2 numbers in the text (83%, 18 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"beta-then-alpha","kind":"pairing","name":"Beta radioligand → alpha radioligand","route":"/pairings/beta-then-alpha/","detail":"1 number in the text (60%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","detail":"6 numbers in the text (HR 0.81, HR 0.75, 36.4 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","detail":"1 number in the text (9 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-biomarker-quadruplet-gastric","kind":"idea","name":"Biomarker-directed first-line quadruplets in gastric cancer","route":"/ideas/idea-biomarker-quadruplet-gastric/","detail":"1 number in the text (20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-bladder-preservation-mibc","kind":"idea","name":"Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response","route":"/ideas/idea-bladder-preservation-mibc/","detail":"1 number in the text (57%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"blinatumomab-frontline-consolidation","kind":"pairing","name":"Blinatumomab added to frontline chemotherapy","route":"/pairings/blinatumomab-frontline-consolidation/","detail":"2 numbers in the text (HR 0.41, HR 0.39) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-hcc-blood-surveillance","kind":"idea","name":"Blood-based HCC surveillance to replace six-monthly ultrasound","route":"/ideas/idea-hcc-blood-surveillance/","detail":"1 number in the text (85%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-mced-new-onset-diabetes","kind":"idea","name":"Blood-based pancreatic cancer detection in new-onset diabetes","route":"/ideas/idea-mced-new-onset-diabetes/","detail":"1 number in the text (1%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"braf-mek-neoadjuvant-atc","kind":"pairing","name":"BRAF/MEK inhibition → surgery in anaplastic thyroid cancer","route":"/pairings/braf-mek-neoadjuvant-atc/","detail":"1 number in the text (90%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-atc-triplet-io","kind":"idea","name":"BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer","route":"/ideas/idea-atc-triplet-io/","detail":"1 number in the text (15 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"breakthrough-designation","kind":"term","name":"Breakthrough Therapy / Priority Review / Priority Voucher","route":"/terms/breakthrough-designation/","detail":"2 numbers in the text (6 months, 2 month) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","detail":"2 numbers in the text ($8, $4) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-btk-degrader-frontline","kind":"idea","name":"BTK degraders to pre-empt resistance in frontline CLL","route":"/ideas/idea-btk-degrader-frontline/","detail":"1 number in the text (86%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"btki-plus-venetoclax-fixed-duration","kind":"pairing","name":"BTK inhibitor + venetoclax, fixed duration","route":"/pairings/btki-plus-venetoclax-fixed-duration/","detail":"1 number in the text (15 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-prs-ancestry-portability-standard","kind":"idea","name":"Build polygenic scores that work in every ancestry before deploying any","route":"/ideas/idea-prev-prs-ancestry-portability-standard/","detail":"1 number in the text (20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-fund-lmic-burden-match","kind":"idea","name":"Burden-matched funding for trials led in low- and middle-income countries","route":"/ideas/idea-fund-lmic-burden-match/","detail":"1 number in the text (15%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/","detail":"2 numbers in the text (33%, HR 0.64) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"caix-pet","kind":"technology","name":"CAIX PET (89Zr-girentuximab)","route":"/technologies/caix-pet/","detail":"2 numbers in the text (86%, 87%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","detail":"2 numbers in the text (HR 0.44, 9.2 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/","detail":"3 numbers in the text (HR 0.62, 15.2 months, 3.7 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-tdxd-first-then-nothing","kind":"idea","name":"Can T-DXd alone cure early HER2-positive disease?","route":"/ideas/idea-tdxd-first-then-nothing/","detail":"1 number in the text (67%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/","detail":"1 number in the text (£400M) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"variant-knowledgebases","kind":"technology","name":"Cancer variant knowledgebases and molecular tumour boards","route":"/technologies/variant-knowledgebases/","detail":"2 numbers in the text (50%, 25%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"capecitabine-temozolomide","kind":"drug","name":"Capecitabine + temozolomide (CAPTEM)","route":"/drugs/capecitabine-temozolomide/","detail":"1 number in the text (14.4 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/","detail":"1 number in the text (50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"io-varices-caution","kind":"pairing","name":"Caution: bevacizumab-based regimens with untreated varices","route":"/pairings/io-varices-caution/","detail":"2 numbers in the text (7%, 6 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"bleomycin-omission-caution","kind":"pairing","name":"Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF","route":"/pairings/bleomycin-omission-caution/","detail":"1 number in the text (44%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"doxorubicin-cardio-caution","kind":"pairing","name":"Caution: cumulative anthracycline dose and the heart","route":"/pairings/doxorubicin-cardio-caution/","detail":"2 numbers in the text (5%, 26%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ild-overlap-caution","kind":"pairing","name":"Caution: DXd ADC + agents with pneumonitis risk","route":"/pairings/ild-overlap-caution/","detail":"2 numbers in the text (15%, 5%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"btki-ibrutinib-cardiac-caution","kind":"pairing","name":"Caution: ibrutinib in patients with cardiac risk","route":"/pairings/btki-ibrutinib-cardiac-caution/","detail":"2 numbers in the text (16%, 40%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"il2-anti-gd2-caution","kind":"pairing","name":"Caution: IL-2 added to anti-GD2 therapy","route":"/pairings/il2-anti-gd2-caution/","detail":"2 numbers in the text (60%, 56%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"inotuzumab-then-transplant-caution","kind":"pairing","name":"Caution: inotuzumab before transplant (veno-occlusive disease)","route":"/pairings/inotuzumab-then-transplant-caution/","detail":"1 number in the text (22%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"caution-mis-radical-hysterectomy","kind":"pairing","name":"Caution: minimally invasive radical hysterectomy for early cervical cancer","route":"/pairings/caution-mis-radical-hysterectomy/","detail":"3 numbers in the text (86.0%, 96.5%, HR 6.0) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"bispecific-infection-prophylaxis","kind":"pairing","name":"Caution: T-cell redirectors and infections","route":"/pairings/bispecific-infection-prophylaxis/","detail":"1 number in the text (45%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-cd30-car-t-hodgkin","kind":"idea","name":"CD30 CAR-T for multiply relapsed Hodgkin lymphoma","route":"/ideas/idea-cd30-car-t-hodgkin/","detail":"2 numbers in the text (72%, 60%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cd38-plus-triplet","kind":"pairing","name":"CD38 antibody added to PI-IMiD-dex (quadruplet induction)","route":"/pairings/cd38-plus-triplet/","detail":"4 numbers in the text (HR 0.42, HR 0.57, HR 0.60, HR 0.68) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cellares","kind":"company","name":"Cellares","route":"/companies/cellares/","detail":"1 number in the text ($255M) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-fragmentomics-first-tier","kind":"idea","name":"Cheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests","route":"/ideas/idea-prev-fragmentomics-first-tier/","detail":"1 number in the text (10%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"chemo-io-first-line-endometrial","kind":"pairing","name":"Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer","route":"/pairings/chemo-io-first-line-endometrial/","detail":"2 numbers in the text (HR 0.30, 28.2 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-chemo-free-hodgkin","kind":"idea","name":"Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage","route":"/ideas/idea-chemo-free-hodgkin/","detail":"2 numbers in the text (90%, 80%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"clinical-complete-response","kind":"term","name":"Clinical complete response (cCR)","route":"/terms/clinical-complete-response/","detail":"1 number in the text (12 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-nl-antioxidant-supplement-harm-confirmation","kind":"idea","name":"Confirm or refute the harm of antioxidant supplements during chemotherapy","route":"/ideas/idea-nl-antioxidant-supplement-harm-confirmation/","detail":"3 numbers in the text (40%, 41%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cms-subtypes","kind":"term","name":"Consensus molecular subtypes (CMS1-4)","route":"/terms/cms-subtypes/","detail":"4 numbers in the text (14%, 37%, 13%, 23%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cradle-bio","kind":"company","name":"Cradle","route":"/companies/cradle-bio/","detail":"2 numbers in the text ($73 million, 73 million) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/","detail":"3 numbers in the text (75%, 75.2%, 41.8%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cross-then-nivolumab","kind":"pairing","name":"CROSS chemoradiation → surgery → adjuvant nivolumab if residual disease","route":"/pairings/cross-then-nivolumab/","detail":"4 numbers in the text (38%, 70%, HR 0.85, 11.0 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ctdna-mrd-to-adjuvant","kind":"pairing","name":"ctDNA MRD → adjuvant therapy decision","route":"/pairings/ctdna-mrd-to-adjuvant/","detail":"1 number in the text (HR 0.59) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-hcv-test-treat-surveillance-linkage","kind":"idea","name":"Cure hepatitis C in prisons and drug services, and enrol the cured in liver cancer surveillance","route":"/ideas/idea-prev-hcv-test-treat-surveillance-linkage/","detail":"1 number in the text (95%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/","detail":"1 number in the text ($2) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"del17p-tp53","kind":"term","name":"del(17p) / TP53 aberration in CLL","route":"/terms/del17p-tp53/","detail":"3 numbers in the text (10%, 40%, 72%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"double-hit-lymphoma","kind":"term","name":"Double-hit / high-grade B-cell lymphoma","route":"/terms/double-hit-lymphoma/","detail":"1 number in the text (8%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"dual-her2-blockade","kind":"term","name":"Dual HER2 blockade","route":"/terms/dual-her2-blockade/","detail":"1 number in the text (16 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"durvalumab-plus-bcg","kind":"pairing","name":"Durvalumab + BCG in BCG-naive high-risk NMIBC","route":"/pairings/durvalumab-plus-bcg/","detail":"1 number in the text (HR 0.68) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"pet-adapted-her2-deescalation","kind":"pairing","name":"Early FDG-PET response → chemotherapy omission (HER2+)","route":"/pairings/pet-adapted-her2-deescalation/","detail":"1 number in the text (95.4%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-acc-earmarked-palliative-budget-share","kind":"idea","name":"Earmark a fixed share of every national cancer budget for palliative care","route":"/ideas/idea-acc-earmarked-palliative-budget-share/","detail":"1 number in the text (5%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"c797s","kind":"term","name":"EGFR C797S","route":"/terms/c797s/","detail":"1 number in the text (15%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"egfr-exon19-l858r","kind":"term","name":"EGFR exon 19 deletion & L858R","route":"/terms/egfr-exon19-l858r/","detail":"3 numbers in the text (85%, 45%, 40%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"egfr-exon20-insertion","kind":"term","name":"EGFR exon 20 insertion","route":"/terms/egfr-exon20-insertion/","detail":"2 numbers in the text (2%, 10%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"egfr-bispecific-plus-pd1-hnscc","kind":"pairing","name":"EGFR-directed bispecific + PD-1 blockade","route":"/pairings/egfr-bispecific-plus-pd1-hnscc/","detail":"1 number in the text (63%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"elironrasib","kind":"drug","name":"Elironrasib","route":"/drugs/elironrasib/","detail":"1 number in the text (2%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"endocrine-resistance","kind":"term","name":"Endocrine resistance","route":"/terms/endocrine-resistance/","detail":"2 numbers in the text (6 months, 12 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ev-pembro-continuum","kind":"pairing","name":"Enfortumab vedotin + pembrolizumab across the bladder cancer continuum","route":"/pairings/ev-pembro-continuum/","detail":"2 numbers in the text (HR 0.47, HR 0.40) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"epithelioid-vs-sarcomatoid","kind":"term","name":"Epithelioid vs sarcomatoid (biphasic) mesothelioma","route":"/terms/epithelioid-vs-sarcomatoid/","detail":"6 numbers in the text (70%, 20%, 18 months, 12 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-nl-alcohol-minimum-pricing-cancer-endpoints","kind":"idea","name":"Evaluate alcohol minimum unit pricing against cancer incidence","route":"/ideas/idea-nl-alcohol-minimum-pricing-cancer-endpoints/","detail":"2 numbers in the text (3%, 13%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-bio1-p53-mutant-reactivator-expansion","kind":"idea","name":"Extend p53 reactivation beyond the Y220C mutation","route":"/ideas/idea-bio1-p53-mutant-reactivator-expansion/","detail":"1 number in the text (1 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-tr1-extended-interval-checkpoint-dosing","kind":"idea","name":"Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable","route":"/ideas/idea-tr1-extended-interval-checkpoint-dosing/","detail":"1 number in the text (6 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-tcr-t-beyond-hla-a2","kind":"idea","name":"Extending sarcoma TCR-T beyond HLA-A*02","route":"/ideas/idea-tcr-t-beyond-hla-a2/","detail":"1 number in the text (50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-fap-theranostics-pancancer","kind":"idea","name":"FAP theranostics as a pan-cancer stromal strategy","route":"/ideas/idea-fap-theranostics-pancancer/","detail":"1 number in the text (90%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"fertility-sparing-endometrial","kind":"technology","name":"Fertility-sparing hormonal treatment of early endometrial cancer","route":"/technologies/fertility-sparing-endometrial/","detail":"4 numbers in the text (80%, 30%, 40%, 12 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"fgfr2-fusion","kind":"term","name":"FGFR2 fusions and rearrangements","route":"/terms/fgfr2-fusion/","detail":"2 numbers in the text (37%, 42%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/","detail":"1 number in the text ($1) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"flt3i-plus-7-3","kind":"pairing","name":"FLT3 inhibitor + intensive chemotherapy","route":"/pairings/flt3i-plus-7-3/","detail":"2 numbers in the text (HR 0.78, HR 0.776) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"fran-visco","kind":"person","name":"Fran Visco","route":"/people/fran-visco/","detail":"2 numbers in the text ($210 million, 210 million) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-fund-open-results-bonus","kind":"idea","name":"Funder bonuses for releasing results and data within six months, negatives included","route":"/ideas/idea-fund-open-results-bonus/","detail":"1 number in the text (5%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","detail":"1 number in the text ($2) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"g12d-plus-pan-ras","kind":"pairing","name":"G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)","route":"/pairings/g12d-plus-pan-ras/","detail":"2 numbers in the text (50%, 97%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-gd2-car-t-frontline-consolidation","kind":"idea","name":"GD2 CAR-T as consolidation in high-risk neuroblastoma","route":"/ideas/idea-gd2-car-t-frontline-consolidation/","detail":"1 number in the text (50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"tar-200","kind":"drug","name":"Gemcitabine intravesical system (TAR-200)","route":"/drugs/tar-200/","detail":"1 number in the text (82%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"gemcis-plus-io-btc","kind":"pairing","name":"Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer","route":"/pairings/gemcis-plus-io-btc/","detail":"2 numbers in the text (HR 0.76, HR 0.83) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"geriatric-assessment","kind":"technology","name":"Geriatric assessment","route":"/technologies/geriatric-assessment/","detail":"1 number in the text (20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"germline-to-parp","kind":"pairing","name":"Germline BRCA test → adjuvant PARP inhibitor","route":"/pairings/germline-to-parp/","detail":"2 numbers in the text (HR 0.58, HR 0.72) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-lynch-aspirin-implementation","kind":"idea","name":"Get every Lynch syndrome carrier onto the right dose of aspirin","route":"/ideas/idea-prev-lynch-aspirin-implementation/","detail":"1 number in the text (50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/","detail":"3 numbers in the text (30%, HR 0.56, HR 0.38) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-glp1-endometrial-hyperplasia","kind":"idea","name":"GLP-1 drugs to reverse endometrial precancer in women with obesity","route":"/ideas/idea-prev-glp1-endometrial-hyperplasia/","detail":"1 number in the text (30%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-nl-glp1-adjuvant-hr-breast","kind":"idea","name":"GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer","route":"/ideas/idea-nl-glp1-adjuvant-hr-breast/","detail":"1 number in the text (30%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"golcadomide","kind":"drug","name":"Golcadomide","route":"/drugs/golcadomide/","detail":"1 number in the text (50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-fund-phase-two-failure-reinsurance","kind":"idea","name":"Government reinsurance for phase 2 failures of first-in-class cancer drugs","route":"/ideas/idea-fund-phase-two-failure-reinsurance/","detail":"1 number in the text (40%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-her2-adc-serous-endometrial","kind":"idea","name":"HER2 ADCs as standard for HER2-positive serous endometrial cancer","route":"/ideas/idea-her2-adc-serous-endometrial/","detail":"2 numbers in the text (84.6%, 30%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"her2-gastric-sequence","kind":"pairing","name":"HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd","route":"/pairings/her2-gastric-sequence/","detail":"3 numbers in the text (30%, 8.1 months, 11.4 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"her2-low","kind":"term","name":"HER2-low and HER2-ultralow","route":"/terms/her2-low/","detail":"3 numbers in the text (50%, 35%, 10%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"her2-brain-metastases","kind":"term","name":"HER2-positive brain metastases","route":"/terms/her2-brain-metastases/","detail":"3 numbers in the text (50%, 71.7%, HR 0.32) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"hgsoc","kind":"term","name":"High-grade serous ovarian carcinoma (HGSOC)","route":"/terms/hgsoc/","detail":"3 numbers in the text (70%, 50%, 20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"high-risk-myeloma","kind":"term","name":"High-risk cytogenetics (myeloma)","route":"/terms/high-risk-myeloma/","detail":"1 number in the text (20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"high-throughput-screening-libraries","kind":"technology","name":"High-throughput screening and DNA-encoded libraries","route":"/technologies/high-throughput-screening-libraries/","detail":"1 number in the text (2 million) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"hipec-at-interval-surgery","kind":"pairing","name":"HIPEC at interval cytoreductive surgery","route":"/pairings/hipec-at-interval-surgery/","detail":"2 numbers in the text (HR 0.67, 33.9 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"histologic-transformation","kind":"term","name":"Histologic transformation","route":"/terms/histologic-transformation/","detail":"1 number in the text (15%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"histology-directs-first-line-meso","kind":"pairing","name":"Histology → first-line choice in mesothelioma","route":"/pairings/histology-directs-first-line-meso/","detail":"1 number in the text (8.8 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"histosonics","kind":"company","name":"HistoSonics","route":"/companies/histosonics/","detail":"1 number in the text ($2) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"hla-a02-restriction","kind":"term","name":"HLA-A*02:01 restriction","route":"/terms/hla-a02-restriction/","detail":"2 numbers in the text (50%, 20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-fund-protected-time-physician-scientists","kind":"idea","name":"Hospital-funded protected time for clinician-scientists, repaid by trial revenue","route":"/ideas/idea-fund-protected-time-physician-scientists/","detail":"1 number in the text (40%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/","detail":"1 number in the text (26%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/","detail":"1 number in the text (55%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"imdc-risk","kind":"term","name":"IMDC risk groups (favourable / intermediate / poor)","route":"/terms/imdc-risk/","detail":"1 number in the text (80%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/","detail":"4 numbers in the text (HR 0.62, HR 0.59, 23.1 months, 5.5 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"io-first-then-braf-mek","kind":"pairing","name":"Immunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)","route":"/pairings/io-first-then-braf-mek/","detail":"2 numbers in the text (71.8%, 51.5%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/","detail":"1 number in the text (80%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/","detail":"1 number in the text ($2) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-moon-in-vivo-cart-generic-price","kind":"idea","name":"In vivo CAR-T manufactured and priced like a generic biologic","route":"/ideas/idea-moon-in-vivo-cart-generic-price/","detail":"1 number in the text ($5,000) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"induction-chemo-then-crt","kind":"pairing","name":"Induction chemotherapy → chemoradiation (locally advanced cervical cancer)","route":"/pairings/induction-chemo-then-crt/","detail":"4 numbers in the text (40%, 80%, 72%, HR 0.60) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","detail":"1 number in the text (5.8 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"komodo-health","kind":"company","name":"Komodo Health","route":"/companies/komodo-health/","detail":"1 number in the text (330 million) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"kras-plus-egfr-crc","kind":"pairing","name":"KRAS G12C inhibitor + anti-EGFR antibody (colorectal)","route":"/pairings/kras-plus-egfr-crc/","detail":"2 numbers in the text (10%, 45%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"late-recurrence","kind":"term","name":"Late recurrence","route":"/terms/late-recurrence/","detail":"1 number in the text (2%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"lenvatinib-plus-pembrolizumab","kind":"pairing","name":"Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)","route":"/pairings/lenvatinib-plus-pembrolizumab/","detail":"4 numbers in the text (67%, 33%, 11.4 months, 12.0 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-cascade-direct-contact-relatives","kind":"idea","name":"Let clinics contact relatives directly when a cancer gene is found","route":"/ideas/idea-prev-cascade-direct-contact-relatives/","detail":"1 number in the text (40%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/","detail":"4 numbers in the text (42%, 41%, 43%, 12.2 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"lila-sciences","kind":"company","name":"Lila Sciences","route":"/companies/lila-sciences/","detail":"2 numbers in the text ($500 million, 500 million) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"limited-vs-extensive-stage","kind":"term","name":"Limited-stage vs extensive-stage (SCLC)","route":"/terms/limited-vs-extensive-stage/","detail":"2 numbers in the text (35%, 15 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","detail":"2 numbers in the text (70%, 45%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-bio1-baseline-ultradeep-resistant-clones","kind":"idea","name":"Look for the resistant sub-population before the first dose","route":"/ideas/idea-bio1-baseline-ultradeep-resistant-clones/","detail":"1 number in the text (0.01 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-low-dose-tamoxifen-uptake","kind":"idea","name":"Low-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses","route":"/ideas/idea-prev-low-dose-tamoxifen-uptake/","detail":"1 number in the text (10%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","detail":"3 numbers in the text (10%, 50%, 25%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-lung-screening-risk-model-eligibility","kind":"idea","name":"Lung screening eligibility by risk score, not pack-years, including high-risk never-smokers","route":"/ideas/idea-prev-lung-screening-risk-model-eligibility/","detail":"1 number in the text (1.5%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"major-pathological-response","kind":"term","name":"Major pathological response (MPR)","route":"/terms/major-pathological-response/","detail":"3 numbers in the text (10%, 0%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-immunotherapy-mss-crc","kind":"idea","name":"Making microsatellite-stable colorectal cancer immunotherapy-responsive","route":"/ideas/idea-immunotherapy-mss-crc/","detail":"1 number in the text (20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-radon-testing-at-property-sale","kind":"idea","name":"Mandatory radon testing when homes are sold, with subsidised mitigation","route":"/ideas/idea-prev-radon-testing-at-property-sale/","detail":"1 number in the text (14%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","detail":"1 number in the text (100%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"menin-plus-venetoclax-hma","kind":"pairing","name":"Menin inhibitor + venetoclax + azacitidine","route":"/pairings/menin-plus-venetoclax-hma/","detail":"1 number in the text (80%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-menin-infant-all","kind":"idea","name":"Menin inhibitors for infant KMT2A-rearranged ALL","route":"/ideas/idea-menin-infant-all/","detail":"1 number in the text (50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"met-amplification","kind":"term","name":"MET amplification (bypass resistance)","route":"/terms/met-amplification/","detail":"1 number in the text (20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"mezigdomide","kind":"drug","name":"Mezigdomide","route":"/drugs/mezigdomide/","detail":"3 numbers in the text (40%, 41%, 30%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-microbiome-io-fmt","kind":"idea","name":"Microbiome transplant as a routine immunotherapy adjunct","route":"/ideas/idea-microbiome-io-fmt/","detail":"1 number in the text (40%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-minimum-unit-pricing-cancer-endpoints","kind":"idea","name":"Minimum alcohol pricing evaluated with cancer endpoints","route":"/ideas/idea-prev-minimum-unit-pricing-cancer-endpoints/","detail":"1 number in the text (13%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"mrd-negativity-myeloma","kind":"term","name":"MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)","route":"/terms/mrd-negativity-myeloma/","detail":"2 numbers in the text (12 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-mrd-guided-stop-cll","kind":"idea","name":"MRD-guided treatment duration in CLL","route":"/ideas/idea-mrd-guided-stop-cll/","detail":"1 number in the text (15 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"nemtabrutinib","kind":"drug","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/","detail":"1 number in the text (53%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"neoadjuvant-io-dmmr","kind":"pairing","name":"Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer","route":"/pairings/neoadjuvant-io-dmmr/","detail":"3 numbers in the text (68%, 100%, HR 0.50) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-new-onset-diabetes-pancreas-pathway","kind":"idea","name":"New diabetes after 50 plus weight loss triggers a pancreatic cancer check","route":"/ideas/idea-prev-new-onset-diabetes-pancreas-pathway/","detail":"1 number in the text (4%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"next-gen-short-read-platforms","kind":"technology","name":"New short-read sequencing platforms","route":"/technologies/next-gen-short-read-platforms/","detail":"1 number in the text ($100) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","detail":"1 number in the text (71%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","detail":"1 number in the text (75%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","detail":"1 number in the text ($1) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/","detail":"6 numbers in the text (77%, 55%, 2.4%, 7%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/","detail":"4 numbers in the text (52%, 31%, 80%, 73%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-shared-kras-vaccine-adjuvant","kind":"idea","name":"Off-the-shelf KRAS vaccines after pancreatic cancer surgery","route":"/ideas/idea-shared-kras-vaccine-adjuvant/","detail":"1 number in the text (80%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-blood-crc-test-for-non-responders","kind":"idea","name":"Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy","route":"/ideas/idea-prev-blood-crc-test-for-non-responders/","detail":"2 numbers in the text (83%, 13%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"oncolytic-plus-pd1","kind":"pairing","name":"Oncolytic virus + PD-1 blockade","route":"/pairings/oncolytic-plus-pd1/","detail":"1 number in the text (33%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-data-access-programme-outcomes","kind":"idea","name":"One outcome record for every donated or discounted cancer drug pack","route":"/ideas/idea-data-access-programme-outcomes/","detail":"1 number in the text (12 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"oral-serd-plus-cdk46-after-esr1","kind":"pairing","name":"Oral SERD + CDK4/6 inhibitor after ESR1 emergence","route":"/pairings/oral-serd-plus-cdk46-after-esr1/","detail":"2 numbers in the text (HR 0.44, HR 0.57) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/","detail":"1 number in the text (56%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"pacbio","kind":"company","name":"PacBio","route":"/companies/pacbio/","detail":"1 number in the text (99.9%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"parp-plus-bevacizumab","kind":"pairing","name":"PARP inhibitor + bevacizumab maintenance (HRD-positive)","route":"/pairings/parp-plus-bevacizumab/","detail":"4 numbers in the text (65.5%, 48.4%, HR 0.33, 17.7 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"pasritamig","kind":"drug","name":"Pasritamig","route":"/drugs/pasritamig/","detail":"1 number in the text (40%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","detail":"1 number in the text (30%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"pd1-plus-avd-hodgkin","kind":"pairing","name":"PD-1 blockade + AVD chemotherapy","route":"/pairings/pd1-plus-avd-hodgkin/","detail":"2 numbers in the text (92%, 83%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"io-plus-crt-cervical","kind":"pairing","name":"PD-1 blockade + chemoradiation (locally advanced cervical cancer)","route":"/pairings/io-plus-crt-cervical/","detail":"3 numbers in the text (82.6%, 74.8%, HR 0.67) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"pd1-plus-chemo-pdl1-low","kind":"pairing","name":"PD-1 blockade + chemotherapy in PD-L1-low NSCLC","route":"/pairings/pd1-plus-chemo-pdl1-low/","detail":"1 number in the text (1%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"pdac-organoid-pharmacotyping","kind":"technology","name":"PDAC organoid pharmacotyping","route":"/technologies/pdac-organoid-pharmacotyping/","detail":"1 number in the text (70%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"peritoneal-metastasis","kind":"term","name":"Peritoneal metastasis","route":"/terms/peritoneal-metastasis/","detail":"1 number in the text (30%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"vaccine-plus-pd1","kind":"pairing","name":"Personalised neoantigen vaccine + PD-1 blockade","route":"/pairings/vaccine-plus-pd1/","detail":"1 number in the text (49%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/","detail":"1 number in the text ($1) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ph-positive-all","kind":"term","name":"Ph-positive ALL","route":"/terms/ph-positive-all/","detail":"4 numbers in the text (25%, 34.4%, 16.7%, 95%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"pi3k-pathway-plus-endocrine","kind":"pairing","name":"PI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)","route":"/pairings/pi3k-pathway-plus-endocrine/","detail":"1 number in the text (HR 0.67) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-fund-technique-innovation-prize","kind":"idea","name":"Prizes for unpatentable surgical and radiotherapy techniques proven in trials","route":"/ideas/idea-fund-technique-innovation-prize/","detail":"3 numbers in the text ($5, $20 million, 20 million) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-mtap-prmt5-mesothelioma","kind":"idea","name":"PRMT5/MAT2A synthetic lethality for MTAP-deleted mesothelioma","route":"/ideas/idea-mtap-prmt5-mesothelioma/","detail":"1 number in the text (50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"providence-health","kind":"institution","name":"Providence Health & Services","route":"/institutions/providence-health/","detail":"1 number in the text (1.3 billion) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","detail":"4 numbers in the text (90%, 46%, 66%, 37%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-reg-lmic-public-cart-manufacturing","kind":"idea","name":"Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000","route":"/ideas/idea-reg-lmic-public-cart-manufacturing/","detail":"2 numbers in the text ($40,000, $50,000) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/","detail":"2 numbers in the text (6.8 months, 10.4 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"rai-refractory","kind":"term","name":"Radioiodine-refractory (RAI-R) thyroid cancer","route":"/terms/rai-refractory/","detail":"2 numbers in the text (15%, 12 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"radionuclide-generators-kits","kind":"technology","name":"Radionuclide generators and cold kits","route":"/technologies/radionuclide-generators-kits/","detail":"1 number in the text (12 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/","detail":"1 number in the text (46%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-tr2-random-audit","kind":"idea","name":"Random audits of published, funded research, like tax audits","route":"/ideas/idea-tr2-random-audit/","detail":"1 number in the text (2%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-tr1-immunotherapy-stop-trials","kind":"idea","name":"Randomised trials of stopping immunotherapy after one year versus continuing","route":"/ideas/idea-tr1-immunotherapy-stop-trials/","detail":"2 numbers in the text (12 months, 24 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-ras-inhibitor-neoadjuvant-pdac","kind":"idea","name":"RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable","route":"/ideas/idea-ras-inhibitor-neoadjuvant-pdac/","detail":"2 numbers in the text (20%, 30%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","route":"/companies/rayzebio/","detail":"1 number in the text ($4) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-tr1-response-adapted-dose-reduction","kind":"idea","name":"Reduce the dose once the cancer responds: response-adapted de-escalation trials","route":"/ideas/idea-tr1-response-adapted-dose-reduction/","detail":"1 number in the text (50 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-hcc-blood-surveillance-cirrhosis","kind":"idea","name":"Replace six-monthly ultrasound with a blood test for liver cancer in cirrhosis","route":"/ideas/idea-prev-hcc-blood-surveillance-cirrhosis/","detail":"1 number in the text (30%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-reg-weight-based-io-dosing-label","kind":"idea","name":"Restore weight-based dosing and vial sharing for immunotherapy in the label","route":"/ideas/idea-reg-weight-based-io-dosing-label/","detail":"1 number in the text (30%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"rigel-pharmaceuticals","kind":"company","name":"Rigel Pharmaceuticals","route":"/companies/rigel-pharmaceuticals/","detail":"1 number in the text (35%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"rinatabart-sesutecan","kind":"drug","name":"Rinatabart sesutecan","route":"/drugs/rinatabart-sesutecan/","detail":"2 numbers in the text (55.6%, 50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"rindopepimut","kind":"drug","name":"Rindopepimut","route":"/drugs/rindopepimut/","detail":"1 number in the text (20.0 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-mammography-ai-stepped-wedge","kind":"idea","name":"Roll out AI-supported mammography nationally as a stepped-wedge trial","route":"/ideas/idea-prev-mammography-ai-stepped-wedge/","detail":"1 number in the text (44%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"sarcomatoid-rcc","kind":"term","name":"Sarcomatoid differentiation (RCC)","route":"/terms/sarcomatoid-rcc/","detail":"3 numbers in the text (10%, 60%, 20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"targeted-before-io-nsclc","kind":"pairing","name":"Sequence: targeted therapy before immunotherapy in driver-positive NSCLC","route":"/pairings/targeted-before-io-nsclc/","detail":"1 number in the text (15%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/","detail":"1 number in the text (10.9 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","detail":"3 numbers in the text (83%, 13%, 90%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/","detail":"1 number in the text ($9) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-single-dose-hpv-self-sampling-elimination","kind":"idea","name":"Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries","route":"/ideas/idea-single-dose-hpv-self-sampling-elimination/","detail":"2 numbers in the text (97.5%, 27%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-weight-loss-auto-alert","kind":"idea","name":"Smart scales and health records flag unexplained weight loss for a cancer check","route":"/ideas/idea-prev-weight-loss-auto-alert/","detail":"2 numbers in the text (3%, 5%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cmg901","kind":"drug","name":"Sonesitatug vedotin","route":"/drugs/cmg901/","detail":"1 number in the text (33%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","detail":"2 numbers in the text (52%, 15.8 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"springworks","kind":"company","name":"SpringWorks Therapeutics (Merck KGaA)","route":"/companies/springworks/","detail":"1 number in the text ($3) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"escc-vs-eac","kind":"term","name":"Squamous cell carcinoma vs adenocarcinoma of the oesophagus","route":"/terms/escc-vs-eac/","detail":"2 numbers in the text (85%, 20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-tr1-start-low-titrate-up-oral-agents","kind":"idea","name":"Start low and step up: individualised titration of oral cancer drugs, randomised","route":"/ideas/idea-tr1-start-low-titrate-up-oral-agents/","detail":"1 number in the text (70 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-tr1-aggressive-futility-boundaries","kind":"idea","name":"Stop failing trials earlier with pre-registered aggressive futility rules","route":"/ideas/idea-tr1-aggressive-futility-boundaries/","detail":"1 number in the text (50 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-cns-first-adc-strategy","kind":"idea","name":"Systemic-first management of HER2-positive brain metastases","route":"/ideas/idea-cns-first-adc-strategy/","detail":"1 number in the text (72%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/","detail":"1 number in the text ($8) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"tace-plus-systemic","kind":"pairing","name":"TACE + immunotherapy/anti-VEGF","route":"/pairings/tace-plus-systemic/","detail":"2 numbers in the text (30%, HR of 0.98) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-mobile-lung-screening-deprived-areas","kind":"idea","name":"Take lung screening scanners to supermarket car parks in the poorest areas","route":"/ideas/idea-prev-mobile-lung-screening-deprived-areas/","detail":"1 number in the text (80%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"tandem-transplant","kind":"technology","name":"Tandem autologous transplant","route":"/technologies/tandem-transplant/","detail":"2 numbers in the text (61.6%, 48.4%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/","detail":"1 number in the text (35%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"tert-promoter","kind":"term","name":"TERT promoter mutation","route":"/terms/tert-promoter/","detail":"1 number in the text (10%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"precancer-ablation","kind":"technology","name":"Thermal ablation and cryotherapy for cervical precancer","route":"/technologies/precancer-ablation/","detail":"2 numbers in the text (95%, 90%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"thyroid-fna-molecular","kind":"technology","name":"Thyroid nodule FNA, Bethesda cytology & molecular classifiers","route":"/technologies/thyroid-fna-molecular/","detail":"2 numbers in the text (20%, 97%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-til-guided-deescalation","kind":"idea","name":"TIL-based omission of chemotherapy in stage I TNBC","route":"/ideas/idea-til-guided-deescalation/","detail":"2 numbers in the text (90%, 50%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/","detail":"1 number in the text (6 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-transplant-free-ph-all","kind":"idea","name":"Transplant-free Ph-positive ALL for MRD-negative adults","route":"/ideas/idea-transplant-free-ph-all/","detail":"1 number in the text (85%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"trastuzumab-cardiotoxicity","kind":"term","name":"Trastuzumab cardiotoxicity","route":"/terms/trastuzumab-cardiotoxicity/","detail":"4 numbers in the text (15%, 4%, 4.1%, 0.8%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/","detail":"5 numbers in the text (74.5%, 5%, HR 0.22, 11.5 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"tucatinib-triplet-brain-mets","kind":"pairing","name":"Tucatinib + trastuzumab + capecitabine for brain metastases","route":"/pairings/tucatinib-triplet-brain-mets/","detail":"2 numbers in the text (HR 0.32, 12.0 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"tps","kind":"term","name":"Tumour proportion score (TPS)","route":"/terms/tps/","detail":"3 numbers in the text (50%, 49%, 1%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-fund-translational-fellowships","kind":"idea","name":"Two-year translational fellowships that pay scientists to develop their own discovery","route":"/ideas/idea-fund-translational-fellowships/","detail":"2 numbers in the text ($250,000, $500,000) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ultima-genomics","kind":"company","name":"Ultima Genomics","route":"/companies/ultima-genomics/","detail":"2 numbers in the text ($100, $600M) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prev-blood-count-trend-flags","kind":"idea","name":"Use the trend in routine blood counts, not a single threshold, to spot cancer","route":"/ideas/idea-prev-blood-count-trend-flags/","detail":"1 number in the text (20%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"vaf","kind":"term","name":"Variant allele frequency (VAF)","route":"/terms/vaf/","detail":"1 number in the text (0.1%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"venetoclax-plus-hma","kind":"pairing","name":"Venetoclax + hypomethylating agent","route":"/pairings/venetoclax-plus-hma/","detail":"3 numbers in the text (36.7%, 17.9%, 9.6 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"venetoclax-plus-obinutuzumab","kind":"pairing","name":"Venetoclax + obinutuzumab (12 months)","route":"/pairings/venetoclax-plus-obinutuzumab/","detail":"3 numbers in the text (53%, 70%, 81%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"vevo-therapeutics","kind":"company","name":"Vevo Therapeutics","route":"/companies/vevo-therapeutics/","detail":"1 number in the text (100 million) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"vimseltinib","kind":"drug","name":"Vimseltinib","route":"/drugs/vimseltinib/","detail":"2 numbers in the text (40%, 0%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","detail":"1 number in the text (33%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-chip-risk-modifiers","kind":"idea","name":"Which patients' blood clones will become leukaemia after treatment?","route":"/ideas/idea-chip-risk-modifiers/","detail":"1 number in the text (2%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"xaira-therapeutics","kind":"company","name":"Xaira Therapeutics","route":"/companies/xaira-therapeutics/","detail":"2 numbers in the text ($1 billion, 1 billion) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ziftomenib","kind":"drug","name":"Ziftomenib","route":"/drugs/ziftomenib/","detail":"3 numbers in the text (23%, 33%, 6.6 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","detail":"1 number in the text (71%) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"zymeworks","kind":"company","name":"Zymeworks","route":"/companies/zymeworks/","detail":"1 number in the text (52%) but no link, Wikipedia page or registry id"},{"check":"approvals-vs-regional","severity":"low","id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","detail":"regional-approvals.ts records EU conditional 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"avapritinib","kind":"drug","name":"Avapritinib","route":"/drugs/avapritinib/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"axitinib","kind":"drug","name":"Axitinib","route":"/drugs/axitinib/","detail":"regional-approvals.ts records EU approved 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/","detail":"regional-approvals.ts records EU approved 2008 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","detail":"regional-approvals.ts records EU approved 2025 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","detail":"regional-approvals.ts records EU conditional 2025 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","detail":"regional-approvals.ts records EU approved 2005 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","detail":"regional-approvals.ts records EU approved 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"capmatinib-tepotinib","kind":"drug","name":"Capmatinib & tepotinib","route":"/drugs/capmatinib-tepotinib/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","detail":"regional-approvals.ts records EU approved 1986 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/","detail":"regional-approvals.ts records EU approved 1979 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","detail":"regional-approvals.ts records EU approved 2025 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"decitabine-cedazuridine","kind":"drug","name":"Decitabine + cedazuridine (oral)","route":"/drugs/decitabine-cedazuridine/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","detail":"regional-approvals.ts records EU approved 1995 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/","detail":"regional-approvals.ts records EU approved 1971 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","detail":"regional-approvals.ts records EU approved 2009 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/","detail":"regional-approvals.ts records EU approved 1999 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/","detail":"regional-approvals.ts records EU approved 1987 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","detail":"regional-approvals.ts records EU approved 1980 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","detail":"regional-approvals.ts records EU approved 2001 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/","detail":"regional-approvals.ts records EU approved 2026 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","detail":"regional-approvals.ts records EU approved 2025 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/","detail":"regional-approvals.ts records EU approved 2008 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/","detail":"regional-approvals.ts records EU approved 2025 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/","detail":"regional-approvals.ts records EU approved 2007 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","detail":"regional-approvals.ts records EU approved 1996 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","detail":"regional-approvals.ts records EU conditional 2025 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/","detail":"regional-approvals.ts records EU conditional 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"nadofaragene-firadenovec","kind":"drug","name":"Nadofaragene firadenovec","route":"/drugs/nadofaragene-firadenovec/","detail":"regional-approvals.ts records EU conditional 2026 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","detail":"regional-approvals.ts records EU conditional 2026 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","detail":"regional-approvals.ts records EU approved 2014 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","detail":"regional-approvals.ts records EU approved 2014 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","detail":"regional-approvals.ts records EU approved 1993 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/","detail":"regional-approvals.ts records EU approved 2007 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","detail":"regional-approvals.ts records EU approved 2010 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","detail":"regional-approvals.ts records EU approved 1996 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"megestrol-progestins","kind":"drug","name":"Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)","route":"/drugs/megestrol-progestins/","detail":"regional-approvals.ts records EU approved 1970 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","detail":"regional-approvals.ts records EU approved 1990 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/","detail":"regional-approvals.ts records EU approved 2014 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/","detail":"regional-approvals.ts records EU conditional 2025 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","detail":"regional-approvals.ts records EU approved 1998 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/","detail":"regional-approvals.ts records EU conditional 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","detail":"regional-approvals.ts records EU approved 1988 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","detail":"regional-approvals.ts records EU conditional 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/","detail":"regional-approvals.ts records EU conditional 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/","detail":"regional-approvals.ts records EU approved 1973 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","detail":"regional-approvals.ts records EU conditional 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","detail":"regional-approvals.ts records EU approved 2025 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tivozanib","kind":"drug","name":"Tivozanib","route":"/drugs/tivozanib/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/","detail":"regional-approvals.ts records EU approved 1996 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","detail":"regional-approvals.ts records EU approved 2000 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/","detail":"regional-approvals.ts records EU conditional 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","detail":"regional-approvals.ts records EU approved 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","detail":"regional-approvals.ts records EU approved 2025 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","detail":"regional-approvals.ts records EU conditional 2025 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"future-year-in-text","severity":"low","id":"idea-reg-pd1-biosimilar-advance-commitment","kind":"idea","name":"An advance market commitment for PD-1 biosimilars for lower-income countries","route":"/ideas/idea-reg-pd1-biosimilar-advance-commitment/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azur-1","kind":"trial","name":"AZUR-1","route":"/trials/azur-1/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","route":"/companies/c4-therapeutics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"estro","kind":"institution","name":"European Society for Radiotherapy and Oncology","route":"/institutions/estro/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/","detail":"mentions 2036 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ficerafusp-alfa","kind":"drug","name":"Ficerafusp alfa","route":"/drugs/ficerafusp-alfa/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"golseek-1","kind":"trial","name":"GOLSEEK-1","route":"/trials/golseek-1/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/","detail":"mentions 2056 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"masked-adc","kind":"technology","name":"Masked / conditionally active ADC","route":"/technologies/masked-adc/","detail":"mentions 2051 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mevpro-1","kind":"trial","name":"MEVPRO-1","route":"/trials/mevpro-1/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"personalis","kind":"company","name":"Personalis (Tempus)","route":"/companies/personalis/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idea-moon-radiotherapy-for-everyone-2040","kind":"idea","name":"Radiotherapy for everyone who needs it by 2040","route":"/ideas/idea-moon-radiotherapy-for-everyone-2040/","detail":"mentions 2040 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"senticol-iii","kind":"trial","name":"SENTICOL III","route":"/trials/senticol-iii/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tscan","kind":"company","name":"TScan Therapeutics","route":"/companies/tscan/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/","detail":"mentions 2027 (looks forward-looking)"},{"check":"name-collision-across-kinds","severity":"low","id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","detail":"\"cancer of unknown primary\" is also Primary tumour (primary-tumour, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","detail":"\"cell\" is also Cell (cell-term, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","detail":"\"cell\" is also Cell (cell, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/","detail":"\"hormonal therapy\" is also Hormone therapy (hormone-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hormone-therapy","kind":"term","name":"Hormone therapy","route":"/terms/hormone-therapy/","detail":"\"hormonal therapy\" is also Hormonal Therapy (hormonal, section); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","detail":"\"leukemia\" is also Leukemia (leukemia, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukemia","kind":"journal","name":"Leukemia","route":"/journals/leukemia/","detail":"\"leukemia\" is also Leukaemia (tissue type) (leukaemia-type, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"primary-tumour","kind":"term","name":"Primary tumour","route":"/terms/primary-tumour/","detail":"\"cancer of unknown primary\" is also Cancer of unknown primary (CUP) (cancer-of-unknown-primary, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/","detail":"\"radiation therapy\" is also Radiotherapy (radiotherapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","detail":"\"radiation therapy\" is also Radiation Therapy (radiation, section); cross-link them with `related` or merge if they describe one thing"},{"check":"orphan","severity":"low","id":"340b-program","kind":"term","name":"340B Drug Pricing Program","route":"/terms/340b-program/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"idea-moon-unproven-clinic-registry","kind":"idea","name":"A public registry of unproven cancer clinics and reported outcomes","route":"/ideas/idea-moon-unproven-clinic-registry/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-adc-review","kind":"collection","name":"ADC Review","route":"/collections/src-adc-review/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"all-of-us","kind":"collection","name":"All of Us Research Program","route":"/collections/all-of-us/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-cancer-org-asco","kind":"collection","name":"American Cancer Society (cancer.org, incl. former Cancer.Net)","route":"/collections/src-cancer-org-asco/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"annals-internal-medicine","kind":"journal","name":"Annals of Internal Medicine","route":"/journals/annals-internal-medicine/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-asco-daily-news","kind":"collection","name":"ASCO Daily News","route":"/collections/src-asco-daily-news/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"idea-moon-ban-unproven-therapy-ads","kind":"idea","name":"Ban and enforce against paid advertising of unproven cancer treatments","route":"/ideas/idea-moon-ban-unproven-therapy-ads/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-biocentury","kind":"collection","name":"BioCentury","route":"/collections/src-biocentury/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-biopharma-dive","kind":"collection","name":"BioPharma Dive","route":"/collections/src-biopharma-dive/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"blood-advances","kind":"journal","name":"Blood Advances","route":"/journals/blood-advances/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"bmj","kind":"journal","name":"BMJ","route":"/journals/bmj/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"british-journal-of-cancer","kind":"journal","name":"British Journal of Cancer","route":"/journals/british-journal-of-cancer/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"cancer-epidemiology-biomarkers-prevention","kind":"journal","name":"Cancer Epidemiology, Biomarkers & Prevention","route":"/journals/cancer-epidemiology-biomarkers-prevention/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"cancer-immunology-research","kind":"journal","name":"Cancer Immunology Research","route":"/journals/cancer-immunology-research/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-cruk-about-cancer","kind":"collection","name":"Cancer Research UK: About Cancer","route":"/collections/src-cruk-about-cancer/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-cancer-network","kind":"collection","name":"CancerNetwork (ONCOLOGY)","route":"/collections/src-cancer-network/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"cancers-mdpi","kind":"journal","name":"Cancers","route":"/journals/cancers-mdpi/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"candace-johnson","kind":"person","name":"Candace S. Johnson","route":"/people/candace-johnson/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"cell-stem-cell","kind":"journal","name":"Cell Stem Cell","route":"/journals/cell-stem-cell/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"cellfm","kind":"technology","name":"CellFM","route":"/technologies/cellfm/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"clinical-pharmacology-and-therapeutics","kind":"journal","name":"Clinical Pharmacology & Therapeutics","route":"/journals/clinical-pharmacology-and-therapeutics/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"cradle-bio","kind":"company","name":"Cradle","route":"/companies/cradle-bio/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-dimensions","kind":"collection","name":"Dimensions","route":"/collections/src-dimensions/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"elife","kind":"journal","name":"eLife","route":"/journals/elife/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-endpoints-news","kind":"collection","name":"Endpoints News","route":"/collections/src-endpoints-news/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"european-journal-of-cancer","kind":"journal","name":"European Journal of Cancer","route":"/journals/european-journal-of-cancer/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"european-urology-oncology","kind":"journal","name":"European Urology Oncology","route":"/journals/european-urology-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"idea-acc-fast-track-relicensing-oncologists","kind":"idea","name":"Fast-track relicensing for refugee, migrant and returning oncology professionals","route":"/ideas/idea-acc-fast-track-relicensing-oncologists/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-fierce-biotech","kind":"collection","name":"Fierce Biotech","route":"/collections/src-fierce-biotech/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"filippo-de-braud","kind":"person","name":"Filippo de Braud","route":"/people/filippo-de-braud/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"genes-and-development","kind":"journal","name":"Genes & Development","route":"/journals/genes-and-development/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"genesis-molecular-ai","kind":"company","name":"Genesis Molecular AI (formerly Genesis Therapeutics)","route":"/companies/genesis-molecular-ai/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"gynecologic-oncology","kind":"journal","name":"Gynecologic Oncology","route":"/journals/gynecologic-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"haematologica","kind":"journal","name":"Haematologica","route":"/journals/haematologica/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-healio-hemonc","kind":"collection","name":"Healio Hematology/Oncology","route":"/collections/src-healio-hemonc/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"icer-value-assessment","kind":"term","name":"ICER and health technology assessment","route":"/terms/icer-value-assessment/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ijrobp","kind":"journal","name":"International Journal of Radiation Oncology, Biology, Physics","route":"/journals/ijrobp/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"jama-internal-medicine","kind":"journal","name":"JAMA Internal Medicine","route":"/journals/jama-internal-medicine/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"jitc","kind":"journal","name":"Journal for ImmunoTherapy of Cancer","route":"/journals/jitc/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"jci","kind":"journal","name":"Journal of Clinical Investigation","route":"/journals/jci/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"jnccn","kind":"journal","name":"Journal of the National Comprehensive Cancer Network","route":"/journals/jnccn/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","route":"/journals/journal-of-thoracic-oncology/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"latent-labs","kind":"company","name":"Latent Labs","route":"/companies/latent-labs/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"leukemia","kind":"journal","name":"Leukemia","route":"/journals/leukemia/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-lbbc","kind":"collection","name":"Living Beyond Breast Cancer","route":"/collections/src-lbbc/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-medscape-oncology","kind":"collection","name":"Medscape Oncology","route":"/collections/src-medscape-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nature-biotechnology","kind":"journal","name":"Nature Biotechnology","route":"/journals/nature-biotechnology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nature-cancer","kind":"journal","name":"Nature Cancer","route":"/journals/nature-cancer/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nature-genetics","kind":"journal","name":"Nature Genetics","route":"/journals/nature-genetics/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nature-index","kind":"collection","name":"Nature Index – Healthcare and Cancer institutions","route":"/collections/nature-index/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nature-reviews-clinical-oncology","kind":"journal","name":"Nature Reviews Clinical Oncology","route":"/journals/nature-reviews-clinical-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nature-reviews-drug-discovery","kind":"journal","name":"Nature Reviews Drug Discovery","route":"/journals/nature-reviews-drug-discovery/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","route":"/journals/nejm-evidence/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"neuro-oncology","kind":"journal","name":"Neuro-Oncology","route":"/journals/neuro-oncology/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"newsweek-hospitals","kind":"collection","name":"Newsweek/Statista World's Best Specialized Hospitals – Oncology","route":"/collections/newsweek-hospitals/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-npj-precision-oncology","kind":"collection","name":"npj Precision Oncology","route":"/collections/src-npj-precision-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nucleotide-transformer","kind":"technology","name":"Nucleotide Transformer (InstaDeep)","route":"/technologies/nucleotide-transformer/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-onclive","kind":"collection","name":"OncLive","route":"/collections/src-onclive/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-oncodaily","kind":"collection","name":"OncoDaily","route":"/collections/src-oncodaily/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"idea-reg-single-global-dossier","kind":"idea","name":"One structured global dossier: submit the cancer drug file once, to a shared cloud","route":"/ideas/idea-reg-single-global-dossier/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"pathology-benchmarks","kind":"collection","name":"Pathology AI benchmarks (CAMELYON, PANDA, TCGA slide tasks)","route":"/collections/pathology-benchmarks/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"pediatric-blood-and-cancer","kind":"journal","name":"Pediatric Blood & Cancer","route":"/journals/pediatric-blood-and-cancer/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"plos-medicine","kind":"journal","name":"PLOS Medicine","route":"/journals/plos-medicine/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"pnas","kind":"journal","name":"Proceedings of the National Academy of Sciences","route":"/journals/pnas/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"profluent-bio","kind":"company","name":"Profluent","route":"/companies/profluent-bio/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"project-orbis","kind":"term","name":"Project Orbis","route":"/terms/project-orbis/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"idea-moon-question-prompt-lists","kind":"idea","name":"Question prompt lists sent to patients before every major consultation","route":"/ideas/idea-moon-question-prompt-lists/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"radiology","kind":"journal","name":"Radiology","route":"/journals/radiology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"radiotherapy-and-oncology","kind":"journal","name":"Radiotherapy and Oncology","route":"/journals/radiotherapy-and-oncology/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-sabcs","kind":"collection","name":"San Antonio Breast Cancer Symposium","route":"/collections/src-sabcs/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"science","kind":"journal","name":"Science","route":"/journals/science/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"scimago-oncology","kind":"collection","name":"SCImago Institutions Rankings – Oncology","route":"/collections/scimago-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-semantic-scholar","kind":"collection","name":"Semantic Scholar","route":"/collections/src-semantic-scholar/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-stat-news","kind":"collection","name":"STAT News","route":"/collections/src-stat-news/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","route":"/collections/src-targeted-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-asco-post","kind":"collection","name":"The ASCO Post","route":"/collections/src-asco-post/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-cancer-letter","kind":"collection","name":"The Cancer Letter","route":"/collections/src-cancer-letter/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"lancet-digital-health","kind":"journal","name":"The Lancet Digital Health","route":"/journals/lancet-digital-health/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"lancet-global-health","kind":"journal","name":"The Lancet Global Health","route":"/journals/lancet-global-health/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"lancet-haematology","kind":"journal","name":"The Lancet Haematology","route":"/journals/lancet-haematology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ttd","kind":"collection","name":"Therapeutic Target Database (TTD)","route":"/collections/ttd/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-tnbc-foundation","kind":"collection","name":"Triple Negative Breast Cancer Foundation","route":"/collections/src-tnbc-foundation/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"uk-biobank","kind":"collection","name":"UK Biobank","route":"/collections/uk-biobank/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"src-urotoday","kind":"collection","name":"UroToday","route":"/collections/src-urotoday/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"regional-approval-only","severity":"low","id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/","detail":"approved only outside US/EU (China 2023); status \"phase-3\" describes the global stage"},{"check":"regional-approval-only","severity":"low","id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","detail":"approved only outside US/EU (China 2024); status \"phase-3\" describes the global stage"},{"check":"regional-approval-only","severity":"low","id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","detail":"approved only outside US/EU (China 2024); status \"phase-3\" describes the global stage"},{"check":"text-says-approved","severity":"low","id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","detail":"text mentions approval but status is \"established\""},{"check":"unsourced","severity":"low","id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-mfbg-pet-replaces-mibg","kind":"idea","name":"18F-MFBG PET replacing 123I-MIBG scintigraphy","route":"/ideas/idea-mfbg-pet-replaces-mibg/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-repurposing-prize","kind":"idea","name":"A $50 million prize for the first off-patent drug proven to extend cancer survival","route":"/ideas/idea-reg-repurposing-prize/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-mced-positive-resolution-pathway","kind":"idea","name":"A 28-day national pathway for people with a positive multi-cancer blood test","route":"/ideas/idea-prev-mced-positive-resolution-pathway/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-vitamin-d-digestive-cancer-biomarker-trial","kind":"idea","name":"A biomarker-directed trial of vitamin D after surgery for digestive tract cancers","route":"/ideas/idea-reg-vitamin-d-digestive-cancer-biomarker-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-premetastatic-niche-assay","kind":"idea","name":"A blood test for the pre-metastatic niche","route":"/ideas/idea-bio2-premetastatic-niche-assay/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-brca1-denosumab-prevention","kind":"idea","name":"A bone drug to prevent breast cancer in BRCA1 carriers","route":"/ideas/idea-prev-brca1-denosumab-prevention/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-marrow-niche-on-chip","kind":"idea","name":"A bone marrow niche on a chip to study human dormancy","route":"/ideas/idea-bio2-marrow-niche-on-chip/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-breath-voc-symptomatic-ruleout","kind":"idea","name":"A breath test to rule out cancer in people with vague symptoms","route":"/ideas/idea-prev-breath-voc-symptomatic-ruleout/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-emergency-department-cancer-test","kind":"idea","name":"A cancer blood test for older people arriving at A&E with unexplained symptoms","route":"/ideas/idea-prev-emergency-department-cancer-test/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-genetic-counselling-chatbot","kind":"idea","name":"A chatbot for pre-test genetic counselling so counsellors see only who needs them","route":"/ideas/idea-prev-genetic-counselling-chatbot/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-low-dose-olanzapine-appetite","kind":"idea","name":"A cheap old tablet to restore appetite","route":"/ideas/idea-bio2-low-dose-olanzapine-appetite/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-ctdna-clone-report","kind":"idea","name":"A clone report from blood at every treatment cycle","route":"/ideas/idea-bio1-ctdna-clone-report/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-surgical-video-commons","kind":"idea","name":"A consented commons of surgical video linked to pathology and outcomes","route":"/ideas/idea-data-surgical-video-commons/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-mrd-clinic-service","kind":"idea","name":"A dedicated clinic for people whose blood test says the cancer is back","route":"/ideas/idea-bio2-mrd-clinic-service/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-global-cancer-financing-window","kind":"idea","name":"A dedicated global financing window for cancer, modelled on the Global Fund","route":"/ideas/idea-acc-global-cancer-financing-window/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-cachexia-programme","kind":"idea","name":"A dedicated programme for cachexia and treatment toxicity research","route":"/ideas/idea-fund-cachexia-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-dementia-and-cancer-pathway","kind":"idea","name":"A defined pathway for patients with both dementia and cancer","route":"/ideas/idea-acc-dementia-and-cancer-pathway/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-delinked-market-entry-reward","kind":"idea","name":"A delinked market-entry reward paid by payers when a repurposed generic wins approval","route":"/ideas/idea-reg-delinked-market-entry-reward/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-dietitian-in-every-mdt","kind":"idea","name":"A dietitian in every gastrointestinal and head and neck tumour board","route":"/ideas/idea-nl-dietitian-in-every-mdt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-72-hour-second-opinion-network","kind":"idea","name":"A digital second-opinion network answering community oncologists within 72 hours","route":"/ideas/idea-data-72-hour-second-opinion-network/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-royalty-pool-academic-assets","kind":"idea","name":"A diversified royalty pool that finances academic phase 1 trials across fifty assets","route":"/ideas/idea-fund-royalty-pool-academic-assets/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-exercise-dose-finding","kind":"idea","name":"A dose-finding trial for exercise after cancer","route":"/ideas/idea-nl-exercise-dose-finding/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-dormancy-selective-screen","kind":"idea","name":"A drug screen that only rewards killing sleeping cancer cells","route":"/ideas/idea-bio2-dormancy-selective-screen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-generic-targeted-therapy-drup","kind":"idea","name":"A DRUP-style protocol for off-label generic targeted drugs in rare tumours","route":"/ideas/idea-reg-generic-targeted-therapy-drup/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-federated-learning-consortium","kind":"idea","name":"A federated learning consortium of cancer centres that jointly own the models","route":"/ideas/idea-fund-federated-learning-consortium/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-implementation-quota","kind":"idea","name":"A fixed share of trial-group funding for getting proven care to patients","route":"/ideas/idea-fund-implementation-quota/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-prospective-retrospective-path","kind":"idea","name":"A formal regulatory route for validating a biomarker on archived trial samples","route":"/ideas/idea-tr2-prospective-retrospective-path/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-lynch-vaccine-phase3","kind":"idea","name":"A frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval","route":"/ideas/idea-moon-lynch-vaccine-phase3/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-hrd-functional-standard","kind":"idea","name":"A functional test for homologous recombination deficiency validated across laboratories","route":"/ideas/idea-tr2-hrd-functional-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-biomarker-validation-fund","kind":"idea","name":"A fund for prospective validation of academic biomarkers and companion diagnostics","route":"/ideas/idea-fund-biomarker-validation-fund/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-funded-second-opinion","kind":"idea","name":"A funded expert second opinion for every new high-stakes or rare cancer diagnosis","route":"/ideas/idea-moon-funded-second-opinion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-organ-preservation-programme","kind":"idea","name":"A funded programme of organ-preservation trials to avoid radical surgery","route":"/ideas/idea-fund-organ-preservation-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-negative-results-journal","kind":"idea","name":"A funder-backed, indexed journal of negative and inconclusive cancer results","route":"/ideas/idea-tr2-negative-results-journal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-federated-rwe-network","kind":"idea","name":"A global federated real-world evidence network at regulatory grade","route":"/ideas/idea-moon-federated-rwe-network/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-global-academic-phase-one-network","kind":"idea","name":"A global first-in-human network for academic cancer trials with single ethics review","route":"/ideas/idea-fund-global-academic-phase-one-network/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-negative-results-ledger","kind":"idea","name":"A global ledger of negative results and failed compounds with mandatory deposition","route":"/ideas/idea-moon-negative-results-ledger/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-isotope-supply-observatory","kind":"idea","name":"A global medical isotope supply observatory with forecasts and shortage alerts","route":"/ideas/idea-reg-isotope-supply-observatory/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-undruggable-market-commitment","kind":"idea","name":"A guaranteed purchase prize for the first drug against a named hard target","route":"/ideas/idea-bio1-undruggable-market-commitment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-guideline-fast-track-repurposed","kind":"idea","name":"A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer","route":"/ideas/idea-reg-guideline-fast-track-repurposed/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-literacy-first-design-standard","kind":"idea","name":"A health-literacy certification standard for oncology portals, letters and apps","route":"/ideas/idea-moon-literacy-first-design-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-negative-preclinical-repository","kind":"idea","name":"A home for the animal and organoid experiments that failed","route":"/ideas/idea-bio1-negative-preclinical-repository/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-middle-income-negotiation-bloc","kind":"idea","name":"A joint price negotiation bloc for middle-income countries, modelled on Beneluxa","route":"/ideas/idea-reg-middle-income-negotiation-bloc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-ai-liability-safe-harbour","kind":"idea","name":"A liability framework for clinical AI: safe harbour for clinicians, liability for makers","route":"/ideas/idea-data-ai-liability-safe-harbour/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-adult-late-effects-registry","kind":"idea","name":"A lifelong late-effects registry linked to every treatment for adult survivors","route":"/ideas/idea-moon-adult-late-effects-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-live-trial-slot-api","kind":"idea","name":"A live 'seats available' feed for trial slots, like airline inventory","route":"/ideas/idea-tr1-live-trial-slot-api/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-live-stage-dashboard","kind":"idea","name":"A live national dashboard of stage at diagnosis as the scorecard for early detection","route":"/ideas/idea-prev-live-stage-dashboard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-chemo-stockout-early-warning","kind":"idea","name":"A live stock-out map for essential chemotherapy drugs","route":"/ideas/idea-acc-chemo-stockout-early-warning/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-failure-taxonomy","kind":"idea","name":"A machine-readable taxonomy of why cancer drugs fail","route":"/ideas/idea-tr2-failure-taxonomy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-portable-treatment-summary","kind":"idea","name":"A machine-readable treatment summary handed to every patient and readable by any hospital","route":"/ideas/idea-acc-portable-treatment-summary/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-mced-pretest-decision-aid","kind":"idea","name":"A mandatory decision aid before any multi-cancer blood test","route":"/ideas/idea-prev-mced-pretest-decision-aid/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-silent-trial-before-deployment","kind":"idea","name":"A mandatory silent (shadow) trial before any cancer AI goes live","route":"/ideas/idea-data-silent-trial-before-deployment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-tumour-board-trial-line-item","kind":"idea","name":"A mandatory trial line in every tumour board recommendation","route":"/ideas/idea-tr1-tumour-board-trial-line-item/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-living-llm-oncology-benchmark","kind":"idea","name":"A monthly-updated benchmark for AI answers to oncology questions with citation accuracy","route":"/ideas/idea-data-living-llm-oncology-benchmark/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-national-late-effects-registry","kind":"idea","name":"A national late-effects registry linking treatment exposures to outcomes decades later","route":"/ideas/idea-acc-national-late-effects-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-public-nonprofit-cro","kind":"idea","name":"A national non-profit contract research organisation for academic oncology trials","route":"/ideas/idea-fund-public-nonprofit-cro/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-national-mrd-platform","kind":"idea","name":"A national platform trial that every ctDNA-positive patient can join","route":"/ideas/idea-bio2-national-mrd-platform/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-radiotherapy-dose-repository","kind":"idea","name":"A national repository of radiotherapy dose plans linked to outcomes","route":"/ideas/idea-data-radiotherapy-dose-repository/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-mrd-weather-service","kind":"idea","name":"A national residual-disease weather service: serial blood tests for every curatively treated patient, pooled","route":"/ideas/idea-moon-mrd-weather-service/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-rt-io-platform","kind":"idea","name":"A neutral platform trial for radiotherapy plus immunotherapy combinations","route":"/ideas/idea-fund-rt-io-platform/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-neutral-ai-evaluator","kind":"idea","name":"A neutral public evaluator for cancer AI, on the model of NIST","route":"/ideas/idea-data-neutral-ai-evaluator/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-manufacturing-slot-exchange","kind":"idea","name":"A neutral slot exchange so unused CAR-T manufacturing slots go to the next patient","route":"/ideas/idea-reg-manufacturing-slot-exchange/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-nonprofit-marketing-authorisation-holder","kind":"idea","name":"A non-profit company to hold marketing authorisations for repurposed cancer drugs","route":"/ideas/idea-reg-nonprofit-marketing-authorisation-holder/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-combination-utility","kind":"idea","name":"A non-profit phase 1b combination unit that any drug owner can use","route":"/ideas/idea-tr2-combination-utility/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-paediatric-palliative-in-every-childhood-unit","kind":"idea","name":"A paediatric palliative care team in every childhood cancer unit","route":"/ideas/idea-acc-paediatric-palliative-in-every-childhood-unit/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-funded-navigator-per-diagnosis","kind":"idea","name":"A paid patient navigator for every new cancer diagnosis, reimbursed as a service","route":"/ideas/idea-acc-funded-navigator-per-diagnosis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-combination-patent-pool","kind":"idea","name":"A patent pool for combination method-of-use claims","route":"/ideas/idea-tr2-combination-patent-pool/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-supportive-care-platform-trial","kind":"idea","name":"A permanent platform trial for supportive-care interventions inside cooperative groups","route":"/ideas/idea-moon-supportive-care-platform-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-phase-zero-fund","kind":"idea","name":"A phase 0 fund to test academic compounds in humans with microdoses and imaging","route":"/ideas/idea-fund-phase-zero-fund/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-patient-explainers-per-recommendation","kind":"idea","name":"A plain-language explainer for every guideline recommendation, in every major language","route":"/ideas/idea-data-patient-explainers-per-recommendation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-metronomic-lmic-platform-trial","kind":"idea","name":"A platform trial of very-low-cost metronomic chemotherapy in LMIC common cancers","route":"/ideas/idea-acc-metronomic-lmic-platform-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-intraoperative-imaging-trials","kind":"idea","name":"A pragmatic trial network for intraoperative margin tools, paid on margin reduction","route":"/ideas/idea-fund-intraoperative-imaging-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-statin-hcc-prevention-trial","kind":"idea","name":"A pragmatic trial of statins to prevent liver cancer in people with cirrhosis","route":"/ideas/idea-reg-statin-hcc-prevention-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-precompetitive-cancer-foundation-model","kind":"idea","name":"A pre-competitive consortium to train a shared multimodal cancer foundation model","route":"/ideas/idea-data-precompetitive-cancer-foundation-model/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-neuropathy-prevention-programme","kind":"idea","name":"A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression","route":"/ideas/idea-moon-neuropathy-prevention-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-standard-of-care-api","kind":"idea","name":"A public API serving the current standard of care for any cancer, stage and biomarker","route":"/ideas/idea-data-standard-of-care-api/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-ai-cancer-answer-audit","kind":"idea","name":"A public benchmark and audit of chatbot answers to cancer questions","route":"/ideas/idea-moon-ai-cancer-answer-audit/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-biomarker-validation-utility","kind":"idea","name":"A public biomarker validation utility with pre-diagnostic biobanks and blinded testing","route":"/ideas/idea-moon-biomarker-validation-utility/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-site-equity-index","kind":"idea","name":"A public equity index for trial sites and sponsors, tied to funding","route":"/ideas/idea-tr1-site-equity-index/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-generics-for-cancer-fund","kind":"idea","name":"A public fund and label pathway to trial generic drugs against cancer","route":"/ideas/idea-moon-generics-for-cancer-fund/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-academic-sponsor-indemnity-pool","kind":"idea","name":"A public indemnity pool so universities can sponsor first-in-human cancer trials","route":"/ideas/idea-fund-academic-sponsor-indemnity-pool/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-label-divergence-index","kind":"idea","name":"A public index of how the same cancer drug's label differs between countries","route":"/ideas/idea-reg-label-divergence-index/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-trial-desert-map","kind":"idea","name":"A public map of trial deserts to steer where new sites open","route":"/ideas/idea-tr1-trial-desert-map/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-reversal-registry","kind":"idea","name":"A public registry of cancer treatments that were later shown not to work","route":"/ideas/idea-tr2-reversal-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-unproven-clinic-registry","kind":"idea","name":"A public registry of unproven cancer clinics and reported outcomes","route":"/ideas/idea-moon-unproven-clinic-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-evidence-to-adoption-tracker","kind":"idea","name":"A public tracker of how long each country takes to adopt new evidence","route":"/ideas/idea-data-evidence-to-adoption-tracker/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-public-phase1-factory","kind":"idea","name":"A public-benefit phase 1 factory that takes academic discoveries into first-in-human trials","route":"/ideas/idea-moon-public-phase1-factory/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-lynch-frameshift-vaccine-rct","kind":"idea","name":"A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers","route":"/ideas/idea-prev-lynch-frameshift-vaccine-rct/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-llm-documentation-rct-oncology","kind":"idea","name":"A randomised trial of AI scribes in oncology clinics measuring errors and time","route":"/ideas/idea-data-llm-documentation-rct-oncology/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-ai-vs-tumour-board-rct","kind":"idea","name":"A randomised trial of AI-generated treatment recommendations versus tumour boards","route":"/ideas/idea-data-ai-vs-tumour-board-rct/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-sequencing-analysis-per-approval","kind":"idea","name":"A real-world sequencing analysis within a year of every new approval","route":"/ideas/idea-data-sequencing-analysis-per-approval/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-preclinical-negative-registry","kind":"idea","name":"A registry for preclinical experiments that did not work","route":"/ideas/idea-tr2-preclinical-negative-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-sequence-registry","kind":"idea","name":"A registry of every treatment sequence patients actually receive, with outcomes","route":"/ideas/idea-tr2-sequence-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-ai-external-validation-registry","kind":"idea","name":"A registry of external validation datasets for cancer AI models, with mandatory reporting","route":"/ideas/idea-tr2-ai-external-validation-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-diagnostic-reliance-pathway","kind":"idea","name":"A reliance pathway for companion diagnostics so the test arrives with the drug","route":"/ideas/idea-reg-diagnostic-reliance-pathway/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-repurposing-indication-exclusivity","kind":"idea","name":"A repurposing label pathway with short exclusivity that non-profits can hold","route":"/ideas/idea-fund-repurposing-indication-exclusivity/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-risk-stratified-cardio-oncology-pathway","kind":"idea","name":"A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy","route":"/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-rare-cancer-telepathology-network","kind":"idea","name":"A same-week expert second opinion for every rare cancer diagnosis","route":"/ideas/idea-bio2-rare-cancer-telepathology-network/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-shared-ai-review-assistant","kind":"idea","name":"A shared AI review assistant that maps one dossier to every regulator's questions","route":"/ideas/idea-reg-shared-ai-review-assistant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-shared-compound-access-pool","kind":"idea","name":"A shared compound library that rare cancer researchers can actually use","route":"/ideas/idea-bio2-shared-compound-access-pool/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-window-of-opportunity-default","kind":"idea","name":"A short pre-surgery drug window as the default early test of new agents","route":"/ideas/idea-tr1-window-of-opportunity-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-bundled-cancer-check-at-60","kind":"idea","name":"A single 'cancer check at 60' appointment bundling all screening tests","route":"/ideas/idea-prev-bundled-cancer-check-at-60/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-implanted-ultrasound-repeat-dosing","kind":"idea","name":"A skull ultrasound implant that opens the barrier at every cycle","route":"/ideas/idea-bio2-implanted-ultrasound-repeat-dosing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-repurposing-social-impact-bond","kind":"idea","name":"A social impact bond: investors fund a repurposing trial, payers repay from savings","route":"/ideas/idea-reg-repurposing-social-impact-bond/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-ai-pathology-evaluation-standard","kind":"idea","name":"A standard evaluation pathway for AI-assisted pathology, from reader study to deployment","route":"/ideas/idea-data-ai-pathology-evaluation-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-evolvability-index","kind":"idea","name":"A standard evolvability score for every tumour","route":"/ideas/idea-bio1-evolvability-index/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-drift-monitoring-standard","kind":"idea","name":"A standard for monitoring AI performance drift with pause thresholds","route":"/ideas/idea-data-drift-monitoring-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-tumour-agnostic-approval-standard","kind":"idea","name":"A standard for tumour-agnostic approvals: minimum histologies and hierarchical modelling","route":"/ideas/idea-tr1-tumour-agnostic-approval-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-transition-handoff-medication-reconciliation","kind":"idea","name":"A standard handoff with medication reconciliation at every cancer care transition","route":"/ideas/idea-acc-transition-handoff-medication-reconciliation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-brain-delivery-platform","kind":"idea","name":"A standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics","route":"/ideas/idea-moon-brain-delivery-platform/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-resistance-platform-trial","kind":"idea","name":"A standing platform trial that assigns treatment by how the tumour escaped","route":"/ideas/idea-bio1-resistance-platform-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-non-drug-trial-quota","kind":"idea","name":"A statutory minimum share of public trial money for surgery and radiotherapy","route":"/ideas/idea-fund-non-drug-trial-quota/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-generic-chemo-strategic-reserve","kind":"idea","name":"A strategic reserve of essential generic cancer drugs to end recurring shortages","route":"/ideas/idea-reg-generic-chemo-strategic-reserve/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-treatment-refusal-pathway","kind":"idea","name":"A structured pathway for patients declining proven treatment","route":"/ideas/idea-moon-treatment-refusal-pathway/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-survivor-biobank-late-effect-prediction","kind":"idea","name":"A survivor biobank to find who will develop late effects before they do","route":"/ideas/idea-acc-survivor-biobank-late-effect-prediction/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-aya-survivorship-passport","kind":"idea","name":"A survivorship passport app for adolescent and young adult survivors","route":"/ideas/idea-acc-aya-survivorship-passport/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-survivorship-endowment-levy","kind":"idea","name":"A survivorship research endowment funded by a levy on curative therapy prices","route":"/ideas/idea-fund-survivorship-endowment-levy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-capsule-sponge-pharmacy","kind":"idea","name":"A swallowable sponge test for reflux patients, offered in pharmacies","route":"/ideas/idea-prev-capsule-sponge-pharmacy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-lmic-five-cancer-methylation-test","kind":"idea","name":"A ten-dollar blood test for the five cancers that kill most people in poorer countries","route":"/ideas/idea-prev-lmic-five-cancer-methylation-test/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-incidentaloma-natural-history-cohort","kind":"idea","name":"A ten-year cohort of incidental findings to calibrate follow-up guidelines","route":"/ideas/idea-prev-incidentaloma-natural-history-cohort/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-oligometastatic-signature","kind":"idea","name":"A test to tell true oligometastatic disease from hidden widespread spread","route":"/ideas/idea-bio2-oligometastatic-signature/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-therapeutic-hpv-vaccine-cin","kind":"idea","name":"A therapeutic vaccine to clear cervical precancer without surgery","route":"/ideas/idea-prev-therapeutic-hpv-vaccine-cin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-device-and-technique-translation-fund","kind":"idea","name":"A translation fund for academic surgical devices and radiotherapy technology","route":"/ideas/idea-fund-device-and-technique-translation-fund/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-glp1-cancer-prevention-rct","kind":"idea","name":"A trial of GLP-1 weight-loss drugs with cancer as the primary outcome","route":"/ideas/idea-prev-glp1-cancer-prevention-rct/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-older-patients-trial-fund","kind":"idea","name":"A trials fund reserved for older and multimorbid patients","route":"/ideas/idea-fund-older-patients-trial-fund/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-tumour-board-evidence-assistant","kind":"idea","name":"A tumour board assistant that cites its evidence and tracks outcomes","route":"/ideas/idea-data-tumour-board-evidence-assistant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-urine-dna-haematuria-triage","kind":"idea","name":"A urine DNA test to decide who with blood in the urine needs a camera test","route":"/ideas/idea-prev-urine-dna-haematuria-triage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-hpylori-childhood-vaccine","kind":"idea","name":"A vaccine against H. pylori for children in high-risk regions","route":"/ideas/idea-prev-hpylori-childhood-vaccine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-surgical-video-registry","kind":"idea","name":"A video-based surgical quality registry linking assessed skill to cancer outcomes","route":"/ideas/idea-fund-surgical-video-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-virtual-cell-perturbation","kind":"idea","name":"A virtual cancer cell that predicts what a drug will do before you test it","route":"/ideas/idea-bio1-virtual-cell-perturbation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-blood-precursor-watch-registry","kind":"idea","name":"A watch-and-wait registry for blood precursor conditions found by chance","route":"/ideas/idea-prev-blood-precursor-watch-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-population-interception","kind":"idea","name":"A whole-population cancer interception programme: risk-stratify every adult, detect and intercept early","route":"/ideas/idea-moon-population-interception/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"keith-stewart","kind":"person","name":"A. Keith Stewart","route":"/people/keith-stewart/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"aaron-schimmer","kind":"person","name":"Aaron D. Schimmer","route":"/people/aaron-schimmer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hydrazone","kind":"term","name":"Acid-labile hydrazone (AcBut)","route":"/terms/hydrazone/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-ptmc-active-surveillance-default","kind":"idea","name":"Active surveillance as the default for tiny papillary thyroid cancers","route":"/ideas/idea-prev-ptmc-active-surveillance-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"active-surveillance-thyroid","kind":"technology","name":"Active surveillance of papillary microcarcinoma","route":"/technologies/active-surveillance-thyroid/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-acute-oncology-assessment-units","kind":"idea","name":"Acute oncology assessment units so sick cancer patients bypass the emergency department","route":"/ideas/idea-acc-acute-oncology-assessment-units/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"adc-plus-io","kind":"pairing","name":"ADC + checkpoint inhibitor","route":"/pairings/adc-plus-io/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"adc-cdmo-manufacturing","kind":"technology","name":"ADC bioconjugation manufacturing (CDMOs)","route":"/technologies/adc-cdmo-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-post-neoadjuvant-adc","kind":"idea","name":"ADC for residual disease after KEYNOTE-522","route":"/ideas/idea-post-neoadjuvant-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"adc-generations","kind":"roadmap","name":"ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs","route":"/roadmaps/adc-generations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"adc-sequencing","kind":"term","name":"ADC sequencing","route":"/terms/adc-sequencing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-factorial-addon-arms-cooperative-trials","kind":"idea","name":"Add a cheap-drug factorial arm to every cooperative-group adjuvant cancer trial","route":"/ideas/idea-reg-factorial-addon-arms-cooperative-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-molecular-progression-add-on","kind":"idea","name":"Add a drug when the blood test turns, without stopping the one that works","route":"/ideas/idea-bio1-molecular-progression-add-on/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-upfront-bypass-combination","kind":"idea","name":"Add the second drug on day one when the escape route is predictable","route":"/ideas/idea-bio1-upfront-bypass-combination/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-tumour-agnostic-reliance","kind":"idea","name":"Adopt tumour-agnostic cancer drug labels across regions by reliance, not re-review","route":"/ideas/idea-reg-tumour-agnostic-reliance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"adrian-krainer","kind":"person","name":"Adrian R. Krainer","route":"/people/adrian-krainer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-advanced-practice-radiation-therapists","kind":"idea","name":"Advanced-practice radiation therapists doing contouring and on-treatment reviews","route":"/ideas/idea-acc-advanced-practice-radiation-therapists/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-low-risk-dcis-surveillance-pathway","kind":"idea","name":"After the COMET trial: surveillance pathways and a new name for low-risk DCIS","route":"/ideas/idea-prev-low-risk-dcis-surveillance-pathway/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-aggregated-n-of-1-supportive-care","kind":"idea","name":"Aggregated single-patient crossover trials for symptom and supportive treatments","route":"/ideas/idea-tr1-aggregated-n-of-1-supportive-care/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-bayesian-borrowing-acceptance","kind":"idea","name":"Agree in advance how to borrow evidence between similar rare cancers","route":"/ideas/idea-bio2-bayesian-borrowing-acceptance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"auto-contouring-ai","kind":"technology","name":"AI auto-contouring and adaptive planning","route":"/technologies/auto-contouring-ai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-ldct-ai-negative-triage","kind":"idea","name":"AI clears the normal lung screening scans so radiologists read only the suspicious ones","route":"/ideas/idea-prev-ldct-ai-negative-triage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ai-compute-platforms","kind":"technology","name":"AI compute and model platforms for oncology","route":"/technologies/ai-compute-platforms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ai-oncology-clinic","kind":"roadmap","name":"AI in the oncology clinic: from narrow cleared tools to multimodal decision support","route":"/roadmaps/ai-oncology-clinic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-lung-nodule-ai-discharge","kind":"idea","name":"AI malignancy scores to end repeat scans and biopsies for benign lung nodules","route":"/ideas/idea-prev-lung-nodule-ai-discharge/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ai-pathology-to-adt","kind":"pairing","name":"AI pathology → androgen deprivation duration","route":"/pairings/ai-pathology-to-adt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-ai-her2-low-scoring","kind":"idea","name":"AI quantification of HER2-low and HER2-ultralow","route":"/ideas/idea-ai-her2-low-scoring/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-pathology-ai-borderline-anchor","kind":"idea","name":"AI second reads to stop borderline lesions being upgraded to cancer","route":"/ideas/idea-prev-pathology-ai-borderline-anchor/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-pancreas-ai-prediagnostic-ct","kind":"idea","name":"AI that spots pancreatic cancer on scans taken a year before diagnosis","route":"/ideas/idea-prev-pancreas-ai-prediagnostic-ct/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-ai-central-imaging-reads","kind":"idea","name":"AI-assisted central imaging reads to cut endpoint cost and variability","route":"/ideas/idea-tr1-ai-central-imaging-reads/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-ai-binders-disordered-regions","kind":"idea","name":"AI-designed proteins that grip the floppy parts of cancer drivers","route":"/ideas/idea-bio1-ai-binders-disordered-regions/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-ai-first-pathology-common-cases","kind":"idea","name":"AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions","route":"/ideas/idea-acc-ai-first-pathology-common-cases/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ak146d1","kind":"drug","name":"AK146D1","route":"/drugs/ak146d1/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alessandro-gronchi","kind":"person","name":"Alessandro Gronchi","route":"/people/alessandro-gronchi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alexander-eggermont","kind":"person","name":"Alexander Eggermont","route":"/people/alexander-eggermont/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-goals-conversation-trigger","kind":"idea","name":"Algorithm-triggered goals-of-care conversations before crisis","route":"/ideas/idea-moon-goals-conversation-trigger/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"allogeneic-cell-banking","kind":"technology","name":"Allogeneic donor and iPSC master cell banks","route":"/technologies/allogeneic-cell-banking/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-alpha-first-mhspc","kind":"idea","name":"Alpha-emitting PSMA therapy at first metastatic diagnosis","route":"/ideas/idea-alpha-first-mhspc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-ambient-ai-documentation-oncology","kind":"idea","name":"Ambient AI note-taking to give oncologists back a day a week","route":"/ideas/idea-acc-ambient-ai-documentation-oncology/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"amivantamab-plus-lazertinib","kind":"pairing","name":"Amivantamab + lazertinib (first-line EGFR NSCLC)","route":"/pairings/amivantamab-plus-lazertinib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-clinical-officer-oncology-track","kind":"idea","name":"An 18-month oncology track for clinical officers and physician associates","route":"/ideas/idea-acc-clinical-officer-oncology-track/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-abbreviated-pathway-me-too-biologics","kind":"idea","name":"An abbreviated approval path for follow-on antibodies within a validated class","route":"/ideas/idea-fund-abbreviated-pathway-me-too-biologics/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-pd1-biosimilar-advance-commitment","kind":"idea","name":"An advance market commitment for PD-1 biosimilars for lower-income countries","route":"/ideas/idea-reg-pd1-biosimilar-advance-commitment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-antitrust-safe-harbour","kind":"idea","name":"An antitrust safe harbour for cross-company combination trials and data pooling","route":"/ideas/idea-fund-antitrust-safe-harbour/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-universal-asynchronous-second-opinion","kind":"idea","name":"An asynchronous expert second opinion for every new advanced-cancer diagnosis","route":"/ideas/idea-acc-universal-asynchronous-second-opinion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-target-trial-emulation-pipeline","kind":"idea","name":"An automated pipeline emulating trials of every common drug against every cancer","route":"/ideas/idea-reg-target-trial-emulation-pipeline/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-electronic-frailty-index-oncology","kind":"idea","name":"An automatic electronic frailty index inside the oncology record","route":"/ideas/idea-acc-electronic-frailty-index-oncology/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-ebv-vaccine","kind":"idea","name":"An Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomas","route":"/ideas/idea-prev-ebv-vaccine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-surgical-ai-robotics-evaluation","kind":"idea","name":"An independent evaluation unit for surgical robots and AI, paid on evidence","route":"/ideas/idea-fund-surgical-ai-robotics-evaluation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-hype-index","kind":"idea","name":"An independent hype index grading cancer press releases and news stories","route":"/ideas/idea-moon-hype-index/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-independent-replication-institute","kind":"idea","name":"An independent replication institute that re-tests key preclinical cancer findings before trials","route":"/ideas/idea-moon-independent-replication-institute/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-indolent-lesion-nomenclature-body","kind":"idea","name":"An international body to rename indolent lesions so 'cancer' means something","route":"/ideas/idea-prev-indolent-lesion-nomenclature-body/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-paediatric-rwe-consortium","kind":"idea","name":"An international consortium pooling the outcome of every treated child with cancer","route":"/ideas/idea-data-paediatric-rwe-consortium/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-net-price-transparency-registry","kind":"idea","name":"An international registry of real (net) cancer drug prices paid by public payers","route":"/ideas/idea-reg-net-price-transparency-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-collateral-sensitivity-atlas","kind":"idea","name":"An open atlas of collateral sensitivity for every approved targeted drug","route":"/ideas/idea-bio1-collateral-sensitivity-atlas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-combination-forecast-tournament","kind":"idea","name":"An open forecasting tournament on which combination trials will succeed","route":"/ideas/idea-tr2-combination-forecast-tournament/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-open-oncology-workforce-model","kind":"idea","name":"An open global model of cancer workforce supply and demand by country","route":"/ideas/idea-acc-open-oncology-workforce-model/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-closed-manufacturing-interop-standard","kind":"idea","name":"An open interoperability standard for closed automated cell-processing machines","route":"/ideas/idea-reg-closed-manufacturing-interop-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-rwe-rct-calibration-library","kind":"idea","name":"An open library pairing completed cancer trials with real-world emulations","route":"/ideas/idea-data-rwe-rct-calibration-library/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-covalent-ligandability-atlas","kind":"idea","name":"An open map of which cancer proteins any drug can stick to","route":"/ideas/idea-bio1-covalent-ligandability-atlas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-rare-tumour-model-bank","kind":"idea","name":"An open model bank for the rare tumours nobody has models for","route":"/ideas/idea-bio2-rare-tumour-model-bank/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-rare-cancer-organoid-bank","kind":"idea","name":"An open organoid bank for cancers too rare to have models","route":"/ideas/idea-bio1-rare-cancer-organoid-bank/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-supplement-interaction-database","kind":"idea","name":"An open supplement-drug interaction checker built into oncology prescribing","route":"/ideas/idea-moon-supplement-interaction-database/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-organotropism-atlas","kind":"idea","name":"An organotropism atlas that predicts where a cancer will spread","route":"/ideas/idea-bio2-organotropism-atlas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-sex-stratified-pk-and-dosing","kind":"idea","name":"Analyse and dose by sex: women get more toxicity from many cancer drugs at the same dose","route":"/ideas/idea-tr1-sex-stratified-pk-and-dosing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ananya-choudhury","kind":"person","name":"Ananya Choudhury","route":"/people/ananya-choudhury/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-tumour-anchored-tgfbeta-trap","kind":"idea","name":"Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere","route":"/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ilbawi-andre","kind":"person","name":"André Ilbawi","route":"/people/ilbawi-andre/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andreas-trumpp","kind":"person","name":"Andreas Trumpp","route":"/people/andreas-trumpp/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andreas-von-deimling","kind":"person","name":"Andreas von Deimling","route":"/people/andreas-von-deimling/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andres-cervantes","kind":"person","name":"Andrés Cervantes","route":"/people/andres-cervantes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrew-aguirre","kind":"person","name":"Andrew J. Aguirre","route":"/people/andrew-aguirre/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrew-tutt","kind":"person","name":"Andrew Tutt","route":"/people/andrew-tutt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrew-wardley","kind":"person","name":"Andrew Wardley","route":"/people/andrew-wardley/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"angela-demichele","kind":"person","name":"Angela DeMichele","route":"/people/angela-demichele/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"angelika-eggert","kind":"person","name":"Angelika Eggert","route":"/people/angelika-eggert/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"anitocabtagene-autoleucel","kind":"drug","name":"Anitocabtagene autoleucel","route":"/drugs/anitocabtagene-autoleucel/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ann-partridge","kind":"person","name":"Ann H. Partridge","route":"/people/ann-partridge/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"anna-fagotti","kind":"person","name":"Anna Fagotti","route":"/people/anna-fagotti/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"anthony-goncalves","kind":"person","name":"Anthony Gonçalves","route":"/people/anthony-goncalves/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"anthony-letai","kind":"person","name":"Anthony Letai","route":"/people/anthony-letai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"anti-egfr-left-sided","kind":"pairing","name":"Anti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC","route":"/pairings/anti-egfr-left-sided/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"anti-gd2-plus-chemo-relapse","kind":"pairing","name":"Anti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)","route":"/pairings/anti-gd2-plus-chemo-relapse/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-hpylori-stool-resistance-guided","kind":"idea","name":"Antibiotic-resistance testing from a stool sample before treating H. pylori","route":"/ideas/idea-prev-hpylori-stool-resistance-guided/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-pmhc-bispecifics-public-drivers","kind":"idea","name":"Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface","route":"/ideas/idea-bio1-pmhc-bispecifics-public-drivers/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"monoclonal-antibody-manufacturing","kind":"technology","name":"Antibody manufacturing (CHO bioprocessing)","route":"/technologies/monoclonal-antibody-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"apheresis-starting-material","kind":"technology","name":"Apheresis and starting-material collection","route":"/technologies/apheresis-starting-material/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"artera-ai-breast","kind":"drug","name":"ArteraAI Breast","route":"/drugs/artera-ai-breast/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"artera-ai-prostate","kind":"drug","name":"ArteraAI Prostate","route":"/drugs/artera-ai-prostate/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"katz-artur","kind":"person","name":"Artur Katz","route":"/people/katz-artur/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","route":"/people/arul-chinnaiyan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"arx788","kind":"drug","name":"ARX788","route":"/drugs/arx788/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-ask-about-diet-prebunking","kind":"idea","name":"Ask about diet at diagnosis, and prebunk the myths before the internet does","route":"/ideas/idea-nl-ask-about-diet-prebunking/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"atirmociclib","kind":"drug","name":"Atirmociclib","route":"/drugs/atirmociclib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-ecdna-targeting","kind":"idea","name":"Attack extrachromosomal DNA, the engine of oncogene amplification","route":"/ideas/idea-ecdna-targeting/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-paralog-synthetic-lethality","kind":"idea","name":"Attack the backup copy when a tumour has lost the original gene","route":"/ideas/idea-bio1-paralog-synthetic-lethality/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-tumour-board-implementation-audit","kind":"idea","name":"Audit whether tumour board recommendations were actually carried out","route":"/ideas/idea-acc-tumour-board-implementation-audit/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"aurelien-marabelle","kind":"person","name":"Aurélien Marabelle","route":"/people/aurelien-marabelle/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-automated-combination-discovery","kind":"idea","name":"Automated combination discovery: patient-sample screens feeding Bayesian platform trials","route":"/ideas/idea-moon-automated-combination-discovery/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-reflex-germline-testing","kind":"idea","name":"Automatic germline testing for every cancer type where it changes care","route":"/ideas/idea-prev-reflex-germline-testing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-shelved-asset-escrow","kind":"idea","name":"Automatic offer of shelved cancer assets to non-profits after two years","route":"/ideas/idea-fund-shelved-asset-escrow/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-market-expansion-repricing","kind":"idea","name":"Automatic price cuts when a cancer drug's approved indications and volumes expand","route":"/ideas/idea-reg-market-expansion-repricing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-orphan-designation-reciprocity","kind":"idea","name":"Automatic reciprocity of orphan and rare-paediatric designations between regulators","route":"/ideas/idea-reg-orphan-designation-reciprocity/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-closed-loop-adaptive-therapy","kind":"idea","name":"Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models","route":"/ideas/idea-moon-closed-loop-adaptive-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-ban-unproven-therapy-ads","kind":"idea","name":"Ban and enforce against paid advertising of unproven cancer treatments","route":"/ideas/idea-moon-ban-unproven-therapy-ads/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-commercial-sunbed-ban","kind":"idea","name":"Ban commercial sunbeds","route":"/ideas/idea-prev-commercial-sunbed-ban/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-genetic-non-discrimination-insurance","kind":"idea","name":"Ban life and disability insurers from using genetic results","route":"/ideas/idea-prev-genetic-non-discrimination-insurance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-survivor-plasma-biobank","kind":"idea","name":"Bank yearly blood from cancer survivors so future tests can be validated","route":"/ideas/idea-bio2-survivor-plasma-biobank/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-reagent-lot-ledger","kind":"idea","name":"Barcode every reagent lot so batch effects can be traced across experiments and labs","route":"/ideas/idea-tr2-reagent-lot-ledger/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-barcoded-avatars-clonal-fitness","kind":"idea","name":"Barcode patient-derived tumours to watch which clones win under each drug","route":"/ideas/idea-bio1-barcoded-avatars-clonal-fitness/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-shrinkage-subgroup-analysis","kind":"idea","name":"Bayesian shrinkage for subgroup claims to stop false 'works in this group' stories","route":"/ideas/idea-tr1-shrinkage-subgroup-analysis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bcg-unresponsive","kind":"term","name":"BCG-unresponsive","route":"/terms/bcg-unresponsive/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bcma-then-gprc5d","kind":"pairing","name":"BCMA-directed therapy → GPRC5D-directed therapy","route":"/pairings/bcma-then-gprc5d/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tki-plus-blinatumomab-ph-all","kind":"pairing","name":"BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)","route":"/pairings/tki-plus-blinatumomab-ph-all/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"beatriz-castelo","kind":"person","name":"Beatriz Castelo","route":"/people/beatriz-castelo/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"benjamin-besse","kind":"person","name":"Benjamin Besse","route":"/people/benjamin-besse/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"solomon-benjamin","kind":"person","name":"Benjamin Solomon","route":"/people/solomon-benjamin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"beta-then-alpha","kind":"pairing","name":"Beta radioligand → alpha radioligand","route":"/pairings/beta-then-alpha/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bethesda-category","kind":"term","name":"Bethesda category (thyroid cytology)","route":"/terms/bethesda-category/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"biobanking","kind":"technology","name":"Biobanking and tissue procurement","route":"/technologies/biobanking/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-biomarker-quadruplet-gastric","kind":"idea","name":"Biomarker-directed first-line quadruplets in gastric cancer","route":"/ideas/idea-biomarker-quadruplet-gastric/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-cardioprotection-by-default","kind":"idea","name":"Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy","route":"/ideas/idea-moon-cardioprotection-by-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-adjuvant-selection-rcc","kind":"idea","name":"Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)","route":"/ideas/idea-adjuvant-selection-rcc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-outlier-lesion-biopsy","kind":"idea","name":"Biopsy the one lesion that is growing while the others shrink","route":"/ideas/idea-bio1-outlier-lesion-biopsy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"biosecure-act","kind":"term","name":"BIOSECURE Act","route":"/terms/biosecure-act/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-biosimilar-first-default-switching","kind":"idea","name":"Biosimilar-first defaults and payment parity in every cancer day unit","route":"/ideas/idea-reg-biosimilar-first-default-switching/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-myeloid-engager-bispecific","kind":"idea","name":"Bispecific antibodies that engage macrophages instead of T cells","route":"/ideas/idea-bio2-myeloid-engager-bispecific/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bladder-preservation-mibc","kind":"idea","name":"Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response","route":"/ideas/idea-bladder-preservation-mibc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"blinatumomab-frontline-consolidation","kind":"pairing","name":"Blinatumomab added to frontline chemotherapy","route":"/pairings/blinatumomab-frontline-consolidation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bicr","kind":"term","name":"Blinded independent central review (BICR)","route":"/terms/bicr/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-epigenetic-persister-blockade","kind":"idea","name":"Block the chemical switch that lets cells hide from treatment","route":"/ideas/idea-bio1-epigenetic-persister-blockade/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-complement-c5ar-blockade","kind":"idea","name":"Block the complement signal that recruits tumour-protecting cells","route":"/ideas/idea-bio2-complement-c5ar-blockade/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-autophagy-block-mrd","kind":"idea","name":"Block the recycling that keeps dormant cells alive","route":"/ideas/idea-bio2-autophagy-block-mrd/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-stromal-resistance-blockade","kind":"idea","name":"Block the survival signals the tumour's neighbours provide","route":"/ideas/idea-bio1-stromal-resistance-blockade/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-ebv-dna-npc-screening-scaleup","kind":"idea","name":"Blood EBV DNA screening for nasopharyngeal cancer across southern China and Southeast Asia","route":"/ideas/idea-prev-ebv-dna-npc-screening-scaleup/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-hcc-blood-surveillance","kind":"idea","name":"Blood-based HCC surveillance to replace six-monthly ultrasound","route":"/ideas/idea-hcc-blood-surveillance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-mced-new-onset-diabetes","kind":"idea","name":"Blood-based pancreatic cancer detection in new-onset diabetes","route":"/ideas/idea-mced-new-onset-diabetes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-il1-awakening-blockade","kind":"idea","name":"Blunt the inflammation that wakes sleeping cancer cells","route":"/ideas/idea-bio2-il1-awakening-blockade/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bob-li","kind":"person","name":"Bob T. Li","route":"/people/bob-li/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-replication-bounties","kind":"idea","name":"Bounties for documented failed replications of high-impact findings","route":"/ideas/idea-tr2-replication-bounties/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bradley-bernstein","kind":"person","name":"Bradley E. Bernstein","route":"/people/bradley-bernstein/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"braf-plus-mek","kind":"pairing","name":"BRAF inhibitor + MEK inhibitor","route":"/pairings/braf-plus-mek/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"braf-mek-neoadjuvant-atc","kind":"pairing","name":"BRAF/MEK inhibition → surgery in anaplastic thyroid cancer","route":"/pairings/braf-mek-neoadjuvant-atc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-atc-triplet-io","kind":"idea","name":"BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer","route":"/ideas/idea-atc-triplet-io/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-net-blockade-perioperative","kind":"idea","name":"Break the neutrophil DNA nets that catch tumour cells after surgery","route":"/ideas/idea-bio2-net-blockade-perioperative/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-condensate-disruptors","kind":"idea","name":"Break up the liquid droplets where oncogenic transcription happens","route":"/ideas/idea-bio1-condensate-disruptors/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"breakthrough-designation","kind":"term","name":"Breakthrough Therapy / Priority Review / Priority Voucher","route":"/terms/breakthrough-designation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-consent-in-the-pathway","kind":"idea","name":"Broad research consent as a routine step of the cancer pathway","route":"/ideas/idea-data-consent-in-the-pathway/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bruce-levine","kind":"person","name":"Bruce L. Levine","route":"/people/bruce-levine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bruce-stillman","kind":"person","name":"Bruce W. Stillman","route":"/people/bruce-stillman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-btk-degrader-frontline","kind":"idea","name":"BTK degraders to pre-empt resistance in frontline CLL","route":"/ideas/idea-btk-degrader-frontline/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"btki-plus-venetoclax-fixed-duration","kind":"pairing","name":"BTK inhibitor + venetoclax, fixed duration","route":"/pairings/btki-plus-venetoclax-fixed-duration/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bud-romine","kind":"person","name":"Bud Romine","route":"/people/bud-romine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-blood-csf-barrier-model","kind":"idea","name":"Build a human model of the barrier that guards the brain fluid","route":"/ideas/idea-bio2-blood-csf-barrier-model/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-metastatic-niche-models","kind":"idea","name":"Build laboratory models of the organs cancer spreads to","route":"/ideas/idea-bio1-metastatic-niche-models/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-prs-ancestry-portability-standard","kind":"idea","name":"Build polygenic scores that work in every ancestry before deploying any","route":"/ideas/idea-prev-prs-ancestry-portability-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-episode-payment-tied-to-concordance","kind":"idea","name":"Bundled episode payments for cancer care with bonuses for guideline concordance","route":"/ideas/idea-acc-episode-payment-tied-to-concordance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-lmic-burden-match","kind":"idea","name":"Burden-matched funding for trials led in low- and middle-income countries","route":"/ideas/idea-fund-lmic-burden-match/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-patent-buyout-prize","kind":"idea","name":"Buy out the patent on a curative cancer drug and sell it at generic prices","route":"/ideas/idea-reg-patent-buyout-prize/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bystander-effect","kind":"term","name":"Bystander effect (ADC)","route":"/terms/bystander-effect/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"caetano-reis-e-sousa","kind":"person","name":"Caetano Reis e Sousa","route":"/people/caetano-reis-e-sousa/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"caix-pet","kind":"technology","name":"CAIX PET (89Zr-girentuximab)","route":"/technologies/caix-pet/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-caix-theranostics","kind":"idea","name":"CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy","route":"/ideas/idea-caix-theranostics/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-drugging-myc","kind":"idea","name":"Can MYC be drugged directly, and will patients tolerate it?","route":"/ideas/idea-drugging-myc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tdxd-first-then-nothing","kind":"idea","name":"Can T-DXd alone cure early HER2-positive disease?","route":"/ideas/idea-tdxd-first-then-nothing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-interception-vaccines","kind":"idea","name":"Cancer interception vaccines for high-risk carriers","route":"/ideas/idea-interception-vaccines/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cancer-registries-surveillance","kind":"technology","name":"Cancer registries and population surveillance","route":"/technologies/cancer-registries-surveillance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-ehr-symptom-signature-prompts","kind":"idea","name":"Cancer risk scores running automatically in GP records to prompt urgent referral","route":"/ideas/idea-prev-ehr-symptom-signature-prompts/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"variant-knowledgebases","kind":"technology","name":"Cancer variant knowledgebases and molecular tumour boards","route":"/technologies/variant-knowledgebases/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-alcohol-cancer-warning-labels","kind":"idea","name":"Cancer warnings on alcohol labels, evaluated as a natural experiment","route":"/ideas/idea-prev-alcohol-cancer-warning-labels/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"candace-johnson","kind":"person","name":"Candace S. Johnson","route":"/people/candace-johnson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-price-anchored-to-mcbs","kind":"idea","name":"Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales","route":"/ideas/idea-reg-price-anchored-to-mcbs/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"capecitabine-temozolomide","kind":"drug","name":"Capecitabine + temozolomide (CAPTEM)","route":"/drugs/capecitabine-temozolomide/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-diet-covariates-io-trials","kind":"idea","name":"Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial","route":"/ideas/idea-nl-diet-covariates-io-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-cardiometabolic-clinic-hormone-therapy","kind":"idea","name":"Cardiometabolic screening and treatment for survivors on long-term hormone therapy","route":"/ideas/idea-acc-cardiometabolic-clinic-hormone-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-caregiver-training-as-covered-service","kind":"idea","name":"Caregiver training and respite as a covered service in cancer care for older patients","route":"/ideas/idea-acc-caregiver-training-as-covered-service/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"carl-june","kind":"person","name":"Carl H. June","route":"/people/carl-june/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"caroline-dive","kind":"person","name":"Caroline Dive","route":"/people/caroline-dive/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"carsten-bokemeyer","kind":"person","name":"Carsten Bokemeyer","route":"/people/carsten-bokemeyer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"carsten-denkert","kind":"person","name":"Carsten Denkert","route":"/people/carsten-denkert/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-abandonment-stipends","kind":"idea","name":"Cash for transport and food to stop families abandoning curative treatment","route":"/ideas/idea-acc-abandonment-stipends/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-remote-weight-step-monitoring","kind":"idea","name":"Catch wasting early with a smart scale and a step counter","route":"/ideas/idea-bio2-remote-weight-step-monitoring/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-hpv-male-catchup-oropharynx","kind":"idea","name":"Catch-up HPV vaccination for men to prevent throat cancer","route":"/ideas/idea-prev-hpv-male-catchup-oropharynx/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"io-varices-caution","kind":"pairing","name":"Caution: bevacizumab-based regimens with untreated varices","route":"/pairings/io-varices-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bleomycin-omission-caution","kind":"pairing","name":"Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF","route":"/pairings/bleomycin-omission-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"caution-pd1-first-line-ovarian","kind":"pairing","name":"Caution: checkpoint inhibitors in first-line ovarian cancer","route":"/pairings/caution-pd1-first-line-ovarian/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cit-in-del17p-caution","kind":"pairing","name":"Caution: chemoimmunotherapy in del(17p)/TP53 CLL","route":"/pairings/cit-in-del17p-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"doxorubicin-cardio-caution","kind":"pairing","name":"Caution: cumulative anthracycline dose and the heart","route":"/pairings/doxorubicin-cardio-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hpv-deescalation-caution","kind":"pairing","name":"Caution: de-escalating radiation on HPV status alone","route":"/pairings/hpv-deescalation-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ild-overlap-caution","kind":"pairing","name":"Caution: DXd ADC + agents with pneumonitis risk","route":"/pairings/ild-overlap-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"btki-ibrutinib-cardiac-caution","kind":"pairing","name":"Caution: ibrutinib in patients with cardiac risk","route":"/pairings/btki-ibrutinib-cardiac-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"il2-anti-gd2-caution","kind":"pairing","name":"Caution: IL-2 added to anti-GD2 therapy","route":"/pairings/il2-anti-gd2-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"inotuzumab-then-transplant-caution","kind":"pairing","name":"Caution: inotuzumab before transplant (veno-occlusive disease)","route":"/pairings/inotuzumab-then-transplant-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lag3-adjuvant-caution","kind":"pairing","name":"Caution: LAG-3 blockade outside active disease","route":"/pairings/lag3-adjuvant-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"caution-mis-radical-hysterectomy","kind":"pairing","name":"Caution: minimally invasive radical hysterectomy for early cervical cancer","route":"/pairings/caution-mis-radical-hysterectomy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"io-rechallenge-caution-rcc","kind":"pairing","name":"Caution: PD-1 rechallenge after progression on immunotherapy (RCC)","route":"/pairings/io-rechallenge-caution-rcc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bispecific-infection-prophylaxis","kind":"pairing","name":"Caution: T-cell redirectors and infections","route":"/pairings/bispecific-infection-prophylaxis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tigit-plus-pd1-caution","kind":"pairing","name":"Caution: TIGIT + PD-(L)1 blockade","route":"/pairings/tigit-plus-pd1-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"adc-after-adc-caution","kind":"pairing","name":"Caution: TOP1 ADC immediately after TOP1 ADC","route":"/pairings/adc-after-adc-caution/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bispecific-plus-adc-lymphoma","kind":"pairing","name":"CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab)","route":"/pairings/bispecific-plus-adc-lymphoma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-cd30-car-t-hodgkin","kind":"idea","name":"CD30 CAR-T for multiply relapsed Hodgkin lymphoma","route":"/ideas/idea-cd30-car-t-hodgkin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cd38-plus-triplet","kind":"pairing","name":"CD38 antibody added to PI-IMiD-dex (quadruplet induction)","route":"/pairings/cd38-plus-triplet/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-cd8-pet-io","kind":"idea","name":"CD8 PET to stop or switch immunotherapy early","route":"/ideas/idea-cd8-pet-io/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-cdk4-selective-first-line","kind":"idea","name":"CDK4-selective inhibitors as the new first-line backbone","route":"/ideas/idea-cdk4-selective-first-line/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cdk46-plus-endocrine","kind":"pairing","name":"CDK4/6 inhibitor + endocrine therapy","route":"/pairings/cdk46-plus-endocrine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cell-of-origin","kind":"term","name":"Cell of origin (GCB vs ABC)","route":"/terms/cell-of-origin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cell-therapy-roadmap","kind":"roadmap","name":"Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR","route":"/roadmaps/cell-therapy-roadmap/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cell-therapy-orchestration-software","kind":"technology","name":"Cell-therapy orchestration and chain-of-identity software","route":"/technologies/cell-therapy-orchestration-software/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cell-therapy-release-testing","kind":"technology","name":"Cell-therapy release and potency testing","route":"/technologies/cell-therapy-release-testing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-certified-decision-aids","kind":"idea","name":"Certified decision aids required for every preference-sensitive cancer decision","route":"/ideas/idea-moon-certified-decision-aids/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"qi-changsong","kind":"person","name":"Changsong Qi","route":"/people/qi-changsong/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"charu-aggarwal","kind":"person","name":"Charu Aggarwal","route":"/people/charu-aggarwal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-fragmentomics-first-tier","kind":"idea","name":"Cheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests","route":"/ideas/idea-prev-fragmentomics-first-tier/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-perioperative-betablocker-nsaid","kind":"idea","name":"Cheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress","route":"/ideas/idea-bio2-perioperative-betablocker-nsaid/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-antigen-presentation-triage","kind":"idea","name":"Check whether a tumour can still show itself to the immune system","route":"/ideas/idea-bio2-antigen-presentation-triage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"chemo-io-then-maintenance-sclc","kind":"pairing","name":"Chemo-immunotherapy induction → maintenance intensification (SCLC)","route":"/pairings/chemo-io-then-maintenance-sclc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"chemo-io-first-line-endometrial","kind":"pairing","name":"Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer","route":"/pairings/chemo-io-first-line-endometrial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-chemo-free-hodgkin","kind":"idea","name":"Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage","route":"/ideas/idea-chemo-free-hodgkin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"christian-blank","kind":"person","name":"Christian Blank","route":"/people/christian-blank/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"christine-chung","kind":"person","name":"Christine H. Chung","route":"/people/christine-chung/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"christof-von-kalle","kind":"person","name":"Christof von Kalle","route":"/people/christof-von-kalle/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"christophe-le-tourneau","kind":"person","name":"Christophe Le Tourneau","route":"/people/christophe-le-tourneau/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"chris-lord","kind":"person","name":"Christopher Lord","route":"/people/chris-lord/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"christopher-vakoc","kind":"person","name":"Christopher R. Vakoc","route":"/people/christopher-vakoc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-ctc-clearance-go-nogo","kind":"idea","name":"Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs","route":"/ideas/idea-bio2-ctc-clearance-go-nogo/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cthpv-dna","kind":"technology","name":"Circulating tumour HPV DNA (ctHPV-DNA)","route":"/technologies/cthpv-dna/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cl2a","kind":"term","name":"CL2A","route":"/terms/cl2a/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"claus-belka","kind":"person","name":"Claus Belka","route":"/people/claus-belka/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cldn18-antibody-then-adc","kind":"pairing","name":"CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression","route":"/pairings/cldn18-antibody-then-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-cxcr2-neutrophil-blockade","kind":"idea","name":"Clear the suppressive neutrophils out of pancreatic tumours first","route":"/ideas/idea-bio2-cxcr2-neutrophil-blockade/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-senolytics-after-therapy","kind":"idea","name":"Clear the zombie cells left behind by chemotherapy and radiotherapy","route":"/ideas/idea-bio1-senolytics-after-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","route":"/people/clemens-kratochwil/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"clinical-complete-response","kind":"term","name":"Clinical complete response (cCR)","route":"/terms/clinical-complete-response/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ngs-bioinformatics-software","kind":"technology","name":"Clinical NGS bioinformatics and variant interpretation","route":"/technologies/ngs-bioinformatics-software/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"clinical-trial-software","kind":"technology","name":"Clinical trial software (EDC, eCOA, CTMS, RTSM)","route":"/technologies/clinical-trial-software/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"closed-automated-cell-manufacturing","kind":"technology","name":"Closed automated cell-therapy manufacturing","route":"/technologies/closed-automated-cell-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-early-apheresis-banking","kind":"idea","name":"Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy","route":"/ideas/idea-reg-early-apheresis-banking/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-resistance-mechanism-baskets","kind":"idea","name":"Combination baskets defined by resistance mechanism rather than by cancer type","route":"/ideas/idea-tr2-resistance-mechanism-baskets/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cps","kind":"term","name":"Combined positive score (CPS)","route":"/terms/cps/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-community-health-worker-recruitment","kind":"idea","name":"Community health workers and trusted local organisations paid to recruit for trials","route":"/ideas/idea-tr1-community-health-worker-recruitment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-community-health-workers-oncology","kind":"idea","name":"Community health workers trained in cancer triage, navigation and home palliative care","route":"/ideas/idea-acc-community-health-workers-oncology/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-oral-cancer-community-smartphone-ai","kind":"idea","name":"Community health workers with smartphone AI screen for mouth cancer in South Asia","route":"/ideas/idea-prev-oral-cancer-community-smartphone-ai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"community-oncology-networks","kind":"technology","name":"Community oncology and site networks","route":"/technologies/community-oncology-networks/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-pharmacy-prevention-hub","kind":"idea","name":"Community pharmacies as one-stop cancer prevention hubs","route":"/ideas/idea-prev-pharmacy-prevention-hub/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-hpv-vaccine-confidence","kind":"idea","name":"Community-tailored HPV vaccine confidence campaigns with school-based delivery","route":"/ideas/idea-moon-hpv-vaccine-confidence/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-compact-flash-proton","kind":"idea","name":"Compact FLASH and proton systems at the price of a conventional linac","route":"/ideas/idea-moon-compact-flash-proton/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"companion-diagnostic-term","kind":"term","name":"Companion diagnostic","route":"/terms/companion-diagnostic-term/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-comparability-by-design-digital-twin","kind":"idea","name":"Comparability by design: a digital twin and sentinel panel for cell process changes","route":"/ideas/idea-reg-comparability-by-design-digital-twin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-shared-control-arms-across-sponsors","kind":"idea","name":"Competing sponsors share one control arm in the same indication","route":"/ideas/idea-tr1-shared-control-arms-across-sponsors/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-conditional-approval-sunset","kind":"idea","name":"Conditional approvals that lapse automatically if the confirmatory trial is late","route":"/ideas/idea-reg-conditional-approval-sunset/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-olanzapine-cachexia-global-confirmation","kind":"idea","name":"Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide","route":"/ideas/idea-reg-olanzapine-cachexia-global-confirmation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-antioxidant-supplement-harm-confirmation","kind":"idea","name":"Confirm or refute the harm of antioxidant supplements during chemotherapy","route":"/ideas/idea-nl-antioxidant-supplement-harm-confirmation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-low-dose-immunotherapy-for-lmic","kind":"idea","name":"Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live","route":"/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cms-subtypes","kind":"term","name":"Consensus molecular subtypes (CMS1-4)","route":"/terms/cms-subtypes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-continuous-ai-validation-registry","kind":"idea","name":"Continuous prospective validation for every oncology AI tool after deployment","route":"/ideas/idea-moon-continuous-ai-validation-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-hpapi-continuous-flow","kind":"idea","name":"Continuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze","route":"/ideas/idea-reg-hpapi-continuous-flow/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"contract-research-organisations","kind":"technology","name":"Contract research organisations (CROs)","route":"/technologies/contract-research-organisations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-upf-controlled-feeding-trial","kind":"idea","name":"Controlled feeding trials to separate ultra-processing from calories","route":"/ideas/idea-nl-upf-controlled-feeding-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"costas-lyssiotis","kind":"person","name":"Costas A. Lyssiotis","route":"/people/costas-lyssiotis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-pan-ras-covalent-g12d","kind":"idea","name":"Covalent chemistry for the RAS mutations that still have no drug","route":"/ideas/idea-bio1-pan-ras-covalent-g12d/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-adaptive-radiotherapy-evidence","kind":"idea","name":"Coverage-with-evidence registries for MR-guided and adaptive radiotherapy","route":"/ideas/idea-fund-adaptive-radiotherapy-evidence/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-diaspora-tele-tumour-boards","kind":"idea","name":"Credentialed diaspora oncologists staffing remote tumour boards for home-country hospitals","route":"/ideas/idea-acc-diaspora-tele-tumour-boards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cross-then-nivolumab","kind":"pairing","name":"CROSS chemoradiation → surgery → adjuvant nivolumab if residual disease","route":"/pairings/cross-then-nivolumab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cell-therapy-cold-chain","kind":"technology","name":"Cryopreservation and cell-therapy cold chain","route":"/technologies/cell-therapy-cold-chain/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ctdna-genotype-gist-tki","kind":"pairing","name":"ctDNA KIT genotyping → TKI selection in GIST","route":"/pairings/ctdna-genotype-gist-tki/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ctdna-lymphoma-monitoring","kind":"technology","name":"ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)","route":"/technologies/ctdna-lymphoma-monitoring/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ctdna-mrd-to-adjuvant","kind":"pairing","name":"ctDNA MRD → adjuvant therapy decision","route":"/pairings/ctdna-mrd-to-adjuvant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-ctdna-guided-adjuvant-crc","kind":"idea","name":"ctDNA-guided adjuvant therapy as the default in stage II-III colon cancer","route":"/ideas/idea-ctdna-guided-adjuvant-crc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-ctdna-guided-adjuvant-melanoma","kind":"idea","name":"ctDNA-guided adjuvant therapy in stage II-III melanoma","route":"/ideas/idea-ctdna-guided-adjuvant-melanoma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-ctdna-adaptive-tki","kind":"idea","name":"ctDNA-guided dose holidays for lung cancer targeted therapy","route":"/ideas/idea-bio1-ctdna-adaptive-tki/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-ctdna-guided-parp-duration","kind":"idea","name":"ctDNA-guided duration of PARP maintenance","route":"/ideas/idea-ctdna-guided-parp-duration/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-ctdna-guided-dlbcl-frontline","kind":"idea","name":"ctDNA-guided escalation and de-escalation in frontline DLBCL","route":"/ideas/idea-ctdna-guided-dlbcl-frontline/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-btc-ctdna-fgfr-resistance","kind":"idea","name":"ctDNA-guided switching among FGFR inhibitors","route":"/ideas/idea-btc-ctdna-fgfr-resistance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-ctdna-escalation-tnbc","kind":"idea","name":"ctDNA-triggered escalation in early TNBC","route":"/ideas/idea-ctdna-escalation-tnbc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-cthpv-adapted-deescalation","kind":"idea","name":"ctHPV-DNA-adapted de-escalation of chemoradiation","route":"/ideas/idea-cthpv-adapted-deescalation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-hcv-test-treat-surveillance-linkage","kind":"idea","name":"Cure hepatitis C in prisons and drug services, and enrol the cured in liver cancer surveillance","route":"/ideas/idea-prev-hcv-test-treat-surveillance-linkage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-stress-response-blockade","kind":"idea","name":"Cut off the emergency programme cancer cells use to survive treatment","route":"/ideas/idea-bio1-stress-response-blockade/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nerve-tumour-blockade","kind":"idea","name":"Cut the nerve supply to tumours with old drugs","route":"/ideas/idea-nerve-tumour-blockade/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lee-dae-ho","kind":"person","name":"Dae Ho Lee","route":"/people/lee-dae-ho/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"david-tuveson","kind":"person","name":"David A. Tuveson","route":"/people/david-tuveson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"david-solit","kind":"person","name":"David B. Solit","route":"/people/david-solit/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"david-cameron","kind":"person","name":"David Cameron","route":"/people/david-cameron/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"david-cunningham","kind":"person","name":"David Cunningham","route":"/people/david-cunningham/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"david-porter","kind":"person","name":"David L. Porter","route":"/people/david-porter/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-lactate-acid-axis","kind":"idea","name":"De-acidify the tumour so T cells can work in it","route":"/ideas/idea-bio2-lactate-acid-axis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"deauville-score","kind":"term","name":"Deauville five-point scale","route":"/terms/deauville-score/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"decentralised-clinical-trials","kind":"technology","name":"Decentralised and hybrid clinical trials","route":"/technologies/decentralised-clinical-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"decipher-prostate","kind":"drug","name":"Decipher Prostate","route":"/drugs/decipher-prostate/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-embedded-decision-aids","kind":"idea","name":"Decision aids built into the record for every preference-sensitive cancer choice","route":"/ideas/idea-acc-embedded-decision-aids/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-provenance-first-decision-support","kind":"idea","name":"Decision support that cites the exact trial and guideline line it relies on","route":"/ideas/idea-data-provenance-first-decision-support/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-ecog-2-dedicated-cohorts","kind":"idea","name":"Dedicated cohorts for patients with performance status 2 in first-line trials","route":"/ideas/idea-tr1-ecog-2-dedicated-cohorts/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-default-fertility-preservation-referral","kind":"idea","name":"Default fertility preservation referral for every patient under 40 before treatment","route":"/ideas/idea-acc-default-fertility-preservation-referral/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-mutant-p53-degrader","kind":"idea","name":"Degrade the damaged p53 protein rather than trying to repair it","route":"/ideas/idea-bio1-mutant-p53-degrader/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"degrader-antibody-conjugate","kind":"technology","name":"Degrader-antibody conjugate (DAC)","route":"/technologies/degrader-antibody-conjugate/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-fusion-tf-degraders","kind":"idea","name":"Degraders for the fusion proteins that drive childhood sarcomas","route":"/ideas/idea-bio1-fusion-tf-degraders/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"del17p-tp53","kind":"term","name":"del(17p) / TP53 aberration in CLL","route":"/terms/del17p-tp53/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-intraventricular-car-t","kind":"idea","name":"Deliver CAR-T cells straight into the fluid around the brain","route":"/ideas/idea-bio2-intraventricular-car-t/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-intranasal-delivery","kind":"idea","name":"Deliver drugs and cells to the brain through the nose","route":"/ideas/idea-bio2-intranasal-delivery/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"denis-lacombe","kind":"person","name":"Denis Lacombe","route":"/people/denis-lacombe/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-structured-trial-results-deposit","kind":"idea","name":"Deposit trial results as structured data, not just PDFs","route":"/ideas/idea-data-structured-trial-results-deposit/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dermoscopy-ai","kind":"technology","name":"Dermoscopy, total-body photography & AI skin analysis","route":"/technologies/dermoscopy-ai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-evolutionary-double-bind","kind":"idea","name":"Design drug pairs where resisting one makes you vulnerable to the other","route":"/ideas/idea-bio1-evolutionary-double-bind/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-brain-penetrant-glue-degraders","kind":"idea","name":"Design protein degraders small enough to get into the brain","route":"/ideas/idea-bio2-brain-penetrant-glue-degraders/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-arv7-degrader","kind":"idea","name":"Destroy the truncated androgen receptor that hormone drugs cannot touch","route":"/ideas/idea-bio1-arv7-degrader/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-cfrna-plasticity-tracking","kind":"idea","name":"Detect tumours changing cell type from RNA in the blood","route":"/ideas/idea-bio1-cfrna-plasticity-tracking/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-paediatric-first-development","kind":"idea","name":"Develop drugs in children first when the target is a children's target","route":"/ideas/idea-bio2-paediatric-first-development/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-ablation-versus-surgery-trials","kind":"idea","name":"Device-agnostic public trials of ablation technologies against surgery","route":"/ideas/idea-fund-ablation-versus-surgery-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"devices","kind":"section","name":"Devices & Physical Therapies","route":"/fronts/devices/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-ai-process-control-cell-manufacturing","kind":"idea","name":"Digital batch records and AI process control to halve cell therapy batch failures","route":"/ideas/idea-reg-ai-process-control-cell-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-digital-twin-predict-then-observe","kind":"idea","name":"Digital twins for treatment selection, validated by predicting before observing","route":"/ideas/idea-data-digital-twin-predict-then-observe/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-national-slide-archive","kind":"idea","name":"Digitise the nation's pathology slides and link them to outcomes","route":"/ideas/idea-data-national-slide-archive/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ye-dingwei","kind":"person","name":"Dingwei Ye","route":"/people/ye-dingwei/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-rd-cost-disclosure-condition","kind":"idea","name":"Disclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage","route":"/ideas/idea-reg-rd-cost-disclosure-condition/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dm4","kind":"term","name":"DM4","route":"/terms/dm4/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dna-alkylator-payloads","kind":"term","name":"DNA alkylator payloads","route":"/terms/dna-alkylator-payloads/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dna-cleaver-payloads","kind":"term","name":"DNA cleaver payloads (enediynes)","route":"/terms/dna-cleaver-payloads/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pbd-dimer-payloads","kind":"term","name":"DNA crosslinker payloads (PBD dimers)","route":"/terms/pbd-dimer-payloads/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","route":"/people/oh-do-youn/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tu-dongsheng","kind":"person","name":"Dongsheng Tu","route":"/people/tu-dongsheng/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-adc-dose-and-schedule-optimisation","kind":"idea","name":"Dose and schedule optimisation trials specific to antibody-drug conjugates","route":"/ideas/idea-tr1-adc-dose-and-schedule-optimisation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-lean-mass-dosing","kind":"idea","name":"Dose chemotherapy by muscle mass, not body surface area","route":"/ideas/idea-bio2-lean-mass-dosing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-geriatric-dose-finding-cohorts","kind":"idea","name":"Dose-finding in older and frail patients, not extrapolation from fit ones","route":"/ideas/idea-tr1-geriatric-dose-finding-cohorts/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-net-dosimetry-prrt","kind":"idea","name":"Dosimetry-personalised PRRT instead of four fixed cycles","route":"/ideas/idea-net-dosimetry-prrt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-task-shifting-ai-oncology-capacity","kind":"idea","name":"Double oncology capacity in low-resource settings with task-shifting and AI decision support","route":"/ideas/idea-moon-task-shifting-ai-oncology-capacity/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"double-hit-lymphoma","kind":"term","name":"Double-hit / high-grade B-cell lymphoma","route":"/terms/double-hit-lymphoma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-lytac-surface-degraders","kind":"idea","name":"Drag cancer's surface and secreted proteins to the cell's recycling bin","route":"/ideas/idea-bio1-lytac-surface-degraders/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"drew-weissman","kind":"person","name":"Drew Weissman","route":"/people/drew-weissman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-drop-non-essential-biopsies","kind":"idea","name":"Drop mandatory fresh biopsies where blood or archival tissue would do","route":"/ideas/idea-tr1-drop-non-essential-biopsies/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-label-assay-concordance","kind":"idea","name":"Drug labels must state which biomarker assays were validated and how they compare","route":"/ideas/idea-tr2-label-assay-concordance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dar","kind":"term","name":"Drug-to-antibody ratio (DAR)","route":"/terms/dar/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dual-her2-blockade","kind":"term","name":"Dual HER2 blockade","route":"/terms/dual-her2-blockade/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-dual-payload-first","kind":"idea","name":"Dual-payload ADCs in first line to prevent resistance","route":"/ideas/idea-dual-payload-first/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"durvalumab-plus-bcg","kind":"pairing","name":"Durvalumab + BCG in BCG-naive high-risk NMIBC","route":"/pairings/durvalumab-plus-bcg/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dxd","kind":"term","name":"DXd","route":"/terms/dxd/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-dynamic-consent-app","kind":"idea","name":"Dynamic consent with usage receipts","route":"/ideas/idea-data-dynamic-consent-app/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"early-detection-roadmap","kind":"roadmap","name":"Early detection roadmap: organ screening → blood tests for many cancers","route":"/roadmaps/early-detection-roadmap/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pet-adapted-her2-deescalation","kind":"pairing","name":"Early FDG-PET response → chemotherapy omission (HER2+)","route":"/pairings/pet-adapted-her2-deescalation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"car-t-before-transplant-lbcl","kind":"pairing","name":"Early relapse: CAR-T before transplant","route":"/pairings/car-t-before-transplant-lbcl/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-earmarked-palliative-budget-share","kind":"idea","name":"Earmark a fixed share of every national cancer budget for palliative care","route":"/ideas/idea-acc-earmarked-palliative-budget-share/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-efflux-agnostic","kind":"idea","name":"Efflux-agnostic therapy for mesenchymal TNBC","route":"/ideas/idea-efflux-agnostic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"c797s","kind":"term","name":"EGFR C797S","route":"/terms/c797s/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"egfr-exon19-l858r","kind":"term","name":"EGFR exon 19 deletion & L858R","route":"/terms/egfr-exon19-l858r/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"egfr-exon20-insertion","kind":"term","name":"EGFR exon 20 insertion","route":"/terms/egfr-exon20-insertion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tki-then-adc-lung","kind":"pairing","name":"EGFR TKI → ADC on progression","route":"/pairings/tki-then-adc-lung/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"egfr-bispecific-plus-pd1-hnscc","kind":"pairing","name":"EGFR-directed bispecific + PD-1 blockade","route":"/pairings/egfr-bispecific-plus-pd1-hnscc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"eileen-oreilly","kind":"person","name":"Eileen M. O'Reilly","route":"/people/eileen-oreilly/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"remote-patient-monitoring","kind":"technology","name":"Electronic patient-reported outcomes and remote monitoring","route":"/technologies/remote-patient-monitoring/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"elena-elez","kind":"person","name":"Elena Élez","route":"/people/elena-elez/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"elena-garralda","kind":"person","name":"Elena Garralda","route":"/people/elena-garralda/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"eliane-piaggio","kind":"person","name":"Eliane Piaggio","route":"/people/eliane-piaggio/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","route":"/people/eliezer-van-allen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"elironrasib","kind":"drug","name":"Elironrasib","route":"/drugs/elironrasib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"weiderpass-elisabete","kind":"person","name":"Elisabete Weiderpass","route":"/people/weiderpass-elisabete/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"emile-voest","kind":"person","name":"Emile Voest","route":"/people/emile-voest/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-rwe-combination-emulation","kind":"idea","name":"Emulate combination trials from real-world data to triage which ones to run","route":"/ideas/idea-tr2-rwe-combination-emulation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-target-trial-emulation-to-prioritise-rcts","kind":"idea","name":"Emulate the trial in real-world data first to decide which trials to run","route":"/ideas/idea-tr1-target-trial-emulation-to-prioritise-rcts/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-full-data-with-abstract","kind":"idea","name":"End the abstract-to-paper gap: require full results with any conference presentation","route":"/ideas/idea-data-full-data-with-abstract/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"endocrine-resistance","kind":"term","name":"Endocrine resistance","route":"/terms/endocrine-resistance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ev-pembro-continuum","kind":"pairing","name":"Enfortumab vedotin + pembrolizumab across the bladder cancer continuum","route":"/pairings/ev-pembro-continuum/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-engineered-bacteria-payloads","kind":"idea","name":"Engineered bacteria that live in tumours and manufacture drugs there","route":"/ideas/idea-bio2-engineered-bacteria-payloads/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-engineered-immune-surveillance","kind":"idea","name":"Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer","route":"/ideas/idea-moon-engineered-immune-surveillance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"enrique-espinosa","kind":"person","name":"Enrique Espinosa","route":"/people/enrique-espinosa/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"epithelioid-vs-sarcomatoid","kind":"term","name":"Epithelioid vs sarcomatoid (biphasic) mesothelioma","route":"/terms/epithelioid-vs-sarcomatoid/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-dormancy-eradication-programme","kind":"idea","name":"Eradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells","route":"/ideas/idea-moon-dormancy-eradication-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"eric-haura","kind":"person","name":"Eric B. Haura","route":"/people/eric-haura/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"eric-fearon","kind":"person","name":"Eric R. Fearon","route":"/people/eric-fearon/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"erik-sahai","kind":"person","name":"Erik Sahai","route":"/people/erik-sahai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"eunice-wang","kind":"person","name":"Eunice S. Wang","route":"/people/eunice-wang/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-alcohol-minimum-pricing-cancer-endpoints","kind":"idea","name":"Evaluate alcohol minimum unit pricing against cancer incidence","route":"/ideas/idea-nl-alcohol-minimum-pricing-cancer-endpoints/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-clean-air-never-smoker-endpoints","kind":"idea","name":"Evaluate clean-air policies using lung cancer in never-smokers","route":"/ideas/idea-prev-clean-air-never-smoker-endpoints/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"evandro-de-azambuja","kind":"person","name":"Evandro de Azambuja","route":"/people/evandro-de-azambuja/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-evening-weekend-trial-clinics","kind":"idea","name":"Evening and weekend trial clinics for working-age patients","route":"/ideas/idea-tr1-evening-weekend-trial-clinics/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"efs","kind":"term","name":"Event-free / disease-free survival (EFS, DFS, iDFS, RFS)","route":"/terms/efs/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-ai-audit-trail-in-ehr","kind":"idea","name":"Every AI output logged in the record with input hash, version and clinician response","route":"/ideas/idea-data-ai-audit-trail-in-ehr/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-combo-readiness-dossier","kind":"idea","name":"Every approved cancer drug ships with a public combination-readiness data pack","route":"/ideas/idea-tr2-combo-readiness-dossier/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-phd-replication-year","kind":"idea","name":"Every cancer biology PhD begins with a funded replication of a published finding","route":"/ideas/idea-tr2-phd-replication-year/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-reference-compound-panels","kind":"idea","name":"Every drug screen includes standard reference compounds whose performance is published","route":"/ideas/idea-tr2-reference-compound-panels/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-opt-out-cessation-in-lung-screening","kind":"idea","name":"Every lung screening visit includes stop-smoking medicine, opt-out","route":"/ideas/idea-prev-opt-out-cessation-in-lung-screening/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-results-in-plain-words","kind":"idea","name":"Every pathology and genomic report ships with a signed plain-language version","route":"/ideas/idea-moon-results-in-plain-words/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-accelerated-approval-registry-condition","kind":"idea","name":"Every patient on an accelerated-approval drug enrolled in a registry until confirmation","route":"/ideas/idea-data-accelerated-approval-registry-condition/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-universal-routine-cost-coverage","kind":"idea","name":"Every payer covers routine care costs for trial participants, in every country","route":"/ideas/idea-tr1-universal-routine-cost-coverage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-reverse-translation-resistance-models","kind":"idea","name":"Every resistance mechanism found in a patient must be rebuilt in the laboratory","route":"/ideas/idea-bio1-reverse-translation-resistance-models/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-opportunistic-ct-ai-registry","kind":"idea","name":"Every routine CT scan checked by AI for early cancer signs, with a tracked follow-up pathway","route":"/ideas/idea-prev-opportunistic-ct-ai-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-annual-overdiagnosis-reporting","kind":"idea","name":"Every screening programme must publish its overdiagnosis rate each year","route":"/ideas/idea-prev-annual-overdiagnosis-reporting/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-ngs-report-live-trial-match","kind":"idea","name":"Every tumour sequencing report lists open, nearby, matched trials pulled live","route":"/ideas/idea-tr1-ngs-report-live-trial-match/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-integrative-oncology-bridge","kind":"idea","name":"Evidence-based integrative oncology in every cancer centre to meet demand safely","route":"/ideas/idea-moon-integrative-oncology-bridge/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-evolutionary-tumour-boards","kind":"idea","name":"Evolutionary tumour boards with a modeller in the room","route":"/ideas/idea-bio1-evolutionary-tumour-boards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"exercise-oncology","kind":"technology","name":"Exercise & lifestyle oncology","route":"/technologies/exercise-oncology/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-rapid-guideline-translation","kind":"idea","name":"Expert-verified translation of guideline updates into 20 languages within 30 days","route":"/ideas/idea-data-rapid-guideline-translation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-p53-mutant-reactivator-expansion","kind":"idea","name":"Extend p53 reactivation beyond the Y220C mutation","route":"/ideas/idea-bio1-p53-mutant-reactivator-expansion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-extended-interval-checkpoint-dosing","kind":"idea","name":"Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable","route":"/ideas/idea-tr1-extended-interval-checkpoint-dosing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tcr-t-beyond-hla-a2","kind":"idea","name":"Extending sarcoma TCR-T beyond HLA-A*02","route":"/ideas/idea-tcr-t-beyond-hla-a2/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-multisite-validation-precondition","kind":"idea","name":"External validation at five or more sites in two countries before clearance","route":"/ideas/idea-data-multisite-validation-precondition/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-duration-trial-exclusivity","kind":"idea","name":"Extra exclusivity for sponsors who run treatment-duration and de-escalation trials","route":"/ideas/idea-fund-duration-trial-exclusivity/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","route":"/people/fabrice-barlesi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-factorial-dose-finding-for-combinations","kind":"idea","name":"Factorial dose finding for drug combinations instead of full dose of everything","route":"/ideas/idea-tr1-factorial-dose-finding-for-combinations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-family-history-auto-match","kind":"idea","name":"Family history collected by app and matched to testing criteria automatically","route":"/ideas/idea-prev-family-history-auto-match/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-hpylori-family-test-and-treat","kind":"idea","name":"Family-based H. pylori test-and-treat to prevent stomach cancer","route":"/ideas/idea-prev-hpylori-family-test-and-treat/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fap-theranostics-pancancer","kind":"idea","name":"FAP theranostics as a pan-cancer stromal strategy","route":"/ideas/idea-fap-theranostics-pancancer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-mced-plus-fapi","kind":"idea","name":"FAPI PET as the workup for MCED positives","route":"/ideas/idea-mced-plus-fapi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-fast-track-relicensing-oncologists","kind":"idea","name":"Fast-track relicensing for refugee, migrant and returning oncology professionals","route":"/ideas/idea-acc-fast-track-relicensing-oncologists/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fc-effector","kind":"term","name":"Fc engineering / effector function","route":"/terms/fc-effector/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"federated-learning-medical-ai","kind":"technology","name":"Federated learning and privacy-preserving AI","route":"/technologies/federated-learning-medical-ai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ma-fei","kind":"person","name":"Fei Ma","route":"/people/ma-fei/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"wang-feng-sysucc","kind":"person","name":"Feng Wang","route":"/people/wang-feng-sysucc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-fertility-preservation-default","kind":"idea","name":"Fertility preservation offered and funded by default before gonadotoxic treatment","route":"/ideas/idea-moon-fertility-preservation-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fertility-sparing-endometrial","kind":"technology","name":"Fertility-sparing hormonal treatment of early endometrial cancer","route":"/technologies/fertility-sparing-endometrial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fgfr2-fusion","kind":"term","name":"FGFR2 fusions and rearrangements","route":"/terms/fgfr2-fusion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fgfr3","kind":"term","name":"FGFR3 alterations (bladder cancer)","route":"/terms/fgfr3/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"filippo-de-braud","kind":"person","name":"Filippo de Braud","route":"/people/filippo-de-braud/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-tumour-restricted-e3-atlas","kind":"idea","name":"Find E3 ligases that only tumours have, and build degraders around them","route":"/ideas/idea-bio1-tumour-restricted-e3-atlas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-drug-exposure-sanctuary-mapping","kind":"idea","name":"Find the parts of a tumour the drug never reaches","route":"/ideas/idea-bio1-drug-exposure-sanctuary-mapping/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fiona-blackhall","kind":"person","name":"Fiona Blackhall","route":"/people/fiona-blackhall/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-duffy-null-neutrophil-threshold","kind":"idea","name":"Fix the neutrophil count rule that excludes many people of African ancestry","route":"/ideas/idea-tr1-duffy-null-neutrophil-threshold/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"flotufolastat","kind":"drug","name":"Flotufolastat F-18","route":"/drugs/flotufolastat/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"flt3i-plus-7-3","kind":"pairing","name":"FLT3 inhibitor + intensive chemotherapy","route":"/pairings/flt3i-plus-7-3/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"flt3-itd-allelic-ratio","kind":"term","name":"FLT3-ITD allelic ratio","route":"/terms/flt3-itd-allelic-ratio/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-cxcr4-mobilise-then-kill","kind":"idea","name":"Flush dormant cells out of bone marrow, then kill them","route":"/ideas/idea-bio2-cxcr4-mobilise-then-kill/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fnclcc-grade","kind":"term","name":"FNCLCC grade (soft-tissue sarcoma)","route":"/terms/fnclcc-grade/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fus-plus-adc-glioma","kind":"idea","name":"Focused-ultrasound BBB opening to deliver ADCs and radioligands to glioma","route":"/ideas/idea-fus-plus-adc-glioma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bbb-focused-ultrasound","kind":"technology","name":"Focused-ultrasound blood-brain barrier opening","route":"/technologies/bbb-focused-ultrasound/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-registry-follow-up-of-trial-participants","kind":"idea","name":"Follow every trial participant for 30 years through registry linkage","route":"/ideas/idea-data-registry-follow-up-of-trial-participants/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-evolution-forecasting","kind":"idea","name":"Forecast the next resistance mutation like the weather","route":"/ideas/idea-bio1-evolution-forecasting/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-caregiver-in-the-plan","kind":"idea","name":"Formal caregiver assessment and training written into every treatment plan","route":"/ideas/idea-moon-caregiver-in-the-plan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-primary-care-shared-care-agreements","kind":"idea","name":"Formal shared-care agreements between oncology and family doctors, with same-day e-consult","route":"/ideas/idea-acc-primary-care-shared-care-agreements/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-prehabilitation-standard","kind":"idea","name":"Four weeks of training and nutrition before major cancer surgery, as standard","route":"/ideas/idea-bio2-prehabilitation-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fran-visco","kind":"person","name":"Fran Visco","route":"/people/fran-visco/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"francisca-vazquez","kind":"person","name":"Francisca Vazquez","route":"/people/francisca-vazquez/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"francois-clement-bidard","kind":"person","name":"François-Clément Bidard","route":"/people/francois-clement-bidard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-mandatory-progression-biopsy","kind":"idea","name":"Fund a biopsy at progression, every time, as standard care","route":"/ideas/idea-bio1-mandatory-progression-biopsy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-diverse-investigator-pipeline","kind":"idea","name":"Fund investigators from under-represented communities and community sites to lead trials","route":"/ideas/idea-tr1-diverse-investigator-pipeline/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-hair-preservation-for-all","kind":"idea","name":"Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen","route":"/ideas/idea-moon-hair-preservation-for-all/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-open-results-bonus","kind":"idea","name":"Funder bonuses for releasing results and data within six months, negatives included","route":"/ideas/idea-fund-open-results-bonus/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"g12d-plus-pan-ras","kind":"pairing","name":"G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)","route":"/pairings/g12d-plus-pan-ras/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gad-getz","kind":"person","name":"Gad Getz","route":"/people/gad-getz/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-gd2-car-t-frontline-consolidation","kind":"idea","name":"GD2 CAR-T as consolidation in high-risk neuroblastoma","route":"/ideas/idea-gd2-car-t-frontline-consolidation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tar-200","kind":"drug","name":"Gemcitabine intravesical system (TAR-200)","route":"/drugs/tar-200/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gemcis-plus-io-btc","kind":"pairing","name":"Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer","route":"/pairings/gemcis-plus-io-btc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"genomic-assay-to-chemo-omission","kind":"pairing","name":"Gene-expression assay → chemotherapy omission","route":"/pairings/genomic-assay-to-chemo-omission/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"generic-drug-shortage-response","kind":"technology","name":"Generic oncology drug supply and shortage mitigation","route":"/technologies/generic-drug-shortage-response/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"genomics-cloud-platforms","kind":"technology","name":"Genomics cloud and secure research environments","route":"/technologies/genomics-cloud-platforms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"geriatric-assessment","kind":"technology","name":"Geriatric assessment","route":"/technologies/geriatric-assessment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-geriatric-assessment-default","kind":"idea","name":"Geriatric assessment by default for every older patient, and trials that admit them","route":"/ideas/idea-moon-geriatric-assessment-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-geriatric-co-management-surgery","kind":"idea","name":"Geriatrician co-management for older patients having cancer surgery","route":"/ideas/idea-acc-geriatric-co-management-surgery/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"germline-to-parp","kind":"pairing","name":"Germline BRCA test → adjuvant PARP inhibitor","route":"/pairings/germline-to-parp/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-lynch-aspirin-implementation","kind":"idea","name":"Get every Lynch syndrome carrier onto the right dose of aspirin","route":"/ideas/idea-prev-lynch-aspirin-implementation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-anamorelin-access","kind":"idea","name":"Get the one approved appetite drug licensed beyond a single country","route":"/ideas/idea-bio2-anamorelin-access/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"giampaolo-tortora","kind":"person","name":"Giampaolo Tortora","route":"/people/giampaolo-tortora/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-chronotherapy-immunotherapy","kind":"idea","name":"Give immunotherapy in the morning","route":"/ideas/idea-chronotherapy-immunotherapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-negative-plenaries","kind":"idea","name":"Give negative trials plenary slots at the big cancer conferences","route":"/ideas/idea-tr2-negative-plenaries/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-glp1-endometrial-hyperplasia","kind":"idea","name":"GLP-1 drugs to reverse endometrial precancer in women with obesity","route":"/ideas/idea-prev-glp1-endometrial-hyperplasia/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-glp1-adjuvant-hr-breast","kind":"idea","name":"GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer","route":"/ideas/idea-nl-glp1-adjuvant-hr-breast/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-cgm-glycaemic-drift-pancreas","kind":"idea","name":"Glucose monitor data as an early pancreatic cancer signal","route":"/ideas/idea-prev-cgm-glycaemic-drift-pancreas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-traceback-deceased-probands","kind":"idea","name":"Go back to families of women who died of ovarian cancer and offer BRCA testing","route":"/ideas/idea-prev-traceback-deceased-probands/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"golcadomide","kind":"drug","name":"Golcadomide","route":"/drugs/golcadomide/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-phase-two-failure-reinsurance","kind":"idea","name":"Government reinsurance for phase 2 failures of first-in-class cancer drugs","route":"/ideas/idea-fund-phase-two-failure-reinsurance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-tiered-pricing-for-exclusivity","kind":"idea","name":"Grant extra exclusivity only in exchange for binding low prices in poorer countries","route":"/ideas/idea-reg-tiered-pricing-for-exclusivity/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mcarthur-grant","kind":"person","name":"Grant McArthur","route":"/people/mcarthur-grant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-null-result-reporting","kind":"idea","name":"Grant progress reports must list what did not work","route":"/ideas/idea-tr2-null-result-reporting/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-mechanism-defined-baskets","kind":"idea","name":"Group trials by broken mechanism, not by organ or single mutation","route":"/ideas/idea-bio2-mechanism-defined-baskets/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-ctc-culture-functional-testing","kind":"idea","name":"Grow blood-borne tumour cells to test drugs on the cells that actually spread","route":"/ideas/idea-bio2-ctc-culture-functional-testing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-organoid-coclinical-arms","kind":"idea","name":"Grow each trial patient's tumour as organoids to decide which platform arm opens next","route":"/ideas/idea-tr2-organoid-coclinical-arms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-tertiary-lymphoid-induction","kind":"idea","name":"Grow immune command posts inside tumours","route":"/ideas/idea-bio2-tertiary-lymphoid-induction/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-ctc-derived-explants","kind":"idea","name":"Grow models from tumour cells in the blood when a biopsy is impossible","route":"/ideas/idea-bio1-ctc-derived-explants/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-organoid-immune-coculture","kind":"idea","name":"Grow tumour organoids together with the patient's own immune cells","route":"/ideas/idea-bio1-organoid-immune-coculture/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-open-trials-inside-guidelines","kind":"idea","name":"Guidelines list the open trials at every decision point, updated monthly","route":"/ideas/idea-tr1-open-trials-inside-guidelines/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gunter-von-minckwitz","kind":"person","name":"Gunter von Minckwitz","route":"/people/gunter-von-minckwitz/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hans-gustaf-ljunggren","kind":"person","name":"Hans-Gustaf Ljunggren","route":"/people/hans-gustaf-ljunggren/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-hospital-exemption-harmonised","kind":"idea","name":"Harmonise Europe's hospital exemption for academic cell therapies, with one registry","route":"/ideas/idea-reg-hospital-exemption-harmonised/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fukuda-haruhiko","kind":"person","name":"Haruhiko Fukuda","route":"/people/fukuda-haruhiko/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hatem-soliman","kind":"person","name":"Hatem Soliman","route":"/people/hatem-soliman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bispecific-vs-car-t-second-line","kind":"idea","name":"Head-to-head bispecific vs CAR-T in second-line LBCL","route":"/ideas/idea-bispecific-vs-car-t-second-line/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-her2-adc-serous-endometrial","kind":"idea","name":"HER2 ADCs as standard for HER2-positive serous endometrial cancer","route":"/ideas/idea-her2-adc-serous-endometrial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"her2-gastric-sequence","kind":"pairing","name":"HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd","route":"/pairings/her2-gastric-sequence/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"her2-low","kind":"term","name":"HER2-low and HER2-ultralow","route":"/terms/her2-low/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"her2-low-to-tdxd","kind":"pairing","name":"HER2-low scoring → T-DXd","route":"/pairings/her2-low-to-tdxd/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"her2-brain-metastases","kind":"term","name":"HER2-positive brain metastases","route":"/terms/her2-brain-metastases/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hermann-brenner","kind":"person","name":"Hermann Brenner","route":"/people/hermann-brenner/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hgsoc","kind":"term","name":"High-grade serous ovarian carcinoma (HGSOC)","route":"/terms/hgsoc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"high-risk-myeloma","kind":"term","name":"High-risk cytogenetics (myeloma)","route":"/terms/high-risk-myeloma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"high-throughput-screening-libraries","kind":"technology","name":"High-throughput screening and DNA-encoded libraries","route":"/technologies/high-throughput-screening-libraries/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hipec-at-interval-surgery","kind":"pairing","name":"HIPEC at interval cytoreductive surgery","route":"/pairings/hipec-at-interval-surgery/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"histologic-transformation","kind":"term","name":"Histologic transformation","route":"/terms/histologic-transformation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"histology-directs-first-line-meso","kind":"pairing","name":"Histology → first-line choice in mesothelioma","route":"/pairings/histology-directs-first-line-meso/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ihc-autostainers-histology-automation","kind":"technology","name":"Histology automation and IHC autostainers","route":"/technologies/ihc-autostainers-histology-automation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sarcoma-histotype-tailoring","kind":"term","name":"Histotype-tailored therapy","route":"/terms/sarcoma-histotype-tailoring/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nakagama-hitoshi","kind":"person","name":"Hitoshi Nakagama","route":"/people/nakagama-hitoshi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hla-a02-restriction","kind":"term","name":"HLA-A*02:01 restriction","route":"/terms/hla-a02-restriction/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lim-ho-yeong","kind":"person","name":"Ho Yeong Lim","route":"/people/lim-ho-yeong/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-organoid-assay-clinical-validation","kind":"idea","name":"Hold organoid drug tests to the same standard as a diagnostic test","route":"/ideas/idea-bio1-organoid-assay-clinical-validation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-home-chemotherapy-older-patients","kind":"idea","name":"Home administration of selected chemotherapy and immunotherapy for older and frail patients","route":"/ideas/idea-acc-home-chemotherapy-older-patients/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-home-based-end-of-life-kits","kind":"idea","name":"Home end-of-life care kits and trained family carers where no hospice exists","route":"/ideas/idea-acc-home-based-end-of-life-kits/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-frail-elderly-primary-endocrine-breast","kind":"idea","name":"Hormone tablets instead of surgery for small breast cancers in the frail over-80s","route":"/ideas/idea-prev-frail-elderly-primary-endocrine-breast/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-hospital-at-home-oncology","kind":"idea","name":"Hospital-at-home for oncology: treating low-risk febrile neutropenia and dehydration at home","route":"/ideas/idea-acc-hospital-at-home-oncology/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-public-car-t-manufacturing","kind":"idea","name":"Hospital-based CAR-T manufacturing at cost through a public network","route":"/ideas/idea-fund-public-car-t-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-hospital-exemption-registry","kind":"idea","name":"Hospital-exemption cell therapies at scale, backed by a shared registry","route":"/ideas/idea-fund-hospital-exemption-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-protected-time-physician-scientists","kind":"idea","name":"Hospital-funded protected time for clinician-scientists, repaid by trial revenue","route":"/ideas/idea-fund-protected-time-physician-scientists/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-hpv-ctdna-cervical","kind":"idea","name":"HPV circulating tumour DNA to guide cervical cancer therapy","route":"/ideas/idea-hpv-ctdna-cervical/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hrd-testing","kind":"technology","name":"HRD & BRCA testing","route":"/technologies/hrd-testing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-immune-matched-humanised-mice","kind":"idea","name":"Humanised mice with an immune system matched to the tumour donor","route":"/ideas/idea-bio1-immune-matched-humanised-mice/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hydrophilic-next-gen","kind":"term","name":"Hydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing)","route":"/terms/hydrophilic-next-gen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kim-hye-ryun","kind":"person","name":"Hye Ryun Kim","route":"/people/kim-hye-ryun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"iain-foulkes","kind":"person","name":"Iain Foulkes","route":"/people/iain-foulkes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cree-ian","kind":"person","name":"Ian Cree","route":"/people/cree-ian/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"igor-puzanov","kind":"person","name":"Igor Puzanov","route":"/people/igor-puzanov/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"imaging-core-labs","kind":"technology","name":"Imaging core labs and central review","route":"/technologies/imaging-core-labs/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"risk-directed-first-line-rcc","kind":"pairing","name":"IMDC risk → first-line regimen choice (RCC)","route":"/pairings/risk-directed-first-line-rcc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"imdc-risk","kind":"term","name":"IMDC risk groups (favourable / intermediate / poor)","route":"/terms/imdc-risk/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"io-before-surgery-hnscc","kind":"pairing","name":"Immunotherapy before surgery rather than with chemoradiation (HNSCC)","route":"/pairings/io-before-surgery-hnscc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-hcc-io-before-transplant","kind":"idea","name":"Immunotherapy downstaging to transplant with a safe washout","route":"/ideas/idea-hcc-io-before-transplant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"io-first-then-braf-mek","kind":"pairing","name":"Immunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)","route":"/pairings/io-first-then-braf-mek/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-implantable-microdevice-screen","kind":"idea","name":"Implant a tiny device that tests twenty drugs inside the patient's own tumour","route":"/ideas/idea-bio2-implantable-microdevice-screen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-in-silico-trials-dose","kind":"idea","name":"In silico trials to choose the dose before the first patient","route":"/ideas/idea-bio1-in-silico-trials-dose/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-in-silico-trials-calibrated","kind":"idea","name":"In silico trials to prioritise combinations, scored against later real trials","route":"/ideas/idea-data-in-silico-trials-calibrated/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-in-vivo-car-solid","kind":"idea","name":"In vivo CAR-T against solid-tumour antigens","route":"/ideas/idea-in-vivo-car-solid/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-in-vivo-cart-off-the-shelf-vial","kind":"idea","name":"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma","route":"/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-in-vivo-cart-generic-price","kind":"idea","name":"In vivo CAR-T manufactured and priced like a generic biologic","route":"/ideas/idea-moon-in-vivo-cart-generic-price/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-replication-before-ind","kind":"idea","name":"Independent replication of the key experiment before first-in-human academic trials","route":"/ideas/idea-tr2-replication-before-ind/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"induction-chemo-then-crt","kind":"pairing","name":"Induction chemotherapy → chemoradiation (locally advanced cervical cancer)","route":"/pairings/induction-chemo-then-crt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"infusion-devices-vascular-access","kind":"technology","name":"Infusion pumps, ports, and ambulatory chemotherapy devices","route":"/technologies/infusion-devices-vascular-access/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-inhaled-lung-niche-immunotherapy","kind":"idea","name":"Inhaled immune therapy to make the lung hostile to arriving tumour cells","route":"/ideas/idea-bio2-inhaled-lung-niche-immunotherapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-prebunking-at-diagnosis","kind":"idea","name":"Inoculate newly diagnosed patients against common cancer scams","route":"/ideas/idea-moon-prebunking-at-diagnosis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-mrna-intrabodies","kind":"idea","name":"Instruct tumour cells to make antibodies against their own oncoprotein","route":"/ideas/idea-bio1-mrna-intrabodies/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-field-interception","kind":"idea","name":"Intercept cancer at the field stage","route":"/ideas/idea-field-interception/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-late-recurrence-interception","kind":"idea","name":"Intercepting late recurrence with ctDNA surveillance and oral SERDs","route":"/ideas/idea-late-recurrence-interception/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-desmoid-intermittent-dosing","kind":"idea","name":"Intermittent or stop-and-restart nirogacestat in desmoid tumours","route":"/ideas/idea-desmoid-intermittent-dosing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-targeting-aneuploidy","kind":"idea","name":"Is aneuploidy itself a druggable vulnerability?","route":"/ideas/idea-targeting-aneuploidy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jae-park","kind":"person","name":"Jae H. Park","route":"/people/jae-park/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lee-jae-lyun","kind":"person","name":"Jae Lyun Lee","route":"/people/lee-jae-lyun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jaime-feliu","kind":"person","name":"Jaime Feliu","route":"/people/jaime-feliu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jame-abraham","kind":"person","name":"Jame Abraham","route":"/people/jame-abraham/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"james-larkin","kind":"person","name":"James Larkin","route":"/people/james-larkin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dancey-janet","kind":"person","name":"Janet Dancey","route":"/people/dancey-janet/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jaroslaw-maciejewski","kind":"person","name":"Jaroslaw P. Maciejewski","route":"/people/jaroslaw-maciejewski/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jean-charles-soria","kind":"person","name":"Jean-Charles Soria","route":"/people/jean-charles-soria/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","route":"/people/jean-yves-blay/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lee-jeeyun","kind":"person","name":"Jeeyun Lee","route":"/people/lee-jeeyun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"he-jie","kind":"person","name":"Jie He","route":"/people/he-jie/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"wang-jie-cams","kind":"person","name":"Jie Wang","route":"/people/wang-jie-cams/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"li-jin-fuscc","kind":"person","name":"Jin Li","route":"/people/li-jin-fuscc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"huang-jing-cams","kind":"person","name":"Jing Huang","route":"/people/huang-jing-cams/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"joaquin-arribas","kind":"person","name":"Joaquín Arribas","route":"/people/joaquin-arribas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-dick","kind":"person","name":"John E. Dick","route":"/people/john-dick/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-dipersio","kind":"person","name":"John F. DiPersio","route":"/people/john-dipersio/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jonas-bergh","kind":"person","name":"Jonas Bergh","route":"/people/jonas-bergh/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trapani-joseph","kind":"person","name":"Joseph Trapani","route":"/people/trapani-joseph/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"joshua-brody","kind":"person","name":"Joshua Brody","route":"/people/joshua-brody/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-data-link-enforcement","kind":"idea","name":"Journals check that data links actually work, and flag papers whose data vanish","route":"/ideas/idea-tr2-data-link-enforcement/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-programme-officer-incentives","kind":"idea","name":"Judge funding programme officers on burden alignment and trials completed","route":"/ideas/idea-fund-programme-officer-incentives/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-melanoma-ai-thick-melanoma-metric","kind":"idea","name":"Judge skin cancer AI by the thick melanomas it prevents, not the thin ones it finds","route":"/ideas/idea-prev-melanoma-ai-thick-melanoma-metric/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"judy-garber","kind":"person","name":"Judy E. Garber","route":"/people/judy-garber/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ma-jun","kind":"person","name":"Jun Ma","route":"/people/ma-jun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"juergen-debus","kind":"person","name":"Jürgen Debus","route":"/people/juergen-debus/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"juergen-wolf","kind":"person","name":"Jürgen Wolf","route":"/people/juergen-wolf/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"justin-lathia","kind":"person","name":"Justin D. Lathia","route":"/people/justin-lathia/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"justin-gainor","kind":"person","name":"Justin F. Gainor","route":"/people/justin-gainor/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-ex-vivo-perfused-tumour","kind":"idea","name":"Keep a freshly removed tumour alive on a pump and test drugs in it","route":"/ideas/idea-bio1-ex-vivo-perfused-tumour/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-pro-dormancy-therapy","kind":"idea","name":"Keep dormant cells asleep instead of trying to kill them","route":"/ideas/idea-bio2-pro-dormancy-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-dormancy-maintenance-therapy","kind":"idea","name":"Keep them asleep: dormancy maintenance as adjuvant therapy","route":"/ideas/idea-dormancy-maintenance-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","route":"/people/keith-flaherty/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kellie-smith","kind":"person","name":"Kellie N. Smith","route":"/people/kellie-smith/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kevin-harrington","kind":"person","name":"Kevin Harrington","route":"/people/kevin-harrington/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-organ-impairment-pk-before-approval","kind":"idea","name":"Kidney and liver impairment dosing studies completed before approval, not years after","route":"/ideas/idea-tr1-organ-impairment-pk-before-approval/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-ctdna-futility-gates","kind":"idea","name":"Kill combination arms early using circulating tumour DNA, before waiting for scans","route":"/ideas/idea-tr2-ctdna-futility-gates/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-ferroptosis-persisters","kind":"idea","name":"Kill drug-tolerant persisters through ferroptosis","route":"/ideas/idea-ferroptosis-persisters/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-persister-ferroptosis","kind":"idea","name":"Kill the sleeping survivor cells with iron-dependent cell death","route":"/ideas/idea-bio1-persister-ferroptosis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"klaus-pantel","kind":"person","name":"Klaus Pantel","route":"/people/klaus-pantel/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kras-plus-egfr-crc","kind":"pairing","name":"KRAS G12C inhibitor + anti-EGFR antibody (colorectal)","route":"/pairings/kras-plus-egfr-crc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kras-roadmap","kind":"roadmap","name":"KRAS roadmap: undruggable → G12C → pan-RAS","route":"/roadmaps/kras-roadmap/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kristian-helin","kind":"person","name":"Kristian Helin","route":"/people/kristian-helin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-biomarker-evidence-grading","kind":"idea","name":"Label every biomarker claim with an evidence phase, like drugs","route":"/ideas/idea-tr2-biomarker-evidence-grading/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-truncal-branch-labelling","kind":"idea","name":"Label every targetable mutation as truncal or branch on the report","route":"/ideas/idea-bio1-truncal-branch-labelling/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lars-bullinger","kind":"person","name":"Lars Bullinger","route":"/people/lars-bullinger/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"late-recurrence","kind":"term","name":"Late recurrence","route":"/terms/late-recurrence/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"laurence-zitvogel","kind":"person","name":"Laurence Zitvogel","route":"/people/laurence-zitvogel/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-lay-trial-navigators","kind":"idea","name":"Lay trial navigators funded per centre, evaluated in a randomised trial","route":"/ideas/idea-tr1-lay-trial-navigators/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"leif-ellisen","kind":"person","name":"Leif W. Ellisen","route":"/people/leif-ellisen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lenvatinib-plus-pembrolizumab","kind":"pairing","name":"Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)","route":"/pairings/lenvatinib-plus-pembrolizumab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-cascade-direct-contact-relatives","kind":"idea","name":"Let clinics contact relatives directly when a cancer gene is found","route":"/ideas/idea-prev-cascade-direct-contact-relatives/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-patient-partnered-rare-commons","kind":"idea","name":"Let patients themselves donate their records and samples for ultra-rare cancers","route":"/ideas/idea-bio2-patient-partnered-rare-commons/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-bandit-allocation","kind":"idea","name":"Let the trial learn: response-adaptive allocation across many combination arms","route":"/ideas/idea-tr2-bandit-allocation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lgr5","kind":"term","name":"LGR5","route":"/terms/lgr5/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"li-ding","kind":"person","name":"Li Ding","route":"/people/li-ding/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"zhang-li-sysucc","kind":"person","name":"Li Zhang","route":"/people/zhang-li-sysucc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lillian-siu","kind":"person","name":"Lillian L. Siu","route":"/people/lillian-siu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-secondary-patent-thicket-limits","kind":"idea","name":"Limit secondary patents and pay-for-delay so cancer generics arrive on time","route":"/ideas/idea-reg-secondary-patent-thicket-limits/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"limited-vs-extensive-stage","kind":"term","name":"Limited-stage vs extensive-stage (SCLC)","route":"/terms/limited-vs-extensive-stage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"first-line","kind":"term","name":"Lines of therapy","route":"/terms/first-line/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-bariatric-cancer-registry-linkage","kind":"idea","name":"Link bariatric and GLP-1 registries to cancer registries in every country that has both","route":"/ideas/idea-nl-bariatric-cancer-registry-linkage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-atlas-to-outcome-linkage","kind":"idea","name":"Link single-cell and spatial tumour atlases to clinical outcomes","route":"/ideas/idea-data-atlas-to-outcome-linkage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-multi-organ-chip-tox","kind":"idea","name":"Linked human organ chips to predict side effects before people are dosed","route":"/ideas/idea-bio1-multi-organ-chip-tox/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-linked-pharmacovigilance-interactions","kind":"idea","name":"Linked prescribing and outcome data to find drug interactions with cancer therapy","route":"/ideas/idea-data-linked-pharmacovigilance-interactions/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-material-failure-disclosure","kind":"idea","name":"Listed companies must disclose top-line data, not just 'did not meet endpoint'","route":"/ideas/idea-tr2-material-failure-disclosure/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-guideline-concordance-dashboards","kind":"idea","name":"Live guideline-concordance dashboards for every tumour board, generated from the record","route":"/ideas/idea-acc-guideline-concordance-dashboards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-approval-access-lag-tracker","kind":"idea","name":"Live tracker of the lag from first approval to real availability in every country","route":"/ideas/idea-reg-approval-access-lag-tracker/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-living-plain-evidence-summaries","kind":"idea","name":"Living plain-language evidence summaries for every common cancer question in 20 languages","route":"/ideas/idea-moon-living-plain-evidence-summaries/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-living-machine-readable-guidelines","kind":"idea","name":"Living, machine-readable guidelines pushed to the point of care in every country","route":"/ideas/idea-moon-living-machine-readable-guidelines/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-local-oral-morphine-production","kind":"idea","name":"Locally prepared oral morphine solution, licensed for nurse prescribing","route":"/ideas/idea-acc-local-oral-morphine-production/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-cutpoint-lock","kind":"idea","name":"Lock the biomarker cut-off before phase 3, and publish it","route":"/ideas/idea-tr2-cutpoint-lock/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"long-read-sequencing","kind":"technology","name":"Long-read sequencing (PacBio, Oxford Nanopore)","route":"/technologies/long-read-sequencing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-baseline-ultradeep-resistant-clones","kind":"idea","name":"Look for the resistant sub-population before the first dose","route":"/ideas/idea-bio1-baseline-ultradeep-resistant-clones/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-losartan-pancreatic-stroma","kind":"idea","name":"Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3","route":"/ideas/idea-reg-losartan-pancreatic-stroma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-frugal-hdr-brachytherapy","kind":"idea","name":"Low-cost cobalt-60 brachytherapy for cervical cancer in every regional centre","route":"/ideas/idea-acc-frugal-hdr-brachytherapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-low-dose-tamoxifen-uptake","kind":"idea","name":"Low-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses","route":"/ideas/idea-prev-low-dose-tamoxifen-uptake/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"low-risk-dtc","kind":"term","name":"Low-risk differentiated thyroid cancer (ATA risk)","route":"/terms/low-risk-dtc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-lung-screening-risk-model-eligibility","kind":"idea","name":"Lung screening eligibility by risk score, not pack-years, including high-risk never-smokers","route":"/ideas/idea-prev-lung-screening-risk-model-eligibility/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-macrocycle-ppi-campaign","kind":"idea","name":"Macrocyclic peptides to cover protein surfaces that pills cannot","route":"/ideas/idea-bio1-macrocycle-ppi-campaign/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"major-pathological-response","kind":"term","name":"Major pathological response (MPR)","route":"/terms/major-pathological-response/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-dental-oral-exam-standard","kind":"idea","name":"Make a two-minute mouth cancer check part of every dental visit","route":"/ideas/idea-prev-dental-oral-exam-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-somatic-crispr-gemms","kind":"idea","name":"Make bespoke mouse cancer models in weeks with in vivo gene editing","route":"/ideas/idea-bio1-somatic-crispr-gemms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-clonal-clearance-endpoint","kind":"idea","name":"Make clonal clearance, not tumour shrinkage, a trial endpoint","route":"/ideas/idea-bio1-clonal-clearance-endpoint/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-cold-to-hot-programme","kind":"idea","name":"Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours","route":"/ideas/idea-moon-cold-to-hot-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-metastasis-screen-standard","kind":"idea","name":"Make in vivo metastasis screens a required step in drug discovery","route":"/ideas/idea-bio2-metastasis-screen-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-approval-linked-progression-sampling","kind":"idea","name":"Make post-progression sampling a condition of accelerated approval","route":"/ideas/idea-bio1-approval-linked-progression-sampling/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-omit-radiotherapy-low-risk-breast-default","kind":"idea","name":"Make skipping radiotherapy the default for very low-risk breast cancer","route":"/ideas/idea-prev-omit-radiotherapy-low-risk-breast-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-broad-eligibility-as-regulatory-default","kind":"idea","name":"Make sponsors justify every trial exclusion of older and multimorbid patients","route":"/ideas/idea-acc-broad-eligibility-as-regulatory-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-immunotherapy-mss-crc","kind":"idea","name":"Making microsatellite-stable colorectal cancer immunotherapy-responsive","route":"/ideas/idea-immunotherapy-mss-crc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"malachi-griffith","kind":"person","name":"Malachi Griffith","route":"/people/malachi-griffith/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mc-non-cleavable","kind":"term","name":"Maleimidocaproyl (mc), non-cleavable","route":"/terms/mc-non-cleavable/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-interval-cancer-audit-blood-tests","kind":"idea","name":"Mandatory interval-cancer audit for every blood-based screening test","route":"/ideas/idea-prev-interval-cancer-audit-blood-tests/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-national-virtual-mdt-rare-complex","kind":"idea","name":"Mandatory national virtual tumour boards for rare and complex cancers","route":"/ideas/idea-acc-national-virtual-mdt-rare-complex/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-ai-post-market-performance-reporting","kind":"idea","name":"Mandatory post-market performance reporting for cancer AI","route":"/ideas/idea-data-ai-post-market-performance-reporting/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-vein-to-vein-public-benchmark","kind":"idea","name":"Mandatory public reporting of vein-to-vein time and failure rate per CAR-T product","route":"/ideas/idea-reg-vein-to-vein-public-benchmark/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-radon-testing-at-property-sale","kind":"idea","name":"Mandatory radon testing when homes are sold, with subsidised mitigation","route":"/ideas/idea-prev-radon-testing-at-property-sale/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-excluded-populations-rwe-mandate","kind":"idea","name":"Mandatory real-world reporting for patients excluded from pivotal trials","route":"/ideas/idea-data-excluded-populations-rwe-mandate/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-subgroup-performance-reporting-mandate","kind":"idea","name":"Mandatory subgroup performance reporting for cancer AI","route":"/ideas/idea-data-subgroup-performance-reporting-mandate/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-metabolic-vulnerability-mapping","kind":"idea","name":"Map metabolic dependencies in the patient, not the dish","route":"/ideas/idea-metabolic-vulnerability-mapping/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-spatial-clone-immune-map","kind":"idea","name":"Map which tumour clones sit next to which immune cells before choosing therapy","route":"/ideas/idea-bio1-spatial-clone-immune-map/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"redifferentiation-rai","kind":"pairing","name":"MAPK inhibitor redifferentiation → radioiodine","route":"/pairings/redifferentiation-rai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"marco-guzzo","kind":"person","name":"Marco Guzzo","route":"/people/marco-guzzo/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"markus-graefen","kind":"person","name":"Markus Graefen","route":"/people/markus-graefen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"masked-adc","kind":"technology","name":"Masked / conditionally active ADC","route":"/technologies/masked-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-clone-to-lesion-mapping","kind":"idea","name":"Match each blood-detected clone to the lesion it comes from on the scan","route":"/ideas/idea-bio1-clone-to-lesion-mapping/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-caf-subtype-assignment","kind":"idea","name":"Match therapy to the type of scar-forming cell in the tumour","route":"/ideas/idea-bio2-caf-subtype-assignment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"matthew-galsky","kind":"person","name":"Matthew D. Galsky","route":"/people/matthew-galsky/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"max-wicha","kind":"person","name":"Max S. Wicha","route":"/people/max-wicha/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mc-vc-pabc","kind":"term","name":"mc-Val-Cit-PABC","route":"/terms/mc-vc-pabc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-pain-control-public-audit","kind":"idea","name":"Measure and publish pain control rates in every cancer centre","route":"/ideas/idea-acc-pain-control-public-audit/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-cognitive-toxicity-programme","kind":"idea","name":"Measure and treat chemo brain with objective digital cognitive testing","route":"/ideas/idea-moon-cognitive-toxicity-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-therapeutic-drug-monitoring-for-oral-tkis","kind":"idea","name":"Measure blood levels of oral targeted drugs and adjust doses to a target range","route":"/ideas/idea-tr1-therapeutic-drug-monitoring-for-oral-tkis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-histotripsy-immune-priming","kind":"idea","name":"Mechanically pulverise one tumour with ultrasound to wake the immune system","route":"/ideas/idea-bio2-histotripsy-immune-priming/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"medical-cyclotrons-synthesis-modules","kind":"technology","name":"Medical cyclotrons, hot cells, and synthesis modules","route":"/technologies/medical-cyclotrons-synthesis-modules/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mel-greaves","kind":"person","name":"Mel Greaves","route":"/people/mel-greaves/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"menin-plus-venetoclax-hma","kind":"pairing","name":"Menin inhibitor + venetoclax + azacitidine","route":"/pairings/menin-plus-venetoclax-hma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-menin-infant-all","kind":"idea","name":"Menin inhibitors for infant KMT2A-rearranged ALL","route":"/ideas/idea-menin-infant-all/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"met-amplification","kind":"term","name":"MET amplification (bypass resistance)","route":"/terms/met-amplification/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-metastasis-prevention-indication","kind":"idea","name":"Metastasis prevention as a formal indication with its own trials and regulatory pathway","route":"/ideas/idea-moon-metastasis-prevention-indication/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mezigdomide","kind":"drug","name":"Mezigdomide","route":"/drugs/mezigdomide/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-baumann","kind":"person","name":"Michael Baumann","route":"/people/michael-baumann/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-hallek","kind":"person","name":"Michael Hallek","route":"/people/michael-hallek/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-von-bergwelt","kind":"person","name":"Michael von Bergwelt","route":"/people/michael-von-bergwelt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-weller","kind":"person","name":"Michael Weller","route":"/people/michael-weller/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michelle-mitchell","kind":"person","name":"Michelle Mitchell","route":"/people/michelle-mitchell/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-thirty-day-practice-change-learning","kind":"idea","name":"Micro-learning pushed to community oncologists within 30 days of a practice change","route":"/ideas/idea-data-thirty-day-practice-change-learning/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-microbiome-io-fmt","kind":"idea","name":"Microbiome transplant as a routine immunotherapy adjunct","route":"/ideas/idea-microbiome-io-fmt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"miguel-martin","kind":"person","name":"Miguel Martín","route":"/people/miguel-martin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-first-in-class-prize","kind":"idea","name":"Milestone prizes for first-in-class mechanisms reaching human proof of concept","route":"/ideas/idea-fund-first-in-class-prize/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ryu-min-hee","kind":"person","name":"Min-Hee Ryu","route":"/people/ryu-min-hee/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-minimum-unit-pricing-cancer-endpoints","kind":"idea","name":"Minimum alcohol pricing evaluated with cancer endpoints","route":"/ideas/idea-prev-minimum-unit-pricing-cancer-endpoints/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"miriam-merad","kind":"person","name":"Miriam Merad","route":"/people/miriam-merad/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-mobile-see-and-treat-units","kind":"idea","name":"Mobile diagnostic units that biopsy, scan and treat on the same visit","route":"/ideas/idea-acc-mobile-see-and-treat-units/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-mobile-research-units","kind":"idea","name":"Mobile research units bring trial visits to rural towns","route":"/ideas/idea-tr1-mobile-research-units/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-individualised-dosing-all-oral-drugs","kind":"idea","name":"Model-informed individual dosing with drug-level monitoring for every oral cancer drug","route":"/ideas/idea-moon-individualised-dosing-all-oral-drugs/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-modern-autopsy-reservoir-studies","kind":"idea","name":"Modern autopsy studies to measure how much silent cancer people carry","route":"/ideas/idea-prev-modern-autopsy-reservoir-studies/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-modern-cobalt-bridge","kind":"idea","name":"Modernised cobalt-60 machines as a deliberate bridge where linacs cannot be kept running","route":"/ideas/idea-acc-modern-cobalt-bridge/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-myc-max-molecular-glue","kind":"idea","name":"Molecular glues that break the MYC-MAX partnership","route":"/ideas/idea-bio1-myc-max-molecular-glue/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-indolence-classifiers-with-screening","kind":"idea","name":"Molecular indolence classifiers bundled with every screening programme","route":"/ideas/idea-moon-indolence-classifiers-with-screening/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-molecular-class-adjuvant-endometrial","kind":"idea","name":"Molecular-class-directed adjuvant therapy in endometrial cancer","route":"/ideas/idea-molecular-class-adjuvant-endometrial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-ctdna-switch-generalised","kind":"idea","name":"Molecular-progression switching beyond ESR1","route":"/ideas/idea-ctdna-switch-generalised/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-positivity-rate-surveillance","kind":"idea","name":"Monitor biomarker positivity rates across labs in real time to catch assay drift","route":"/ideas/idea-tr2-positivity-rate-surveillance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mrd-negativity-myeloma","kind":"term","name":"MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)","route":"/terms/mrd-negativity-myeloma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-mrd-guided-transplant-aml","kind":"idea","name":"MRD-guided transplant decisions in intermediate-risk AML","route":"/ideas/idea-mrd-guided-transplant-aml/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-mrd-guided-stop-cll","kind":"idea","name":"MRD-guided treatment duration in CLL","route":"/ideas/idea-mrd-guided-stop-cll/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-mrd-guided-stop-myeloma","kind":"idea","name":"MRD-guided treatment-free intervals in myeloma","route":"/ideas/idea-mrd-guided-stop-myeloma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mrd-negative-cr","kind":"term","name":"MRD-negative complete remission","route":"/terms/mrd-negative-cr/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-mri-surveillance-replaces-pci","kind":"idea","name":"MRI surveillance replaces prophylactic cranial irradiation in SCLC","route":"/ideas/idea-mri-surveillance-replaces-pci/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-omomyc-mrna","kind":"idea","name":"mRNA-delivered MYC decoy proteins instead of MYC inhibitors","route":"/ideas/idea-bio1-omomyc-mrna/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mrtx1133","kind":"drug","name":"MRTX1133","route":"/drugs/mrtx1133/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"zeng-mu-sheng","kind":"person","name":"Mu-Sheng Zeng","route":"/people/zeng-mu-sheng/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-mced-non-specific-symptom-triage","kind":"idea","name":"Multi-cancer blood test as the first step for patients with non-specific symptoms","route":"/ideas/idea-prev-mced-non-specific-symptom-triage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-multicentre-mouse-trials","kind":"idea","name":"Multi-centre randomised animal trials before committing to a human trial","route":"/ideas/idea-bio1-multicentre-mouse-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-prehabilitation-older-surgery","kind":"idea","name":"Multimodal prehabilitation for older patients before major cancer surgery","route":"/ideas/idea-acc-prehabilitation-older-surgery/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-mutual-recognition-inspections-atmp","kind":"idea","name":"Mutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants","route":"/ideas/idea-reg-mutual-recognition-inspections-atmp/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"myriam-chalabi","kind":"person","name":"Myriam Chalabi","route":"/people/myriam-chalabi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","route":"/people/ahn-myung-ju/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"natasha-leighl","kind":"person","name":"Natasha B. Leighl","route":"/people/natasha-leighl/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nathan-pennell","kind":"person","name":"Nathan A. Pennell","route":"/people/nathan-pennell/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nathan-cherny","kind":"person","name":"Nathan Cherny","route":"/people/nathan-cherny/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nemtabrutinib","kind":"drug","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-neoadjuvant-adc-io","kind":"idea","name":"Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC","route":"/ideas/idea-neoadjuvant-adc-io/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"neoadjuvant-io-dmmr","kind":"pairing","name":"Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer","route":"/pairings/neoadjuvant-io-dmmr/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"neoadjuvant-io-response-adapted","kind":"pairing","name":"Neoadjuvant immunotherapy → response-adapted adjuvant","route":"/pairings/neoadjuvant-io-response-adapted/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-neoadjuvant-io-glioblastoma","kind":"idea","name":"Neoadjuvant immunotherapy with surgical window for glioblastoma","route":"/ideas/idea-neoadjuvant-io-glioblastoma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-new-onset-diabetes-pancreas-pathway","kind":"idea","name":"New diabetes after 50 plus weight loss triggers a pancreatic cancer check","route":"/ideas/idea-prev-new-onset-diabetes-pancreas-pathway/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"next-gen-short-read-platforms","kind":"technology","name":"New short-read sequencing platforms","route":"/technologies/next-gen-short-read-platforms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nicholas-james","kind":"person","name":"Nicholas James","route":"/people/nicholas-james/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nicholas-turner","kind":"person","name":"Nicholas Turner","route":"/people/nicholas-turner/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nina-bhardwaj","kind":"person","name":"Nina Bhardwaj","route":"/people/nina-bhardwaj/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-contribution-of-components-mandate","kind":"idea","name":"No accelerated approval for a combination without proof each part contributes","route":"/ideas/idea-tr2-contribution-of-components-mandate/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-irb-results-gate","kind":"idea","name":"No new trial approval until the sponsor has reported its old ones","route":"/ideas/idea-tr2-irb-results-gate/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","route":"/people/yamamoto-noboru/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-non-endoscopic-barretts-screening","kind":"idea","name":"Non-endoscopic screening for Barrett's oesophagus and early adenocarcinoma","route":"/ideas/idea-non-endoscopic-barretts-screening/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-open-source-lentiviral-vectors","kind":"idea","name":"Non-profit, open-licence lentiviral vectors and producer cell lines for CAR-T","route":"/ideas/idea-reg-open-source-lentiviral-vectors/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-non-viral-cart-manufacturing","kind":"idea","name":"Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route","route":"/ideas/idea-reg-non-viral-cart-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nuclear-medicine-hardware","kind":"technology","name":"Nuclear medicine and total-body PET hardware","route":"/technologies/nuclear-medicine-hardware/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-nurse-led-chemotherapy-units","kind":"idea","name":"Nurse-led chemotherapy day units with a doctor on a screen","route":"/ideas/idea-acc-nurse-led-chemotherapy-units/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-nurse-led-follow-up-clinics","kind":"idea","name":"Nurse-led follow-up clinics for survivors, freeing oncologists for active treatment","route":"/ideas/idea-acc-nurse-led-follow-up-clinics/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"obi-griffith","kind":"person","name":"Obi L. Griffith","route":"/people/obi-griffith/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-shared-kras-vaccine-adjuvant","kind":"idea","name":"Off-the-shelf KRAS vaccines after pancreatic cancer surgery","route":"/ideas/idea-shared-kras-vaccine-adjuvant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-nk-cells-for-mrd","kind":"idea","name":"Off-the-shelf natural killer cells to sweep up residual disease","route":"/ideas/idea-bio2-nk-cells-for-mrd/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-hpv-vaccinate-at-screening","kind":"idea","name":"Offer HPV vaccination to women when they come for cervical screening or treatment","route":"/ideas/idea-prev-hpv-vaccinate-at-screening/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-blood-crc-test-for-non-responders","kind":"idea","name":"Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy","route":"/ideas/idea-prev-blood-crc-test-for-non-responders/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"oligoprogression","kind":"term","name":"Oligoprogression","route":"/terms/oligoprogression/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"olivier-delattre","kind":"person","name":"Olivier Delattre","route":"/people/olivier-delattre/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"oncology-real-world-data","kind":"technology","name":"Oncology EHR and real-world data platforms","route":"/technologies/oncology-real-world-data/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hospital-information-systems-oncology","kind":"technology","name":"Oncology EHR modules and treatment pathways","route":"/technologies/hospital-information-systems-oncology/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-oncology-hospital-at-home","kind":"idea","name":"Oncology hospital-at-home with remote monitoring for toxicity","route":"/ideas/idea-moon-oncology-hospital-at-home/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-oncology-pharmacist-prescribing","kind":"idea","name":"Oncology pharmacists as protocol prescribers for supportive care and dose adjustments","route":"/ideas/idea-acc-oncology-pharmacist-prescribing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pharmacy-automation","kind":"technology","name":"Oncology pharmacy automation and compounding robots","route":"/technologies/pharmacy-automation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-mainstream-tele-genetic-counselling","kind":"idea","name":"Oncology teams order germline tests; tele-genetic counsellors handle the results","route":"/ideas/idea-acc-mainstream-tele-genetic-counselling/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"oncolytic-plus-pd1","kind":"pairing","name":"Oncolytic virus + PD-1 blockade","route":"/pairings/oncolytic-plus-pd1/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-oncolytic-regulated-il12","kind":"idea","name":"Oncolytic viruses that make interleukin-12 only inside the tumour","route":"/ideas/idea-bio2-oncolytic-regulated-il12/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-car-t-replaces-transplant","kind":"idea","name":"One CAR-T infusion instead of autologous transplant","route":"/ideas/idea-car-t-replaces-transplant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-global-trial-application-portal","kind":"idea","name":"One clinical trial application accepted by regulators in every major region","route":"/ideas/idea-reg-global-trial-application-portal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-ketogenic-gbm-definitive-trial","kind":"idea","name":"One definitive ketogenic diet trial in glioblastoma, then stop","route":"/ideas/idea-nl-ketogenic-gbm-definitive-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-pdl1-digital-calibration","kind":"idea","name":"One digital PD-L1 scale that maps across all the competing assays","route":"/ideas/idea-tr2-pdl1-digital-calibration/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-single-paediatric-plan","kind":"idea","name":"One global paediatric cancer development plan instead of separate FDA and EMA plans","route":"/ideas/idea-reg-single-paediatric-plan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-rare-cancer-global-network","kind":"idea","name":"One global rare cancer network with n-of-1 and Bayesian trial frameworks","route":"/ideas/idea-moon-rare-cancer-global-network/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-shared-postmarketing-registry-condition","kind":"idea","name":"One international registry, not one per country, for conditional approvals","route":"/ideas/idea-reg-shared-postmarketing-registry-condition/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-chemoprevention-master-protocol","kind":"idea","name":"One master trial for cancer prevention drugs across many precancers","route":"/ideas/idea-prev-chemoprevention-master-protocol/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-remote-medical-physics-qa","kind":"idea","name":"One medical physicist covering many radiotherapy machines through remote quality assurance","route":"/ideas/idea-acc-remote-medical-physics-qa/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-open-resistance-atlas","kind":"idea","name":"One open atlas of how tumours escape every drug","route":"/ideas/idea-bio1-open-resistance-atlas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-access-programme-outcomes","kind":"idea","name":"One outcome record for every donated or discounted cancer drug pack","route":"/ideas/idea-data-access-programme-outcomes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-rare-cancer-umbrella-platform","kind":"idea","name":"One standing umbrella trial for all rare cancers in a country","route":"/ideas/idea-bio2-rare-cancer-umbrella-platform/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-one-stop-breast-diagnostic-clinic","kind":"idea","name":"One-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit","route":"/ideas/idea-acc-one-stop-breast-diagnostic-clinic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-senolytics-after-chemo","kind":"idea","name":"One-two punch: clear senescent cells after chemotherapy","route":"/ideas/idea-senolytics-after-chemo/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-open-licensed-guidelines","kind":"idea","name":"Open licences for publicly funded cancer guidelines","route":"/ideas/idea-data-open-licensed-guidelines/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-fus-for-cell-entry","kind":"idea","name":"Open the barrier so engineered immune cells can enter the brain","route":"/ideas/idea-bio2-fus-for-cell-entry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-open-source-dossier-tools","kind":"idea","name":"Open-source dossier-building software for academic sponsors and generic makers","route":"/ideas/idea-reg-open-source-dossier-tools/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-open-source-oncology-drug-discovery","kind":"idea","name":"Open-source drug discovery to clinical proof of concept for neglected cancers","route":"/ideas/idea-moon-open-source-oncology-drug-discovery/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-open-line-of-therapy-algorithms","kind":"idea","name":"Open, benchmarked algorithms for lines of therapy and progression from routine data","route":"/ideas/idea-data-open-line-of-therapy-algorithms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"oral-serd","kind":"term","name":"Oral SERD","route":"/terms/oral-serd/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"oral-serd-plus-cdk46-after-esr1","kind":"pairing","name":"Oral SERD + CDK4/6 inhibitor after ESR1 emergence","route":"/pairings/oral-serd-plus-cdk46-after-esr1/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-organ-preservation-esophageal","kind":"idea","name":"Organ preservation as the default after complete response in oesophageal cancer","route":"/ideas/idea-organ-preservation-esophageal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-pay-for-cure-annuities","kind":"idea","name":"Outcome-based annuity payments for potentially curative one-time therapies","route":"/ideas/idea-fund-pay-for-cure-annuities/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ovarian-function-suppression","kind":"term","name":"Ovarian function suppression (OFS)","route":"/terms/ovarian-function-suppression/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-paid-community-advisory-boards","kind":"idea","name":"Paid community advisory boards with power to change protocol burden","route":"/ideas/idea-tr1-paid-community-advisory-boards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-paid-statistical-review","kind":"idea","name":"Paid independent statistical review for preclinical papers that inform trials","route":"/ideas/idea-tr2-paid-statistical-review/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-peer-navigator-workforce","kind":"idea","name":"Paid survivor peer-navigators as a recognised health workforce role","route":"/ideas/idea-moon-peer-navigator-workforce/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-palliative-care-from-diagnosis-everywhere","kind":"idea","name":"Palliative care from diagnosis for every advanced cancer, including opioid access, worldwide","route":"/ideas/idea-moon-palliative-care-from-diagnosis-everywhere/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pamela-ohashi","kind":"person","name":"Pamela S. Ohashi","route":"/people/pamela-ohashi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","route":"/people/chaturvedi-pankaj/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paolo-veronesi","kind":"person","name":"Paolo Veronesi","route":"/people/paolo-veronesi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-parallel-comorbidity-cohorts","kind":"idea","name":"Parallel real-world cohorts for sicker patients alongside every pivotal trial","route":"/ideas/idea-tr1-parallel-comorbidity-cohorts/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"parp-plus-arpi","kind":"pairing","name":"PARP inhibitor + AR pathway inhibitor (prostate)","route":"/pairings/parp-plus-arpi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"parp-plus-bevacizumab","kind":"pairing","name":"PARP inhibitor + bevacizumab maintenance (HRD-positive)","route":"/pairings/parp-plus-bevacizumab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"parp-pet","kind":"technology","name":"PARP PET","route":"/technologies/parp-pet/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"basu-partha","kind":"person","name":"Partha Basu","route":"/people/basu-partha/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pasritamig","kind":"drug","name":"Pasritamig","route":"/drugs/pasritamig/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-value-based-patent-extension","kind":"idea","name":"Patent term extension scaled to proven survival gain","route":"/ideas/idea-fund-value-based-patent-extension/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-pathologist-assistants-and-ai-triage","kind":"idea","name":"Pathologist assistants plus AI triage to multiply pathologist capacity","route":"/ideas/idea-acc-pathologist-assistants-and-ai-triage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-reflex-genomic-profiling-at-diagnosis","kind":"idea","name":"Pathologists order genomic profiling automatically at diagnosis of advanced cancer","route":"/ideas/idea-acc-reflex-genomic-profiling-at-diagnosis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cure-paths","kind":"roadmap","name":"Paths to cures: interception, eradication, control","route":"/roadmaps/cure-paths/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-organoid-guided-adc","kind":"idea","name":"Patient-derived organoids to pick ADC payloads","route":"/ideas/idea-organoid-guided-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-multimodal-foundation-model","kind":"idea","name":"Patient-level multimodal foundation models for treatment selection","route":"/ideas/idea-multimodal-foundation-model/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-trial-eligibility-at-every-decision","kind":"idea","name":"Patients are told which trials they qualify for at every treatment decision, in writing","route":"/ideas/idea-moon-trial-eligibility-at-every-decision/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-patient-facing-model-cards","kind":"idea","name":"Patients told which AI is used in their care, in plain language","route":"/ideas/idea-data-patient-facing-model-cards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"patrick-hwu","kind":"person","name":"Patrick Hwu","route":"/people/patrick-hwu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"patrick-forde","kind":"person","name":"Patrick M. Forde","route":"/people/patrick-forde/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paul-richardson","kind":"person","name":"Paul G. Richardson","route":"/people/paul-richardson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paul-nurse","kind":"person","name":"Paul Nurse","route":"/people/paul-nurse/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paul-workman","kind":"person","name":"Paul Workman","route":"/people/paul-workman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hoff-paulo","kind":"person","name":"Paulo Hoff","route":"/people/hoff-paulo/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-drug-holiday-resensitisation","kind":"idea","name":"Pause a failed drug so the tumour becomes sensitive to it again","route":"/ideas/idea-bio1-drug-holiday-resensitisation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pawel-kalinski","kind":"person","name":"Pawel Kalinski","route":"/people/pawel-kalinski/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-indication-specific-pricing","kind":"idea","name":"Pay a different price for the same cancer drug depending on the indication","route":"/ideas/idea-reg-indication-specific-pricing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-ai-reimbursement-tied-to-outcomes","kind":"idea","name":"Pay for cancer AI only when it has outcome evidence, then pay properly","route":"/ideas/idea-data-ai-reimbursement-tied-to-outcomes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-biomarker-cwe","kind":"idea","name":"Pay for new biomarker tests only while evidence of clinical utility is being collected","route":"/ideas/idea-tr2-biomarker-cwe/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-annuity-payment-durable-therapies","kind":"idea","name":"Pay for one-time curative therapies as an annuity that stops at relapse","route":"/ideas/idea-reg-annuity-payment-durable-therapies/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-mrd-coverage-with-evidence","kind":"idea","name":"Pay for residual disease tests only inside a trial or registry","route":"/ideas/idea-bio2-mrd-coverage-with-evidence/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-exercise-reimbursement","kind":"idea","name":"Pay for supervised exercise the way we pay for drugs","route":"/ideas/idea-bio2-exercise-reimbursement/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-pay-for-prevention-outcomes","kind":"idea","name":"Pay insurers and health systems for cancers prevented and caught early","route":"/ideas/idea-prev-pay-for-prevention-outcomes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-protected-physician-time-for-enrolment","kind":"idea","name":"Pay oncologists for the time it takes to enrol a patient","route":"/ideas/idea-tr1-protected-physician-time-for-enrolment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-course-based-radiotherapy-payment","kind":"idea","name":"Pay per course of radiotherapy, not per session, so short courses are not penalised","route":"/ideas/idea-fund-course-based-radiotherapy-payment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-pay-for-cure-contracts","kind":"idea","name":"Pay-for-cure contracts: instalment payments for curative therapies contingent on durable remission","route":"/ideas/idea-moon-pay-for-cure-contracts/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-omission-deescalation-trials","kind":"idea","name":"Payer-funded trials that omit surgery or radiotherapy in low-risk patients","route":"/ideas/idea-fund-omission-deescalation-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-payer-combo-cwe","kind":"idea","name":"Payers cover off-label combinations only inside registry-randomised trials","route":"/ideas/idea-tr2-payer-combo-cwe/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-payer-coverage-off-label-generic-commitment","kind":"idea","name":"Payers pre-commit to cover off-label generics when a definitive trial is positive","route":"/ideas/idea-reg-payer-coverage-off-label-generic-commitment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-quality-adjusted-pricing","kind":"idea","name":"Payers price drugs on quality-adjusted benefit, so toxicity costs the manufacturer","route":"/ideas/idea-moon-quality-adjusted-pricing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-payload-switching","kind":"idea","name":"Payload-class switching as the rule for ADC sequencing","route":"/ideas/idea-payload-switching/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"high-potency-payload-synthesis","kind":"technology","name":"Payload-linker synthesis (high-potency API)","route":"/technologies/high-potency-payload-synthesis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pd1-plus-avd-hodgkin","kind":"pairing","name":"PD-1 blockade + AVD chemotherapy","route":"/pairings/pd1-plus-avd-hodgkin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"io-plus-crt-cervical","kind":"pairing","name":"PD-1 blockade + chemoradiation (locally advanced cervical cancer)","route":"/pairings/io-plus-crt-cervical/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pd1-plus-chemo-pdl1-low","kind":"pairing","name":"PD-1 blockade + chemotherapy in PD-L1-low NSCLC","route":"/pairings/pd1-plus-chemo-pdl1-low/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"io-plus-vegf","kind":"pairing","name":"PD-1 blockade + VEGF inhibition","route":"/pairings/io-plus-vegf/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"io-then-til","kind":"pairing","name":"PD-1 failure → TIL therapy","route":"/pairings/io-then-til/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pdac-organoid-pharmacotyping","kind":"technology","name":"PDAC organoid pharmacotyping","route":"/technologies/pdac-organoid-pharmacotyping/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"per-hall","kind":"person","name":"Per Hall","route":"/people/per-hall/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-perioperative-propranolol-etodolac","kind":"idea","name":"Perioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery","route":"/ideas/idea-reg-perioperative-propranolol-etodolac/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"peritoneal-metastasis","kind":"term","name":"Peritoneal metastasis","route":"/terms/peritoneal-metastasis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-peritoneal-directed-gastric","kind":"idea","name":"Peritoneal-directed therapy for gastric cancer","route":"/ideas/idea-peritoneal-directed-gastric/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-neoantigen-vaccines-at-scale","kind":"idea","name":"Personalised cancer vaccines at commodity cost through fully automated manufacturing","route":"/ideas/idea-moon-neoantigen-vaccines-at-scale/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vaccine-plus-pd1","kind":"pairing","name":"Personalised neoantigen vaccine + PD-1 blockade","route":"/pairings/vaccine-plus-pd1/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-fit-risk-adapted-thresholds","kind":"idea","name":"Personalised stool-test cut-offs by age, sex and prior results","route":"/ideas/idea-prev-fit-risk-adapted-thresholds/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-mrd-triggered-neoantigen-vaccine","kind":"idea","name":"Personalised vaccines given only when the blood test turns positive","route":"/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pet-tracer-manufacturing","kind":"technology","name":"PET tracer manufacturing and distribution","route":"/technologies/pet-tracer-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","route":"/people/peter-bartenstein/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ph-positive-all","kind":"term","name":"Ph-positive ALL","route":"/terms/ph-positive-all/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-pharmacist-interaction-review-oral-anticancer","kind":"idea","name":"Pharmacist interaction check before every oral cancer-drug prescription","route":"/ideas/idea-acc-pharmacist-interaction-review-oral-anticancer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-mucositis-taste-programme","kind":"idea","name":"Photobiomodulation and a taste and swallowing programme for mouth and throat toxicity","route":"/ideas/idea-moon-mucositis-taste-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-photoimmunotherapy-plus-pd1","kind":"idea","name":"Photoimmunotherapy as an in situ vaccine with PD-1 blockade","route":"/ideas/idea-photoimmunotherapy-plus-pd1/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pi3k-pathway-plus-endocrine","kind":"pairing","name":"PI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)","route":"/pairings/pi3k-pathway-plus-endocrine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-radiotherapy-sting-fractionation","kind":"idea","name":"Pick the radiation dose that switches the immune alarm on, not off","route":"/ideas/idea-bio2-radiotherapy-sting-fractionation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pier-giuseppe-pelicci","kind":"person","name":"Pier Giuseppe Pelicci","route":"/people/pier-giuseppe-pelicci/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pilar-garrido","kind":"person","name":"Pilar Garrido","route":"/people/pilar-garrido/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-lmic-sites-in-pivotal-trials","kind":"idea","name":"Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded","route":"/ideas/idea-tr1-lmic-sites-in-pivotal-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-adaptive-car-antigen-switch","kind":"idea","name":"Plan the second CAR-T target before the first one is lost","route":"/ideas/idea-bio1-adaptive-car-antigen-switch/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"plasmid-dna-manufacturing","kind":"technology","name":"Plasmid DNA and mRNA raw-material manufacturing","route":"/technologies/plasmid-dna-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"platinum-plus-hrd","kind":"pairing","name":"Platinum chemotherapy in HRD tumours","route":"/pairings/platinum-plus-hrd/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"point-of-care-cell-manufacturing","kind":"technology","name":"Point-of-care and decentralised cell manufacturing","route":"/technologies/point-of-care-cell-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-point-of-care-randomisation","kind":"idea","name":"Point-of-care randomisation built into the oncology record","route":"/ideas/idea-data-point-of-care-randomisation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-io-biomarker-data-commons","kind":"idea","name":"Pool every immunotherapy trial's biomarker data into one commons","route":"/ideas/idea-bio2-io-biomarker-data-commons/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-population-germline-screening","kind":"idea","name":"Population germline screening for hereditary cancer genes with cascade testing","route":"/ideas/idea-moon-population-germline-screening/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-hpv-self-sampling-mailed-default","kind":"idea","name":"Post every woman an HPV self-test kit instead of asking her to book a smear","route":"/ideas/idea-prev-hpv-self-sampling-mailed-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-post-marketing-safety-by-ancestry-and-sex","kind":"idea","name":"Post-marketing safety monitoring stratified by ancestry and sex, with label updates","route":"/ideas/idea-tr1-post-marketing-safety-by-ancestry-and-sex/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-pragmatic-trials-over-75-function-endpoints","kind":"idea","name":"Pragmatic trials in patients over 75 with function, not just survival, as the primary endpoint","route":"/ideas/idea-acc-pragmatic-trials-over-75-function-endpoints/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-mced-change-control-plan","kind":"idea","name":"Pre-agreed update rules so an MCED test is not obsolete when its trial reads out","route":"/ideas/idea-prev-mced-change-control-plan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"preanalytics-sample-stabilisation","kind":"technology","name":"Pre-analytics: blood-collection tubes and tissue fixation","route":"/technologies/preanalytics-sample-stabilisation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-pre-consented-cohort-randomisation","kind":"idea","name":"Pre-consented cohorts that can be randomised to future trials (TwiCs)","route":"/ideas/idea-tr1-pre-consented-cohort-randomisation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-biomarker-study-registry","kind":"idea","name":"Pre-register biomarker validation studies the way trials are registered","route":"/ideas/idea-tr2-biomarker-study-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-preregistered-ai-repurposing-scoring","kind":"idea","name":"Pre-registered, publicly scored AI ranking of repurposing candidates for cancer","route":"/ideas/idea-reg-preregistered-ai-repurposing-scoring/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-crossover-adjusted-survival-standard","kind":"idea","name":"Pre-specified crossover-adjusted survival in every trial that allows crossover","route":"/ideas/idea-tr1-crossover-adjusted-survival-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-irae-prediction-and-prevention","kind":"idea","name":"Predict immune side-effects before they happen and pre-empt them","route":"/ideas/idea-moon-irae-prediction-and-prevention/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-brain-met-prevention-trials","kind":"idea","name":"Prevention trials aimed only at brain metastasis","route":"/ideas/idea-bio2-brain-met-prevention-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-privacy-preserving-linkage-tokens","kind":"idea","name":"Privacy-preserving linkage tokens for every cancer data holder","route":"/ideas/idea-data-privacy-preserving-linkage-tokens/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-technique-innovation-prize","kind":"idea","name":"Prizes for unpatentable surgical and radiotherapy techniques proven in trials","route":"/ideas/idea-fund-technique-innovation-prize/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-mtap-prmt5-mesothelioma","kind":"idea","name":"PRMT5/MAT2A synthetic lethality for MTAP-deleted mesothelioma","route":"/ideas/idea-mtap-prmt5-mesothelioma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-lymphoedema-prospective-surveillance","kind":"idea","name":"Prospective arm-volume surveillance to catch and reverse lymphoedema early","route":"/ideas/idea-acc-lymphoedema-prospective-surveillance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-prostate-as-triggered-biopsy","kind":"idea","name":"Prostate active surveillance without scheduled biopsies: MRI and blood tests decide","route":"/ideas/idea-prev-prostate-as-triggered-biopsy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-hearing-protection-cisplatin","kind":"idea","name":"Protect hearing from cisplatin in adults as we now do in children","route":"/ideas/idea-moon-hearing-protection-cisplatin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-antibiotic-stewardship-io","kind":"idea","name":"Protect the gut flora of patients about to start immunotherapy","route":"/ideas/idea-bio2-antibiotic-stewardship-io/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"proteomics-platforms","kind":"technology","name":"Proteomics instruments and affinity platforms","route":"/technologies/proteomics-platforms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-provisional-price-until-os","kind":"idea","name":"Provisional prices for surrogate-endpoint approvals, reset when survival data arrive","route":"/ideas/idea-reg-provisional-price-until-os/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"psma-pet-to-rlt","kind":"pairing","name":"PSMA PET → PSMA radioligand therapy","route":"/pairings/psma-pet-to-rlt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-psma-pet-guided-mdt","kind":"idea","name":"PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer","route":"/ideas/idea-psma-pet-guided-mdt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-public-cell-therapy-foundries","kind":"idea","name":"Public cell-therapy foundries at cancer centres for academics and start-ups","route":"/ideas/idea-reg-public-cell-therapy-foundries/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-quality-scorecards","kind":"idea","name":"Public data-quality scorecards for every cancer centre","route":"/ideas/idea-data-quality-scorecards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-academic-cart-at-cost-coverage","kind":"idea","name":"Public payers cover academic CAR-T at cost as a benchmark for commercial prices","route":"/ideas/idea-reg-academic-cart-at-cost-coverage/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-termination-reports","kind":"idea","name":"Public post-mortem reports when a cancer drug programme is stopped","route":"/ideas/idea-tr2-termination-reports/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-procurement-open-api-clauses","kind":"idea","name":"Public procurement clauses banning data export fees and lock-in","route":"/ideas/idea-data-procurement-open-api-clauses/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-cart-potency-reference-standards","kind":"idea","name":"Public reference standards and potency assays for CAR-T so every lab measures alike","route":"/ideas/idea-reg-cart-potency-reference-standards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-lmic-public-cart-manufacturing","kind":"idea","name":"Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000","route":"/ideas/idea-reg-lmic-public-cart-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-open-weights-for-public-funded-ai","kind":"idea","name":"Publicly funded cancer AI must release open weights and model cards","route":"/ideas/idea-data-open-weights-for-public-funded-ai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-public-deescalation-trials-for-cost","kind":"idea","name":"Publicly funded trials of lower and less frequent doses of expensive cancer drugs","route":"/ideas/idea-reg-public-deescalation-trials-for-cost/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-publish-all-rejections","kind":"idea","name":"Publish every complete response letter and negative opinion across all regulators","route":"/ideas/idea-reg-publish-all-rejections/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-bicr-discordance-public","kind":"idea","name":"Publish the disagreement between trial doctors and independent reviewers for every trial","route":"/ideas/idea-tr2-bicr-discordance-public/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-public-screen-fail-reasons","kind":"idea","name":"Publish why patients were screened out of each trial","route":"/ideas/idea-tr1-public-screen-fail-reasons/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-whole-genome-mrd-depth","kind":"idea","name":"Push residual disease detection a hundredfold deeper with whole-genome methods","route":"/ideas/idea-bio2-whole-genome-mrd-depth/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-cytisine-essential-medicine","kind":"idea","name":"Put cytisine, a cheap plant-based quit-smoking pill, on every essential medicines list","route":"/ideas/idea-prev-cytisine-essential-medicine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"puxitatug-samrotecan","kind":"drug","name":"Puxitatug samrotecan","route":"/drugs/puxitatug-samrotecan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-ipsc-master-bank-qualified-once","kind":"idea","name":"Qualify one iPSC master cell bank once for many off-the-shelf cell products","route":"/ideas/idea-reg-ipsc-master-bank-qualified-once/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-quality-adjusted-survival-standard","kind":"idea","name":"Quality-adjusted survival reported in every trial publication and label","route":"/ideas/idea-moon-quality-adjusted-survival-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-preference-studies-before-phase3","kind":"idea","name":"Quantitative patient preference studies set the benefit-risk bar before phase 3","route":"/ideas/idea-moon-preference-studies-before-phase3/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-question-prompt-lists","kind":"idea","name":"Question prompt lists sent to patients before every major consultation","route":"/ideas/idea-moon-question-prompt-lists/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rai-refractory","kind":"term","name":"Radioiodine-refractory (RAI-R) thyroid cancer","route":"/terms/rai-refractory/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"radionuclide-generators-kits","kind":"technology","name":"Radionuclide generators and cold kits","route":"/technologies/radionuclide-generators-kits/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"radiation-plus-io","kind":"pairing","name":"Radiotherapy + immunotherapy","route":"/pairings/radiation-plus-io/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"treatment-planning-systems","kind":"technology","name":"Radiotherapy treatment planning and QA software","route":"/technologies/treatment-planning-systems/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kaliks-rafael","kind":"person","name":"Rafael Kaliks","route":"/people/kaliks-rafael/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"raffit-hassan","kind":"person","name":"Raffit Hassan","route":"/people/raffit-hassan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","route":"/people/badwe-rajendra/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ramaswamy-govindan","kind":"person","name":"Ramaswamy Govindan","route":"/people/ramaswamy-govindan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ramon-parsons","kind":"person","name":"Ramon E. Parsons","route":"/people/ramon-parsons/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-random-audit","kind":"idea","name":"Random audits of published, funded research, like tax audits","route":"/ideas/idea-tr2-random-audit/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-antihistamine-plus-io-trial","kind":"idea","name":"Randomise a cheap antihistamine alongside immunotherapy","route":"/ideas/idea-reg-antihistamine-plus-io-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the registry that already follows every patient","route":"/ideas/idea-bio2-registry-embedded-randomisation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-pre-randomised-sequencing-trials","kind":"idea","name":"Randomise the next line of treatment before the first one fails","route":"/ideas/idea-bio1-pre-randomised-sequencing-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-implementation-trials-programme","kind":"idea","name":"Randomised trials of how to spread proven cancer treatments, not just what works","route":"/ideas/idea-data-implementation-trials-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-immunotherapy-stop-trials","kind":"idea","name":"Randomised trials of stopping immunotherapy after one year versus continuing","route":"/ideas/idea-tr1-immunotherapy-stop-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-biomarker-negative-arms","kind":"idea","name":"Randomised trials to test whether biomarker-negative patients really do not benefit","route":"/ideas/idea-tr2-biomarker-negative-arms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-rapid-diagnostic-centres-vague-symptoms","kind":"idea","name":"Rapid diagnostic centres for people with vague but worrying symptoms","route":"/ideas/idea-acc-rapid-diagnostic-centres-vague-symptoms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-ras-inhibitor-neoadjuvant-pdac","kind":"idea","name":"RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable","route":"/ideas/idea-ras-inhibitor-neoadjuvant-pdac/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-antigen-mapping-at-progression","kind":"idea","name":"Re-map the tumour's surface proteins before choosing the next antibody drug","route":"/ideas/idea-bio1-antigen-mapping-at-progression/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-rebiopsy-before-switch","kind":"idea","name":"Re-test the metastasis, not the old primary, before every change of treatment","route":"/ideas/idea-bio1-rebiopsy-before-switch/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-ai-sarcopenia-from-ct","kind":"idea","name":"Read muscle loss automatically from scans patients already have","route":"/ideas/idea-bio2-ai-sarcopenia-from-ct/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-csf-ctdna-monitoring","kind":"idea","name":"Read the spinal fluid to track brain tumours without opening the skull","route":"/ideas/idea-bio2-csf-ctdna-monitoring/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-guideline-concordance-dashboards","kind":"idea","name":"Real-time guideline-concordance feedback for every cancer centre","route":"/ideas/idea-data-guideline-concordance-dashboards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-image-guided-surgery-everywhere","kind":"idea","name":"Real-time margin assessment and image-guided surgery as the global standard","route":"/ideas/idea-moon-image-guided-surgery-everywhere/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-outcome-based-price-reassessment","kind":"idea","name":"Reassess cancer drug prices at three years using real-world outcomes","route":"/ideas/idea-data-outcome-based-price-reassessment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-reciprocal-tumour-agnostic-approvals","kind":"idea","name":"Reciprocal recognition of tumour-agnostic and rare-indication approvals across regulators","route":"/ideas/idea-moon-reciprocal-tumour-agnostic-approvals/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-diagnostic-interval-public-registry","kind":"idea","name":"Record and publish the symptom-to-diagnosis interval for every cancer, by hospital","route":"/ideas/idea-acc-diagnostic-interval-public-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-preanalytics-in-report","kind":"idea","name":"Record how long tissue waited before fixation in every pathology report","route":"/ideas/idea-tr2-preanalytics-in-report/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-off-label-outcome-registry","kind":"idea","name":"Record what happens when doctors use cancer drugs off-label","route":"/ideas/idea-tr2-off-label-outcome-registry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-recorded-consultations","kind":"idea","name":"Recorded, AI-summarised consultations given to patients by default","route":"/ideas/idea-moon-recorded-consultations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-ai-red-team-programme","kind":"idea","name":"Red-team programmes that attack cancer AI before patients do","route":"/ideas/idea-data-ai-red-team-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-response-adapted-dose-reduction","kind":"idea","name":"Reduce the dose once the cancer responds: response-adapted de-escalation trials","route":"/ideas/idea-tr1-response-adapted-dose-reduction/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"reference-laboratories","kind":"technology","name":"Reference laboratories and companion-diagnostic testing","route":"/technologies/reference-laboratories/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-mrd-reference-standards","kind":"idea","name":"Reference materials and open proficiency testing for residual disease tests","route":"/ideas/idea-bio2-mrd-reference-standards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-ac225-accelerator-pharmacopoeia","kind":"idea","name":"Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit","route":"/ideas/idea-reg-ac225-accelerator-pharmacopoeia/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-regional-radiopharmacy-hubs","kind":"idea","name":"Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes","route":"/ideas/idea-reg-regional-radiopharmacy-hubs/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-regional-oncology-training-hubs","kind":"idea","name":"Regional training hubs that produce oncologists, physicists and radiographers in-region","route":"/ideas/idea-acc-regional-oncology-training-hubs/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-mesothelin-car-t-regional","kind":"idea","name":"Regionally delivered mesothelin CAR-T with PD-1 blockade","route":"/ideas/idea-mesothelin-car-t-regional/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-mced-registry-randomised","kind":"idea","name":"Registry-based randomised MCED trial: a million people, no study visits","route":"/ideas/idea-prev-mced-registry-randomised/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-registry-based-rcts","kind":"idea","name":"Registry-based randomised trials for oncology comparative effectiveness","route":"/ideas/idea-data-registry-based-rcts/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-pragmatic-sequence-randomisation","kind":"idea","name":"Registry-embedded randomisation of treatment order in routine care","route":"/ideas/idea-tr2-pragmatic-sequence-randomisation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-precursor-endpoints-for-approval","kind":"idea","name":"Regulators accept shrinking of precancer as the endpoint for prevention drug approval","route":"/ideas/idea-prev-precursor-endpoints-for-approval/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-cdx-mutual-recognition","kind":"idea","name":"Regulators recognise each other's companion diagnostic approvals","route":"/ideas/idea-tr2-cdx-mutual-recognition/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"reinhard-buettner","kind":"person","name":"Reinhard Büttner","route":"/people/reinhard-buettner/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-remote-consent-tele-screening","kind":"idea","name":"Remote consent and tele-screening so the first trial visit is a video call","route":"/ideas/idea-tr1-remote-consent-tele-screening/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-disability-and-mental-illness-inclusion","kind":"idea","name":"Remove blanket exclusions for mental illness and dementia; support consent instead","route":"/ideas/idea-tr1-disability-and-mental-illness-inclusion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-opportunistic-salpingectomy-default","kind":"idea","name":"Remove the fallopian tubes during any pelvic surgery once childbearing is finished","route":"/ideas/idea-prev-opportunistic-salpingectomy-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rene-bernards","kind":"person","name":"René Bernards","route":"/people/rene-bernards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","route":"/people/renier-brentjens/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-hcc-blood-surveillance-cirrhosis","kind":"idea","name":"Replace six-monthly ultrasound with a blood test for liver cancer in cirrhosis","route":"/ideas/idea-prev-hcc-blood-surveillance-cirrhosis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-time-toxicity-reporting","kind":"idea","name":"Report time toxicity, the days a treatment consumes, in every trial and decision aid","route":"/ideas/idea-moon-time-toxicity-reporting/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-time-toxicity-reporting","kind":"idea","name":"Report time toxicity, the days spent in healthcare, as a standard outcome for older patients","route":"/ideas/idea-acc-time-toxicity-reporting/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-trem2-myeloid-reprogramming","kind":"idea","name":"Reprogramme suppressive macrophages instead of trying to delete them","route":"/ideas/idea-bio2-trem2-myeloid-reprogramming/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-liver-niche-kupffer-reprogramming","kind":"idea","name":"Reprogramme the liver's own immune cells to refuse metastases","route":"/ideas/idea-bio2-liver-niche-kupffer-reprogramming/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-randomised-phase-2-before-phase-3","kind":"idea","name":"Require a randomised phase 2 before any phase 3","route":"/ideas/idea-tr1-randomised-phase-2-before-phase-3/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-brain-exposure-disclosure","kind":"idea","name":"Require every oncology candidate to publish how much reaches the brain","route":"/ideas/idea-bio2-brain-exposure-disclosure/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-evidence-gate-before-repurposing-phase3","kind":"idea","name":"Require genetic and target-trial evidence before funding any repurposing phase 3","route":"/ideas/idea-reg-evidence-gate-before-repurposing-phase3/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-head-to-head-mandate","kind":"idea","name":"Require head-to-head trials against the best in class for later entrants","route":"/ideas/idea-fund-head-to-head-mandate/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-post-approval-evidence-over-75","kind":"idea","name":"Require post-approval evidence in patients over 75 and update labels accordingly","route":"/ideas/idea-acc-post-approval-evidence-over-75/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-ai-screening-endpoints","kind":"idea","name":"Require stage-shift or interval-cancer endpoints for AI in cancer screening","route":"/ideas/idea-data-ai-screening-endpoints/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-failed-trial-biobank","kind":"idea","name":"Rescue the biological samples from failed trials for biomarker research","route":"/ideas/idea-tr2-failed-trial-biobank/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-weight-based-io-dosing-label","kind":"idea","name":"Restore weight-based dosing and vial sharing for immunotherapy in the label","route":"/ideas/idea-reg-weight-based-io-dosing-label/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-retention-packages-oncology","kind":"idea","name":"Retention packages so trained oncology staff stay: bonds, top-ups, working equipment","route":"/ideas/idea-acc-retention-packages-oncology/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-model-based-dose-finding-with-late-toxicity","kind":"idea","name":"Retire the 3+3: model-based dose finding that counts late and chronic side effects","route":"/ideas/idea-tr1-model-based-dose-finding-with-late-toxicity/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rinatabart-sesutecan","kind":"drug","name":"Rinatabart sesutecan","route":"/drugs/rinatabart-sesutecan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rindopepimut","kind":"drug","name":"Rindopepimut","route":"/drugs/rindopepimut/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-risk-stratified-follow-up","kind":"idea","name":"Risk-stratified follow-up: low-risk survivors to primary care with fast re-entry","route":"/ideas/idea-acc-risk-stratified-follow-up/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-survivor-lifelong-care-model","kind":"idea","name":"Risk-stratified lifelong care for tens of millions of survivors, automated and shared with primary care","route":"/ideas/idea-moon-survivor-lifelong-care-model/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-fenstermaker","kind":"person","name":"Robert A. Fenstermaker","route":"/people/robert-fenstermaker/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-schreiber","kind":"person","name":"Robert D. Schreiber","route":"/people/robert-schreiber/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-mach","kind":"person","name":"Robert H. Mach","route":"/people/robert-mach/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","route":"/people/robert-vonderheide/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-sandler","kind":"person","name":"Robert Sandler","route":"/people/robert-sandler/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"roberto-orecchia","kind":"person","name":"Roberto Orecchia","route":"/people/roberto-orecchia/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-robotic-convection-delivery","kind":"idea","name":"Robot-placed catheters and live imaging for drug infusion into brain tumours","route":"/ideas/idea-bio2-robotic-convection-delivery/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"roger-stupp","kind":"person","name":"Roger Stupp","route":"/people/roger-stupp/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rolf-kiessling","kind":"person","name":"Rolf Kiessling","route":"/people/rolf-kiessling/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-mammography-ai-stepped-wedge","kind":"idea","name":"Roll out AI-supported mammography nationally as a stepped-wedge trial","route":"/ideas/idea-prev-mammography-ai-stepped-wedge/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"roman-thomas","kind":"person","name":"Roman Thomas","route":"/people/roman-thomas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ross-levine","kind":"person","name":"Ross L. Levine","route":"/people/ross-levine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-alternating-schedules","kind":"idea","name":"Rotate between drugs on a fixed schedule instead of waiting for failure","route":"/ideas/idea-bio1-alternating-schedules/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-remote-planning-hubs","kind":"idea","name":"Round-the-clock remote treatment-planning hubs for clinics without physicists","route":"/ideas/idea-acc-remote-planning-hubs/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-ai-decommissioning-rules","kind":"idea","name":"Rules for retiring cancer AI when performance drops or the standard of care moves","route":"/ideas/idea-data-ai-decommissioning-rules/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-co-clinical-avatar-trials","kind":"idea","name":"Run the mouse or organoid trial at the same time as the human trial","route":"/ideas/idea-bio1-co-clinical-avatar-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ruth-plummer","kind":"person","name":"Ruth Plummer","route":"/people/ruth-plummer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","route":"/people/ryan-corcoran/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","route":"/people/ryan-sullivan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sabine-linn","kind":"person","name":"Sabine Linn","route":"/people/sabine-linn/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","route":"/people/shin-sang-joon/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sara-lopez-tarruella","kind":"person","name":"Sara López-Tarruella","route":"/people/sara-lopez-tarruella/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dawson-sarah-jane","kind":"person","name":"Sarah-Jane Dawson","route":"/people/dawson-sarah-jane/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sarcomatoid-rcc","kind":"term","name":"Sarcomatoid differentiation (RCC)","route":"/terms/sarcomatoid-rcc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-scoop-protection-policy","kind":"idea","name":"Scoop protection and co-publication norms to reduce academic secrecy","route":"/ideas/idea-fund-scoop-protection-policy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-model-predictivity-benchmark","kind":"idea","name":"Score every model system on how well it predicted real trial results","route":"/ideas/idea-bio1-model-predictivity-benchmark/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-model-report-cards","kind":"idea","name":"Score every preclinical model by how often it predicted the clinical result","route":"/ideas/idea-tr2-model-report-cards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-financial-toxicity-vital-sign","kind":"idea","name":"Screen every cancer patient for financial toxicity as a vital sign, with navigation","route":"/ideas/idea-reg-financial-toxicity-vital-sign/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-financial-toxicity-screening-at-diagnosis","kind":"idea","name":"Screen every patient for financial hardship at diagnosis and connect them to help","route":"/ideas/idea-acc-financial-toxicity-screening-at-diagnosis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-financial-toxicity-screening","kind":"idea","name":"Screen every patient for financial toxicity at diagnosis and refer like any other symptom","route":"/ideas/idea-moon-financial-toxicity-screening/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-glue-degrader-atlas","kind":"idea","name":"Screen glue-like compounds against every cancer cell line and publish it","route":"/ideas/idea-bio1-glue-degrader-atlas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","route":"/people/lee-se-hoon/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-seamless-2-3-with-prespecified-go","kind":"idea","name":"Seamless phase 2/3 with pre-registered go rules as the default for new agents","route":"/ideas/idea-tr1-seamless-2-3-with-prespecified-go/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-til-reactivity-selection","kind":"idea","name":"Select patients for cell therapy by whether their tumour holds reactive T cells","route":"/ideas/idea-bio2-til-reactivity-selection/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-self-driving-cancer-labs","kind":"idea","name":"Self-driving laboratories that run the cancer biology hypothesis loop autonomously","route":"/ideas/idea-moon-self-driving-cancer-labs/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","route":"/people/selwyn-vickers/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"semir-beyaz","kind":"person","name":"Semir Beyaz","route":"/people/semir-beyaz/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-screening-default-appointments","kind":"idea","name":"Send screening invitations with a pre-booked time, not a request to call","route":"/ideas/idea-prev-screening-default-appointments/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fra-adc-sequencing-ovarian","kind":"idea","name":"Sequence folate-receptor ADCs by payload class","route":"/ideas/idea-fra-adc-sequencing-ovarian/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"targeted-before-io-nsclc","kind":"pairing","name":"Sequence: targeted therapy before immunotherapy in driver-positive NSCLC","route":"/pairings/targeted-before-io-nsclc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tarlatamab-vs-idxd-sequence","kind":"pairing","name":"Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC","route":"/pairings/tarlatamab-vs-idxd-sequence/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-her2-adc-sequencing-payload","kind":"idea","name":"Sequencing HER2 ADCs by payload after T-DXd","route":"/ideas/idea-her2-adc-sequencing-payload/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-smart-sequencing-adc","kind":"idea","name":"Sequential multiple-assignment randomised trials to find the best order of ADCs","route":"/ideas/idea-tr2-smart-sequencing-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sergio-roman-roman","kind":"person","name":"Sergio Roman-Roman","route":"/people/sergio-roman-roman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-incidence-weighted-enrolment-targets","kind":"idea","name":"Set trial enrolment targets from who actually gets the disease, and publish progress live","route":"/ideas/idea-tr1-incidence-weighted-enrolment-targets/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-sexual-health-as-toxicity-domain","kind":"idea","name":"Sexual health assessed and treated as a standard toxicity domain","route":"/ideas/idea-moon-sexual-health-as-toxicity-domain/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shaomeng-wang","kind":"person","name":"Shaomeng Wang","route":"/people/shaomeng-wang/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-splice-neoantigens","kind":"idea","name":"Shared splice-derived neoantigens as off-the-shelf vaccine targets","route":"/ideas/idea-splice-neoantigens/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","route":"/people/shari-pilon-thomas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sharon-belvin","kind":"person","name":"Sharon Belvin","route":"/people/sharon-belvin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shilpa-gupta","kind":"person","name":"Shilpa Gupta","route":"/people/shilpa-gupta/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ohno-shinji","kind":"person","name":"Shinji Ohno","route":"/people/ohno-shinji/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-benefit-indexed-exclusivity","kind":"idea","name":"Shorter exclusivity for later-in-class drugs without added benefit","route":"/ideas/idea-fund-benefit-indexed-exclusivity/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-shortened-venetoclax","kind":"idea","name":"Shorter venetoclax courses in unfit AML","route":"/ideas/idea-shortened-venetoclax/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"takahashi-shunji","kind":"person","name":"Shunji Takahashi","route":"/people/takahashi-shunji/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-pathway-capacity-simulation","kind":"idea","name":"Simulate each hospital's cancer pathway as a queue to find and remove the waits","route":"/ideas/idea-acc-pathway-capacity-simulation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-single-dose-hpv-self-sampling-elimination","kind":"idea","name":"Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries","route":"/ideas/idea-single-dose-hpv-self-sampling-elimination/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-single-fraction-palliative-radiotherapy-default","kind":"idea","name":"Single-fraction radiotherapy as the default for painful bone metastases","route":"/ideas/idea-acc-single-fraction-palliative-radiotherapy-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-apobec-inhibitor-adjunct","kind":"idea","name":"Slow the tumour's mutation engine with APOBEC inhibitors during targeted therapy","route":"/ideas/idea-bio1-apobec-inhibitor-adjunct/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-writeup-grants","kind":"idea","name":"Small grants that pay scientists to write up abandoned projects","route":"/ideas/idea-tr2-writeup-grants/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-rna-targeting-small-molecules","kind":"idea","name":"Small molecules that cut the RNA message of an undruggable oncogene","route":"/ideas/idea-bio1-rna-targeting-small-molecules/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-smart-designs-for-adaptive-strategies","kind":"idea","name":"SMART designs to test treatment strategies, not just single drugs","route":"/ideas/idea-tr1-smart-designs-for-adaptive-strategies/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-weight-loss-auto-alert","kind":"idea","name":"Smart scales and health records flag unexplained weight loss for a cancer check","route":"/ideas/idea-prev-weight-loss-auto-alert/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"smcc","kind":"term","name":"SMCC (thioether, non-cleavable)","route":"/terms/smcc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-social-impact-bonds-prevention","kind":"idea","name":"Social impact bonds for cancer prevention, repaid from avoided treatment costs","route":"/ideas/idea-fund-social-impact-bonds-prevention/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-social-impact-bond-switching","kind":"idea","name":"Social impact bonds that fund biosimilar switching, repaid from payer savings","route":"/ideas/idea-reg-social-impact-bond-switching/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-matrix-stiffness-prevention","kind":"idea","name":"Soften the tissue that new metastases need in order to grow","route":"/ideas/idea-bio2-matrix-stiffness-prevention/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"solange-peters","kind":"person","name":"Solange Peters","route":"/people/solange-peters/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-solar-microgrids-for-cancer-units","kind":"idea","name":"Solar microgrids so radiotherapy, pathology and drug fridges never lose power","route":"/ideas/idea-acc-solar-microgrids-for-cancer-units/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cmg901","kind":"drug","name":"Sonesitatug vedotin","route":"/drugs/cmg901/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"spatial-biology-instruments","kind":"technology","name":"Spatial biology instruments","route":"/technologies/spatial-biology-instruments/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-confirmatory-trial-escrow","kind":"idea","name":"Sponsors deposit the confirmatory trial budget in escrow at accelerated approval","route":"/ideas/idea-reg-confirmatory-trial-escrow/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"escc-vs-eac","kind":"term","name":"Squamous cell carcinoma vs adenocarcinoma of the oesophagus","route":"/terms/escc-vs-eac/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-net-antagonist-ligands","kind":"idea","name":"SSTR antagonist radioligands to increase tumour dose","route":"/ideas/idea-net-antagonist-ligands/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sstr-pet-to-prrt","kind":"pairing","name":"SSTR PET → PRRT","route":"/pairings/sstr-pet-to-prrt/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"stage-shift","kind":"term","name":"Stage shift","route":"/terms/stage-shift/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-external-control-arm-standard","kind":"idea","name":"Standards for external control arms built from federated real-world data","route":"/ideas/idea-data-external-control-arm-standard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-spatial-biomarker-standards","kind":"idea","name":"Standards for spatial and multiplex tissue biomarkers before they reach the clinic","route":"/ideas/idea-tr2-spatial-biomarker-standards/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-reflex-biomarker-panels-by-tumour","kind":"idea","name":"Standing reflex biomarker panels per tumour type, run without an oncologist's order","route":"/ideas/idea-acc-reflex-biomarker-panels-by-tumour/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-start-low-titrate-up-oral-agents","kind":"idea","name":"Start low and step up: individualised titration of oral cancer drugs, randomised","route":"/ideas/idea-tr1-start-low-titrate-up-oral-agents/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-translation-dependency-myc","kind":"idea","name":"Starve MYC-driven tumours by blocking protein production machinery","route":"/ideas/idea-bio1-translation-dependency-myc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-persister-metabolic-vulnerability","kind":"idea","name":"Starve the survivors: target the energy pathway drug-tolerant cells switch to","route":"/ideas/idea-bio1-persister-metabolic-vulnerability/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"stefan-froehling","kind":"person","name":"Stefan Fröhling","route":"/people/stefan-froehling/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"stefan-pfister","kind":"person","name":"Stefan Pfister","route":"/people/stefan-pfister/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","route":"/people/stephen-baylin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sterile-fill-finish","kind":"technology","name":"Sterile fill-finish and lyophilisation","route":"/technologies/sterile-fill-finish/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"steven-le-gouill","kind":"person","name":"Steven Le Gouill","route":"/people/steven-le-gouill/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-gastric-serology-migrant-screening","kind":"idea","name":"Stomach cancer serology screening for high-risk migrant communities in low-incidence countries","route":"/ideas/idea-prev-gastric-serology-migrant-screening/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-thyroid-no-screening-no-small-biopsy","kind":"idea","name":"Stop biopsying small thyroid nodules and never screen the thyroid","route":"/ideas/idea-prev-thyroid-no-screening-no-small-biopsy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-aggressive-futility-boundaries","kind":"idea","name":"Stop failing trials earlier with pre-registered aggressive futility rules","route":"/ideas/idea-tr1-aggressive-futility-boundaries/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-include-pregnancy-capable-people-sensibly","kind":"idea","name":"Stop over-excluding people who could become pregnant; study pregnancy exposure","route":"/ideas/idea-tr1-include-pregnancy-capable-people-sensibly/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-barrett-surveillance-deescalation","kind":"idea","name":"Stop routine endoscopies for non-dysplastic Barrett's oesophagus","route":"/ideas/idea-prev-barrett-surveillance-deescalation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-screening-stop-by-life-expectancy","kind":"idea","name":"Stop screening by life expectancy, not birthday, with a tool in the record","route":"/ideas/idea-prev-screening-stop-by-life-expectancy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-ipmn-surveillance-stop-rule","kind":"idea","name":"Stop watching stable low-risk pancreatic cysts after five years","route":"/ideas/idea-prev-ipmn-surveillance-stop-rule/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-platelet-cloak-aspirin-mrd","kind":"idea","name":"Strip the platelet coat off travelling tumour cells in ctDNA-positive patients","route":"/ideas/idea-bio2-platelet-cloak-aspirin-mrd/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"structural-biology-infrastructure","kind":"technology","name":"Structural biology infrastructure (cryo-EM, synchrotrons, AlphaFold)","route":"/technologies/structural-biology-infrastructure/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-exercise-as-adjuvant","kind":"idea","name":"Structured exercise prescribed like a drug in all curative-intent cancer care","route":"/ideas/idea-exercise-as-adjuvant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-district-surgeon-oncology-mentorship","kind":"idea","name":"Structured mentorship so district general surgeons perform common cancer operations safely","route":"/ideas/idea-acc-district-surgeon-oncology-mentorship/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-structured-radiology-response","kind":"idea","name":"Structured, coded radiology reports for cancer response instead of free text","route":"/ideas/idea-data-structured-radiology-response/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-standard-of-care-change-alerts","kind":"idea","name":"Subscribable alerts when the standard of care changes for a patient's situation","route":"/ideas/idea-data-standard-of-care-change-alerts/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-io-subscription-national","kind":"idea","name":"Subscription pricing for checkpoint inhibitors: fixed national fee, unlimited use","route":"/ideas/idea-reg-io-subscription-national/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-sclc-subtype-directed","kind":"idea","name":"Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)","route":"/ideas/idea-sclc-subtype-directed/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sulfo-spdb","kind":"term","name":"Sulfo-SPDB (disulfide)","route":"/terms/sulfo-spdb/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rha-sun-young","kind":"person","name":"Sun Young Rha","route":"/people/rha-sun-young/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sundar-jagannath","kind":"person","name":"Sundar Jagannath","route":"/people/sundar-jagannath/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lee-sung-gyu","kind":"person","name":"Sung-Gyu Lee","route":"/people/lee-sung-gyu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-first-strike-second-strike","kind":"idea","name":"Switch drugs at maximum response, not at relapse","route":"/ideas/idea-bio1-first-strike-second-strike/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-epigenetic-silencing-in-vivo","kind":"idea","name":"Switch off an undruggable oncogene permanently with epigenetic editing","route":"/ideas/idea-bio1-epigenetic-silencing-in-vivo/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-cns-first-adc-strategy","kind":"idea","name":"Systemic-first management of HER2-positive brain metastases","route":"/ideas/idea-cns-first-adc-strategy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"t030","kind":"term","name":"T030 (belotecan derivative)","route":"/terms/t030/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tace-plus-systemic","kind":"pairing","name":"TACE + immunotherapy/anti-VEGF","route":"/pairings/tace-plus-systemic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kim-tae-you","kind":"person","name":"Tae-You Kim","route":"/people/kim-tae-you/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-tailored-second-cancer-screening","kind":"idea","name":"Tailored screening for second cancers in survivors with known high-risk exposures","route":"/ideas/idea-acc-tailored-second-cancer-screening/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tak-mak","kind":"person","name":"Tak W. Mak","route":"/people/tak-mak/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kohno-takashi","kind":"person","name":"Takashi Kohno","route":"/people/kohno-takashi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ueno-takayuki","kind":"person","name":"Takayuki Ueno","route":"/people/ueno-takayuki/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-fmt-plus-checkpoint-phase3","kind":"idea","name":"Take faecal transplant plus immunotherapy to a definitive trial","route":"/ideas/idea-bio2-fmt-plus-checkpoint-phase3/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-mobile-lung-screening-deprived-areas","kind":"idea","name":"Take lung screening scanners to supermarket car parks in the poorest areas","route":"/ideas/idea-prev-mobile-lung-screening-deprived-areas/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-circadian-mrd-sampling","kind":"idea","name":"Take the blood test, and give the drug, at the right time of day","route":"/ideas/idea-bio2-circadian-mrd-sampling/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sano-takeshi","kind":"person","name":"Takeshi Sano","route":"/people/sano-takeshi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tandem-transplant","kind":"technology","name":"Tandem autologous transplant","route":"/technologies/tandem-transplant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prame-tcr-beyond-a02","kind":"idea","name":"TCR therapeutics for non-HLA-A*02 patients","route":"/ideas/idea-prame-tcr-beyond-a02/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"telemedicine-teleoncology","kind":"technology","name":"Telemedicine, teleoncology, and telepathology","route":"/technologies/telemedicine-teleoncology/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tert-promoter","kind":"term","name":"TERT promoter mutation","route":"/terms/tert-promoter/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-fibre-diet-io-trial","kind":"idea","name":"Test a high-fibre diet as an immunotherapy adjunct","route":"/ideas/idea-bio2-fibre-diet-io-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-alternating-vs-concurrent","kind":"idea","name":"Test alternating drug schedules against giving both drugs at once","route":"/ideas/idea-tr2-alternating-vs-concurrent/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-aged-comorbid-models","kind":"idea","name":"Test cancer drugs in old and unhealthy animals, not just young fit ones","route":"/ideas/idea-bio1-aged-comorbid-models/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-tumour-slice-cultures","kind":"idea","name":"Test drugs on freshly cut slices of the patient's own tumour","route":"/ideas/idea-bio1-tumour-slice-cultures/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-functional-precision-rare","kind":"idea","name":"Test drugs on the patient's own cancer cells when there is no trial to join","route":"/ideas/idea-bio2-functional-precision-rare/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-vus-saturation-editing-consortium","kind":"idea","name":"Test every possible mutation in every cancer gene so no result is 'uncertain'","route":"/ideas/idea-prev-vus-saturation-editing-consortium/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-weight-based-vs-flat-dosing-trials","kind":"idea","name":"Test flat versus weight-based dosing of antibodies, and use dose banding to cut waste","route":"/ideas/idea-tr1-weight-based-vs-flat-dosing-trials/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-protein-plus-training-during-io","kind":"idea","name":"Test protein and resistance training during immunotherapy","route":"/ideas/idea-bio2-protein-plus-training-during-io/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-marker-stratified-default","kind":"idea","name":"Test the drug in biomarker-negative patients too, so the biomarker can be validated","route":"/ideas/idea-tr2-marker-stratified-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-gleason6-terminology-rct","kind":"idea","name":"Test whether calling Gleason 6 'not cancer' changes what men choose","route":"/ideas/idea-prev-gleason6-terminology-rct/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ggfg","kind":"term","name":"Tetrapeptide GGFG (maleimide-GGFG-aminomethyl)","route":"/terms/ggfg/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-pathology-triggered-referral","kind":"idea","name":"The pathology lab triggers a trial referral the day a rare cancer is diagnosed","route":"/ideas/idea-tr1-pathology-triggered-referral/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"theodore-hong","kind":"person","name":"Theodore S. Hong","route":"/people/theodore-hong/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"theodore-lawrence","kind":"person","name":"Theodore S. Lawrence","route":"/people/theodore-lawrence/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"precancer-ablation","kind":"technology","name":"Thermal ablation and cryotherapy for cervical precancer","route":"/technologies/precancer-ablation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"thomas-bachelot","kind":"person","name":"Thomas Bachelot","route":"/people/thomas-bachelot/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"thomas-marron","kind":"person","name":"Thomas U. Marron","route":"/people/thomas-marron/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-new-indication-exclusivity-off-patent","kind":"idea","name":"Three years of indication-specific exclusivity for proving a new cancer use of an old drug","route":"/ideas/idea-reg-new-indication-exclusivity-off-patent/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"thyroid-fna-molecular","kind":"technology","name":"Thyroid nodule FNA, Bethesda cytology & molecular classifiers","route":"/technologies/thyroid-fna-molecular/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-til-guided-deescalation","kind":"idea","name":"TIL-based omission of chemotherapy in stage I TNBC","route":"/ideas/idea-til-guided-deescalation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tilatamig-samrotecan","kind":"drug","name":"Tilatamig samrotecan","route":"/drugs/tilatamig-samrotecan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-immunopeptidome-timing","kind":"idea","name":"Time immunotherapy to the moment targeted drugs make tumours visible","route":"/ideas/idea-bio1-immunopeptidome-timing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-timestamped-eln","kind":"idea","name":"Time-stamped electronic lab notebooks submitted with the paper","route":"/ideas/idea-tr2-timestamped-eln/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"timothy-chan","kind":"person","name":"Timothy A. Chan","route":"/people/timothy-chan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"timothy-eberlein","kind":"person","name":"Timothy J. Eberlein","route":"/people/timothy-eberlein/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"timothy-ley","kind":"person","name":"Timothy J. Ley","route":"/people/timothy-ley/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tnbc-history","kind":"roadmap","name":"TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line","route":"/roadmaps/tnbc-history/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tobias-janowitz","kind":"person","name":"Tobias Janowitz","route":"/people/tobias-janowitz/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-toxicity-first-endpoints","kind":"idea","name":"Tolerability as a co-primary endpoint with its own label claim","route":"/ideas/idea-moon-toxicity-first-endpoints/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ton-schumacher","kind":"person","name":"Ton Schumacher","route":"/people/ton-schumacher/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","route":"/people/toni-choueiri/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-two-lab-rule","kind":"idea","name":"Top journals require an independent lab to reproduce key findings before publication","route":"/ideas/idea-tr2-two-lab-rule/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"topoisomerase-i-payloads","kind":"term","name":"Topoisomerase-I inhibitor payloads","route":"/terms/topoisomerase-i-payloads/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-total-body-pet-dosimetry","kind":"idea","name":"Total-body PET for personalised radioligand dosing","route":"/ideas/idea-total-body-pet-dosimetry/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-toxicity-cds-for-nurses","kind":"idea","name":"Toxicity-management decision support for nurses and pharmacists","route":"/ideas/idea-data-toxicity-cds-for-nurses/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-methylation-clone-tracking","kind":"idea","name":"Track clones in blood with methylation patterns instead of mutations","route":"/ideas/idea-bio1-methylation-clone-tracking/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-clinician-creator-programme","kind":"idea","name":"Train and fund oncology clinicians as public content creators","route":"/ideas/idea-moon-clinician-creator-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-serious-illness-conversation-prompts","kind":"idea","name":"Train every oncology team in serious-illness conversations and prompt them in the record","route":"/ideas/idea-acc-serious-illness-conversation-prompts/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-trained-immunity-priming","kind":"idea","name":"Train the bone marrow to make better anti-tumour immune cells","route":"/ideas/idea-bio2-trained-immunity-priming/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-patient-community-moderators","kind":"idea","name":"Trained moderators with evidence tools in online patient communities","route":"/ideas/idea-moon-patient-community-moderators/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-transplant-free-ph-all","kind":"idea","name":"Transplant-free Ph-positive ALL for MRD-negative adults","route":"/ideas/idea-transplant-free-ph-all/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trastuzumab-brengitecan","kind":"drug","name":"Trastuzumab brengitecan","route":"/drugs/trastuzumab-brengitecan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trastuzumab-cardiotoxicity","kind":"term","name":"Trastuzumab cardiotoxicity","route":"/terms/trastuzumab-cardiotoxicity/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-brain-metastases-programme","kind":"idea","name":"Treat brain metastases as a disease with its own trials programme","route":"/ideas/idea-fund-brain-metastases-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-cachexia-as-treatable-disease","kind":"idea","name":"Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles","route":"/ideas/idea-moon-cachexia-as-treatable-disease/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-cachexia-gdf15-prevention","kind":"idea","name":"Treat cachexia before it starts","route":"/ideas/idea-cachexia-gdf15-prevention/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-steroid-sparing-irae","kind":"idea","name":"Treat immunotherapy side-effects without wiping out the response","route":"/ideas/idea-bio2-steroid-sparing-irae/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-nl-sleep-circadian-survivorship-rct","kind":"idea","name":"Treat insomnia in survivors and measure whether the cancer notices","route":"/ideas/idea-nl-sleep-circadian-survivorship-rct/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-real-world-resistance-surveillance","kind":"idea","name":"Treat resistance like an infectious disease and run national surveillance","route":"/ideas/idea-bio1-real-world-resistance-surveillance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-intracavitary-immunotherapy","kind":"idea","name":"Treat the body cavity, not the bloodstream, for surface spread","route":"/ideas/idea-bio2-intracavitary-immunotherapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-lymph-node-immune-priming","kind":"idea","name":"Treat the draining lymph node before removing it","route":"/ideas/idea-bio2-lymph-node-immune-priming/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-cachexia-pathway-code","kind":"idea","name":"Treat wasting like sepsis: a trigger, a bundle, an audit","route":"/ideas/idea-bio2-cachexia-pathway-code/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","route":"/people/trevor-pugh/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-rare-cancer-trial-in-a-box","kind":"idea","name":"Trial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer","route":"/ideas/idea-tr1-rare-cancer-trial-in-a-box/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-methadone-and-alternatives-where-morphine-fails","kind":"idea","name":"Trials of low-cost opioid alternatives where morphine supply is unreliable","route":"/ideas/idea-acc-methadone-and-alternatives-where-morphine-fails/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-cognitive-rehabilitation-after-chemotherapy","kind":"idea","name":"Trials of structured cognitive rehabilitation for cancer-related cognitive impairment","route":"/ideas/idea-acc-cognitive-rehabilitation-after-chemotherapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trop2-adc-roadmap","kind":"roadmap","name":"TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET","route":"/roadmaps/trop2-adc-roadmap/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trop2-pet-to-adc","kind":"pairing","name":"TROP2 PET → TROP2 ADC selection","route":"/pairings/trop2-pet-to-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tsh-suppression","kind":"term","name":"TSH suppression","route":"/terms/tsh-suppression/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tucatinib-triplet-brain-mets","kind":"pairing","name":"Tucatinib + trastuzumab + capecitabine for brain metastases","route":"/pairings/tucatinib-triplet-brain-mets/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tps","kind":"term","name":"Tumour proportion score (TPS)","route":"/terms/tps/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-tumour-on-chip-penetration","kind":"idea","name":"Tumour-on-a-chip with blood flow to test whether big drugs actually get in","route":"/ideas/idea-bio1-tumour-on-chip-penetration/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-pp2a-activators","kind":"idea","name":"Turn a brake back on: drugs that reactivate the PP2A phosphatase","route":"/ideas/idea-bio1-pp2a-activators/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-cin-vulnerability-kif18a","kind":"idea","name":"Turn chromosomal chaos into a weakness with KIF18A inhibitors","route":"/ideas/idea-bio1-cin-vulnerability-kif18a/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-mutagenesis-blockade-rev1","kind":"idea","name":"Turn off the error-prone repair that manufactures resistance mutations","route":"/ideas/idea-bio1-mutagenesis-blockade-rev1/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-in-situ-vaccination-solid","kind":"idea","name":"Turn one tumour into a vaccine to treat all the others","route":"/ideas/idea-bio2-in-situ-vaccination-solid/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-spatial-signature-cdx","kind":"idea","name":"Turn the map of immune cells inside a tumour into a standardised test","route":"/ideas/idea-bio2-spatial-signature-cdx/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-two-day-cart-rapid-release","kind":"idea","name":"Two-day CAR-T manufacture paired with rapid release tests that regulators accept","route":"/ideas/idea-reg-two-day-cart-rapid-release/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-plain-language-consent","kind":"idea","name":"Two-page plain-language consent with teach-back for every cancer trial and treatment","route":"/ideas/idea-moon-plain-language-consent/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-dual-antigen-adc-escape","kind":"idea","name":"Two-target antibody drugs to close the antigen escape route","route":"/ideas/idea-bio1-dual-antigen-adc-escape/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-window-of-opportunity-triplets","kind":"idea","name":"Two-week pre-operative windows to compare combination biology head to head","route":"/ideas/idea-tr2-window-of-opportunity-triplets/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-translational-fellowships","kind":"idea","name":"Two-year translational fellowships that pay scientists to develop their own discovery","route":"/ideas/idea-fund-translational-fellowships/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ulceration-melanoma","kind":"term","name":"Ulceration (melanoma)","route":"/terms/ulceration-melanoma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ulrich-keilholz","kind":"person","name":"Ulrich Keilholz","route":"/people/ulrich-keilholz/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-thyroid-overdiagnosis-reversal","kind":"idea","name":"Ultrasound restraint and surveillance to reverse thyroid cancer overdiagnosis","route":"/ideas/idea-thyroid-overdiagnosis-reversal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-epigenetic-priming-cold-tumours","kind":"idea","name":"Unmask hidden antigens with a short epigenetic course before immunotherapy","route":"/ideas/idea-bio2-epigenetic-priming-cold-tumours/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-order-set-defaults-30-days","kind":"idea","name":"Update hospital order sets within 30 days of a guideline change","route":"/ideas/idea-data-order-set-defaults-30-days/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-upfront-reduced-dose-trials-frail","kind":"idea","name":"Upfront reduced-dose regimens tested head-to-head in frail older patients","route":"/ideas/idea-acc-upfront-reduced-dose-trials-frail/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-urine-ctdna-surveillance","kind":"idea","name":"Urine tumour DNA to replace surveillance cystoscopy in NMIBC","route":"/ideas/idea-urine-ctdna-surveillance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-ctdna-six-week-io-switch","kind":"idea","name":"Use a blood test at six weeks to decide whether to keep going","route":"/ideas/idea-bio2-ctdna-six-week-io-switch/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-hypoxia-guided-adenosine","kind":"idea","name":"Use a hypoxia scan to pick patients for adenosine-pathway drugs","route":"/ideas/idea-bio2-hypoxia-guided-adenosine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-prs-screening-start-age","kind":"idea","name":"Use a polygenic risk score to set when screening starts","route":"/ideas/idea-prev-prs-screening-start-age/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-antibody-degrader-conjugates","kind":"idea","name":"Use antibodies to deliver protein-destroying drugs into the right cells","route":"/ideas/idea-bio1-antibody-degrader-conjugates/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-food-effect-dose-reduction","kind":"idea","name":"Use food effects to cut the dose and cost of oral drugs that absorb better with meals","route":"/ideas/idea-tr1-food-effect-dose-reduction/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-vascular-normalisation-window","kind":"idea","name":"Use imaging to find the window when tumour blood vessels are working properly","route":"/ideas/idea-bio2-vascular-normalisation-window/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-organoid-cell-therapy-potency","kind":"idea","name":"Use patient organoids to check a cell therapy will work before infusing it","route":"/ideas/idea-bio1-organoid-cell-therapy-potency/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-neoadjuvant-biomarker-engine","kind":"idea","name":"Use pre-surgery immunotherapy windows as the field's biomarker engine","route":"/ideas/idea-bio2-neoadjuvant-biomarker-engine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-mrd-guided-endocrine-duration","kind":"idea","name":"Use residual disease tests to decide who needs ten years of hormone therapy","route":"/ideas/idea-bio2-mrd-guided-endocrine-duration/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-slfn11-payload-guidance","kind":"idea","name":"Use SLFN11 status to decide which antibody-drug payload to give next","route":"/ideas/idea-bio1-slfn11-payload-guidance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-transferrin-shuttle-adc","kind":"idea","name":"Use the brain's own transport door to carry antibody drugs across","route":"/ideas/idea-bio2-transferrin-shuttle-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-blood-count-trend-flags","kind":"idea","name":"Use the trend in routine blood counts, not a single threshold, to spot cancer","route":"/ideas/idea-prev-blood-count-trend-flags/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-ctdna-guided-stop-in-metastatic-disease","kind":"idea","name":"Use tumour DNA in blood to decide when to pause treatment in metastatic cancer","route":"/ideas/idea-tr1-ctdna-guided-stop-in-metastatic-disease/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"uwe-oelfke","kind":"person","name":"Uwe Oelfke","route":"/people/uwe-oelfke/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-resistance-mutation-vaccine","kind":"idea","name":"Vaccinate against the resistance mutation before it takes over","route":"/ideas/idea-bio1-resistance-mutation-vaccine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-clonal-neoantigen-vaccines","kind":"idea","name":"Vaccines aimed only at mutations shared by every tumour cell","route":"/ideas/idea-bio1-clonal-neoantigen-vaccines/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"val-ala","kind":"term","name":"Val-Ala dipeptide","route":"/terms/val-ala/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-fund-rt-planning-ai-capacity","kind":"idea","name":"Validate and reimburse AI contouring and planning to expand radiotherapy capacity","route":"/ideas/idea-fund-rt-planning-ai-capacity/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-reg-metronomic-lmic-phase3-to-label","kind":"idea","name":"Validate low-cost metronomic oral regimens in phase 3 and carry them into guidelines","route":"/ideas/idea-reg-metronomic-lmic-phase3-to-label/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-rwpfs-validation-programme","kind":"idea","name":"Validate real-world progression against central imaging review","route":"/ideas/idea-data-rwpfs-validation-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr1-validate-real-world-progression-endpoints","kind":"idea","name":"Validate real-world progression endpoints so pragmatic trials can use them","route":"/ideas/idea-tr1-validate-real-world-progression-endpoints/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"noronha-vanita","kind":"person","name":"Vanita Noronha","route":"/people/noronha-vanita/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vaf","kind":"term","name":"Variant allele frequency (VAF)","route":"/terms/vaf/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"venetoclax-plus-hma","kind":"pairing","name":"Venetoclax + hypomethylating agent","route":"/pairings/venetoclax-plus-hma/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"venetoclax-plus-obinutuzumab","kind":"pairing","name":"Venetoclax + obinutuzumab (12 months)","route":"/pairings/venetoclax-plus-obinutuzumab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-ai-cdx-change-control","kind":"idea","name":"Version control and locked reference sets for AI algorithms used as companion diagnostics","route":"/ideas/idea-tr2-ai-cdx-change-control/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-tele-palliative-care-default","kind":"idea","name":"Video palliative care as an equivalent default option for patients far from a team","route":"/ideas/idea-acc-tele-palliative-care-default/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"patil-vijay","kind":"person","name":"Vijay Patil","route":"/people/patil-vijay/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vimseltinib","kind":"drug","name":"Vimseltinib","route":"/drugs/vimseltinib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","route":"/people/vincent-tuohy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vincenzo-valentini","kind":"person","name":"Vincenzo Valentini","route":"/people/vincenzo-valentini/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"viral-vector-manufacturing","kind":"technology","name":"Viral vector manufacturing (lentiviral, retroviral, AAV)","route":"/technologies/viral-vector-manufacturing/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"virtual-cell","kind":"roadmap","name":"Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell","route":"/roadmaps/virtual-cell/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-return-to-work-rehabilitation","kind":"idea","name":"Vocational rehabilitation integrated into cancer care so survivors can return to work","route":"/ideas/idea-acc-return-to-work-rehabilitation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"volker-heinemann","kind":"person","name":"Volker Heinemann","route":"/people/volker-heinemann/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-neighbourhood-palliative-networks","kind":"idea","name":"Volunteer-led neighbourhood palliative networks, the Kerala model, adapted elsewhere","route":"/ideas/idea-acc-neighbourhood-palliative-networks/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-tr2-antagonism-surveillance","kind":"idea","name":"Watch routine care for drug combinations that quietly make cancer treatment worse","route":"/ideas/idea-tr2-antagonism-surveillance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-small-renal-mass-surveillance","kind":"idea","name":"Watch small kidney tumours rather than remove them, with a national registry","route":"/ideas/idea-prev-small-renal-mass-surveillance/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-tcr-repertoire-early-readout","kind":"idea","name":"Watch the immune system's response in the blood three weeks in","route":"/ideas/idea-bio2-tcr-repertoire-early-readout/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-data-wearable-endpoints-validation","kind":"idea","name":"Wearable activity data as a validated real-world endpoint","route":"/ideas/idea-data-wearable-endpoints-validation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"li-weimin","kind":"person","name":"Weimin Li","route":"/people/li-weimin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"weiping-zou","kind":"person","name":"Weiping Zou","route":"/people/weiping-zou/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"parulekar-wendy","kind":"person","name":"Wendy Parulekar","route":"/people/parulekar-wendy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","route":"/people/fang-wenfeng/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-immune-exclusion-drivers","kind":"idea","name":"What actually holds T cells at the tumour border?","route":"/ideas/idea-immune-exclusion-drivers/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-dtc-colonisation-determinants","kind":"idea","name":"What decides which disseminated cells ever colonise?","route":"/ideas/idea-dtc-colonisation-determinants/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-neoantigen-immunogenicity-rules","kind":"idea","name":"What makes a neoantigen actually immunogenic?","route":"/ideas/idea-neoantigen-immunogenicity-rules/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio2-localise-the-mrd","kind":"idea","name":"When the blood test is positive, hunt for the lesion with sensitive imaging","route":"/ideas/idea-bio2-localise-the-mrd/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-chip-risk-modifiers","kind":"idea","name":"Which patients' blood clones will become leukaemia after treatment?","route":"/ideas/idea-chip-risk-modifiers/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-acc-biosimilar-prequalification-pool","kind":"idea","name":"WHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator","route":"/ideas/idea-acc-biosimilar-prequalification-pool/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"whole-body-mri","kind":"technology","name":"Whole-body MRI","route":"/technologies/whole-body-mri/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prev-li-fraumeni-mri-plus-cfdna","kind":"idea","name":"Whole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome","route":"/ideas/idea-prev-li-fraumeni-mri-plus-cfdna/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-moon-validated-digital-twins","kind":"idea","name":"Whole-patient digital twins validated in prospective randomised trials","route":"/ideas/idea-moon-validated-digital-twins/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"whole-slide-scanners","kind":"technology","name":"Whole-slide scanners and image management","route":"/technologies/whole-slide-scanners/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"william-kaelin","kind":"person","name":"William G. Kaelin Jr.","route":"/people/william-kaelin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kang-won-ki","kind":"person","name":"Won Ki Kang","route":"/people/kang-won-ki/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"park-woong-yang","kind":"person","name":"Woong-Yang Park","route":"/people/park-woong-yang/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-wrn-msi-programme","kind":"idea","name":"WRN inhibitors: a second synthetic-lethal win for mismatch-repair cancers","route":"/ideas/idea-bio1-wrn-msi-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hu-xichun","kind":"person","name":"Xichun Hu","route":"/people/hu-xichun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","route":"/people/wu-yi-long/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","route":"/people/jiang-yi-zhou/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","route":"/people/kang-yoon-koo/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"lu-you","kind":"person","name":"You Lu","route":"/people/lu-you/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shi-yuankai","kind":"person","name":"Yuankai Shi","route":"/people/shi-yuankai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","route":"/people/ohe-yuichiro/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kitagawa-yuko","kind":"person","name":"Yuko Kitagawa","route":"/people/kitagawa-yuko/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","route":"/people/bang-yung-jue/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"wei-yuquan","kind":"person","name":"Yuquan Wei","route":"/people/wei-yuquan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-bio1-zebrafish-avatars","kind":"idea","name":"Zebrafish avatars for a drug answer within a week","route":"/ideas/idea-bio1-zebrafish-avatars/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"zelenectide-pevedotin","kind":"drug","name":"Zelenectide pevedotin","route":"/drugs/zelenectide-pevedotin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ziftomenib","kind":"drug","name":"Ziftomenib","route":"/drugs/ziftomenib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","detail":"no external link or Wikipedia reference"}],"staleness":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","asOf":"2026-09-04","days":5},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","asOf":"2026-09-04","days":5},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/","asOf":"2026-09-04","days":5},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","asOf":"2026-09-04","days":5},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/","asOf":"2026-09-04","days":5},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","asOf":"2026-09-04","days":5},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/","asOf":"2026-09-04","days":5},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","asOf":"2026-09-04","days":5},{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/","asOf":"2026-09-04","days":5},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/","asOf":"2026-09-04","days":5},{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/","asOf":"2026-09-04","days":5},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/","asOf":"2026-09-04","days":5},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/","asOf":"2026-09-04","days":5},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/","asOf":"2026-09-04","days":5},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/","asOf":"2026-09-04","days":5},{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/","asOf":"2026-09-04","days":5},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/","asOf":"2026-09-04","days":5},{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/","asOf":"2026-09-04","days":5},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/","asOf":"2026-09-04","days":5},{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/","asOf":"2026-09-04","days":5},{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/","asOf":"2026-09-04","days":5},{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/","asOf":"2026-09-04","days":5},{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/","asOf":"2026-09-04","days":5},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/","asOf":"2026-09-04","days":5},{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/","asOf":"2026-09-04","days":5},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/","asOf":"2026-09-04","days":5},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/","asOf":"2026-09-04","days":5},{"id":"nutrition-lifestyle","kind":"section","name":"Diet, Exercise & Lifestyle","route":"/fronts/nutrition-lifestyle/","asOf":"2026-09-04","days":5},{"id":"devices","kind":"section","name":"Devices & Physical Therapies","route":"/fronts/devices/","asOf":"2026-09-04","days":5},{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/","asOf":"2026-09-04","days":5},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/","asOf":"2026-09-04","days":5},{"id":"ultrasound","kind":"technology","name":"Ultrasound","route":"/technologies/ultrasound/","asOf":"2026-09-04","days":5},{"id":"mammography","kind":"technology","name":"Mammography & tomosynthesis","route":"/technologies/mammography/","asOf":"2026-09-04","days":5},{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/","asOf":"2026-09-04","days":5},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/","asOf":"2026-09-04","days":5},{"id":"pet-mri","kind":"technology","name":"PET/MRI","route":"/technologies/pet-mri/","asOf":"2026-09-04","days":5},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/","asOf":"2026-09-04","days":5},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/","asOf":"2026-09-04","days":5},{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/","asOf":"2026-09-04","days":5},{"id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/","asOf":"2026-09-04","days":5},{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/","asOf":"2026-09-04","days":5},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/","asOf":"2026-09-04","days":5},{"id":"parp-pet","kind":"technology","name":"PARP PET","route":"/technologies/parp-pet/","asOf":"2026-09-04","days":5},{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/","asOf":"2026-09-04","days":5},{"id":"whole-body-mri","kind":"technology","name":"Whole-body MRI","route":"/technologies/whole-body-mri/","asOf":"2026-09-04","days":5},{"id":"radiology-ai-screening","kind":"technology","name":"AI in radiology","route":"/technologies/radiology-ai-screening/","asOf":"2026-09-04","days":5},{"id":"optical-imaging","kind":"technology","name":"Optical & fluorescence imaging","route":"/technologies/optical-imaging/","asOf":"2026-09-04","days":5},{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/","asOf":"2026-09-04","days":5},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/","asOf":"2026-09-04","days":5},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/","asOf":"2026-09-04","days":5},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/","asOf":"2026-09-04","days":5},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/","asOf":"2026-09-04","days":5},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/","asOf":"2026-09-04","days":5},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/","asOf":"2026-09-04","days":5},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/","asOf":"2026-09-04","days":5},{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/","asOf":"2026-09-04","days":5},{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/","asOf":"2026-09-04","days":5},{"id":"hrd-testing","kind":"technology","name":"HRD & BRCA testing","route":"/technologies/hrd-testing/","asOf":"2026-09-04","days":5},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","asOf":"2026-09-04","days":5},{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/","asOf":"2026-09-04","days":5},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/","asOf":"2026-09-04","days":5},{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/","asOf":"2026-09-04","days":5},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/","asOf":"2026-09-04","days":5},{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/","asOf":"2026-09-04","days":5},{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/","asOf":"2026-09-04","days":5},{"id":"fluorescence-guided-surgery","kind":"technology","name":"Fluorescence-guided surgery","route":"/technologies/fluorescence-guided-surgery/","asOf":"2026-09-04","days":5},{"id":"sentinel-node","kind":"technology","name":"Sentinel lymph node biopsy","route":"/technologies/sentinel-node/","asOf":"2026-09-04","days":5},{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/","asOf":"2026-09-04","days":5},{"id":"hifu-histotripsy","kind":"technology","name":"Focused ultrasound & histotripsy","route":"/technologies/hifu-histotripsy/","asOf":"2026-09-04","days":5},{"id":"irreversible-electroporation","kind":"technology","name":"Irreversible electroporation (NanoKnife)","route":"/technologies/irreversible-electroporation/","asOf":"2026-09-04","days":5},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/","asOf":"2026-09-04","days":5},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/","asOf":"2026-09-04","days":5},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/","asOf":"2026-09-04","days":5},{"id":"carbon-ion","kind":"technology","name":"Carbon-ion therapy","route":"/technologies/carbon-ion/","asOf":"2026-09-04","days":5},{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/","asOf":"2026-09-04","days":5},{"id":"mr-linac","kind":"technology","name":"MR-guided adaptive radiotherapy","route":"/technologies/mr-linac/","asOf":"2026-09-04","days":5},{"id":"flash-rt","kind":"technology","name":"FLASH radiotherapy","route":"/technologies/flash-rt/","asOf":"2026-09-04","days":5},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/","asOf":"2026-09-04","days":5},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/","asOf":"2026-09-04","days":5},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/","asOf":"2026-09-04","days":5},{"id":"bnct","kind":"technology","name":"Boron neutron capture therapy","route":"/technologies/bnct/","asOf":"2026-09-04","days":5},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/","asOf":"2026-09-04","days":5},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/","asOf":"2026-09-04","days":5},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/","asOf":"2026-09-04","days":5},{"id":"hipec","kind":"technology","name":"HIPEC / PIPAC (intraperitoneal chemotherapy)","route":"/technologies/hipec/","asOf":"2026-09-04","days":5},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/","asOf":"2026-09-04","days":5},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/","asOf":"2026-09-04","days":5},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/","asOf":"2026-09-04","days":5},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/","asOf":"2026-09-04","days":5},{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/","asOf":"2026-09-04","days":5},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/","asOf":"2026-09-04","days":5},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/","asOf":"2026-09-04","days":5},{"id":"antisense-sirna","kind":"technology","name":"Oligonucleotide therapeutics","route":"/technologies/antisense-sirna/","asOf":"2026-09-04","days":5},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/","asOf":"2026-09-04","days":5},{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/","asOf":"2026-09-04","days":5},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/","asOf":"2026-09-04","days":5},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/","asOf":"2026-09-04","days":5},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/","asOf":"2026-09-04","days":5},{"id":"degrader-antibody-conjugate","kind":"technology","name":"Degrader-antibody conjugate (DAC)","route":"/technologies/degrader-antibody-conjugate/","asOf":"2026-09-04","days":5},{"id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/","asOf":"2026-09-04","days":5},{"id":"masked-adc","kind":"technology","name":"Masked / conditionally active ADC","route":"/technologies/masked-adc/","asOf":"2026-09-04","days":5},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/","asOf":"2026-09-04","days":5},{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/","asOf":"2026-09-04","days":5},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/","asOf":"2026-09-04","days":5},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/","asOf":"2026-09-04","days":5},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/","asOf":"2026-09-04","days":5},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/","asOf":"2026-09-04","days":5},{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/","asOf":"2026-09-04","days":5},{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/","asOf":"2026-09-04","days":5},{"id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/","asOf":"2026-09-04","days":5},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/","asOf":"2026-09-04","days":5},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/","asOf":"2026-09-04","days":5},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/","asOf":"2026-09-04","days":5},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/","asOf":"2026-09-04","days":5},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/","asOf":"2026-09-04","days":5},{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/","asOf":"2026-09-04","days":5},{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/","asOf":"2026-09-04","days":5},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/","asOf":"2026-09-04","days":5},{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/","asOf":"2026-09-04","days":5},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/","asOf":"2026-09-04","days":5},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling","route":"/technologies/scalp-cooling/","asOf":"2026-09-04","days":5},{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/","asOf":"2026-09-04","days":5},{"id":"exercise-oncology","kind":"technology","name":"Exercise & lifestyle oncology","route":"/technologies/exercise-oncology/","asOf":"2026-09-04","days":5},{"id":"geriatric-assessment","kind":"technology","name":"Geriatric assessment","route":"/technologies/geriatric-assessment/","asOf":"2026-09-04","days":5},{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/","asOf":"2026-09-04","days":5},{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/","asOf":"2026-09-04","days":5},{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/","asOf":"2026-09-04","days":5},{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/","asOf":"2026-09-04","days":5},{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/","asOf":"2026-09-04","days":5},{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/","asOf":"2026-09-04","days":5},{"id":"ttfields","kind":"technology","name":"Tumour treating fields (TTFields)","route":"/technologies/ttfields/","asOf":"2026-09-04","days":5},{"id":"photoimmunotherapy","kind":"technology","name":"Photoimmunotherapy & photodynamic therapy","route":"/technologies/photoimmunotherapy/","asOf":"2026-09-04","days":5},{"id":"hyperthermia","kind":"technology","name":"Hyperthermia","route":"/technologies/hyperthermia/","asOf":"2026-09-04","days":5},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","asOf":"2026-09-04","days":5},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","asOf":"2026-09-04","days":5},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/","asOf":"2026-09-04","days":5},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","asOf":"2026-09-04","days":5},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/","asOf":"2026-09-04","days":5},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","asOf":"2026-09-04","days":5},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/","asOf":"2026-09-04","days":5},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","asOf":"2026-09-04","days":5},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","asOf":"2026-09-04","days":5},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","asOf":"2026-09-04","days":5},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","asOf":"2026-09-04","days":5},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","asOf":"2026-09-04","days":5},{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/","asOf":"2026-09-04","days":5},{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/","asOf":"2026-09-04","days":5},{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","asOf":"2026-09-04","days":5},{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/","asOf":"2026-09-04","days":5},{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/","asOf":"2026-09-04","days":5},{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/","asOf":"2026-09-04","days":5},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/","asOf":"2026-09-04","days":5},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/","asOf":"2026-09-04","days":5},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","asOf":"2026-09-04","days":5},{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/","asOf":"2026-09-04","days":5},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/","asOf":"2026-09-04","days":5},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/","asOf":"2026-09-04","days":5},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/","asOf":"2026-09-04","days":5},{"id":"cd33","kind":"target","name":"CD33","route":"/targets/cd33/","asOf":"2026-09-04","days":5},{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/","asOf":"2026-09-04","days":5},{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/","asOf":"2026-09-04","days":5},{"id":"gp100","kind":"target","name":"gp100 (PMEL)","route":"/targets/gp100/","asOf":"2026-09-04","days":5},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/","asOf":"2026-09-04","days":5},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","asOf":"2026-09-04","days":5},{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/","asOf":"2026-09-04","days":5},{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/","asOf":"2026-09-04","days":5},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/","asOf":"2026-09-04","days":5},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","asOf":"2026-09-04","days":5},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","asOf":"2026-09-04","days":5},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","asOf":"2026-09-04","days":5},{"id":"met","kind":"target","name":"MET","route":"/targets/met/","asOf":"2026-09-04","days":5},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/","asOf":"2026-09-04","days":5},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","asOf":"2026-09-04","days":5},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/","asOf":"2026-09-04","days":5},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/","asOf":"2026-09-04","days":5},{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/","asOf":"2026-09-04","days":5},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","asOf":"2026-09-04","days":5},{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/","asOf":"2026-09-04","days":5},{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/","asOf":"2026-09-04","days":5},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","asOf":"2026-09-04","days":5},{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/","asOf":"2026-09-04","days":5},{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/","asOf":"2026-09-04","days":5},{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/","asOf":"2026-09-04","days":5},{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/","asOf":"2026-09-04","days":5},{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/","asOf":"2026-09-04","days":5},{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/","asOf":"2026-09-04","days":5},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/","asOf":"2026-09-04","days":5},{"id":"hif2a","kind":"target","name":"HIF-2α","route":"/targets/hif2a/","asOf":"2026-09-04","days":5},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/","asOf":"2026-09-04","days":5},{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/","asOf":"2026-09-04","days":5},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","asOf":"2026-09-04","days":5},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","asOf":"2026-09-04","days":5},{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/","asOf":"2026-09-04","days":5},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","asOf":"2026-09-04","days":5},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","asOf":"2026-09-04","days":5},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","asOf":"2026-09-04","days":5},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","asOf":"2026-09-04","days":5},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","asOf":"2026-09-04","days":5},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","asOf":"2026-09-04","days":5},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","asOf":"2026-09-04","days":5},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","asOf":"2026-09-04","days":5},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","asOf":"2026-09-04","days":5},{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/","asOf":"2026-09-04","days":5},{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/","asOf":"2026-09-04","days":5},{"id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","asOf":"2026-09-04","days":5},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","asOf":"2026-09-04","days":5},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/","asOf":"2026-09-04","days":5},{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","asOf":"2026-09-04","days":5},{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/","asOf":"2026-09-04","days":5},{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/","asOf":"2026-09-04","days":5},{"id":"tilatamig-samrotecan","kind":"drug","name":"Tilatamig samrotecan","route":"/drugs/tilatamig-samrotecan/","asOf":"2026-09-04","days":5},{"id":"ak146d1","kind":"drug","name":"AK146D1","route":"/drugs/ak146d1/","asOf":"2026-09-04","days":5},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","asOf":"2026-09-04","days":5},{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/","asOf":"2026-09-04","days":5},{"id":"cmg901","kind":"drug","name":"Sonesitatug vedotin","route":"/drugs/cmg901/","asOf":"2026-09-04","days":5},{"id":"puxitatug-samrotecan","kind":"drug","name":"Puxitatug samrotecan","route":"/drugs/puxitatug-samrotecan/","asOf":"2026-09-04","days":5},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","asOf":"2026-09-04","days":5},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","asOf":"2026-09-04","days":5},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","asOf":"2026-09-04","days":5},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","asOf":"2026-09-04","days":5},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","asOf":"2026-09-04","days":5},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","asOf":"2026-09-04","days":5},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","asOf":"2026-09-04","days":5},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","asOf":"2026-09-04","days":5},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","asOf":"2026-09-04","days":5},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","asOf":"2026-09-04","days":5},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","asOf":"2026-09-04","days":5},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","asOf":"2026-09-04","days":5},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","asOf":"2026-09-04","days":5},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","asOf":"2026-09-04","days":5},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","asOf":"2026-09-04","days":5},{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","asOf":"2026-09-04","days":5},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","asOf":"2026-09-04","days":5},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","asOf":"2026-09-04","days":5},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","asOf":"2026-09-04","days":5},{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/","asOf":"2026-09-04","days":5},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/","asOf":"2026-09-04","days":5},{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","asOf":"2026-09-04","days":5},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","asOf":"2026-09-04","days":5},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","asOf":"2026-09-04","days":5},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","asOf":"2026-09-04","days":5},{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","asOf":"2026-09-04","days":5},{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","asOf":"2026-09-04","days":5},{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","asOf":"2026-09-04","days":5},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","asOf":"2026-09-04","days":5},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","asOf":"2026-09-04","days":5},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","asOf":"2026-09-04","days":5},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","asOf":"2026-09-04","days":5},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","asOf":"2026-09-04","days":5},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","asOf":"2026-09-04","days":5},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","asOf":"2026-09-04","days":5},{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","asOf":"2026-09-04","days":5},{"id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","asOf":"2026-09-04","days":5},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","asOf":"2026-09-04","days":5},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","asOf":"2026-09-04","days":5},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","asOf":"2026-09-04","days":5},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","asOf":"2026-09-04","days":5},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","asOf":"2026-09-04","days":5},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","asOf":"2026-09-04","days":5},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","asOf":"2026-09-04","days":5},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","asOf":"2026-09-04","days":5},{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","asOf":"2026-09-04","days":5},{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","asOf":"2026-09-04","days":5},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","asOf":"2026-09-04","days":5},{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","asOf":"2026-09-04","days":5},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/","asOf":"2026-09-04","days":5},{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/","asOf":"2026-09-04","days":5},{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","asOf":"2026-09-04","days":5},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","asOf":"2026-09-04","days":5},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","asOf":"2026-09-04","days":5},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","asOf":"2026-09-04","days":5},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","asOf":"2026-09-04","days":5},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","asOf":"2026-09-04","days":5},{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/","asOf":"2026-09-04","days":5},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","asOf":"2026-09-04","days":5},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","asOf":"2026-09-04","days":5},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","asOf":"2026-09-04","days":5},{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","asOf":"2026-09-04","days":5},{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","asOf":"2026-09-04","days":5},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","asOf":"2026-09-04","days":5},{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","asOf":"2026-09-04","days":5},{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/","asOf":"2026-09-04","days":5},{"id":"artera-ai-prostate","kind":"drug","name":"ArteraAI Prostate","route":"/drugs/artera-ai-prostate/","asOf":"2026-09-04","days":5},{"id":"artera-ai-breast","kind":"drug","name":"ArteraAI Breast","route":"/drugs/artera-ai-breast/","asOf":"2026-09-04","days":5},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","asOf":"2026-09-04","days":5},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","asOf":"2026-09-04","days":5},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","asOf":"2026-09-04","days":5},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","asOf":"2026-09-04","days":5},{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/","asOf":"2026-09-04","days":5},{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/","asOf":"2026-09-04","days":5},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","asOf":"2026-09-04","days":5},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/","asOf":"2026-09-04","days":5},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","asOf":"2026-09-04","days":5},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/","asOf":"2026-09-04","days":5},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/","asOf":"2026-09-04","days":5},{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/","asOf":"2026-09-04","days":5},{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/","asOf":"2026-09-04","days":5},{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/","asOf":"2026-09-04","days":5},{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/","asOf":"2026-09-04","days":5},{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/","asOf":"2026-09-04","days":5},{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/","asOf":"2026-09-04","days":5},{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/","asOf":"2026-09-04","days":5},{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/","asOf":"2026-09-04","days":5},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/","asOf":"2026-09-04","days":5},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/","asOf":"2026-09-04","days":5},{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/","asOf":"2026-09-04","days":5},{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/","asOf":"2026-09-04","days":5},{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/","asOf":"2026-09-04","days":5},{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/","asOf":"2026-09-04","days":5},{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/","asOf":"2026-09-04","days":5},{"id":"adc-therapeutics","kind":"company","name":"ADC Therapeutics","route":"/companies/adc-therapeutics/","asOf":"2026-09-04","days":5},{"id":"zymeworks","kind":"company","name":"Zymeworks","route":"/companies/zymeworks/","asOf":"2026-09-04","days":5},{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","route":"/companies/jazz/","asOf":"2026-09-04","days":5},{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/","asOf":"2026-09-04","days":5},{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/","asOf":"2026-09-04","days":5},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/","asOf":"2026-09-04","days":5},{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/","asOf":"2026-09-04","days":5},{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/","asOf":"2026-09-04","days":5},{"id":"merus","kind":"company","name":"Merus","route":"/companies/merus/","asOf":"2026-09-04","days":5},{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/","asOf":"2026-09-04","days":5},{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","route":"/companies/revolution-medicines/","asOf":"2026-09-04","days":5},{"id":"arvinas","kind":"company","name":"Arvinas","route":"/companies/arvinas/","asOf":"2026-09-04","days":5},{"id":"nuvalent","kind":"company","name":"Nuvalent","route":"/companies/nuvalent/","asOf":"2026-09-04","days":5},{"id":"celcuity","kind":"company","name":"Celcuity","route":"/companies/celcuity/","asOf":"2026-09-04","days":5},{"id":"menarini","kind":"company","name":"Menarini / Stemline","route":"/companies/menarini/","asOf":"2026-09-04","days":5},{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","asOf":"2026-09-04","days":5},{"id":"syndax","kind":"company","name":"Syndax Pharmaceuticals","route":"/companies/syndax/","asOf":"2026-09-04","days":5},{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/","asOf":"2026-09-04","days":5},{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/","asOf":"2026-09-04","days":5},{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/","asOf":"2026-09-04","days":5},{"id":"immunocore","kind":"company","name":"Immunocore","route":"/companies/immunocore/","asOf":"2026-09-04","days":5},{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/","asOf":"2026-09-04","days":5},{"id":"legend-biotech","kind":"company","name":"Legend Biotech","route":"/companies/legend-biotech/","asOf":"2026-09-04","days":5},{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/","asOf":"2026-09-04","days":5},{"id":"adaptimmune","kind":"company","name":"Adaptimmune","route":"/companies/adaptimmune/","asOf":"2026-09-04","days":5},{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/","asOf":"2026-09-04","days":5},{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","asOf":"2026-09-04","days":5},{"id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","route":"/companies/rayzebio/","asOf":"2026-09-04","days":5},{"id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","asOf":"2026-09-04","days":5},{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/","asOf":"2026-09-04","days":5},{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","route":"/companies/terrapower-isotopes/","asOf":"2026-09-04","days":5},{"id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/","asOf":"2026-09-04","days":5},{"id":"foundation-medicine","kind":"company","name":"Foundation Medicine (Roche)","route":"/companies/foundation-medicine/","asOf":"2026-09-04","days":5},{"id":"guardant-health","kind":"company","name":"Guardant Health","route":"/companies/guardant-health/","asOf":"2026-09-04","days":5},{"id":"natera","kind":"company","name":"Natera","route":"/companies/natera/","asOf":"2026-09-04","days":5},{"id":"grail","kind":"company","name":"GRAIL","route":"/companies/grail/","asOf":"2026-09-04","days":5},{"id":"exact-sciences","kind":"company","name":"Exact Sciences (Abbott)","route":"/companies/exact-sciences/","asOf":"2026-09-04","days":5},{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/","asOf":"2026-09-04","days":5},{"id":"caris","kind":"company","name":"Caris Life Sciences","route":"/companies/caris/","asOf":"2026-09-04","days":5},{"id":"bostongene","kind":"company","name":"BostonGene","route":"/companies/bostongene/","asOf":"2026-09-04","days":5},{"id":"illumina","kind":"company","name":"Illumina","route":"/companies/illumina/","asOf":"2026-09-04","days":5},{"id":"10x-genomics","kind":"company","name":"10x Genomics","route":"/companies/10x-genomics/","asOf":"2026-09-04","days":5},{"id":"artera","kind":"company","name":"Artera","route":"/companies/artera/","asOf":"2026-09-04","days":5},{"id":"paige","kind":"company","name":"Paige AI","route":"/companies/paige/","asOf":"2026-09-04","days":5},{"id":"pathai","kind":"company","name":"PathAI","route":"/companies/pathai/","asOf":"2026-09-04","days":5},{"id":"owkin","kind":"company","name":"Owkin","route":"/companies/owkin/","asOf":"2026-09-04","days":5},{"id":"novocure","kind":"company","name":"Novocure","route":"/companies/novocure/","asOf":"2026-09-04","days":5},{"id":"intuitive-surgical","kind":"company","name":"Intuitive Surgical","route":"/companies/intuitive-surgical/","asOf":"2026-09-04","days":5},{"id":"histosonics","kind":"company","name":"HistoSonics","route":"/companies/histosonics/","asOf":"2026-09-04","days":5},{"id":"insightec","kind":"company","name":"Insightec","route":"/companies/insightec/","asOf":"2026-09-04","days":5},{"id":"varian","kind":"company","name":"Varian (Siemens Healthineers)","route":"/companies/varian/","asOf":"2026-09-04","days":5},{"id":"elekta","kind":"company","name":"Elekta","route":"/companies/elekta/","asOf":"2026-09-04","days":5},{"id":"reflexion","kind":"company","name":"RefleXion Medical","route":"/companies/reflexion/","asOf":"2026-09-04","days":5},{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","route":"/companies/iba/","asOf":"2026-09-04","days":5},{"id":"mevion","kind":"company","name":"Mevion Medical Systems","route":"/companies/mevion/","asOf":"2026-09-04","days":5},{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/","asOf":"2026-09-04","days":5},{"id":"siemens-healthineers","kind":"company","name":"Siemens Healthineers","route":"/companies/siemens-healthineers/","asOf":"2026-09-04","days":5},{"id":"united-imaging","kind":"company","name":"United Imaging","route":"/companies/united-imaging/","asOf":"2026-09-04","days":5},{"id":"cancer-commons","kind":"company","name":"Cancer Commons","route":"/companies/cancer-commons/","asOf":"2026-09-04","days":5},{"id":"celldex","kind":"company","name":"Celldex Therapeutics","route":"/companies/celldex/","asOf":"2026-09-04","days":5},{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/","asOf":"2026-09-04","days":5},{"id":"keymed","kind":"company","name":"Keymed Biosciences (KYM Biosciences)","route":"/companies/keymed/","asOf":"2026-09-04","days":5},{"id":"morphosys","kind":"company","name":"MorphoSys (Novartis)","route":"/companies/morphosys/","asOf":"2026-09-04","days":5},{"id":"gritstone","kind":"company","name":"Gritstone bio","route":"/companies/gritstone/","asOf":"2026-09-04","days":5},{"id":"serova","kind":"company","name":"Serova","route":"/companies/serova/","asOf":"2026-09-04","days":5},{"id":"bulsara-bioworks","kind":"company","name":"Bulsara Bioworks","route":"/companies/bulsara-bioworks/","asOf":"2026-09-04","days":5},{"id":"circle-pharma","kind":"company","name":"Circle Pharma","route":"/companies/circle-pharma/","asOf":"2026-09-04","days":5},{"id":"valius","kind":"company","name":"Valius Sciences","route":"/companies/valius/","asOf":"2026-09-04","days":5},{"id":"elucidate-bio","kind":"company","name":"Elucidate Bio","route":"/companies/elucidate-bio/","asOf":"2026-09-04","days":5},{"id":"sengine","kind":"company","name":"SEngine Precision Medicine","route":"/companies/sengine/","asOf":"2026-09-04","days":5},{"id":"champions-oncology","kind":"company","name":"Champions Oncology","route":"/companies/champions-oncology/","asOf":"2026-09-04","days":5},{"id":"navexio","kind":"company","name":"Navexio","route":"/companies/navexio/","asOf":"2026-09-04","days":5},{"id":"patient-data-vault","kind":"company","name":"Patient Data Vault (data-vault.health)","route":"/companies/patient-data-vault/","asOf":"2026-09-04","days":5},{"id":"more-health","kind":"company","name":"MORE Health","route":"/companies/more-health/","asOf":"2026-09-04","days":5},{"id":"finaldose","kind":"company","name":"FinalDose","route":"/companies/finaldose/","asOf":"2026-09-04","days":5},{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","route":"/companies/orna-therapeutics/","asOf":"2026-09-04","days":5},{"id":"umoja-biopharma","kind":"company","name":"Umoja Biopharma","route":"/companies/umoja-biopharma/","asOf":"2026-09-04","days":5},{"id":"interius","kind":"company","name":"Interius BioTherapeutics","route":"/companies/interius/","asOf":"2026-09-04","days":5},{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","route":"/companies/insilico-medicine/","asOf":"2026-09-04","days":5},{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/","asOf":"2026-09-04","days":5},{"id":"isomorphic-labs","kind":"company","name":"Isomorphic Labs","route":"/companies/isomorphic-labs/","asOf":"2026-09-04","days":5},{"id":"generate-biomedicines","kind":"company","name":"Generate:Biomedicines","route":"/companies/generate-biomedicines/","asOf":"2026-09-04","days":5},{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/","asOf":"2026-09-04","days":5},{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","route":"/companies/clarity-pharmaceuticals/","asOf":"2026-09-04","days":5},{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/","asOf":"2026-09-04","days":5},{"id":"radiomedix","kind":"company","name":"RadioMedix","route":"/companies/radiomedix/","asOf":"2026-09-04","days":5},{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","route":"/companies/sutro-biopharma/","asOf":"2026-09-04","days":5},{"id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/","asOf":"2026-09-04","days":5},{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/","asOf":"2026-09-04","days":5},{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/","asOf":"2026-09-04","days":5},{"id":"synaffix","kind":"company","name":"Synaffix (Lonza)","route":"/companies/synaffix/","asOf":"2026-09-04","days":5},{"id":"kymera","kind":"company","name":"Kymera Therapeutics","route":"/companies/kymera/","asOf":"2026-09-04","days":5},{"id":"nurix","kind":"company","name":"Nurix Therapeutics","route":"/companies/nurix/","asOf":"2026-09-04","days":5},{"id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","route":"/companies/c4-therapeutics/","asOf":"2026-09-04","days":5},{"id":"monte-rosa","kind":"company","name":"Monte Rosa Therapeutics","route":"/companies/monte-rosa/","asOf":"2026-09-04","days":5},{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/","asOf":"2026-09-04","days":5},{"id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/","asOf":"2026-09-04","days":5},{"id":"quanta-therapeutics","kind":"company","name":"Quanta Therapeutics","route":"/companies/quanta-therapeutics/","asOf":"2026-09-04","days":5},{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/","asOf":"2026-09-04","days":5},{"id":"sana-biotechnology","kind":"company","name":"Sana Biotechnology","route":"/companies/sana-biotechnology/","asOf":"2026-09-04","days":5},{"id":"allogene","kind":"company","name":"Allogene Therapeutics","route":"/companies/allogene/","asOf":"2026-09-04","days":5},{"id":"caribou","kind":"company","name":"Caribou Biosciences","route":"/companies/caribou/","asOf":"2026-09-04","days":5},{"id":"nkarta","kind":"company","name":"Nkarta","route":"/companies/nkarta/","asOf":"2026-09-04","days":5},{"id":"fate-therapeutics","kind":"company","name":"Fate Therapeutics","route":"/companies/fate-therapeutics/","asOf":"2026-09-04","days":5},{"id":"freenome","kind":"company","name":"Freenome","route":"/companies/freenome/","asOf":"2026-09-04","days":5},{"id":"delfi-diagnostics","kind":"company","name":"DELFI Diagnostics","route":"/companies/delfi-diagnostics/","asOf":"2026-09-04","days":5},{"id":"harbinger-health","kind":"company","name":"Harbinger Health","route":"/companies/harbinger-health/","asOf":"2026-09-04","days":5},{"id":"personalis","kind":"company","name":"Personalis (Tempus)","route":"/companies/personalis/","asOf":"2026-09-04","days":5},{"id":"foresight-diagnostics","kind":"company","name":"Foresight Diagnostics","route":"/companies/foresight-diagnostics/","asOf":"2026-09-04","days":5},{"id":"lunit","kind":"company","name":"Lunit","route":"/companies/lunit/","asOf":"2026-09-04","days":5},{"id":"aidoc","kind":"company","name":"Aidoc","route":"/companies/aidoc/","asOf":"2026-09-04","days":5},{"id":"xilis","kind":"company","name":"Xilis","route":"/companies/xilis/","asOf":"2026-09-04","days":5},{"id":"curesponse","kind":"company","name":"Curesponse","route":"/companies/curesponse/","asOf":"2026-09-04","days":5},{"id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/","asOf":"2026-09-04","days":5},{"id":"tscan","kind":"company","name":"TScan Therapeutics","route":"/companies/tscan/","asOf":"2026-09-04","days":5},{"id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/","asOf":"2026-09-04","days":5},{"id":"sofie-biosciences","kind":"company","name":"SOFIE Biosciences","route":"/companies/sofie-biosciences/","asOf":"2026-09-04","days":5},{"id":"nouscom","kind":"company","name":"Nouscom","route":"/companies/nouscom/","asOf":"2026-09-04","days":5},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","asOf":"2026-09-04","days":5},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","asOf":"2026-09-04","days":5},{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/","asOf":"2026-09-04","days":5},{"id":"asan-medical-center","kind":"institution","name":"Asan Medical Center","route":"/institutions/asan-medical-center/","asOf":"2026-09-04","days":5},{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","asOf":"2026-09-04","days":5},{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/","asOf":"2026-09-04","days":5},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/","asOf":"2026-09-04","days":5},{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/","asOf":"2026-09-04","days":5},{"id":"princess-margaret","kind":"institution","name":"Princess Margaret Cancer Centre","route":"/institutions/princess-margaret/","asOf":"2026-09-04","days":5},{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/","asOf":"2026-09-04","days":5},{"id":"ieo-milan","kind":"institution","name":"IEO – European Institute of Oncology","route":"/institutions/ieo-milan/","asOf":"2026-09-04","days":5},{"id":"charite","kind":"institution","name":"Charité – Universitätsmedizin Berlin","route":"/institutions/charite/","asOf":"2026-09-04","days":5},{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/","asOf":"2026-09-04","days":5},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/","asOf":"2026-09-04","days":5},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/","asOf":"2026-09-04","days":5},{"id":"mgh","kind":"institution","name":"Massachusetts General Hospital Cancer Center","route":"/institutions/mgh/","asOf":"2026-09-04","days":5},{"id":"einstein-sao-paulo","kind":"institution","name":"Hospital Israelita Albert Einstein","route":"/institutions/einstein-sao-paulo/","asOf":"2026-09-04","days":5},{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/","asOf":"2026-09-04","days":5},{"id":"sirio-libanes","kind":"institution","name":"Hospital Sírio-Libanês","route":"/institutions/sirio-libanes/","asOf":"2026-09-04","days":5},{"id":"cleveland-clinic","kind":"institution","name":"Cleveland Clinic Taussig Cancer Institute","route":"/institutions/cleveland-clinic/","asOf":"2026-09-04","days":5},{"id":"institut-curie","kind":"institution","name":"Institut Curie","route":"/institutions/institut-curie/","asOf":"2026-09-04","days":5},{"id":"severance","kind":"institution","name":"Severance Hospital, Yonsei University","route":"/institutions/severance/","asOf":"2026-09-04","days":5},{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/","asOf":"2026-09-04","days":5},{"id":"uke-hamburg","kind":"institution","name":"Universitätsklinikum Hamburg-Eppendorf","route":"/institutions/uke-hamburg/","asOf":"2026-09-04","days":5},{"id":"jfcr","kind":"institution","name":"Cancer Institute Hospital of JFCR","route":"/institutions/jfcr/","asOf":"2026-09-04","days":5},{"id":"int-milan","kind":"institution","name":"Fondazione IRCCS Istituto Nazionale dei Tumori","route":"/institutions/int-milan/","asOf":"2026-09-04","days":5},{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/","asOf":"2026-09-04","days":5},{"id":"gemelli","kind":"institution","name":"Policlinico Universitario A. Gemelli","route":"/institutions/gemelli/","asOf":"2026-09-04","days":5},{"id":"stanford","kind":"institution","name":"Stanford Health Care / Stanford Cancer Institute","route":"/institutions/stanford/","asOf":"2026-09-04","days":5},{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/","asOf":"2026-09-04","days":5},{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/","asOf":"2026-09-04","days":5},{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/","asOf":"2026-09-04","days":5},{"id":"mount-sinai","kind":"institution","name":"The Mount Sinai Hospital / Tisch Cancer Institute","route":"/institutions/mount-sinai/","asOf":"2026-09-04","days":5},{"id":"la-paz","kind":"institution","name":"Hospital Universitario La Paz","route":"/institutions/la-paz/","asOf":"2026-09-04","days":5},{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/","asOf":"2026-09-04","days":5},{"id":"gregorio-maranon","kind":"institution","name":"Hospital General Universitario Gregorio Marañón","route":"/institutions/gregorio-maranon/","asOf":"2026-09-04","days":5},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/","asOf":"2026-09-04","days":5},{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/","asOf":"2026-09-04","days":5},{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/","asOf":"2026-09-04","days":5},{"id":"city-of-hope","kind":"institution","name":"City of Hope","route":"/institutions/city-of-hope/","asOf":"2026-09-04","days":5},{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/","asOf":"2026-09-04","days":5},{"id":"michigan-rogel","kind":"institution","name":"University of Michigan Rogel Cancer Center","route":"/institutions/michigan-rogel/","asOf":"2026-09-04","days":5},{"id":"wustl-siteman","kind":"institution","name":"Siteman Cancer Center, Washington University","route":"/institutions/wustl-siteman/","asOf":"2026-09-04","days":5},{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/","asOf":"2026-09-04","days":5},{"id":"roswell-park","kind":"institution","name":"Roswell Park Comprehensive Cancer Center","route":"/institutions/roswell-park/","asOf":"2026-09-04","days":5},{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/","asOf":"2026-09-04","days":5},{"id":"cold-spring-harbor","kind":"institution","name":"Cold Spring Harbor Laboratory","route":"/institutions/cold-spring-harbor/","asOf":"2026-09-04","days":5},{"id":"francis-crick","kind":"institution","name":"The Francis Crick Institute","route":"/institutions/francis-crick/","asOf":"2026-09-04","days":5},{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/","asOf":"2026-09-04","days":5},{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/","asOf":"2026-09-04","days":5},{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/","asOf":"2026-09-04","days":5},{"id":"dkfz","kind":"institution","name":"German Cancer Research Center (DKFZ)","route":"/institutions/dkfz/","asOf":"2026-09-04","days":5},{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/","asOf":"2026-09-04","days":5},{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","asOf":"2026-09-04","days":5},{"id":"west-china","kind":"institution","name":"West China Hospital, Sichuan University","route":"/institutions/west-china/","asOf":"2026-09-04","days":5},{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-cancer-hospital/","asOf":"2026-09-04","days":5},{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/","asOf":"2026-09-04","days":5},{"id":"curie-nki-eortc","kind":"institution","name":"EORTC","route":"/institutions/curie-nki-eortc/","asOf":"2026-09-04","days":5},{"id":"asco","kind":"institution","name":"American Society of Clinical Oncology (ASCO)","route":"/institutions/asco/","asOf":"2026-09-04","days":5},{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/","asOf":"2026-09-04","days":5},{"id":"aacr","kind":"institution","name":"American Association for Cancer Research (AACR)","route":"/institutions/aacr/","asOf":"2026-09-04","days":5},{"id":"iarc","kind":"institution","name":"International Agency for Research on Cancer (IARC / WHO)","route":"/institutions/iarc/","asOf":"2026-09-04","days":5},{"id":"pi3k-akt-mtor","kind":"pathway","name":"PI3K / AKT / mTOR","route":"/pathways/pi3k-akt-mtor/","asOf":"2026-09-04","days":5},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/","asOf":"2026-09-04","days":5},{"id":"p53-cell-cycle","kind":"pathway","name":"p53 / RB / cell-cycle checkpoint","route":"/pathways/p53-cell-cycle/","asOf":"2026-09-04","days":5},{"id":"ddr","kind":"pathway","name":"DNA damage response & homologous recombination","route":"/pathways/ddr/","asOf":"2026-09-04","days":5},{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/","asOf":"2026-09-04","days":5},{"id":"cgas-sting","kind":"pathway","name":"cGAS–STING innate sensing","route":"/pathways/cgas-sting/","asOf":"2026-09-04","days":5},{"id":"er-signaling","kind":"pathway","name":"Oestrogen receptor signalling","route":"/pathways/er-signaling/","asOf":"2026-09-04","days":5},{"id":"ar-signaling","kind":"pathway","name":"Androgen receptor signalling","route":"/pathways/ar-signaling/","asOf":"2026-09-04","days":5},{"id":"apoptosis-bcl2","kind":"pathway","name":"Intrinsic apoptosis (BCL-2 family)","route":"/pathways/apoptosis-bcl2/","asOf":"2026-09-04","days":5},{"id":"vegf-angiogenesis","kind":"pathway","name":"VEGF angiogenesis","route":"/pathways/vegf-angiogenesis/","asOf":"2026-09-04","days":5},{"id":"hif-vhl","kind":"pathway","name":"VHL / HIF oxygen sensing","route":"/pathways/hif-vhl/","asOf":"2026-09-04","days":5},{"id":"wnt","kind":"pathway","name":"Wnt / β-catenin","route":"/pathways/wnt/","asOf":"2026-09-04","days":5},{"id":"emt","kind":"pathway","name":"Epithelial–mesenchymal transition & drug efflux","route":"/pathways/emt/","asOf":"2026-09-04","days":5},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/","asOf":"2026-09-04","days":5},{"id":"linker","kind":"term","name":"Linker (ADC)","route":"/terms/linker/","asOf":"2026-09-04","days":5},{"id":"dar","kind":"term","name":"Drug-to-antibody ratio (DAR)","route":"/terms/dar/","asOf":"2026-09-04","days":5},{"id":"bystander-effect","kind":"term","name":"Bystander effect (ADC)","route":"/terms/bystander-effect/","asOf":"2026-09-04","days":5},{"id":"ild","kind":"term","name":"Interstitial lung disease (ILD) / pneumonitis","route":"/terms/ild/","asOf":"2026-09-04","days":5},{"id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/","asOf":"2026-09-04","days":5},{"id":"resistance","kind":"term","name":"Drug resistance (primary and acquired)","route":"/terms/resistance/","asOf":"2026-09-04","days":5},{"id":"orr","kind":"term","name":"Objective response rate (ORR)","route":"/terms/orr/","asOf":"2026-09-04","days":5},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/","asOf":"2026-09-04","days":5},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/","asOf":"2026-09-04","days":5},{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/","asOf":"2026-09-04","days":5},{"id":"efs","kind":"term","name":"Event-free / disease-free survival (EFS, DFS, iDFS, RFS)","route":"/terms/efs/","asOf":"2026-09-04","days":5},{"id":"hazard-ratio","kind":"term","name":"Hazard ratio (HR)","route":"/terms/hazard-ratio/","asOf":"2026-09-04","days":5},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/","asOf":"2026-09-04","days":5},{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/","asOf":"2026-09-04","days":5},{"id":"ppv","kind":"term","name":"Positive predictive value (PPV)","route":"/terms/ppv/","asOf":"2026-09-04","days":5},{"id":"stage-shift","kind":"term","name":"Stage shift","route":"/terms/stage-shift/","asOf":"2026-09-04","days":5},{"id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","asOf":"2026-09-04","days":5},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/","asOf":"2026-09-04","days":5},{"id":"her2-low","kind":"term","name":"HER2-low and HER2-ultralow","route":"/terms/her2-low/","asOf":"2026-09-04","days":5},{"id":"cps","kind":"term","name":"Combined positive score (CPS)","route":"/terms/cps/","asOf":"2026-09-04","days":5},{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/","asOf":"2026-09-04","days":5},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/","asOf":"2026-09-04","days":5},{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/","asOf":"2026-09-04","days":5},{"id":"hrd","kind":"term","name":"Homologous recombination deficiency (HRD)","route":"/terms/hrd/","asOf":"2026-09-04","days":5},{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/","asOf":"2026-09-04","days":5},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/","asOf":"2026-09-04","days":5},{"id":"vaf","kind":"term","name":"Variant allele frequency (VAF)","route":"/terms/vaf/","asOf":"2026-09-04","days":5},{"id":"vus","kind":"term","name":"Variant of uncertain significance (VUS)","route":"/terms/vus/","asOf":"2026-09-04","days":5},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/","asOf":"2026-09-04","days":5},{"id":"gene-fusion","kind":"term","name":"Gene fusion","route":"/terms/gene-fusion/","asOf":"2026-09-04","days":5},{"id":"mutational-signature","kind":"term","name":"Mutational signature","route":"/terms/mutational-signature/","asOf":"2026-09-04","days":5},{"id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/","asOf":"2026-09-04","days":5},{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/","asOf":"2026-09-04","days":5},{"id":"oncogene-addiction","kind":"term","name":"Oncogene addiction","route":"/terms/oncogene-addiction/","asOf":"2026-09-04","days":5},{"id":"synthetic-lethality","kind":"term","name":"Synthetic lethality","route":"/terms/synthetic-lethality/","asOf":"2026-09-04","days":5},{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/","asOf":"2026-09-04","days":5},{"id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/","asOf":"2026-09-04","days":5},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/","asOf":"2026-09-04","days":5},{"id":"abscopal-effect","kind":"term","name":"Abscopal effect","route":"/terms/abscopal-effect/","asOf":"2026-09-04","days":5},{"id":"immunogenic-cell-death","kind":"term","name":"Immunogenic cell death","route":"/terms/immunogenic-cell-death/","asOf":"2026-09-04","days":5},{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","route":"/terms/adcc/","asOf":"2026-09-04","days":5},{"id":"fc-effector","kind":"term","name":"Fc engineering / effector function","route":"/terms/fc-effector/","asOf":"2026-09-04","days":5},{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/","asOf":"2026-09-04","days":5},{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/","asOf":"2026-09-04","days":5},{"id":"first-line","kind":"term","name":"Lines of therapy","route":"/terms/first-line/","asOf":"2026-09-04","days":5},{"id":"standard-of-care","kind":"term","name":"Standard of care","route":"/terms/standard-of-care/","asOf":"2026-09-04","days":5},{"id":"accelerated-approval","kind":"term","name":"Accelerated approval","route":"/terms/accelerated-approval/","asOf":"2026-09-04","days":5},{"id":"breakthrough-designation","kind":"term","name":"Breakthrough Therapy / Priority Review / Priority Voucher","route":"/terms/breakthrough-designation/","asOf":"2026-09-04","days":5},{"id":"companion-diagnostic-term","kind":"term","name":"Companion diagnostic","route":"/terms/companion-diagnostic-term/","asOf":"2026-09-04","days":5},{"id":"tumour-agnostic","kind":"term","name":"Tumour-agnostic (tissue-agnostic) approval","route":"/terms/tumour-agnostic/","asOf":"2026-09-04","days":5},{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/","asOf":"2026-09-04","days":5},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/","asOf":"2026-09-04","days":5},{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/","asOf":"2026-09-04","days":5},{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/","asOf":"2026-09-04","days":5},{"id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/","asOf":"2026-09-04","days":5},{"id":"germline-vs-somatic","kind":"term","name":"Germline vs somatic mutations","route":"/terms/germline-vs-somatic/","asOf":"2026-09-04","days":5},{"id":"tnm-staging","kind":"term","name":"TNM staging","route":"/terms/tnm-staging/","asOf":"2026-09-04","days":5},{"id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/","asOf":"2026-09-04","days":5},{"id":"adc-sequencing","kind":"term","name":"ADC sequencing","route":"/terms/adc-sequencing/","asOf":"2026-09-04","days":5},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","asOf":"2026-09-04","days":5},{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/","asOf":"2026-09-04","days":5},{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","asOf":"2026-09-04","days":5},{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","asOf":"2026-09-04","days":5},{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","asOf":"2026-09-04","days":5},{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","asOf":"2026-09-04","days":5},{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/","asOf":"2026-09-04","days":5},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","asOf":"2026-09-04","days":5},{"id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/","asOf":"2026-09-04","days":5},{"id":"bl-b01d1-307","kind":"trial","name":"BL-B01D1-307","route":"/trials/bl-b01d1-307/","asOf":"2026-09-04","days":5},{"id":"izabright-breast01","kind":"trial","name":"IZABRIGHT-Breast01","route":"/trials/izabright-breast01/","asOf":"2026-09-04","days":5},{"id":"optimice-pcr","kind":"trial","name":"OptimICE-pCR (A012103)","route":"/trials/optimice-pcr/","asOf":"2026-09-04","days":5},{"id":"scarlet-s2212","kind":"trial","name":"SCARLET (SWOG S2212)","route":"/trials/scarlet-s2212/","asOf":"2026-09-04","days":5},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","asOf":"2026-09-04","days":5},{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/","asOf":"2026-09-04","days":5},{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/","asOf":"2026-09-04","days":5},{"id":"destiny-breast06","kind":"trial","name":"DESTINY-Breast06","route":"/trials/destiny-breast06/","asOf":"2026-09-04","days":5},{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/","asOf":"2026-09-04","days":5},{"id":"destiny-breast11","kind":"trial","name":"DESTINY-Breast11","route":"/trials/destiny-breast11/","asOf":"2026-09-04","days":5},{"id":"natalee","kind":"trial","name":"NATALEE","route":"/trials/natalee/","asOf":"2026-09-04","days":5},{"id":"monarche","kind":"trial","name":"monarchE","route":"/trials/monarche/","asOf":"2026-09-04","days":5},{"id":"veritac-2","kind":"trial","name":"VERITAC-2","route":"/trials/veritac-2/","asOf":"2026-09-04","days":5},{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","asOf":"2026-09-04","days":5},{"id":"flaura2","kind":"trial","name":"FLAURA2","route":"/trials/flaura2/","asOf":"2026-09-04","days":5},{"id":"mariposa","kind":"trial","name":"MARIPOSA","route":"/trials/mariposa/","asOf":"2026-09-04","days":5},{"id":"tropion-lung01","kind":"trial","name":"TROPION-Lung01","route":"/trials/tropion-lung01/","asOf":"2026-09-04","days":5},{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/","asOf":"2026-09-04","days":5},{"id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/","asOf":"2026-09-04","days":5},{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/","asOf":"2026-09-04","days":5},{"id":"interpath-001","kind":"trial","name":"INTerpath-001 (V940-001)","route":"/trials/interpath-001/","asOf":"2026-09-04","days":5},{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/","asOf":"2026-09-04","days":5},{"id":"imvigor011","kind":"trial","name":"IMvigor011","route":"/trials/imvigor011/","asOf":"2026-09-04","days":5},{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","asOf":"2026-09-04","days":5},{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","asOf":"2026-09-04","days":5},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","asOf":"2026-09-04","days":5},{"id":"pathfinder-2","kind":"trial","name":"PATHFINDER 2","route":"/trials/pathfinder-2/","asOf":"2026-09-04","days":5},{"id":"dynamic","kind":"trial","name":"DYNAMIC","route":"/trials/dynamic/","asOf":"2026-09-04","days":5},{"id":"adc-plus-io","kind":"pairing","name":"ADC + checkpoint inhibitor","route":"/pairings/adc-plus-io/","asOf":"2026-09-04","days":5},{"id":"cdk46-plus-endocrine","kind":"pairing","name":"CDK4/6 inhibitor + endocrine therapy","route":"/pairings/cdk46-plus-endocrine/","asOf":"2026-09-04","days":5},{"id":"braf-plus-mek","kind":"pairing","name":"BRAF inhibitor + MEK inhibitor","route":"/pairings/braf-plus-mek/","asOf":"2026-09-04","days":5},{"id":"kras-plus-egfr-crc","kind":"pairing","name":"KRAS G12C inhibitor + anti-EGFR antibody (colorectal)","route":"/pairings/kras-plus-egfr-crc/","asOf":"2026-09-04","days":5},{"id":"io-plus-vegf","kind":"pairing","name":"PD-1 blockade + VEGF inhibition","route":"/pairings/io-plus-vegf/","asOf":"2026-09-04","days":5},{"id":"parp-plus-arpi","kind":"pairing","name":"PARP inhibitor + AR pathway inhibitor (prostate)","route":"/pairings/parp-plus-arpi/","asOf":"2026-09-04","days":5},{"id":"vaccine-plus-pd1","kind":"pairing","name":"Personalised neoantigen vaccine + PD-1 blockade","route":"/pairings/vaccine-plus-pd1/","asOf":"2026-09-04","days":5},{"id":"radiation-plus-io","kind":"pairing","name":"Radiotherapy + immunotherapy","route":"/pairings/radiation-plus-io/","asOf":"2026-09-04","days":5},{"id":"oncolytic-plus-pd1","kind":"pairing","name":"Oncolytic virus + PD-1 blockade","route":"/pairings/oncolytic-plus-pd1/","asOf":"2026-09-04","days":5},{"id":"platinum-plus-hrd","kind":"pairing","name":"Platinum chemotherapy in HRD tumours","route":"/pairings/platinum-plus-hrd/","asOf":"2026-09-04","days":5},{"id":"psma-pet-to-rlt","kind":"pairing","name":"PSMA PET → PSMA radioligand therapy","route":"/pairings/psma-pet-to-rlt/","asOf":"2026-09-04","days":5},{"id":"trop2-pet-to-adc","kind":"pairing","name":"TROP2 PET → TROP2 ADC selection","route":"/pairings/trop2-pet-to-adc/","asOf":"2026-09-04","days":5},{"id":"ctdna-mrd-to-adjuvant","kind":"pairing","name":"ctDNA MRD → adjuvant therapy decision","route":"/pairings/ctdna-mrd-to-adjuvant/","asOf":"2026-09-04","days":5},{"id":"her2-low-to-tdxd","kind":"pairing","name":"HER2-low scoring → T-DXd","route":"/pairings/her2-low-to-tdxd/","asOf":"2026-09-04","days":5},{"id":"germline-to-parp","kind":"pairing","name":"Germline BRCA test → adjuvant PARP inhibitor","route":"/pairings/germline-to-parp/","asOf":"2026-09-04","days":5},{"id":"ai-pathology-to-adt","kind":"pairing","name":"AI pathology → androgen deprivation duration","route":"/pairings/ai-pathology-to-adt/","asOf":"2026-09-04","days":5},{"id":"tki-then-adc-lung","kind":"pairing","name":"EGFR TKI → ADC on progression","route":"/pairings/tki-then-adc-lung/","asOf":"2026-09-04","days":5},{"id":"io-then-til","kind":"pairing","name":"PD-1 failure → TIL therapy","route":"/pairings/io-then-til/","asOf":"2026-09-04","days":5},{"id":"beta-then-alpha","kind":"pairing","name":"Beta radioligand → alpha radioligand","route":"/pairings/beta-then-alpha/","asOf":"2026-09-04","days":5},{"id":"adc-after-adc-caution","kind":"pairing","name":"Caution: TOP1 ADC immediately after TOP1 ADC","route":"/pairings/adc-after-adc-caution/","asOf":"2026-09-04","days":5},{"id":"tigit-plus-pd1-caution","kind":"pairing","name":"Caution: TIGIT + PD-(L)1 blockade","route":"/pairings/tigit-plus-pd1-caution/","asOf":"2026-09-04","days":5},{"id":"ild-overlap-caution","kind":"pairing","name":"Caution: DXd ADC + agents with pneumonitis risk","route":"/pairings/ild-overlap-caution/","asOf":"2026-09-04","days":5},{"id":"adc-generations","kind":"roadmap","name":"ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs","route":"/roadmaps/adc-generations/","asOf":"2026-09-04","days":5},{"id":"trop2-adc-roadmap","kind":"roadmap","name":"TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET","route":"/roadmaps/trop2-adc-roadmap/","asOf":"2026-09-04","days":5},{"id":"tnbc-history","kind":"roadmap","name":"TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line","route":"/roadmaps/tnbc-history/","asOf":"2026-09-04","days":5},{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/","asOf":"2026-09-04","days":5},{"id":"cell-therapy-roadmap","kind":"roadmap","name":"Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR","route":"/roadmaps/cell-therapy-roadmap/","asOf":"2026-09-04","days":5},{"id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/","asOf":"2026-09-04","days":5},{"id":"early-detection-roadmap","kind":"roadmap","name":"Early detection roadmap: organ screening → blood tests for many cancers","route":"/roadmaps/early-detection-roadmap/","asOf":"2026-09-04","days":5},{"id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/","asOf":"2026-09-04","days":5},{"id":"kras-roadmap","kind":"roadmap","name":"KRAS roadmap: undruggable → G12C → pan-RAS","route":"/roadmaps/kras-roadmap/","asOf":"2026-09-04","days":5},{"id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/","asOf":"2026-09-04","days":5},{"id":"idea-payload-switching","kind":"idea","name":"Payload-class switching as the rule for ADC sequencing","route":"/ideas/idea-payload-switching/","asOf":"2026-09-04","days":5},{"id":"idea-post-neoadjuvant-adc","kind":"idea","name":"ADC for residual disease after KEYNOTE-522","route":"/ideas/idea-post-neoadjuvant-adc/","asOf":"2026-09-04","days":5},{"id":"idea-ctdna-escalation-tnbc","kind":"idea","name":"ctDNA-triggered escalation in early TNBC","route":"/ideas/idea-ctdna-escalation-tnbc/","asOf":"2026-09-04","days":5},{"id":"idea-efflux-agnostic","kind":"idea","name":"Efflux-agnostic therapy for mesenchymal TNBC","route":"/ideas/idea-efflux-agnostic/","asOf":"2026-09-04","days":5},{"id":"idea-fap-theranostics-pancancer","kind":"idea","name":"FAP theranostics as a pan-cancer stromal strategy","route":"/ideas/idea-fap-theranostics-pancancer/","asOf":"2026-09-04","days":5},{"id":"idea-in-vivo-car-solid","kind":"idea","name":"In vivo CAR-T against solid-tumour antigens","route":"/ideas/idea-in-vivo-car-solid/","asOf":"2026-09-04","days":5},{"id":"idea-neoadjuvant-adc-io","kind":"idea","name":"Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC","route":"/ideas/idea-neoadjuvant-adc-io/","asOf":"2026-09-04","days":5},{"id":"idea-til-guided-deescalation","kind":"idea","name":"TIL-based omission of chemotherapy in stage I TNBC","route":"/ideas/idea-til-guided-deescalation/","asOf":"2026-09-04","days":5},{"id":"idea-ai-her2-low-scoring","kind":"idea","name":"AI quantification of HER2-low and HER2-ultralow","route":"/ideas/idea-ai-her2-low-scoring/","asOf":"2026-09-04","days":5},{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/","asOf":"2026-09-04","days":5},{"id":"idea-shared-kras-vaccine-adjuvant","kind":"idea","name":"Off-the-shelf KRAS vaccines after pancreatic cancer surgery","route":"/ideas/idea-shared-kras-vaccine-adjuvant/","asOf":"2026-09-04","days":5},{"id":"idea-mced-plus-fapi","kind":"idea","name":"FAPI PET as the workup for MCED positives","route":"/ideas/idea-mced-plus-fapi/","asOf":"2026-09-04","days":5},{"id":"idea-total-body-pet-dosimetry","kind":"idea","name":"Total-body PET for personalised radioligand dosing","route":"/ideas/idea-total-body-pet-dosimetry/","asOf":"2026-09-04","days":5},{"id":"idea-organoid-guided-adc","kind":"idea","name":"Patient-derived organoids to pick ADC payloads","route":"/ideas/idea-organoid-guided-adc/","asOf":"2026-09-04","days":5},{"id":"idea-dual-payload-first","kind":"idea","name":"Dual-payload ADCs in first line to prevent resistance","route":"/ideas/idea-dual-payload-first/","asOf":"2026-09-04","days":5},{"id":"idea-cd8-pet-io","kind":"idea","name":"CD8 PET to stop or switch immunotherapy early","route":"/ideas/idea-cd8-pet-io/","asOf":"2026-09-04","days":5},{"id":"idea-exercise-as-adjuvant","kind":"idea","name":"Structured exercise prescribed like a drug in all curative-intent cancer care","route":"/ideas/idea-exercise-as-adjuvant/","asOf":"2026-09-04","days":5},{"id":"idea-multimodal-foundation-model","kind":"idea","name":"Patient-level multimodal foundation models for treatment selection","route":"/ideas/idea-multimodal-foundation-model/","asOf":"2026-09-04","days":5},{"id":"idea-interception-vaccines","kind":"idea","name":"Cancer interception vaccines for high-risk carriers","route":"/ideas/idea-interception-vaccines/","asOf":"2026-09-04","days":5},{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/","asOf":"2026-09-04","days":5},{"id":"oncokb","kind":"collection","name":"OncoKB","route":"/collections/oncokb/","asOf":"2026-09-04","days":5},{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/","asOf":"2026-09-04","days":5},{"id":"cbioportal","kind":"collection","name":"cBioPortal for Cancer Genomics","route":"/collections/cbioportal/","asOf":"2026-09-04","days":5},{"id":"tcga-gdc","kind":"collection","name":"TCGA / NCI Genomic Data Commons","route":"/collections/tcga-gdc/","asOf":"2026-09-04","days":5},{"id":"depmap","kind":"collection","name":"DepMap (Cancer Dependency Map)","route":"/collections/depmap/","asOf":"2026-09-04","days":5},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/","asOf":"2026-09-04","days":5},{"id":"cosmic","kind":"collection","name":"COSMIC (Catalogue of Somatic Mutations in Cancer)","route":"/collections/cosmic/","asOf":"2026-09-04","days":5},{"id":"clinvar","kind":"collection","name":"ClinVar","route":"/collections/clinvar/","asOf":"2026-09-04","days":5},{"id":"drugbank-chembl","kind":"collection","name":"DrugBank & ChEMBL","route":"/collections/drugbank-chembl/","asOf":"2026-09-04","days":5},{"id":"ttd","kind":"collection","name":"Therapeutic Target Database (TTD)","route":"/collections/ttd/","asOf":"2026-09-04","days":5},{"id":"adcdb","kind":"collection","name":"ADCdb / ADC Review","route":"/collections/adcdb/","asOf":"2026-09-04","days":5},{"id":"nccn","kind":"collection","name":"NCCN Guidelines","route":"/collections/nccn/","asOf":"2026-09-04","days":5},{"id":"esmo-guidelines","kind":"collection","name":"ESMO Clinical Practice Guidelines & MCBS","route":"/collections/esmo-guidelines/","asOf":"2026-09-04","days":5},{"id":"fda-approvals","kind":"collection","name":"FDA Oncology Approvals (OCE) & Novel Drug Approvals","route":"/collections/fda-approvals/","asOf":"2026-09-04","days":5},{"id":"seer","kind":"collection","name":"SEER (Surveillance, Epidemiology, and End Results)","route":"/collections/seer/","asOf":"2026-09-04","days":5},{"id":"globocan","kind":"collection","name":"GLOBOCAN / Global Cancer Observatory","route":"/collections/globocan/","asOf":"2026-09-04","days":5},{"id":"cancer-gov-pdq","kind":"collection","name":"NCI PDQ Cancer Information Summaries","route":"/collections/cancer-gov-pdq/","asOf":"2026-09-04","days":5},{"id":"awesome-cancer-variant-resources","kind":"collection","name":"awesome-cancer-variant-resources","route":"/collections/awesome-cancer-variant-resources/","asOf":"2026-09-04","days":5},{"id":"genie","kind":"collection","name":"AACR Project GENIE","route":"/collections/genie/","asOf":"2026-09-04","days":5},{"id":"hpa","kind":"collection","name":"Human Protein Atlas","route":"/collections/hpa/","asOf":"2026-09-04","days":5},{"id":"cptac","kind":"collection","name":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","route":"/collections/cptac/","asOf":"2026-09-04","days":5},{"id":"cellxgene-hca","kind":"collection","name":"CZ CELLxGENE / Human Cell Atlas","route":"/collections/cellxgene-hca/","asOf":"2026-09-04","days":5},{"id":"cancer-models","kind":"collection","name":"Cancer Models (PDCM Finder) & HCMI","route":"/collections/cancer-models/","asOf":"2026-09-04","days":5},{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/","asOf":"2026-09-04","days":5},{"id":"eudract-ctis","kind":"collection","name":"EU Clinical Trials Register / CTIS","route":"/collections/eudract-ctis/","asOf":"2026-09-04","days":5},{"id":"newsweek-hospitals","kind":"collection","name":"Newsweek/Statista World's Best Specialized Hospitals – Oncology","route":"/collections/newsweek-hospitals/","asOf":"2026-09-04","days":5},{"id":"nature-index","kind":"collection","name":"Nature Index – Healthcare and Cancer institutions","route":"/collections/nature-index/","asOf":"2026-09-04","days":5},{"id":"scimago-oncology","kind":"collection","name":"SCImago Institutions Rankings – Oncology","route":"/collections/scimago-oncology/","asOf":"2026-09-04","days":5},{"id":"nci-cancer-centers","kind":"collection","name":"NCI-Designated Cancer Centers","route":"/collections/nci-cancer-centers/","asOf":"2026-09-04","days":5},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","asOf":"2026-09-06","days":3},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","asOf":"2026-09-06","days":3},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","asOf":"2026-09-06","days":3},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/","asOf":"2026-09-06","days":3},{"id":"nlst-nelson","kind":"trial","name":"NLST & NELSON (low-dose CT screening)","route":"/trials/nlst-nelson/","asOf":"2026-09-06","days":3},{"id":"crown","kind":"trial","name":"CROWN","route":"/trials/crown/","asOf":"2026-09-06","days":3},{"id":"alina","kind":"trial","name":"ALINA","route":"/trials/alina/","asOf":"2026-09-06","days":3},{"id":"pacific","kind":"trial","name":"PACIFIC","route":"/trials/pacific/","asOf":"2026-09-06","days":3},{"id":"laura","kind":"trial","name":"LAURA","route":"/trials/laura/","asOf":"2026-09-06","days":3},{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/","asOf":"2026-09-06","days":3},{"id":"keynote-671","kind":"trial","name":"KEYNOTE-671","route":"/trials/keynote-671/","asOf":"2026-09-06","days":3},{"id":"keynote-024-189","kind":"trial","name":"KEYNOTE-024 & KEYNOTE-189","route":"/trials/keynote-024-189/","asOf":"2026-09-06","days":3},{"id":"harmoni-2","kind":"trial","name":"HARMONi-2","route":"/trials/harmoni-2/","asOf":"2026-09-06","days":3},{"id":"harmoni-3","kind":"trial","name":"HARMONi-3","route":"/trials/harmoni-3/","asOf":"2026-09-06","days":3},{"id":"herthena-lung02","kind":"trial","name":"HERTHENA-Lung02","route":"/trials/herthena-lung02/","asOf":"2026-09-06","days":3},{"id":"tropion-lung05","kind":"trial","name":"TROPION-Lung05","route":"/trials/tropion-lung05/","asOf":"2026-09-06","days":3},{"id":"krystal-12","kind":"trial","name":"KRYSTAL-12","route":"/trials/krystal-12/","asOf":"2026-09-06","days":3},{"id":"codebreak-200","kind":"trial","name":"CodeBreaK 200","route":"/trials/codebreak-200/","asOf":"2026-09-06","days":3},{"id":"krascendo-1","kind":"trial","name":"Krascendo 1","route":"/trials/krascendo-1/","asOf":"2026-09-06","days":3},{"id":"libretto-431","kind":"trial","name":"LIBRETTO-431","route":"/trials/libretto-431/","asOf":"2026-09-06","days":3},{"id":"telimet-nsclc-01","kind":"trial","name":"TeliMET NSCLC-01","route":"/trials/telimet-nsclc-01/","asOf":"2026-09-06","days":3},{"id":"alkove-1","kind":"trial","name":"ALKOVE-1","route":"/trials/alkove-1/","asOf":"2026-09-06","days":3},{"id":"soho-01","kind":"trial","name":"SOHO-01","route":"/trials/soho-01/","asOf":"2026-09-06","days":3},{"id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/","asOf":"2026-09-06","days":3},{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/","asOf":"2026-09-06","days":3},{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/","asOf":"2026-09-06","days":3},{"id":"capmatinib-tepotinib","kind":"drug","name":"Capmatinib & tepotinib","route":"/drugs/capmatinib-tepotinib/","asOf":"2026-09-06","days":3},{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/","asOf":"2026-09-06","days":3},{"id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","asOf":"2026-09-06","days":3},{"id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/","asOf":"2026-09-06","days":3},{"id":"divarasib","kind":"drug","name":"Divarasib","route":"/drugs/divarasib/","asOf":"2026-09-06","days":3},{"id":"olomorasib","kind":"drug","name":"Olomorasib","route":"/drugs/olomorasib/","asOf":"2026-09-06","days":3},{"id":"neladalkib","kind":"drug","name":"Neladalkib","route":"/drugs/neladalkib/","asOf":"2026-09-06","days":3},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/","asOf":"2026-09-06","days":3},{"id":"ros1","kind":"target","name":"ROS1","route":"/targets/ros1/","asOf":"2026-09-06","days":3},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","asOf":"2026-09-06","days":3},{"id":"robotic-bronchoscopy","kind":"technology","name":"Robotic and navigational bronchoscopy","route":"/technologies/robotic-bronchoscopy/","asOf":"2026-09-06","days":3},{"id":"tps","kind":"term","name":"Tumour proportion score (TPS)","route":"/terms/tps/","asOf":"2026-09-06","days":3},{"id":"egfr-exon19-l858r","kind":"term","name":"EGFR exon 19 deletion & L858R","route":"/terms/egfr-exon19-l858r/","asOf":"2026-09-06","days":3},{"id":"egfr-exon20-insertion","kind":"term","name":"EGFR exon 20 insertion","route":"/terms/egfr-exon20-insertion/","asOf":"2026-09-06","days":3},{"id":"c797s","kind":"term","name":"EGFR C797S","route":"/terms/c797s/","asOf":"2026-09-06","days":3},{"id":"met-amplification","kind":"term","name":"MET amplification (bypass resistance)","route":"/terms/met-amplification/","asOf":"2026-09-06","days":3},{"id":"histologic-transformation","kind":"term","name":"Histologic transformation","route":"/terms/histologic-transformation/","asOf":"2026-09-06","days":3},{"id":"oligoprogression","kind":"term","name":"Oligoprogression","route":"/terms/oligoprogression/","asOf":"2026-09-06","days":3},{"id":"amivantamab-plus-lazertinib","kind":"pairing","name":"Amivantamab + lazertinib (first-line EGFR NSCLC)","route":"/pairings/amivantamab-plus-lazertinib/","asOf":"2026-09-06","days":3},{"id":"pd1-plus-chemo-pdl1-low","kind":"pairing","name":"PD-1 blockade + chemotherapy in PD-L1-low NSCLC","route":"/pairings/pd1-plus-chemo-pdl1-low/","asOf":"2026-09-06","days":3},{"id":"targeted-before-io-nsclc","kind":"pairing","name":"Sequence: targeted therapy before immunotherapy in driver-positive NSCLC","route":"/pairings/targeted-before-io-nsclc/","asOf":"2026-09-06","days":3},{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/","asOf":"2026-09-06","days":3},{"id":"sumitomo-pharma","kind":"company","name":"Sumitomo Pharma (Myovant)","route":"/companies/sumitomo-pharma/","asOf":"2026-09-06","days":3},{"id":"veracyte","kind":"company","name":"Veracyte (Decipher)","route":"/companies/veracyte/","asOf":"2026-09-06","days":3},{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/","asOf":"2026-09-06","days":3},{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","route":"/companies/essa-pharma/","asOf":"2026-09-06","days":3},{"id":"steap1","kind":"target","name":"STEAP1","route":"/targets/steap1/","asOf":"2026-09-06","days":3},{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/","asOf":"2026-09-06","days":3},{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","asOf":"2026-09-06","days":3},{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/","asOf":"2026-09-06","days":3},{"id":"mp-mri","kind":"technology","name":"Multiparametric prostate MRI (PI-RADS)","route":"/technologies/mp-mri/","asOf":"2026-09-06","days":3},{"id":"psa","kind":"term","name":"PSA (prostate-specific antigen)","route":"/terms/psa/","asOf":"2026-09-06","days":3},{"id":"gleason-grade-group","kind":"term","name":"Gleason score / Grade Group","route":"/terms/gleason-grade-group/","asOf":"2026-09-06","days":3},{"id":"castration-resistance","kind":"term","name":"Castration-resistant prostate cancer (CRPC)","route":"/terms/castration-resistance/","asOf":"2026-09-06","days":3},{"id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","asOf":"2026-09-06","days":3},{"id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","asOf":"2026-09-06","days":3},{"id":"ar-v7","kind":"term","name":"AR-V7 splice variant","route":"/terms/ar-v7/","asOf":"2026-09-06","days":3},{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","asOf":"2026-09-06","days":3},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","asOf":"2026-09-06","days":3},{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","asOf":"2026-09-06","days":3},{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","asOf":"2026-09-06","days":3},{"id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","asOf":"2026-09-06","days":3},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","asOf":"2026-09-06","days":3},{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","asOf":"2026-09-06","days":3},{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","asOf":"2026-09-06","days":3},{"id":"lu177-psma-it","kind":"drug","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/","asOf":"2026-09-06","days":3},{"id":"xaluritamig","kind":"drug","name":"Xaluritamig","route":"/drugs/xaluritamig/","asOf":"2026-09-06","days":3},{"id":"pasritamig","kind":"drug","name":"Pasritamig","route":"/drugs/pasritamig/","asOf":"2026-09-06","days":3},{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","asOf":"2026-09-06","days":3},{"id":"flotufolastat","kind":"drug","name":"Flotufolastat F-18","route":"/drugs/flotufolastat/","asOf":"2026-09-06","days":3},{"id":"mevrometostat","kind":"drug","name":"Mevrometostat","route":"/drugs/mevrometostat/","asOf":"2026-09-06","days":3},{"id":"masofaniten","kind":"drug","name":"Masofaniten","route":"/drugs/masofaniten/","asOf":"2026-09-06","days":3},{"id":"decipher-prostate","kind":"drug","name":"Decipher Prostate","route":"/drugs/decipher-prostate/","asOf":"2026-09-06","days":3},{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","asOf":"2026-09-06","days":3},{"id":"precision-mri","kind":"trial","name":"PRECISION","route":"/trials/precision-mri/","asOf":"2026-09-06","days":3},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","asOf":"2026-09-06","days":3},{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","asOf":"2026-09-06","days":3},{"id":"latitude","kind":"trial","name":"LATITUDE","route":"/trials/latitude/","asOf":"2026-09-06","days":3},{"id":"arches","kind":"trial","name":"ARCHES","route":"/trials/arches/","asOf":"2026-09-06","days":3},{"id":"arasens","kind":"trial","name":"ARASENS","route":"/trials/arasens/","asOf":"2026-09-06","days":3},{"id":"peace-1","kind":"trial","name":"PEACE-1","route":"/trials/peace-1/","asOf":"2026-09-06","days":3},{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/","asOf":"2026-09-06","days":3},{"id":"profound","kind":"trial","name":"PROfound","route":"/trials/profound/","asOf":"2026-09-06","days":3},{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/","asOf":"2026-09-06","days":3},{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/","asOf":"2026-09-06","days":3},{"id":"magnitude","kind":"trial","name":"MAGNITUDE","route":"/trials/magnitude/","asOf":"2026-09-06","days":3},{"id":"capitello-281","kind":"trial","name":"CAPItello-281","route":"/trials/capitello-281/","asOf":"2026-09-06","days":3},{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/","asOf":"2026-09-06","days":3},{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/","asOf":"2026-09-06","days":3},{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/","asOf":"2026-09-06","days":3},{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","asOf":"2026-09-06","days":3},{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/","asOf":"2026-09-06","days":3},{"id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","asOf":"2026-09-06","days":3},{"id":"alphabreak","kind":"trial","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","route":"/trials/alphabreak/","asOf":"2026-09-06","days":3},{"id":"xalute","kind":"trial","name":"XALute","route":"/trials/xalute/","asOf":"2026-09-06","days":3},{"id":"mevpro-1","kind":"trial","name":"MEVPRO-1","route":"/trials/mevpro-1/","asOf":"2026-09-06","days":3},{"id":"idea-psma-pet-guided-mdt","kind":"idea","name":"PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer","route":"/ideas/idea-psma-pet-guided-mdt/","asOf":"2026-09-06","days":3},{"id":"idea-alpha-first-mhspc","kind":"idea","name":"Alpha-emitting PSMA therapy at first metastatic diagnosis","route":"/ideas/idea-alpha-first-mhspc/","asOf":"2026-09-06","days":3},{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/","asOf":"2026-09-06","days":3},{"id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/","asOf":"2026-09-06","days":3},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/","asOf":"2026-09-06","days":3},{"id":"zoldonrasib","kind":"drug","name":"Zoldonrasib","route":"/drugs/zoldonrasib/","asOf":"2026-09-06","days":3},{"id":"elironrasib","kind":"drug","name":"Elironrasib","route":"/drugs/elironrasib/","asOf":"2026-09-06","days":3},{"id":"mrtx1133","kind":"drug","name":"MRTX1133","route":"/drugs/mrtx1133/","asOf":"2026-09-06","days":3},{"id":"eli-002-7p","kind":"drug","name":"ELI-002 7P","route":"/drugs/eli-002-7p/","asOf":"2026-09-06","days":3},{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","asOf":"2026-09-06","days":3},{"id":"napoli-3","kind":"trial","name":"NAPOLI 3","route":"/trials/napoli-3/","asOf":"2026-09-06","days":3},{"id":"prodige-24","kind":"trial","name":"PRODIGE 24 / CCTG PA6","route":"/trials/prodige-24/","asOf":"2026-09-06","days":3},{"id":"preopanc","kind":"trial","name":"PREOPANC-1 / PREOPANC-2","route":"/trials/preopanc/","asOf":"2026-09-06","days":3},{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/","asOf":"2026-09-06","days":3},{"id":"panova-3","kind":"trial","name":"PANOVA-3","route":"/trials/panova-3/","asOf":"2026-09-06","days":3},{"id":"amplify-7p","kind":"trial","name":"AMPLIFY-7P","route":"/trials/amplify-7p/","asOf":"2026-09-06","days":3},{"id":"pancreatic-surveillance","kind":"technology","name":"High-risk pancreatic surveillance (CAPS / PRECEDE)","route":"/technologies/pancreatic-surveillance/","asOf":"2026-09-06","days":3},{"id":"pdac-organoid-pharmacotyping","kind":"technology","name":"PDAC organoid pharmacotyping","route":"/technologies/pdac-organoid-pharmacotyping/","asOf":"2026-09-06","days":3},{"id":"ca19-9","kind":"term","name":"CA 19-9","route":"/terms/ca19-9/","asOf":"2026-09-06","days":3},{"id":"desmoplasia","kind":"term","name":"Desmoplasia (tumour stroma)","route":"/terms/desmoplasia/","asOf":"2026-09-06","days":3},{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/","asOf":"2026-09-06","days":3},{"id":"elicio-therapeutics","kind":"company","name":"Elicio Therapeutics","route":"/companies/elicio-therapeutics/","asOf":"2026-09-06","days":3},{"id":"idea-ras-inhibitor-neoadjuvant-pdac","kind":"idea","name":"RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable","route":"/ideas/idea-ras-inhibitor-neoadjuvant-pdac/","asOf":"2026-09-06","days":3},{"id":"idea-mced-new-onset-diabetes","kind":"idea","name":"Blood-based pancreatic cancer detection in new-onset diabetes","route":"/ideas/idea-mced-new-onset-diabetes/","asOf":"2026-09-06","days":3},{"id":"g12d-plus-pan-ras","kind":"pairing","name":"G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)","route":"/pairings/g12d-plus-pan-ras/","asOf":"2026-09-06","days":3},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/","asOf":"2026-09-06","days":3},{"id":"lomustine","kind":"drug","name":"Lomustine (CCNU)","route":"/drugs/lomustine/","asOf":"2026-09-06","days":3},{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/","asOf":"2026-09-06","days":3},{"id":"dordaviprone","kind":"drug","name":"Dordaviprone","route":"/drugs/dordaviprone/","asOf":"2026-09-06","days":3},{"id":"tovorafenib","kind":"drug","name":"Tovorafenib","route":"/drugs/tovorafenib/","asOf":"2026-09-06","days":3},{"id":"dcvax-l","kind":"drug","name":"DCVax-L","route":"/drugs/dcvax-l/","asOf":"2026-09-06","days":3},{"id":"rindopepimut","kind":"drug","name":"Rindopepimut","route":"/drugs/rindopepimut/","asOf":"2026-09-06","days":3},{"id":"eortc-26981","kind":"trial","name":"EORTC 26981 / NCIC CE.3 (Stupp trial)","route":"/trials/eortc-26981/","asOf":"2026-09-06","days":3},{"id":"ef-14","kind":"trial","name":"EF-14","route":"/trials/ef-14/","asOf":"2026-09-06","days":3},{"id":"indigo","kind":"trial","name":"INDIGO","route":"/trials/indigo/","asOf":"2026-09-06","days":3},{"id":"checkmate-548","kind":"trial","name":"CheckMate 548 & CheckMate 143 & CheckMate 498","route":"/trials/checkmate-548/","asOf":"2026-09-06","days":3},{"id":"act-iv","kind":"trial","name":"ACT IV","route":"/trials/act-iv/","asOf":"2026-09-06","days":3},{"id":"litt","kind":"technology","name":"Laser interstitial thermal therapy (LITT)","route":"/technologies/litt/","asOf":"2026-09-06","days":3},{"id":"bbb-focused-ultrasound","kind":"technology","name":"Focused-ultrasound blood-brain barrier opening","route":"/technologies/bbb-focused-ultrasound/","asOf":"2026-09-06","days":3},{"id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/","asOf":"2026-09-06","days":3},{"id":"mgmt","kind":"term","name":"MGMT promoter methylation","route":"/terms/mgmt/","asOf":"2026-09-06","days":3},{"id":"h3k27m","kind":"term","name":"H3 K27M (diffuse midline glioma)","route":"/terms/h3k27m/","asOf":"2026-09-06","days":3},{"id":"egfrviii","kind":"term","name":"EGFRvIII","route":"/terms/egfrviii/","asOf":"2026-09-06","days":3},{"id":"blood-brain-barrier","kind":"term","name":"Blood-brain barrier (BBB)","route":"/terms/blood-brain-barrier/","asOf":"2026-09-06","days":3},{"id":"day-one-biopharmaceuticals","kind":"company","name":"Day One Biopharmaceuticals","route":"/companies/day-one-biopharmaceuticals/","asOf":"2026-09-06","days":3},{"id":"northwest-biotherapeutics","kind":"company","name":"Northwest Biotherapeutics","route":"/companies/northwest-biotherapeutics/","asOf":"2026-09-06","days":3},{"id":"idea-neoadjuvant-io-glioblastoma","kind":"idea","name":"Neoadjuvant immunotherapy with surgical window for glioblastoma","route":"/ideas/idea-neoadjuvant-io-glioblastoma/","asOf":"2026-09-06","days":3},{"id":"idea-fus-plus-adc-glioma","kind":"idea","name":"Focused-ultrasound BBB opening to deliver ADCs and radioligands to glioma","route":"/ideas/idea-fus-plus-adc-glioma/","asOf":"2026-09-06","days":3},{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/","asOf":"2026-09-06","days":3},{"id":"magrolimab","kind":"drug","name":"Magrolimab","route":"/drugs/magrolimab/","asOf":"2026-09-06","days":3},{"id":"rovalpituzumab-tesirine","kind":"drug","name":"Rovalpituzumab tesirine","route":"/drugs/rovalpituzumab-tesirine/","asOf":"2026-09-06","days":3},{"id":"iniparib","kind":"drug","name":"Iniparib","route":"/drugs/iniparib/","asOf":"2026-09-06","days":3},{"id":"bempegaldesleukin","kind":"drug","name":"Bempegaldesleukin","route":"/drugs/bempegaldesleukin/","asOf":"2026-09-06","days":3},{"id":"adu-s100","kind":"drug","name":"ADU-S100 (MIW815)","route":"/drugs/adu-s100/","asOf":"2026-09-06","days":3},{"id":"eprenetapopt","kind":"drug","name":"Eprenetapopt","route":"/drugs/eprenetapopt/","asOf":"2026-09-06","days":3},{"id":"tusamitamab-ravtansine","kind":"drug","name":"Tusamitamab ravtansine","route":"/drugs/tusamitamab-ravtansine/","asOf":"2026-09-06","days":3},{"id":"impassion131","kind":"trial","name":"IMpassion131","route":"/trials/impassion131/","asOf":"2026-09-06","days":3},{"id":"epacadostat","kind":"drug","name":"Epacadostat","route":"/drugs/epacadostat/","asOf":"2026-09-06","days":3},{"id":"trastuzumab-duocarmazine","kind":"drug","name":"Trastuzumab duocarmazine","route":"/drugs/trastuzumab-duocarmazine/","asOf":"2026-09-06","days":3},{"id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/","asOf":"2026-09-06","days":3},{"id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/","asOf":"2026-09-06","days":3},{"id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/","asOf":"2026-09-06","days":3},{"id":"swog","kind":"institution","name":"SWOG Cancer Research Network","route":"/institutions/swog/","asOf":"2026-09-06","days":3},{"id":"nrg-oncology","kind":"institution","name":"NRG Oncology","route":"/institutions/nrg-oncology/","asOf":"2026-09-06","days":3},{"id":"alliance-oncology","kind":"institution","name":"Alliance for Clinical Trials in Oncology","route":"/institutions/alliance-oncology/","asOf":"2026-09-06","days":3},{"id":"ecog-acrin","kind":"institution","name":"ECOG-ACRIN Cancer Research Group","route":"/institutions/ecog-acrin/","asOf":"2026-09-06","days":3},{"id":"childrens-oncology-group","kind":"institution","name":"Children's Oncology Group (COG)","route":"/institutions/childrens-oncology-group/","asOf":"2026-09-06","days":3},{"id":"cctg","kind":"institution","name":"Canadian Cancer Trials Group (CCTG)","route":"/institutions/cctg/","asOf":"2026-09-06","days":3},{"id":"big","kind":"institution","name":"Breast International Group (BIG)","route":"/institutions/big/","asOf":"2026-09-06","days":3},{"id":"gbg","kind":"institution","name":"German Breast Group (GBG)","route":"/institutions/gbg/","asOf":"2026-09-06","days":3},{"id":"jcog","kind":"institution","name":"Japan Clinical Oncology Group (JCOG)","route":"/institutions/jcog/","asOf":"2026-09-06","days":3},{"id":"unicancer","kind":"institution","name":"UNICANCER","route":"/institutions/unicancer/","asOf":"2026-09-06","days":3},{"id":"nccn-org","kind":"institution","name":"National Comprehensive Cancer Network (NCCN)","route":"/institutions/nccn-org/","asOf":"2026-09-06","days":3},{"id":"programmable-dna-targeting-therapeutics","kind":"technology","name":"Programmable DNA-targeting therapeutics","route":"/technologies/programmable-dna-targeting-therapeutics/","asOf":"2026-09-06","days":3},{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/","asOf":"2026-09-06","days":3},{"id":"adc-payload-neutralizer","kind":"technology","name":"ADC payload neutralisers","route":"/technologies/adc-payload-neutralizer/","asOf":"2026-09-06","days":3},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","asOf":"2026-09-07","days":2},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","asOf":"2026-09-07","days":2},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","asOf":"2026-09-07","days":2},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","asOf":"2026-09-07","days":2},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","asOf":"2026-09-07","days":2},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","asOf":"2026-09-07","days":2},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/","asOf":"2026-09-07","days":2},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","asOf":"2026-09-07","days":2},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","asOf":"2026-09-07","days":2},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","asOf":"2026-09-07","days":2},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","asOf":"2026-09-07","days":2},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/","asOf":"2026-09-07","days":2},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","asOf":"2026-09-07","days":2},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/","asOf":"2026-09-07","days":2},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","asOf":"2026-09-07","days":2},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","asOf":"2026-09-07","days":2},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/","asOf":"2026-09-07","days":2},{"id":"monaleesa-2","kind":"trial","name":"MONALEESA-2","route":"/trials/monaleesa-2/","asOf":"2026-09-07","days":2},{"id":"monarch-3","kind":"trial","name":"MONARCH 3","route":"/trials/monarch-3/","asOf":"2026-09-07","days":2},{"id":"paloma-2","kind":"trial","name":"PALOMA-2","route":"/trials/paloma-2/","asOf":"2026-09-07","days":2},{"id":"solar-1","kind":"trial","name":"SOLAR-1","route":"/trials/solar-1/","asOf":"2026-09-07","days":2},{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/","asOf":"2026-09-07","days":2},{"id":"inavo120","kind":"trial","name":"INAVO120","route":"/trials/inavo120/","asOf":"2026-09-07","days":2},{"id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/","asOf":"2026-09-07","days":2},{"id":"ember-3","kind":"trial","name":"EMBER-3","route":"/trials/ember-3/","asOf":"2026-09-07","days":2},{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/","asOf":"2026-09-07","days":2},{"id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","asOf":"2026-09-07","days":2},{"id":"persevera","kind":"trial","name":"persevERA","route":"/trials/persevera/","asOf":"2026-09-07","days":2},{"id":"lidera","kind":"trial","name":"lidERA","route":"/trials/lidera/","asOf":"2026-09-07","days":2},{"id":"postmonarch","kind":"trial","name":"postMONARCH","route":"/trials/postmonarch/","asOf":"2026-09-07","days":2},{"id":"tailorx","kind":"trial","name":"TAILORx","route":"/trials/tailorx/","asOf":"2026-09-07","days":2},{"id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/","asOf":"2026-09-07","days":2},{"id":"soft-text","kind":"trial","name":"SOFT & TEXT","route":"/trials/soft-text/","asOf":"2026-09-07","days":2},{"id":"pallas-penelope-b","kind":"trial","name":"PALLAS & PENELOPE-B","route":"/trials/pallas-penelope-b/","asOf":"2026-09-07","days":2},{"id":"tropics-02","kind":"trial","name":"TROPiCS-02","route":"/trials/tropics-02/","asOf":"2026-09-07","days":2},{"id":"fourlight-1","kind":"trial","name":"FOURLIGHT-1","route":"/trials/fourlight-1/","asOf":"2026-09-07","days":2},{"id":"cambria","kind":"trial","name":"CAMBRIA-1 & CAMBRIA-2","route":"/trials/cambria/","asOf":"2026-09-07","days":2},{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","asOf":"2026-09-07","days":2},{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/","asOf":"2026-09-07","days":2},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/","asOf":"2026-09-07","days":2},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","asOf":"2026-09-07","days":2},{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","asOf":"2026-09-07","days":2},{"id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/","asOf":"2026-09-07","days":2},{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/","asOf":"2026-09-07","days":2},{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","asOf":"2026-09-07","days":2},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","asOf":"2026-09-07","days":2},{"id":"atirmociclib","kind":"drug","name":"Atirmociclib","route":"/drugs/atirmociclib/","asOf":"2026-09-07","days":2},{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/","asOf":"2026-09-07","days":2},{"id":"mammaprint","kind":"drug","name":"MammaPrint (70-gene signature)","route":"/drugs/mammaprint/","asOf":"2026-09-07","days":2},{"id":"esr1-mutation","kind":"term","name":"ESR1 mutation","route":"/terms/esr1-mutation/","asOf":"2026-09-07","days":2},{"id":"oral-serd","kind":"term","name":"Oral SERD","route":"/terms/oral-serd/","asOf":"2026-09-07","days":2},{"id":"endocrine-resistance","kind":"term","name":"Endocrine resistance","route":"/terms/endocrine-resistance/","asOf":"2026-09-07","days":2},{"id":"ovarian-function-suppression","kind":"term","name":"Ovarian function suppression (OFS)","route":"/terms/ovarian-function-suppression/","asOf":"2026-09-07","days":2},{"id":"late-recurrence","kind":"term","name":"Late recurrence","route":"/terms/late-recurrence/","asOf":"2026-09-07","days":2},{"id":"oral-serd-plus-cdk46-after-esr1","kind":"pairing","name":"Oral SERD + CDK4/6 inhibitor after ESR1 emergence","route":"/pairings/oral-serd-plus-cdk46-after-esr1/","asOf":"2026-09-07","days":2},{"id":"pi3k-pathway-plus-endocrine","kind":"pairing","name":"PI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)","route":"/pairings/pi3k-pathway-plus-endocrine/","asOf":"2026-09-07","days":2},{"id":"genomic-assay-to-chemo-omission","kind":"pairing","name":"Gene-expression assay → chemotherapy omission","route":"/pairings/genomic-assay-to-chemo-omission/","asOf":"2026-09-07","days":2},{"id":"idea-ctdna-switch-generalised","kind":"idea","name":"Molecular-progression switching beyond ESR1","route":"/ideas/idea-ctdna-switch-generalised/","asOf":"2026-09-07","days":2},{"id":"idea-cdk4-selective-first-line","kind":"idea","name":"CDK4-selective inhibitors as the new first-line backbone","route":"/ideas/idea-cdk4-selective-first-line/","asOf":"2026-09-07","days":2},{"id":"idea-late-recurrence-interception","kind":"idea","name":"Intercepting late recurrence with ctDNA surveillance and oral SERDs","route":"/ideas/idea-late-recurrence-interception/","asOf":"2026-09-07","days":2},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/","asOf":"2026-09-07","days":2},{"id":"puma-biotechnology","kind":"company","name":"Puma Biotechnology","route":"/companies/puma-biotechnology/","asOf":"2026-09-07","days":2},{"id":"macrogenics","kind":"company","name":"MacroGenics","route":"/companies/macrogenics/","asOf":"2026-09-07","days":2},{"id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/","asOf":"2026-09-07","days":2},{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/","asOf":"2026-09-07","days":2},{"id":"aphinity","kind":"trial","name":"APHINITY","route":"/trials/aphinity/","asOf":"2026-09-07","days":2},{"id":"katherine","kind":"trial","name":"KATHERINE","route":"/trials/katherine/","asOf":"2026-09-07","days":2},{"id":"destiny-breast05","kind":"trial","name":"DESTINY-Breast05","route":"/trials/destiny-breast05/","asOf":"2026-09-07","days":2},{"id":"her2climb","kind":"trial","name":"HER2CLIMB","route":"/trials/her2climb/","asOf":"2026-09-07","days":2},{"id":"her2climb-02","kind":"trial","name":"HER2CLIMB-02","route":"/trials/her2climb-02/","asOf":"2026-09-07","days":2},{"id":"her2climb-05","kind":"trial","name":"HER2CLIMB-05","route":"/trials/her2climb-05/","asOf":"2026-09-07","days":2},{"id":"destiny-breast12","kind":"trial","name":"DESTINY-Breast12","route":"/trials/destiny-breast12/","asOf":"2026-09-07","days":2},{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/","asOf":"2026-09-07","days":2},{"id":"persephone","kind":"trial","name":"PERSEPHONE","route":"/trials/persephone/","asOf":"2026-09-07","days":2},{"id":"apt-trial","kind":"trial","name":"APT (adjuvant paclitaxel-trastuzumab)","route":"/trials/apt-trial/","asOf":"2026-09-07","days":2},{"id":"horizon-breast01","kind":"trial","name":"HORIZON-Breast01","route":"/trials/horizon-breast01/","asOf":"2026-09-07","days":2},{"id":"ace-breast-02","kind":"trial","name":"ACE-Breast-02","route":"/trials/ace-breast-02/","asOf":"2026-09-07","days":2},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/","asOf":"2026-09-07","days":2},{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/","asOf":"2026-09-07","days":2},{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/","asOf":"2026-09-07","days":2},{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/","asOf":"2026-09-07","days":2},{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/","asOf":"2026-09-07","days":2},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/","asOf":"2026-09-07","days":2},{"id":"trastuzumab-brengitecan","kind":"drug","name":"Trastuzumab brengitecan","route":"/drugs/trastuzumab-brengitecan/","asOf":"2026-09-07","days":2},{"id":"arx788","kind":"drug","name":"ARX788","route":"/drugs/arx788/","asOf":"2026-09-07","days":2},{"id":"trastuzumab-biosimilars","kind":"drug","name":"Trastuzumab biosimilars","route":"/drugs/trastuzumab-biosimilars/","asOf":"2026-09-07","days":2},{"id":"dual-her2-blockade","kind":"term","name":"Dual HER2 blockade","route":"/terms/dual-her2-blockade/","asOf":"2026-09-07","days":2},{"id":"her2-brain-metastases","kind":"term","name":"HER2-positive brain metastases","route":"/terms/her2-brain-metastases/","asOf":"2026-09-07","days":2},{"id":"trastuzumab-cardiotoxicity","kind":"term","name":"Trastuzumab cardiotoxicity","route":"/terms/trastuzumab-cardiotoxicity/","asOf":"2026-09-07","days":2},{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/","asOf":"2026-09-07","days":2},{"id":"tucatinib-triplet-brain-mets","kind":"pairing","name":"Tucatinib + trastuzumab + capecitabine for brain metastases","route":"/pairings/tucatinib-triplet-brain-mets/","asOf":"2026-09-07","days":2},{"id":"pet-adapted-her2-deescalation","kind":"pairing","name":"Early FDG-PET response → chemotherapy omission (HER2+)","route":"/pairings/pet-adapted-her2-deescalation/","asOf":"2026-09-07","days":2},{"id":"idea-tdxd-first-then-nothing","kind":"idea","name":"Can T-DXd alone cure early HER2-positive disease?","route":"/ideas/idea-tdxd-first-then-nothing/","asOf":"2026-09-07","days":2},{"id":"idea-cns-first-adc-strategy","kind":"idea","name":"Systemic-first management of HER2-positive brain metastases","route":"/ideas/idea-cns-first-adc-strategy/","asOf":"2026-09-07","days":2},{"id":"idea-her2-adc-sequencing-payload","kind":"idea","name":"Sequencing HER2 ADCs by payload after T-DXd","route":"/ideas/idea-her2-adc-sequencing-payload/","asOf":"2026-09-07","days":2},{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","asOf":"2026-09-07","days":2},{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","asOf":"2026-09-07","days":2},{"id":"elevar-therapeutics","kind":"company","name":"Elevar Therapeutics (HLB)","route":"/companies/elevar-therapeutics/","asOf":"2026-09-07","days":2},{"id":"jiangsu-hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/jiangsu-hengrui/","asOf":"2026-09-07","days":2},{"id":"sirtex","kind":"company","name":"Sirtex Medical","route":"/companies/sirtex/","asOf":"2026-09-07","days":2},{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/","asOf":"2026-09-07","days":2},{"id":"tace","kind":"technology","name":"Transarterial chemoembolisation (TACE)","route":"/technologies/tace/","asOf":"2026-09-07","days":2},{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","asOf":"2026-09-07","days":2},{"id":"liver-transplant-oncology","kind":"technology","name":"Liver transplantation for cancer (Milan criteria and beyond)","route":"/technologies/liver-transplant-oncology/","asOf":"2026-09-07","days":2},{"id":"hcc-surveillance","kind":"technology","name":"HCC surveillance in cirrhosis (ultrasound + AFP)","route":"/technologies/hcc-surveillance/","asOf":"2026-09-07","days":2},{"id":"afp","kind":"term","name":"Alpha-fetoprotein (AFP)","route":"/terms/afp/","asOf":"2026-09-07","days":2},{"id":"child-pugh-albi","kind":"term","name":"Child-Pugh and ALBI liver-function scores","route":"/terms/child-pugh-albi/","asOf":"2026-09-07","days":2},{"id":"bclc-staging","kind":"term","name":"BCLC staging","route":"/terms/bclc-staging/","asOf":"2026-09-07","days":2},{"id":"hbv-hcv","kind":"term","name":"Hepatitis B and C as cancer causes","route":"/terms/hbv-hcv/","asOf":"2026-09-07","days":2},{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","asOf":"2026-09-07","days":2},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","asOf":"2026-09-07","days":2},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/","asOf":"2026-09-07","days":2},{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","asOf":"2026-09-07","days":2},{"id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/","asOf":"2026-09-07","days":2},{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/","asOf":"2026-09-07","days":2},{"id":"sharp","kind":"trial","name":"SHARP","route":"/trials/sharp/","asOf":"2026-09-07","days":2},{"id":"reflect","kind":"trial","name":"REFLECT","route":"/trials/reflect/","asOf":"2026-09-07","days":2},{"id":"resorce","kind":"trial","name":"RESORCE","route":"/trials/resorce/","asOf":"2026-09-07","days":2},{"id":"celestial","kind":"trial","name":"CELESTIAL","route":"/trials/celestial/","asOf":"2026-09-07","days":2},{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","asOf":"2026-09-07","days":2},{"id":"himalaya","kind":"trial","name":"HIMALAYA","route":"/trials/himalaya/","asOf":"2026-09-07","days":2},{"id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","asOf":"2026-09-07","days":2},{"id":"leap-002","kind":"trial","name":"LEAP-002","route":"/trials/leap-002/","asOf":"2026-09-07","days":2},{"id":"cares-310","kind":"trial","name":"CARES-310","route":"/trials/cares-310/","asOf":"2026-09-07","days":2},{"id":"imbrave050","kind":"trial","name":"IMbrave050","route":"/trials/imbrave050/","asOf":"2026-09-07","days":2},{"id":"emerald-1","kind":"trial","name":"EMERALD-1","route":"/trials/emerald-1/","asOf":"2026-09-07","days":2},{"id":"leap-012","kind":"trial","name":"LEAP-012","route":"/trials/leap-012/","asOf":"2026-09-07","days":2},{"id":"emerald-3","kind":"trial","name":"EMERALD-3","route":"/trials/emerald-3/","asOf":"2026-09-07","days":2},{"id":"sarah-sirvenib","kind":"trial","name":"SARAH and SIRveNIB","route":"/trials/sarah-sirvenib/","asOf":"2026-09-07","days":2},{"id":"tace-plus-systemic","kind":"pairing","name":"TACE + immunotherapy/anti-VEGF","route":"/pairings/tace-plus-systemic/","asOf":"2026-09-07","days":2},{"id":"io-varices-caution","kind":"pairing","name":"Caution: bevacizumab-based regimens with untreated varices","route":"/pairings/io-varices-caution/","asOf":"2026-09-07","days":2},{"id":"idea-hcc-io-before-transplant","kind":"idea","name":"Immunotherapy downstaging to transplant with a safe washout","route":"/ideas/idea-hcc-io-before-transplant/","asOf":"2026-09-07","days":2},{"id":"idea-hcc-blood-surveillance","kind":"idea","name":"Blood-based HCC surveillance to replace six-monthly ultrasound","route":"/ideas/idea-hcc-blood-surveillance/","asOf":"2026-09-07","days":2},{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","asOf":"2026-09-07","days":2},{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","route":"/companies/taiho/","asOf":"2026-09-07","days":2},{"id":"transthera","kind":"company","name":"TransThera Sciences","route":"/companies/transthera/","asOf":"2026-09-07","days":2},{"id":"biliary-stenting-drainage","kind":"technology","name":"Biliary stenting and drainage","route":"/technologies/biliary-stenting-drainage/","asOf":"2026-09-07","days":2},{"id":"biliary-anatomy-subtypes","kind":"term","name":"Intrahepatic, perihilar, distal and gallbladder cancer","route":"/terms/biliary-anatomy-subtypes/","asOf":"2026-09-07","days":2},{"id":"fgfr2-fusion","kind":"term","name":"FGFR2 fusions and rearrangements","route":"/terms/fgfr2-fusion/","asOf":"2026-09-07","days":2},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/","asOf":"2026-09-07","days":2},{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/","asOf":"2026-09-07","days":2},{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/","asOf":"2026-09-07","days":2},{"id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","asOf":"2026-09-07","days":2},{"id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/","asOf":"2026-09-07","days":2},{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/","asOf":"2026-09-07","days":2},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","asOf":"2026-09-07","days":2},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","asOf":"2026-09-07","days":2},{"id":"keynote-966","kind":"trial","name":"KEYNOTE-966","route":"/trials/keynote-966/","asOf":"2026-09-07","days":2},{"id":"fight-202","kind":"trial","name":"FIGHT-202","route":"/trials/fight-202/","asOf":"2026-09-07","days":2},{"id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","asOf":"2026-09-07","days":2},{"id":"claridhy","kind":"trial","name":"ClarIDHy","route":"/trials/claridhy/","asOf":"2026-09-07","days":2},{"id":"herizon-btc-302","kind":"trial","name":"HERIZON-BTC-302","route":"/trials/herizon-btc-302/","asOf":"2026-09-07","days":2},{"id":"first-308","kind":"trial","name":"FIRST-308","route":"/trials/first-308/","asOf":"2026-09-07","days":2},{"id":"naliricc","kind":"trial","name":"NALIRICC (AIO)","route":"/trials/naliricc/","asOf":"2026-09-07","days":2},{"id":"gemcis-plus-io-btc","kind":"pairing","name":"Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer","route":"/pairings/gemcis-plus-io-btc/","asOf":"2026-09-07","days":2},{"id":"idea-btc-ctdna-fgfr-resistance","kind":"idea","name":"ctDNA-guided switching among FGFR inhibitors","route":"/ideas/idea-btc-ctdna-fgfr-resistance/","asOf":"2026-09-07","days":2},{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/","asOf":"2026-09-07","days":2},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/","asOf":"2026-09-07","days":2},{"id":"net-grade-ki67","kind":"term","name":"Neuroendocrine tumour grade (Ki-67) and WHO classification","route":"/terms/net-grade-ki67/","asOf":"2026-09-07","days":2},{"id":"chromogranin-a","kind":"term","name":"Chromogranin A","route":"/terms/chromogranin-a/","asOf":"2026-09-07","days":2},{"id":"carcinoid-syndrome","kind":"term","name":"Carcinoid syndrome and carcinoid heart disease","route":"/terms/carcinoid-syndrome/","asOf":"2026-09-07","days":2},{"id":"men1-hereditary-net","kind":"term","name":"MEN1 and hereditary neuroendocrine syndromes","route":"/terms/men1-hereditary-net/","asOf":"2026-09-07","days":2},{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","asOf":"2026-09-07","days":2},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","asOf":"2026-09-07","days":2},{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","asOf":"2026-09-07","days":2},{"id":"alphamedix","kind":"drug","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/","asOf":"2026-09-07","days":2},{"id":"capecitabine-temozolomide","kind":"drug","name":"Capecitabine + temozolomide (CAPTEM)","route":"/drugs/capecitabine-temozolomide/","asOf":"2026-09-07","days":2},{"id":"promid","kind":"trial","name":"PROMID","route":"/trials/promid/","asOf":"2026-09-07","days":2},{"id":"clarinet","kind":"trial","name":"CLARINET","route":"/trials/clarinet/","asOf":"2026-09-07","days":2},{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","asOf":"2026-09-07","days":2},{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","asOf":"2026-09-07","days":2},{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","asOf":"2026-09-07","days":2},{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/","asOf":"2026-09-07","days":2},{"id":"action-1","kind":"trial","name":"ACTION-1","route":"/trials/action-1/","asOf":"2026-09-07","days":2},{"id":"sanet","kind":"trial","name":"SANET-ep and SANET-p","route":"/trials/sanet/","asOf":"2026-09-07","days":2},{"id":"sstr-pet-to-prrt","kind":"pairing","name":"SSTR PET → PRRT","route":"/pairings/sstr-pet-to-prrt/","asOf":"2026-09-07","days":2},{"id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/","asOf":"2026-09-07","days":2},{"id":"idea-net-dosimetry-prrt","kind":"idea","name":"Dosimetry-personalised PRRT instead of four fixed cycles","route":"/ideas/idea-net-dosimetry-prrt/","asOf":"2026-09-07","days":2},{"id":"idea-net-antagonist-ligands","kind":"idea","name":"SSTR antagonist radioligands to increase tumour dose","route":"/ideas/idea-net-antagonist-ligands/","asOf":"2026-09-07","days":2},{"id":"keynote-006","kind":"trial","name":"KEYNOTE-006","route":"/trials/keynote-006/","asOf":"2026-09-07","days":2},{"id":"relativity-047","kind":"trial","name":"RELATIVITY-047","route":"/trials/relativity-047/","asOf":"2026-09-07","days":2},{"id":"nadina","kind":"trial","name":"NADINA","route":"/trials/nadina/","asOf":"2026-09-07","days":2},{"id":"swog-s1801","kind":"trial","name":"SWOG S1801","route":"/trials/swog-s1801/","asOf":"2026-09-07","days":2},{"id":"keynote-716","kind":"trial","name":"KEYNOTE-716","route":"/trials/keynote-716/","asOf":"2026-09-07","days":2},{"id":"combi-ad","kind":"trial","name":"COMBI-AD","route":"/trials/combi-ad/","asOf":"2026-09-07","days":2},{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/","asOf":"2026-09-07","days":2},{"id":"dreamseq","kind":"trial","name":"DREAMseq (ECOG-ACRIN EA6134)","route":"/trials/dreamseq/","asOf":"2026-09-07","days":2},{"id":"c-144-01","kind":"trial","name":"C-144-01","route":"/trials/c-144-01/","asOf":"2026-09-07","days":2},{"id":"imcgp100-202","kind":"trial","name":"IMCgp100-202","route":"/trials/imcgp100-202/","asOf":"2026-09-07","days":2},{"id":"mslt-ii","kind":"trial","name":"MSLT-II","route":"/trials/mslt-ii/","asOf":"2026-09-07","days":2},{"id":"prism-mel-301","kind":"trial","name":"PRISM-MEL-301","route":"/trials/prism-mel-301/","asOf":"2026-09-07","days":2},{"id":"fianlimab-phase3-melanoma","kind":"trial","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","route":"/trials/fianlimab-phase3-melanoma/","asOf":"2026-09-07","days":2},{"id":"relativity-098","kind":"trial","name":"RELATIVITY-098","route":"/trials/relativity-098/","asOf":"2026-09-07","days":2},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","asOf":"2026-09-07","days":2},{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","asOf":"2026-09-07","days":2},{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/","asOf":"2026-09-07","days":2},{"id":"brenetafusp","kind":"drug","name":"Brenetafusp","route":"/drugs/brenetafusp/","asOf":"2026-09-07","days":2},{"id":"fianlimab","kind":"drug","name":"Fianlimab","route":"/drugs/fianlimab/","asOf":"2026-09-07","days":2},{"id":"dermoscopy-ai","kind":"technology","name":"Dermoscopy, total-body photography & AI skin analysis","route":"/technologies/dermoscopy-ai/","asOf":"2026-09-07","days":2},{"id":"breslow-thickness","kind":"term","name":"Breslow thickness","route":"/terms/breslow-thickness/","asOf":"2026-09-07","days":2},{"id":"ulceration-melanoma","kind":"term","name":"Ulceration (melanoma)","route":"/terms/ulceration-melanoma/","asOf":"2026-09-07","days":2},{"id":"major-pathological-response","kind":"term","name":"Major pathological response (MPR)","route":"/terms/major-pathological-response/","asOf":"2026-09-07","days":2},{"id":"hla-a02-restriction","kind":"term","name":"HLA-A*02:01 restriction","route":"/terms/hla-a02-restriction/","asOf":"2026-09-07","days":2},{"id":"io-first-then-braf-mek","kind":"pairing","name":"Immunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)","route":"/pairings/io-first-then-braf-mek/","asOf":"2026-09-07","days":2},{"id":"neoadjuvant-io-response-adapted","kind":"pairing","name":"Neoadjuvant immunotherapy → response-adapted adjuvant","route":"/pairings/neoadjuvant-io-response-adapted/","asOf":"2026-09-07","days":2},{"id":"lag3-adjuvant-caution","kind":"pairing","name":"Caution: LAG-3 blockade outside active disease","route":"/pairings/lag3-adjuvant-caution/","asOf":"2026-09-07","days":2},{"id":"idea-ctdna-guided-adjuvant-melanoma","kind":"idea","name":"ctDNA-guided adjuvant therapy in stage II-III melanoma","route":"/ideas/idea-ctdna-guided-adjuvant-melanoma/","asOf":"2026-09-07","days":2},{"id":"idea-prame-tcr-beyond-a02","kind":"idea","name":"TCR therapeutics for non-HLA-A*02 patients","route":"/ideas/idea-prame-tcr-beyond-a02/","asOf":"2026-09-07","days":2},{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/","asOf":"2026-09-07","days":2},{"id":"keynote-048","kind":"trial","name":"KEYNOTE-048","route":"/trials/keynote-048/","asOf":"2026-09-07","days":2},{"id":"keynote-689","kind":"trial","name":"KEYNOTE-689","route":"/trials/keynote-689/","asOf":"2026-09-07","days":2},{"id":"extreme","kind":"trial","name":"EXTREME","route":"/trials/extreme/","asOf":"2026-09-07","days":2},{"id":"checkmate-141","kind":"trial","name":"CheckMate 141","route":"/trials/checkmate-141/","asOf":"2026-09-07","days":2},{"id":"rtog-0129","kind":"trial","name":"RTOG 0129 (HPV analysis)","route":"/trials/rtog-0129/","asOf":"2026-09-07","days":2},{"id":"nrg-hn002-hn005","kind":"trial","name":"NRG-HN002 & NRG-HN005 (HPV+ de-escalation)","route":"/trials/nrg-hn002-hn005/","asOf":"2026-09-07","days":2},{"id":"javelin-hn-100","kind":"trial","name":"JAVELIN Head and Neck 100","route":"/trials/javelin-hn-100/","asOf":"2026-09-07","days":2},{"id":"trilynx","kind":"trial","name":"TrilynX","route":"/trials/trilynx/","asOf":"2026-09-07","days":2},{"id":"jupiter-02","kind":"trial","name":"JUPITER-02","route":"/trials/jupiter-02/","asOf":"2026-09-07","days":2},{"id":"liger-hn1","kind":"trial","name":"LiGeR-HN1","route":"/trials/liger-hn1/","asOf":"2026-09-07","days":2},{"id":"fortifi-hn01","kind":"trial","name":"FORTIFI-HN01","route":"/trials/fortifi-hn01/","asOf":"2026-09-07","days":2},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/","asOf":"2026-09-07","days":2},{"id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/","asOf":"2026-09-07","days":2},{"id":"ficerafusp-alfa","kind":"drug","name":"Ficerafusp alfa","route":"/drugs/ficerafusp-alfa/","asOf":"2026-09-07","days":2},{"id":"cetuximab-sarotalocan","kind":"drug","name":"Cetuximab sarotalocan","route":"/drugs/cetuximab-sarotalocan/","asOf":"2026-09-07","days":2},{"id":"tors","kind":"technology","name":"Transoral robotic surgery (TORS)","route":"/technologies/tors/","asOf":"2026-09-07","days":2},{"id":"cthpv-dna","kind":"technology","name":"Circulating tumour HPV DNA (ctHPV-DNA)","route":"/technologies/cthpv-dna/","asOf":"2026-09-07","days":2},{"id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/","asOf":"2026-09-07","days":2},{"id":"lgr5","kind":"term","name":"LGR5","route":"/terms/lgr5/","asOf":"2026-09-07","days":2},{"id":"io-before-surgery-hnscc","kind":"pairing","name":"Immunotherapy before surgery rather than with chemoradiation (HNSCC)","route":"/pairings/io-before-surgery-hnscc/","asOf":"2026-09-07","days":2},{"id":"egfr-bispecific-plus-pd1-hnscc","kind":"pairing","name":"EGFR-directed bispecific + PD-1 blockade","route":"/pairings/egfr-bispecific-plus-pd1-hnscc/","asOf":"2026-09-07","days":2},{"id":"hpv-deescalation-caution","kind":"pairing","name":"Caution: de-escalating radiation on HPV status alone","route":"/pairings/hpv-deescalation-caution/","asOf":"2026-09-07","days":2},{"id":"idea-cthpv-adapted-deescalation","kind":"idea","name":"ctHPV-DNA-adapted de-escalation of chemoradiation","route":"/ideas/idea-cthpv-adapted-deescalation/","asOf":"2026-09-07","days":2},{"id":"idea-photoimmunotherapy-plus-pd1","kind":"idea","name":"Photoimmunotherapy as an in situ vaccine with PD-1 blockade","route":"/ideas/idea-photoimmunotherapy-plus-pd1/","asOf":"2026-09-07","days":2},{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","asOf":"2026-09-07","days":2},{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/","asOf":"2026-09-07","days":2},{"id":"libretto-531","kind":"trial","name":"LIBRETTO-531","route":"/trials/libretto-531/","asOf":"2026-09-07","days":2},{"id":"arrow-thyroid","kind":"trial","name":"ARROW (thyroid cohorts)","route":"/trials/arrow-thyroid/","asOf":"2026-09-07","days":2},{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","asOf":"2026-09-07","days":2},{"id":"ion-trial","kind":"trial","name":"IoN","route":"/trials/ion-trial/","asOf":"2026-09-07","days":2},{"id":"hilo","kind":"trial","name":"HiLo","route":"/trials/hilo/","asOf":"2026-09-07","days":2},{"id":"roar-atc","kind":"trial","name":"ROAR (anaplastic thyroid cancer cohort)","route":"/trials/roar-atc/","asOf":"2026-09-07","days":2},{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","asOf":"2026-09-07","days":2},{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","asOf":"2026-09-07","days":2},{"id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/","asOf":"2026-09-07","days":2},{"id":"radioiodine-therapy","kind":"technology","name":"Radioiodine therapy and whole-body iodine scanning","route":"/technologies/radioiodine-therapy/","asOf":"2026-09-07","days":2},{"id":"thyroid-fna-molecular","kind":"technology","name":"Thyroid nodule FNA, Bethesda cytology & molecular classifiers","route":"/technologies/thyroid-fna-molecular/","asOf":"2026-09-07","days":2},{"id":"active-surveillance-thyroid","kind":"technology","name":"Active surveillance of papillary microcarcinoma","route":"/technologies/active-surveillance-thyroid/","asOf":"2026-09-07","days":2},{"id":"rai-refractory","kind":"term","name":"Radioiodine-refractory (RAI-R) thyroid cancer","route":"/terms/rai-refractory/","asOf":"2026-09-07","days":2},{"id":"low-risk-dtc","kind":"term","name":"Low-risk differentiated thyroid cancer (ATA risk)","route":"/terms/low-risk-dtc/","asOf":"2026-09-07","days":2},{"id":"bethesda-category","kind":"term","name":"Bethesda category (thyroid cytology)","route":"/terms/bethesda-category/","asOf":"2026-09-07","days":2},{"id":"tsh-suppression","kind":"term","name":"TSH suppression","route":"/terms/tsh-suppression/","asOf":"2026-09-07","days":2},{"id":"tert-promoter","kind":"term","name":"TERT promoter mutation","route":"/terms/tert-promoter/","asOf":"2026-09-07","days":2},{"id":"braf-mek-neoadjuvant-atc","kind":"pairing","name":"BRAF/MEK inhibition → surgery in anaplastic thyroid cancer","route":"/pairings/braf-mek-neoadjuvant-atc/","asOf":"2026-09-07","days":2},{"id":"redifferentiation-rai","kind":"pairing","name":"MAPK inhibitor redifferentiation → radioiodine","route":"/pairings/redifferentiation-rai/","asOf":"2026-09-07","days":2},{"id":"idea-thyroid-overdiagnosis-reversal","kind":"idea","name":"Ultrasound restraint and surveillance to reverse thyroid cancer overdiagnosis","route":"/ideas/idea-thyroid-overdiagnosis-reversal/","asOf":"2026-09-07","days":2},{"id":"idea-atc-triplet-io","kind":"idea","name":"BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer","route":"/ideas/idea-atc-triplet-io/","asOf":"2026-09-07","days":2},{"id":"keynote-177","kind":"trial","name":"KEYNOTE-177","route":"/trials/keynote-177/","asOf":"2026-09-07","days":2},{"id":"checkmate-8hw","kind":"trial","name":"CheckMate 8HW","route":"/trials/checkmate-8hw/","asOf":"2026-09-07","days":2},{"id":"niche-2","kind":"trial","name":"NICHE-2","route":"/trials/niche-2/","asOf":"2026-09-07","days":2},{"id":"atomic","kind":"trial","name":"ATOMIC (Alliance A021502)","route":"/trials/atomic/","asOf":"2026-09-07","days":2},{"id":"azur-1","kind":"trial","name":"AZUR-1","route":"/trials/azur-1/","asOf":"2026-09-07","days":2},{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/","asOf":"2026-09-07","days":2},{"id":"paradigm","kind":"trial","name":"PARADIGM","route":"/trials/paradigm/","asOf":"2026-09-07","days":2},{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","asOf":"2026-09-07","days":2},{"id":"mountaineer","kind":"trial","name":"MOUNTAINEER & MOUNTAINEER-03","route":"/trials/mountaineer/","asOf":"2026-09-07","days":2},{"id":"destiny-crc02","kind":"trial","name":"DESTINY-CRC02","route":"/trials/destiny-crc02/","asOf":"2026-09-07","days":2},{"id":"sunlight","kind":"trial","name":"SUNLIGHT","route":"/trials/sunlight/","asOf":"2026-09-07","days":2},{"id":"fresco-2","kind":"trial","name":"FRESCO-2","route":"/trials/fresco-2/","asOf":"2026-09-07","days":2},{"id":"circulate-japan","kind":"trial","name":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)","route":"/trials/circulate-japan/","asOf":"2026-09-07","days":2},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/","asOf":"2026-09-07","days":2},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/","asOf":"2026-09-07","days":2},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","asOf":"2026-09-07","days":2},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","asOf":"2026-09-07","days":2},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/","asOf":"2026-09-07","days":2},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/","asOf":"2026-09-07","days":2},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/","asOf":"2026-09-07","days":2},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/","asOf":"2026-09-07","days":2},{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/","asOf":"2026-09-07","days":2},{"id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/","asOf":"2026-09-07","days":2},{"id":"cms-subtypes","kind":"term","name":"Consensus molecular subtypes (CMS1-4)","route":"/terms/cms-subtypes/","asOf":"2026-09-07","days":2},{"id":"lynch-syndrome","kind":"term","name":"Lynch syndrome","route":"/terms/lynch-syndrome/","asOf":"2026-09-07","days":2},{"id":"fit-test","kind":"term","name":"Faecal immunochemical test (FIT)","route":"/terms/fit-test/","asOf":"2026-09-07","days":2},{"id":"clinical-complete-response","kind":"term","name":"Clinical complete response (cCR)","route":"/terms/clinical-complete-response/","asOf":"2026-09-07","days":2},{"id":"anti-egfr-left-sided","kind":"pairing","name":"Anti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC","route":"/pairings/anti-egfr-left-sided/","asOf":"2026-09-07","days":2},{"id":"neoadjuvant-io-dmmr","kind":"pairing","name":"Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer","route":"/pairings/neoadjuvant-io-dmmr/","asOf":"2026-09-07","days":2},{"id":"idea-ctdna-guided-adjuvant-crc","kind":"idea","name":"ctDNA-guided adjuvant therapy as the default in stage II-III colon cancer","route":"/ideas/idea-ctdna-guided-adjuvant-crc/","asOf":"2026-09-07","days":2},{"id":"idea-immunotherapy-mss-crc","kind":"idea","name":"Making microsatellite-stable colorectal cancer immunotherapy-responsive","route":"/ideas/idea-immunotherapy-mss-crc/","asOf":"2026-09-07","days":2},{"id":"toga","kind":"trial","name":"ToGA","route":"/trials/toga/","asOf":"2026-09-07","days":2},{"id":"checkmate-649","kind":"trial","name":"CheckMate 649","route":"/trials/checkmate-649/","asOf":"2026-09-07","days":2},{"id":"keynote-859","kind":"trial","name":"KEYNOTE-859","route":"/trials/keynote-859/","asOf":"2026-09-07","days":2},{"id":"spotlight-glow","kind":"trial","name":"SPOTLIGHT & GLOW","route":"/trials/spotlight-glow/","asOf":"2026-09-07","days":2},{"id":"matterhorn","kind":"trial","name":"MATTERHORN","route":"/trials/matterhorn/","asOf":"2026-09-07","days":2},{"id":"fortitude-101","kind":"trial","name":"FORTITUDE-101","route":"/trials/fortitude-101/","asOf":"2026-09-07","days":2},{"id":"herizon-gea-01","kind":"trial","name":"HERIZON-GEA-01","route":"/trials/herizon-gea-01/","asOf":"2026-09-07","days":2},{"id":"destiny-gastric04","kind":"trial","name":"DESTINY-Gastric04","route":"/trials/destiny-gastric04/","asOf":"2026-09-07","days":2},{"id":"rainbow","kind":"trial","name":"RAINBOW","route":"/trials/rainbow/","asOf":"2026-09-07","days":2},{"id":"clarity-gastric01","kind":"trial","name":"CLARITY-Gastric 01","route":"/trials/clarity-gastric01/","asOf":"2026-09-07","days":2},{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/","asOf":"2026-09-07","days":2},{"id":"bemarituzumab","kind":"drug","name":"Bemarituzumab","route":"/drugs/bemarituzumab/","asOf":"2026-09-07","days":2},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/","asOf":"2026-09-07","days":2},{"id":"siewert-classification","kind":"term","name":"Siewert classification (GEJ tumours)","route":"/terms/siewert-classification/","asOf":"2026-09-07","days":2},{"id":"lauren-classification","kind":"term","name":"Lauren classification (intestinal vs diffuse)","route":"/terms/lauren-classification/","asOf":"2026-09-07","days":2},{"id":"peritoneal-metastasis","kind":"term","name":"Peritoneal metastasis","route":"/terms/peritoneal-metastasis/","asOf":"2026-09-07","days":2},{"id":"her2-gastric-sequence","kind":"pairing","name":"HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd","route":"/pairings/her2-gastric-sequence/","asOf":"2026-09-07","days":2},{"id":"cldn18-antibody-then-adc","kind":"pairing","name":"CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression","route":"/pairings/cldn18-antibody-then-adc/","asOf":"2026-09-07","days":2},{"id":"idea-biomarker-quadruplet-gastric","kind":"idea","name":"Biomarker-directed first-line quadruplets in gastric cancer","route":"/ideas/idea-biomarker-quadruplet-gastric/","asOf":"2026-09-07","days":2},{"id":"idea-peritoneal-directed-gastric","kind":"idea","name":"Peritoneal-directed therapy for gastric cancer","route":"/ideas/idea-peritoneal-directed-gastric/","asOf":"2026-09-07","days":2},{"id":"cross","kind":"trial","name":"CROSS","route":"/trials/cross/","asOf":"2026-09-07","days":2},{"id":"sano","kind":"trial","name":"SANO","route":"/trials/sano/","asOf":"2026-09-07","days":2},{"id":"checkmate-577","kind":"trial","name":"CheckMate 577","route":"/trials/checkmate-577/","asOf":"2026-09-07","days":2},{"id":"keynote-590","kind":"trial","name":"KEYNOTE-590","route":"/trials/keynote-590/","asOf":"2026-09-07","days":2},{"id":"checkmate-648","kind":"trial","name":"CheckMate 648","route":"/trials/checkmate-648/","asOf":"2026-09-07","days":2},{"id":"rationale-306","kind":"trial","name":"RATIONALE-306","route":"/trials/rationale-306/","asOf":"2026-09-07","days":2},{"id":"escort-1st","kind":"trial","name":"ESCORT-1st","route":"/trials/escort-1st/","asOf":"2026-09-07","days":2},{"id":"panku-esophagus01","kind":"trial","name":"PANKU-Esophagus01 (BL-B01D1-305)","route":"/trials/panku-esophagus01/","asOf":"2026-09-07","days":2},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/","asOf":"2026-09-07","days":2},{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/","asOf":"2026-09-07","days":2},{"id":"endoscopic-resection","kind":"technology","name":"Endoscopic resection (EMR / ESD)","route":"/technologies/endoscopic-resection/","asOf":"2026-09-07","days":2},{"id":"barretts-esophagus","kind":"term","name":"Barrett's oesophagus","route":"/terms/barretts-esophagus/","asOf":"2026-09-07","days":2},{"id":"escc-vs-eac","kind":"term","name":"Squamous cell carcinoma vs adenocarcinoma of the oesophagus","route":"/terms/escc-vs-eac/","asOf":"2026-09-07","days":2},{"id":"cross-then-nivolumab","kind":"pairing","name":"CROSS chemoradiation → surgery → adjuvant nivolumab if residual disease","route":"/pairings/cross-then-nivolumab/","asOf":"2026-09-07","days":2},{"id":"idea-organ-preservation-esophageal","kind":"idea","name":"Organ preservation as the default after complete response in oesophageal cancer","route":"/ideas/idea-organ-preservation-esophageal/","asOf":"2026-09-07","days":2},{"id":"idea-non-endoscopic-barretts-screening","kind":"idea","name":"Non-endoscopic screening for Barrett's oesophagus and early adenocarcinoma","route":"/ideas/idea-non-endoscopic-barretts-screening/","asOf":"2026-09-07","days":2},{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/","asOf":"2026-09-07","days":2},{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/","asOf":"2026-09-07","days":2},{"id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/","asOf":"2026-09-07","days":2},{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/","asOf":"2026-09-07","days":2},{"id":"atlantis","kind":"trial","name":"ATLANTIS","route":"/trials/atlantis/","asOf":"2026-09-07","days":2},{"id":"dellphi-305","kind":"trial","name":"DeLLphi-305","route":"/trials/dellphi-305/","asOf":"2026-09-07","days":2},{"id":"ideate-lung02","kind":"trial","name":"IDeate-Lung02","route":"/trials/ideate-lung02/","asOf":"2026-09-07","days":2},{"id":"astrum-005","kind":"trial","name":"ASTRUM-005","route":"/trials/astrum-005/","asOf":"2026-09-07","days":2},{"id":"convert","kind":"trial","name":"CONVERT","route":"/trials/convert/","asOf":"2026-09-07","days":2},{"id":"platinum-etoposide","kind":"drug","name":"Platinum + etoposide (EP / CE)","route":"/drugs/platinum-etoposide/","asOf":"2026-09-07","days":2},{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/","asOf":"2026-09-07","days":2},{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/","asOf":"2026-09-07","days":2},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/","asOf":"2026-09-07","days":2},{"id":"prophylactic-cranial-irradiation","kind":"technology","name":"Prophylactic cranial irradiation vs MRI surveillance","route":"/technologies/prophylactic-cranial-irradiation/","asOf":"2026-09-07","days":2},{"id":"limited-vs-extensive-stage","kind":"term","name":"Limited-stage vs extensive-stage (SCLC)","route":"/terms/limited-vs-extensive-stage/","asOf":"2026-09-07","days":2},{"id":"pharmamar","kind":"company","name":"PharmaMar","route":"/companies/pharmamar/","asOf":"2026-09-07","days":2},{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/","asOf":"2026-09-07","days":2},{"id":"chemo-io-then-maintenance-sclc","kind":"pairing","name":"Chemo-immunotherapy induction → maintenance intensification (SCLC)","route":"/pairings/chemo-io-then-maintenance-sclc/","asOf":"2026-09-07","days":2},{"id":"tarlatamab-vs-idxd-sequence","kind":"pairing","name":"Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC","route":"/pairings/tarlatamab-vs-idxd-sequence/","asOf":"2026-09-07","days":2},{"id":"idea-sclc-subtype-directed","kind":"idea","name":"Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)","route":"/ideas/idea-sclc-subtype-directed/","asOf":"2026-09-07","days":2},{"id":"idea-mri-surveillance-replaces-pci","kind":"idea","name":"MRI surveillance replaces prophylactic cranial irradiation in SCLC","route":"/ideas/idea-mri-surveillance-replaces-pci/","asOf":"2026-09-07","days":2},{"id":"checkmate-743","kind":"trial","name":"CheckMate 743","route":"/trials/checkmate-743/","asOf":"2026-09-07","days":2},{"id":"keynote-483","kind":"trial","name":"IND.227 / KEYNOTE-483","route":"/trials/keynote-483/","asOf":"2026-09-07","days":2},{"id":"maps","kind":"trial","name":"MAPS","route":"/trials/maps/","asOf":"2026-09-07","days":2},{"id":"mars-2","kind":"trial","name":"MARS 2","route":"/trials/mars-2/","asOf":"2026-09-07","days":2},{"id":"lume-meso","kind":"trial","name":"LUME-Meso","route":"/trials/lume-meso/","asOf":"2026-09-07","days":2},{"id":"beat-meso","kind":"trial","name":"BEAT-meso (ETOP 13-18)","route":"/trials/beat-meso/","asOf":"2026-09-07","days":2},{"id":"dream3r","kind":"trial","name":"DREAM3R","route":"/trials/dream3r/","asOf":"2026-09-07","days":2},{"id":"stellar","kind":"trial","name":"STELLAR","route":"/trials/stellar/","asOf":"2026-09-07","days":2},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/","asOf":"2026-09-07","days":2},{"id":"nintedanib","kind":"drug","name":"Nintedanib","route":"/drugs/nintedanib/","asOf":"2026-09-07","days":2},{"id":"pleurectomy-decortication","kind":"technology","name":"Extended pleurectomy/decortication & radical mesothelioma surgery","route":"/technologies/pleurectomy-decortication/","asOf":"2026-09-07","days":2},{"id":"epithelioid-vs-sarcomatoid","kind":"term","name":"Epithelioid vs sarcomatoid (biphasic) mesothelioma","route":"/terms/epithelioid-vs-sarcomatoid/","asOf":"2026-09-07","days":2},{"id":"histology-directs-first-line-meso","kind":"pairing","name":"Histology → first-line choice in mesothelioma","route":"/pairings/histology-directs-first-line-meso/","asOf":"2026-09-07","days":2},{"id":"idea-mtap-prmt5-mesothelioma","kind":"idea","name":"PRMT5/MAT2A synthetic lethality for MTAP-deleted mesothelioma","route":"/ideas/idea-mtap-prmt5-mesothelioma/","asOf":"2026-09-07","days":2},{"id":"idea-mesothelin-car-t-regional","kind":"idea","name":"Regionally delivered mesothelin CAR-T with PD-1 blockade","route":"/ideas/idea-mesothelin-car-t-regional/","asOf":"2026-09-07","days":2},{"id":"niagara","kind":"trial","name":"NIAGARA","route":"/trials/niagara/","asOf":"2026-09-07","days":2},{"id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","asOf":"2026-09-07","days":2},{"id":"ev-304","kind":"trial","name":"EV-304 / KEYNOTE-B15","route":"/trials/ev-304/","asOf":"2026-09-07","days":2},{"id":"checkmate-274","kind":"trial","name":"CheckMate 274","route":"/trials/checkmate-274/","asOf":"2026-09-07","days":2},{"id":"potomac","kind":"trial","name":"POTOMAC","route":"/trials/potomac/","asOf":"2026-09-07","days":2},{"id":"sunrise-1","kind":"trial","name":"SunRISe-1","route":"/trials/sunrise-1/","asOf":"2026-09-07","days":2},{"id":"bond-003","kind":"trial","name":"BOND-003","route":"/trials/bond-003/","asOf":"2026-09-07","days":2},{"id":"quilt-3-032","kind":"trial","name":"QUILT 3.032","route":"/trials/quilt-3-032/","asOf":"2026-09-07","days":2},{"id":"thor","kind":"trial","name":"THOR","route":"/trials/thor/","asOf":"2026-09-07","days":2},{"id":"javelin-bladder-100","kind":"trial","name":"JAVELIN Bladder 100","route":"/trials/javelin-bladder-100/","asOf":"2026-09-07","days":2},{"id":"bcg-intravesical","kind":"drug","name":"Intravesical BCG","route":"/drugs/bcg-intravesical/","asOf":"2026-09-07","days":2},{"id":"tar-200","kind":"drug","name":"Gemcitabine intravesical system (TAR-200)","route":"/drugs/tar-200/","asOf":"2026-09-07","days":2},{"id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/","asOf":"2026-09-07","days":2},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","asOf":"2026-09-07","days":2},{"id":"nadofaragene-firadenovec","kind":"drug","name":"Nadofaragene firadenovec","route":"/drugs/nadofaragene-firadenovec/","asOf":"2026-09-07","days":2},{"id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/","asOf":"2026-09-07","days":2},{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/","asOf":"2026-09-07","days":2},{"id":"zelenectide-pevedotin","kind":"drug","name":"Zelenectide pevedotin","route":"/drugs/zelenectide-pevedotin/","asOf":"2026-09-07","days":2},{"id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/","asOf":"2026-09-07","days":2},{"id":"cystoscopy-turbt","kind":"technology","name":"Cystoscopy, blue-light imaging & TURBT","route":"/technologies/cystoscopy-turbt/","asOf":"2026-09-07","days":2},{"id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","asOf":"2026-09-07","days":2},{"id":"bcg-unresponsive","kind":"term","name":"BCG-unresponsive","route":"/terms/bcg-unresponsive/","asOf":"2026-09-07","days":2},{"id":"fgfr3","kind":"term","name":"FGFR3 alterations (bladder cancer)","route":"/terms/fgfr3/","asOf":"2026-09-07","days":2},{"id":"cg-oncology","kind":"company","name":"CG Oncology","route":"/companies/cg-oncology/","asOf":"2026-09-07","days":2},{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/","asOf":"2026-09-07","days":2},{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/","asOf":"2026-09-07","days":2},{"id":"bicycle-therapeutics","kind":"company","name":"Bicycle Therapeutics","route":"/companies/bicycle-therapeutics/","asOf":"2026-09-07","days":2},{"id":"ev-pembro-continuum","kind":"pairing","name":"Enfortumab vedotin + pembrolizumab across the bladder cancer continuum","route":"/pairings/ev-pembro-continuum/","asOf":"2026-09-07","days":2},{"id":"durvalumab-plus-bcg","kind":"pairing","name":"Durvalumab + BCG in BCG-naive high-risk NMIBC","route":"/pairings/durvalumab-plus-bcg/","asOf":"2026-09-07","days":2},{"id":"idea-bladder-preservation-mibc","kind":"idea","name":"Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response","route":"/ideas/idea-bladder-preservation-mibc/","asOf":"2026-09-07","days":2},{"id":"idea-urine-ctdna-surveillance","kind":"idea","name":"Urine tumour DNA to replace surveillance cystoscopy in NMIBC","route":"/ideas/idea-urine-ctdna-surveillance/","asOf":"2026-09-07","days":2},{"id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/","asOf":"2026-09-07","days":2},{"id":"keynote-426","kind":"trial","name":"KEYNOTE-426","route":"/trials/keynote-426/","asOf":"2026-09-07","days":2},{"id":"checkmate-9er","kind":"trial","name":"CheckMate 9ER","route":"/trials/checkmate-9er/","asOf":"2026-09-07","days":2},{"id":"clear","kind":"trial","name":"CLEAR (KEYNOTE-581)","route":"/trials/clear/","asOf":"2026-09-07","days":2},{"id":"keynote-564","kind":"trial","name":"KEYNOTE-564","route":"/trials/keynote-564/","asOf":"2026-09-07","days":2},{"id":"litespark-022","kind":"trial","name":"LITESPARK-022","route":"/trials/litespark-022/","asOf":"2026-09-07","days":2},{"id":"litespark-005","kind":"trial","name":"LITESPARK-005","route":"/trials/litespark-005/","asOf":"2026-09-07","days":2},{"id":"litespark-012","kind":"trial","name":"LITESPARK-012","route":"/trials/litespark-012/","asOf":"2026-09-07","days":2},{"id":"cosmic-313","kind":"trial","name":"COSMIC-313","route":"/trials/cosmic-313/","asOf":"2026-09-07","days":2},{"id":"contact-03","kind":"trial","name":"CONTACT-03","route":"/trials/contact-03/","asOf":"2026-09-07","days":2},{"id":"tinivo-2","kind":"trial","name":"TiNivo-2","route":"/trials/tinivo-2/","asOf":"2026-09-07","days":2},{"id":"axitinib","kind":"drug","name":"Axitinib","route":"/drugs/axitinib/","asOf":"2026-09-07","days":2},{"id":"tivozanib","kind":"drug","name":"Tivozanib","route":"/drugs/tivozanib/","asOf":"2026-09-07","days":2},{"id":"partial-nephrectomy-active-surveillance","kind":"technology","name":"Partial nephrectomy, ablation & active surveillance of small renal masses","route":"/technologies/partial-nephrectomy-active-surveillance/","asOf":"2026-09-07","days":2},{"id":"caix-pet","kind":"technology","name":"CAIX PET (89Zr-girentuximab)","route":"/technologies/caix-pet/","asOf":"2026-09-07","days":2},{"id":"imdc-risk","kind":"term","name":"IMDC risk groups (favourable / intermediate / poor)","route":"/terms/imdc-risk/","asOf":"2026-09-07","days":2},{"id":"sarcomatoid-rcc","kind":"term","name":"Sarcomatoid differentiation (RCC)","route":"/terms/sarcomatoid-rcc/","asOf":"2026-09-07","days":2},{"id":"aveo","kind":"company","name":"AVEO Oncology (LG Chem)","route":"/companies/aveo/","asOf":"2026-09-07","days":2},{"id":"io-rechallenge-caution-rcc","kind":"pairing","name":"Caution: PD-1 rechallenge after progression on immunotherapy (RCC)","route":"/pairings/io-rechallenge-caution-rcc/","asOf":"2026-09-07","days":2},{"id":"risk-directed-first-line-rcc","kind":"pairing","name":"IMDC risk → first-line regimen choice (RCC)","route":"/pairings/risk-directed-first-line-rcc/","asOf":"2026-09-07","days":2},{"id":"idea-adjuvant-selection-rcc","kind":"idea","name":"Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)","route":"/ideas/idea-adjuvant-selection-rcc/","asOf":"2026-09-07","days":2},{"id":"idea-caix-theranostics","kind":"idea","name":"CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy","route":"/ideas/idea-caix-theranostics/","asOf":"2026-09-07","days":2},{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/","asOf":"2026-09-07","days":2},{"id":"prima","kind":"trial","name":"PRIMA / ENGOT-OV26","route":"/trials/prima/","asOf":"2026-09-07","days":2},{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/","asOf":"2026-09-07","days":2},{"id":"athena-mono","kind":"trial","name":"ATHENA-MONO / GOG-3020","route":"/trials/athena-mono/","asOf":"2026-09-07","days":2},{"id":"duo-o","kind":"trial","name":"DUO-O / ENGOT-ov46","route":"/trials/duo-o/","asOf":"2026-09-07","days":2},{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/","asOf":"2026-09-07","days":2},{"id":"ovhipec-1","kind":"trial","name":"OVHIPEC-1","route":"/trials/ovhipec-1/","asOf":"2026-09-07","days":2},{"id":"desktop-iii","kind":"trial","name":"DESKTOP III / ENGOT-ov20","route":"/trials/desktop-iii/","asOf":"2026-09-07","days":2},{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/","asOf":"2026-09-07","days":2},{"id":"rosella","kind":"trial","name":"ROSELLA / GOG-3073","route":"/trials/rosella/","asOf":"2026-09-07","days":2},{"id":"keynote-b96","kind":"trial","name":"KEYNOTE-B96 / ENGOT-ov65","route":"/trials/keynote-b96/","asOf":"2026-09-07","days":2},{"id":"ramp-201","kind":"trial","name":"RAMP 201","route":"/trials/ramp-201/","asOf":"2026-09-07","days":2},{"id":"rejoice-ovarian01","kind":"trial","name":"REJOICE-Ovarian01","route":"/trials/rejoice-ovarian01/","asOf":"2026-09-07","days":2},{"id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/","asOf":"2026-09-07","days":2},{"id":"ukctocs","kind":"trial","name":"UKCTOCS","route":"/trials/ukctocs/","asOf":"2026-09-07","days":2},{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","asOf":"2026-09-07","days":2},{"id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/","asOf":"2026-09-07","days":2},{"id":"trabectedin","kind":"drug","name":"Trabectedin","route":"/drugs/trabectedin/","asOf":"2026-09-07","days":2},{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","asOf":"2026-09-07","days":2},{"id":"luveltamab-tazevibulin","kind":"drug","name":"Luveltamab tazevibulin","route":"/drugs/luveltamab-tazevibulin/","asOf":"2026-09-07","days":2},{"id":"rinatabart-sesutecan","kind":"drug","name":"Rinatabart sesutecan","route":"/drugs/rinatabart-sesutecan/","asOf":"2026-09-07","days":2},{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/","asOf":"2026-09-07","days":2},{"id":"ca-125","kind":"term","name":"CA-125","route":"/terms/ca-125/","asOf":"2026-09-07","days":2},{"id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","asOf":"2026-09-07","days":2},{"id":"hgsoc","kind":"term","name":"High-grade serous ovarian carcinoma (HGSOC)","route":"/terms/hgsoc/","asOf":"2026-09-07","days":2},{"id":"risk-reducing-salpingectomy","kind":"technology","name":"Risk-reducing and opportunistic salpingectomy","route":"/technologies/risk-reducing-salpingectomy/","asOf":"2026-09-07","days":2},{"id":"parp-plus-bevacizumab","kind":"pairing","name":"PARP inhibitor + bevacizumab maintenance (HRD-positive)","route":"/pairings/parp-plus-bevacizumab/","asOf":"2026-09-07","days":2},{"id":"hipec-at-interval-surgery","kind":"pairing","name":"HIPEC at interval cytoreductive surgery","route":"/pairings/hipec-at-interval-surgery/","asOf":"2026-09-07","days":2},{"id":"caution-pd1-first-line-ovarian","kind":"pairing","name":"Caution: checkpoint inhibitors in first-line ovarian cancer","route":"/pairings/caution-pd1-first-line-ovarian/","asOf":"2026-09-07","days":2},{"id":"idea-fra-adc-sequencing-ovarian","kind":"idea","name":"Sequence folate-receptor ADCs by payload class","route":"/ideas/idea-fra-adc-sequencing-ovarian/","asOf":"2026-09-07","days":2},{"id":"idea-ctdna-guided-parp-duration","kind":"idea","name":"ctDNA-guided duration of PARP maintenance","route":"/ideas/idea-ctdna-guided-parp-duration/","asOf":"2026-09-07","days":2},{"id":"ruby","kind":"trial","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/","asOf":"2026-09-07","days":2},{"id":"nrg-gy018-keynote-868","kind":"trial","name":"NRG-GY018 / KEYNOTE-868","route":"/trials/nrg-gy018-keynote-868/","asOf":"2026-09-07","days":2},{"id":"duo-e","kind":"trial","name":"DUO-E / GOG-3041 / ENGOT-EN10","route":"/trials/duo-e/","asOf":"2026-09-07","days":2},{"id":"keynote-775","kind":"trial","name":"KEYNOTE-775 / Study 309","route":"/trials/keynote-775/","asOf":"2026-09-07","days":2},{"id":"portec-3","kind":"trial","name":"PORTEC-3","route":"/trials/portec-3/","asOf":"2026-09-07","days":2},{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","asOf":"2026-09-07","days":2},{"id":"xport-ec-042","kind":"trial","name":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083","route":"/trials/xport-ec-042/","asOf":"2026-09-07","days":2},{"id":"fires-sentor","kind":"trial","name":"FIRES & SENTOR (sentinel node mapping)","route":"/trials/fires-sentor/","asOf":"2026-09-07","days":2},{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/","asOf":"2026-09-07","days":2},{"id":"megestrol-progestins","kind":"drug","name":"Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)","route":"/drugs/megestrol-progestins/","asOf":"2026-09-07","days":2},{"id":"endometrial-molecular-classes","kind":"term","name":"Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)","route":"/terms/endometrial-molecular-classes/","asOf":"2026-09-07","days":2},{"id":"fertility-sparing-endometrial","kind":"technology","name":"Fertility-sparing hormonal treatment of early endometrial cancer","route":"/technologies/fertility-sparing-endometrial/","asOf":"2026-09-07","days":2},{"id":"chemo-io-first-line-endometrial","kind":"pairing","name":"Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer","route":"/pairings/chemo-io-first-line-endometrial/","asOf":"2026-09-07","days":2},{"id":"lenvatinib-plus-pembrolizumab","kind":"pairing","name":"Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)","route":"/pairings/lenvatinib-plus-pembrolizumab/","asOf":"2026-09-07","days":2},{"id":"idea-molecular-class-adjuvant-endometrial","kind":"idea","name":"Molecular-class-directed adjuvant therapy in endometrial cancer","route":"/ideas/idea-molecular-class-adjuvant-endometrial/","asOf":"2026-09-07","days":2},{"id":"idea-her2-adc-serous-endometrial","kind":"idea","name":"HER2 ADCs as standard for HER2-positive serous endometrial cancer","route":"/ideas/idea-her2-adc-serous-endometrial/","asOf":"2026-09-07","days":2},{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/","asOf":"2026-09-07","days":2},{"id":"interlace","kind":"trial","name":"INTERLACE","route":"/trials/interlace/","asOf":"2026-09-07","days":2},{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/","asOf":"2026-09-07","days":2},{"id":"beatcc","kind":"trial","name":"BEATcc / ENGOT-Cx10 / GOG-3030","route":"/trials/beatcc/","asOf":"2026-09-07","days":2},{"id":"compassion-16","kind":"trial","name":"COMPASSION-16 / AK104-303","route":"/trials/compassion-16/","asOf":"2026-09-07","days":2},{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/","asOf":"2026-09-07","days":2},{"id":"empower-cervical-1","kind":"trial","name":"EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9","route":"/trials/empower-cervical-1/","asOf":"2026-09-07","days":2},{"id":"outback","kind":"trial","name":"OUTBACK / ANZGOG 0902 / GOG-0274","route":"/trials/outback/","asOf":"2026-09-07","days":2},{"id":"lacc","kind":"trial","name":"LACC (Laparoscopic Approach to Cervical Cancer)","route":"/trials/lacc/","asOf":"2026-09-07","days":2},{"id":"ken-she","kind":"trial","name":"KEN SHE (single-dose HPV vaccine)","route":"/trials/ken-she/","asOf":"2026-09-07","days":2},{"id":"senticol-iii","kind":"trial","name":"SENTICOL III","route":"/trials/senticol-iii/","asOf":"2026-09-07","days":2},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/","asOf":"2026-09-07","days":2},{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/","asOf":"2026-09-07","days":2},{"id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","asOf":"2026-09-07","days":2},{"id":"cin-hsil","kind":"term","name":"Cervical precancer (CIN, HSIL/LSIL)","route":"/terms/cin-hsil/","asOf":"2026-09-07","days":2},{"id":"hpv-testing","kind":"technology","name":"HPV DNA testing and self-sampling","route":"/technologies/hpv-testing/","asOf":"2026-09-07","days":2},{"id":"colposcopy-excision","kind":"technology","name":"Colposcopy and excisional treatment (LEEP/LLETZ, cone)","route":"/technologies/colposcopy-excision/","asOf":"2026-09-07","days":2},{"id":"precancer-ablation","kind":"technology","name":"Thermal ablation and cryotherapy for cervical precancer","route":"/technologies/precancer-ablation/","asOf":"2026-09-07","days":2},{"id":"induction-chemo-then-crt","kind":"pairing","name":"Induction chemotherapy → chemoradiation (locally advanced cervical cancer)","route":"/pairings/induction-chemo-then-crt/","asOf":"2026-09-07","days":2},{"id":"io-plus-crt-cervical","kind":"pairing","name":"PD-1 blockade + chemoradiation (locally advanced cervical cancer)","route":"/pairings/io-plus-crt-cervical/","asOf":"2026-09-07","days":2},{"id":"caution-mis-radical-hysterectomy","kind":"pairing","name":"Caution: minimally invasive radical hysterectomy for early cervical cancer","route":"/pairings/caution-mis-radical-hysterectomy/","asOf":"2026-09-07","days":2},{"id":"idea-single-dose-hpv-self-sampling-elimination","kind":"idea","name":"Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries","route":"/ideas/idea-single-dose-hpv-self-sampling-elimination/","asOf":"2026-09-07","days":2},{"id":"idea-hpv-ctdna-cervical","kind":"idea","name":"HPV circulating tumour DNA to guide cervical cancer therapy","route":"/ideas/idea-hpv-ctdna-cervical/","asOf":"2026-09-07","days":2},{"id":"kura-oncology","kind":"company","name":"Kura Oncology","route":"/companies/kura-oncology/","asOf":"2026-09-07","days":2},{"id":"taiho-oncology","kind":"company","name":"Taiho Oncology (Otsuka)","route":"/companies/taiho-oncology/","asOf":"2026-09-07","days":2},{"id":"rigel-pharmaceuticals","kind":"company","name":"Rigel Pharmaceuticals","route":"/companies/rigel-pharmaceuticals/","asOf":"2026-09-07","days":2},{"id":"kmt2a","kind":"target","name":"KMT2A (MLL) rearrangement","route":"/targets/kmt2a/","asOf":"2026-09-07","days":2},{"id":"npm1","kind":"target","name":"NPM1 mutation","route":"/targets/npm1/","asOf":"2026-09-07","days":2},{"id":"cd22","kind":"target","name":"CD22","route":"/targets/cd22/","asOf":"2026-09-07","days":2},{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/","asOf":"2026-09-07","days":2},{"id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/","asOf":"2026-09-07","days":2},{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/","asOf":"2026-09-07","days":2},{"id":"flow-cytometry-mrd","kind":"technology","name":"Multiparameter flow cytometry MRD","route":"/technologies/flow-cytometry-mrd/","asOf":"2026-09-07","days":2},{"id":"ngs-mrd-clonoseq","kind":"technology","name":"NGS-based MRD (clonoSEQ and molecular MRD)","route":"/technologies/ngs-mrd-clonoseq/","asOf":"2026-09-07","days":2},{"id":"cytogenetics-fish","kind":"technology","name":"Cytogenetics and FISH","route":"/technologies/cytogenetics-fish/","asOf":"2026-09-07","days":2},{"id":"bh3-profiling","kind":"technology","name":"BH3 profiling (functional apoptosis testing)","route":"/technologies/bh3-profiling/","asOf":"2026-09-07","days":2},{"id":"eln-risk","kind":"term","name":"ELN 2022 risk classification","route":"/terms/eln-risk/","asOf":"2026-09-07","days":2},{"id":"flt3-itd-allelic-ratio","kind":"term","name":"FLT3-ITD allelic ratio","route":"/terms/flt3-itd-allelic-ratio/","asOf":"2026-09-07","days":2},{"id":"ighv-status","kind":"term","name":"IGHV mutational status","route":"/terms/ighv-status/","asOf":"2026-09-07","days":2},{"id":"del17p-tp53","kind":"term","name":"del(17p) / TP53 aberration in CLL","route":"/terms/del17p-tp53/","asOf":"2026-09-07","days":2},{"id":"richter-transformation","kind":"term","name":"Richter transformation","route":"/terms/richter-transformation/","asOf":"2026-09-07","days":2},{"id":"mrd-negative-cr","kind":"term","name":"MRD-negative complete remission","route":"/terms/mrd-negative-cr/","asOf":"2026-09-07","days":2},{"id":"tumor-lysis-syndrome","kind":"term","name":"Tumour lysis syndrome (TLS)","route":"/terms/tumor-lysis-syndrome/","asOf":"2026-09-07","days":2},{"id":"differentiation-syndrome","kind":"term","name":"Differentiation syndrome","route":"/terms/differentiation-syndrome/","asOf":"2026-09-07","days":2},{"id":"ph-positive-all","kind":"term","name":"Ph-positive ALL","route":"/terms/ph-positive-all/","asOf":"2026-09-07","days":2},{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/","asOf":"2026-09-07","days":2},{"id":"decitabine-cedazuridine","kind":"drug","name":"Decitabine + cedazuridine (oral)","route":"/drugs/decitabine-cedazuridine/","asOf":"2026-09-07","days":2},{"id":"cytarabine-7-3","kind":"drug","name":"Cytarabine + anthracycline ('7+3')","route":"/drugs/cytarabine-7-3/","asOf":"2026-09-07","days":2},{"id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","asOf":"2026-09-07","days":2},{"id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/","asOf":"2026-09-07","days":2},{"id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/","asOf":"2026-09-07","days":2},{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/","asOf":"2026-09-07","days":2},{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","asOf":"2026-09-07","days":2},{"id":"olutasidenib","kind":"drug","name":"Olutasidenib","route":"/drugs/olutasidenib/","asOf":"2026-09-07","days":2},{"id":"ziftomenib","kind":"drug","name":"Ziftomenib","route":"/drugs/ziftomenib/","asOf":"2026-09-07","days":2},{"id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","asOf":"2026-09-07","days":2},{"id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/","asOf":"2026-09-07","days":2},{"id":"viale-a","kind":"trial","name":"VIALE-A","route":"/trials/viale-a/","asOf":"2026-09-07","days":2},{"id":"quantum-first","kind":"trial","name":"QuANTUM-First","route":"/trials/quantum-first/","asOf":"2026-09-07","days":2},{"id":"admiral","kind":"trial","name":"ADMIRAL","route":"/trials/admiral/","asOf":"2026-09-07","days":2},{"id":"agile","kind":"trial","name":"AGILE","route":"/trials/agile/","asOf":"2026-09-07","days":2},{"id":"alfa-0701","kind":"trial","name":"ALFA-0701","route":"/trials/alfa-0701/","asOf":"2026-09-07","days":2},{"id":"augment-101","kind":"trial","name":"AUGMENT-101","route":"/trials/augment-101/","asOf":"2026-09-07","days":2},{"id":"komet-001","kind":"trial","name":"KOMET-001","route":"/trials/komet-001/","asOf":"2026-09-07","days":2},{"id":"cpx-351-301","kind":"trial","name":"CPX-351 Study 301","route":"/trials/cpx-351-301/","asOf":"2026-09-07","days":2},{"id":"ascertain-v","kind":"trial","name":"ASCERTAIN-V","route":"/trials/ascertain-v/","asOf":"2026-09-07","days":2},{"id":"myelomatch","kind":"trial","name":"myeloMATCH","route":"/trials/myelomatch/","asOf":"2026-09-07","days":2},{"id":"venetoclax-plus-hma","kind":"pairing","name":"Venetoclax + hypomethylating agent","route":"/pairings/venetoclax-plus-hma/","asOf":"2026-09-07","days":2},{"id":"flt3i-plus-7-3","kind":"pairing","name":"FLT3 inhibitor + intensive chemotherapy","route":"/pairings/flt3i-plus-7-3/","asOf":"2026-09-07","days":2},{"id":"menin-plus-venetoclax-hma","kind":"pairing","name":"Menin inhibitor + venetoclax + azacitidine","route":"/pairings/menin-plus-venetoclax-hma/","asOf":"2026-09-07","days":2},{"id":"idea-mrd-guided-transplant-aml","kind":"idea","name":"MRD-guided transplant decisions in intermediate-risk AML","route":"/ideas/idea-mrd-guided-transplant-aml/","asOf":"2026-09-07","days":2},{"id":"idea-shortened-venetoclax","kind":"idea","name":"Shorter venetoclax courses in unfit AML","route":"/ideas/idea-shortened-venetoclax/","asOf":"2026-09-07","days":2},{"id":"autolus","kind":"company","name":"Autolus Therapeutics","route":"/companies/autolus/","asOf":"2026-09-07","days":2},{"id":"adaptive-biotechnologies","kind":"company","name":"Adaptive Biotechnologies","route":"/companies/adaptive-biotechnologies/","asOf":"2026-09-07","days":2},{"id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/","asOf":"2026-09-07","days":2},{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/","asOf":"2026-09-07","days":2},{"id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/","asOf":"2026-09-07","days":2},{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/","asOf":"2026-09-07","days":2},{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/","asOf":"2026-09-07","days":2},{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","asOf":"2026-09-07","days":2},{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/","asOf":"2026-09-07","days":2},{"id":"aall1731","kind":"trial","name":"COG AALL1731","route":"/trials/aall1731/","asOf":"2026-09-07","days":2},{"id":"tower","kind":"trial","name":"TOWER","route":"/trials/tower/","asOf":"2026-09-07","days":2},{"id":"ino-vate","kind":"trial","name":"INO-VATE ALL","route":"/trials/ino-vate/","asOf":"2026-09-07","days":2},{"id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/","asOf":"2026-09-07","days":2},{"id":"felix","kind":"trial","name":"FELIX","route":"/trials/felix/","asOf":"2026-09-07","days":2},{"id":"phallcon","kind":"trial","name":"PhALLCON","route":"/trials/phallcon/","asOf":"2026-09-07","days":2},{"id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","route":"/trials/d-alba/","asOf":"2026-09-07","days":2},{"id":"interfant-06","kind":"trial","name":"Interfant-06","route":"/trials/interfant-06/","asOf":"2026-09-07","days":2},{"id":"tki-plus-blinatumomab-ph-all","kind":"pairing","name":"BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)","route":"/pairings/tki-plus-blinatumomab-ph-all/","asOf":"2026-09-07","days":2},{"id":"blinatumomab-frontline-consolidation","kind":"pairing","name":"Blinatumomab added to frontline chemotherapy","route":"/pairings/blinatumomab-frontline-consolidation/","asOf":"2026-09-07","days":2},{"id":"inotuzumab-then-transplant-caution","kind":"pairing","name":"Caution: inotuzumab before transplant (veno-occlusive disease)","route":"/pairings/inotuzumab-then-transplant-caution/","asOf":"2026-09-07","days":2},{"id":"idea-transplant-free-ph-all","kind":"idea","name":"Transplant-free Ph-positive ALL for MRD-negative adults","route":"/ideas/idea-transplant-free-ph-all/","asOf":"2026-09-07","days":2},{"id":"idea-menin-infant-all","kind":"idea","name":"Menin inhibitors for infant KMT2A-rearranged ALL","route":"/ideas/idea-menin-infant-all/","asOf":"2026-09-07","days":2},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/","asOf":"2026-09-07","days":2},{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","asOf":"2026-09-07","days":2},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","asOf":"2026-09-07","days":2},{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","asOf":"2026-09-07","days":2},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","asOf":"2026-09-07","days":2},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","asOf":"2026-09-07","days":2},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","asOf":"2026-09-07","days":2},{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","asOf":"2026-09-07","days":2},{"id":"bgb-16673","kind":"drug","name":"BGB-16673","route":"/drugs/bgb-16673/","asOf":"2026-09-07","days":2},{"id":"nemtabrutinib","kind":"drug","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/","asOf":"2026-09-07","days":2},{"id":"resonate","kind":"trial","name":"RESONATE","route":"/trials/resonate/","asOf":"2026-09-07","days":2},{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/","asOf":"2026-09-07","days":2},{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/","asOf":"2026-09-07","days":2},{"id":"elevate-tn","kind":"trial","name":"ELEVATE-TN","route":"/trials/elevate-tn/","asOf":"2026-09-07","days":2},{"id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","asOf":"2026-09-07","days":2},{"id":"alpine","kind":"trial","name":"ALPINE","route":"/trials/alpine/","asOf":"2026-09-07","days":2},{"id":"captivate","kind":"trial","name":"CAPTIVATE","route":"/trials/captivate/","asOf":"2026-09-07","days":2},{"id":"glow","kind":"trial","name":"GLOW","route":"/trials/glow/","asOf":"2026-09-07","days":2},{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/","asOf":"2026-09-07","days":2},{"id":"bruin-cll-321","kind":"trial","name":"BRUIN CLL-321","route":"/trials/bruin-cll-321/","asOf":"2026-09-07","days":2},{"id":"transcend-cll-004","kind":"trial","name":"TRANSCEND CLL 004","route":"/trials/transcend-cll-004/","asOf":"2026-09-07","days":2},{"id":"celestial-tncll","kind":"trial","name":"CELESTIAL-TNCLL","route":"/trials/celestial-tncll/","asOf":"2026-09-07","days":2},{"id":"cadance-304","kind":"trial","name":"CaDAnCe-304","route":"/trials/cadance-304/","asOf":"2026-09-07","days":2},{"id":"bellwave-011","kind":"trial","name":"BELLWAVE-011","route":"/trials/bellwave-011/","asOf":"2026-09-07","days":2},{"id":"btki-plus-venetoclax-fixed-duration","kind":"pairing","name":"BTK inhibitor + venetoclax, fixed duration","route":"/pairings/btki-plus-venetoclax-fixed-duration/","asOf":"2026-09-07","days":2},{"id":"venetoclax-plus-obinutuzumab","kind":"pairing","name":"Venetoclax + obinutuzumab (12 months)","route":"/pairings/venetoclax-plus-obinutuzumab/","asOf":"2026-09-07","days":2},{"id":"cit-in-del17p-caution","kind":"pairing","name":"Caution: chemoimmunotherapy in del(17p)/TP53 CLL","route":"/pairings/cit-in-del17p-caution/","asOf":"2026-09-07","days":2},{"id":"btki-ibrutinib-cardiac-caution","kind":"pairing","name":"Caution: ibrutinib in patients with cardiac risk","route":"/pairings/btki-ibrutinib-cardiac-caution/","asOf":"2026-09-07","days":2},{"id":"idea-mrd-guided-stop-cll","kind":"idea","name":"MRD-guided treatment duration in CLL","route":"/ideas/idea-mrd-guided-stop-cll/","asOf":"2026-09-07","days":2},{"id":"idea-btk-degrader-frontline","kind":"idea","name":"BTK degraders to pre-empt resistance in frontline CLL","route":"/ideas/idea-btk-degrader-frontline/","asOf":"2026-09-07","days":2},{"id":"ctdna-lymphoma-monitoring","kind":"technology","name":"ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)","route":"/technologies/ctdna-lymphoma-monitoring/","asOf":"2026-09-07","days":2},{"id":"ipi-score","kind":"term","name":"International Prognostic Index (IPI)","route":"/terms/ipi-score/","asOf":"2026-09-07","days":2},{"id":"cell-of-origin","kind":"term","name":"Cell of origin (GCB vs ABC)","route":"/terms/cell-of-origin/","asOf":"2026-09-07","days":2},{"id":"double-hit-lymphoma","kind":"term","name":"Double-hit / high-grade B-cell lymphoma","route":"/terms/double-hit-lymphoma/","asOf":"2026-09-07","days":2},{"id":"lugano-classification","kind":"term","name":"Lugano classification / Ann Arbor staging","route":"/terms/lugano-classification/","asOf":"2026-09-07","days":2},{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/","asOf":"2026-09-07","days":2},{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/","asOf":"2026-09-07","days":2},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/","asOf":"2026-09-07","days":2},{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/","asOf":"2026-09-07","days":2},{"id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/","asOf":"2026-09-07","days":2},{"id":"golcadomide","kind":"drug","name":"Golcadomide","route":"/drugs/golcadomide/","asOf":"2026-09-07","days":2},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","asOf":"2026-09-07","days":2},{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/","asOf":"2026-09-07","days":2},{"id":"transform","kind":"trial","name":"TRANSFORM","route":"/trials/transform/","asOf":"2026-09-07","days":2},{"id":"starglo","kind":"trial","name":"STARGLO","route":"/trials/starglo/","asOf":"2026-09-07","days":2},{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/","asOf":"2026-09-07","days":2},{"id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","asOf":"2026-09-07","days":2},{"id":"epcore-dlbcl-2","kind":"trial","name":"EPCORE DLBCL-2","route":"/trials/epcore-dlbcl-2/","asOf":"2026-09-07","days":2},{"id":"frontmind","kind":"trial","name":"frontMIND","route":"/trials/frontmind/","asOf":"2026-09-07","days":2},{"id":"l-mind","kind":"trial","name":"L-MIND","route":"/trials/l-mind/","asOf":"2026-09-07","days":2},{"id":"lotis-2","kind":"trial","name":"LOTIS-2","route":"/trials/lotis-2/","asOf":"2026-09-07","days":2},{"id":"waveline-003","kind":"trial","name":"waveLINE-003","route":"/trials/waveline-003/","asOf":"2026-09-07","days":2},{"id":"sunmo","kind":"trial","name":"SUNMO","route":"/trials/sunmo/","asOf":"2026-09-07","days":2},{"id":"golseek-1","kind":"trial","name":"GOLSEEK-1","route":"/trials/golseek-1/","asOf":"2026-09-07","days":2},{"id":"belinda","kind":"trial","name":"BELINDA","route":"/trials/belinda/","asOf":"2026-09-07","days":2},{"id":"bispecific-plus-adc-lymphoma","kind":"pairing","name":"CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab)","route":"/pairings/bispecific-plus-adc-lymphoma/","asOf":"2026-09-07","days":2},{"id":"car-t-before-transplant-lbcl","kind":"pairing","name":"Early relapse: CAR-T before transplant","route":"/pairings/car-t-before-transplant-lbcl/","asOf":"2026-09-07","days":2},{"id":"idea-ctdna-guided-dlbcl-frontline","kind":"idea","name":"ctDNA-guided escalation and de-escalation in frontline DLBCL","route":"/ideas/idea-ctdna-guided-dlbcl-frontline/","asOf":"2026-09-07","days":2},{"id":"idea-bispecific-vs-car-t-second-line","kind":"idea","name":"Head-to-head bispecific vs CAR-T in second-line LBCL","route":"/ideas/idea-bispecific-vs-car-t-second-line/","asOf":"2026-09-07","days":2},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/","asOf":"2026-09-07","days":2},{"id":"r-iss","kind":"term","name":"R-ISS / R2-ISS staging","route":"/terms/r-iss/","asOf":"2026-09-07","days":2},{"id":"high-risk-myeloma","kind":"term","name":"High-risk cytogenetics (myeloma)","route":"/terms/high-risk-myeloma/","asOf":"2026-09-07","days":2},{"id":"mrd-negativity-myeloma","kind":"term","name":"MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)","route":"/terms/mrd-negativity-myeloma/","asOf":"2026-09-07","days":2},{"id":"smoldering-myeloma","kind":"term","name":"Smouldering myeloma / MGUS","route":"/terms/smoldering-myeloma/","asOf":"2026-09-07","days":2},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/","asOf":"2026-09-07","days":2},{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/","asOf":"2026-09-07","days":2},{"id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/","asOf":"2026-09-07","days":2},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","asOf":"2026-09-07","days":2},{"id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/","asOf":"2026-09-07","days":2},{"id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/","asOf":"2026-09-07","days":2},{"id":"anitocabtagene-autoleucel","kind":"drug","name":"Anitocabtagene autoleucel","route":"/drugs/anitocabtagene-autoleucel/","asOf":"2026-09-07","days":2},{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","asOf":"2026-09-07","days":2},{"id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/","asOf":"2026-09-07","days":2},{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","asOf":"2026-09-07","days":2},{"id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/","asOf":"2026-09-07","days":2},{"id":"mezigdomide","kind":"drug","name":"Mezigdomide","route":"/drugs/mezigdomide/","asOf":"2026-09-07","days":2},{"id":"perseus","kind":"trial","name":"PERSEUS","route":"/trials/perseus/","asOf":"2026-09-07","days":2},{"id":"cepheus","kind":"trial","name":"CEPHEUS","route":"/trials/cepheus/","asOf":"2026-09-07","days":2},{"id":"imroz","kind":"trial","name":"IMROZ","route":"/trials/imroz/","asOf":"2026-09-07","days":2},{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/","asOf":"2026-09-07","days":2},{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/","asOf":"2026-09-07","days":2},{"id":"karmma-3","kind":"trial","name":"KarMMa-3","route":"/trials/karmma-3/","asOf":"2026-09-07","days":2},{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/","asOf":"2026-09-07","days":2},{"id":"majestec-3","kind":"trial","name":"MajesTEC-3","route":"/trials/majestec-3/","asOf":"2026-09-07","days":2},{"id":"magnetismm-3","kind":"trial","name":"MagnetisMM-3","route":"/trials/magnetismm-3/","asOf":"2026-09-07","days":2},{"id":"monumental-1","kind":"trial","name":"MonumenTAL-1","route":"/trials/monumental-1/","asOf":"2026-09-07","days":2},{"id":"linker-mm1","kind":"trial","name":"LINKER-MM1","route":"/trials/linker-mm1/","asOf":"2026-09-07","days":2},{"id":"dreamm-7","kind":"trial","name":"DREAMM-7","route":"/trials/dreamm-7/","asOf":"2026-09-07","days":2},{"id":"dreamm-8","kind":"trial","name":"DREAMM-8","route":"/trials/dreamm-8/","asOf":"2026-09-07","days":2},{"id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/","asOf":"2026-09-07","days":2},{"id":"cartitude-5","kind":"trial","name":"CARTITUDE-5","route":"/trials/cartitude-5/","asOf":"2026-09-07","days":2},{"id":"istopmm","kind":"trial","name":"iStopMM","route":"/trials/istopmm/","asOf":"2026-09-07","days":2},{"id":"cd38-plus-triplet","kind":"pairing","name":"CD38 antibody added to PI-IMiD-dex (quadruplet induction)","route":"/pairings/cd38-plus-triplet/","asOf":"2026-09-07","days":2},{"id":"bcma-then-gprc5d","kind":"pairing","name":"BCMA-directed therapy → GPRC5D-directed therapy","route":"/pairings/bcma-then-gprc5d/","asOf":"2026-09-07","days":2},{"id":"bispecific-infection-prophylaxis","kind":"pairing","name":"Caution: T-cell redirectors and infections","route":"/pairings/bispecific-infection-prophylaxis/","asOf":"2026-09-07","days":2},{"id":"idea-mrd-guided-stop-myeloma","kind":"idea","name":"MRD-guided treatment-free intervals in myeloma","route":"/ideas/idea-mrd-guided-stop-myeloma/","asOf":"2026-09-07","days":2},{"id":"idea-car-t-replaces-transplant","kind":"idea","name":"One CAR-T infusion instead of autologous transplant","route":"/ideas/idea-car-t-replaces-transplant/","asOf":"2026-09-07","days":2},{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/","asOf":"2026-09-07","days":2},{"id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/","asOf":"2026-09-07","days":2},{"id":"deauville-score","kind":"term","name":"Deauville five-point scale","route":"/terms/deauville-score/","asOf":"2026-09-07","days":2},{"id":"reed-sternberg-cell","kind":"term","name":"Reed-Sternberg cell","route":"/terms/reed-sternberg-cell/","asOf":"2026-09-07","days":2},{"id":"echelon-1","kind":"trial","name":"ECHELON-1","route":"/trials/echelon-1/","asOf":"2026-09-07","days":2},{"id":"swog-s1826","kind":"trial","name":"SWOG S1826","route":"/trials/swog-s1826/","asOf":"2026-09-07","days":2},{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","asOf":"2026-09-07","days":2},{"id":"rathl","kind":"trial","name":"RATHL","route":"/trials/rathl/","asOf":"2026-09-07","days":2},{"id":"keynote-204","kind":"trial","name":"KEYNOTE-204","route":"/trials/keynote-204/","asOf":"2026-09-07","days":2},{"id":"checkmate-205","kind":"trial","name":"CheckMate 205","route":"/trials/checkmate-205/","asOf":"2026-09-07","days":2},{"id":"ahod2131","kind":"trial","name":"AHOD2131 (COG / NCTN)","route":"/trials/ahod2131/","asOf":"2026-09-07","days":2},{"id":"aethera","kind":"trial","name":"AETHERA","route":"/trials/aethera/","asOf":"2026-09-07","days":2},{"id":"pd1-plus-avd-hodgkin","kind":"pairing","name":"PD-1 blockade + AVD chemotherapy","route":"/pairings/pd1-plus-avd-hodgkin/","asOf":"2026-09-07","days":2},{"id":"bleomycin-omission-caution","kind":"pairing","name":"Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF","route":"/pairings/bleomycin-omission-caution/","asOf":"2026-09-07","days":2},{"id":"idea-chemo-free-hodgkin","kind":"idea","name":"Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage","route":"/ideas/idea-chemo-free-hodgkin/","asOf":"2026-09-07","days":2},{"id":"idea-cd30-car-t-hodgkin","kind":"idea","name":"CD30 CAR-T for multiply relapsed Hodgkin lymphoma","route":"/ideas/idea-cd30-car-t-hodgkin/","asOf":"2026-09-07","days":2},{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/","asOf":"2026-09-07","days":2},{"id":"springworks","kind":"company","name":"SpringWorks Therapeutics (Merck KGaA)","route":"/companies/springworks/","asOf":"2026-09-07","days":2},{"id":"us-worldmeds","kind":"company","name":"US WorldMeds","route":"/companies/us-worldmeds/","asOf":"2026-09-07","days":2},{"id":"limb-salvage-surgery","kind":"technology","name":"Limb-salvage surgery and endoprosthetic reconstruction","route":"/technologies/limb-salvage-surgery/","asOf":"2026-09-07","days":2},{"id":"fnclcc-grade","kind":"term","name":"FNCLCC grade (soft-tissue sarcoma)","route":"/terms/fnclcc-grade/","asOf":"2026-09-07","days":2},{"id":"sarcoma-histotype-tailoring","kind":"term","name":"Histotype-tailored therapy","route":"/terms/sarcoma-histotype-tailoring/","asOf":"2026-09-07","days":2},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/","asOf":"2026-09-07","days":2},{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","asOf":"2026-09-07","days":2},{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","asOf":"2026-09-07","days":2},{"id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/","asOf":"2026-09-07","days":2},{"id":"avapritinib","kind":"drug","name":"Avapritinib","route":"/drugs/avapritinib/","asOf":"2026-09-07","days":2},{"id":"nirogacestat","kind":"drug","name":"Nirogacestat","route":"/drugs/nirogacestat/","asOf":"2026-09-07","days":2},{"id":"vimseltinib","kind":"drug","name":"Vimseltinib","route":"/drugs/vimseltinib/","asOf":"2026-09-07","days":2},{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/","asOf":"2026-09-07","days":2},{"id":"isg-sts-1001","kind":"trial","name":"ISG-STS 1001","route":"/trials/isg-sts-1001/","asOf":"2026-09-07","days":2},{"id":"announce","kind":"trial","name":"ANNOUNCE","route":"/trials/announce/","asOf":"2026-09-07","days":2},{"id":"invictus","kind":"trial","name":"INVICTUS","route":"/trials/invictus/","asOf":"2026-09-07","days":2},{"id":"insight-gist","kind":"trial","name":"INSIGHT","route":"/trials/insight-gist/","asOf":"2026-09-07","days":2},{"id":"voyager","kind":"trial","name":"VOYAGER","route":"/trials/voyager/","asOf":"2026-09-07","days":2},{"id":"defi","kind":"trial","name":"DeFi","route":"/trials/defi/","asOf":"2026-09-07","days":2},{"id":"motion","kind":"trial","name":"MOTION","route":"/trials/motion/","asOf":"2026-09-07","days":2},{"id":"ignyte-eso","kind":"trial","name":"IGNYTE-ESO","route":"/trials/ignyte-eso/","asOf":"2026-09-07","days":2},{"id":"euro-ewing-2012","kind":"trial","name":"Euro Ewing 2012","route":"/trials/euro-ewing-2012/","asOf":"2026-09-07","days":2},{"id":"int-0091","kind":"trial","name":"INT-0091 (Ewing sarcoma)","route":"/trials/int-0091/","asOf":"2026-09-07","days":2},{"id":"ssgxviii","kind":"trial","name":"SSGXVIII/AIO (adjuvant imatinib in GIST)","route":"/trials/ssgxviii/","asOf":"2026-09-07","days":2},{"id":"ctdna-genotype-gist-tki","kind":"pairing","name":"ctDNA KIT genotyping → TKI selection in GIST","route":"/pairings/ctdna-genotype-gist-tki/","asOf":"2026-09-07","days":2},{"id":"doxorubicin-cardio-caution","kind":"pairing","name":"Caution: cumulative anthracycline dose and the heart","route":"/pairings/doxorubicin-cardio-caution/","asOf":"2026-09-07","days":2},{"id":"idea-tcr-t-beyond-hla-a2","kind":"idea","name":"Extending sarcoma TCR-T beyond HLA-A*02","route":"/ideas/idea-tcr-t-beyond-hla-a2/","asOf":"2026-09-07","days":2},{"id":"idea-desmoid-intermittent-dosing","kind":"idea","name":"Intermittent or stop-and-restart nirogacestat in desmoid tumours","route":"/ideas/idea-desmoid-intermittent-dosing/","asOf":"2026-09-07","days":2},{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/","asOf":"2026-09-07","days":2},{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/","asOf":"2026-09-07","days":2},{"id":"tandem-transplant","kind":"technology","name":"Tandem autologous transplant","route":"/technologies/tandem-transplant/","asOf":"2026-09-07","days":2},{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/","asOf":"2026-09-07","days":2},{"id":"inrg-staging","kind":"term","name":"INRG staging and risk groups","route":"/terms/inrg-staging/","asOf":"2026-09-07","days":2},{"id":"mycn-amplification","kind":"term","name":"MYCN amplification","route":"/terms/mycn-amplification/","asOf":"2026-09-07","days":2},{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/","asOf":"2026-09-07","days":2},{"id":"naxitamab","kind":"drug","name":"Naxitamab","route":"/drugs/naxitamab/","asOf":"2026-09-07","days":2},{"id":"eflornithine","kind":"drug","name":"Eflornithine (DFMO)","route":"/drugs/eflornithine/","asOf":"2026-09-07","days":2},{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","asOf":"2026-09-07","days":2},{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/","asOf":"2026-09-07","days":2},{"id":"anbl0532","kind":"trial","name":"COG ANBL0532","route":"/trials/anbl0532/","asOf":"2026-09-07","days":2},{"id":"hr-nbl1","kind":"trial","name":"SIOPEN HR-NBL1","route":"/trials/hr-nbl1/","asOf":"2026-09-07","days":2},{"id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/","asOf":"2026-09-07","days":2},{"id":"gd2-cart01","kind":"trial","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/","asOf":"2026-09-07","days":2},{"id":"naxitamab-201","kind":"trial","name":"Naxitamab Study 201","route":"/trials/naxitamab-201/","asOf":"2026-09-07","days":2},{"id":"nmtrc003","kind":"trial","name":"NMTRC003/003B (DFMO maintenance)","route":"/trials/nmtrc003/","asOf":"2026-09-07","days":2},{"id":"anti-gd2-plus-chemo-relapse","kind":"pairing","name":"Anti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)","route":"/pairings/anti-gd2-plus-chemo-relapse/","asOf":"2026-09-07","days":2},{"id":"il2-anti-gd2-caution","kind":"pairing","name":"Caution: IL-2 added to anti-GD2 therapy","route":"/pairings/il2-anti-gd2-caution/","asOf":"2026-09-07","days":2},{"id":"idea-gd2-car-t-frontline-consolidation","kind":"idea","name":"GD2 CAR-T as consolidation in high-risk neuroblastoma","route":"/ideas/idea-gd2-car-t-frontline-consolidation/","asOf":"2026-09-07","days":2},{"id":"idea-mfbg-pet-replaces-mibg","kind":"idea","name":"18F-MFBG PET replacing 123I-MIBG scintigraphy","route":"/ideas/idea-mfbg-pet-replaces-mibg/","asOf":"2026-09-07","days":2},{"id":"in-vivo-gene-editing-cancer","kind":"technology","name":"In vivo base and prime editing for cancer","route":"/technologies/in-vivo-gene-editing-cancer/","asOf":"2026-09-08","days":1},{"id":"epigenetic-editing","kind":"technology","name":"Epigenetic editing (durable gene silencing)","route":"/technologies/epigenetic-editing/","asOf":"2026-09-08","days":1},{"id":"self-amplifying-rna","kind":"technology","name":"Self-amplifying and circular RNA therapeutics","route":"/technologies/self-amplifying-rna/","asOf":"2026-09-08","days":1},{"id":"stroma-directed-car","kind":"technology","name":"CAR-T against stroma: fibroblasts and myeloid cells","route":"/technologies/stroma-directed-car/","asOf":"2026-09-08","days":1},{"id":"engineered-bacteria-therapy","kind":"technology","name":"Engineered bacteria as living cancer drugs","route":"/technologies/engineered-bacteria-therapy/","asOf":"2026-09-08","days":1},{"id":"phage-delivery","kind":"technology","name":"Bacteriophage-based tumour delivery","route":"/technologies/phage-delivery/","asOf":"2026-09-08","days":1},{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/","asOf":"2026-09-08","days":1},{"id":"tumour-microbiome-targeting","kind":"technology","name":"Targeting the tumour's own microbes","route":"/technologies/tumour-microbiome-targeting/","asOf":"2026-09-08","days":1},{"id":"dna-origami-nanorobots","kind":"technology","name":"DNA origami nanorobots","route":"/technologies/dna-origami-nanorobots/","asOf":"2026-09-08","days":1},{"id":"magnetic-nanoparticle-hyperthermia","kind":"technology","name":"Magnetic nanoparticle hyperthermia","route":"/technologies/magnetic-nanoparticle-hyperthermia/","asOf":"2026-09-08","days":1},{"id":"photothermal-nanoparticles","kind":"technology","name":"Photothermal (plasmonic) nanoparticle ablation","route":"/technologies/photothermal-nanoparticles/","asOf":"2026-09-08","days":1},{"id":"sonodynamic-therapy","kind":"technology","name":"Sonodynamic therapy","route":"/technologies/sonodynamic-therapy/","asOf":"2026-09-08","days":1},{"id":"radiodynamic-therapy","kind":"technology","name":"Radiodynamic therapy and radiosensitising nanoparticles","route":"/technologies/radiodynamic-therapy/","asOf":"2026-09-08","days":1},{"id":"vhee-radiotherapy","kind":"technology","name":"Very-high-energy electron therapy","route":"/technologies/vhee-radiotherapy/","asOf":"2026-09-08","days":1},{"id":"proton-arc-therapy","kind":"technology","name":"Proton arc therapy","route":"/technologies/proton-arc-therapy/","asOf":"2026-09-08","days":1},{"id":"lattice-radiotherapy","kind":"technology","name":"Lattice and GRID radiotherapy","route":"/technologies/lattice-radiotherapy/","asOf":"2026-09-08","days":1},{"id":"auger-electron-therapy","kind":"technology","name":"Auger-electron therapy","route":"/technologies/auger-electron-therapy/","asOf":"2026-09-08","days":1},{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/","asOf":"2026-09-08","days":1},{"id":"radionuclide-parp-combination","kind":"technology","name":"Radioligand plus DNA-repair inhibitor combinations","route":"/technologies/radionuclide-parp-combination/","asOf":"2026-09-08","days":1},{"id":"nerve-tumour-denervation","kind":"technology","name":"Cancer neuroscience: cutting the nerve supply","route":"/technologies/nerve-tumour-denervation/","asOf":"2026-09-08","days":1},{"id":"cachexia-therapy","kind":"technology","name":"Cachexia-directed therapy (GDF-15 blockade)","route":"/technologies/cachexia-therapy/","asOf":"2026-09-08","days":1},{"id":"chronotherapy","kind":"technology","name":"Chronotherapy: timing treatment to the body clock","route":"/technologies/chronotherapy/","asOf":"2026-09-08","days":1},{"id":"metabolic-therapy","kind":"technology","name":"Metabolic therapy: starving the tumour of a nutrient","route":"/technologies/metabolic-therapy/","asOf":"2026-09-08","days":1},{"id":"senescence-targeting","kind":"technology","name":"Senolytics and senescence-directed therapy","route":"/technologies/senescence-targeting/","asOf":"2026-09-08","days":1},{"id":"il12-electroporation","kind":"technology","name":"Intratumoural gene electrotransfer (IL-12 plasmid)","route":"/technologies/il12-electroporation/","asOf":"2026-09-08","days":1},{"id":"de-novo-protein-design","kind":"technology","name":"De novo designed protein binders","route":"/technologies/de-novo-protein-design/","asOf":"2026-09-08","days":1},{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/","asOf":"2026-09-08","days":1},{"id":"antibody-oligonucleotide-conjugates","kind":"technology","name":"Antibody-oligonucleotide conjugates","route":"/technologies/antibody-oligonucleotide-conjugates/","asOf":"2026-09-08","days":1},{"id":"logic-gated-therapeutics","kind":"technology","name":"Logic-gated therapeutics (AND, NOT gates)","route":"/technologies/logic-gated-therapeutics/","asOf":"2026-09-08","days":1},{"id":"in-situ-vaccination","kind":"technology","name":"In situ vaccination","route":"/technologies/in-situ-vaccination/","asOf":"2026-09-08","days":1},{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","route":"/technologies/interception-vaccination/","asOf":"2026-09-08","days":1},{"id":"trained-innate-immunity","kind":"technology","name":"Trained innate immunity","route":"/technologies/trained-innate-immunity/","asOf":"2026-09-08","days":1},{"id":"histotripsy-immune-priming","kind":"technology","name":"Histotripsy as an immune primer","route":"/technologies/histotripsy-immune-priming/","asOf":"2026-09-08","days":1},{"id":"mechanobiology-therapy","kind":"technology","name":"Targeting tumour mechanics and pressure","route":"/technologies/mechanobiology-therapy/","asOf":"2026-09-08","days":1},{"id":"hypoxia-activated-therapy","kind":"technology","name":"Hypoxia-activated prodrugs","route":"/technologies/hypoxia-activated-therapy/","asOf":"2026-09-08","days":1},{"id":"digital-twins-trials","kind":"technology","name":"Digital twins and virtual control arms","route":"/technologies/digital-twins-trials/","asOf":"2026-09-08","days":1},{"id":"n-of-1-platforms","kind":"technology","name":"N-of-1 and rapid platform trials","route":"/technologies/n-of-1-platforms/","asOf":"2026-09-08","days":1},{"id":"continuous-ctdna-monitoring","kind":"technology","name":"Continuous and near-continuous ctDNA monitoring","route":"/technologies/continuous-ctdna-monitoring/","asOf":"2026-09-08","days":1},{"id":"breath-vocs","kind":"technology","name":"Breath and volatile-organic-compound detection","route":"/technologies/breath-vocs/","asOf":"2026-09-08","days":1},{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/","asOf":"2026-09-08","days":1},{"id":"total-body-pet-screening","kind":"technology","name":"Total-body PET for screening and ultra-low-dose imaging","route":"/technologies/total-body-pet-screening/","asOf":"2026-09-08","days":1},{"id":"quantum-dot-imaging","kind":"technology","name":"Quantum-dot and molecular ultrasound imaging agents","route":"/technologies/quantum-dot-imaging/","asOf":"2026-09-08","days":1},{"id":"organoid-guided-therapy-scale","kind":"technology","name":"Organoid-guided therapy at scale","route":"/technologies/organoid-guided-therapy-scale/","asOf":"2026-09-08","days":1},{"id":"spatial-omics-guided-therapy","kind":"technology","name":"Spatial-omics-guided treatment selection","route":"/technologies/spatial-omics-guided-therapy/","asOf":"2026-09-08","days":1},{"id":"exosome-therapeutics","kind":"technology","name":"Engineered exosomes as drug carriers","route":"/technologies/exosome-therapeutics/","asOf":"2026-09-08","days":1},{"id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","route":"/people/fabrice-barlesi/","asOf":"2026-09-08","days":1},{"id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/","asOf":"2026-09-08","days":1},{"id":"jean-charles-soria","kind":"person","name":"Jean-Charles Soria","route":"/people/jean-charles-soria/","asOf":"2026-09-08","days":1},{"id":"benjamin-besse","kind":"person","name":"Benjamin Besse","route":"/people/benjamin-besse/","asOf":"2026-09-08","days":1},{"id":"aurelien-marabelle","kind":"person","name":"Aurélien Marabelle","route":"/people/aurelien-marabelle/","asOf":"2026-09-08","days":1},{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","asOf":"2026-09-08","days":1},{"id":"laurence-zitvogel","kind":"person","name":"Laurence Zitvogel","route":"/people/laurence-zitvogel/","asOf":"2026-09-08","days":1},{"id":"nicholas-turner","kind":"person","name":"Nicholas Turner","route":"/people/nicholas-turner/","asOf":"2026-09-08","days":1},{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/","asOf":"2026-09-08","days":1},{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","route":"/people/andrew-tutt/","asOf":"2026-09-08","days":1},{"id":"nicholas-james","kind":"person","name":"Nicholas James","route":"/people/nicholas-james/","asOf":"2026-09-08","days":1},{"id":"david-cunningham","kind":"person","name":"David Cunningham","route":"/people/david-cunningham/","asOf":"2026-09-08","days":1},{"id":"james-larkin","kind":"person","name":"James Larkin","route":"/people/james-larkin/","asOf":"2026-09-08","days":1},{"id":"uwe-oelfke","kind":"person","name":"Uwe Oelfke","route":"/people/uwe-oelfke/","asOf":"2026-09-08","days":1},{"id":"kristian-helin","kind":"person","name":"Kristian Helin","route":"/people/kristian-helin/","asOf":"2026-09-08","days":1},{"id":"paul-workman","kind":"person","name":"Paul Workman","route":"/people/paul-workman/","asOf":"2026-09-08","days":1},{"id":"chris-lord","kind":"person","name":"Christopher Lord","route":"/people/chris-lord/","asOf":"2026-09-08","days":1},{"id":"kevin-harrington","kind":"person","name":"Kevin Harrington","route":"/people/kevin-harrington/","asOf":"2026-09-08","days":1},{"id":"mel-greaves","kind":"person","name":"Mel Greaves","route":"/people/mel-greaves/","asOf":"2026-09-08","days":1},{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","asOf":"2026-09-08","days":1},{"id":"paul-nurse","kind":"person","name":"Paul Nurse","route":"/people/paul-nurse/","asOf":"2026-09-08","days":1},{"id":"caetano-reis-e-sousa","kind":"person","name":"Caetano Reis e Sousa","route":"/people/caetano-reis-e-sousa/","asOf":"2026-09-08","days":1},{"id":"erik-sahai","kind":"person","name":"Erik Sahai","route":"/people/erik-sahai/","asOf":"2026-09-08","days":1},{"id":"michelle-mitchell","kind":"person","name":"Michelle Mitchell","route":"/people/michelle-mitchell/","asOf":"2026-09-08","days":1},{"id":"iain-foulkes","kind":"person","name":"Iain Foulkes","route":"/people/iain-foulkes/","asOf":"2026-09-08","days":1},{"id":"ruth-plummer","kind":"person","name":"Ruth Plummer","route":"/people/ruth-plummer/","asOf":"2026-09-08","days":1},{"id":"caroline-dive","kind":"person","name":"Caroline Dive","route":"/people/caroline-dive/","asOf":"2026-09-08","days":1},{"id":"fiona-blackhall","kind":"person","name":"Fiona Blackhall","route":"/people/fiona-blackhall/","asOf":"2026-09-08","days":1},{"id":"andrew-wardley","kind":"person","name":"Andrew Wardley","route":"/people/andrew-wardley/","asOf":"2026-09-08","days":1},{"id":"ananya-choudhury","kind":"person","name":"Ananya Choudhury","route":"/people/ananya-choudhury/","asOf":"2026-09-08","days":1},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/","asOf":"2026-09-08","days":1},{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/","asOf":"2026-09-08","days":1},{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","route":"/people/clemens-kratochwil/","asOf":"2026-09-08","days":1},{"id":"stefan-froehling","kind":"person","name":"Stefan Fröhling","route":"/people/stefan-froehling/","asOf":"2026-09-08","days":1},{"id":"juergen-debus","kind":"person","name":"Jürgen Debus","route":"/people/juergen-debus/","asOf":"2026-09-08","days":1},{"id":"andreas-von-deimling","kind":"person","name":"Andreas von Deimling","route":"/people/andreas-von-deimling/","asOf":"2026-09-08","days":1},{"id":"michael-baumann","kind":"person","name":"Michael Baumann","route":"/people/michael-baumann/","asOf":"2026-09-08","days":1},{"id":"stefan-pfister","kind":"person","name":"Stefan Pfister","route":"/people/stefan-pfister/","asOf":"2026-09-08","days":1},{"id":"hermann-brenner","kind":"person","name":"Hermann Brenner","route":"/people/hermann-brenner/","asOf":"2026-09-08","days":1},{"id":"andreas-trumpp","kind":"person","name":"Andreas Trumpp","route":"/people/andreas-trumpp/","asOf":"2026-09-08","days":1},{"id":"steven-le-gouill","kind":"person","name":"Steven Le Gouill","route":"/people/steven-le-gouill/","asOf":"2026-09-08","days":1},{"id":"francois-clement-bidard","kind":"person","name":"François-Clément Bidard","route":"/people/francois-clement-bidard/","asOf":"2026-09-08","days":1},{"id":"sergio-roman-roman","kind":"person","name":"Sergio Roman-Roman","route":"/people/sergio-roman-roman/","asOf":"2026-09-08","days":1},{"id":"olivier-delattre","kind":"person","name":"Olivier Delattre","route":"/people/olivier-delattre/","asOf":"2026-09-08","days":1},{"id":"eliane-piaggio","kind":"person","name":"Eliane Piaggio","route":"/people/eliane-piaggio/","asOf":"2026-09-08","days":1},{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/","asOf":"2026-09-08","days":1},{"id":"paolo-veronesi","kind":"person","name":"Paolo Veronesi","route":"/people/paolo-veronesi/","asOf":"2026-09-08","days":1},{"id":"roberto-orecchia","kind":"person","name":"Roberto Orecchia","route":"/people/roberto-orecchia/","asOf":"2026-09-08","days":1},{"id":"pier-giuseppe-pelicci","kind":"person","name":"Pier Giuseppe Pelicci","route":"/people/pier-giuseppe-pelicci/","asOf":"2026-09-08","days":1},{"id":"alessandro-gronchi","kind":"person","name":"Alessandro Gronchi","route":"/people/alessandro-gronchi/","asOf":"2026-09-08","days":1},{"id":"filippo-de-braud","kind":"person","name":"Filippo de Braud","route":"/people/filippo-de-braud/","asOf":"2026-09-08","days":1},{"id":"marco-guzzo","kind":"person","name":"Marco Guzzo","route":"/people/marco-guzzo/","asOf":"2026-09-08","days":1},{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/","asOf":"2026-09-08","days":1},{"id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/","asOf":"2026-09-08","days":1},{"id":"elena-garralda","kind":"person","name":"Elena Garralda","route":"/people/elena-garralda/","asOf":"2026-09-08","days":1},{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","asOf":"2026-09-08","days":1},{"id":"elena-elez","kind":"person","name":"Elena Élez","route":"/people/elena-elez/","asOf":"2026-09-08","days":1},{"id":"joaquin-arribas","kind":"person","name":"Joaquín Arribas","route":"/people/joaquin-arribas/","asOf":"2026-09-08","days":1},{"id":"ulrich-keilholz","kind":"person","name":"Ulrich Keilholz","route":"/people/ulrich-keilholz/","asOf":"2026-09-08","days":1},{"id":"lars-bullinger","kind":"person","name":"Lars Bullinger","route":"/people/lars-bullinger/","asOf":"2026-09-08","days":1},{"id":"angelika-eggert","kind":"person","name":"Angelika Eggert","route":"/people/angelika-eggert/","asOf":"2026-09-08","days":1},{"id":"christof-von-kalle","kind":"person","name":"Christof von Kalle","route":"/people/christof-von-kalle/","asOf":"2026-09-08","days":1},{"id":"markus-graefen","kind":"person","name":"Markus Graefen","route":"/people/markus-graefen/","asOf":"2026-09-08","days":1},{"id":"carsten-bokemeyer","kind":"person","name":"Carsten Bokemeyer","route":"/people/carsten-bokemeyer/","asOf":"2026-09-08","days":1},{"id":"klaus-pantel","kind":"person","name":"Klaus Pantel","route":"/people/klaus-pantel/","asOf":"2026-09-08","days":1},{"id":"volker-heinemann","kind":"person","name":"Volker Heinemann","route":"/people/volker-heinemann/","asOf":"2026-09-08","days":1},{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","route":"/people/peter-bartenstein/","asOf":"2026-09-08","days":1},{"id":"michael-von-bergwelt","kind":"person","name":"Michael von Bergwelt","route":"/people/michael-von-bergwelt/","asOf":"2026-09-08","days":1},{"id":"claus-belka","kind":"person","name":"Claus Belka","route":"/people/claus-belka/","asOf":"2026-09-08","days":1},{"id":"michael-hallek","kind":"person","name":"Michael Hallek","route":"/people/michael-hallek/","asOf":"2026-09-08","days":1},{"id":"juergen-wolf","kind":"person","name":"Jürgen Wolf","route":"/people/juergen-wolf/","asOf":"2026-09-08","days":1},{"id":"reinhard-buettner","kind":"person","name":"Reinhard Büttner","route":"/people/reinhard-buettner/","asOf":"2026-09-08","days":1},{"id":"roman-thomas","kind":"person","name":"Roman Thomas","route":"/people/roman-thomas/","asOf":"2026-09-08","days":1},{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/","asOf":"2026-09-08","days":1},{"id":"anna-fagotti","kind":"person","name":"Anna Fagotti","route":"/people/anna-fagotti/","asOf":"2026-09-08","days":1},{"id":"giampaolo-tortora","kind":"person","name":"Giampaolo Tortora","route":"/people/giampaolo-tortora/","asOf":"2026-09-08","days":1},{"id":"vincenzo-valentini","kind":"person","name":"Vincenzo Valentini","route":"/people/vincenzo-valentini/","asOf":"2026-09-08","days":1},{"id":"jonas-bergh","kind":"person","name":"Jonas Bergh","route":"/people/jonas-bergh/","asOf":"2026-09-08","days":1},{"id":"per-hall","kind":"person","name":"Per Hall","route":"/people/per-hall/","asOf":"2026-09-08","days":1},{"id":"rolf-kiessling","kind":"person","name":"Rolf Kiessling","route":"/people/rolf-kiessling/","asOf":"2026-09-08","days":1},{"id":"hans-gustaf-ljunggren","kind":"person","name":"Hans-Gustaf Ljunggren","route":"/people/hans-gustaf-ljunggren/","asOf":"2026-09-08","days":1},{"id":"christian-blank","kind":"person","name":"Christian Blank","route":"/people/christian-blank/","asOf":"2026-09-08","days":1},{"id":"myriam-chalabi","kind":"person","name":"Myriam Chalabi","route":"/people/myriam-chalabi/","asOf":"2026-09-08","days":1},{"id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/","asOf":"2026-09-08","days":1},{"id":"emile-voest","kind":"person","name":"Emile Voest","route":"/people/emile-voest/","asOf":"2026-09-08","days":1},{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","route":"/people/ton-schumacher/","asOf":"2026-09-08","days":1},{"id":"rene-bernards","kind":"person","name":"René Bernards","route":"/people/rene-bernards/","asOf":"2026-09-08","days":1},{"id":"sabine-linn","kind":"person","name":"Sabine Linn","route":"/people/sabine-linn/","asOf":"2026-09-08","days":1},{"id":"jaime-feliu","kind":"person","name":"Jaime Feliu","route":"/people/jaime-feliu/","asOf":"2026-09-08","days":1},{"id":"enrique-espinosa","kind":"person","name":"Enrique Espinosa","route":"/people/enrique-espinosa/","asOf":"2026-09-08","days":1},{"id":"beatriz-castelo","kind":"person","name":"Beatriz Castelo","route":"/people/beatriz-castelo/","asOf":"2026-09-08","days":1},{"id":"miguel-martin","kind":"person","name":"Miguel Martín","route":"/people/miguel-martin/","asOf":"2026-09-08","days":1},{"id":"sara-lopez-tarruella","kind":"person","name":"Sara López-Tarruella","route":"/people/sara-lopez-tarruella/","asOf":"2026-09-08","days":1},{"id":"pilar-garrido","kind":"person","name":"Pilar Garrido","route":"/people/pilar-garrido/","asOf":"2026-09-08","days":1},{"id":"denis-lacombe","kind":"person","name":"Denis Lacombe","route":"/people/denis-lacombe/","asOf":"2026-09-08","days":1},{"id":"alexander-eggermont","kind":"person","name":"Alexander Eggermont","route":"/people/alexander-eggermont/","asOf":"2026-09-08","days":1},{"id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/","asOf":"2026-09-08","days":1},{"id":"michael-weller","kind":"person","name":"Michael Weller","route":"/people/michael-weller/","asOf":"2026-09-08","days":1},{"id":"roger-stupp","kind":"person","name":"Roger Stupp","route":"/people/roger-stupp/","asOf":"2026-09-08","days":1},{"id":"nathan-cherny","kind":"person","name":"Nathan Cherny","route":"/people/nathan-cherny/","asOf":"2026-09-08","days":1},{"id":"andres-cervantes","kind":"person","name":"Andrés Cervantes","route":"/people/andres-cervantes/","asOf":"2026-09-08","days":1},{"id":"solange-peters","kind":"person","name":"Solange Peters","route":"/people/solange-peters/","asOf":"2026-09-08","days":1},{"id":"david-cameron","kind":"person","name":"David Cameron","route":"/people/david-cameron/","asOf":"2026-09-08","days":1},{"id":"evandro-de-azambuja","kind":"person","name":"Evandro de Azambuja","route":"/people/evandro-de-azambuja/","asOf":"2026-09-08","days":1},{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","asOf":"2026-09-08","days":1},{"id":"gunter-von-minckwitz","kind":"person","name":"Gunter von Minckwitz","route":"/people/gunter-von-minckwitz/","asOf":"2026-09-08","days":1},{"id":"carsten-denkert","kind":"person","name":"Carsten Denkert","route":"/people/carsten-denkert/","asOf":"2026-09-08","days":1},{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","route":"/people/jean-yves-blay/","asOf":"2026-09-08","days":1},{"id":"thomas-bachelot","kind":"person","name":"Thomas Bachelot","route":"/people/thomas-bachelot/","asOf":"2026-09-08","days":1},{"id":"christophe-le-tourneau","kind":"person","name":"Christophe Le Tourneau","route":"/people/christophe-le-tourneau/","asOf":"2026-09-08","days":1},{"id":"anthony-goncalves","kind":"person","name":"Anthony Gonçalves","route":"/people/anthony-goncalves/","asOf":"2026-09-08","days":1},{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","route":"/people/ahn-myung-ju/","asOf":"2026-09-08","days":1},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","asOf":"2026-09-08","days":1},{"id":"lee-jeeyun","kind":"person","name":"Jeeyun Lee","route":"/people/lee-jeeyun/","asOf":"2026-09-08","days":1},{"id":"kang-won-ki","kind":"person","name":"Won Ki Kang","route":"/people/kang-won-ki/","asOf":"2026-09-08","days":1},{"id":"lim-ho-yeong","kind":"person","name":"Ho Yeong Lim","route":"/people/lim-ho-yeong/","asOf":"2026-09-08","days":1},{"id":"park-woong-yang","kind":"person","name":"Woong-Yang Park","route":"/people/park-woong-yang/","asOf":"2026-09-08","days":1},{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/","asOf":"2026-09-08","days":1},{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","route":"/people/kang-yoon-koo/","asOf":"2026-09-08","days":1},{"id":"ryu-min-hee","kind":"person","name":"Min-Hee Ryu","route":"/people/ryu-min-hee/","asOf":"2026-09-08","days":1},{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","asOf":"2026-09-08","days":1},{"id":"lee-jae-lyun","kind":"person","name":"Jae Lyun Lee","route":"/people/lee-jae-lyun/","asOf":"2026-09-08","days":1},{"id":"lee-dae-ho","kind":"person","name":"Dae Ho Lee","route":"/people/lee-dae-ho/","asOf":"2026-09-08","days":1},{"id":"lee-sung-gyu","kind":"person","name":"Sung-Gyu Lee","route":"/people/lee-sung-gyu/","asOf":"2026-09-08","days":1},{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","route":"/people/bang-yung-jue/","asOf":"2026-09-08","days":1},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","asOf":"2026-09-08","days":1},{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","route":"/people/oh-do-youn/","asOf":"2026-09-08","days":1},{"id":"kim-tae-you","kind":"person","name":"Tae-You Kim","route":"/people/kim-tae-you/","asOf":"2026-09-08","days":1},{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","asOf":"2026-09-08","days":1},{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","route":"/people/lee-se-hoon/","asOf":"2026-09-08","days":1},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","asOf":"2026-09-08","days":1},{"id":"rha-sun-young","kind":"person","name":"Sun Young Rha","route":"/people/rha-sun-young/","asOf":"2026-09-08","days":1},{"id":"kim-hye-ryun","kind":"person","name":"Hye Ryun Kim","route":"/people/kim-hye-ryun/","asOf":"2026-09-08","days":1},{"id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","route":"/people/shin-sang-joon/","asOf":"2026-09-08","days":1},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","asOf":"2026-09-08","days":1},{"id":"nakagama-hitoshi","kind":"person","name":"Hitoshi Nakagama","route":"/people/nakagama-hitoshi/","asOf":"2026-09-08","days":1},{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","route":"/people/ohe-yuichiro/","asOf":"2026-09-08","days":1},{"id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","route":"/people/yamamoto-noboru/","asOf":"2026-09-08","days":1},{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/","asOf":"2026-09-08","days":1},{"id":"kohno-takashi","kind":"person","name":"Takashi Kohno","route":"/people/kohno-takashi/","asOf":"2026-09-08","days":1},{"id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/","asOf":"2026-09-08","days":1},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","asOf":"2026-09-08","days":1},{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","asOf":"2026-09-08","days":1},{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/","asOf":"2026-09-08","days":1},{"id":"sano-takeshi","kind":"person","name":"Takeshi Sano","route":"/people/sano-takeshi/","asOf":"2026-09-08","days":1},{"id":"takahashi-shunji","kind":"person","name":"Shunji Takahashi","route":"/people/takahashi-shunji/","asOf":"2026-09-08","days":1},{"id":"ohno-shinji","kind":"person","name":"Shinji Ohno","route":"/people/ohno-shinji/","asOf":"2026-09-08","days":1},{"id":"ueno-takayuki","kind":"person","name":"Takayuki Ueno","route":"/people/ueno-takayuki/","asOf":"2026-09-08","days":1},{"id":"fukuda-haruhiko","kind":"person","name":"Haruhiko Fukuda","route":"/people/fukuda-haruhiko/","asOf":"2026-09-08","days":1},{"id":"kitagawa-yuko","kind":"person","name":"Yuko Kitagawa","route":"/people/kitagawa-yuko/","asOf":"2026-09-08","days":1},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","asOf":"2026-09-08","days":1},{"id":"mcarthur-grant","kind":"person","name":"Grant McArthur","route":"/people/mcarthur-grant/","asOf":"2026-09-08","days":1},{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/","asOf":"2026-09-08","days":1},{"id":"solomon-benjamin","kind":"person","name":"Benjamin Solomon","route":"/people/solomon-benjamin/","asOf":"2026-09-08","days":1},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","asOf":"2026-09-08","days":1},{"id":"dawson-sarah-jane","kind":"person","name":"Sarah-Jane Dawson","route":"/people/dawson-sarah-jane/","asOf":"2026-09-08","days":1},{"id":"trapani-joseph","kind":"person","name":"Joseph Trapani","route":"/people/trapani-joseph/","asOf":"2026-09-08","days":1},{"id":"kaliks-rafael","kind":"person","name":"Rafael Kaliks","route":"/people/kaliks-rafael/","asOf":"2026-09-08","days":1},{"id":"hoff-paulo","kind":"person","name":"Paulo Hoff","route":"/people/hoff-paulo/","asOf":"2026-09-08","days":1},{"id":"katz-artur","kind":"person","name":"Artur Katz","route":"/people/katz-artur/","asOf":"2026-09-08","days":1},{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","asOf":"2026-09-08","days":1},{"id":"ma-jun","kind":"person","name":"Jun Ma","route":"/people/ma-jun/","asOf":"2026-09-08","days":1},{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/","asOf":"2026-09-08","days":1},{"id":"zhang-li-sysucc","kind":"person","name":"Li Zhang","route":"/people/zhang-li-sysucc/","asOf":"2026-09-08","days":1},{"id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","route":"/people/fang-wenfeng/","asOf":"2026-09-08","days":1},{"id":"zeng-mu-sheng","kind":"person","name":"Mu-Sheng Zeng","route":"/people/zeng-mu-sheng/","asOf":"2026-09-08","days":1},{"id":"wang-feng-sysucc","kind":"person","name":"Feng Wang","route":"/people/wang-feng-sysucc/","asOf":"2026-09-08","days":1},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","asOf":"2026-09-08","days":1},{"id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","route":"/people/jiang-yi-zhou/","asOf":"2026-09-08","days":1},{"id":"hu-xichun","kind":"person","name":"Xichun Hu","route":"/people/hu-xichun/","asOf":"2026-09-08","days":1},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","asOf":"2026-09-08","days":1},{"id":"ye-dingwei","kind":"person","name":"Dingwei Ye","route":"/people/ye-dingwei/","asOf":"2026-09-08","days":1},{"id":"li-jin-fuscc","kind":"person","name":"Jin Li","route":"/people/li-jin-fuscc/","asOf":"2026-09-08","days":1},{"id":"wei-yuquan","kind":"person","name":"Yuquan Wei","route":"/people/wei-yuquan/","asOf":"2026-09-08","days":1},{"id":"lu-you","kind":"person","name":"You Lu","route":"/people/lu-you/","asOf":"2026-09-08","days":1},{"id":"li-weimin","kind":"person","name":"Weimin Li","route":"/people/li-weimin/","asOf":"2026-09-08","days":1},{"id":"he-jie","kind":"person","name":"Jie He","route":"/people/he-jie/","asOf":"2026-09-08","days":1},{"id":"shi-yuankai","kind":"person","name":"Yuankai Shi","route":"/people/shi-yuankai/","asOf":"2026-09-08","days":1},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","asOf":"2026-09-08","days":1},{"id":"wang-jie-cams","kind":"person","name":"Jie Wang","route":"/people/wang-jie-cams/","asOf":"2026-09-08","days":1},{"id":"ma-fei","kind":"person","name":"Fei Ma","route":"/people/ma-fei/","asOf":"2026-09-08","days":1},{"id":"huang-jing-cams","kind":"person","name":"Jing Huang","route":"/people/huang-jing-cams/","asOf":"2026-09-08","days":1},{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","asOf":"2026-09-08","days":1},{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/","asOf":"2026-09-08","days":1},{"id":"qi-changsong","kind":"person","name":"Changsong Qi","route":"/people/qi-changsong/","asOf":"2026-09-08","days":1},{"id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","route":"/people/wu-yi-long/","asOf":"2026-09-08","days":1},{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/","asOf":"2026-09-08","days":1},{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/","asOf":"2026-09-08","days":1},{"id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","route":"/people/badwe-rajendra/","asOf":"2026-09-08","days":1},{"id":"patil-vijay","kind":"person","name":"Vijay Patil","route":"/people/patil-vijay/","asOf":"2026-09-08","days":1},{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/","asOf":"2026-09-08","days":1},{"id":"noronha-vanita","kind":"person","name":"Vanita Noronha","route":"/people/noronha-vanita/","asOf":"2026-09-08","days":1},{"id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","route":"/people/chaturvedi-pankaj/","asOf":"2026-09-08","days":1},{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/","asOf":"2026-09-08","days":1},{"id":"dancey-janet","kind":"person","name":"Janet Dancey","route":"/people/dancey-janet/","asOf":"2026-09-08","days":1},{"id":"tu-dongsheng","kind":"person","name":"Dongsheng Tu","route":"/people/tu-dongsheng/","asOf":"2026-09-08","days":1},{"id":"parulekar-wendy","kind":"person","name":"Wendy Parulekar","route":"/people/parulekar-wendy/","asOf":"2026-09-08","days":1},{"id":"weiderpass-elisabete","kind":"person","name":"Elisabete Weiderpass","route":"/people/weiderpass-elisabete/","asOf":"2026-09-08","days":1},{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","asOf":"2026-09-08","days":1},{"id":"basu-partha","kind":"person","name":"Partha Basu","route":"/people/basu-partha/","asOf":"2026-09-08","days":1},{"id":"cree-ian","kind":"person","name":"Ian Cree","route":"/people/cree-ian/","asOf":"2026-09-08","days":1},{"id":"ilbawi-andre","kind":"person","name":"André Ilbawi","route":"/people/ilbawi-andre/","asOf":"2026-09-08","days":1},{"id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","route":"/people/selwyn-vickers/","asOf":"2026-09-08","days":1},{"id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/","asOf":"2026-09-08","days":1},{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/","asOf":"2026-09-08","days":1},{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","asOf":"2026-09-08","days":1},{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","asOf":"2026-09-08","days":1},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","asOf":"2026-09-08","days":1},{"id":"bob-li","kind":"person","name":"Bob T. Li","route":"/people/bob-li/","asOf":"2026-09-08","days":1},{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/","asOf":"2026-09-08","days":1},{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/","asOf":"2026-09-08","days":1},{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","asOf":"2026-09-08","days":1},{"id":"eileen-oreilly","kind":"person","name":"Eileen M. O'Reilly","route":"/people/eileen-oreilly/","asOf":"2026-09-08","days":1},{"id":"ross-levine","kind":"person","name":"Ross L. Levine","route":"/people/ross-levine/","asOf":"2026-09-08","days":1},{"id":"jae-park","kind":"person","name":"Jae H. Park","route":"/people/jae-park/","asOf":"2026-09-08","days":1},{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","asOf":"2026-09-08","days":1},{"id":"david-solit","kind":"person","name":"David B. Solit","route":"/people/david-solit/","asOf":"2026-09-08","days":1},{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","asOf":"2026-09-08","days":1},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","asOf":"2026-09-08","days":1},{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/","asOf":"2026-09-08","days":1},{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","asOf":"2026-09-08","days":1},{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/","asOf":"2026-09-08","days":1},{"id":"paul-richardson","kind":"person","name":"Paul G. Richardson","route":"/people/paul-richardson/","asOf":"2026-09-08","days":1},{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/","asOf":"2026-09-08","days":1},{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","route":"/people/toni-choueiri/","asOf":"2026-09-08","days":1},{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","asOf":"2026-09-08","days":1},{"id":"william-kaelin","kind":"person","name":"William G. Kaelin Jr.","route":"/people/william-kaelin/","asOf":"2026-09-08","days":1},{"id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","route":"/people/eliezer-van-allen/","asOf":"2026-09-08","days":1},{"id":"judy-garber","kind":"person","name":"Judy E. Garber","route":"/people/judy-garber/","asOf":"2026-09-08","days":1},{"id":"ann-partridge","kind":"person","name":"Ann H. Partridge","route":"/people/ann-partridge/","asOf":"2026-09-08","days":1},{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/","asOf":"2026-09-08","days":1},{"id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","route":"/people/keith-flaherty/","asOf":"2026-09-08","days":1},{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/","asOf":"2026-09-08","days":1},{"id":"justin-gainor","kind":"person","name":"Justin F. Gainor","route":"/people/justin-gainor/","asOf":"2026-09-08","days":1},{"id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","route":"/people/ryan-corcoran/","asOf":"2026-09-08","days":1},{"id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","route":"/people/ryan-sullivan/","asOf":"2026-09-08","days":1},{"id":"theodore-hong","kind":"person","name":"Theodore S. Hong","route":"/people/theodore-hong/","asOf":"2026-09-08","days":1},{"id":"leif-ellisen","kind":"person","name":"Leif W. Ellisen","route":"/people/leif-ellisen/","asOf":"2026-09-08","days":1},{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","asOf":"2026-09-08","days":1},{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","asOf":"2026-09-08","days":1},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","asOf":"2026-09-08","days":1},{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","asOf":"2026-09-08","days":1},{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/","asOf":"2026-09-08","days":1},{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","asOf":"2026-09-08","days":1},{"id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","asOf":"2026-09-08","days":1},{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/","asOf":"2026-09-08","days":1},{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","route":"/people/patrick-forde/","asOf":"2026-09-08","days":1},{"id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","route":"/people/stephen-baylin/","asOf":"2026-09-08","days":1},{"id":"kellie-smith","kind":"person","name":"Kellie N. Smith","route":"/people/kellie-smith/","asOf":"2026-09-08","days":1},{"id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","route":"/people/robert-vonderheide/","asOf":"2026-09-08","days":1},{"id":"carl-june","kind":"person","name":"Carl H. June","route":"/people/carl-june/","asOf":"2026-09-08","days":1},{"id":"bruce-levine","kind":"person","name":"Bruce L. Levine","route":"/people/bruce-levine/","asOf":"2026-09-08","days":1},{"id":"drew-weissman","kind":"person","name":"Drew Weissman","route":"/people/drew-weissman/","asOf":"2026-09-08","days":1},{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","asOf":"2026-09-08","days":1},{"id":"angela-demichele","kind":"person","name":"Angela DeMichele","route":"/people/angela-demichele/","asOf":"2026-09-08","days":1},{"id":"charu-aggarwal","kind":"person","name":"Charu Aggarwal","route":"/people/charu-aggarwal/","asOf":"2026-09-08","days":1},{"id":"robert-mach","kind":"person","name":"Robert H. Mach","route":"/people/robert-mach/","asOf":"2026-09-08","days":1},{"id":"david-porter","kind":"person","name":"David L. Porter","route":"/people/david-porter/","asOf":"2026-09-08","days":1},{"id":"anthony-letai","kind":"person","name":"Anthony Letai","route":"/people/anthony-letai/","asOf":"2026-09-08","days":1},{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/","asOf":"2026-09-08","days":1},{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","asOf":"2026-09-08","days":1},{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/","asOf":"2026-09-08","days":1},{"id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/","asOf":"2026-09-08","days":1},{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/","asOf":"2026-09-08","days":1},{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/","asOf":"2026-09-08","days":1},{"id":"raffit-hassan","kind":"person","name":"Raffit Hassan","route":"/people/raffit-hassan/","asOf":"2026-09-08","days":1},{"id":"ramon-parsons","kind":"person","name":"Ramon E. Parsons","route":"/people/ramon-parsons/","asOf":"2026-09-08","days":1},{"id":"miriam-merad","kind":"person","name":"Miriam Merad","route":"/people/miriam-merad/","asOf":"2026-09-08","days":1},{"id":"sundar-jagannath","kind":"person","name":"Sundar Jagannath","route":"/people/sundar-jagannath/","asOf":"2026-09-08","days":1},{"id":"joshua-brody","kind":"person","name":"Joshua Brody","route":"/people/joshua-brody/","asOf":"2026-09-08","days":1},{"id":"matthew-galsky","kind":"person","name":"Matthew D. Galsky","route":"/people/matthew-galsky/","asOf":"2026-09-08","days":1},{"id":"nina-bhardwaj","kind":"person","name":"Nina Bhardwaj","route":"/people/nina-bhardwaj/","asOf":"2026-09-08","days":1},{"id":"thomas-marron","kind":"person","name":"Thomas U. Marron","route":"/people/thomas-marron/","asOf":"2026-09-08","days":1},{"id":"candace-johnson","kind":"person","name":"Candace S. Johnson","route":"/people/candace-johnson/","asOf":"2026-09-08","days":1},{"id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","route":"/people/renier-brentjens/","asOf":"2026-09-08","days":1},{"id":"igor-puzanov","kind":"person","name":"Igor Puzanov","route":"/people/igor-puzanov/","asOf":"2026-09-08","days":1},{"id":"robert-fenstermaker","kind":"person","name":"Robert A. Fenstermaker","route":"/people/robert-fenstermaker/","asOf":"2026-09-08","days":1},{"id":"eunice-wang","kind":"person","name":"Eunice S. Wang","route":"/people/eunice-wang/","asOf":"2026-09-08","days":1},{"id":"pawel-kalinski","kind":"person","name":"Pawel Kalinski","route":"/people/pawel-kalinski/","asOf":"2026-09-08","days":1},{"id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/","asOf":"2026-09-08","days":1},{"id":"gad-getz","kind":"person","name":"Gad Getz","route":"/people/gad-getz/","asOf":"2026-09-08","days":1},{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/","asOf":"2026-09-08","days":1},{"id":"francisca-vazquez","kind":"person","name":"Francisca Vazquez","route":"/people/francisca-vazquez/","asOf":"2026-09-08","days":1},{"id":"andrew-aguirre","kind":"person","name":"Andrew J. Aguirre","route":"/people/andrew-aguirre/","asOf":"2026-09-08","days":1},{"id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","asOf":"2026-09-08","days":1},{"id":"bradley-bernstein","kind":"person","name":"Bradley E. Bernstein","route":"/people/bradley-bernstein/","asOf":"2026-09-08","days":1},{"id":"bruce-stillman","kind":"person","name":"Bruce W. Stillman","route":"/people/bruce-stillman/","asOf":"2026-09-08","days":1},{"id":"david-tuveson","kind":"person","name":"David A. Tuveson","route":"/people/david-tuveson/","asOf":"2026-09-08","days":1},{"id":"christopher-vakoc","kind":"person","name":"Christopher R. Vakoc","route":"/people/christopher-vakoc/","asOf":"2026-09-08","days":1},{"id":"adrian-krainer","kind":"person","name":"Adrian R. Krainer","route":"/people/adrian-krainer/","asOf":"2026-09-08","days":1},{"id":"tobias-janowitz","kind":"person","name":"Tobias Janowitz","route":"/people/tobias-janowitz/","asOf":"2026-09-08","days":1},{"id":"semir-beyaz","kind":"person","name":"Semir Beyaz","route":"/people/semir-beyaz/","asOf":"2026-09-08","days":1},{"id":"timothy-eberlein","kind":"person","name":"Timothy J. Eberlein","route":"/people/timothy-eberlein/","asOf":"2026-09-08","days":1},{"id":"timothy-ley","kind":"person","name":"Timothy J. Ley","route":"/people/timothy-ley/","asOf":"2026-09-08","days":1},{"id":"li-ding","kind":"person","name":"Li Ding","route":"/people/li-ding/","asOf":"2026-09-08","days":1},{"id":"malachi-griffith","kind":"person","name":"Malachi Griffith","route":"/people/malachi-griffith/","asOf":"2026-09-08","days":1},{"id":"obi-griffith","kind":"person","name":"Obi L. Griffith","route":"/people/obi-griffith/","asOf":"2026-09-08","days":1},{"id":"john-dipersio","kind":"person","name":"John F. DiPersio","route":"/people/john-dipersio/","asOf":"2026-09-08","days":1},{"id":"ramaswamy-govindan","kind":"person","name":"Ramaswamy Govindan","route":"/people/ramaswamy-govindan/","asOf":"2026-09-08","days":1},{"id":"robert-schreiber","kind":"person","name":"Robert D. Schreiber","route":"/people/robert-schreiber/","asOf":"2026-09-08","days":1},{"id":"eric-fearon","kind":"person","name":"Eric R. Fearon","route":"/people/eric-fearon/","asOf":"2026-09-08","days":1},{"id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","route":"/people/arul-chinnaiyan/","asOf":"2026-09-08","days":1},{"id":"shaomeng-wang","kind":"person","name":"Shaomeng Wang","route":"/people/shaomeng-wang/","asOf":"2026-09-08","days":1},{"id":"max-wicha","kind":"person","name":"Max S. Wicha","route":"/people/max-wicha/","asOf":"2026-09-08","days":1},{"id":"weiping-zou","kind":"person","name":"Weiping Zou","route":"/people/weiping-zou/","asOf":"2026-09-08","days":1},{"id":"theodore-lawrence","kind":"person","name":"Theodore S. Lawrence","route":"/people/theodore-lawrence/","asOf":"2026-09-08","days":1},{"id":"costas-lyssiotis","kind":"person","name":"Costas A. Lyssiotis","route":"/people/costas-lyssiotis/","asOf":"2026-09-08","days":1},{"id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","route":"/people/vincent-tuohy/","asOf":"2026-09-08","days":1},{"id":"timothy-chan","kind":"person","name":"Timothy A. Chan","route":"/people/timothy-chan/","asOf":"2026-09-08","days":1},{"id":"jame-abraham","kind":"person","name":"Jame Abraham","route":"/people/jame-abraham/","asOf":"2026-09-08","days":1},{"id":"justin-lathia","kind":"person","name":"Justin D. Lathia","route":"/people/justin-lathia/","asOf":"2026-09-08","days":1},{"id":"jaroslaw-maciejewski","kind":"person","name":"Jaroslaw P. Maciejewski","route":"/people/jaroslaw-maciejewski/","asOf":"2026-09-08","days":1},{"id":"shilpa-gupta","kind":"person","name":"Shilpa Gupta","route":"/people/shilpa-gupta/","asOf":"2026-09-08","days":1},{"id":"nathan-pennell","kind":"person","name":"Nathan A. Pennell","route":"/people/nathan-pennell/","asOf":"2026-09-08","days":1},{"id":"patrick-hwu","kind":"person","name":"Patrick Hwu","route":"/people/patrick-hwu/","asOf":"2026-09-08","days":1},{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/","asOf":"2026-09-08","days":1},{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/","asOf":"2026-09-08","days":1},{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/","asOf":"2026-09-08","days":1},{"id":"eric-haura","kind":"person","name":"Eric B. Haura","route":"/people/eric-haura/","asOf":"2026-09-08","days":1},{"id":"hatem-soliman","kind":"person","name":"Hatem Soliman","route":"/people/hatem-soliman/","asOf":"2026-09-08","days":1},{"id":"christine-chung","kind":"person","name":"Christine H. Chung","route":"/people/christine-chung/","asOf":"2026-09-08","days":1},{"id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","route":"/people/shari-pilon-thomas/","asOf":"2026-09-08","days":1},{"id":"keith-stewart","kind":"person","name":"A. Keith Stewart","route":"/people/keith-stewart/","asOf":"2026-09-08","days":1},{"id":"john-dick","kind":"person","name":"John E. Dick","route":"/people/john-dick/","asOf":"2026-09-08","days":1},{"id":"lillian-siu","kind":"person","name":"Lillian L. Siu","route":"/people/lillian-siu/","asOf":"2026-09-08","days":1},{"id":"tak-mak","kind":"person","name":"Tak W. Mak","route":"/people/tak-mak/","asOf":"2026-09-08","days":1},{"id":"pamela-ohashi","kind":"person","name":"Pamela S. Ohashi","route":"/people/pamela-ohashi/","asOf":"2026-09-08","days":1},{"id":"aaron-schimmer","kind":"person","name":"Aaron D. Schimmer","route":"/people/aaron-schimmer/","asOf":"2026-09-08","days":1},{"id":"natasha-leighl","kind":"person","name":"Natasha B. Leighl","route":"/people/natasha-leighl/","asOf":"2026-09-08","days":1},{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/","asOf":"2026-09-08","days":1},{"id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","route":"/people/trevor-pugh/","asOf":"2026-09-08","days":1},{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","asOf":"2026-09-08","days":1},{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","asOf":"2026-09-08","days":1},{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","asOf":"2026-09-08","days":1},{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","asOf":"2026-09-08","days":1},{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","asOf":"2026-09-08","days":1},{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","asOf":"2026-09-08","days":1},{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","asOf":"2026-09-08","days":1},{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","asOf":"2026-09-08","days":1},{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","asOf":"2026-09-08","days":1},{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","asOf":"2026-09-08","days":1},{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","asOf":"2026-09-08","days":1},{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","asOf":"2026-09-08","days":1},{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","asOf":"2026-09-08","days":1},{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","asOf":"2026-09-08","days":1},{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","asOf":"2026-09-08","days":1},{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","asOf":"2026-09-08","days":1},{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","asOf":"2026-09-08","days":1},{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","asOf":"2026-09-08","days":1},{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","asOf":"2026-09-08","days":1},{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","asOf":"2026-09-08","days":1},{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","asOf":"2026-09-08","days":1},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","asOf":"2026-09-08","days":1},{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","asOf":"2026-09-08","days":1},{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","asOf":"2026-09-08","days":1},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","asOf":"2026-09-08","days":1},{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","asOf":"2026-09-08","days":1},{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","asOf":"2026-09-08","days":1},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","asOf":"2026-09-08","days":1},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","asOf":"2026-09-08","days":1},{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","asOf":"2026-09-08","days":1},{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","asOf":"2026-09-08","days":1},{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","asOf":"2026-09-08","days":1},{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","asOf":"2026-09-08","days":1},{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","asOf":"2026-09-08","days":1},{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","asOf":"2026-09-08","days":1},{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","asOf":"2026-09-08","days":1},{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","asOf":"2026-09-08","days":1},{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","asOf":"2026-09-08","days":1},{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","asOf":"2026-09-08","days":1},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","asOf":"2026-09-08","days":1},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","asOf":"2026-09-08","days":1},{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","asOf":"2026-09-08","days":1},{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","asOf":"2026-09-08","days":1},{"id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","asOf":"2026-09-08","days":1},{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","asOf":"2026-09-08","days":1},{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","asOf":"2026-09-08","days":1},{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","asOf":"2026-09-08","days":1},{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","asOf":"2026-09-08","days":1},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","asOf":"2026-09-08","days":1},{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","asOf":"2026-09-08","days":1},{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","asOf":"2026-09-08","days":1},{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","asOf":"2026-09-08","days":1},{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","asOf":"2026-09-08","days":1},{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","asOf":"2026-09-08","days":1},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","asOf":"2026-09-08","days":1},{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","asOf":"2026-09-08","days":1},{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","asOf":"2026-09-08","days":1},{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","asOf":"2026-09-08","days":1},{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","asOf":"2026-09-08","days":1},{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","asOf":"2026-09-08","days":1},{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","asOf":"2026-09-08","days":1},{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","asOf":"2026-09-08","days":1},{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","asOf":"2026-09-08","days":1},{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","asOf":"2026-09-08","days":1},{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","asOf":"2026-09-08","days":1},{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","asOf":"2026-09-08","days":1},{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","asOf":"2026-09-08","days":1},{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","asOf":"2026-09-08","days":1},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","asOf":"2026-09-08","days":1},{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","asOf":"2026-09-08","days":1},{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","asOf":"2026-09-08","days":1},{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","asOf":"2026-09-08","days":1},{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","asOf":"2026-09-08","days":1},{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","asOf":"2026-09-08","days":1},{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","asOf":"2026-09-08","days":1},{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","asOf":"2026-09-08","days":1},{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","asOf":"2026-09-08","days":1},{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","asOf":"2026-09-08","days":1},{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","asOf":"2026-09-08","days":1},{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","asOf":"2026-09-08","days":1},{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","asOf":"2026-09-08","days":1},{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","asOf":"2026-09-08","days":1},{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","asOf":"2026-09-08","days":1},{"id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","asOf":"2026-09-08","days":1},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/","asOf":"2026-09-08","days":1},{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/","asOf":"2026-09-08","days":1},{"id":"b-preclinical-models","kind":"bottleneck","name":"Preclinical models that do not predict people","route":"/bottlenecks/b-preclinical-models/","asOf":"2026-09-08","days":1},{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/","asOf":"2026-09-08","days":1},{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/","asOf":"2026-09-08","days":1},{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/","asOf":"2026-09-08","days":1},{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/","asOf":"2026-09-08","days":1},{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/","asOf":"2026-09-08","days":1},{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/","asOf":"2026-09-08","days":1},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/","asOf":"2026-09-08","days":1},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/","asOf":"2026-09-08","days":1},{"id":"b-early-detection","kind":"bottleneck","name":"Most lethal cancers are found late","route":"/bottlenecks/b-early-detection/","asOf":"2026-09-08","days":1},{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/","asOf":"2026-09-08","days":1},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","asOf":"2026-09-08","days":1},{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/","asOf":"2026-09-08","days":1},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/","asOf":"2026-09-08","days":1},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","asOf":"2026-09-08","days":1},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/","asOf":"2026-09-08","days":1},{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","asOf":"2026-09-08","days":1},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/","asOf":"2026-09-08","days":1},{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/","asOf":"2026-09-08","days":1},{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/","asOf":"2026-09-08","days":1},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/","asOf":"2026-09-08","days":1},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","asOf":"2026-09-08","days":1},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","asOf":"2026-09-08","days":1},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/","asOf":"2026-09-08","days":1},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","asOf":"2026-09-08","days":1},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/","asOf":"2026-09-08","days":1},{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/","asOf":"2026-09-08","days":1},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/","asOf":"2026-09-08","days":1},{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/","asOf":"2026-09-08","days":1},{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/","asOf":"2026-09-08","days":1},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/","asOf":"2026-09-08","days":1},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/","asOf":"2026-09-08","days":1},{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","asOf":"2026-09-08","days":1},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/","asOf":"2026-09-08","days":1},{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/","asOf":"2026-09-08","days":1},{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/","asOf":"2026-09-08","days":1},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","asOf":"2026-09-08","days":1},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/","asOf":"2026-09-08","days":1},{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/","asOf":"2026-09-08","days":1},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/","asOf":"2026-09-08","days":1},{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/","asOf":"2026-09-08","days":1},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","asOf":"2026-09-08","days":1},{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-multiregion-blocks-default","kind":"idea","name":"Bank three spatially separate tumour blocks from every resection","route":"/ideas/idea-bio1-multiregion-blocks-default/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-rapid-autopsy-network","kind":"idea","name":"A national rapid research autopsy network for end-stage cancer","route":"/ideas/idea-bio1-rapid-autopsy-network/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-ctdna-clone-report","kind":"idea","name":"A clone report from blood at every treatment cycle","route":"/ideas/idea-bio1-ctdna-clone-report/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-truncal-branch-labelling","kind":"idea","name":"Label every targetable mutation as truncal or branch on the report","route":"/ideas/idea-bio1-truncal-branch-labelling/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-outlier-lesion-biopsy","kind":"idea","name":"Biopsy the one lesion that is growing while the others shrink","route":"/ideas/idea-bio1-outlier-lesion-biopsy/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-barcoded-avatars-clonal-fitness","kind":"idea","name":"Barcode patient-derived tumours to watch which clones win under each drug","route":"/ideas/idea-bio1-barcoded-avatars-clonal-fitness/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-evolvability-index","kind":"idea","name":"A standard evolvability score for every tumour","route":"/ideas/idea-bio1-evolvability-index/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-adaptive-therapy-platform","kind":"idea","name":"A multi-cancer platform trial of adaptive (dose-holiday) therapy","route":"/ideas/idea-bio1-adaptive-therapy-platform/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-ctdna-adaptive-tki","kind":"idea","name":"ctDNA-guided dose holidays for lung cancer targeted therapy","route":"/ideas/idea-bio1-ctdna-adaptive-tki/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-first-strike-second-strike","kind":"idea","name":"Switch drugs at maximum response, not at relapse","route":"/ideas/idea-bio1-first-strike-second-strike/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-collateral-sensitivity-atlas","kind":"idea","name":"An open atlas of collateral sensitivity for every approved targeted drug","route":"/ideas/idea-bio1-collateral-sensitivity-atlas/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-evolutionary-double-bind","kind":"idea","name":"Design drug pairs where resisting one makes you vulnerable to the other","route":"/ideas/idea-bio1-evolutionary-double-bind/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-spatial-clone-immune-map","kind":"idea","name":"Map which tumour clones sit next to which immune cells before choosing therapy","route":"/ideas/idea-bio1-spatial-clone-immune-map/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-methylation-clone-tracking","kind":"idea","name":"Track clones in blood with methylation patterns instead of mutations","route":"/ideas/idea-bio1-methylation-clone-tracking/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-clonal-clearance-endpoint","kind":"idea","name":"Make clonal clearance, not tumour shrinkage, a trial endpoint","route":"/ideas/idea-bio1-clonal-clearance-endpoint/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-evolution-forecasting","kind":"idea","name":"Forecast the next resistance mutation like the weather","route":"/ideas/idea-bio1-evolution-forecasting/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-baseline-ultradeep-resistant-clones","kind":"idea","name":"Look for the resistant sub-population before the first dose","route":"/ideas/idea-bio1-baseline-ultradeep-resistant-clones/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-cfrna-plasticity-tracking","kind":"idea","name":"Detect tumours changing cell type from RNA in the blood","route":"/ideas/idea-bio1-cfrna-plasticity-tracking/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-evolutionary-tumour-boards","kind":"idea","name":"Evolutionary tumour boards with a modeller in the room","route":"/ideas/idea-bio1-evolutionary-tumour-boards/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-apobec-inhibitor-adjunct","kind":"idea","name":"Slow the tumour's mutation engine with APOBEC inhibitors during targeted therapy","route":"/ideas/idea-bio1-apobec-inhibitor-adjunct/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-cin-vulnerability-kif18a","kind":"idea","name":"Turn chromosomal chaos into a weakness with KIF18A inhibitors","route":"/ideas/idea-bio1-cin-vulnerability-kif18a/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-federated-evolution-atlas","kind":"idea","name":"Pool every multi-sample tumour genome into one open evolution atlas","route":"/ideas/idea-bio1-federated-evolution-atlas/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-clone-to-lesion-mapping","kind":"idea","name":"Match each blood-detected clone to the lesion it comes from on the scan","route":"/ideas/idea-bio1-clone-to-lesion-mapping/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-rebiopsy-before-switch","kind":"idea","name":"Re-test the metastasis, not the old primary, before every change of treatment","route":"/ideas/idea-bio1-rebiopsy-before-switch/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-clonal-neoantigen-vaccines","kind":"idea","name":"Vaccines aimed only at mutations shared by every tumour cell","route":"/ideas/idea-bio1-clonal-neoantigen-vaccines/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-myc-max-molecular-glue","kind":"idea","name":"Molecular glues that break the MYC-MAX partnership","route":"/ideas/idea-bio1-myc-max-molecular-glue/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-omomyc-mrna","kind":"idea","name":"mRNA-delivered MYC decoy proteins instead of MYC inhibitors","route":"/ideas/idea-bio1-omomyc-mrna/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-p53-mutant-reactivator-expansion","kind":"idea","name":"Extend p53 reactivation beyond the Y220C mutation","route":"/ideas/idea-bio1-p53-mutant-reactivator-expansion/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-mutant-p53-degrader","kind":"idea","name":"Degrade the damaged p53 protein rather than trying to repair it","route":"/ideas/idea-bio1-mutant-p53-degrader/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-pan-ras-covalent-g12d","kind":"idea","name":"Covalent chemistry for the RAS mutations that still have no drug","route":"/ideas/idea-bio1-pan-ras-covalent-g12d/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-covalent-ligandability-atlas","kind":"idea","name":"An open map of which cancer proteins any drug can stick to","route":"/ideas/idea-bio1-covalent-ligandability-atlas/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-glue-degrader-atlas","kind":"idea","name":"Screen glue-like compounds against every cancer cell line and publish it","route":"/ideas/idea-bio1-glue-degrader-atlas/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-fusion-tf-degraders","kind":"idea","name":"Degraders for the fusion proteins that drive childhood sarcomas","route":"/ideas/idea-bio1-fusion-tf-degraders/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-condensate-disruptors","kind":"idea","name":"Break up the liquid droplets where oncogenic transcription happens","route":"/ideas/idea-bio1-condensate-disruptors/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-tumour-restricted-e3-atlas","kind":"idea","name":"Find E3 ligases that only tumours have, and build degraders around them","route":"/ideas/idea-bio1-tumour-restricted-e3-atlas/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-antibody-degrader-conjugates","kind":"idea","name":"Use antibodies to deliver protein-destroying drugs into the right cells","route":"/ideas/idea-bio1-antibody-degrader-conjugates/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-lytac-surface-degraders","kind":"idea","name":"Drag cancer's surface and secreted proteins to the cell's recycling bin","route":"/ideas/idea-bio1-lytac-surface-degraders/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-rna-targeting-small-molecules","kind":"idea","name":"Small molecules that cut the RNA message of an undruggable oncogene","route":"/ideas/idea-bio1-rna-targeting-small-molecules/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-epigenetic-silencing-in-vivo","kind":"idea","name":"Switch off an undruggable oncogene permanently with epigenetic editing","route":"/ideas/idea-bio1-epigenetic-silencing-in-vivo/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-paralog-synthetic-lethality","kind":"idea","name":"Attack the backup copy when a tumour has lost the original gene","route":"/ideas/idea-bio1-paralog-synthetic-lethality/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-pp2a-activators","kind":"idea","name":"Turn a brake back on: drugs that reactivate the PP2A phosphatase","route":"/ideas/idea-bio1-pp2a-activators/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-wrn-msi-programme","kind":"idea","name":"WRN inhibitors: a second synthetic-lethal win for mismatch-repair cancers","route":"/ideas/idea-bio1-wrn-msi-programme/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-macrocycle-ppi-campaign","kind":"idea","name":"Macrocyclic peptides to cover protein surfaces that pills cannot","route":"/ideas/idea-bio1-macrocycle-ppi-campaign/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-arv7-degrader","kind":"idea","name":"Destroy the truncated androgen receptor that hormone drugs cannot touch","route":"/ideas/idea-bio1-arv7-degrader/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-ai-binders-disordered-regions","kind":"idea","name":"AI-designed proteins that grip the floppy parts of cancer drivers","route":"/ideas/idea-bio1-ai-binders-disordered-regions/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-pmhc-bispecifics-public-drivers","kind":"idea","name":"Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface","route":"/ideas/idea-bio1-pmhc-bispecifics-public-drivers/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-mrna-intrabodies","kind":"idea","name":"Instruct tumour cells to make antibodies against their own oncoprotein","route":"/ideas/idea-bio1-mrna-intrabodies/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-translation-dependency-myc","kind":"idea","name":"Starve MYC-driven tumours by blocking protein production machinery","route":"/ideas/idea-bio1-translation-dependency-myc/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-undruggable-open-consortium","kind":"idea","name":"A precompetitive consortium for the twenty hardest cancer targets","route":"/ideas/idea-bio1-undruggable-open-consortium/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-undruggable-market-commitment","kind":"idea","name":"A guaranteed purchase prize for the first drug against a named hard target","route":"/ideas/idea-bio1-undruggable-market-commitment/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-immune-matched-humanised-mice","kind":"idea","name":"Humanised mice with an immune system matched to the tumour donor","route":"/ideas/idea-bio1-immune-matched-humanised-mice/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-co-clinical-avatar-trials","kind":"idea","name":"Run the mouse or organoid trial at the same time as the human trial","route":"/ideas/idea-bio1-co-clinical-avatar-trials/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-organoid-immune-coculture","kind":"idea","name":"Grow tumour organoids together with the patient's own immune cells","route":"/ideas/idea-bio1-organoid-immune-coculture/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-tumour-on-chip-penetration","kind":"idea","name":"Tumour-on-a-chip with blood flow to test whether big drugs actually get in","route":"/ideas/idea-bio1-tumour-on-chip-penetration/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-in-silico-trials-dose","kind":"idea","name":"In silico trials to choose the dose before the first patient","route":"/ideas/idea-bio1-in-silico-trials-dose/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-preclinical-preregistration","kind":"idea","name":"Pre-register animal efficacy studies like clinical trials","route":"/ideas/idea-bio1-preclinical-preregistration/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-multicentre-mouse-trials","kind":"idea","name":"Multi-centre randomised animal trials before committing to a human trial","route":"/ideas/idea-bio1-multicentre-mouse-trials/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-model-predictivity-benchmark","kind":"idea","name":"Score every model system on how well it predicted real trial results","route":"/ideas/idea-bio1-model-predictivity-benchmark/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-negative-preclinical-repository","kind":"idea","name":"A home for the animal and organoid experiments that failed","route":"/ideas/idea-bio1-negative-preclinical-repository/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-tumour-slice-cultures","kind":"idea","name":"Test drugs on freshly cut slices of the patient's own tumour","route":"/ideas/idea-bio1-tumour-slice-cultures/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-metastatic-niche-models","kind":"idea","name":"Build laboratory models of the organs cancer spreads to","route":"/ideas/idea-bio1-metastatic-niche-models/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-aged-comorbid-models","kind":"idea","name":"Test cancer drugs in old and unhealthy animals, not just young fit ones","route":"/ideas/idea-bio1-aged-comorbid-models/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-comparative-oncology-dogs","kind":"idea","name":"Pet dogs with spontaneous cancer as a bridge before human trials","route":"/ideas/idea-bio1-comparative-oncology-dogs/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-zebrafish-avatars","kind":"idea","name":"Zebrafish avatars for a drug answer within a week","route":"/ideas/idea-bio1-zebrafish-avatars/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-multi-organ-chip-tox","kind":"idea","name":"Linked human organ chips to predict side effects before people are dosed","route":"/ideas/idea-bio1-multi-organ-chip-tox/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-rare-cancer-organoid-bank","kind":"idea","name":"An open organoid bank for cancers too rare to have models","route":"/ideas/idea-bio1-rare-cancer-organoid-bank/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-organoid-assay-clinical-validation","kind":"idea","name":"Hold organoid drug tests to the same standard as a diagnostic test","route":"/ideas/idea-bio1-organoid-assay-clinical-validation/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-organoid-cell-therapy-potency","kind":"idea","name":"Use patient organoids to check a cell therapy will work before infusing it","route":"/ideas/idea-bio1-organoid-cell-therapy-potency/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-somatic-crispr-gemms","kind":"idea","name":"Make bespoke mouse cancer models in weeks with in vivo gene editing","route":"/ideas/idea-bio1-somatic-crispr-gemms/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-ctc-derived-explants","kind":"idea","name":"Grow models from tumour cells in the blood when a biopsy is impossible","route":"/ideas/idea-bio1-ctc-derived-explants/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-model-authentication-mandate","kind":"idea","name":"Prove the cell line is what you say it is, or the paper does not run","route":"/ideas/idea-bio1-model-authentication-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-reverse-translation-resistance-models","kind":"idea","name":"Every resistance mechanism found in a patient must be rebuilt in the laboratory","route":"/ideas/idea-bio1-reverse-translation-resistance-models/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-ex-vivo-perfused-tumour","kind":"idea","name":"Keep a freshly removed tumour alive on a pump and test drugs in it","route":"/ideas/idea-bio1-ex-vivo-perfused-tumour/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-model-patient-matching","kind":"idea","name":"Pick the laboratory model that matches the patient, not the one to hand","route":"/ideas/idea-bio1-model-patient-matching/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-virtual-cell-perturbation","kind":"idea","name":"A virtual cancer cell that predicts what a drug will do before you test it","route":"/ideas/idea-bio1-virtual-cell-perturbation/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-mandatory-progression-biopsy","kind":"idea","name":"Fund a biopsy at progression, every time, as standard care","route":"/ideas/idea-bio1-mandatory-progression-biopsy/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-open-resistance-atlas","kind":"idea","name":"One open atlas of how tumours escape every drug","route":"/ideas/idea-bio1-open-resistance-atlas/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-upfront-bypass-combination","kind":"idea","name":"Add the second drug on day one when the escape route is predictable","route":"/ideas/idea-bio1-upfront-bypass-combination/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-pre-randomised-sequencing-trials","kind":"idea","name":"Randomise the next line of treatment before the first one fails","route":"/ideas/idea-bio1-pre-randomised-sequencing-trials/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-antigen-mapping-at-progression","kind":"idea","name":"Re-map the tumour's surface proteins before choosing the next antibody drug","route":"/ideas/idea-bio1-antigen-mapping-at-progression/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-dual-antigen-adc-escape","kind":"idea","name":"Two-target antibody drugs to close the antigen escape route","route":"/ideas/idea-bio1-dual-antigen-adc-escape/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-adaptive-car-antigen-switch","kind":"idea","name":"Plan the second CAR-T target before the first one is lost","route":"/ideas/idea-bio1-adaptive-car-antigen-switch/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-drug-holiday-resensitisation","kind":"idea","name":"Pause a failed drug so the tumour becomes sensitive to it again","route":"/ideas/idea-bio1-drug-holiday-resensitisation/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-persister-ferroptosis","kind":"idea","name":"Kill the sleeping survivor cells with iron-dependent cell death","route":"/ideas/idea-bio1-persister-ferroptosis/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-epigenetic-persister-blockade","kind":"idea","name":"Block the chemical switch that lets cells hide from treatment","route":"/ideas/idea-bio1-epigenetic-persister-blockade/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-mutagenesis-blockade-rev1","kind":"idea","name":"Turn off the error-prone repair that manufactures resistance mutations","route":"/ideas/idea-bio1-mutagenesis-blockade-rev1/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-stress-response-blockade","kind":"idea","name":"Cut off the emergency programme cancer cells use to survive treatment","route":"/ideas/idea-bio1-stress-response-blockade/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-senolytics-after-therapy","kind":"idea","name":"Clear the zombie cells left behind by chemotherapy and radiotherapy","route":"/ideas/idea-bio1-senolytics-after-therapy/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-persister-metabolic-vulnerability","kind":"idea","name":"Starve the survivors: target the energy pathway drug-tolerant cells switch to","route":"/ideas/idea-bio1-persister-metabolic-vulnerability/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-molecular-progression-add-on","kind":"idea","name":"Add a drug when the blood test turns, without stopping the one that works","route":"/ideas/idea-bio1-molecular-progression-add-on/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-alternating-schedules","kind":"idea","name":"Rotate between drugs on a fixed schedule instead of waiting for failure","route":"/ideas/idea-bio1-alternating-schedules/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-resistance-mutation-vaccine","kind":"idea","name":"Vaccinate against the resistance mutation before it takes over","route":"/ideas/idea-bio1-resistance-mutation-vaccine/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-mechanism-matched-access","kind":"idea","name":"A fast route to the matched drug when it is licensed for another cancer","route":"/ideas/idea-bio1-mechanism-matched-access/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-resistance-platform-trial","kind":"idea","name":"A standing platform trial that assigns treatment by how the tumour escaped","route":"/ideas/idea-bio1-resistance-platform-trial/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-slfn11-payload-guidance","kind":"idea","name":"Use SLFN11 status to decide which antibody-drug payload to give next","route":"/ideas/idea-bio1-slfn11-payload-guidance/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-stromal-resistance-blockade","kind":"idea","name":"Block the survival signals the tumour's neighbours provide","route":"/ideas/idea-bio1-stromal-resistance-blockade/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-real-world-resistance-surveillance","kind":"idea","name":"Treat resistance like an infectious disease and run national surveillance","route":"/ideas/idea-bio1-real-world-resistance-surveillance/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-approval-linked-progression-sampling","kind":"idea","name":"Make post-progression sampling a condition of accelerated approval","route":"/ideas/idea-bio1-approval-linked-progression-sampling/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-drug-exposure-sanctuary-mapping","kind":"idea","name":"Find the parts of a tumour the drug never reaches","route":"/ideas/idea-bio1-drug-exposure-sanctuary-mapping/","asOf":"2026-09-08","days":1},{"id":"idea-bio1-immunopeptidome-timing","kind":"idea","name":"Time immunotherapy to the moment targeted drugs make tumours visible","route":"/ideas/idea-bio1-immunopeptidome-timing/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-antimetastatic-endpoint","kind":"idea","name":"A regulatory endpoint for drugs that block spread, not tumours","route":"/ideas/idea-bio2-antimetastatic-endpoint/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-ctc-clearance-go-nogo","kind":"idea","name":"Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs","route":"/ideas/idea-bio2-ctc-clearance-go-nogo/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-net-blockade-perioperative","kind":"idea","name":"Break the neutrophil DNA nets that catch tumour cells after surgery","route":"/ideas/idea-bio2-net-blockade-perioperative/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-perioperative-betablocker-nsaid","kind":"idea","name":"Cheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress","route":"/ideas/idea-bio2-perioperative-betablocker-nsaid/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-premetastatic-niche-assay","kind":"idea","name":"A blood test for the pre-metastatic niche","route":"/ideas/idea-bio2-premetastatic-niche-assay/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-inhaled-lung-niche-immunotherapy","kind":"idea","name":"Inhaled immune therapy to make the lung hostile to arriving tumour cells","route":"/ideas/idea-bio2-inhaled-lung-niche-immunotherapy/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-liver-niche-kupffer-reprogramming","kind":"idea","name":"Reprogramme the liver's own immune cells to refuse metastases","route":"/ideas/idea-bio2-liver-niche-kupffer-reprogramming/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-cxcr4-mobilise-then-kill","kind":"idea","name":"Flush dormant cells out of bone marrow, then kill them","route":"/ideas/idea-bio2-cxcr4-mobilise-then-kill/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-platelet-cloak-aspirin-mrd","kind":"idea","name":"Strip the platelet coat off travelling tumour cells in ctDNA-positive patients","route":"/ideas/idea-bio2-platelet-cloak-aspirin-mrd/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-rapid-autopsy-commons","kind":"idea","name":"A global rapid tissue donation network for metastatic disease","route":"/ideas/idea-bio2-rapid-autopsy-commons/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-metastasis-screen-standard","kind":"idea","name":"Make in vivo metastasis screens a required step in drug discovery","route":"/ideas/idea-bio2-metastasis-screen-standard/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-ctc-culture-functional-testing","kind":"idea","name":"Grow blood-borne tumour cells to test drugs on the cells that actually spread","route":"/ideas/idea-bio2-ctc-culture-functional-testing/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-lymph-node-immune-priming","kind":"idea","name":"Treat the draining lymph node before removing it","route":"/ideas/idea-bio2-lymph-node-immune-priming/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-organotropism-atlas","kind":"idea","name":"An organotropism atlas that predicts where a cancer will spread","route":"/ideas/idea-bio2-organotropism-atlas/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-metastasis-funding-floor","kind":"idea","name":"Ring-fence a fifth of national cancer research money for metastasis","route":"/ideas/idea-bio2-metastasis-funding-floor/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-matrix-stiffness-prevention","kind":"idea","name":"Soften the tissue that new metastases need in order to grow","route":"/ideas/idea-bio2-matrix-stiffness-prevention/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-brain-met-prevention-trials","kind":"idea","name":"Prevention trials aimed only at brain metastasis","route":"/ideas/idea-bio2-brain-met-prevention-trials/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-oligometastatic-signature","kind":"idea","name":"A test to tell true oligometastatic disease from hidden widespread spread","route":"/ideas/idea-bio2-oligometastatic-signature/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-dormancy-selective-screen","kind":"idea","name":"A drug screen that only rewards killing sleeping cancer cells","route":"/ideas/idea-bio2-dormancy-selective-screen/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-autophagy-block-mrd","kind":"idea","name":"Block the recycling that keeps dormant cells alive","route":"/ideas/idea-bio2-autophagy-block-mrd/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-pro-dormancy-therapy","kind":"idea","name":"Keep dormant cells asleep instead of trying to kill them","route":"/ideas/idea-bio2-pro-dormancy-therapy/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-il1-awakening-blockade","kind":"idea","name":"Blunt the inflammation that wakes sleeping cancer cells","route":"/ideas/idea-bio2-il1-awakening-blockade/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-national-mrd-platform","kind":"idea","name":"A national platform trial that every ctDNA-positive patient can join","route":"/ideas/idea-bio2-national-mrd-platform/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-mrd-reference-standards","kind":"idea","name":"Reference materials and open proficiency testing for residual disease tests","route":"/ideas/idea-bio2-mrd-reference-standards/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-mrd-triggered-neoantigen-vaccine","kind":"idea","name":"Personalised vaccines given only when the blood test turns positive","route":"/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-nk-cells-for-mrd","kind":"idea","name":"Off-the-shelf natural killer cells to sweep up residual disease","route":"/ideas/idea-bio2-nk-cells-for-mrd/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-whole-genome-mrd-depth","kind":"idea","name":"Push residual disease detection a hundredfold deeper with whole-genome methods","route":"/ideas/idea-bio2-whole-genome-mrd-depth/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-marrow-niche-on-chip","kind":"idea","name":"A bone marrow niche on a chip to study human dormancy","route":"/ideas/idea-bio2-marrow-niche-on-chip/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-localise-the-mrd","kind":"idea","name":"When the blood test is positive, hunt for the lesion with sensitive imaging","route":"/ideas/idea-bio2-localise-the-mrd/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-circadian-mrd-sampling","kind":"idea","name":"Take the blood test, and give the drug, at the right time of day","route":"/ideas/idea-bio2-circadian-mrd-sampling/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-mrd-guided-endocrine-duration","kind":"idea","name":"Use residual disease tests to decide who needs ten years of hormone therapy","route":"/ideas/idea-bio2-mrd-guided-endocrine-duration/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-mrd-coverage-with-evidence","kind":"idea","name":"Pay for residual disease tests only inside a trial or registry","route":"/ideas/idea-bio2-mrd-coverage-with-evidence/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-mrd-clinic-service","kind":"idea","name":"A dedicated clinic for people whose blood test says the cancer is back","route":"/ideas/idea-bio2-mrd-clinic-service/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-survivor-plasma-biobank","kind":"idea","name":"Bank yearly blood from cancer survivors so future tests can be validated","route":"/ideas/idea-bio2-survivor-plasma-biobank/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-trem2-myeloid-reprogramming","kind":"idea","name":"Reprogramme suppressive macrophages instead of trying to delete them","route":"/ideas/idea-bio2-trem2-myeloid-reprogramming/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-in-situ-vaccination-solid","kind":"idea","name":"Turn one tumour into a vaccine to treat all the others","route":"/ideas/idea-bio2-in-situ-vaccination-solid/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-oncolytic-regulated-il12","kind":"idea","name":"Oncolytic viruses that make interleukin-12 only inside the tumour","route":"/ideas/idea-bio2-oncolytic-regulated-il12/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-engineered-bacteria-payloads","kind":"idea","name":"Engineered bacteria that live in tumours and manufacture drugs there","route":"/ideas/idea-bio2-engineered-bacteria-payloads/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-tumour-anchored-tgfbeta-trap","kind":"idea","name":"Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere","route":"/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-lactate-acid-axis","kind":"idea","name":"De-acidify the tumour so T cells can work in it","route":"/ideas/idea-bio2-lactate-acid-axis/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-radiotherapy-sting-fractionation","kind":"idea","name":"Pick the radiation dose that switches the immune alarm on, not off","route":"/ideas/idea-bio2-radiotherapy-sting-fractionation/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-tertiary-lymphoid-induction","kind":"idea","name":"Grow immune command posts inside tumours","route":"/ideas/idea-bio2-tertiary-lymphoid-induction/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-cxcr2-neutrophil-blockade","kind":"idea","name":"Clear the suppressive neutrophils out of pancreatic tumours first","route":"/ideas/idea-bio2-cxcr2-neutrophil-blockade/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-caf-subtype-assignment","kind":"idea","name":"Match therapy to the type of scar-forming cell in the tumour","route":"/ideas/idea-bio2-caf-subtype-assignment/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-implantable-microdevice-screen","kind":"idea","name":"Implant a tiny device that tests twenty drugs inside the patient's own tumour","route":"/ideas/idea-bio2-implantable-microdevice-screen/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-vascular-normalisation-window","kind":"idea","name":"Use imaging to find the window when tumour blood vessels are working properly","route":"/ideas/idea-bio2-vascular-normalisation-window/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-complement-c5ar-blockade","kind":"idea","name":"Block the complement signal that recruits tumour-protecting cells","route":"/ideas/idea-bio2-complement-c5ar-blockade/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-intracavitary-immunotherapy","kind":"idea","name":"Treat the body cavity, not the bloodstream, for surface spread","route":"/ideas/idea-bio2-intracavitary-immunotherapy/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-myeloid-engager-bispecific","kind":"idea","name":"Bispecific antibodies that engage macrophages instead of T cells","route":"/ideas/idea-bio2-myeloid-engager-bispecific/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-hypoxia-guided-adenosine","kind":"idea","name":"Use a hypoxia scan to pick patients for adenosine-pathway drugs","route":"/ideas/idea-bio2-hypoxia-guided-adenosine/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-histotripsy-immune-priming","kind":"idea","name":"Mechanically pulverise one tumour with ultrasound to wake the immune system","route":"/ideas/idea-bio2-histotripsy-immune-priming/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-trained-immunity-priming","kind":"idea","name":"Train the bone marrow to make better anti-tumour immune cells","route":"/ideas/idea-bio2-trained-immunity-priming/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-sonobiopsy","kind":"idea","name":"Ultrasound-assisted blood test instead of a brain biopsy","route":"/ideas/idea-bio2-sonobiopsy/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-intraventricular-car-t","kind":"idea","name":"Deliver CAR-T cells straight into the fluid around the brain","route":"/ideas/idea-bio2-intraventricular-car-t/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-robotic-convection-delivery","kind":"idea","name":"Robot-placed catheters and live imaging for drug infusion into brain tumours","route":"/ideas/idea-bio2-robotic-convection-delivery/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-transferrin-shuttle-adc","kind":"idea","name":"Use the brain's own transport door to carry antibody drugs across","route":"/ideas/idea-bio2-transferrin-shuttle-adc/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-implanted-ultrasound-repeat-dosing","kind":"idea","name":"A skull ultrasound implant that opens the barrier at every cycle","route":"/ideas/idea-bio2-implanted-ultrasound-repeat-dosing/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-cns-cohort-mandate","kind":"idea","name":"Stop excluding brain metastases from cancer trials","route":"/ideas/idea-bio2-cns-cohort-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-csf-ctdna-monitoring","kind":"idea","name":"Read the spinal fluid to track brain tumours without opening the skull","route":"/ideas/idea-bio2-csf-ctdna-monitoring/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-brain-exposure-disclosure","kind":"idea","name":"Require every oncology candidate to publish how much reaches the brain","route":"/ideas/idea-bio2-brain-exposure-disclosure/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-intranasal-delivery","kind":"idea","name":"Deliver drugs and cells to the brain through the nose","route":"/ideas/idea-bio2-intranasal-delivery/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-blood-csf-barrier-model","kind":"idea","name":"Build a human model of the barrier that guards the brain fluid","route":"/ideas/idea-bio2-blood-csf-barrier-model/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-fus-for-cell-entry","kind":"idea","name":"Open the barrier so engineered immune cells can enter the brain","route":"/ideas/idea-bio2-fus-for-cell-entry/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-brain-penetrant-glue-degraders","kind":"idea","name":"Design protein degraders small enough to get into the brain","route":"/ideas/idea-bio2-brain-penetrant-glue-degraders/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-gdf15-plus-exercise","kind":"idea","name":"Combine the new anti-wasting antibody with exercise and protein","route":"/ideas/idea-bio2-gdf15-plus-exercise/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-gdf15-stratified-enrolment","kind":"idea","name":"Select cachexia trial patients by the hormone driving their wasting","route":"/ideas/idea-bio2-gdf15-stratified-enrolment/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-cachexia-function-endpoint","kind":"idea","name":"Qualify a physical function endpoint so anti-wasting drugs can be approved","route":"/ideas/idea-bio2-cachexia-function-endpoint/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-prehabilitation-standard","kind":"idea","name":"Four weeks of training and nutrition before major cancer surgery, as standard","route":"/ideas/idea-bio2-prehabilitation-standard/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-exercise-reimbursement","kind":"idea","name":"Pay for supervised exercise the way we pay for drugs","route":"/ideas/idea-bio2-exercise-reimbursement/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-anamorelin-access","kind":"idea","name":"Get the one approved appetite drug licensed beyond a single country","route":"/ideas/idea-bio2-anamorelin-access/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-ai-sarcopenia-from-ct","kind":"idea","name":"Read muscle loss automatically from scans patients already have","route":"/ideas/idea-bio2-ai-sarcopenia-from-ct/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-lean-mass-dosing","kind":"idea","name":"Dose chemotherapy by muscle mass, not body surface area","route":"/ideas/idea-bio2-lean-mass-dosing/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-low-dose-olanzapine-appetite","kind":"idea","name":"A cheap old tablet to restore appetite","route":"/ideas/idea-bio2-low-dose-olanzapine-appetite/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-cachexia-pathway-code","kind":"idea","name":"Treat wasting like sepsis: a trigger, a bundle, an audit","route":"/ideas/idea-bio2-cachexia-pathway-code/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-protein-plus-training-during-io","kind":"idea","name":"Test protein and resistance training during immunotherapy","route":"/ideas/idea-bio2-protein-plus-training-during-io/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-remote-weight-step-monitoring","kind":"idea","name":"Catch wasting early with a smart scale and a step counter","route":"/ideas/idea-bio2-remote-weight-step-monitoring/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-rare-cancer-umbrella-platform","kind":"idea","name":"One standing umbrella trial for all rare cancers in a country","route":"/ideas/idea-bio2-rare-cancer-umbrella-platform/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-n-of-1-framework","kind":"idea","name":"A standing rulebook for one-patient treatments","route":"/ideas/idea-bio2-n-of-1-framework/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-paediatric-first-development","kind":"idea","name":"Develop drugs in children first when the target is a children's target","route":"/ideas/idea-bio2-paediatric-first-development/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-rare-cancer-telepathology-network","kind":"idea","name":"A same-week expert second opinion for every rare cancer diagnosis","route":"/ideas/idea-bio2-rare-cancer-telepathology-network/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-functional-precision-rare","kind":"idea","name":"Test drugs on the patient's own cancer cells when there is no trial to join","route":"/ideas/idea-bio2-functional-precision-rare/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-rare-cancer-prize-fund","kind":"idea","name":"Pay a prize for rare cancer drugs instead of hoping for a market","route":"/ideas/idea-bio2-rare-cancer-prize-fund/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the registry that already follows every patient","route":"/ideas/idea-bio2-registry-embedded-randomisation/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-patient-partnered-rare-commons","kind":"idea","name":"Let patients themselves donate their records and samples for ultra-rare cancers","route":"/ideas/idea-bio2-patient-partnered-rare-commons/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-mechanism-defined-baskets","kind":"idea","name":"Group trials by broken mechanism, not by organ or single mutation","route":"/ideas/idea-bio2-mechanism-defined-baskets/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-shared-compound-access-pool","kind":"idea","name":"A shared compound library that rare cancer researchers can actually use","route":"/ideas/idea-bio2-shared-compound-access-pool/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-bayesian-borrowing-acceptance","kind":"idea","name":"Agree in advance how to borrow evidence between similar rare cancers","route":"/ideas/idea-bio2-bayesian-borrowing-acceptance/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-rare-tumour-model-bank","kind":"idea","name":"An open model bank for the rare tumours nobody has models for","route":"/ideas/idea-bio2-rare-tumour-model-bank/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-tcr-repertoire-early-readout","kind":"idea","name":"Watch the immune system's response in the blood three weeks in","route":"/ideas/idea-bio2-tcr-repertoire-early-readout/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-fmt-plus-checkpoint-phase3","kind":"idea","name":"Take faecal transplant plus immunotherapy to a definitive trial","route":"/ideas/idea-bio2-fmt-plus-checkpoint-phase3/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-antibiotic-stewardship-io","kind":"idea","name":"Protect the gut flora of patients about to start immunotherapy","route":"/ideas/idea-bio2-antibiotic-stewardship-io/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-spatial-signature-cdx","kind":"idea","name":"Turn the map of immune cells inside a tumour into a standardised test","route":"/ideas/idea-bio2-spatial-signature-cdx/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-ctdna-six-week-io-switch","kind":"idea","name":"Use a blood test at six weeks to decide whether to keep going","route":"/ideas/idea-bio2-ctdna-six-week-io-switch/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-io-biomarker-data-commons","kind":"idea","name":"Pool every immunotherapy trial's biomarker data into one commons","route":"/ideas/idea-bio2-io-biomarker-data-commons/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-til-reactivity-selection","kind":"idea","name":"Select patients for cell therapy by whether their tumour holds reactive T cells","route":"/ideas/idea-bio2-til-reactivity-selection/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-antigen-presentation-triage","kind":"idea","name":"Check whether a tumour can still show itself to the immune system","route":"/ideas/idea-bio2-antigen-presentation-triage/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-epigenetic-priming-cold-tumours","kind":"idea","name":"Unmask hidden antigens with a short epigenetic course before immunotherapy","route":"/ideas/idea-bio2-epigenetic-priming-cold-tumours/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-neoadjuvant-biomarker-engine","kind":"idea","name":"Use pre-surgery immunotherapy windows as the field's biomarker engine","route":"/ideas/idea-bio2-neoadjuvant-biomarker-engine/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-steroid-sparing-irae","kind":"idea","name":"Treat immunotherapy side-effects without wiping out the response","route":"/ideas/idea-bio2-steroid-sparing-irae/","asOf":"2026-09-08","days":1},{"id":"idea-bio2-fibre-diet-io-trial","kind":"idea","name":"Test a high-fibre diet as an immunotherapy adjunct","route":"/ideas/idea-bio2-fibre-diet-io-trial/","asOf":"2026-09-08","days":1},{"id":"idea-prev-mced-stage-endpoint-surrogate","kind":"idea","name":"Let MCED trials read out on late-stage incidence, with mortality follow-up mandated","route":"/ideas/idea-prev-mced-stage-endpoint-surrogate/","asOf":"2026-09-08","days":1},{"id":"idea-prev-mced-registry-randomised","kind":"idea","name":"Registry-based randomised MCED trial: a million people, no study visits","route":"/ideas/idea-prev-mced-registry-randomised/","asOf":"2026-09-08","days":1},{"id":"idea-prev-mced-change-control-plan","kind":"idea","name":"Pre-agreed update rules so an MCED test is not obsolete when its trial reads out","route":"/ideas/idea-prev-mced-change-control-plan/","asOf":"2026-09-08","days":1},{"id":"idea-prev-mced-positive-resolution-pathway","kind":"idea","name":"A 28-day national pathway for people with a positive multi-cancer blood test","route":"/ideas/idea-prev-mced-positive-resolution-pathway/","asOf":"2026-09-08","days":1},{"id":"idea-prev-interval-cancer-audit-blood-tests","kind":"idea","name":"Mandatory interval-cancer audit for every blood-based screening test","route":"/ideas/idea-prev-interval-cancer-audit-blood-tests/","asOf":"2026-09-08","days":1},{"id":"idea-prev-ai-mammogram-risk-intervals","kind":"idea","name":"Set each woman's mammogram interval from her last mammogram, using AI risk","route":"/ideas/idea-prev-ai-mammogram-risk-intervals/","asOf":"2026-09-08","days":1},{"id":"idea-prev-lung-screening-risk-model-eligibility","kind":"idea","name":"Lung screening eligibility by risk score, not pack-years, including high-risk never-smokers","route":"/ideas/idea-prev-lung-screening-risk-model-eligibility/","asOf":"2026-09-08","days":1},{"id":"idea-prev-ldct-ai-negative-triage","kind":"idea","name":"AI clears the normal lung screening scans so radiologists read only the suspicious ones","route":"/ideas/idea-prev-ldct-ai-negative-triage/","asOf":"2026-09-08","days":1},{"id":"idea-prev-mammography-ai-stepped-wedge","kind":"idea","name":"Roll out AI-supported mammography nationally as a stepped-wedge trial","route":"/ideas/idea-prev-mammography-ai-stepped-wedge/","asOf":"2026-09-08","days":1},{"id":"idea-prev-opportunistic-ct-ai-registry","kind":"idea","name":"Every routine CT scan checked by AI for early cancer signs, with a tracked follow-up pathway","route":"/ideas/idea-prev-opportunistic-ct-ai-registry/","asOf":"2026-09-08","days":1},{"id":"idea-prev-pancreas-ai-prediagnostic-ct","kind":"idea","name":"AI that spots pancreatic cancer on scans taken a year before diagnosis","route":"/ideas/idea-prev-pancreas-ai-prediagnostic-ct/","asOf":"2026-09-08","days":1},{"id":"idea-prev-new-onset-diabetes-pancreas-pathway","kind":"idea","name":"New diabetes after 50 plus weight loss triggers a pancreatic cancer check","route":"/ideas/idea-prev-new-onset-diabetes-pancreas-pathway/","asOf":"2026-09-08","days":1},{"id":"idea-prev-breath-voc-symptomatic-ruleout","kind":"idea","name":"A breath test to rule out cancer in people with vague symptoms","route":"/ideas/idea-prev-breath-voc-symptomatic-ruleout/","asOf":"2026-09-08","days":1},{"id":"idea-prev-urine-dna-haematuria-triage","kind":"idea","name":"A urine DNA test to decide who with blood in the urine needs a camera test","route":"/ideas/idea-prev-urine-dna-haematuria-triage/","asOf":"2026-09-08","days":1},{"id":"idea-prev-weight-loss-auto-alert","kind":"idea","name":"Smart scales and health records flag unexplained weight loss for a cancer check","route":"/ideas/idea-prev-weight-loss-auto-alert/","asOf":"2026-09-08","days":1},{"id":"idea-prev-cgm-glycaemic-drift-pancreas","kind":"idea","name":"Glucose monitor data as an early pancreatic cancer signal","route":"/ideas/idea-prev-cgm-glycaemic-drift-pancreas/","asOf":"2026-09-08","days":1},{"id":"idea-prev-ehr-symptom-signature-prompts","kind":"idea","name":"Cancer risk scores running automatically in GP records to prompt urgent referral","route":"/ideas/idea-prev-ehr-symptom-signature-prompts/","asOf":"2026-09-08","days":1},{"id":"idea-prev-mced-non-specific-symptom-triage","kind":"idea","name":"Multi-cancer blood test as the first step for patients with non-specific symptoms","route":"/ideas/idea-prev-mced-non-specific-symptom-triage/","asOf":"2026-09-08","days":1},{"id":"idea-prev-blood-count-trend-flags","kind":"idea","name":"Use the trend in routine blood counts, not a single threshold, to spot cancer","route":"/ideas/idea-prev-blood-count-trend-flags/","asOf":"2026-09-08","days":1},{"id":"idea-prev-fit-risk-adapted-thresholds","kind":"idea","name":"Personalised stool-test cut-offs by age, sex and prior results","route":"/ideas/idea-prev-fit-risk-adapted-thresholds/","asOf":"2026-09-08","days":1},{"id":"idea-prev-blood-crc-test-for-non-responders","kind":"idea","name":"Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy","route":"/ideas/idea-prev-blood-crc-test-for-non-responders/","asOf":"2026-09-08","days":1},{"id":"idea-prev-capsule-sponge-pharmacy","kind":"idea","name":"A swallowable sponge test for reflux patients, offered in pharmacies","route":"/ideas/idea-prev-capsule-sponge-pharmacy/","asOf":"2026-09-08","days":1},{"id":"idea-prev-gastric-serology-migrant-screening","kind":"idea","name":"Stomach cancer serology screening for high-risk migrant communities in low-incidence countries","route":"/ideas/idea-prev-gastric-serology-migrant-screening/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hcc-blood-surveillance-cirrhosis","kind":"idea","name":"Replace six-monthly ultrasound with a blood test for liver cancer in cirrhosis","route":"/ideas/idea-prev-hcc-blood-surveillance-cirrhosis/","asOf":"2026-09-08","days":1},{"id":"idea-prev-mri-first-prostate-screening-prs","kind":"idea","name":"MRI-first prostate screening with genetic pre-selection","route":"/ideas/idea-prev-mri-first-prostate-screening-prs/","asOf":"2026-09-08","days":1},{"id":"idea-prev-oral-cancer-community-smartphone-ai","kind":"idea","name":"Community health workers with smartphone AI screen for mouth cancer in South Asia","route":"/ideas/idea-prev-oral-cancer-community-smartphone-ai/","asOf":"2026-09-08","days":1},{"id":"idea-prev-lmic-five-cancer-methylation-test","kind":"idea","name":"A ten-dollar blood test for the five cancers that kill most people in poorer countries","route":"/ideas/idea-prev-lmic-five-cancer-methylation-test/","asOf":"2026-09-08","days":1},{"id":"idea-prev-fragmentomics-first-tier","kind":"idea","name":"Cheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests","route":"/ideas/idea-prev-fragmentomics-first-tier/","asOf":"2026-09-08","days":1},{"id":"idea-prev-live-stage-dashboard","kind":"idea","name":"A live national dashboard of stage at diagnosis as the scorecard for early detection","route":"/ideas/idea-prev-live-stage-dashboard/","asOf":"2026-09-08","days":1},{"id":"idea-prev-open-stage-shift-microsimulation","kind":"idea","name":"Open-source models that translate stage shift into lives saved, for every cancer","route":"/ideas/idea-prev-open-stage-shift-microsimulation/","asOf":"2026-09-08","days":1},{"id":"idea-prev-emergency-department-cancer-test","kind":"idea","name":"A cancer blood test for older people arriving at A&E with unexplained symptoms","route":"/ideas/idea-prev-emergency-department-cancer-test/","asOf":"2026-09-08","days":1},{"id":"idea-prev-mobile-lung-screening-deprived-areas","kind":"idea","name":"Take lung screening scanners to supermarket car parks in the poorest areas","route":"/ideas/idea-prev-mobile-lung-screening-deprived-areas/","asOf":"2026-09-08","days":1},{"id":"idea-prev-ebv-dna-npc-screening-scaleup","kind":"idea","name":"Blood EBV DNA screening for nasopharyngeal cancer across southern China and Southeast Asia","route":"/ideas/idea-prev-ebv-dna-npc-screening-scaleup/","asOf":"2026-09-08","days":1},{"id":"idea-prev-dental-oral-exam-standard","kind":"idea","name":"Make a two-minute mouth cancer check part of every dental visit","route":"/ideas/idea-prev-dental-oral-exam-standard/","asOf":"2026-09-08","days":1},{"id":"idea-prev-bundled-cancer-check-at-60","kind":"idea","name":"A single 'cancer check at 60' appointment bundling all screening tests","route":"/ideas/idea-prev-bundled-cancer-check-at-60/","asOf":"2026-09-08","days":1},{"id":"idea-prev-thyroid-no-screening-no-small-biopsy","kind":"idea","name":"Stop biopsying small thyroid nodules and never screen the thyroid","route":"/ideas/idea-prev-thyroid-no-screening-no-small-biopsy/","asOf":"2026-09-08","days":1},{"id":"idea-prev-ptmc-active-surveillance-default","kind":"idea","name":"Active surveillance as the default for tiny papillary thyroid cancers","route":"/ideas/idea-prev-ptmc-active-surveillance-default/","asOf":"2026-09-08","days":1},{"id":"idea-prev-low-risk-dcis-surveillance-pathway","kind":"idea","name":"After the COMET trial: surveillance pathways and a new name for low-risk DCIS","route":"/ideas/idea-prev-low-risk-dcis-surveillance-pathway/","asOf":"2026-09-08","days":1},{"id":"idea-prev-indolent-lesion-nomenclature-body","kind":"idea","name":"An international body to rename indolent lesions so 'cancer' means something","route":"/ideas/idea-prev-indolent-lesion-nomenclature-body/","asOf":"2026-09-08","days":1},{"id":"idea-prev-gleason6-terminology-rct","kind":"idea","name":"Test whether calling Gleason 6 'not cancer' changes what men choose","route":"/ideas/idea-prev-gleason6-terminology-rct/","asOf":"2026-09-08","days":1},{"id":"idea-prev-prostate-as-triggered-biopsy","kind":"idea","name":"Prostate active surveillance without scheduled biopsies: MRI and blood tests decide","route":"/ideas/idea-prev-prostate-as-triggered-biopsy/","asOf":"2026-09-08","days":1},{"id":"idea-prev-small-renal-mass-surveillance","kind":"idea","name":"Watch small kidney tumours rather than remove them, with a national registry","route":"/ideas/idea-prev-small-renal-mass-surveillance/","asOf":"2026-09-08","days":1},{"id":"idea-prev-lung-nodule-ai-discharge","kind":"idea","name":"AI malignancy scores to end repeat scans and biopsies for benign lung nodules","route":"/ideas/idea-prev-lung-nodule-ai-discharge/","asOf":"2026-09-08","days":1},{"id":"idea-prev-blood-precursor-watch-registry","kind":"idea","name":"A watch-and-wait registry for blood precursor conditions found by chance","route":"/ideas/idea-prev-blood-precursor-watch-registry/","asOf":"2026-09-08","days":1},{"id":"idea-prev-annual-overdiagnosis-reporting","kind":"idea","name":"Every screening programme must publish its overdiagnosis rate each year","route":"/ideas/idea-prev-annual-overdiagnosis-reporting/","asOf":"2026-09-08","days":1},{"id":"idea-prev-screening-stop-by-life-expectancy","kind":"idea","name":"Stop screening by life expectancy, not birthday, with a tool in the record","route":"/ideas/idea-prev-screening-stop-by-life-expectancy/","asOf":"2026-09-08","days":1},{"id":"idea-prev-mced-pretest-decision-aid","kind":"idea","name":"A mandatory decision aid before any multi-cancer blood test","route":"/ideas/idea-prev-mced-pretest-decision-aid/","asOf":"2026-09-08","days":1},{"id":"idea-prev-barrett-surveillance-deescalation","kind":"idea","name":"Stop routine endoscopies for non-dysplastic Barrett's oesophagus","route":"/ideas/idea-prev-barrett-surveillance-deescalation/","asOf":"2026-09-08","days":1},{"id":"idea-prev-melanoma-ai-thick-melanoma-metric","kind":"idea","name":"Judge skin cancer AI by the thick melanomas it prevents, not the thin ones it finds","route":"/ideas/idea-prev-melanoma-ai-thick-melanoma-metric/","asOf":"2026-09-08","days":1},{"id":"idea-prev-incidentaloma-natural-history-cohort","kind":"idea","name":"A ten-year cohort of incidental findings to calibrate follow-up guidelines","route":"/ideas/idea-prev-incidentaloma-natural-history-cohort/","asOf":"2026-09-08","days":1},{"id":"idea-prev-ipmn-surveillance-stop-rule","kind":"idea","name":"Stop watching stable low-risk pancreatic cysts after five years","route":"/ideas/idea-prev-ipmn-surveillance-stop-rule/","asOf":"2026-09-08","days":1},{"id":"idea-prev-pathology-ai-borderline-anchor","kind":"idea","name":"AI second reads to stop borderline lesions being upgraded to cancer","route":"/ideas/idea-prev-pathology-ai-borderline-anchor/","asOf":"2026-09-08","days":1},{"id":"idea-prev-frail-elderly-primary-endocrine-breast","kind":"idea","name":"Hormone tablets instead of surgery for small breast cancers in the frail over-80s","route":"/ideas/idea-prev-frail-elderly-primary-endocrine-breast/","asOf":"2026-09-08","days":1},{"id":"idea-prev-omit-radiotherapy-low-risk-breast-default","kind":"idea","name":"Make skipping radiotherapy the default for very low-risk breast cancer","route":"/ideas/idea-prev-omit-radiotherapy-low-risk-breast-default/","asOf":"2026-09-08","days":1},{"id":"idea-prev-modern-autopsy-reservoir-studies","kind":"idea","name":"Modern autopsy studies to measure how much silent cancer people carry","route":"/ideas/idea-prev-modern-autopsy-reservoir-studies/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hpv-single-dose-switch-catchup","kind":"idea","name":"Switch every country to single-dose HPV vaccination and add catch-up to age 26","route":"/ideas/idea-prev-hpv-single-dose-switch-catchup/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hpv-vaccinate-at-screening","kind":"idea","name":"Offer HPV vaccination to women when they come for cervical screening or treatment","route":"/ideas/idea-prev-hpv-vaccinate-at-screening/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hpv-self-sampling-mailed-default","kind":"idea","name":"Post every woman an HPV self-test kit instead of asking her to book a smear","route":"/ideas/idea-prev-hpv-self-sampling-mailed-default/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hpv-same-day-screen-and-treat","kind":"idea","name":"Same-day HPV test and heat treatment of precancer by nurses in low-income settings","route":"/ideas/idea-prev-hpv-same-day-screen-and-treat/","asOf":"2026-09-08","days":1},{"id":"idea-prev-therapeutic-hpv-vaccine-cin","kind":"idea","name":"A therapeutic vaccine to clear cervical precancer without surgery","route":"/ideas/idea-prev-therapeutic-hpv-vaccine-cin/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hbv-treat-all-hcc","kind":"idea","name":"Treat everyone with chronic hepatitis B to prevent liver cancer","route":"/ideas/idea-prev-hbv-treat-all-hcc/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hcv-test-treat-surveillance-linkage","kind":"idea","name":"Cure hepatitis C in prisons and drug services, and enrol the cured in liver cancer surveillance","route":"/ideas/idea-prev-hcv-test-treat-surveillance-linkage/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hpylori-family-test-and-treat","kind":"idea","name":"Family-based H. pylori test-and-treat to prevent stomach cancer","route":"/ideas/idea-prev-hpylori-family-test-and-treat/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hpylori-stool-resistance-guided","kind":"idea","name":"Antibiotic-resistance testing from a stool sample before treating H. pylori","route":"/ideas/idea-prev-hpylori-stool-resistance-guided/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hpylori-childhood-vaccine","kind":"idea","name":"A vaccine against H. pylori for children in high-risk regions","route":"/ideas/idea-prev-hpylori-childhood-vaccine/","asOf":"2026-09-08","days":1},{"id":"idea-prev-smokefree-generation-evaluation","kind":"idea","name":"Smoke-free generation laws with a built-in evaluation across countries","route":"/ideas/idea-prev-smokefree-generation-evaluation/","asOf":"2026-09-08","days":1},{"id":"idea-prev-very-low-nicotine-mandate","kind":"idea","name":"Make cigarettes non-addictive by capping their nicotine","route":"/ideas/idea-prev-very-low-nicotine-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-prev-opt-out-cessation-in-lung-screening","kind":"idea","name":"Every lung screening visit includes stop-smoking medicine, opt-out","route":"/ideas/idea-prev-opt-out-cessation-in-lung-screening/","asOf":"2026-09-08","days":1},{"id":"idea-prev-cytisine-essential-medicine","kind":"idea","name":"Put cytisine, a cheap plant-based quit-smoking pill, on every essential medicines list","route":"/ideas/idea-prev-cytisine-essential-medicine/","asOf":"2026-09-08","days":1},{"id":"idea-prev-alcohol-cancer-warning-labels","kind":"idea","name":"Cancer warnings on alcohol labels, evaluated as a natural experiment","route":"/ideas/idea-prev-alcohol-cancer-warning-labels/","asOf":"2026-09-08","days":1},{"id":"idea-prev-minimum-unit-pricing-cancer-endpoints","kind":"idea","name":"Minimum alcohol pricing evaluated with cancer endpoints","route":"/ideas/idea-prev-minimum-unit-pricing-cancer-endpoints/","asOf":"2026-09-08","days":1},{"id":"idea-prev-glp1-cancer-prevention-rct","kind":"idea","name":"A trial of GLP-1 weight-loss drugs with cancer as the primary outcome","route":"/ideas/idea-prev-glp1-cancer-prevention-rct/","asOf":"2026-09-08","days":1},{"id":"idea-prev-glp1-endometrial-hyperplasia","kind":"idea","name":"GLP-1 drugs to reverse endometrial precancer in women with obesity","route":"/ideas/idea-prev-glp1-endometrial-hyperplasia/","asOf":"2026-09-08","days":1},{"id":"idea-prev-chemoprevention-master-protocol","kind":"idea","name":"One master trial for cancer prevention drugs across many precancers","route":"/ideas/idea-prev-chemoprevention-master-protocol/","asOf":"2026-09-08","days":1},{"id":"idea-prev-low-dose-tamoxifen-uptake","kind":"idea","name":"Low-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses","route":"/ideas/idea-prev-low-dose-tamoxifen-uptake/","asOf":"2026-09-08","days":1},{"id":"idea-prev-opportunistic-salpingectomy-default","kind":"idea","name":"Remove the fallopian tubes during any pelvic surgery once childbearing is finished","route":"/ideas/idea-prev-opportunistic-salpingectomy-default/","asOf":"2026-09-08","days":1},{"id":"idea-prev-commercial-sunbed-ban","kind":"idea","name":"Ban commercial sunbeds","route":"/ideas/idea-prev-commercial-sunbed-ban/","asOf":"2026-09-08","days":1},{"id":"idea-prev-radon-testing-at-property-sale","kind":"idea","name":"Mandatory radon testing when homes are sold, with subsidised mitigation","route":"/ideas/idea-prev-radon-testing-at-property-sale/","asOf":"2026-09-08","days":1},{"id":"idea-prev-clean-air-never-smoker-endpoints","kind":"idea","name":"Evaluate clean-air policies using lung cancer in never-smokers","route":"/ideas/idea-prev-clean-air-never-smoker-endpoints/","asOf":"2026-09-08","days":1},{"id":"idea-prev-screening-default-appointments","kind":"idea","name":"Send screening invitations with a pre-booked time, not a request to call","route":"/ideas/idea-prev-screening-default-appointments/","asOf":"2026-09-08","days":1},{"id":"idea-prev-pharmacy-prevention-hub","kind":"idea","name":"Community pharmacies as one-stop cancer prevention hubs","route":"/ideas/idea-prev-pharmacy-prevention-hub/","asOf":"2026-09-08","days":1},{"id":"idea-prev-pay-for-prevention-outcomes","kind":"idea","name":"Pay insurers and health systems for cancers prevented and caught early","route":"/ideas/idea-prev-pay-for-prevention-outcomes/","asOf":"2026-09-08","days":1},{"id":"idea-prev-precursor-endpoints-for-approval","kind":"idea","name":"Regulators accept shrinking of precancer as the endpoint for prevention drug approval","route":"/ideas/idea-prev-precursor-endpoints-for-approval/","asOf":"2026-09-08","days":1},{"id":"idea-prev-hpv-male-catchup-oropharynx","kind":"idea","name":"Catch-up HPV vaccination for men to prevent throat cancer","route":"/ideas/idea-prev-hpv-male-catchup-oropharynx/","asOf":"2026-09-08","days":1},{"id":"idea-prev-ebv-vaccine","kind":"idea","name":"An Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomas","route":"/ideas/idea-prev-ebv-vaccine/","asOf":"2026-09-08","days":1},{"id":"idea-prev-cascade-direct-contact-relatives","kind":"idea","name":"Let clinics contact relatives directly when a cancer gene is found","route":"/ideas/idea-prev-cascade-direct-contact-relatives/","asOf":"2026-09-08","days":1},{"id":"idea-prev-population-germline-screening-at-30","kind":"idea","name":"Offer everyone at 30 a test for the cancer genes that matter","route":"/ideas/idea-prev-population-germline-screening-at-30/","asOf":"2026-09-08","days":1},{"id":"idea-prev-deferred-disclosure-newborn-genomes","kind":"idea","name":"Store adult-onset cancer gene results from newborn genomes and disclose at 18","route":"/ideas/idea-prev-deferred-disclosure-newborn-genomes/","asOf":"2026-09-08","days":1},{"id":"idea-prev-prs-screening-start-age","kind":"idea","name":"Use a polygenic risk score to set when screening starts","route":"/ideas/idea-prev-prs-screening-start-age/","asOf":"2026-09-08","days":1},{"id":"idea-prev-prs-ancestry-portability-standard","kind":"idea","name":"Build polygenic scores that work in every ancestry before deploying any","route":"/ideas/idea-prev-prs-ancestry-portability-standard/","asOf":"2026-09-08","days":1},{"id":"idea-prev-lynch-frameshift-vaccine-rct","kind":"idea","name":"A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers","route":"/ideas/idea-prev-lynch-frameshift-vaccine-rct/","asOf":"2026-09-08","days":1},{"id":"idea-prev-brca1-denosumab-prevention","kind":"idea","name":"A bone drug to prevent breast cancer in BRCA1 carriers","route":"/ideas/idea-prev-brca1-denosumab-prevention/","asOf":"2026-09-08","days":1},{"id":"idea-prev-lynch-aspirin-implementation","kind":"idea","name":"Get every Lynch syndrome carrier onto the right dose of aspirin","route":"/ideas/idea-prev-lynch-aspirin-implementation/","asOf":"2026-09-08","days":1},{"id":"idea-prev-reflex-germline-testing","kind":"idea","name":"Automatic germline testing for every cancer type where it changes care","route":"/ideas/idea-prev-reflex-germline-testing/","asOf":"2026-09-08","days":1},{"id":"idea-prev-traceback-deceased-probands","kind":"idea","name":"Go back to families of women who died of ovarian cancer and offer BRCA testing","route":"/ideas/idea-prev-traceback-deceased-probands/","asOf":"2026-09-08","days":1},{"id":"idea-prev-vus-saturation-editing-consortium","kind":"idea","name":"Test every possible mutation in every cancer gene so no result is 'uncertain'","route":"/ideas/idea-prev-vus-saturation-editing-consortium/","asOf":"2026-09-08","days":1},{"id":"idea-prev-li-fraumeni-mri-plus-cfdna","kind":"idea","name":"Whole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome","route":"/ideas/idea-prev-li-fraumeni-mri-plus-cfdna/","asOf":"2026-09-08","days":1},{"id":"idea-prev-genetic-counselling-chatbot","kind":"idea","name":"A chatbot for pre-test genetic counselling so counsellors see only who needs them","route":"/ideas/idea-prev-genetic-counselling-chatbot/","asOf":"2026-09-08","days":1},{"id":"idea-prev-family-history-auto-match","kind":"idea","name":"Family history collected by app and matched to testing criteria automatically","route":"/ideas/idea-prev-family-history-auto-match/","asOf":"2026-09-08","days":1},{"id":"idea-prev-genetic-non-discrimination-insurance","kind":"idea","name":"Ban life and disability insurers from using genetic results","route":"/ideas/idea-prev-genetic-non-discrimination-insurance/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-justify-every-exclusion","kind":"idea","name":"Default-inclusive eligibility: sponsors must justify every exclusion criterion","route":"/ideas/idea-tr1-justify-every-exclusion/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-brain-mets-default-included","kind":"idea","name":"Brain metastases included by default in every solid-tumour trial","route":"/ideas/idea-tr1-brain-mets-default-included/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-pk-informed-organ-thresholds","kind":"idea","name":"Replace fixed kidney and liver cut-offs with drug-specific, pharmacology-based thresholds","route":"/ideas/idea-tr1-pk-informed-organ-thresholds/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-prior-cancer-hiv-hepatitis-inclusion","kind":"idea","name":"Stop excluding people with a prior cancer, controlled HIV, or treated hepatitis","route":"/ideas/idea-tr1-prior-cancer-hiv-hepatitis-inclusion/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-ehr-point-of-care-trial-alert","kind":"idea","name":"Trial matching inside the electronic record at the moment a treatment is chosen","route":"/ideas/idea-tr1-ehr-point-of-care-trial-alert/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-tumour-board-trial-line-item","kind":"idea","name":"A mandatory trial line in every tumour board recommendation","route":"/ideas/idea-tr1-tumour-board-trial-line-item/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-ngs-report-live-trial-match","kind":"idea","name":"Every tumour sequencing report lists open, nearby, matched trials pulled live","route":"/ideas/idea-tr1-ngs-report-live-trial-match/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-just-in-time-site-network","kind":"idea","name":"Just-in-time site activation: open a site in two weeks when a patient appears","route":"/ideas/idea-tr1-just-in-time-site-network/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-national-master-trial-agreement","kind":"idea","name":"One national master contract and budget template for all cancer trials","route":"/ideas/idea-tr1-national-master-trial-agreement/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-mutual-recognition-ethics-review","kind":"idea","name":"Mutual recognition of ethics review across countries","route":"/ideas/idea-tr1-mutual-recognition-ethics-review/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-home-infusion-trial-drugs","kind":"idea","name":"Home infusion and local blood draws for trial drugs after the first cycles","route":"/ideas/idea-tr1-home-infusion-trial-drugs/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-remote-consent-tele-screening","kind":"idea","name":"Remote consent and tele-screening so the first trial visit is a video call","route":"/ideas/idea-tr1-remote-consent-tele-screening/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-community-site-quota","kind":"idea","name":"At least a third of pivotal-trial sites in community and rural settings","route":"/ideas/idea-tr1-community-site-quota/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-travel-lodging-in-every-budget","kind":"idea","name":"Travel, lodging and meals reimbursed as a standard line in every trial budget","route":"/ideas/idea-tr1-travel-lodging-in-every-budget/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-pay-participants-for-time","kind":"idea","name":"Pay trial participants for their time, not only their expenses","route":"/ideas/idea-tr1-pay-participants-for-time/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-lay-trial-navigators","kind":"idea","name":"Lay trial navigators funded per centre, evaluated in a randomised trial","route":"/ideas/idea-tr1-lay-trial-navigators/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-opt-out-research-contact-register","kind":"idea","name":"Every patient is asked once at diagnosis whether researchers may contact them","route":"/ideas/idea-tr1-opt-out-research-contact-register/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the cancer registry: registry-based trials for everyday questions","route":"/ideas/idea-tr1-registry-embedded-randomisation/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-rare-cancer-trial-in-a-box","kind":"idea","name":"Trial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer","route":"/ideas/idea-tr1-rare-cancer-trial-in-a-box/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-pre-consented-cohort-randomisation","kind":"idea","name":"Pre-consented cohorts that can be randomised to future trials (TwiCs)","route":"/ideas/idea-tr1-pre-consented-cohort-randomisation/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-public-screen-fail-reasons","kind":"idea","name":"Publish why patients were screened out of each trial","route":"/ideas/idea-tr1-public-screen-fail-reasons/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-eligibility-impact-statement","kind":"idea","name":"Simulate eligibility against real-world data before every protocol is locked","route":"/ideas/idea-tr1-eligibility-impact-statement/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-live-trial-slot-api","kind":"idea","name":"A live 'seats available' feed for trial slots, like airline inventory","route":"/ideas/idea-tr1-live-trial-slot-api/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-pathology-triggered-referral","kind":"idea","name":"The pathology lab triggers a trial referral the day a rare cancer is diagnosed","route":"/ideas/idea-tr1-pathology-triggered-referral/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-evening-weekend-trial-clinics","kind":"idea","name":"Evening and weekend trial clinics for working-age patients","route":"/ideas/idea-tr1-evening-weekend-trial-clinics/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-universal-routine-cost-coverage","kind":"idea","name":"Every payer covers routine care costs for trial participants, in every country","route":"/ideas/idea-tr1-universal-routine-cost-coverage/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-protected-physician-time-for-enrolment","kind":"idea","name":"Pay oncologists for the time it takes to enrol a patient","route":"/ideas/idea-tr1-protected-physician-time-for-enrolment/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-open-trials-inside-guidelines","kind":"idea","name":"Guidelines list the open trials at every decision point, updated monthly","route":"/ideas/idea-tr1-open-trials-inside-guidelines/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-mobile-research-units","kind":"idea","name":"Mobile research units bring trial visits to rural towns","route":"/ideas/idea-tr1-mobile-research-units/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-drop-non-essential-biopsies","kind":"idea","name":"Drop mandatory fresh biopsies where blood or archival tissue would do","route":"/ideas/idea-tr1-drop-non-essential-biopsies/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-external-control-rulebook","kind":"idea","name":"A public rulebook for when an external or synthetic control arm is acceptable","route":"/ideas/idea-tr1-external-control-rulebook/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-bayesian-borrowing-smaller-controls","kind":"idea","name":"Borrow from past control arms to shrink the control group in phase 3","route":"/ideas/idea-tr1-bayesian-borrowing-smaller-controls/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-seamless-2-3-with-prespecified-go","kind":"idea","name":"Seamless phase 2/3 with pre-registered go rules as the default for new agents","route":"/ideas/idea-tr1-seamless-2-3-with-prespecified-go/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-standing-platform-per-cancer","kind":"idea","name":"A standing platform trial for every major cancer, funded as infrastructure","route":"/ideas/idea-tr1-standing-platform-per-cancer/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-surrogate-validation-programme","kind":"idea","name":"An independent programme that validates surrogate endpoints, setting by setting","route":"/ideas/idea-tr1-surrogate-validation-programme/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-crossover-adjusted-survival-standard","kind":"idea","name":"Pre-specified crossover-adjusted survival in every trial that allows crossover","route":"/ideas/idea-tr1-crossover-adjusted-survival-standard/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-ttf-and-qol-coprimary","kind":"idea","name":"Time to treatment failure and quality of life as co-primary endpoints in non-curative trials","route":"/ideas/idea-tr1-ttf-and-qol-coprimary/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-win-ratio-net-benefit-endpoint","kind":"idea","name":"Win-ratio endpoints that weigh survival, toxicity and quality of life together","route":"/ideas/idea-tr1-win-ratio-net-benefit-endpoint/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-public-de-escalation-trial-fund","kind":"idea","name":"A public fund for trials that test less treatment","route":"/ideas/idea-tr1-public-de-escalation-trial-fund/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-immunotherapy-stop-trials","kind":"idea","name":"Randomised trials of stopping immunotherapy after one year versus continuing","route":"/ideas/idea-tr1-immunotherapy-stop-trials/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-ctdna-guided-stop-in-metastatic-disease","kind":"idea","name":"Use tumour DNA in blood to decide when to pause treatment in metastatic cancer","route":"/ideas/idea-tr1-ctdna-guided-stop-in-metastatic-disease/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-mams-for-sequencing-questions","kind":"idea","name":"Multi-arm, multi-stage trials to answer which order to give approved drugs","route":"/ideas/idea-tr1-mams-for-sequencing-questions/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-post-approval-pragmatic-trial-in-excluded","kind":"idea","name":"After approval, a pragmatic trial in the patients the pivotal trial excluded","route":"/ideas/idea-tr1-post-approval-pragmatic-trial-in-excluded/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-shared-control-arms-across-sponsors","kind":"idea","name":"Competing sponsors share one control arm in the same indication","route":"/ideas/idea-tr1-shared-control-arms-across-sponsors/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-tolerability-estimands","kind":"idea","name":"Define tolerability endpoints as rigorously as efficacy endpoints","route":"/ideas/idea-tr1-tolerability-estimands/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-power-for-meaningful-benefit","kind":"idea","name":"Power trials to detect a benefit patients would value, not the smallest detectable one","route":"/ideas/idea-tr1-power-for-meaningful-benefit/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-registry-linked-os-followup","kind":"idea","name":"Cheap long-term survival follow-up by linking trial participants to registries","route":"/ideas/idea-tr1-registry-linked-os-followup/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-shrinkage-subgroup-analysis","kind":"idea","name":"Bayesian shrinkage for subgroup claims to stop false 'works in this group' stories","route":"/ideas/idea-tr1-shrinkage-subgroup-analysis/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-ai-central-imaging-reads","kind":"idea","name":"AI-assisted central imaging reads to cut endpoint cost and variability","route":"/ideas/idea-tr1-ai-central-imaging-reads/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-public-trial-cost-benchmarks","kind":"idea","name":"Publish per-patient trial cost benchmarks and target halving them","route":"/ideas/idea-tr1-public-trial-cost-benchmarks/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-esource-ehr-to-edc","kind":"idea","name":"Direct record-to-database data capture: no manual transcription, no full source verification","route":"/ideas/idea-tr1-esource-ehr-to-edc/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-aggregated-n-of-1-supportive-care","kind":"idea","name":"Aggregated single-patient crossover trials for symptom and supportive treatments","route":"/ideas/idea-tr1-aggregated-n-of-1-supportive-care/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-aggressive-futility-boundaries","kind":"idea","name":"Stop failing trials earlier with pre-registered aggressive futility rules","route":"/ideas/idea-tr1-aggressive-futility-boundaries/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-window-of-opportunity-default","kind":"idea","name":"A short pre-surgery drug window as the default early test of new agents","route":"/ideas/idea-tr1-window-of-opportunity-default/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-randomised-phase-2-before-phase-3","kind":"idea","name":"Require a randomised phase 2 before any phase 3","route":"/ideas/idea-tr1-randomised-phase-2-before-phase-3/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-smart-designs-for-adaptive-strategies","kind":"idea","name":"SMART designs to test treatment strategies, not just single drugs","route":"/ideas/idea-tr1-smart-designs-for-adaptive-strategies/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-target-trial-emulation-to-prioritise-rcts","kind":"idea","name":"Emulate the trial in real-world data first to decide which trials to run","route":"/ideas/idea-tr1-target-trial-emulation-to-prioritise-rcts/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-tumour-agnostic-approval-standard","kind":"idea","name":"A standard for tumour-agnostic approvals: minimum histologies and hierarchical modelling","route":"/ideas/idea-tr1-tumour-agnostic-approval-standard/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-open-protocol-and-sap-library","kind":"idea","name":"Open-source protocol and statistical analysis plan templates with runnable code","route":"/ideas/idea-tr1-open-protocol-and-sap-library/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-validate-real-world-progression-endpoints","kind":"idea","name":"Validate real-world progression endpoints so pragmatic trials can use them","route":"/ideas/idea-tr1-validate-real-world-progression-endpoints/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-diversity-plans-with-consequences","kind":"idea","name":"Diversity action plans with consequences: unmet targets trigger post-approval requirements","route":"/ideas/idea-tr1-diversity-plans-with-consequences/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-incidence-weighted-enrolment-targets","kind":"idea","name":"Set trial enrolment targets from who actually gets the disease, and publish progress live","route":"/ideas/idea-tr1-incidence-weighted-enrolment-targets/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-ancestry-aware-pharmacology-programme","kind":"idea","name":"Ancestry-aware pharmacology: drug-level sub-studies across populations before approval","route":"/ideas/idea-tr1-ancestry-aware-pharmacology-programme/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-duffy-null-neutrophil-threshold","kind":"idea","name":"Fix the neutrophil count rule that excludes many people of African ancestry","route":"/ideas/idea-tr1-duffy-null-neutrophil-threshold/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-mandatory-older-adult-cohort","kind":"idea","name":"A mandatory over-70s cohort with geriatric assessment in every pivotal trial","route":"/ideas/idea-tr1-mandatory-older-adult-cohort/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-parallel-comorbidity-cohorts","kind":"idea","name":"Parallel real-world cohorts for sicker patients alongside every pivotal trial","route":"/ideas/idea-tr1-parallel-comorbidity-cohorts/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-lmic-sites-in-pivotal-trials","kind":"idea","name":"Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded","route":"/ideas/idea-tr1-lmic-sites-in-pivotal-trials/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-community-health-worker-recruitment","kind":"idea","name":"Community health workers and trusted local organisations paid to recruit for trials","route":"/ideas/idea-tr1-community-health-worker-recruitment/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-language-access-in-trials","kind":"idea","name":"Drop the 'must speak English' rule: translated consent and questionnaires as standard","route":"/ideas/idea-tr1-language-access-in-trials/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-site-equity-index","kind":"idea","name":"A public equity index for trial sites and sponsors, tied to funding","route":"/ideas/idea-tr1-site-equity-index/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-include-pregnancy-capable-people-sensibly","kind":"idea","name":"Stop over-excluding people who could become pregnant; study pregnancy exposure","route":"/ideas/idea-tr1-include-pregnancy-capable-people-sensibly/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-age-floor-twelve-for-adult-trials","kind":"idea","name":"Let adolescents from age 12 into adult trials when the cancer biology is the same","route":"/ideas/idea-tr1-age-floor-twelve-for-adult-trials/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-sex-stratified-pk-and-dosing","kind":"idea","name":"Analyse and dose by sex: women get more toxicity from many cancer drugs at the same dose","route":"/ideas/idea-tr1-sex-stratified-pk-and-dosing/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-disability-and-mental-illness-inclusion","kind":"idea","name":"Remove blanket exclusions for mental illness and dementia; support consent instead","route":"/ideas/idea-tr1-disability-and-mental-illness-inclusion/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-representativeness-in-the-label","kind":"idea","name":"Print the participation-to-prevalence ratio in every drug label and assessment report","route":"/ideas/idea-tr1-representativeness-in-the-label/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-diverse-investigator-pipeline","kind":"idea","name":"Fund investigators from under-represented communities and community sites to lead trials","route":"/ideas/idea-tr1-diverse-investigator-pipeline/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-paid-community-advisory-boards","kind":"idea","name":"Paid community advisory boards with power to change protocol burden","route":"/ideas/idea-tr1-paid-community-advisory-boards/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-post-marketing-safety-by-ancestry-and-sex","kind":"idea","name":"Post-marketing safety monitoring stratified by ancestry and sex, with label updates","route":"/ideas/idea-tr1-post-marketing-safety-by-ancestry-and-sex/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-ecog-2-dedicated-cohorts","kind":"idea","name":"Dedicated cohorts for patients with performance status 2 in first-line trials","route":"/ideas/idea-tr1-ecog-2-dedicated-cohorts/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-trial-desert-map","kind":"idea","name":"A public map of trial deserts to steer where new sites open","route":"/ideas/idea-tr1-trial-desert-map/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-randomised-dose-comparison-before-pivotal","kind":"idea","name":"Randomise at least two doses in phase 2 before any pivotal trial","route":"/ideas/idea-tr1-randomised-dose-comparison-before-pivotal/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-exposure-response-before-dose-selection","kind":"idea","name":"Exposure-response modelling with a pre-set target exposure before any dose is chosen","route":"/ideas/idea-tr1-exposure-response-before-dose-selection/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-public-dose-reduction-trials-of-approved-drugs","kind":"idea","name":"Publicly funded dose-reduction trials of expensive approved drugs","route":"/ideas/idea-tr1-public-dose-reduction-trials-of-approved-drugs/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-weight-based-vs-flat-dosing-trials","kind":"idea","name":"Test flat versus weight-based dosing of antibodies, and use dose banding to cut waste","route":"/ideas/idea-tr1-weight-based-vs-flat-dosing-trials/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-extended-interval-checkpoint-dosing","kind":"idea","name":"Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable","route":"/ideas/idea-tr1-extended-interval-checkpoint-dosing/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-therapeutic-drug-monitoring-for-oral-tkis","kind":"idea","name":"Measure blood levels of oral targeted drugs and adjust doses to a target range","route":"/ideas/idea-tr1-therapeutic-drug-monitoring-for-oral-tkis/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-intermittent-dosing-to-delay-resistance","kind":"idea","name":"Test intermittent dosing of targeted drugs to delay resistance, with honest priors","route":"/ideas/idea-tr1-intermittent-dosing-to-delay-resistance/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-adaptive-therapy-randomised-phase-2","kind":"idea","name":"Evolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials","route":"/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-start-low-titrate-up-oral-agents","kind":"idea","name":"Start low and step up: individualised titration of oral cancer drugs, randomised","route":"/ideas/idea-tr1-start-low-titrate-up-oral-agents/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-pre-emptive-pharmacogenomic-testing","kind":"idea","name":"Test DPYD, UGT1A1 and TPMT/NUDT15 before the first dose, everywhere","route":"/ideas/idea-tr1-pre-emptive-pharmacogenomic-testing/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-geriatric-dose-finding-cohorts","kind":"idea","name":"Dose-finding in older and frail patients, not extrapolation from fit ones","route":"/ideas/idea-tr1-geriatric-dose-finding-cohorts/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-model-based-dose-finding-with-late-toxicity","kind":"idea","name":"Retire the 3+3: model-based dose finding that counts late and chronic side effects","route":"/ideas/idea-tr1-model-based-dose-finding-with-late-toxicity/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-adc-dose-and-schedule-optimisation","kind":"idea","name":"Dose and schedule optimisation trials specific to antibody-drug conjugates","route":"/ideas/idea-tr1-adc-dose-and-schedule-optimisation/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-dose-evidence-statement-in-label","kind":"idea","name":"A 'dose evidence' panel in every label: how many doses were tested, and how","route":"/ideas/idea-tr1-dose-evidence-statement-in-label/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-patient-reported-toxicity-dose-algorithms","kind":"idea","name":"Dose adjustments driven by patients' own symptom reports, tested against clinician judgement","route":"/ideas/idea-tr1-patient-reported-toxicity-dose-algorithms/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-food-effect-dose-reduction","kind":"idea","name":"Use food effects to cut the dose and cost of oral drugs that absorb better with meals","route":"/ideas/idea-tr1-food-effect-dose-reduction/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-factorial-dose-finding-for-combinations","kind":"idea","name":"Factorial dose finding for drug combinations instead of full dose of everything","route":"/ideas/idea-tr1-factorial-dose-finding-for-combinations/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-organ-impairment-pk-before-approval","kind":"idea","name":"Kidney and liver impairment dosing studies completed before approval, not years after","route":"/ideas/idea-tr1-organ-impairment-pk-before-approval/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-low-dose-immunotherapy-for-lmic","kind":"idea","name":"Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live","route":"/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/","asOf":"2026-09-08","days":1},{"id":"idea-tr1-response-adapted-dose-reduction","kind":"idea","name":"Reduce the dose once the cancer responds: response-adapted de-escalation trials","route":"/ideas/idea-tr1-response-adapted-dose-reduction/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-perpetual-platforms","kind":"idea","name":"A perpetual platform trial in every major cancer, funded as infrastructure","route":"/ideas/idea-tr2-perpetual-platforms/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-shared-control-network","kind":"idea","name":"Shared concurrent control arms across sponsors' trials in the same setting","route":"/ideas/idea-tr2-shared-control-network/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-synergy-ranking-engine","kind":"idea","name":"An open engine that ranks every drug pair by predicted synergy before anyone runs a trial","route":"/ideas/idea-tr2-synergy-ranking-engine/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-combination-template-agreement","kind":"idea","name":"A standard cross-company combination agreement that takes weeks, not years, to sign","route":"/ideas/idea-tr2-combination-template-agreement/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-public-combination-formulary","kind":"idea","name":"A publicly held library of investigational drugs available for academic combination trials","route":"/ideas/idea-tr2-public-combination-formulary/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-smart-sequencing-adc","kind":"idea","name":"Sequential multiple-assignment randomised trials to find the best order of ADCs","route":"/ideas/idea-tr2-smart-sequencing-adc/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-organoid-coclinical-arms","kind":"idea","name":"Grow each trial patient's tumour as organoids to decide which platform arm opens next","route":"/ideas/idea-tr2-organoid-coclinical-arms/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-organoid-matrix-atlas","kind":"idea","name":"A public atlas of drug-pair responses across a thousand patient-derived organoids","route":"/ideas/idea-tr2-organoid-matrix-atlas/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-combo-dose-matrix","kind":"idea","name":"Find the lowest effective doses of both drugs in a combination, not the highest tolerated","route":"/ideas/idea-tr2-combo-dose-matrix/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-neoadjuvant-combo-platform","kind":"idea","name":"Pre-surgery platform trials that test combinations on pathological response in months","route":"/ideas/idea-tr2-neoadjuvant-combo-platform/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-pragmatic-sequence-randomisation","kind":"idea","name":"Registry-embedded randomisation of treatment order in routine care","route":"/ideas/idea-tr2-pragmatic-sequence-randomisation/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-alternating-vs-concurrent","kind":"idea","name":"Test alternating drug schedules against giving both drugs at once","route":"/ideas/idea-tr2-alternating-vs-concurrent/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-rwe-combination-emulation","kind":"idea","name":"Emulate combination trials from real-world data to triage which ones to run","route":"/ideas/idea-tr2-rwe-combination-emulation/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-factorial-adjuvant-generics","kind":"idea","name":"Factorial trials that test several cheap generics at once in the adjuvant setting","route":"/ideas/idea-tr2-factorial-adjuvant-generics/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-ctdna-futility-gates","kind":"idea","name":"Kill combination arms early using circulating tumour DNA, before waiting for scans","route":"/ideas/idea-tr2-ctdna-futility-gates/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-platform-single-ethics","kind":"idea","name":"One ethics approval and one consent form for a platform trial across countries","route":"/ideas/idea-tr2-platform-single-ethics/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-resistance-mechanism-baskets","kind":"idea","name":"Combination baskets defined by resistance mechanism rather than by cancer type","route":"/ideas/idea-tr2-resistance-mechanism-baskets/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-combination-utility","kind":"idea","name":"A non-profit phase 1b combination unit that any drug owner can use","route":"/ideas/idea-tr2-combination-utility/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-combination-patent-pool","kind":"idea","name":"A patent pool for combination method-of-use claims","route":"/ideas/idea-tr2-combination-patent-pool/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-sequence-registry","kind":"idea","name":"A registry of every treatment sequence patients actually receive, with outcomes","route":"/ideas/idea-tr2-sequence-registry/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-bandit-allocation","kind":"idea","name":"Let the trial learn: response-adaptive allocation across many combination arms","route":"/ideas/idea-tr2-bandit-allocation/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-qsp-combo-dosing","kind":"idea","name":"Mechanistic computer models to pick combination doses before dosing patients","route":"/ideas/idea-tr2-qsp-combo-dosing/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-combo-readiness-dossier","kind":"idea","name":"Every approved cancer drug ships with a public combination-readiness data pack","route":"/ideas/idea-tr2-combo-readiness-dossier/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-rt-drug-platform","kind":"idea","name":"A standing platform for testing new drugs with radiotherapy","route":"/ideas/idea-tr2-rt-drug-platform/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-paediatric-combo-prea","kind":"idea","name":"Make paediatric combination studies part of every relevant adult cancer drug approval","route":"/ideas/idea-tr2-paediatric-combo-prea/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-payer-combo-cwe","kind":"idea","name":"Payers cover off-label combinations only inside registry-randomised trials","route":"/ideas/idea-tr2-payer-combo-cwe/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-combination-forecast-tournament","kind":"idea","name":"An open forecasting tournament on which combination trials will succeed","route":"/ideas/idea-tr2-combination-forecast-tournament/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-antagonism-surveillance","kind":"idea","name":"Watch routine care for drug combinations that quietly make cancer treatment worse","route":"/ideas/idea-tr2-antagonism-surveillance/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-contribution-of-components-mandate","kind":"idea","name":"No accelerated approval for a combination without proof each part contributes","route":"/ideas/idea-tr2-contribution-of-components-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-window-of-opportunity-triplets","kind":"idea","name":"Two-week pre-operative windows to compare combination biology head to head","route":"/ideas/idea-tr2-window-of-opportunity-triplets/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-preclinical-negative-registry","kind":"idea","name":"A registry for preclinical experiments that did not work","route":"/ideas/idea-tr2-preclinical-negative-registry/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-negative-results-journal","kind":"idea","name":"A funder-backed, indexed journal of negative and inconclusive cancer results","route":"/ideas/idea-tr2-negative-results-journal/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-fdaaa-enforcement","kind":"idea","name":"Actually fine sponsors who do not post trial results","route":"/ideas/idea-tr2-fdaaa-enforcement/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-irb-results-gate","kind":"idea","name":"No new trial approval until the sponsor has reported its old ones","route":"/ideas/idea-tr2-irb-results-gate/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-termination-reports","kind":"idea","name":"Public post-mortem reports when a cancer drug programme is stopped","route":"/ideas/idea-tr2-termination-reports/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-shelved-asset-commons","kind":"idea","name":"A commons of shelved cancer drugs with their full data, open to new hypotheses","route":"/ideas/idea-tr2-shelved-asset-commons/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-outcome-switching-monitor","kind":"idea","name":"Automatically detect when a trial changes its outcomes after the fact","route":"/ideas/idea-tr2-outcome-switching-monitor/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-material-failure-disclosure","kind":"idea","name":"Listed companies must disclose top-line data, not just 'did not meet endpoint'","route":"/ideas/idea-tr2-material-failure-disclosure/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-failed-trial-biobank","kind":"idea","name":"Rescue the biological samples from failed trials for biomarker research","route":"/ideas/idea-tr2-failed-trial-biobank/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-failed-trial-ipd-default","kind":"idea","name":"Patient-level data from failed trials becomes open by default after two years","route":"/ideas/idea-tr2-failed-trial-ipd-default/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-writeup-grants","kind":"idea","name":"Small grants that pay scientists to write up abandoned projects","route":"/ideas/idea-tr2-writeup-grants/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-null-result-reporting","kind":"idea","name":"Grant progress reports must list what did not work","route":"/ideas/idea-tr2-null-result-reporting/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-negative-plenaries","kind":"idea","name":"Give negative trials plenary slots at the big cancer conferences","route":"/ideas/idea-tr2-negative-plenaries/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-failure-taxonomy","kind":"idea","name":"A machine-readable taxonomy of why cancer drugs fail","route":"/ideas/idea-tr2-failure-taxonomy/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-model-report-cards","kind":"idea","name":"Score every preclinical model by how often it predicted the clinical result","route":"/ideas/idea-tr2-model-report-cards/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-off-label-outcome-registry","kind":"idea","name":"Record what happens when doctors use cancer drugs off-label","route":"/ideas/idea-tr2-off-label-outcome-registry/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-retraction-propagation","kind":"idea","name":"Alert guidelines and trials when a paper they rely on is retracted","route":"/ideas/idea-tr2-retraction-propagation/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-reversal-registry","kind":"idea","name":"A public registry of cancer treatments that were later shown not to work","route":"/ideas/idea-tr2-reversal-registry/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-sponsor-transparency-score","kind":"idea","name":"A public transparency score for every trial sponsor, used by sites and patients","route":"/ideas/idea-tr2-sponsor-transparency-score/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-target-failure-index","kind":"idea","name":"A target de-risking index that counts failures as well as successes","route":"/ideas/idea-tr2-target-failure-index/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-her2-low-reference-materials","kind":"idea","name":"Calibrated reference slides so every lab scores HER2-low the same way","route":"/ideas/idea-tr2-her2-low-reference-materials/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-pdl1-digital-calibration","kind":"idea","name":"One digital PD-L1 scale that maps across all the competing assays","route":"/ideas/idea-tr2-pdl1-digital-calibration/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-marker-stratified-default","kind":"idea","name":"Test the drug in biomarker-negative patients too, so the biomarker can be validated","route":"/ideas/idea-tr2-marker-stratified-default/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-cdx-mutual-recognition","kind":"idea","name":"Regulators recognise each other's companion diagnostic approvals","route":"/ideas/idea-tr2-cdx-mutual-recognition/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-open-cdx-validation-sets","kind":"idea","name":"Public gold-standard datasets for validating every cancer biomarker test","route":"/ideas/idea-tr2-open-cdx-validation-sets/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-ctdna-mrd-qualification","kind":"idea","name":"Formally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials","route":"/ideas/idea-tr2-ctdna-mrd-qualification/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-psma-volume-qualification","kind":"idea","name":"Qualify PSMA PET tumour volume as a validated imaging biomarker","route":"/ideas/idea-tr2-psma-volume-qualification/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-bicr-discordance-public","kind":"idea","name":"Publish the disagreement between trial doctors and independent reviewers for every trial","route":"/ideas/idea-tr2-bicr-discordance-public/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-biomarker-evidence-grading","kind":"idea","name":"Label every biomarker claim with an evidence phase, like drugs","route":"/ideas/idea-tr2-biomarker-evidence-grading/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-eqa-public-results","kind":"idea","name":"Publish each laboratory's biomarker proficiency results","route":"/ideas/idea-tr2-eqa-public-results/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-ctdna-reference-plasma","kind":"idea","name":"Certified reference samples to benchmark every tumour-DNA blood test","route":"/ideas/idea-tr2-ctdna-reference-plasma/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-tmb-calibration-standard","kind":"idea","name":"A single calibrated tumour mutational burden across all sequencing panels","route":"/ideas/idea-tr2-tmb-calibration-standard/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-hrd-functional-standard","kind":"idea","name":"A functional test for homologous recombination deficiency validated across laboratories","route":"/ideas/idea-tr2-hrd-functional-standard/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-preanalytics-in-report","kind":"idea","name":"Record how long tissue waited before fixation in every pathology report","route":"/ideas/idea-tr2-preanalytics-in-report/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-cutpoint-lock","kind":"idea","name":"Lock the biomarker cut-off before phase 3, and publish it","route":"/ideas/idea-tr2-cutpoint-lock/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-prospective-retrospective-path","kind":"idea","name":"A formal regulatory route for validating a biomarker on archived trial samples","route":"/ideas/idea-tr2-prospective-retrospective-path/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-spatial-biomarker-standards","kind":"idea","name":"Standards for spatial and multiplex tissue biomarkers before they reach the clinic","route":"/ideas/idea-tr2-spatial-biomarker-standards/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-liquid-biopsy-challenge","kind":"idea","name":"An annual blinded shoot-out for liquid biopsy tests","route":"/ideas/idea-tr2-liquid-biopsy-challenge/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-radiomics-ibsi-mandate","kind":"idea","name":"No clinical claims for imaging-derived biomarkers without phantom and standards compliance","route":"/ideas/idea-tr2-radiomics-ibsi-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-biomarker-study-registry","kind":"idea","name":"Pre-register biomarker validation studies the way trials are registered","route":"/ideas/idea-tr2-biomarker-study-registry/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-biomarker-cwe","kind":"idea","name":"Pay for new biomarker tests only while evidence of clinical utility is being collected","route":"/ideas/idea-tr2-biomarker-cwe/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-ai-cdx-change-control","kind":"idea","name":"Version control and locked reference sets for AI algorithms used as companion diagnostics","route":"/ideas/idea-tr2-ai-cdx-change-control/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-label-assay-concordance","kind":"idea","name":"Drug labels must state which biomarker assays were validated and how they compare","route":"/ideas/idea-tr2-label-assay-concordance/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-biomarker-negative-arms","kind":"idea","name":"Randomised trials to test whether biomarker-negative patients really do not benefit","route":"/ideas/idea-tr2-biomarker-negative-arms/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-positivity-rate-surveillance","kind":"idea","name":"Monitor biomarker positivity rates across labs in real time to catch assay drift","route":"/ideas/idea-tr2-positivity-rate-surveillance/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-cell-line-authentication-mandate","kind":"idea","name":"Prove your cell lines are what you say they are, or the paper is not published","route":"/ideas/idea-tr2-cell-line-authentication-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-cell-line-passport","kind":"idea","name":"A digital passport for every cell culture: identity, contamination status, passage number","route":"/ideas/idea-tr2-cell-line-passport/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-preclinical-registered-reports","kind":"idea","name":"Registered reports for cancer biology: the plan is peer-reviewed before the result","route":"/ideas/idea-tr2-preclinical-registered-reports/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-replication-set-aside","kind":"idea","name":"Funders set aside a fixed share of budget for independent replication","route":"/ideas/idea-tr2-replication-set-aside/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-replication-before-ind","kind":"idea","name":"Independent replication of the key experiment before first-in-human academic trials","route":"/ideas/idea-tr2-replication-before-ind/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-automated-stats-check","kind":"idea","name":"Run automated statistics and image checks on every cancer manuscript before review","route":"/ideas/idea-tr2-automated-stats-check/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-raw-image-deposit","kind":"idea","name":"Deposit the raw blots, gels and microscopy images behind every figure","route":"/ideas/idea-tr2-raw-image-deposit/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-arrive-audit","kind":"idea","name":"Audit animal studies for randomisation and blinding, published by institution","route":"/ideas/idea-tr2-arrive-audit/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-multilab-preclinical","kind":"idea","name":"Multi-laboratory preclinical trials as the standard for go/no-go decisions","route":"/ideas/idea-tr2-multilab-preclinical/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-replication-bounties","kind":"idea","name":"Bounties for documented failed replications of high-impact findings","route":"/ideas/idea-tr2-replication-bounties/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-antibody-validation-mandate","kind":"idea","name":"Only use antibodies proven to hit their target with knockout controls","route":"/ideas/idea-tr2-antibody-validation-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-reference-compound-panels","kind":"idea","name":"Every drug screen includes standard reference compounds whose performance is published","route":"/ideas/idea-tr2-reference-compound-panels/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-timestamped-eln","kind":"idea","name":"Time-stamped electronic lab notebooks submitted with the paper","route":"/ideas/idea-tr2-timestamped-eln/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-animal-power-mandate","kind":"idea","name":"Pre-specified sample sizes for animal studies; no more 'representative' experiments","route":"/ideas/idea-tr2-animal-power-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-tenure-replication-credit","kind":"idea","name":"Count replications and open data in hiring and promotion","route":"/ideas/idea-tr2-tenure-replication-credit/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-random-audit","kind":"idea","name":"Random audits of published, funded research, like tax audits","route":"/ideas/idea-tr2-random-audit/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-replication-status-badge","kind":"idea","name":"A replication status badge on every cancer paper, visible in PubMed","route":"/ideas/idea-tr2-replication-status-badge/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-data-link-enforcement","kind":"idea","name":"Journals check that data links actually work, and flag papers whose data vanish","route":"/ideas/idea-tr2-data-link-enforcement/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-paid-statistical-review","kind":"idea","name":"Paid independent statistical review for preclinical papers that inform trials","route":"/ideas/idea-tr2-paid-statistical-review/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-reference-model-panels","kind":"idea","name":"Shared reference organoid and PDX panels that every lab can test against","route":"/ideas/idea-tr2-reference-model-panels/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-ai-external-validation-registry","kind":"idea","name":"A registry of external validation datasets for cancer AI models, with mandatory reporting","route":"/ideas/idea-tr2-ai-external-validation-registry/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-two-lab-rule","kind":"idea","name":"Top journals require an independent lab to reproduce key findings before publication","route":"/ideas/idea-tr2-two-lab-rule/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-preclinical-living-reviews","kind":"idea","name":"Living systematic reviews of animal and organoid evidence before every new trial","route":"/ideas/idea-tr2-preclinical-living-reviews/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-reagent-lot-ledger","kind":"idea","name":"Barcode every reagent lot so batch effects can be traced across experiments and labs","route":"/ideas/idea-tr2-reagent-lot-ledger/","asOf":"2026-09-08","days":1},{"id":"idea-tr2-phd-replication-year","kind":"idea","name":"Every cancer biology PhD begins with a funded replication of a published finding","route":"/ideas/idea-tr2-phd-replication-year/","asOf":"2026-09-08","days":1},{"id":"idea-reg-orbis-work-sharing","kind":"idea","name":"Turn Project Orbis into a work-sharing review with one shared assessment report","route":"/ideas/idea-reg-orbis-work-sharing/","asOf":"2026-09-08","days":1},{"id":"idea-reg-reliance-90-day-lmic","kind":"idea","name":"90-day reliance approval for cancer drugs cleared by two stringent regulators","route":"/ideas/idea-reg-reliance-90-day-lmic/","asOf":"2026-09-08","days":1},{"id":"idea-reg-single-global-dossier","kind":"idea","name":"One structured global dossier: submit the cancer drug file once, to a shared cloud","route":"/ideas/idea-reg-single-global-dossier/","asOf":"2026-09-08","days":1},{"id":"idea-reg-joint-scientific-advice-default","kind":"idea","name":"Joint FDA-EMA-MHRA-PMDA scientific advice by default before pivotal cancer trials","route":"/ideas/idea-reg-joint-scientific-advice-default/","asOf":"2026-09-08","days":1},{"id":"idea-reg-realtime-streaming-submission","kind":"idea","name":"Stream trial data to regulators as it accrues; review starts at last patient visit","route":"/ideas/idea-reg-realtime-streaming-submission/","asOf":"2026-09-08","days":1},{"id":"idea-reg-conditional-approval-sunset","kind":"idea","name":"Conditional approvals that lapse automatically if the confirmatory trial is late","route":"/ideas/idea-reg-conditional-approval-sunset/","asOf":"2026-09-08","days":1},{"id":"idea-reg-confirmatory-trial-escrow","kind":"idea","name":"Sponsors deposit the confirmatory trial budget in escrow at accelerated approval","route":"/ideas/idea-reg-confirmatory-trial-escrow/","asOf":"2026-09-08","days":1},{"id":"idea-reg-public-assessment-reports-all","kind":"idea","name":"Every regulator publishes its full assessment report so others can rely on it","route":"/ideas/idea-reg-public-assessment-reports-all/","asOf":"2026-09-08","days":1},{"id":"idea-reg-mutual-recognition-inspections-atmp","kind":"idea","name":"Mutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants","route":"/ideas/idea-reg-mutual-recognition-inspections-atmp/","asOf":"2026-09-08","days":1},{"id":"idea-reg-global-trial-application-portal","kind":"idea","name":"One clinical trial application accepted by regulators in every major region","route":"/ideas/idea-reg-global-trial-application-portal/","asOf":"2026-09-08","days":1},{"id":"idea-reg-diagnostic-reliance-pathway","kind":"idea","name":"A reliance pathway for companion diagnostics so the test arrives with the drug","route":"/ideas/idea-reg-diagnostic-reliance-pathway/","asOf":"2026-09-08","days":1},{"id":"idea-reg-single-paediatric-plan","kind":"idea","name":"One global paediatric cancer development plan instead of separate FDA and EMA plans","route":"/ideas/idea-reg-single-paediatric-plan/","asOf":"2026-09-08","days":1},{"id":"idea-reg-tumour-agnostic-reliance","kind":"idea","name":"Adopt tumour-agnostic cancer drug labels across regions by reliance, not re-review","route":"/ideas/idea-reg-tumour-agnostic-reliance/","asOf":"2026-09-08","days":1},{"id":"idea-reg-label-divergence-index","kind":"idea","name":"A public index of how the same cancer drug's label differs between countries","route":"/ideas/idea-reg-label-divergence-index/","asOf":"2026-09-08","days":1},{"id":"idea-reg-approval-access-lag-tracker","kind":"idea","name":"Live tracker of the lag from first approval to real availability in every country","route":"/ideas/idea-reg-approval-access-lag-tracker/","asOf":"2026-09-08","days":1},{"id":"idea-reg-joint-regulator-hta-plan","kind":"idea","name":"One evidence plan agreed by regulator and payer before the pivotal trial","route":"/ideas/idea-reg-joint-regulator-hta-plan/","asOf":"2026-09-08","days":1},{"id":"idea-reg-mrct-no-bridging","kind":"idea","name":"One multiregional trial, no bridging studies: enforce ICH E17 in Japan and China","route":"/ideas/idea-reg-mrct-no-bridging/","asOf":"2026-09-08","days":1},{"id":"idea-reg-african-medicines-agency-oncology","kind":"idea","name":"Fund an oncology joint assessment unit inside the African Medicines Agency","route":"/ideas/idea-reg-african-medicines-agency-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-reg-open-source-dossier-tools","kind":"idea","name":"Open-source dossier-building software for academic sponsors and generic makers","route":"/ideas/idea-reg-open-source-dossier-tools/","asOf":"2026-09-08","days":1},{"id":"idea-reg-shared-ai-review-assistant","kind":"idea","name":"A shared AI review assistant that maps one dossier to every regulator's questions","route":"/ideas/idea-reg-shared-ai-review-assistant/","asOf":"2026-09-08","days":1},{"id":"idea-reg-shared-postmarketing-registry-condition","kind":"idea","name":"One international registry, not one per country, for conditional approvals","route":"/ideas/idea-reg-shared-postmarketing-registry-condition/","asOf":"2026-09-08","days":1},{"id":"idea-reg-manufacturing-change-passport","kind":"idea","name":"Manufacturing-change passport: one approved CMC change accepted everywhere in 30 days","route":"/ideas/idea-reg-manufacturing-change-passport/","asOf":"2026-09-08","days":1},{"id":"idea-reg-orphan-designation-reciprocity","kind":"idea","name":"Automatic reciprocity of orphan and rare-paediatric designations between regulators","route":"/ideas/idea-reg-orphan-designation-reciprocity/","asOf":"2026-09-08","days":1},{"id":"idea-reg-publish-all-rejections","kind":"idea","name":"Publish every complete response letter and negative opinion across all regulators","route":"/ideas/idea-reg-publish-all-rejections/","asOf":"2026-09-08","days":1},{"id":"idea-reg-global-dose-optimisation-guideline","kind":"idea","name":"Make pre-approval dose optimisation an ICH standard so it is done once worldwide","route":"/ideas/idea-reg-global-dose-optimisation-guideline/","asOf":"2026-09-08","days":1},{"id":"idea-reg-point-of-care-cart-network","kind":"idea","name":"Hospital-made CAR-T under one shared regulatory master file","route":"/ideas/idea-reg-point-of-care-cart-network/","asOf":"2026-09-08","days":1},{"id":"idea-reg-in-vivo-cart-off-the-shelf-vial","kind":"idea","name":"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma","route":"/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/","asOf":"2026-09-08","days":1},{"id":"idea-reg-two-day-cart-rapid-release","kind":"idea","name":"Two-day CAR-T manufacture paired with rapid release tests that regulators accept","route":"/ideas/idea-reg-two-day-cart-rapid-release/","asOf":"2026-09-08","days":1},{"id":"idea-reg-ipsc-master-bank-qualified-once","kind":"idea","name":"Qualify one iPSC master cell bank once for many off-the-shelf cell products","route":"/ideas/idea-reg-ipsc-master-bank-qualified-once/","asOf":"2026-09-08","days":1},{"id":"idea-reg-closed-manufacturing-interop-standard","kind":"idea","name":"An open interoperability standard for closed automated cell-processing machines","route":"/ideas/idea-reg-closed-manufacturing-interop-standard/","asOf":"2026-09-08","days":1},{"id":"idea-reg-cart-potency-reference-standards","kind":"idea","name":"Public reference standards and potency assays for CAR-T so every lab measures alike","route":"/ideas/idea-reg-cart-potency-reference-standards/","asOf":"2026-09-08","days":1},{"id":"idea-reg-vein-to-vein-public-benchmark","kind":"idea","name":"Mandatory public reporting of vein-to-vein time and failure rate per CAR-T product","route":"/ideas/idea-reg-vein-to-vein-public-benchmark/","asOf":"2026-09-08","days":1},{"id":"idea-reg-legacy-radium-recovery-ac225","kind":"idea","name":"Recover legacy radium-226 sources worldwide as the feedstock for actinium-225","route":"/ideas/idea-reg-legacy-radium-recovery-ac225/","asOf":"2026-09-08","days":1},{"id":"idea-reg-ac225-accelerator-pharmacopoeia","kind":"idea","name":"Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit","route":"/ideas/idea-reg-ac225-accelerator-pharmacopoeia/","asOf":"2026-09-08","days":1},{"id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/","asOf":"2026-09-08","days":1},{"id":"idea-reg-medical-isotope-reactor-reserve","kind":"idea","name":"A coordinated reserve and shared schedule for the world's medical isotope reactors","route":"/ideas/idea-reg-medical-isotope-reactor-reserve/","asOf":"2026-09-08","days":1},{"id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/","asOf":"2026-09-08","days":1},{"id":"idea-reg-regional-radiopharmacy-hubs","kind":"idea","name":"Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes","route":"/ideas/idea-reg-regional-radiopharmacy-hubs/","asOf":"2026-09-08","days":1},{"id":"idea-reg-adc-platform-designation","kind":"idea","name":"Platform designation for ADC linker-payloads so manufacturing data carry across","route":"/ideas/idea-reg-adc-platform-designation/","asOf":"2026-09-08","days":1},{"id":"idea-reg-hpapi-continuous-flow","kind":"idea","name":"Continuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze","route":"/ideas/idea-reg-hpapi-continuous-flow/","asOf":"2026-09-08","days":1},{"id":"idea-reg-open-source-lentiviral-vectors","kind":"idea","name":"Non-profit, open-licence lentiviral vectors and producer cell lines for CAR-T","route":"/ideas/idea-reg-open-source-lentiviral-vectors/","asOf":"2026-09-08","days":1},{"id":"idea-reg-non-viral-cart-manufacturing","kind":"idea","name":"Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route","route":"/ideas/idea-reg-non-viral-cart-manufacturing/","asOf":"2026-09-08","days":1},{"id":"idea-reg-manufacturing-slot-exchange","kind":"idea","name":"A neutral slot exchange so unused CAR-T manufacturing slots go to the next patient","route":"/ideas/idea-reg-manufacturing-slot-exchange/","asOf":"2026-09-08","days":1},{"id":"idea-reg-hospital-exemption-harmonised","kind":"idea","name":"Harmonise Europe's hospital exemption for academic cell therapies, with one registry","route":"/ideas/idea-reg-hospital-exemption-harmonised/","asOf":"2026-09-08","days":1},{"id":"idea-reg-lmic-public-cart-manufacturing","kind":"idea","name":"Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000","route":"/ideas/idea-reg-lmic-public-cart-manufacturing/","asOf":"2026-09-08","days":1},{"id":"idea-reg-ai-process-control-cell-manufacturing","kind":"idea","name":"Digital batch records and AI process control to halve cell therapy batch failures","route":"/ideas/idea-reg-ai-process-control-cell-manufacturing/","asOf":"2026-09-08","days":1},{"id":"idea-reg-early-apheresis-banking","kind":"idea","name":"Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy","route":"/ideas/idea-reg-early-apheresis-banking/","asOf":"2026-09-08","days":1},{"id":"idea-reg-public-cell-therapy-foundries","kind":"idea","name":"Public cell-therapy foundries at cancer centres for academics and start-ups","route":"/ideas/idea-reg-public-cell-therapy-foundries/","asOf":"2026-09-08","days":1},{"id":"idea-reg-comparability-by-design-digital-twin","kind":"idea","name":"Comparability by design: a digital twin and sentinel panel for cell process changes","route":"/ideas/idea-reg-comparability-by-design-digital-twin/","asOf":"2026-09-08","days":1},{"id":"idea-reg-isotope-supply-observatory","kind":"idea","name":"A global medical isotope supply observatory with forecasts and shortage alerts","route":"/ideas/idea-reg-isotope-supply-observatory/","asOf":"2026-09-08","days":1},{"id":"idea-reg-cart-outcomes-refund","kind":"idea","name":"Full refund for CAR-T if the patient has not responded at three months","route":"/ideas/idea-reg-cart-outcomes-refund/","asOf":"2026-09-08","days":1},{"id":"idea-reg-io-subscription-national","kind":"idea","name":"Subscription pricing for checkpoint inhibitors: fixed national fee, unlimited use","route":"/ideas/idea-reg-io-subscription-national/","asOf":"2026-09-08","days":1},{"id":"idea-reg-indication-specific-pricing","kind":"idea","name":"Pay a different price for the same cancer drug depending on the indication","route":"/ideas/idea-reg-indication-specific-pricing/","asOf":"2026-09-08","days":1},{"id":"idea-reg-pooled-procurement-adult-essentials","kind":"idea","name":"Pooled international procurement of essential adult cancer medicines","route":"/ideas/idea-reg-pooled-procurement-adult-essentials/","asOf":"2026-09-08","days":1},{"id":"idea-reg-biosimilar-no-efficacy-trial","kind":"idea","name":"Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials","route":"/ideas/idea-reg-biosimilar-no-efficacy-trial/","asOf":"2026-09-08","days":1},{"id":"idea-reg-pd1-biosimilar-advance-commitment","kind":"idea","name":"An advance market commitment for PD-1 biosimilars for lower-income countries","route":"/ideas/idea-reg-pd1-biosimilar-advance-commitment/","asOf":"2026-09-08","days":1},{"id":"idea-reg-patent-pool-oncology-eml","kind":"idea","name":"Medicines Patent Pool licences for every patented cancer drug on the WHO list","route":"/ideas/idea-reg-patent-pool-oncology-eml/","asOf":"2026-09-08","days":1},{"id":"idea-reg-price-anchored-to-mcbs","kind":"idea","name":"Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales","route":"/ideas/idea-reg-price-anchored-to-mcbs/","asOf":"2026-09-08","days":1},{"id":"idea-reg-weight-based-io-dosing-label","kind":"idea","name":"Restore weight-based dosing and vial sharing for immunotherapy in the label","route":"/ideas/idea-reg-weight-based-io-dosing-label/","asOf":"2026-09-08","days":1},{"id":"idea-reg-public-deescalation-trials-for-cost","kind":"idea","name":"Publicly funded trials of lower and less frequent doses of expensive cancer drugs","route":"/ideas/idea-reg-public-deescalation-trials-for-cost/","asOf":"2026-09-08","days":1},{"id":"idea-reg-financial-toxicity-vital-sign","kind":"idea","name":"Screen every cancer patient for financial toxicity as a vital sign, with navigation","route":"/ideas/idea-reg-financial-toxicity-vital-sign/","asOf":"2026-09-08","days":1},{"id":"idea-reg-net-price-transparency-registry","kind":"idea","name":"An international registry of real (net) cancer drug prices paid by public payers","route":"/ideas/idea-reg-net-price-transparency-registry/","asOf":"2026-09-08","days":1},{"id":"idea-reg-rd-cost-disclosure-condition","kind":"idea","name":"Disclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage","route":"/ideas/idea-reg-rd-cost-disclosure-condition/","asOf":"2026-09-08","days":1},{"id":"idea-reg-provisional-price-until-os","kind":"idea","name":"Provisional prices for surrogate-endpoint approvals, reset when survival data arrive","route":"/ideas/idea-reg-provisional-price-until-os/","asOf":"2026-09-08","days":1},{"id":"idea-reg-patent-buyout-prize","kind":"idea","name":"Buy out the patent on a curative cancer drug and sell it at generic prices","route":"/ideas/idea-reg-patent-buyout-prize/","asOf":"2026-09-08","days":1},{"id":"idea-reg-secondary-patent-thicket-limits","kind":"idea","name":"Limit secondary patents and pay-for-delay so cancer generics arrive on time","route":"/ideas/idea-reg-secondary-patent-thicket-limits/","asOf":"2026-09-08","days":1},{"id":"idea-reg-nonprofit-generic-chemo-manufacturer","kind":"idea","name":"A non-profit manufacturer for generic cancer drugs in chronic shortage","route":"/ideas/idea-reg-nonprofit-generic-chemo-manufacturer/","asOf":"2026-09-08","days":1},{"id":"idea-reg-academic-cart-at-cost-coverage","kind":"idea","name":"Public payers cover academic CAR-T at cost as a benchmark for commercial prices","route":"/ideas/idea-reg-academic-cart-at-cost-coverage/","asOf":"2026-09-08","days":1},{"id":"idea-reg-combination-price-attribution","kind":"idea","name":"A combination pricing rule so two-drug regimens are not priced as two monopolies","route":"/ideas/idea-reg-combination-price-attribution/","asOf":"2026-09-08","days":1},{"id":"idea-reg-middle-income-negotiation-bloc","kind":"idea","name":"A joint price negotiation bloc for middle-income countries, modelled on Beneluxa","route":"/ideas/idea-reg-middle-income-negotiation-bloc/","asOf":"2026-09-08","days":1},{"id":"idea-reg-tiered-pricing-for-exclusivity","kind":"idea","name":"Grant extra exclusivity only in exchange for binding low prices in poorer countries","route":"/ideas/idea-reg-tiered-pricing-for-exclusivity/","asOf":"2026-09-08","days":1},{"id":"idea-reg-biosimilar-first-default-switching","kind":"idea","name":"Biosimilar-first defaults and payment parity in every cancer day unit","route":"/ideas/idea-reg-biosimilar-first-default-switching/","asOf":"2026-09-08","days":1},{"id":"idea-reg-annuity-payment-durable-therapies","kind":"idea","name":"Pay for one-time curative therapies as an annuity that stops at relapse","route":"/ideas/idea-reg-annuity-payment-durable-therapies/","asOf":"2026-09-08","days":1},{"id":"idea-reg-social-impact-bond-switching","kind":"idea","name":"Social impact bonds that fund biosimilar switching, repaid from payer savings","route":"/ideas/idea-reg-social-impact-bond-switching/","asOf":"2026-09-08","days":1},{"id":"idea-reg-market-expansion-repricing","kind":"idea","name":"Automatic price cuts when a cancer drug's approved indications and volumes expand","route":"/ideas/idea-reg-market-expansion-repricing/","asOf":"2026-09-08","days":1},{"id":"idea-reg-global-repurposing-fund","kind":"idea","name":"A public fund that pays for phase 3 trials of cheap, off-patent drugs against cancer","route":"/ideas/idea-reg-global-repurposing-fund/","asOf":"2026-09-08","days":1},{"id":"idea-reg-third-party-label-update","kind":"idea","name":"Let non-profits and academics add a cancer indication to an off-patent drug's label","route":"/ideas/idea-reg-third-party-label-update/","asOf":"2026-09-08","days":1},{"id":"idea-reg-repurposing-prize","kind":"idea","name":"A $50 million prize for the first off-patent drug proven to extend cancer survival","route":"/ideas/idea-reg-repurposing-prize/","asOf":"2026-09-08","days":1},{"id":"idea-reg-repurposing-social-impact-bond","kind":"idea","name":"A social impact bond: investors fund a repurposing trial, payers repay from savings","route":"/ideas/idea-reg-repurposing-social-impact-bond/","asOf":"2026-09-08","days":1},{"id":"idea-reg-aspirin-pik3ca-implementation","kind":"idea","name":"Get biomarker-directed aspirin after colorectal surgery into labels and guidelines","route":"/ideas/idea-reg-aspirin-pik3ca-implementation/","asOf":"2026-09-08","days":1},{"id":"idea-reg-recovery-style-platform-repurposing","kind":"idea","name":"A RECOVERY-style permanent platform trial of cheap drugs added to cancer care","route":"/ideas/idea-reg-recovery-style-platform-repurposing/","asOf":"2026-09-08","days":1},{"id":"idea-reg-perioperative-propranolol-etodolac","kind":"idea","name":"Perioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery","route":"/ideas/idea-reg-perioperative-propranolol-etodolac/","asOf":"2026-09-08","days":1},{"id":"idea-reg-statin-hcc-prevention-trial","kind":"idea","name":"A pragmatic trial of statins to prevent liver cancer in people with cirrhosis","route":"/ideas/idea-reg-statin-hcc-prevention-trial/","asOf":"2026-09-08","days":1},{"id":"idea-reg-evidence-gate-before-repurposing-phase3","kind":"idea","name":"Require genetic and target-trial evidence before funding any repurposing phase 3","route":"/ideas/idea-reg-evidence-gate-before-repurposing-phase3/","asOf":"2026-09-08","days":1},{"id":"idea-reg-target-trial-emulation-pipeline","kind":"idea","name":"An automated pipeline emulating trials of every common drug against every cancer","route":"/ideas/idea-reg-target-trial-emulation-pipeline/","asOf":"2026-09-08","days":1},{"id":"idea-reg-new-indication-exclusivity-off-patent","kind":"idea","name":"Three years of indication-specific exclusivity for proving a new cancer use of an old drug","route":"/ideas/idea-reg-new-indication-exclusivity-off-patent/","asOf":"2026-09-08","days":1},{"id":"idea-reg-delinked-market-entry-reward","kind":"idea","name":"A delinked market-entry reward paid by payers when a repurposed generic wins approval","route":"/ideas/idea-reg-delinked-market-entry-reward/","asOf":"2026-09-08","days":1},{"id":"idea-reg-generic-targeted-therapy-drup","kind":"idea","name":"A DRUP-style protocol for off-label generic targeted drugs in rare tumours","route":"/ideas/idea-reg-generic-targeted-therapy-drup/","asOf":"2026-09-08","days":1},{"id":"idea-reg-antihistamine-plus-io-trial","kind":"idea","name":"Randomise a cheap antihistamine alongside immunotherapy","route":"/ideas/idea-reg-antihistamine-plus-io-trial/","asOf":"2026-09-08","days":1},{"id":"idea-reg-vitamin-d-digestive-cancer-biomarker-trial","kind":"idea","name":"A biomarker-directed trial of vitamin D after surgery for digestive tract cancers","route":"/ideas/idea-reg-vitamin-d-digestive-cancer-biomarker-trial/","asOf":"2026-09-08","days":1},{"id":"idea-reg-losartan-pancreatic-stroma","kind":"idea","name":"Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3","route":"/ideas/idea-reg-losartan-pancreatic-stroma/","asOf":"2026-09-08","days":1},{"id":"idea-reg-regulator-ready-repurposing-dossiers","kind":"idea","name":"Fund regulator-ready evidence dossiers for the 20 best-supported off-patent drugs","route":"/ideas/idea-reg-regulator-ready-repurposing-dossiers/","asOf":"2026-09-08","days":1},{"id":"idea-reg-guideline-fast-track-repurposed","kind":"idea","name":"A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer","route":"/ideas/idea-reg-guideline-fast-track-repurposed/","asOf":"2026-09-08","days":1},{"id":"idea-reg-payer-coverage-off-label-generic-commitment","kind":"idea","name":"Payers pre-commit to cover off-label generics when a definitive trial is positive","route":"/ideas/idea-reg-payer-coverage-off-label-generic-commitment/","asOf":"2026-09-08","days":1},{"id":"idea-reg-nonprofit-marketing-authorisation-holder","kind":"idea","name":"A non-profit company to hold marketing authorisations for repurposed cancer drugs","route":"/ideas/idea-reg-nonprofit-marketing-authorisation-holder/","asOf":"2026-09-08","days":1},{"id":"idea-reg-metronomic-lmic-phase3-to-label","kind":"idea","name":"Validate low-cost metronomic oral regimens in phase 3 and carry them into guidelines","route":"/ideas/idea-reg-metronomic-lmic-phase3-to-label/","asOf":"2026-09-08","days":1},{"id":"idea-reg-generic-chemo-strategic-reserve","kind":"idea","name":"A strategic reserve of essential generic cancer drugs to end recurring shortages","route":"/ideas/idea-reg-generic-chemo-strategic-reserve/","asOf":"2026-09-08","days":1},{"id":"idea-reg-factorial-addon-arms-cooperative-trials","kind":"idea","name":"Add a cheap-drug factorial arm to every cooperative-group adjuvant cancer trial","route":"/ideas/idea-reg-factorial-addon-arms-cooperative-trials/","asOf":"2026-09-08","days":1},{"id":"idea-reg-olanzapine-cachexia-global-confirmation","kind":"idea","name":"Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide","route":"/ideas/idea-reg-olanzapine-cachexia-global-confirmation/","asOf":"2026-09-08","days":1},{"id":"idea-reg-preregistered-ai-repurposing-scoring","kind":"idea","name":"Pre-registered, publicly scored AI ranking of repurposing candidates for cancer","route":"/ideas/idea-reg-preregistered-ai-repurposing-scoring/","asOf":"2026-09-08","days":1},{"id":"idea-acc-open-hardware-linac","kind":"idea","name":"An open-hardware radiotherapy machine built for unreliable power and dust","route":"/ideas/idea-acc-open-hardware-linac/","asOf":"2026-09-08","days":1},{"id":"idea-acc-linac-uptime-contracts","kind":"idea","name":"Pay for radiotherapy machine uptime, not for the machine","route":"/ideas/idea-acc-linac-uptime-contracts/","asOf":"2026-09-08","days":1},{"id":"idea-acc-hypofractionation-default-lmic","kind":"idea","name":"Make one-week radiotherapy the default in overloaded systems","route":"/ideas/idea-acc-hypofractionation-default-lmic/","asOf":"2026-09-08","days":1},{"id":"idea-acc-remote-planning-hubs","kind":"idea","name":"Round-the-clock remote treatment-planning hubs for clinics without physicists","route":"/ideas/idea-acc-remote-planning-hubs/","asOf":"2026-09-08","days":1},{"id":"idea-acc-modern-cobalt-bridge","kind":"idea","name":"Modernised cobalt-60 machines as a deliberate bridge where linacs cannot be kept running","route":"/ideas/idea-acc-modern-cobalt-bridge/","asOf":"2026-09-08","days":1},{"id":"idea-acc-pooled-procurement-radiotherapy","kind":"idea","name":"A Gavi-style pooled purchaser for radiotherapy equipment and service","route":"/ideas/idea-acc-pooled-procurement-radiotherapy/","asOf":"2026-09-08","days":1},{"id":"idea-acc-telepathology-district-network","kind":"idea","name":"Slide scanners in district hospitals wired to pathologists anywhere","route":"/ideas/idea-acc-telepathology-district-network/","asOf":"2026-09-08","days":1},{"id":"idea-acc-ai-first-pathology-common-cases","kind":"idea","name":"AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions","route":"/ideas/idea-acc-ai-first-pathology-common-cases/","asOf":"2026-09-08","days":1},{"id":"idea-acc-nurse-led-chemotherapy-units","kind":"idea","name":"Nurse-led chemotherapy day units with a doctor on a screen","route":"/ideas/idea-acc-nurse-led-chemotherapy-units/","asOf":"2026-09-08","days":1},{"id":"idea-acc-eml-listing-price-commitments","kind":"idea","name":"Tie WHO essential-medicines listing to a published tiered price and supply pledge","route":"/ideas/idea-acc-eml-listing-price-commitments/","asOf":"2026-09-08","days":1},{"id":"idea-acc-biosimilar-prequalification-pool","kind":"idea","name":"WHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator","route":"/ideas/idea-acc-biosimilar-prequalification-pool/","asOf":"2026-09-08","days":1},{"id":"idea-acc-chemo-stockout-early-warning","kind":"idea","name":"A live stock-out map for essential chemotherapy drugs","route":"/ideas/idea-acc-chemo-stockout-early-warning/","asOf":"2026-09-08","days":1},{"id":"idea-acc-childhood-medicines-platform-scale","kind":"idea","name":"Guaranteed-quality childhood cancer medicines free of charge in 50 countries","route":"/ideas/idea-acc-childhood-medicines-platform-scale/","asOf":"2026-09-08","days":1},{"id":"idea-acc-hub-spoke-national-networks","kind":"idea","name":"National hub-and-spoke cancer networks with defined referral tiers","route":"/ideas/idea-acc-hub-spoke-national-networks/","asOf":"2026-09-08","days":1},{"id":"idea-acc-mobile-see-and-treat-units","kind":"idea","name":"Mobile diagnostic units that biopsy, scan and treat on the same visit","route":"/ideas/idea-acc-mobile-see-and-treat-units/","asOf":"2026-09-08","days":1},{"id":"idea-acc-hpv-self-sample-same-day-ablation","kind":"idea","name":"HPV self-testing with same-day treatment as the national cervical programme","route":"/ideas/idea-acc-hpv-self-sample-same-day-ablation/","asOf":"2026-09-08","days":1},{"id":"idea-acc-gbci-country-dashboards","kind":"idea","name":"Public country dashboards for the three WHO breast cancer targets","route":"/ideas/idea-acc-gbci-country-dashboards/","asOf":"2026-09-08","days":1},{"id":"idea-acc-infusion-sparing-regimens","kind":"idea","name":"Choose regimens by infusion-chair hours, not just efficacy, where chairs are the constraint","route":"/ideas/idea-acc-infusion-sparing-regimens/","asOf":"2026-09-08","days":1},{"id":"idea-acc-metronomic-lmic-platform-trial","kind":"idea","name":"A platform trial of very-low-cost metronomic chemotherapy in LMIC common cancers","route":"/ideas/idea-acc-metronomic-lmic-platform-trial/","asOf":"2026-09-08","days":1},{"id":"idea-acc-global-cancer-financing-window","kind":"idea","name":"A dedicated global financing window for cancer, modelled on the Global Fund","route":"/ideas/idea-acc-global-cancer-financing-window/","asOf":"2026-09-08","days":1},{"id":"idea-acc-frugal-hdr-brachytherapy","kind":"idea","name":"Low-cost cobalt-60 brachytherapy for cervical cancer in every regional centre","route":"/ideas/idea-acc-frugal-hdr-brachytherapy/","asOf":"2026-09-08","days":1},{"id":"idea-acc-registries-as-aid-condition","kind":"idea","name":"Make a population cancer registry a condition of every cancer aid programme","route":"/ideas/idea-acc-registries-as-aid-condition/","asOf":"2026-09-08","days":1},{"id":"idea-acc-abandonment-stipends","kind":"idea","name":"Cash for transport and food to stop families abandoning curative treatment","route":"/ideas/idea-acc-abandonment-stipends/","asOf":"2026-09-08","days":1},{"id":"idea-acc-diaspora-tele-tumour-boards","kind":"idea","name":"Credentialed diaspora oncologists staffing remote tumour boards for home-country hospitals","route":"/ideas/idea-acc-diaspora-tele-tumour-boards/","asOf":"2026-09-08","days":1},{"id":"idea-acc-solar-microgrids-for-cancer-units","kind":"idea","name":"Solar microgrids so radiotherapy, pathology and drug fridges never lose power","route":"/ideas/idea-acc-solar-microgrids-for-cancer-units/","asOf":"2026-09-08","days":1},{"id":"idea-acc-clinical-officer-oncology-track","kind":"idea","name":"An 18-month oncology track for clinical officers and physician associates","route":"/ideas/idea-acc-clinical-officer-oncology-track/","asOf":"2026-09-08","days":1},{"id":"idea-acc-oncology-pharmacist-prescribing","kind":"idea","name":"Oncology pharmacists as protocol prescribers for supportive care and dose adjustments","route":"/ideas/idea-acc-oncology-pharmacist-prescribing/","asOf":"2026-09-08","days":1},{"id":"idea-acc-remote-medical-physics-qa","kind":"idea","name":"One medical physicist covering many radiotherapy machines through remote quality assurance","route":"/ideas/idea-acc-remote-medical-physics-qa/","asOf":"2026-09-08","days":1},{"id":"idea-acc-echo-tele-mentoring-oncology","kind":"idea","name":"Project ECHO tele-mentoring for district clinicians managing cancer","route":"/ideas/idea-acc-echo-tele-mentoring-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-acc-retention-packages-oncology","kind":"idea","name":"Retention packages so trained oncology staff stay: bonds, top-ups, working equipment","route":"/ideas/idea-acc-retention-packages-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-acc-regional-oncology-training-hubs","kind":"idea","name":"Regional training hubs that produce oncologists, physicists and radiographers in-region","route":"/ideas/idea-acc-regional-oncology-training-hubs/","asOf":"2026-09-08","days":1},{"id":"idea-acc-ambient-ai-documentation-oncology","kind":"idea","name":"Ambient AI note-taking to give oncologists back a day a week","route":"/ideas/idea-acc-ambient-ai-documentation-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-acc-advanced-practice-radiation-therapists","kind":"idea","name":"Advanced-practice radiation therapists doing contouring and on-treatment reviews","route":"/ideas/idea-acc-advanced-practice-radiation-therapists/","asOf":"2026-09-08","days":1},{"id":"idea-acc-nurse-led-follow-up-clinics","kind":"idea","name":"Nurse-led follow-up clinics for survivors, freeing oncologists for active treatment","route":"/ideas/idea-acc-nurse-led-follow-up-clinics/","asOf":"2026-09-08","days":1},{"id":"idea-acc-pathologist-assistants-and-ai-triage","kind":"idea","name":"Pathologist assistants plus AI triage to multiply pathologist capacity","route":"/ideas/idea-acc-pathologist-assistants-and-ai-triage/","asOf":"2026-09-08","days":1},{"id":"idea-acc-open-oncology-workforce-model","kind":"idea","name":"An open global model of cancer workforce supply and demand by country","route":"/ideas/idea-acc-open-oncology-workforce-model/","asOf":"2026-09-08","days":1},{"id":"idea-acc-fast-track-relicensing-oncologists","kind":"idea","name":"Fast-track relicensing for refugee, migrant and returning oncology professionals","route":"/ideas/idea-acc-fast-track-relicensing-oncologists/","asOf":"2026-09-08","days":1},{"id":"idea-acc-mainstream-tele-genetic-counselling","kind":"idea","name":"Oncology teams order germline tests; tele-genetic counsellors handle the results","route":"/ideas/idea-acc-mainstream-tele-genetic-counselling/","asOf":"2026-09-08","days":1},{"id":"idea-acc-community-health-workers-oncology","kind":"idea","name":"Community health workers trained in cancer triage, navigation and home palliative care","route":"/ideas/idea-acc-community-health-workers-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-acc-district-surgeon-oncology-mentorship","kind":"idea","name":"Structured mentorship so district general surgeons perform common cancer operations safely","route":"/ideas/idea-acc-district-surgeon-oncology-mentorship/","asOf":"2026-09-08","days":1},{"id":"idea-acc-one-stop-breast-diagnostic-clinic","kind":"idea","name":"One-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit","route":"/ideas/idea-acc-one-stop-breast-diagnostic-clinic/","asOf":"2026-09-08","days":1},{"id":"idea-acc-28-day-diagnosis-standard","kind":"idea","name":"A legislated, publicly reported 28-day standard from urgent referral to diagnosis","route":"/ideas/idea-acc-28-day-diagnosis-standard/","asOf":"2026-09-08","days":1},{"id":"idea-acc-funded-navigator-per-diagnosis","kind":"idea","name":"A paid patient navigator for every new cancer diagnosis, reimbursed as a service","route":"/ideas/idea-acc-funded-navigator-per-diagnosis/","asOf":"2026-09-08","days":1},{"id":"idea-acc-reflex-genomic-profiling-at-diagnosis","kind":"idea","name":"Pathologists order genomic profiling automatically at diagnosis of advanced cancer","route":"/ideas/idea-acc-reflex-genomic-profiling-at-diagnosis/","asOf":"2026-09-08","days":1},{"id":"idea-acc-guideline-concordance-dashboards","kind":"idea","name":"Live guideline-concordance dashboards for every tumour board, generated from the record","route":"/ideas/idea-acc-guideline-concordance-dashboards/","asOf":"2026-09-08","days":1},{"id":"idea-acc-national-virtual-mdt-rare-complex","kind":"idea","name":"Mandatory national virtual tumour boards for rare and complex cancers","route":"/ideas/idea-acc-national-virtual-mdt-rare-complex/","asOf":"2026-09-08","days":1},{"id":"idea-acc-portable-treatment-summary","kind":"idea","name":"A machine-readable treatment summary handed to every patient and readable by any hospital","route":"/ideas/idea-acc-portable-treatment-summary/","asOf":"2026-09-08","days":1},{"id":"idea-acc-primary-care-shared-care-agreements","kind":"idea","name":"Formal shared-care agreements between oncology and family doctors, with same-day e-consult","route":"/ideas/idea-acc-primary-care-shared-care-agreements/","asOf":"2026-09-08","days":1},{"id":"idea-acc-electronic-pro-monitoring-standard","kind":"idea","name":"Weekly electronic symptom reporting as a standard of care during systemic therapy","route":"/ideas/idea-acc-electronic-pro-monitoring-standard/","asOf":"2026-09-08","days":1},{"id":"idea-acc-tumour-board-implementation-audit","kind":"idea","name":"Audit whether tumour board recommendations were actually carried out","route":"/ideas/idea-acc-tumour-board-implementation-audit/","asOf":"2026-09-08","days":1},{"id":"idea-acc-acute-oncology-assessment-units","kind":"idea","name":"Acute oncology assessment units so sick cancer patients bypass the emergency department","route":"/ideas/idea-acc-acute-oncology-assessment-units/","asOf":"2026-09-08","days":1},{"id":"idea-acc-diagnostic-interval-public-registry","kind":"idea","name":"Record and publish the symptom-to-diagnosis interval for every cancer, by hospital","route":"/ideas/idea-acc-diagnostic-interval-public-registry/","asOf":"2026-09-08","days":1},{"id":"idea-acc-reflex-biomarker-panels-by-tumour","kind":"idea","name":"Standing reflex biomarker panels per tumour type, run without an oncologist's order","route":"/ideas/idea-acc-reflex-biomarker-panels-by-tumour/","asOf":"2026-09-08","days":1},{"id":"idea-acc-rapid-diagnostic-centres-vague-symptoms","kind":"idea","name":"Rapid diagnostic centres for people with vague but worrying symptoms","route":"/ideas/idea-acc-rapid-diagnostic-centres-vague-symptoms/","asOf":"2026-09-08","days":1},{"id":"idea-acc-embedded-decision-aids","kind":"idea","name":"Decision aids built into the record for every preference-sensitive cancer choice","route":"/ideas/idea-acc-embedded-decision-aids/","asOf":"2026-09-08","days":1},{"id":"idea-acc-financial-toxicity-screening-at-diagnosis","kind":"idea","name":"Screen every patient for financial hardship at diagnosis and connect them to help","route":"/ideas/idea-acc-financial-toxicity-screening-at-diagnosis/","asOf":"2026-09-08","days":1},{"id":"idea-acc-universal-asynchronous-second-opinion","kind":"idea","name":"An asynchronous expert second opinion for every new advanced-cancer diagnosis","route":"/ideas/idea-acc-universal-asynchronous-second-opinion/","asOf":"2026-09-08","days":1},{"id":"idea-acc-episode-payment-tied-to-concordance","kind":"idea","name":"Bundled episode payments for cancer care with bonuses for guideline concordance","route":"/ideas/idea-acc-episode-payment-tied-to-concordance/","asOf":"2026-09-08","days":1},{"id":"idea-acc-transition-handoff-medication-reconciliation","kind":"idea","name":"A standard handoff with medication reconciliation at every cancer care transition","route":"/ideas/idea-acc-transition-handoff-medication-reconciliation/","asOf":"2026-09-08","days":1},{"id":"idea-acc-pathway-capacity-simulation","kind":"idea","name":"Simulate each hospital's cancer pathway as a queue to find and remove the waits","route":"/ideas/idea-acc-pathway-capacity-simulation/","asOf":"2026-09-08","days":1},{"id":"idea-acc-auto-generated-survivorship-plans","kind":"idea","name":"Survivorship care plans generated automatically from the treatment record","route":"/ideas/idea-acc-auto-generated-survivorship-plans/","asOf":"2026-09-08","days":1},{"id":"idea-acc-risk-stratified-cardio-oncology-pathway","kind":"idea","name":"A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy","route":"/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/","asOf":"2026-09-08","days":1},{"id":"idea-acc-default-fertility-preservation-referral","kind":"idea","name":"Default fertility preservation referral for every patient under 40 before treatment","route":"/ideas/idea-acc-default-fertility-preservation-referral/","asOf":"2026-09-08","days":1},{"id":"idea-acc-national-late-effects-registry","kind":"idea","name":"A national late-effects registry linking treatment exposures to outcomes decades later","route":"/ideas/idea-acc-national-late-effects-registry/","asOf":"2026-09-08","days":1},{"id":"idea-acc-risk-stratified-follow-up","kind":"idea","name":"Risk-stratified follow-up: low-risk survivors to primary care with fast re-entry","route":"/ideas/idea-acc-risk-stratified-follow-up/","asOf":"2026-09-08","days":1},{"id":"idea-acc-tailored-second-cancer-screening","kind":"idea","name":"Tailored screening for second cancers in survivors with known high-risk exposures","route":"/ideas/idea-acc-tailored-second-cancer-screening/","asOf":"2026-09-08","days":1},{"id":"idea-acc-return-to-work-rehabilitation","kind":"idea","name":"Vocational rehabilitation integrated into cancer care so survivors can return to work","route":"/ideas/idea-acc-return-to-work-rehabilitation/","asOf":"2026-09-08","days":1},{"id":"idea-acc-cognitive-rehabilitation-after-chemotherapy","kind":"idea","name":"Trials of structured cognitive rehabilitation for cancer-related cognitive impairment","route":"/ideas/idea-acc-cognitive-rehabilitation-after-chemotherapy/","asOf":"2026-09-08","days":1},{"id":"idea-acc-cardiometabolic-clinic-hormone-therapy","kind":"idea","name":"Cardiometabolic screening and treatment for survivors on long-term hormone therapy","route":"/ideas/idea-acc-cardiometabolic-clinic-hormone-therapy/","asOf":"2026-09-08","days":1},{"id":"idea-acc-aya-survivorship-passport","kind":"idea","name":"A survivorship passport app for adolescent and young adult survivors","route":"/ideas/idea-acc-aya-survivorship-passport/","asOf":"2026-09-08","days":1},{"id":"idea-acc-survivor-biobank-late-effect-prediction","kind":"idea","name":"A survivor biobank to find who will develop late effects before they do","route":"/ideas/idea-acc-survivor-biobank-late-effect-prediction/","asOf":"2026-09-08","days":1},{"id":"idea-acc-lymphoedema-prospective-surveillance","kind":"idea","name":"Prospective arm-volume surveillance to catch and reverse lymphoedema early","route":"/ideas/idea-acc-lymphoedema-prospective-surveillance/","asOf":"2026-09-08","days":1},{"id":"idea-acc-automatic-early-palliative-triggers","kind":"idea","name":"Automatic palliative care referral triggered by diagnosis, not by decline","route":"/ideas/idea-acc-automatic-early-palliative-triggers/","asOf":"2026-09-08","days":1},{"id":"idea-acc-balanced-opioid-policy-reform","kind":"idea","name":"National opioid quota reform so morphine reaches cancer patients","route":"/ideas/idea-acc-balanced-opioid-policy-reform/","asOf":"2026-09-08","days":1},{"id":"idea-acc-local-oral-morphine-production","kind":"idea","name":"Locally prepared oral morphine solution, licensed for nurse prescribing","route":"/ideas/idea-acc-local-oral-morphine-production/","asOf":"2026-09-08","days":1},{"id":"idea-acc-neighbourhood-palliative-networks","kind":"idea","name":"Volunteer-led neighbourhood palliative networks, the Kerala model, adapted elsewhere","route":"/ideas/idea-acc-neighbourhood-palliative-networks/","asOf":"2026-09-08","days":1},{"id":"idea-acc-tele-palliative-care-default","kind":"idea","name":"Video palliative care as an equivalent default option for patients far from a team","route":"/ideas/idea-acc-tele-palliative-care-default/","asOf":"2026-09-08","days":1},{"id":"idea-acc-earmarked-palliative-budget-share","kind":"idea","name":"Earmark a fixed share of every national cancer budget for palliative care","route":"/ideas/idea-acc-earmarked-palliative-budget-share/","asOf":"2026-09-08","days":1},{"id":"idea-acc-pain-control-public-audit","kind":"idea","name":"Measure and publish pain control rates in every cancer centre","route":"/ideas/idea-acc-pain-control-public-audit/","asOf":"2026-09-08","days":1},{"id":"idea-acc-serious-illness-conversation-prompts","kind":"idea","name":"Train every oncology team in serious-illness conversations and prompt them in the record","route":"/ideas/idea-acc-serious-illness-conversation-prompts/","asOf":"2026-09-08","days":1},{"id":"idea-acc-single-fraction-palliative-radiotherapy-default","kind":"idea","name":"Single-fraction radiotherapy as the default for painful bone metastases","route":"/ideas/idea-acc-single-fraction-palliative-radiotherapy-default/","asOf":"2026-09-08","days":1},{"id":"idea-acc-essential-palliative-package-in-uhc","kind":"idea","name":"Put the essential palliative care package into every universal health coverage benefit list","route":"/ideas/idea-acc-essential-palliative-package-in-uhc/","asOf":"2026-09-08","days":1},{"id":"idea-acc-paediatric-palliative-in-every-childhood-unit","kind":"idea","name":"A paediatric palliative care team in every childhood cancer unit","route":"/ideas/idea-acc-paediatric-palliative-in-every-childhood-unit/","asOf":"2026-09-08","days":1},{"id":"idea-acc-home-based-end-of-life-kits","kind":"idea","name":"Home end-of-life care kits and trained family carers where no hospice exists","route":"/ideas/idea-acc-home-based-end-of-life-kits/","asOf":"2026-09-08","days":1},{"id":"idea-acc-methadone-and-alternatives-where-morphine-fails","kind":"idea","name":"Trials of low-cost opioid alternatives where morphine supply is unreliable","route":"/ideas/idea-acc-methadone-and-alternatives-where-morphine-fails/","asOf":"2026-09-08","days":1},{"id":"idea-acc-geriatric-assessment-by-default","kind":"idea","name":"Geriatric assessment by default for every patient over 70 starting cancer treatment","route":"/ideas/idea-acc-geriatric-assessment-by-default/","asOf":"2026-09-08","days":1},{"id":"idea-acc-broad-eligibility-as-regulatory-default","kind":"idea","name":"Make sponsors justify every trial exclusion of older and multimorbid patients","route":"/ideas/idea-acc-broad-eligibility-as-regulatory-default/","asOf":"2026-09-08","days":1},{"id":"idea-acc-pragmatic-trials-over-75-function-endpoints","kind":"idea","name":"Pragmatic trials in patients over 75 with function, not just survival, as the primary endpoint","route":"/ideas/idea-acc-pragmatic-trials-over-75-function-endpoints/","asOf":"2026-09-08","days":1},{"id":"idea-acc-structured-deprescribing-at-diagnosis","kind":"idea","name":"Structured deprescribing review at cancer diagnosis and again at transition to palliative care","route":"/ideas/idea-acc-structured-deprescribing-at-diagnosis/","asOf":"2026-09-08","days":1},{"id":"idea-acc-home-chemotherapy-older-patients","kind":"idea","name":"Home administration of selected chemotherapy and immunotherapy for older and frail patients","route":"/ideas/idea-acc-home-chemotherapy-older-patients/","asOf":"2026-09-08","days":1},{"id":"idea-acc-hospital-at-home-oncology","kind":"idea","name":"Hospital-at-home for oncology: treating low-risk febrile neutropenia and dehydration at home","route":"/ideas/idea-acc-hospital-at-home-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-acc-upfront-reduced-dose-trials-frail","kind":"idea","name":"Upfront reduced-dose regimens tested head-to-head in frail older patients","route":"/ideas/idea-acc-upfront-reduced-dose-trials-frail/","asOf":"2026-09-08","days":1},{"id":"idea-acc-electronic-frailty-index-oncology","kind":"idea","name":"An automatic electronic frailty index inside the oncology record","route":"/ideas/idea-acc-electronic-frailty-index-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-acc-geriatric-co-management-surgery","kind":"idea","name":"Geriatrician co-management for older patients having cancer surgery","route":"/ideas/idea-acc-geriatric-co-management-surgery/","asOf":"2026-09-08","days":1},{"id":"idea-acc-post-approval-evidence-over-75","kind":"idea","name":"Require post-approval evidence in patients over 75 and update labels accordingly","route":"/ideas/idea-acc-post-approval-evidence-over-75/","asOf":"2026-09-08","days":1},{"id":"idea-acc-caregiver-training-as-covered-service","kind":"idea","name":"Caregiver training and respite as a covered service in cancer care for older patients","route":"/ideas/idea-acc-caregiver-training-as-covered-service/","asOf":"2026-09-08","days":1},{"id":"idea-acc-pharmacist-interaction-review-oral-anticancer","kind":"idea","name":"Pharmacist interaction check before every oral cancer-drug prescription","route":"/ideas/idea-acc-pharmacist-interaction-review-oral-anticancer/","asOf":"2026-09-08","days":1},{"id":"idea-acc-time-toxicity-reporting","kind":"idea","name":"Report time toxicity, the days spent in healthcare, as a standard outcome for older patients","route":"/ideas/idea-acc-time-toxicity-reporting/","asOf":"2026-09-08","days":1},{"id":"idea-acc-prehabilitation-older-surgery","kind":"idea","name":"Multimodal prehabilitation for older patients before major cancer surgery","route":"/ideas/idea-acc-prehabilitation-older-surgery/","asOf":"2026-09-08","days":1},{"id":"idea-acc-dementia-and-cancer-pathway","kind":"idea","name":"A defined pathway for patients with both dementia and cancer","route":"/ideas/idea-acc-dementia-and-cancer-pathway/","asOf":"2026-09-08","days":1},{"id":"idea-data-mcode-payment-condition","kind":"idea","name":"No mCODE, no payment: tie oncology reimbursement to a minimal structured record","route":"/ideas/idea-data-mcode-payment-condition/","asOf":"2026-09-08","days":1},{"id":"idea-data-oncology-api-certification","kind":"idea","name":"Certify every oncology software product for a standard bulk data export","route":"/ideas/idea-data-oncology-api-certification/","asOf":"2026-09-08","days":1},{"id":"idea-data-national-cancer-data-space","kind":"idea","name":"A national cancer data space with one legal front door","route":"/ideas/idea-data-national-cancer-data-space/","asOf":"2026-09-08","days":1},{"id":"idea-data-federated-analytics-network","kind":"idea","name":"Send the code to the data: a federated analytics network of cancer centres","route":"/ideas/idea-data-federated-analytics-network/","asOf":"2026-09-08","days":1},{"id":"idea-data-federated-learning-imaging","kind":"idea","name":"Federated training of pathology and radiology models across hospitals","route":"/ideas/idea-data-federated-learning-imaging/","asOf":"2026-09-08","days":1},{"id":"idea-data-donor-card","kind":"idea","name":"A cancer data donor card: patient-controlled donation of records for research","route":"/ideas/idea-data-donor-card/","asOf":"2026-09-08","days":1},{"id":"idea-data-dynamic-consent-app","kind":"idea","name":"Dynamic consent with usage receipts","route":"/ideas/idea-data-dynamic-consent-app/","asOf":"2026-09-08","days":1},{"id":"idea-data-consent-in-the-pathway","kind":"idea","name":"Broad research consent as a routine step of the cancer pathway","route":"/ideas/idea-data-consent-in-the-pathway/","asOf":"2026-09-08","days":1},{"id":"idea-data-accredited-tre-network","kind":"idea","name":"Accredited trusted research environments with curated cancer tables","route":"/ideas/idea-data-accredited-tre-network/","asOf":"2026-09-08","days":1},{"id":"idea-data-synthetic-companion-datasets","kind":"idea","name":"A synthetic twin of every restricted cancer dataset for code development","route":"/ideas/idea-data-synthetic-companion-datasets/","asOf":"2026-09-08","days":1},{"id":"idea-data-open-deidentification-pipeline","kind":"idea","name":"One certified open-source de-identification pipeline for scans and slides","route":"/ideas/idea-data-open-deidentification-pipeline/","asOf":"2026-09-08","days":1},{"id":"idea-data-national-slide-archive","kind":"idea","name":"Digitise the nation's pathology slides and link them to outcomes","route":"/ideas/idea-data-national-slide-archive/","asOf":"2026-09-08","days":1},{"id":"idea-data-structured-genomic-reports","kind":"idea","name":"Every tumour genomic report machine-readable and deposited nationally","route":"/ideas/idea-data-structured-genomic-reports/","asOf":"2026-09-08","days":1},{"id":"idea-data-automatic-outcome-linkage","kind":"idea","name":"Automatic weekly linkage of cancer registries to deaths, prescriptions and imaging","route":"/ideas/idea-data-automatic-outcome-linkage/","asOf":"2026-09-08","days":1},{"id":"idea-data-pro-as-structured-standard","kind":"idea","name":"Patient-reported symptoms captured as standard structured data in every clinic","route":"/ideas/idea-data-pro-as-structured-standard/","asOf":"2026-09-08","days":1},{"id":"idea-data-open-line-of-therapy-algorithms","kind":"idea","name":"Open, benchmarked algorithms for lines of therapy and progression from routine data","route":"/ideas/idea-data-open-line-of-therapy-algorithms/","asOf":"2026-09-08","days":1},{"id":"idea-data-point-of-care-randomisation","kind":"idea","name":"Point-of-care randomisation built into the oncology record","route":"/ideas/idea-data-point-of-care-randomisation/","asOf":"2026-09-08","days":1},{"id":"idea-data-procurement-open-api-clauses","kind":"idea","name":"Public procurement clauses banning data export fees and lock-in","route":"/ideas/idea-data-procurement-open-api-clauses/","asOf":"2026-09-08","days":1},{"id":"idea-data-privacy-preserving-linkage-tokens","kind":"idea","name":"Privacy-preserving linkage tokens for every cancer data holder","route":"/ideas/idea-data-privacy-preserving-linkage-tokens/","asOf":"2026-09-08","days":1},{"id":"idea-data-registry-in-a-box","kind":"idea","name":"Open-source cancer registry-in-a-box for low-resource settings","route":"/ideas/idea-data-registry-in-a-box/","asOf":"2026-09-08","days":1},{"id":"idea-data-trial-to-registry-bridge","kind":"idea","name":"Map trial case report forms to the registry standard so trial and routine data join","route":"/ideas/idea-data-trial-to-registry-bridge/","asOf":"2026-09-08","days":1},{"id":"idea-data-atlas-to-outcome-linkage","kind":"idea","name":"Link single-cell and spatial tumour atlases to clinical outcomes","route":"/ideas/idea-data-atlas-to-outcome-linkage/","asOf":"2026-09-08","days":1},{"id":"idea-data-radiotherapy-dose-repository","kind":"idea","name":"A national repository of radiotherapy dose plans linked to outcomes","route":"/ideas/idea-data-radiotherapy-dose-repository/","asOf":"2026-09-08","days":1},{"id":"idea-data-surgical-video-commons","kind":"idea","name":"A consented commons of surgical video linked to pathology and outcomes","route":"/ideas/idea-data-surgical-video-commons/","asOf":"2026-09-08","days":1},{"id":"idea-data-ipd-deposit-enforcement","kind":"idea","name":"Enforce individual participant data sharing as a condition of publication and funding","route":"/ideas/idea-data-ipd-deposit-enforcement/","asOf":"2026-09-08","days":1},{"id":"idea-data-common-biobank-consent-mta","kind":"idea","name":"A common consent and material transfer template for tumour biobanks","route":"/ideas/idea-data-common-biobank-consent-mta/","asOf":"2026-09-08","days":1},{"id":"idea-data-patient-held-cancer-record","kind":"idea","name":"A patient-held cancer record that travels across providers and borders","route":"/ideas/idea-data-patient-held-cancer-record/","asOf":"2026-09-08","days":1},{"id":"idea-data-cross-border-rare-cancer-pool","kind":"idea","name":"One legal framework for pooling rare cancer data across borders","route":"/ideas/idea-data-cross-border-rare-cancer-pool/","asOf":"2026-09-08","days":1},{"id":"idea-data-quality-scorecards","kind":"idea","name":"Public data-quality scorecards for every cancer centre","route":"/ideas/idea-data-quality-scorecards/","asOf":"2026-09-08","days":1},{"id":"idea-data-structured-radiology-response","kind":"idea","name":"Structured, coded radiology reports for cancer response instead of free text","route":"/ideas/idea-data-structured-radiology-response/","asOf":"2026-09-08","days":1},{"id":"idea-data-target-trial-emulation-standard","kind":"idea","name":"A pre-registered standard for emulating trials with real-world data","route":"/ideas/idea-data-target-trial-emulation-standard/","asOf":"2026-09-08","days":1},{"id":"idea-data-rwe-rct-calibration-library","kind":"idea","name":"An open library pairing completed cancer trials with real-world emulations","route":"/ideas/idea-data-rwe-rct-calibration-library/","asOf":"2026-09-08","days":1},{"id":"idea-data-accelerated-approval-registry-condition","kind":"idea","name":"Every patient on an accelerated-approval drug enrolled in a registry until confirmation","route":"/ideas/idea-data-accelerated-approval-registry-condition/","asOf":"2026-09-08","days":1},{"id":"idea-data-rwpfs-validation-programme","kind":"idea","name":"Validate real-world progression against central imaging review","route":"/ideas/idea-data-rwpfs-validation-programme/","asOf":"2026-09-08","days":1},{"id":"idea-data-registry-based-rcts","kind":"idea","name":"Registry-based randomised trials for oncology comparative effectiveness","route":"/ideas/idea-data-registry-based-rcts/","asOf":"2026-09-08","days":1},{"id":"idea-data-coverage-with-evidence-development","kind":"idea","name":"Payers fund cancer drugs conditionally on a registry with a pre-specified analysis","route":"/ideas/idea-data-coverage-with-evidence-development/","asOf":"2026-09-08","days":1},{"id":"idea-data-off-label-outcomes-registry","kind":"idea","name":"A structured registry for every off-label cancer drug use","route":"/ideas/idea-data-off-label-outcomes-registry/","asOf":"2026-09-08","days":1},{"id":"idea-data-real-world-dose-intensity","kind":"idea","name":"Real-world dose intensity and toxicity monitoring to revise labelled doses","route":"/ideas/idea-data-real-world-dose-intensity/","asOf":"2026-09-08","days":1},{"id":"idea-data-excluded-populations-rwe-mandate","kind":"idea","name":"Mandatory real-world reporting for patients excluded from pivotal trials","route":"/ideas/idea-data-excluded-populations-rwe-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-data-linked-pharmacovigilance-interactions","kind":"idea","name":"Linked prescribing and outcome data to find drug interactions with cancer therapy","route":"/ideas/idea-data-linked-pharmacovigilance-interactions/","asOf":"2026-09-08","days":1},{"id":"idea-data-access-programme-outcomes","kind":"idea","name":"One outcome record for every donated or discounted cancer drug pack","route":"/ideas/idea-data-access-programme-outcomes/","asOf":"2026-09-08","days":1},{"id":"idea-data-registry-genomics-linkage-programme","kind":"idea","name":"Link every national cancer registry to tumour genomics","route":"/ideas/idea-data-registry-genomics-linkage-programme/","asOf":"2026-09-08","days":1},{"id":"idea-data-observational-study-registration","kind":"idea","name":"Pre-registration and results reporting for real-world cancer studies","route":"/ideas/idea-data-observational-study-registration/","asOf":"2026-09-08","days":1},{"id":"idea-data-gcp-for-real-world-data","kind":"idea","name":"Good practice standards and inspection for real-world data sources","route":"/ideas/idea-data-gcp-for-real-world-data/","asOf":"2026-09-08","days":1},{"id":"idea-data-registry-follow-up-of-trial-participants","kind":"idea","name":"Follow every trial participant for 30 years through registry linkage","route":"/ideas/idea-data-registry-follow-up-of-trial-participants/","asOf":"2026-09-08","days":1},{"id":"idea-data-wearable-endpoints-validation","kind":"idea","name":"Wearable activity data as a validated real-world endpoint","route":"/ideas/idea-data-wearable-endpoints-validation/","asOf":"2026-09-08","days":1},{"id":"idea-data-external-control-arm-standard","kind":"idea","name":"Standards for external control arms built from federated real-world data","route":"/ideas/idea-data-external-control-arm-standard/","asOf":"2026-09-08","days":1},{"id":"idea-data-paediatric-rwe-consortium","kind":"idea","name":"An international consortium pooling the outcome of every treated child with cancer","route":"/ideas/idea-data-paediatric-rwe-consortium/","asOf":"2026-09-08","days":1},{"id":"idea-data-sequencing-analysis-per-approval","kind":"idea","name":"A real-world sequencing analysis within a year of every new approval","route":"/ideas/idea-data-sequencing-analysis-per-approval/","asOf":"2026-09-08","days":1},{"id":"idea-data-outcome-based-price-reassessment","kind":"idea","name":"Reassess cancer drug prices at three years using real-world outcomes","route":"/ideas/idea-data-outcome-based-price-reassessment/","asOf":"2026-09-08","days":1},{"id":"idea-data-computable-living-guidelines","kind":"idea","name":"Living guidelines published as versioned, computable rules","route":"/ideas/idea-data-computable-living-guidelines/","asOf":"2026-09-08","days":1},{"id":"idea-data-open-evidence-knowledge-graph","kind":"idea","name":"An open knowledge graph linking trials, results, biomarkers, drugs and recommendations","route":"/ideas/idea-data-open-evidence-knowledge-graph/","asOf":"2026-09-08","days":1},{"id":"idea-data-funded-living-systematic-reviews","kind":"idea","name":"Funded living systematic reviews for every major cancer indication","route":"/ideas/idea-data-funded-living-systematic-reviews/","asOf":"2026-09-08","days":1},{"id":"idea-data-plain-language-summary-mandate","kind":"idea","name":"A plain-language summary of every cancer trial result within a year","route":"/ideas/idea-data-plain-language-summary-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-data-structured-trial-results-deposit","kind":"idea","name":"Deposit trial results as structured data, not just PDFs","route":"/ideas/idea-data-structured-trial-results-deposit/","asOf":"2026-09-08","days":1},{"id":"idea-data-provenance-first-decision-support","kind":"idea","name":"Decision support that cites the exact trial and guideline line it relies on","route":"/ideas/idea-data-provenance-first-decision-support/","asOf":"2026-09-08","days":1},{"id":"idea-data-tumour-board-evidence-assistant","kind":"idea","name":"A tumour board assistant that cites its evidence and tracks outcomes","route":"/ideas/idea-data-tumour-board-evidence-assistant/","asOf":"2026-09-08","days":1},{"id":"idea-data-guideline-concordance-dashboards","kind":"idea","name":"Real-time guideline-concordance feedback for every cancer centre","route":"/ideas/idea-data-guideline-concordance-dashboards/","asOf":"2026-09-08","days":1},{"id":"idea-data-thirty-day-practice-change-learning","kind":"idea","name":"Micro-learning pushed to community oncologists within 30 days of a practice change","route":"/ideas/idea-data-thirty-day-practice-change-learning/","asOf":"2026-09-08","days":1},{"id":"idea-data-patient-explainers-per-recommendation","kind":"idea","name":"A plain-language explainer for every guideline recommendation, in every major language","route":"/ideas/idea-data-patient-explainers-per-recommendation/","asOf":"2026-09-08","days":1},{"id":"idea-data-evidence-to-adoption-tracker","kind":"idea","name":"A public tracker of how long each country takes to adopt new evidence","route":"/ideas/idea-data-evidence-to-adoption-tracker/","asOf":"2026-09-08","days":1},{"id":"idea-data-retraction-propagation","kind":"idea","name":"Automatic flagging of retracted or corrected evidence in guidelines and decision support","route":"/ideas/idea-data-retraction-propagation/","asOf":"2026-09-08","days":1},{"id":"idea-data-open-licensed-guidelines","kind":"idea","name":"Open licences for publicly funded cancer guidelines","route":"/ideas/idea-data-open-licensed-guidelines/","asOf":"2026-09-08","days":1},{"id":"idea-data-unanswered-questions-registry","kind":"idea","name":"A public registry of unanswered clinical questions linked to funding calls","route":"/ideas/idea-data-unanswered-questions-registry/","asOf":"2026-09-08","days":1},{"id":"idea-data-living-llm-oncology-benchmark","kind":"idea","name":"A monthly-updated benchmark for AI answers to oncology questions with citation accuracy","route":"/ideas/idea-data-living-llm-oncology-benchmark/","asOf":"2026-09-08","days":1},{"id":"idea-data-rapid-guideline-translation","kind":"idea","name":"Expert-verified translation of guideline updates into 20 languages within 30 days","route":"/ideas/idea-data-rapid-guideline-translation/","asOf":"2026-09-08","days":1},{"id":"idea-data-offline-cds-lmic-generalists","kind":"idea","name":"Offline decision support for generalists treating common cancers in low-resource settings","route":"/ideas/idea-data-offline-cds-lmic-generalists/","asOf":"2026-09-08","days":1},{"id":"idea-data-toxicity-cds-for-nurses","kind":"idea","name":"Toxicity-management decision support for nurses and pharmacists","route":"/ideas/idea-data-toxicity-cds-for-nurses/","asOf":"2026-09-08","days":1},{"id":"idea-data-72-hour-second-opinion-network","kind":"idea","name":"A digital second-opinion network answering community oncologists within 72 hours","route":"/ideas/idea-data-72-hour-second-opinion-network/","asOf":"2026-09-08","days":1},{"id":"idea-data-standard-of-care-change-alerts","kind":"idea","name":"Subscribable alerts when the standard of care changes for a patient's situation","route":"/ideas/idea-data-standard-of-care-change-alerts/","asOf":"2026-09-08","days":1},{"id":"idea-data-full-data-with-abstract","kind":"idea","name":"End the abstract-to-paper gap: require full results with any conference presentation","route":"/ideas/idea-data-full-data-with-abstract/","asOf":"2026-09-08","days":1},{"id":"idea-data-implementation-trials-programme","kind":"idea","name":"Randomised trials of how to spread proven cancer treatments, not just what works","route":"/ideas/idea-data-implementation-trials-programme/","asOf":"2026-09-08","days":1},{"id":"idea-data-wikipedia-oncology-editors","kind":"idea","name":"Fund expert editors for the cancer pages of Wikipedia and Wikidata","route":"/ideas/idea-data-wikipedia-oncology-editors/","asOf":"2026-09-08","days":1},{"id":"idea-data-order-set-defaults-30-days","kind":"idea","name":"Update hospital order sets within 30 days of a guideline change","route":"/ideas/idea-data-order-set-defaults-30-days/","asOf":"2026-09-08","days":1},{"id":"idea-data-standard-of-care-api","kind":"idea","name":"A public API serving the current standard of care for any cancer, stage and biomarker","route":"/ideas/idea-data-standard-of-care-api/","asOf":"2026-09-08","days":1},{"id":"idea-data-prospective-ai-trials-fund","kind":"idea","name":"A dedicated fund for randomised trials of cancer AI with patient outcomes","route":"/ideas/idea-data-prospective-ai-trials-fund/","asOf":"2026-09-08","days":1},{"id":"idea-data-clinical-ai-model-registry","kind":"idea","name":"A public registry of every AI model used in cancer care","route":"/ideas/idea-data-clinical-ai-model-registry/","asOf":"2026-09-08","days":1},{"id":"idea-data-ai-post-market-performance-reporting","kind":"idea","name":"Mandatory post-market performance reporting for cancer AI","route":"/ideas/idea-data-ai-post-market-performance-reporting/","asOf":"2026-09-08","days":1},{"id":"idea-data-drift-monitoring-standard","kind":"idea","name":"A standard for monitoring AI performance drift with pause thresholds","route":"/ideas/idea-data-drift-monitoring-standard/","asOf":"2026-09-08","days":1},{"id":"idea-data-sequestered-prospective-benchmarks","kind":"idea","name":"Sequestered, prospectively collected benchmark datasets that no one can train on","route":"/ideas/idea-data-sequestered-prospective-benchmarks/","asOf":"2026-09-08","days":1},{"id":"idea-data-neutral-ai-evaluator","kind":"idea","name":"A neutral public evaluator for cancer AI, on the model of NIST","route":"/ideas/idea-data-neutral-ai-evaluator/","asOf":"2026-09-08","days":1},{"id":"idea-data-regulatory-sandbox-adaptive-ai","kind":"idea","name":"A regulatory sandbox for continuously learning cancer AI","route":"/ideas/idea-data-regulatory-sandbox-adaptive-ai/","asOf":"2026-09-08","days":1},{"id":"idea-data-ai-liability-safe-harbour","kind":"idea","name":"A liability framework for clinical AI: safe harbour for clinicians, liability for makers","route":"/ideas/idea-data-ai-liability-safe-harbour/","asOf":"2026-09-08","days":1},{"id":"idea-data-ai-reimbursement-tied-to-outcomes","kind":"idea","name":"Pay for cancer AI only when it has outcome evidence, then pay properly","route":"/ideas/idea-data-ai-reimbursement-tied-to-outcomes/","asOf":"2026-09-08","days":1},{"id":"idea-data-silent-trial-before-deployment","kind":"idea","name":"A mandatory silent (shadow) trial before any cancer AI goes live","route":"/ideas/idea-data-silent-trial-before-deployment/","asOf":"2026-09-08","days":1},{"id":"idea-data-subgroup-performance-reporting-mandate","kind":"idea","name":"Mandatory subgroup performance reporting for cancer AI","route":"/ideas/idea-data-subgroup-performance-reporting-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-data-open-cell-foundation-model","kind":"idea","name":"An open foundation model of the cancer cell trained on perturbation data","route":"/ideas/idea-data-open-cell-foundation-model/","asOf":"2026-09-08","days":1},{"id":"idea-data-precompetitive-cancer-foundation-model","kind":"idea","name":"A pre-competitive consortium to train a shared multimodal cancer foundation model","route":"/ideas/idea-data-precompetitive-cancer-foundation-model/","asOf":"2026-09-08","days":1},{"id":"idea-data-open-weights-for-public-funded-ai","kind":"idea","name":"Publicly funded cancer AI must release open weights and model cards","route":"/ideas/idea-data-open-weights-for-public-funded-ai/","asOf":"2026-09-08","days":1},{"id":"idea-data-digital-twin-predict-then-observe","kind":"idea","name":"Digital twins for treatment selection, validated by predicting before observing","route":"/ideas/idea-data-digital-twin-predict-then-observe/","asOf":"2026-09-08","days":1},{"id":"idea-data-in-silico-trials-calibrated","kind":"idea","name":"In silico trials to prioritise combinations, scored against later real trials","route":"/ideas/idea-data-in-silico-trials-calibrated/","asOf":"2026-09-08","days":1},{"id":"idea-data-ai-pathology-evaluation-standard","kind":"idea","name":"A standard evaluation pathway for AI-assisted pathology, from reader study to deployment","route":"/ideas/idea-data-ai-pathology-evaluation-standard/","asOf":"2026-09-08","days":1},{"id":"idea-data-ai-screening-endpoints","kind":"idea","name":"Require stage-shift or interval-cancer endpoints for AI in cancer screening","route":"/ideas/idea-data-ai-screening-endpoints/","asOf":"2026-09-08","days":1},{"id":"idea-data-multisite-validation-precondition","kind":"idea","name":"External validation at five or more sites in two countries before clearance","route":"/ideas/idea-data-multisite-validation-precondition/","asOf":"2026-09-08","days":1},{"id":"idea-data-patient-facing-model-cards","kind":"idea","name":"Patients told which AI is used in their care, in plain language","route":"/ideas/idea-data-patient-facing-model-cards/","asOf":"2026-09-08","days":1},{"id":"idea-data-ai-red-team-programme","kind":"idea","name":"Red-team programmes that attack cancer AI before patients do","route":"/ideas/idea-data-ai-red-team-programme/","asOf":"2026-09-08","days":1},{"id":"idea-data-ai-audit-trail-in-ehr","kind":"idea","name":"Every AI output logged in the record with input hash, version and clinician response","route":"/ideas/idea-data-ai-audit-trail-in-ehr/","asOf":"2026-09-08","days":1},{"id":"idea-data-ai-decommissioning-rules","kind":"idea","name":"Rules for retiring cancer AI when performance drops or the standard of care moves","route":"/ideas/idea-data-ai-decommissioning-rules/","asOf":"2026-09-08","days":1},{"id":"idea-data-llm-documentation-rct-oncology","kind":"idea","name":"A randomised trial of AI scribes in oncology clinics measuring errors and time","route":"/ideas/idea-data-llm-documentation-rct-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-data-ai-vs-tumour-board-rct","kind":"idea","name":"A randomised trial of AI-generated treatment recommendations versus tumour boards","route":"/ideas/idea-data-ai-vs-tumour-board-rct/","asOf":"2026-09-08","days":1},{"id":"idea-fund-burden-weighted-portfolio","kind":"idea","name":"Burden-weighted portfolio targets for every major cancer funder","route":"/ideas/idea-fund-burden-weighted-portfolio/","asOf":"2026-09-08","days":1},{"id":"idea-fund-metastasis-moonshot","kind":"idea","name":"A ring-fenced metastasis programme with metastasis-specific endpoints","route":"/ideas/idea-fund-metastasis-moonshot/","asOf":"2026-09-08","days":1},{"id":"idea-fund-prevention-moonshot","kind":"idea","name":"A delivery-science moonshot for prevention we already own","route":"/ideas/idea-fund-prevention-moonshot/","asOf":"2026-09-08","days":1},{"id":"idea-fund-dollars-per-death-dashboard","kind":"idea","name":"A public dashboard of research money per death for every cancer","route":"/ideas/idea-fund-dollars-per-death-dashboard/","asOf":"2026-09-08","days":1},{"id":"idea-fund-implementation-quota","kind":"idea","name":"A fixed share of trial-group funding for getting proven care to patients","route":"/ideas/idea-fund-implementation-quota/","asOf":"2026-09-08","days":1},{"id":"idea-fund-lmic-burden-match","kind":"idea","name":"Burden-matched funding for trials led in low- and middle-income countries","route":"/ideas/idea-fund-lmic-burden-match/","asOf":"2026-09-08","days":1},{"id":"idea-fund-neglected-cancer-lottery","kind":"idea","name":"Partial lottery funding for good proposals in under-funded cancers","route":"/ideas/idea-fund-neglected-cancer-lottery/","asOf":"2026-09-08","days":1},{"id":"idea-fund-ten-year-hard-problem-awards","kind":"idea","name":"Ten-year awards for scientists who commit to one hard problem","route":"/ideas/idea-fund-ten-year-hard-problem-awards/","asOf":"2026-09-08","days":1},{"id":"idea-fund-survivorship-endowment-levy","kind":"idea","name":"A survivorship research endowment funded by a levy on curative therapy prices","route":"/ideas/idea-fund-survivorship-endowment-levy/","asOf":"2026-09-08","days":1},{"id":"idea-fund-non-drug-trial-quota","kind":"idea","name":"A statutory minimum share of public trial money for surgery and radiotherapy","route":"/ideas/idea-fund-non-drug-trial-quota/","asOf":"2026-09-08","days":1},{"id":"idea-fund-replication-set-aside","kind":"idea","name":"Set aside 3% of grant budgets to replicate findings before translation","route":"/ideas/idea-fund-replication-set-aside/","asOf":"2026-09-08","days":1},{"id":"idea-fund-white-space-map","kind":"idea","name":"An annual map of high-burden questions that nobody is funding","route":"/ideas/idea-fund-white-space-map/","asOf":"2026-09-08","days":1},{"id":"idea-fund-programme-officer-incentives","kind":"idea","name":"Judge funding programme officers on burden alignment and trials completed","route":"/ideas/idea-fund-programme-officer-incentives/","asOf":"2026-09-08","days":1},{"id":"idea-fund-patient-burden-review-criterion","kind":"idea","name":"A formal patient-burden score in grant peer review","route":"/ideas/idea-fund-patient-burden-review-criterion/","asOf":"2026-09-08","days":1},{"id":"idea-fund-global-cancer-fund","kind":"idea","name":"A Global Fund for cancer care in low- and middle-income countries","route":"/ideas/idea-fund-global-cancer-fund/","asOf":"2026-09-08","days":1},{"id":"idea-fund-cachexia-programme","kind":"idea","name":"A dedicated programme for cachexia and treatment toxicity research","route":"/ideas/idea-fund-cachexia-programme/","asOf":"2026-09-08","days":1},{"id":"idea-fund-cross-funder-portfolio-registry","kind":"idea","name":"Mandatory machine-readable portfolio reporting for all large cancer funders","route":"/ideas/idea-fund-cross-funder-portfolio-registry/","asOf":"2026-09-08","days":1},{"id":"idea-fund-older-patients-trial-fund","kind":"idea","name":"A trials fund reserved for older and multimorbid patients","route":"/ideas/idea-fund-older-patients-trial-fund/","asOf":"2026-09-08","days":1},{"id":"idea-fund-fast-grants-oncology","kind":"idea","name":"Forty-eight-hour small grants for bold experiments in neglected cancers","route":"/ideas/idea-fund-fast-grants-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-fund-brain-metastases-programme","kind":"idea","name":"Treat brain metastases as a disease with its own trials programme","route":"/ideas/idea-fund-brain-metastases-programme/","asOf":"2026-09-08","days":1},{"id":"idea-fund-cure-prize","kind":"idea","name":"A billion-dollar prize for the first durable cure of a lethal metastatic cancer","route":"/ideas/idea-fund-cure-prize/","asOf":"2026-09-08","days":1},{"id":"idea-fund-first-in-class-prize","kind":"idea","name":"Milestone prizes for first-in-class mechanisms reaching human proof of concept","route":"/ideas/idea-fund-first-in-class-prize/","asOf":"2026-09-08","days":1},{"id":"idea-fund-amc-paediatric-rare","kind":"idea","name":"Advance market commitments for paediatric and rare cancer drugs","route":"/ideas/idea-fund-amc-paediatric-rare/","asOf":"2026-09-08","days":1},{"id":"idea-fund-conditional-transferable-voucher","kind":"idea","name":"Transferable priority vouchers for first-in-class drugs, with price conditions","route":"/ideas/idea-fund-conditional-transferable-voucher/","asOf":"2026-09-08","days":1},{"id":"idea-fund-value-based-patent-extension","kind":"idea","name":"Patent term extension scaled to proven survival gain","route":"/ideas/idea-fund-value-based-patent-extension/","asOf":"2026-09-08","days":1},{"id":"idea-fund-benefit-indexed-exclusivity","kind":"idea","name":"Shorter exclusivity for later-in-class drugs without added benefit","route":"/ideas/idea-fund-benefit-indexed-exclusivity/","asOf":"2026-09-08","days":1},{"id":"idea-fund-pay-for-cure-annuities","kind":"idea","name":"Outcome-based annuity payments for potentially curative one-time therapies","route":"/ideas/idea-fund-pay-for-cure-annuities/","asOf":"2026-09-08","days":1},{"id":"idea-fund-nonprofit-pharma","kind":"idea","name":"A non-profit pharmaceutical company for the cancers markets ignore","route":"/ideas/idea-fund-nonprofit-pharma/","asOf":"2026-09-08","days":1},{"id":"idea-fund-public-option-generic-oncology","kind":"idea","name":"Public-option manufacturing for essential generic cancer drugs in shortage","route":"/ideas/idea-fund-public-option-generic-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-fund-public-car-t-manufacturing","kind":"idea","name":"Hospital-based CAR-T manufacturing at cost through a public network","route":"/ideas/idea-fund-public-car-t-manufacturing/","asOf":"2026-09-08","days":1},{"id":"idea-fund-mcbs-linked-pricing","kind":"idea","name":"Launch prices indexed to the ESMO benefit scale, revisited when survival matures","route":"/ideas/idea-fund-mcbs-linked-pricing/","asOf":"2026-09-08","days":1},{"id":"idea-fund-head-to-head-mandate","kind":"idea","name":"Require head-to-head trials against the best in class for later entrants","route":"/ideas/idea-fund-head-to-head-mandate/","asOf":"2026-09-08","days":1},{"id":"idea-fund-health-impact-fund-oncology","kind":"idea","name":"A Health Impact Fund pilot that pays for measured health gain instead of price","route":"/ideas/idea-fund-health-impact-fund-oncology/","asOf":"2026-09-08","days":1},{"id":"idea-fund-sovereign-first-in-class-coinvestment","kind":"idea","name":"Public co-investment in first-in-class phase 1 with a royalty return","route":"/ideas/idea-fund-sovereign-first-in-class-coinvestment/","asOf":"2026-09-08","days":1},{"id":"idea-fund-academic-promotion-reform","kind":"idea","name":"Promote academics for trials completed, data shared and findings replicated","route":"/ideas/idea-fund-academic-promotion-reform/","asOf":"2026-09-08","days":1},{"id":"idea-fund-trial-completion-bonus","kind":"idea","name":"Pay investigators for finishing and publishing trials, not for enrolling patients","route":"/ideas/idea-fund-trial-completion-bonus/","asOf":"2026-09-08","days":1},{"id":"idea-fund-payer-funded-pragmatic-trials","kind":"idea","name":"Payers fund trials of cheaper, shorter or lower-dose versions of expensive treatments","route":"/ideas/idea-fund-payer-funded-pragmatic-trials/","asOf":"2026-09-08","days":1},{"id":"idea-fund-duration-trial-exclusivity","kind":"idea","name":"Extra exclusivity for sponsors who run treatment-duration and de-escalation trials","route":"/ideas/idea-fund-duration-trial-exclusivity/","asOf":"2026-09-08","days":1},{"id":"idea-fund-paediatric-deferral-escrow","kind":"idea","name":"Escrow a share of adult revenue until the paediatric study is done","route":"/ideas/idea-fund-paediatric-deferral-escrow/","asOf":"2026-09-08","days":1},{"id":"idea-fund-abbreviated-pathway-me-too-biologics","kind":"idea","name":"An abbreviated approval path for follow-on antibodies within a validated class","route":"/ideas/idea-fund-abbreviated-pathway-me-too-biologics/","asOf":"2026-09-08","days":1},{"id":"idea-fund-open-source-repurposing-leads","kind":"idea","name":"Patent-free open-source development of repurposed and off-patent cancer drugs","route":"/ideas/idea-fund-open-source-repurposing-leads/","asOf":"2026-09-08","days":1},{"id":"idea-fund-repurposing-indication-exclusivity","kind":"idea","name":"A repurposing label pathway with short exclusivity that non-profits can hold","route":"/ideas/idea-fund-repurposing-indication-exclusivity/","asOf":"2026-09-08","days":1},{"id":"idea-fund-social-impact-bonds-prevention","kind":"idea","name":"Social impact bonds for cancer prevention, repaid from avoided treatment costs","route":"/ideas/idea-fund-social-impact-bonds-prevention/","asOf":"2026-09-08","days":1},{"id":"idea-fund-global-access-licensing-royalties","kind":"idea","name":"University licences with royalties indexed to benefit and global access","route":"/ideas/idea-fund-global-access-licensing-royalties/","asOf":"2026-09-08","days":1},{"id":"idea-fund-phase-two-failure-reinsurance","kind":"idea","name":"Government reinsurance for phase 2 failures of first-in-class cancer drugs","route":"/ideas/idea-fund-phase-two-failure-reinsurance/","asOf":"2026-09-08","days":1},{"id":"idea-fund-translational-institutes-gmp","kind":"idea","name":"Regional translational institutes with academic GMP suites and IND teams","route":"/ideas/idea-fund-translational-institutes-gmp/","asOf":"2026-09-08","days":1},{"id":"idea-fund-ind-enabling-fund","kind":"idea","name":"A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks","route":"/ideas/idea-fund-ind-enabling-fund/","asOf":"2026-09-08","days":1},{"id":"idea-fund-milestone-venture-philanthropy","kind":"idea","name":"Milestone-based venture philanthropy with royalties recycled into the pipeline","route":"/ideas/idea-fund-milestone-venture-philanthropy/","asOf":"2026-09-08","days":1},{"id":"idea-fund-phase-zero-fund","kind":"idea","name":"A phase 0 fund to test academic compounds in humans with microdoses and imaging","route":"/ideas/idea-fund-phase-zero-fund/","asOf":"2026-09-08","days":1},{"id":"idea-fund-public-nonprofit-cro","kind":"idea","name":"A national non-profit contract research organisation for academic oncology trials","route":"/ideas/idea-fund-public-nonprofit-cro/","asOf":"2026-09-08","days":1},{"id":"idea-fund-translational-fellowships","kind":"idea","name":"Two-year translational fellowships that pay scientists to develop their own discovery","route":"/ideas/idea-fund-translational-fellowships/","asOf":"2026-09-08","days":1},{"id":"idea-fund-target-validation-consortium","kind":"idea","name":"A pre-competitive consortium to validate or kill academic targets before licensing","route":"/ideas/idea-fund-target-validation-consortium/","asOf":"2026-09-08","days":1},{"id":"idea-fund-academic-adc-bispecific-platform","kind":"idea","name":"An open engineering platform for academic ADCs and bispecifics","route":"/ideas/idea-fund-academic-adc-bispecific-platform/","asOf":"2026-09-08","days":1},{"id":"idea-fund-hospital-exemption-registry","kind":"idea","name":"Hospital-exemption cell therapies at scale, backed by a shared registry","route":"/ideas/idea-fund-hospital-exemption-registry/","asOf":"2026-09-08","days":1},{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/","asOf":"2026-09-08","days":1},{"id":"idea-fund-stalled-asset-registry","kind":"idea","name":"A public registry of stalled academic assets and shelved company compounds","route":"/ideas/idea-fund-stalled-asset-registry/","asOf":"2026-09-08","days":1},{"id":"idea-fund-national-drug-development-office","kind":"idea","name":"Scale up public drug development that takes academic assets to phase 1","route":"/ideas/idea-fund-national-drug-development-office/","asOf":"2026-09-08","days":1},{"id":"idea-fund-device-and-technique-translation-fund","kind":"idea","name":"A translation fund for academic surgical devices and radiotherapy technology","route":"/ideas/idea-fund-device-and-technique-translation-fund/","asOf":"2026-09-08","days":1},{"id":"idea-fund-biomarker-validation-fund","kind":"idea","name":"A fund for prospective validation of academic biomarkers and companion diagnostics","route":"/ideas/idea-fund-biomarker-validation-fund/","asOf":"2026-09-08","days":1},{"id":"idea-fund-organoid-translation-gate","kind":"idea","name":"A funded organoid and PDX panel as the go/no-go gate before IND-enabling money","route":"/ideas/idea-fund-organoid-translation-gate/","asOf":"2026-09-08","days":1},{"id":"idea-fund-shared-personalised-therapy-gmp","kind":"idea","name":"Shared modular GMP facilities for academic personalised vaccines and cell products","route":"/ideas/idea-fund-shared-personalised-therapy-gmp/","asOf":"2026-09-08","days":1},{"id":"idea-fund-protected-time-physician-scientists","kind":"idea","name":"Hospital-funded protected time for clinician-scientists, repaid by trial revenue","route":"/ideas/idea-fund-protected-time-physician-scientists/","asOf":"2026-09-08","days":1},{"id":"idea-fund-royalty-pool-academic-assets","kind":"idea","name":"A diversified royalty pool that finances academic phase 1 trials across fifty assets","route":"/ideas/idea-fund-royalty-pool-academic-assets/","asOf":"2026-09-08","days":1},{"id":"idea-fund-global-academic-phase-one-network","kind":"idea","name":"A global first-in-human network for academic cancer trials with single ethics review","route":"/ideas/idea-fund-global-academic-phase-one-network/","asOf":"2026-09-08","days":1},{"id":"idea-fund-academic-sponsor-indemnity-pool","kind":"idea","name":"A public indemnity pool so universities can sponsor first-in-human cancer trials","route":"/ideas/idea-fund-academic-sponsor-indemnity-pool/","asOf":"2026-09-08","days":1},{"id":"idea-fund-combination-patent-pool","kind":"idea","name":"An oncology patent pool for combination trials across companies","route":"/ideas/idea-fund-combination-patent-pool/","asOf":"2026-09-08","days":1},{"id":"idea-fund-compulsory-combination-access","kind":"idea","name":"A legal right to obtain marketed cancer drugs at cost for combination trials","route":"/ideas/idea-fund-compulsory-combination-access/","asOf":"2026-09-08","days":1},{"id":"idea-fund-standard-combination-agreement","kind":"idea","name":"A regulator-endorsed standard contract for inter-company combination trials","route":"/ideas/idea-fund-standard-combination-agreement/","asOf":"2026-09-08","days":1},{"id":"idea-fund-precompetitive-undruggable-consortium","kind":"idea","name":"An open-science consortium on the undruggable drivers, open until a candidate","route":"/ideas/idea-fund-precompetitive-undruggable-consortium/","asOf":"2026-09-08","days":1},{"id":"idea-fund-trial-data-trust","kind":"idea","name":"A single oncology trial data trust with mandatory deposit within eighteen months","route":"/ideas/idea-fund-trial-data-trust/","asOf":"2026-09-08","days":1},{"id":"idea-fund-control-arm-commons","kind":"idea","name":"A shared library of pooled control arms to shrink and speed future trials","route":"/ideas/idea-fund-control-arm-commons/","asOf":"2026-09-08","days":1},{"id":"idea-fund-universal-mta-fast-lane","kind":"idea","name":"A universal material transfer agreement with a thirty-day default","route":"/ideas/idea-fund-universal-mta-fast-lane/","asOf":"2026-09-08","days":1},{"id":"idea-fund-antitrust-safe-harbour","kind":"idea","name":"An antitrust safe harbour for cross-company combination trials and data pooling","route":"/ideas/idea-fund-antitrust-safe-harbour/","asOf":"2026-09-08","days":1},{"id":"idea-fund-open-results-bonus","kind":"idea","name":"Funder bonuses for releasing results and data within six months, negatives included","route":"/ideas/idea-fund-open-results-bonus/","asOf":"2026-09-08","days":1},{"id":"idea-fund-shelved-asset-escrow","kind":"idea","name":"Automatic offer of shelved cancer assets to non-profits after two years","route":"/ideas/idea-fund-shelved-asset-escrow/","asOf":"2026-09-08","days":1},{"id":"idea-fund-federated-learning-consortium","kind":"idea","name":"A federated learning consortium of cancer centres that jointly own the models","route":"/ideas/idea-fund-federated-learning-consortium/","asOf":"2026-09-08","days":1},{"id":"idea-fund-trial-biospecimen-commons","kind":"idea","name":"A commons for leftover trial biospecimens with standard access for approved research","route":"/ideas/idea-fund-trial-biospecimen-commons/","asOf":"2026-09-08","days":1},{"id":"idea-fund-neutral-platform-sponsor","kind":"idea","name":"A permanent neutral non-profit sponsor for multi-company platform trials","route":"/ideas/idea-fund-neutral-platform-sponsor/","asOf":"2026-09-08","days":1},{"id":"idea-fund-portable-patient-consent","kind":"idea","name":"Patient-held portable consent for reusing samples and data across studies","route":"/ideas/idea-fund-portable-patient-consent/","asOf":"2026-09-08","days":1},{"id":"idea-fund-scoop-protection-policy","kind":"idea","name":"Scoop protection and co-publication norms to reduce academic secrecy","route":"/ideas/idea-fund-scoop-protection-policy/","asOf":"2026-09-08","days":1},{"id":"idea-fund-surgical-trials-network","kind":"idea","name":"A permanently funded international network for randomised cancer surgery trials","route":"/ideas/idea-fund-surgical-trials-network/","asOf":"2026-09-08","days":1},{"id":"idea-fund-radiotherapy-trials-infrastructure","kind":"idea","name":"Core-funded radiotherapy trials infrastructure with central quality assurance","route":"/ideas/idea-fund-radiotherapy-trials-infrastructure/","asOf":"2026-09-08","days":1},{"id":"idea-fund-device-technique-registry","kind":"idea","name":"Mandatory staged registries for new surgical techniques before wide adoption","route":"/ideas/idea-fund-device-technique-registry/","asOf":"2026-09-08","days":1},{"id":"idea-fund-surgical-ai-robotics-evaluation","kind":"idea","name":"An independent evaluation unit for surgical robots and AI, paid on evidence","route":"/ideas/idea-fund-surgical-ai-robotics-evaluation/","asOf":"2026-09-08","days":1},{"id":"idea-fund-flash-evidence-programme","kind":"idea","name":"A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards","route":"/ideas/idea-fund-flash-evidence-programme/","asOf":"2026-09-08","days":1},{"id":"idea-fund-proton-coverage-with-evidence","kind":"idea","name":"Pooled coverage-with-evidence for proton therapy across all centres","route":"/ideas/idea-fund-proton-coverage-with-evidence/","asOf":"2026-09-08","days":1},{"id":"idea-fund-surgeon-scientist-pathway","kind":"idea","name":"Funded research pathways for surgeon-scientists and radiation oncologist-scientists","route":"/ideas/idea-fund-surgeon-scientist-pathway/","asOf":"2026-09-08","days":1},{"id":"idea-fund-course-based-radiotherapy-payment","kind":"idea","name":"Pay per course of radiotherapy, not per session, so short courses are not penalised","route":"/ideas/idea-fund-course-based-radiotherapy-payment/","asOf":"2026-09-08","days":1},{"id":"idea-fund-surgical-video-registry","kind":"idea","name":"A video-based surgical quality registry linking assessed skill to cancer outcomes","route":"/ideas/idea-fund-surgical-video-registry/","asOf":"2026-09-08","days":1},{"id":"idea-fund-organ-preservation-programme","kind":"idea","name":"A funded programme of organ-preservation trials to avoid radical surgery","route":"/ideas/idea-fund-organ-preservation-programme/","asOf":"2026-09-08","days":1},{"id":"idea-fund-omission-deescalation-trials","kind":"idea","name":"Payer-funded trials that omit surgery or radiotherapy in low-risk patients","route":"/ideas/idea-fund-omission-deescalation-trials/","asOf":"2026-09-08","days":1},{"id":"idea-fund-lmic-radiotherapy-finance","kind":"idea","name":"Blended finance and a low-cost linac to close the global radiotherapy gap","route":"/ideas/idea-fund-lmic-radiotherapy-finance/","asOf":"2026-09-08","days":1},{"id":"idea-fund-intraoperative-imaging-trials","kind":"idea","name":"A pragmatic trial network for intraoperative margin tools, paid on margin reduction","route":"/ideas/idea-fund-intraoperative-imaging-trials/","asOf":"2026-09-08","days":1},{"id":"idea-fund-rt-io-platform","kind":"idea","name":"A neutral platform trial for radiotherapy plus immunotherapy combinations","route":"/ideas/idea-fund-rt-io-platform/","asOf":"2026-09-08","days":1},{"id":"idea-fund-adaptive-radiotherapy-evidence","kind":"idea","name":"Coverage-with-evidence registries for MR-guided and adaptive radiotherapy","route":"/ideas/idea-fund-adaptive-radiotherapy-evidence/","asOf":"2026-09-08","days":1},{"id":"idea-fund-surgical-outcomes-public-reporting","kind":"idea","name":"Public risk-adjusted outcome reporting for cancer surgery to drive centralisation","route":"/ideas/idea-fund-surgical-outcomes-public-reporting/","asOf":"2026-09-08","days":1},{"id":"idea-fund-rt-planning-ai-capacity","kind":"idea","name":"Validate and reimburse AI contouring and planning to expand radiotherapy capacity","route":"/ideas/idea-fund-rt-planning-ai-capacity/","asOf":"2026-09-08","days":1},{"id":"idea-fund-ablation-versus-surgery-trials","kind":"idea","name":"Device-agnostic public trials of ablation technologies against surgery","route":"/ideas/idea-fund-ablation-versus-surgery-trials/","asOf":"2026-09-08","days":1},{"id":"idea-fund-radiotherapy-innovation-pathway","kind":"idea","name":"A regulatory pathway for new radiotherapy techniques modelled on drug development","route":"/ideas/idea-fund-radiotherapy-innovation-pathway/","asOf":"2026-09-08","days":1},{"id":"idea-fund-technique-innovation-prize","kind":"idea","name":"Prizes for unpatentable surgical and radiotherapy techniques proven in trials","route":"/ideas/idea-fund-technique-innovation-prize/","asOf":"2026-09-08","days":1},{"id":"idea-moon-navigation-as-a-right","kind":"idea","name":"Patient navigation as a legal entitlement from the day of diagnosis","route":"/ideas/idea-moon-navigation-as-a-right/","asOf":"2026-09-08","days":1},{"id":"idea-moon-plain-language-consent","kind":"idea","name":"Two-page plain-language consent with teach-back for every cancer trial and treatment","route":"/ideas/idea-moon-plain-language-consent/","asOf":"2026-09-08","days":1},{"id":"idea-moon-results-in-plain-words","kind":"idea","name":"Every pathology and genomic report ships with a signed plain-language version","route":"/ideas/idea-moon-results-in-plain-words/","asOf":"2026-09-08","days":1},{"id":"idea-moon-pro-monitoring-standard","kind":"idea","name":"Weekly symptom check-ins with automatic alerts as standard of care on treatment","route":"/ideas/idea-moon-pro-monitoring-standard/","asOf":"2026-09-08","days":1},{"id":"idea-moon-certified-decision-aids","kind":"idea","name":"Certified decision aids required for every preference-sensitive cancer decision","route":"/ideas/idea-moon-certified-decision-aids/","asOf":"2026-09-08","days":1},{"id":"idea-moon-patient-designed-trials","kind":"idea","name":"Patient panels approve trial burden and endpoints as a condition of funding","route":"/ideas/idea-moon-patient-designed-trials/","asOf":"2026-09-08","days":1},{"id":"idea-moon-financial-toxicity-screening","kind":"idea","name":"Screen every patient for financial toxicity at diagnosis and refer like any other symptom","route":"/ideas/idea-moon-financial-toxicity-screening/","asOf":"2026-09-08","days":1},{"id":"idea-moon-goals-conversation-trigger","kind":"idea","name":"Algorithm-triggered goals-of-care conversations before crisis","route":"/ideas/idea-moon-goals-conversation-trigger/","asOf":"2026-09-08","days":1},{"id":"idea-moon-patient-held-cancer-record","kind":"idea","name":"A patient-owned, portable complete cancer record in a standard format","route":"/ideas/idea-moon-patient-held-cancer-record/","asOf":"2026-09-08","days":1},{"id":"idea-moon-funded-second-opinion","kind":"idea","name":"A funded expert second opinion for every new high-stakes or rare cancer diagnosis","route":"/ideas/idea-moon-funded-second-opinion/","asOf":"2026-09-08","days":1},{"id":"idea-moon-recorded-consultations","kind":"idea","name":"Recorded, AI-summarised consultations given to patients by default","route":"/ideas/idea-moon-recorded-consultations/","asOf":"2026-09-08","days":1},{"id":"idea-moon-question-prompt-lists","kind":"idea","name":"Question prompt lists sent to patients before every major consultation","route":"/ideas/idea-moon-question-prompt-lists/","asOf":"2026-09-08","days":1},{"id":"idea-moon-patient-experience-label","kind":"idea","name":"A mandatory patient-experience section in every cancer drug label and approval","route":"/ideas/idea-moon-patient-experience-label/","asOf":"2026-09-08","days":1},{"id":"idea-moon-results-back-to-participants","kind":"idea","name":"Plain-language trial results returned to every participant within a year","route":"/ideas/idea-moon-results-back-to-participants/","asOf":"2026-09-08","days":1},{"id":"idea-moon-peer-navigator-workforce","kind":"idea","name":"Paid survivor peer-navigators as a recognised health workforce role","route":"/ideas/idea-moon-peer-navigator-workforce/","asOf":"2026-09-08","days":1},{"id":"idea-moon-time-toxicity-reporting","kind":"idea","name":"Report time toxicity, the days a treatment consumes, in every trial and decision aid","route":"/ideas/idea-moon-time-toxicity-reporting/","asOf":"2026-09-08","days":1},{"id":"idea-moon-preference-studies-before-phase3","kind":"idea","name":"Quantitative patient preference studies set the benefit-risk bar before phase 3","route":"/ideas/idea-moon-preference-studies-before-phase3/","asOf":"2026-09-08","days":1},{"id":"idea-moon-caregiver-in-the-plan","kind":"idea","name":"Formal caregiver assessment and training written into every treatment plan","route":"/ideas/idea-moon-caregiver-in-the-plan/","asOf":"2026-09-08","days":1},{"id":"idea-moon-literacy-first-design-standard","kind":"idea","name":"A health-literacy certification standard for oncology portals, letters and apps","route":"/ideas/idea-moon-literacy-first-design-standard/","asOf":"2026-09-08","days":1},{"id":"idea-moon-trial-eligibility-at-every-decision","kind":"idea","name":"Patients are told which trials they qualify for at every treatment decision, in writing","route":"/ideas/idea-moon-trial-eligibility-at-every-decision/","asOf":"2026-09-08","days":1},{"id":"idea-moon-toxicity-first-endpoints","kind":"idea","name":"Tolerability as a co-primary endpoint with its own label claim","route":"/ideas/idea-moon-toxicity-first-endpoints/","asOf":"2026-09-08","days":1},{"id":"idea-moon-pro-ctcae-in-every-pivotal-trial","kind":"idea","name":"Patient-reported side-effects (PRO-CTCAE) collected and published in every registrational trial","route":"/ideas/idea-moon-pro-ctcae-in-every-pivotal-trial/","asOf":"2026-09-08","days":1},{"id":"idea-moon-supportive-care-arpa","kind":"idea","name":"An ARPA-style programme to develop supportive-care drugs nobody else will","route":"/ideas/idea-moon-supportive-care-arpa/","asOf":"2026-09-08","days":1},{"id":"idea-moon-neuropathy-prevention-programme","kind":"idea","name":"A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression","route":"/ideas/idea-moon-neuropathy-prevention-programme/","asOf":"2026-09-08","days":1},{"id":"idea-moon-cardioprotection-by-default","kind":"idea","name":"Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy","route":"/ideas/idea-moon-cardioprotection-by-default/","asOf":"2026-09-08","days":1},{"id":"idea-moon-olanzapine-antiemetic-everywhere","kind":"idea","name":"Low-dose olanzapine and generic antiemetic bundles in every guideline and formulary","route":"/ideas/idea-moon-olanzapine-antiemetic-everywhere/","asOf":"2026-09-08","days":1},{"id":"idea-moon-post-approval-dose-deescalation","kind":"idea","name":"Randomised lower-dose trials for approved drugs with quality of life as the primary endpoint","route":"/ideas/idea-moon-post-approval-dose-deescalation/","asOf":"2026-09-08","days":1},{"id":"idea-moon-quality-adjusted-pricing","kind":"idea","name":"Payers price drugs on quality-adjusted benefit, so toxicity costs the manufacturer","route":"/ideas/idea-moon-quality-adjusted-pricing/","asOf":"2026-09-08","days":1},{"id":"idea-moon-adult-late-effects-registry","kind":"idea","name":"A lifelong late-effects registry linked to every treatment for adult survivors","route":"/ideas/idea-moon-adult-late-effects-registry/","asOf":"2026-09-08","days":1},{"id":"idea-moon-cognitive-toxicity-programme","kind":"idea","name":"Measure and treat chemo brain with objective digital cognitive testing","route":"/ideas/idea-moon-cognitive-toxicity-programme/","asOf":"2026-09-08","days":1},{"id":"idea-moon-irae-prediction-and-prevention","kind":"idea","name":"Predict immune side-effects before they happen and pre-empt them","route":"/ideas/idea-moon-irae-prediction-and-prevention/","asOf":"2026-09-08","days":1},{"id":"idea-moon-fertility-preservation-default","kind":"idea","name":"Fertility preservation offered and funded by default before gonadotoxic treatment","route":"/ideas/idea-moon-fertility-preservation-default/","asOf":"2026-09-08","days":1},{"id":"idea-moon-hearing-protection-cisplatin","kind":"idea","name":"Protect hearing from cisplatin in adults as we now do in children","route":"/ideas/idea-moon-hearing-protection-cisplatin/","asOf":"2026-09-08","days":1},{"id":"idea-moon-hair-preservation-for-all","kind":"idea","name":"Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen","route":"/ideas/idea-moon-hair-preservation-for-all/","asOf":"2026-09-08","days":1},{"id":"idea-moon-oncology-hospital-at-home","kind":"idea","name":"Oncology hospital-at-home with remote monitoring for toxicity","route":"/ideas/idea-moon-oncology-hospital-at-home/","asOf":"2026-09-08","days":1},{"id":"idea-moon-supportive-care-platform-trial","kind":"idea","name":"A permanent platform trial for supportive-care interventions inside cooperative groups","route":"/ideas/idea-moon-supportive-care-platform-trial/","asOf":"2026-09-08","days":1},{"id":"idea-moon-open-pro-data-commons","kind":"idea","name":"An open commons of patient-reported outcome data from cancer trials","route":"/ideas/idea-moon-open-pro-data-commons/","asOf":"2026-09-08","days":1},{"id":"idea-moon-mucositis-taste-programme","kind":"idea","name":"Photobiomodulation and a taste and swallowing programme for mouth and throat toxicity","route":"/ideas/idea-moon-mucositis-taste-programme/","asOf":"2026-09-08","days":1},{"id":"idea-moon-sexual-health-as-toxicity-domain","kind":"idea","name":"Sexual health assessed and treated as a standard toxicity domain","route":"/ideas/idea-moon-sexual-health-as-toxicity-domain/","asOf":"2026-09-08","days":1},{"id":"idea-moon-quality-adjusted-survival-standard","kind":"idea","name":"Quality-adjusted survival reported in every trial publication and label","route":"/ideas/idea-moon-quality-adjusted-survival-standard/","asOf":"2026-09-08","days":1},{"id":"idea-moon-misinformation-rapid-response","kind":"idea","name":"A cancer misinformation rapid-response unit that rebuts within 48 hours","route":"/ideas/idea-moon-misinformation-rapid-response/","asOf":"2026-09-08","days":1},{"id":"idea-moon-verified-information-layer","kind":"idea","name":"A verified information layer that labels and links cancer content across platforms","route":"/ideas/idea-moon-verified-information-layer/","asOf":"2026-09-08","days":1},{"id":"idea-moon-clinician-creator-programme","kind":"idea","name":"Train and fund oncology clinicians as public content creators","route":"/ideas/idea-moon-clinician-creator-programme/","asOf":"2026-09-08","days":1},{"id":"idea-moon-prebunking-at-diagnosis","kind":"idea","name":"Inoculate newly diagnosed patients against common cancer scams","route":"/ideas/idea-moon-prebunking-at-diagnosis/","asOf":"2026-09-08","days":1},{"id":"idea-moon-unproven-clinic-registry","kind":"idea","name":"A public registry of unproven cancer clinics and reported outcomes","route":"/ideas/idea-moon-unproven-clinic-registry/","asOf":"2026-09-08","days":1},{"id":"idea-moon-supplement-interaction-database","kind":"idea","name":"An open supplement-drug interaction checker built into oncology prescribing","route":"/ideas/idea-moon-supplement-interaction-database/","asOf":"2026-09-08","days":1},{"id":"idea-moon-ban-unproven-therapy-ads","kind":"idea","name":"Ban and enforce against paid advertising of unproven cancer treatments","route":"/ideas/idea-moon-ban-unproven-therapy-ads/","asOf":"2026-09-08","days":1},{"id":"idea-moon-integrative-oncology-bridge","kind":"idea","name":"Evidence-based integrative oncology in every cancer centre to meet demand safely","route":"/ideas/idea-moon-integrative-oncology-bridge/","asOf":"2026-09-08","days":1},{"id":"idea-moon-ai-cancer-answer-audit","kind":"idea","name":"A public benchmark and audit of chatbot answers to cancer questions","route":"/ideas/idea-moon-ai-cancer-answer-audit/","asOf":"2026-09-08","days":1},{"id":"idea-moon-wikipedia-oncology-fellowships","kind":"idea","name":"Fund oncologists to maintain cancer articles on Wikipedia in many languages","route":"/ideas/idea-moon-wikipedia-oncology-fellowships/","asOf":"2026-09-08","days":1},{"id":"idea-moon-hpv-vaccine-confidence","kind":"idea","name":"Community-tailored HPV vaccine confidence campaigns with school-based delivery","route":"/ideas/idea-moon-hpv-vaccine-confidence/","asOf":"2026-09-08","days":1},{"id":"idea-moon-hype-index","kind":"idea","name":"An independent hype index grading cancer press releases and news stories","route":"/ideas/idea-moon-hype-index/","asOf":"2026-09-08","days":1},{"id":"idea-moon-patient-community-moderators","kind":"idea","name":"Trained moderators with evidence tools in online patient communities","route":"/ideas/idea-moon-patient-community-moderators/","asOf":"2026-09-08","days":1},{"id":"idea-moon-living-plain-evidence-summaries","kind":"idea","name":"Living plain-language evidence summaries for every common cancer question in 20 languages","route":"/ideas/idea-moon-living-plain-evidence-summaries/","asOf":"2026-09-08","days":1},{"id":"idea-moon-treatment-refusal-pathway","kind":"idea","name":"A structured pathway for patients declining proven treatment","route":"/ideas/idea-moon-treatment-refusal-pathway/","asOf":"2026-09-08","days":1},{"id":"idea-moon-population-interception","kind":"idea","name":"A whole-population cancer interception programme: risk-stratify every adult, detect and intercept early","route":"/ideas/idea-moon-population-interception/","asOf":"2026-09-08","days":1},{"id":"idea-moon-universal-sequencing-learning-system","kind":"idea","name":"Universal tumour and germline sequencing at diagnosis feeding a shared learning system","route":"/ideas/idea-moon-universal-sequencing-learning-system/","asOf":"2026-09-08","days":1},{"id":"idea-moon-lynch-vaccine-phase3","kind":"idea","name":"A frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval","route":"/ideas/idea-moon-lynch-vaccine-phase3/","asOf":"2026-09-08","days":1},{"id":"idea-moon-in-vivo-cart-generic-price","kind":"idea","name":"In vivo CAR-T manufactured and priced like a generic biologic","route":"/ideas/idea-moon-in-vivo-cart-generic-price/","asOf":"2026-09-08","days":1},{"id":"idea-moon-closed-loop-adaptive-therapy","kind":"idea","name":"Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models","route":"/ideas/idea-moon-closed-loop-adaptive-therapy/","asOf":"2026-09-08","days":1},{"id":"idea-moon-global-open-trials-os","kind":"idea","name":"A global open trials operating system any hospital can plug into","route":"/ideas/idea-moon-global-open-trials-os/","asOf":"2026-09-08","days":1},{"id":"idea-moon-open-cancer-cell-state-model","kind":"idea","name":"An open model of every cancer cell state, built from perturbation atlases","route":"/ideas/idea-moon-open-cancer-cell-state-model/","asOf":"2026-09-08","days":1},{"id":"idea-moon-cure-prizes","kind":"idea","name":"Cure-focused prizes: pay for verified long-term cures, not for drugs","route":"/ideas/idea-moon-cure-prizes/","asOf":"2026-09-08","days":1},{"id":"idea-moon-engineered-immune-surveillance","kind":"idea","name":"Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer","route":"/ideas/idea-moon-engineered-immune-surveillance/","asOf":"2026-09-08","days":1},{"id":"idea-moon-synthetic-lethality-map-every-driver","kind":"idea","name":"A synthetic lethality map for every cancer driver in every tissue context","route":"/ideas/idea-moon-synthetic-lethality-map-every-driver/","asOf":"2026-09-08","days":1},{"id":"idea-moon-radiotherapy-for-everyone-2040","kind":"idea","name":"Radiotherapy for everyone who needs it by 2040","route":"/ideas/idea-moon-radiotherapy-for-everyone-2040/","asOf":"2026-09-08","days":1},{"id":"idea-moon-eliminate-infection-cancers","kind":"idea","name":"Eliminate infection-caused cancers: HPV, hepatitis B and C, H. pylori and EBV","route":"/ideas/idea-moon-eliminate-infection-cancers/","asOf":"2026-09-08","days":1},{"id":"idea-moon-mrd-weather-service","kind":"idea","name":"A national residual-disease weather service: serial blood tests for every curatively treated patient, pooled","route":"/ideas/idea-moon-mrd-weather-service/","asOf":"2026-09-08","days":1},{"id":"idea-moon-dormancy-eradication-programme","kind":"idea","name":"Eradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells","route":"/ideas/idea-moon-dormancy-eradication-programme/","asOf":"2026-09-08","days":1},{"id":"idea-moon-validated-digital-twins","kind":"idea","name":"Whole-patient digital twins validated in prospective randomised trials","route":"/ideas/idea-moon-validated-digital-twins/","asOf":"2026-09-08","days":1},{"id":"idea-moon-negative-results-ledger","kind":"idea","name":"A global ledger of negative results and failed compounds with mandatory deposition","route":"/ideas/idea-moon-negative-results-ledger/","asOf":"2026-09-08","days":1},{"id":"idea-moon-generics-for-cancer-fund","kind":"idea","name":"A public fund and label pathway to trial generic drugs against cancer","route":"/ideas/idea-moon-generics-for-cancer-fund/","asOf":"2026-09-08","days":1},{"id":"idea-moon-pooled-procurement-licensing-pool","kind":"idea","name":"Pooled procurement and voluntary licensing for essential cancer medicines in low-income countries","route":"/ideas/idea-moon-pooled-procurement-licensing-pool/","asOf":"2026-09-08","days":1},{"id":"idea-moon-brain-delivery-platform","kind":"idea","name":"A standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics","route":"/ideas/idea-moon-brain-delivery-platform/","asOf":"2026-09-08","days":1},{"id":"idea-moon-rare-cancer-global-network","kind":"idea","name":"One global rare cancer network with n-of-1 and Bayesian trial frameworks","route":"/ideas/idea-moon-rare-cancer-global-network/","asOf":"2026-09-08","days":1},{"id":"idea-moon-cold-to-hot-programme","kind":"idea","name":"Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours","route":"/ideas/idea-moon-cold-to-hot-programme/","asOf":"2026-09-08","days":1},{"id":"idea-moon-cachexia-as-treatable-disease","kind":"idea","name":"Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles","route":"/ideas/idea-moon-cachexia-as-treatable-disease/","asOf":"2026-09-08","days":1},{"id":"idea-moon-individualised-dosing-all-oral-drugs","kind":"idea","name":"Model-informed individual dosing with drug-level monitoring for every oral cancer drug","route":"/ideas/idea-moon-individualised-dosing-all-oral-drugs/","asOf":"2026-09-08","days":1},{"id":"idea-moon-automated-combination-discovery","kind":"idea","name":"Automated combination discovery: patient-sample screens feeding Bayesian platform trials","route":"/ideas/idea-moon-automated-combination-discovery/","asOf":"2026-09-08","days":1},{"id":"idea-moon-indolence-classifiers-with-screening","kind":"idea","name":"Molecular indolence classifiers bundled with every screening programme","route":"/ideas/idea-moon-indolence-classifiers-with-screening/","asOf":"2026-09-08","days":1},{"id":"idea-moon-biomarker-validation-utility","kind":"idea","name":"A public biomarker validation utility with pre-diagnostic biobanks and blinded testing","route":"/ideas/idea-moon-biomarker-validation-utility/","asOf":"2026-09-08","days":1},{"id":"idea-moon-open-degrader-consortium","kind":"idea","name":"An open degrader consortium against every undruggable driver transcription factor","route":"/ideas/idea-moon-open-degrader-consortium/","asOf":"2026-09-08","days":1},{"id":"idea-moon-metastasis-prevention-indication","kind":"idea","name":"Metastasis prevention as a formal indication with its own trials and regulatory pathway","route":"/ideas/idea-moon-metastasis-prevention-indication/","asOf":"2026-09-08","days":1},{"id":"idea-moon-survivor-lifelong-care-model","kind":"idea","name":"Risk-stratified lifelong care for tens of millions of survivors, automated and shared with primary care","route":"/ideas/idea-moon-survivor-lifelong-care-model/","asOf":"2026-09-08","days":1},{"id":"idea-moon-palliative-care-from-diagnosis-everywhere","kind":"idea","name":"Palliative care from diagnosis for every advanced cancer, including opioid access, worldwide","route":"/ideas/idea-moon-palliative-care-from-diagnosis-everywhere/","asOf":"2026-09-08","days":1},{"id":"idea-moon-geriatric-assessment-default","kind":"idea","name":"Geriatric assessment by default for every older patient, and trials that admit them","route":"/ideas/idea-moon-geriatric-assessment-default/","asOf":"2026-09-08","days":1},{"id":"idea-moon-self-driving-cancer-labs","kind":"idea","name":"Self-driving laboratories that run the cancer biology hypothesis loop autonomously","route":"/ideas/idea-moon-self-driving-cancer-labs/","asOf":"2026-09-08","days":1},{"id":"idea-moon-task-shifting-ai-oncology-capacity","kind":"idea","name":"Double oncology capacity in low-resource settings with task-shifting and AI decision support","route":"/ideas/idea-moon-task-shifting-ai-oncology-capacity/","asOf":"2026-09-08","days":1},{"id":"idea-moon-federated-rwe-network","kind":"idea","name":"A global federated real-world evidence network at regulatory grade","route":"/ideas/idea-moon-federated-rwe-network/","asOf":"2026-09-08","days":1},{"id":"idea-moon-pay-for-cure-contracts","kind":"idea","name":"Pay-for-cure contracts: instalment payments for curative therapies contingent on durable remission","route":"/ideas/idea-moon-pay-for-cure-contracts/","asOf":"2026-09-08","days":1},{"id":"idea-moon-open-source-oncology-drug-discovery","kind":"idea","name":"Open-source drug discovery to clinical proof of concept for neglected cancers","route":"/ideas/idea-moon-open-source-oncology-drug-discovery/","asOf":"2026-09-08","days":1},{"id":"idea-moon-public-phase1-factory","kind":"idea","name":"A public-benefit phase 1 factory that takes academic discoveries into first-in-human trials","route":"/ideas/idea-moon-public-phase1-factory/","asOf":"2026-09-08","days":1},{"id":"idea-moon-neoantigen-vaccines-at-scale","kind":"idea","name":"Personalised cancer vaccines at commodity cost through fully automated manufacturing","route":"/ideas/idea-moon-neoantigen-vaccines-at-scale/","asOf":"2026-09-08","days":1},{"id":"idea-moon-image-guided-surgery-everywhere","kind":"idea","name":"Real-time margin assessment and image-guided surgery as the global standard","route":"/ideas/idea-moon-image-guided-surgery-everywhere/","asOf":"2026-09-08","days":1},{"id":"idea-moon-compact-flash-proton","kind":"idea","name":"Compact FLASH and proton systems at the price of a conventional linac","route":"/ideas/idea-moon-compact-flash-proton/","asOf":"2026-09-08","days":1},{"id":"idea-moon-population-germline-screening","kind":"idea","name":"Population germline screening for hereditary cancer genes with cascade testing","route":"/ideas/idea-moon-population-germline-screening/","asOf":"2026-09-08","days":1},{"id":"idea-moon-living-machine-readable-guidelines","kind":"idea","name":"Living, machine-readable guidelines pushed to the point of care in every country","route":"/ideas/idea-moon-living-machine-readable-guidelines/","asOf":"2026-09-08","days":1},{"id":"idea-moon-continuous-ai-validation-registry","kind":"idea","name":"Continuous prospective validation for every oncology AI tool after deployment","route":"/ideas/idea-moon-continuous-ai-validation-registry/","asOf":"2026-09-08","days":1},{"id":"idea-moon-reciprocal-tumour-agnostic-approvals","kind":"idea","name":"Reciprocal recognition of tumour-agnostic and rare-indication approvals across regulators","route":"/ideas/idea-moon-reciprocal-tumour-agnostic-approvals/","asOf":"2026-09-08","days":1},{"id":"idea-moon-independent-replication-institute","kind":"idea","name":"An independent replication institute that re-tests key preclinical cancer findings before trials","route":"/ideas/idea-moon-independent-replication-institute/","asOf":"2026-09-08","days":1},{"id":"src-nejm","kind":"collection","name":"New England Journal of Medicine","route":"/collections/src-nejm/","asOf":"2026-09-08","days":1},{"id":"src-lancet-oncology","kind":"collection","name":"The Lancet Oncology","route":"/collections/src-lancet-oncology/","asOf":"2026-09-08","days":1},{"id":"src-jco","kind":"collection","name":"Journal of Clinical Oncology","route":"/collections/src-jco/","asOf":"2026-09-08","days":1},{"id":"src-cancer-discovery","kind":"collection","name":"Cancer Discovery","route":"/collections/src-cancer-discovery/","asOf":"2026-09-08","days":1},{"id":"src-nature-medicine","kind":"collection","name":"Nature Medicine","route":"/collections/src-nature-medicine/","asOf":"2026-09-08","days":1},{"id":"src-nature-cancer","kind":"collection","name":"Nature Cancer","route":"/collections/src-nature-cancer/","asOf":"2026-09-08","days":1},{"id":"src-cancer-cell","kind":"collection","name":"Cancer Cell","route":"/collections/src-cancer-cell/","asOf":"2026-09-08","days":1},{"id":"src-annals-oncology","kind":"collection","name":"Annals of Oncology","route":"/collections/src-annals-oncology/","asOf":"2026-09-08","days":1},{"id":"src-jama-oncology","kind":"collection","name":"JAMA Oncology","route":"/collections/src-jama-oncology/","asOf":"2026-09-08","days":1},{"id":"src-blood","kind":"collection","name":"Blood","route":"/collections/src-blood/","asOf":"2026-09-08","days":1},{"id":"src-cancer-research","kind":"collection","name":"Cancer Research","route":"/collections/src-cancer-research/","asOf":"2026-09-08","days":1},{"id":"src-clinical-cancer-research","kind":"collection","name":"Clinical Cancer Research","route":"/collections/src-clinical-cancer-research/","asOf":"2026-09-08","days":1},{"id":"src-jnci","kind":"collection","name":"JNCI: Journal of the National Cancer Institute","route":"/collections/src-jnci/","asOf":"2026-09-08","days":1},{"id":"src-esmo-open","kind":"collection","name":"ESMO Open","route":"/collections/src-esmo-open/","asOf":"2026-09-08","days":1},{"id":"src-npj-precision-oncology","kind":"collection","name":"npj Precision Oncology","route":"/collections/src-npj-precision-oncology/","asOf":"2026-09-08","days":1},{"id":"src-medrxiv","kind":"collection","name":"medRxiv","route":"/collections/src-medrxiv/","asOf":"2026-09-08","days":1},{"id":"src-biorxiv","kind":"collection","name":"bioRxiv","route":"/collections/src-biorxiv/","asOf":"2026-09-08","days":1},{"id":"src-ema-chmp","kind":"collection","name":"EMA news and CHMP meeting highlights","route":"/collections/src-ema-chmp/","asOf":"2026-09-08","days":1},{"id":"src-nice-ta","kind":"collection","name":"NICE technology appraisals","route":"/collections/src-nice-ta/","asOf":"2026-09-08","days":1},{"id":"src-asco-post","kind":"collection","name":"The ASCO Post","route":"/collections/src-asco-post/","asOf":"2026-09-08","days":1},{"id":"src-onclive","kind":"collection","name":"OncLive","route":"/collections/src-onclive/","asOf":"2026-09-08","days":1},{"id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","route":"/collections/src-targeted-oncology/","asOf":"2026-09-08","days":1},{"id":"src-cancer-network","kind":"collection","name":"CancerNetwork (ONCOLOGY)","route":"/collections/src-cancer-network/","asOf":"2026-09-08","days":1},{"id":"src-cancer-letter","kind":"collection","name":"The Cancer Letter","route":"/collections/src-cancer-letter/","asOf":"2026-09-08","days":1},{"id":"src-endpoints-news","kind":"collection","name":"Endpoints News","route":"/collections/src-endpoints-news/","asOf":"2026-09-08","days":1},{"id":"src-fierce-biotech","kind":"collection","name":"Fierce Biotech","route":"/collections/src-fierce-biotech/","asOf":"2026-09-08","days":1},{"id":"src-stat-news","kind":"collection","name":"STAT News","route":"/collections/src-stat-news/","asOf":"2026-09-08","days":1},{"id":"src-biocentury","kind":"collection","name":"BioCentury","route":"/collections/src-biocentury/","asOf":"2026-09-08","days":1},{"id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/","asOf":"2026-09-08","days":1},{"id":"src-adc-review","kind":"collection","name":"ADC Review","route":"/collections/src-adc-review/","asOf":"2026-09-08","days":1},{"id":"src-urotoday","kind":"collection","name":"UroToday","route":"/collections/src-urotoday/","asOf":"2026-09-08","days":1},{"id":"src-oncodaily","kind":"collection","name":"OncoDaily","route":"/collections/src-oncodaily/","asOf":"2026-09-08","days":1},{"id":"src-healio-hemonc","kind":"collection","name":"Healio Hematology/Oncology","route":"/collections/src-healio-hemonc/","asOf":"2026-09-08","days":1},{"id":"src-medscape-oncology","kind":"collection","name":"Medscape Oncology","route":"/collections/src-medscape-oncology/","asOf":"2026-09-08","days":1},{"id":"src-biopharma-dive","kind":"collection","name":"BioPharma Dive","route":"/collections/src-biopharma-dive/","asOf":"2026-09-08","days":1},{"id":"src-asco-meeting-library","kind":"collection","name":"ASCO Meeting Library","route":"/collections/src-asco-meeting-library/","asOf":"2026-09-08","days":1},{"id":"src-esmo-congress","kind":"collection","name":"ESMO Congress","route":"/collections/src-esmo-congress/","asOf":"2026-09-08","days":1},{"id":"src-aacr-annual","kind":"collection","name":"AACR Annual Meeting","route":"/collections/src-aacr-annual/","asOf":"2026-09-08","days":1},{"id":"src-ash-annual","kind":"collection","name":"ASH Annual Meeting","route":"/collections/src-ash-annual/","asOf":"2026-09-08","days":1},{"id":"src-sabcs","kind":"collection","name":"San Antonio Breast Cancer Symposium","route":"/collections/src-sabcs/","asOf":"2026-09-08","days":1},{"id":"src-astro","kind":"collection","name":"ASTRO Annual Meeting","route":"/collections/src-astro/","asOf":"2026-09-08","days":1},{"id":"src-snmmi","kind":"collection","name":"SNMMI Annual Meeting","route":"/collections/src-snmmi/","asOf":"2026-09-08","days":1},{"id":"src-asco-daily-news","kind":"collection","name":"ASCO Daily News","route":"/collections/src-asco-daily-news/","asOf":"2026-09-08","days":1},{"id":"src-nature-briefing-cancer","kind":"collection","name":"Nature Briefing: Cancer","route":"/collections/src-nature-briefing-cancer/","asOf":"2026-09-08","days":1},{"id":"src-cancer-org-asco","kind":"collection","name":"American Cancer Society (cancer.org, incl. former Cancer.Net)","route":"/collections/src-cancer-org-asco/","asOf":"2026-09-08","days":1},{"id":"src-cruk-about-cancer","kind":"collection","name":"Cancer Research UK: About Cancer","route":"/collections/src-cruk-about-cancer/","asOf":"2026-09-08","days":1},{"id":"src-macmillan","kind":"collection","name":"Macmillan Cancer Support","route":"/collections/src-macmillan/","asOf":"2026-09-08","days":1},{"id":"src-lbbc","kind":"collection","name":"Living Beyond Breast Cancer","route":"/collections/src-lbbc/","asOf":"2026-09-08","days":1},{"id":"src-bcrf","kind":"collection","name":"Breast Cancer Research Foundation","route":"/collections/src-bcrf/","asOf":"2026-09-08","days":1},{"id":"src-pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","route":"/collections/src-pancan/","asOf":"2026-09-08","days":1},{"id":"src-tnbc-foundation","kind":"collection","name":"Triple Negative Breast Cancer Foundation","route":"/collections/src-tnbc-foundation/","asOf":"2026-09-08","days":1},{"id":"src-semantic-scholar","kind":"collection","name":"Semantic Scholar","route":"/collections/src-semantic-scholar/","asOf":"2026-09-08","days":1},{"id":"src-dimensions","kind":"collection","name":"Dimensions","route":"/collections/src-dimensions/","asOf":"2026-09-08","days":1},{"id":"metastatic-cascade","kind":"pathway","name":"The metastatic cascade","route":"/pathways/metastatic-cascade/","asOf":"2026-09-08","days":1},{"id":"tumor-microenvironment","kind":"pathway","name":"Tumour microenvironment (TME)","route":"/pathways/tumor-microenvironment/","asOf":"2026-09-08","days":1},{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/","asOf":"2026-09-08","days":1},{"id":"cancer-metabolism","kind":"pathway","name":"Cancer metabolism","route":"/pathways/cancer-metabolism/","asOf":"2026-09-08","days":1},{"id":"replication-stress","kind":"pathway","name":"DNA replication stress","route":"/pathways/replication-stress/","asOf":"2026-09-08","days":1},{"id":"chromosomal-instability","kind":"pathway","name":"Chromosomal instability & aneuploidy","route":"/pathways/chromosomal-instability/","asOf":"2026-09-08","days":1},{"id":"telomere-maintenance","kind":"pathway","name":"Telomere maintenance & replicative immortality","route":"/pathways/telomere-maintenance/","asOf":"2026-09-08","days":1},{"id":"autophagy","kind":"pathway","name":"Autophagy","route":"/pathways/autophagy/","asOf":"2026-09-08","days":1},{"id":"ferroptosis-cell-death","kind":"pathway","name":"Ferroptosis & regulated cell death","route":"/pathways/ferroptosis-cell-death/","asOf":"2026-09-08","days":1},{"id":"senescence","kind":"pathway","name":"Cellular senescence","route":"/pathways/senescence/","asOf":"2026-09-08","days":1},{"id":"cancer-stem-cells-plasticity","kind":"pathway","name":"Cancer stem cells & phenotypic plasticity","route":"/pathways/cancer-stem-cells-plasticity/","asOf":"2026-09-08","days":1},{"id":"clonal-evolution","kind":"pathway","name":"Clonal evolution & minimal residual disease","route":"/pathways/clonal-evolution/","asOf":"2026-09-08","days":1},{"id":"inflammation-nfkb","kind":"pathway","name":"Inflammation & NF-κB","route":"/pathways/inflammation-nfkb/","asOf":"2026-09-08","days":1},{"id":"hedgehog","kind":"pathway","name":"Hedgehog signalling","route":"/pathways/hedgehog/","asOf":"2026-09-08","days":1},{"id":"notch","kind":"pathway","name":"Notch signalling","route":"/pathways/notch/","asOf":"2026-09-08","days":1},{"id":"jak-stat","kind":"pathway","name":"JAK–STAT signalling","route":"/pathways/jak-stat/","asOf":"2026-09-08","days":1},{"id":"tgf-beta","kind":"pathway","name":"TGF-β signalling","route":"/pathways/tgf-beta/","asOf":"2026-09-08","days":1},{"id":"hippo-yap","kind":"pathway","name":"Hippo–YAP/TAZ","route":"/pathways/hippo-yap/","asOf":"2026-09-08","days":1},{"id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/","asOf":"2026-09-08","days":1},{"id":"keap1-nrf2","kind":"pathway","name":"KEAP1–NRF2 antioxidant pathway","route":"/pathways/keap1-nrf2/","asOf":"2026-09-08","days":1},{"id":"swi-snf-chromatin","kind":"pathway","name":"SWI/SNF chromatin remodelling","route":"/pathways/swi-snf-chromatin/","asOf":"2026-09-08","days":1},{"id":"epigenetic-reprogramming","kind":"pathway","name":"Epigenetic reprogramming","route":"/pathways/epigenetic-reprogramming/","asOf":"2026-09-08","days":1},{"id":"rna-splicing","kind":"pathway","name":"RNA splicing","route":"/pathways/rna-splicing/","asOf":"2026-09-08","days":1},{"id":"mrna-translation-eif4f","kind":"pathway","name":"mRNA translation (eIF4F / mTOR)","route":"/pathways/mrna-translation-eif4f/","asOf":"2026-09-08","days":1},{"id":"circadian-control","kind":"pathway","name":"Circadian control","route":"/pathways/circadian-control/","asOf":"2026-09-08","days":1},{"id":"microbiome-tumour","kind":"pathway","name":"Microbiome–tumour interactions","route":"/pathways/microbiome-tumour/","asOf":"2026-09-08","days":1},{"id":"cancer-neuroscience","kind":"pathway","name":"Cancer neuroscience (nerve–tumour signalling)","route":"/pathways/cancer-neuroscience/","asOf":"2026-09-08","days":1},{"id":"cachexia-biology","kind":"pathway","name":"Cancer cachexia","route":"/pathways/cachexia-biology/","asOf":"2026-09-08","days":1},{"id":"clonal-haematopoiesis","kind":"pathway","name":"Clonal haematopoiesis (CHIP)","route":"/pathways/clonal-haematopoiesis/","asOf":"2026-09-08","days":1},{"id":"field-cancerisation","kind":"pathway","name":"Field cancerisation","route":"/pathways/field-cancerisation/","asOf":"2026-09-08","days":1},{"id":"tumor-dormancy","kind":"pathway","name":"Tumour dormancy","route":"/pathways/tumor-dormancy/","asOf":"2026-09-08","days":1},{"id":"hallmarks-of-cancer","kind":"term","name":"Hallmarks of Cancer","route":"/terms/hallmarks-of-cancer/","asOf":"2026-09-08","days":1},{"id":"sustaining-proliferative-signaling","kind":"term","name":"Hallmark: sustaining proliferative signalling","route":"/terms/sustaining-proliferative-signaling/","asOf":"2026-09-08","days":1},{"id":"evading-growth-suppressors","kind":"term","name":"Hallmark: evading growth suppressors","route":"/terms/evading-growth-suppressors/","asOf":"2026-09-08","days":1},{"id":"resisting-cell-death","kind":"term","name":"Hallmark: resisting cell death","route":"/terms/resisting-cell-death/","asOf":"2026-09-08","days":1},{"id":"enabling-replicative-immortality","kind":"term","name":"Hallmark: enabling replicative immortality","route":"/terms/enabling-replicative-immortality/","asOf":"2026-09-08","days":1},{"id":"inducing-angiogenesis","kind":"term","name":"Hallmark: inducing or accessing vasculature","route":"/terms/inducing-angiogenesis/","asOf":"2026-09-08","days":1},{"id":"activating-invasion-metastasis","kind":"term","name":"Hallmark: activating invasion and metastasis","route":"/terms/activating-invasion-metastasis/","asOf":"2026-09-08","days":1},{"id":"deregulating-cellular-energetics","kind":"term","name":"Hallmark: reprogramming cellular metabolism","route":"/terms/deregulating-cellular-energetics/","asOf":"2026-09-08","days":1},{"id":"avoiding-immune-destruction","kind":"term","name":"Hallmark: avoiding immune destruction","route":"/terms/avoiding-immune-destruction/","asOf":"2026-09-08","days":1},{"id":"genome-instability-mutation","kind":"term","name":"Enabling characteristic: genome instability and mutation","route":"/terms/genome-instability-mutation/","asOf":"2026-09-08","days":1},{"id":"tumor-promoting-inflammation","kind":"term","name":"Enabling characteristic: tumour-promoting inflammation","route":"/terms/tumor-promoting-inflammation/","asOf":"2026-09-08","days":1},{"id":"unlocking-phenotypic-plasticity","kind":"term","name":"Hallmark (2022): unlocking phenotypic plasticity","route":"/terms/unlocking-phenotypic-plasticity/","asOf":"2026-09-08","days":1},{"id":"nonmutational-epigenetic-reprogramming","kind":"term","name":"Hallmark (2022): non-mutational epigenetic reprogramming","route":"/terms/nonmutational-epigenetic-reprogramming/","asOf":"2026-09-08","days":1},{"id":"polymorphic-microbiomes","kind":"term","name":"Hallmark (2022): polymorphic microbiomes","route":"/terms/polymorphic-microbiomes/","asOf":"2026-09-08","days":1},{"id":"senescent-cells","kind":"term","name":"Hallmark (2022): senescent cells","route":"/terms/senescent-cells/","asOf":"2026-09-08","days":1},{"id":"disseminated-tumor-cells","kind":"term","name":"Disseminated tumour cells (DTCs)","route":"/terms/disseminated-tumor-cells/","asOf":"2026-09-08","days":1},{"id":"warburg-effect","kind":"term","name":"Warburg effect","route":"/terms/warburg-effect/","asOf":"2026-09-08","days":1},{"id":"immune-exclusion","kind":"term","name":"Immune exclusion","route":"/terms/immune-exclusion/","asOf":"2026-09-08","days":1},{"id":"cancer-associated-fibroblasts","kind":"term","name":"Cancer-associated fibroblasts (CAFs)","route":"/terms/cancer-associated-fibroblasts/","asOf":"2026-09-08","days":1},{"id":"tumor-associated-macrophages","kind":"term","name":"Tumour-associated macrophages (TAMs)","route":"/terms/tumor-associated-macrophages/","asOf":"2026-09-08","days":1},{"id":"myeloid-derived-suppressor-cells","kind":"term","name":"Myeloid-derived suppressor cells (MDSCs)","route":"/terms/myeloid-derived-suppressor-cells/","asOf":"2026-09-08","days":1},{"id":"whole-genome-doubling","kind":"term","name":"Whole-genome doubling (WGD)","route":"/terms/whole-genome-doubling/","asOf":"2026-09-08","days":1},{"id":"idea-dtc-colonisation-determinants","kind":"idea","name":"What decides which disseminated cells ever colonise?","route":"/ideas/idea-dtc-colonisation-determinants/","asOf":"2026-09-08","days":1},{"id":"idea-immune-exclusion-drivers","kind":"idea","name":"What actually holds T cells at the tumour border?","route":"/ideas/idea-immune-exclusion-drivers/","asOf":"2026-09-08","days":1},{"id":"idea-drugging-myc","kind":"idea","name":"Can MYC be drugged directly, and will patients tolerate it?","route":"/ideas/idea-drugging-myc/","asOf":"2026-09-08","days":1},{"id":"idea-targeting-aneuploidy","kind":"idea","name":"Is aneuploidy itself a druggable vulnerability?","route":"/ideas/idea-targeting-aneuploidy/","asOf":"2026-09-08","days":1},{"id":"idea-neoantigen-immunogenicity-rules","kind":"idea","name":"What makes a neoantigen actually immunogenic?","route":"/ideas/idea-neoantigen-immunogenicity-rules/","asOf":"2026-09-08","days":1},{"id":"idea-dormancy-maintenance-therapy","kind":"idea","name":"Keep them asleep: dormancy maintenance as adjuvant therapy","route":"/ideas/idea-dormancy-maintenance-therapy/","asOf":"2026-09-08","days":1},{"id":"idea-metabolic-vulnerability-mapping","kind":"idea","name":"Map metabolic dependencies in the patient, not the dish","route":"/ideas/idea-metabolic-vulnerability-mapping/","asOf":"2026-09-08","days":1},{"id":"idea-senolytics-after-chemo","kind":"idea","name":"One-two punch: clear senescent cells after chemotherapy","route":"/ideas/idea-senolytics-after-chemo/","asOf":"2026-09-08","days":1},{"id":"idea-microbiome-io-fmt","kind":"idea","name":"Microbiome transplant as a routine immunotherapy adjunct","route":"/ideas/idea-microbiome-io-fmt/","asOf":"2026-09-08","days":1},{"id":"idea-nerve-tumour-blockade","kind":"idea","name":"Cut the nerve supply to tumours with old drugs","route":"/ideas/idea-nerve-tumour-blockade/","asOf":"2026-09-08","days":1},{"id":"idea-cachexia-gdf15-prevention","kind":"idea","name":"Treat cachexia before it starts","route":"/ideas/idea-cachexia-gdf15-prevention/","asOf":"2026-09-08","days":1},{"id":"idea-chip-risk-modifiers","kind":"idea","name":"Which patients' blood clones will become leukaemia after treatment?","route":"/ideas/idea-chip-risk-modifiers/","asOf":"2026-09-08","days":1},{"id":"idea-field-interception","kind":"idea","name":"Intercept cancer at the field stage","route":"/ideas/idea-field-interception/","asOf":"2026-09-08","days":1},{"id":"idea-ferroptosis-persisters","kind":"idea","name":"Kill drug-tolerant persisters through ferroptosis","route":"/ideas/idea-ferroptosis-persisters/","asOf":"2026-09-08","days":1},{"id":"idea-splice-neoantigens","kind":"idea","name":"Shared splice-derived neoantigens as off-the-shelf vaccine targets","route":"/ideas/idea-splice-neoantigens/","asOf":"2026-09-08","days":1},{"id":"idea-chronotherapy-immunotherapy","kind":"idea","name":"Give immunotherapy in the morning","route":"/ideas/idea-chronotherapy-immunotherapy/","asOf":"2026-09-08","days":1},{"id":"idea-ecdna-targeting","kind":"idea","name":"Attack extrachromosomal DNA, the engine of oncogene amplification","route":"/ideas/idea-ecdna-targeting/","asOf":"2026-09-08","days":1},{"id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/","asOf":"2026-09-08","days":1},{"id":"cure-paths","kind":"roadmap","name":"Paths to cures: interception, eradication, control","route":"/roadmaps/cure-paths/","asOf":"2026-09-08","days":1},{"id":"closed-automated-cell-manufacturing","kind":"technology","name":"Closed automated cell-therapy manufacturing","route":"/technologies/closed-automated-cell-manufacturing/","asOf":"2026-09-08","days":1},{"id":"point-of-care-cell-manufacturing","kind":"technology","name":"Point-of-care and decentralised cell manufacturing","route":"/technologies/point-of-care-cell-manufacturing/","asOf":"2026-09-08","days":1},{"id":"viral-vector-manufacturing","kind":"technology","name":"Viral vector manufacturing (lentiviral, retroviral, AAV)","route":"/technologies/viral-vector-manufacturing/","asOf":"2026-09-08","days":1},{"id":"plasmid-dna-manufacturing","kind":"technology","name":"Plasmid DNA and mRNA raw-material manufacturing","route":"/technologies/plasmid-dna-manufacturing/","asOf":"2026-09-08","days":1},{"id":"adc-cdmo-manufacturing","kind":"technology","name":"ADC bioconjugation manufacturing (CDMOs)","route":"/technologies/adc-cdmo-manufacturing/","asOf":"2026-09-08","days":1},{"id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/","asOf":"2026-09-08","days":1},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/","asOf":"2026-09-08","days":1},{"id":"long-read-sequencing","kind":"technology","name":"Long-read sequencing (PacBio, Oxford Nanopore)","route":"/technologies/long-read-sequencing/","asOf":"2026-09-08","days":1},{"id":"next-gen-short-read-platforms","kind":"technology","name":"New short-read sequencing platforms","route":"/technologies/next-gen-short-read-platforms/","asOf":"2026-09-08","days":1},{"id":"spatial-biology-instruments","kind":"technology","name":"Spatial biology instruments","route":"/technologies/spatial-biology-instruments/","asOf":"2026-09-08","days":1},{"id":"whole-slide-scanners","kind":"technology","name":"Whole-slide scanners and image management","route":"/technologies/whole-slide-scanners/","asOf":"2026-09-08","days":1},{"id":"treatment-planning-systems","kind":"technology","name":"Radiotherapy treatment planning and QA software","route":"/technologies/treatment-planning-systems/","asOf":"2026-09-08","days":1},{"id":"auto-contouring-ai","kind":"technology","name":"AI auto-contouring and adaptive planning","route":"/technologies/auto-contouring-ai/","asOf":"2026-09-08","days":1},{"id":"oncology-real-world-data","kind":"technology","name":"Oncology EHR and real-world data platforms","route":"/technologies/oncology-real-world-data/","asOf":"2026-09-08","days":1},{"id":"clinical-trial-software","kind":"technology","name":"Clinical trial software (EDC, eCOA, CTMS, RTSM)","route":"/technologies/clinical-trial-software/","asOf":"2026-09-08","days":1},{"id":"decentralised-clinical-trials","kind":"technology","name":"Decentralised and hybrid clinical trials","route":"/technologies/decentralised-clinical-trials/","asOf":"2026-09-08","days":1},{"id":"community-oncology-networks","kind":"technology","name":"Community oncology and site networks","route":"/technologies/community-oncology-networks/","asOf":"2026-09-08","days":1},{"id":"contract-research-organisations","kind":"technology","name":"Contract research organisations (CROs)","route":"/technologies/contract-research-organisations/","asOf":"2026-09-08","days":1},{"id":"imaging-core-labs","kind":"technology","name":"Imaging core labs and central review","route":"/technologies/imaging-core-labs/","asOf":"2026-09-08","days":1},{"id":"biobanking","kind":"technology","name":"Biobanking and tissue procurement","route":"/technologies/biobanking/","asOf":"2026-09-08","days":1},{"id":"reference-laboratories","kind":"technology","name":"Reference laboratories and companion-diagnostic testing","route":"/technologies/reference-laboratories/","asOf":"2026-09-08","days":1},{"id":"pet-tracer-manufacturing","kind":"technology","name":"PET tracer manufacturing and distribution","route":"/technologies/pet-tracer-manufacturing/","asOf":"2026-09-08","days":1},{"id":"nuclear-medicine-hardware","kind":"technology","name":"Nuclear medicine and total-body PET hardware","route":"/technologies/nuclear-medicine-hardware/","asOf":"2026-09-08","days":1},{"id":"remote-patient-monitoring","kind":"technology","name":"Electronic patient-reported outcomes and remote monitoring","route":"/technologies/remote-patient-monitoring/","asOf":"2026-09-08","days":1},{"id":"pharmacy-automation","kind":"technology","name":"Oncology pharmacy automation and compounding robots","route":"/technologies/pharmacy-automation/","asOf":"2026-09-08","days":1},{"id":"ai-compute-platforms","kind":"technology","name":"AI compute and model platforms for oncology","route":"/technologies/ai-compute-platforms/","asOf":"2026-09-08","days":1},{"id":"sterile-fill-finish","kind":"technology","name":"Sterile fill-finish and lyophilisation","route":"/technologies/sterile-fill-finish/","asOf":"2026-09-08","days":1},{"id":"generic-drug-shortage-response","kind":"technology","name":"Generic oncology drug supply and shortage mitigation","route":"/technologies/generic-drug-shortage-response/","asOf":"2026-09-08","days":1},{"id":"hospital-information-systems-oncology","kind":"technology","name":"Oncology EHR modules and treatment pathways","route":"/technologies/hospital-information-systems-oncology/","asOf":"2026-09-08","days":1},{"id":"high-potency-payload-synthesis","kind":"technology","name":"Payload-linker synthesis (high-potency API)","route":"/technologies/high-potency-payload-synthesis/","asOf":"2026-09-08","days":1},{"id":"apheresis-starting-material","kind":"technology","name":"Apheresis and starting-material collection","route":"/technologies/apheresis-starting-material/","asOf":"2026-09-08","days":1},{"id":"cell-therapy-cold-chain","kind":"technology","name":"Cryopreservation and cell-therapy cold chain","route":"/technologies/cell-therapy-cold-chain/","asOf":"2026-09-08","days":1},{"id":"cell-therapy-orchestration-software","kind":"technology","name":"Cell-therapy orchestration and chain-of-identity software","route":"/technologies/cell-therapy-orchestration-software/","asOf":"2026-09-08","days":1},{"id":"cell-therapy-release-testing","kind":"technology","name":"Cell-therapy release and potency testing","route":"/technologies/cell-therapy-release-testing/","asOf":"2026-09-08","days":1},{"id":"allogeneic-cell-banking","kind":"technology","name":"Allogeneic donor and iPSC master cell banks","route":"/technologies/allogeneic-cell-banking/","asOf":"2026-09-08","days":1},{"id":"monoclonal-antibody-manufacturing","kind":"technology","name":"Antibody manufacturing (CHO bioprocessing)","route":"/technologies/monoclonal-antibody-manufacturing/","asOf":"2026-09-08","days":1},{"id":"medical-cyclotrons-synthesis-modules","kind":"technology","name":"Medical cyclotrons, hot cells, and synthesis modules","route":"/technologies/medical-cyclotrons-synthesis-modules/","asOf":"2026-09-08","days":1},{"id":"radionuclide-generators-kits","kind":"technology","name":"Radionuclide generators and cold kits","route":"/technologies/radionuclide-generators-kits/","asOf":"2026-09-08","days":1},{"id":"ngs-bioinformatics-software","kind":"technology","name":"Clinical NGS bioinformatics and variant interpretation","route":"/technologies/ngs-bioinformatics-software/","asOf":"2026-09-08","days":1},{"id":"genomics-cloud-platforms","kind":"technology","name":"Genomics cloud and secure research environments","route":"/technologies/genomics-cloud-platforms/","asOf":"2026-09-08","days":1},{"id":"variant-knowledgebases","kind":"technology","name":"Cancer variant knowledgebases and molecular tumour boards","route":"/technologies/variant-knowledgebases/","asOf":"2026-09-08","days":1},{"id":"cancer-registries-surveillance","kind":"technology","name":"Cancer registries and population surveillance","route":"/technologies/cancer-registries-surveillance/","asOf":"2026-09-08","days":1},{"id":"proteomics-platforms","kind":"technology","name":"Proteomics instruments and affinity platforms","route":"/technologies/proteomics-platforms/","asOf":"2026-09-08","days":1},{"id":"structural-biology-infrastructure","kind":"technology","name":"Structural biology infrastructure (cryo-EM, synchrotrons, AlphaFold)","route":"/technologies/structural-biology-infrastructure/","asOf":"2026-09-08","days":1},{"id":"high-throughput-screening-libraries","kind":"technology","name":"High-throughput screening and DNA-encoded libraries","route":"/technologies/high-throughput-screening-libraries/","asOf":"2026-09-08","days":1},{"id":"preanalytics-sample-stabilisation","kind":"technology","name":"Pre-analytics: blood-collection tubes and tissue fixation","route":"/technologies/preanalytics-sample-stabilisation/","asOf":"2026-09-08","days":1},{"id":"ihc-autostainers-histology-automation","kind":"technology","name":"Histology automation and IHC autostainers","route":"/technologies/ihc-autostainers-histology-automation/","asOf":"2026-09-08","days":1},{"id":"infusion-devices-vascular-access","kind":"technology","name":"Infusion pumps, ports, and ambulatory chemotherapy devices","route":"/technologies/infusion-devices-vascular-access/","asOf":"2026-09-08","days":1},{"id":"federated-learning-medical-ai","kind":"technology","name":"Federated learning and privacy-preserving AI","route":"/technologies/federated-learning-medical-ai/","asOf":"2026-09-08","days":1},{"id":"telemedicine-teleoncology","kind":"technology","name":"Telemedicine, teleoncology, and telepathology","route":"/technologies/telemedicine-teleoncology/","asOf":"2026-09-08","days":1},{"id":"miltenyi-biotec","kind":"company","name":"Miltenyi Biotec","route":"/companies/miltenyi-biotec/","asOf":"2026-09-08","days":1},{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/","asOf":"2026-09-08","days":1},{"id":"cellares","kind":"company","name":"Cellares","route":"/companies/cellares/","asOf":"2026-09-08","days":1},{"id":"cytiva","kind":"company","name":"Cytiva (Danaher)","route":"/companies/cytiva/","asOf":"2026-09-08","days":1},{"id":"galapagos","kind":"company","name":"Galapagos","route":"/companies/galapagos/","asOf":"2026-09-08","days":1},{"id":"oxford-biomedica","kind":"company","name":"OXB (Oxford Biomedica)","route":"/companies/oxford-biomedica/","asOf":"2026-09-08","days":1},{"id":"thermo-fisher","kind":"company","name":"Thermo Fisher Scientific","route":"/companies/thermo-fisher/","asOf":"2026-09-08","days":1},{"id":"charles-river","kind":"company","name":"Charles River Laboratories","route":"/companies/charles-river/","asOf":"2026-09-08","days":1},{"id":"aldevron","kind":"company","name":"Aldevron (Danaher)","route":"/companies/aldevron/","asOf":"2026-09-08","days":1},{"id":"touchlight","kind":"company","name":"Touchlight","route":"/companies/touchlight/","asOf":"2026-09-08","days":1},{"id":"wuxi-xdc","kind":"company","name":"WuXi XDC","route":"/companies/wuxi-xdc/","asOf":"2026-09-08","days":1},{"id":"samsung-biologics","kind":"company","name":"Samsung Biologics","route":"/companies/samsung-biologics/","asOf":"2026-09-08","days":1},{"id":"piramal-pharma-solutions","kind":"company","name":"Piramal Pharma Solutions","route":"/companies/piramal-pharma-solutions/","asOf":"2026-09-08","days":1},{"id":"abzena","kind":"company","name":"Abzena","route":"/companies/abzena/","asOf":"2026-09-08","days":1},{"id":"catalent","kind":"company","name":"Catalent (Novo Holdings)","route":"/companies/catalent/","asOf":"2026-09-08","days":1},{"id":"petnet-solutions","kind":"company","name":"PETNET Solutions (Siemens Healthineers)","route":"/companies/petnet-solutions/","asOf":"2026-09-08","days":1},{"id":"cardinal-health","kind":"company","name":"Cardinal Health Nuclear & Precision Health Solutions","route":"/companies/cardinal-health/","asOf":"2026-09-08","days":1},{"id":"jubilant-radiopharma","kind":"company","name":"Jubilant Radiopharma","route":"/companies/jubilant-radiopharma/","asOf":"2026-09-08","days":1},{"id":"northstar-medical-radioisotopes","kind":"company","name":"NorthStar Medical Radioisotopes","route":"/companies/northstar-medical-radioisotopes/","asOf":"2026-09-08","days":1},{"id":"shine-technologies","kind":"company","name":"SHINE Technologies","route":"/companies/shine-technologies/","asOf":"2026-09-08","days":1},{"id":"eckert-ziegler","kind":"company","name":"Eckert & Ziegler","route":"/companies/eckert-ziegler/","asOf":"2026-09-08","days":1},{"id":"pacbio","kind":"company","name":"PacBio","route":"/companies/pacbio/","asOf":"2026-09-08","days":1},{"id":"oxford-nanopore","kind":"company","name":"Oxford Nanopore Technologies","route":"/companies/oxford-nanopore/","asOf":"2026-09-08","days":1},{"id":"ultima-genomics","kind":"company","name":"Ultima Genomics","route":"/companies/ultima-genomics/","asOf":"2026-09-08","days":1},{"id":"element-biosciences","kind":"company","name":"Element Biosciences","route":"/companies/element-biosciences/","asOf":"2026-09-08","days":1},{"id":"mgi-tech","kind":"company","name":"MGI Tech","route":"/companies/mgi-tech/","asOf":"2026-09-08","days":1},{"id":"bruker","kind":"company","name":"Bruker (Bruker Spatial Biology)","route":"/companies/bruker/","asOf":"2026-09-08","days":1},{"id":"vizgen","kind":"company","name":"Vizgen","route":"/companies/vizgen/","asOf":"2026-09-08","days":1},{"id":"akoya-biosciences","kind":"company","name":"Akoya Biosciences","route":"/companies/akoya-biosciences/","asOf":"2026-09-08","days":1},{"id":"leica-biosystems","kind":"company","name":"Leica Biosystems (Danaher)","route":"/companies/leica-biosystems/","asOf":"2026-09-08","days":1},{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","asOf":"2026-09-08","days":1},{"id":"3dhistech","kind":"company","name":"3DHISTECH","route":"/companies/3dhistech/","asOf":"2026-09-08","days":1},{"id":"philips","kind":"company","name":"Philips","route":"/companies/philips/","asOf":"2026-09-08","days":1},{"id":"sectra","kind":"company","name":"Sectra","route":"/companies/sectra/","asOf":"2026-09-08","days":1},{"id":"proscia","kind":"company","name":"Proscia","route":"/companies/proscia/","asOf":"2026-09-08","days":1},{"id":"indica-labs","kind":"company","name":"Indica Labs","route":"/companies/indica-labs/","asOf":"2026-09-08","days":1},{"id":"raysearch","kind":"company","name":"RaySearch Laboratories","route":"/companies/raysearch/","asOf":"2026-09-08","days":1},{"id":"sun-nuclear","kind":"company","name":"Sun Nuclear (Mirion)","route":"/companies/sun-nuclear/","asOf":"2026-09-08","days":1},{"id":"brainlab","kind":"company","name":"Brainlab","route":"/companies/brainlab/","asOf":"2026-09-08","days":1},{"id":"limbus-ai","kind":"company","name":"Limbus AI","route":"/companies/limbus-ai/","asOf":"2026-09-08","days":1},{"id":"mim-software","kind":"company","name":"MIM Software (GE HealthCare)","route":"/companies/mim-software/","asOf":"2026-09-08","days":1},{"id":"therapanacea","kind":"company","name":"TheraPanacea","route":"/companies/therapanacea/","asOf":"2026-09-08","days":1},{"id":"mvision-ai","kind":"company","name":"MVision AI","route":"/companies/mvision-ai/","asOf":"2026-09-08","days":1},{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/","asOf":"2026-09-08","days":1},{"id":"concertai","kind":"company","name":"ConcertAI","route":"/companies/concertai/","asOf":"2026-09-08","days":1},{"id":"cota-healthcare","kind":"company","name":"COTA","route":"/companies/cota-healthcare/","asOf":"2026-09-08","days":1},{"id":"trinetx","kind":"company","name":"TriNetX","route":"/companies/trinetx/","asOf":"2026-09-08","days":1},{"id":"komodo-health","kind":"company","name":"Komodo Health","route":"/companies/komodo-health/","asOf":"2026-09-08","days":1},{"id":"datavant","kind":"company","name":"Datavant","route":"/companies/datavant/","asOf":"2026-09-08","days":1},{"id":"medidata","kind":"company","name":"Medidata (Dassault Systèmes)","route":"/companies/medidata/","asOf":"2026-09-08","days":1},{"id":"veeva-systems","kind":"company","name":"Veeva Systems","route":"/companies/veeva-systems/","asOf":"2026-09-08","days":1},{"id":"oracle-health-sciences","kind":"company","name":"Oracle Health (Cerner) & Oracle Life Sciences","route":"/companies/oracle-health-sciences/","asOf":"2026-09-08","days":1},{"id":"epic-systems","kind":"company","name":"Epic Systems","route":"/companies/epic-systems/","asOf":"2026-09-08","days":1},{"id":"medable","kind":"company","name":"Medable","route":"/companies/medable/","asOf":"2026-09-08","days":1},{"id":"science-37","kind":"company","name":"Science 37 (eMed)","route":"/companies/science-37/","asOf":"2026-09-08","days":1},{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","route":"/companies/mckesson-us-oncology/","asOf":"2026-09-08","days":1},{"id":"oneoncology","kind":"company","name":"OneOncology","route":"/companies/oneoncology/","asOf":"2026-09-08","days":1},{"id":"florida-cancer-specialists","kind":"company","name":"Florida Cancer Specialists & Research Institute","route":"/companies/florida-cancer-specialists/","asOf":"2026-09-08","days":1},{"id":"sarah-cannon-research-institute","kind":"company","name":"Sarah Cannon Research Institute","route":"/companies/sarah-cannon-research-institute/","asOf":"2026-09-08","days":1},{"id":"iqvia","kind":"company","name":"IQVIA","route":"/companies/iqvia/","asOf":"2026-09-08","days":1},{"id":"icon-plc","kind":"company","name":"ICON plc","route":"/companies/icon-plc/","asOf":"2026-09-08","days":1},{"id":"parexel","kind":"company","name":"Parexel","route":"/companies/parexel/","asOf":"2026-09-08","days":1},{"id":"fortrea","kind":"company","name":"Fortrea","route":"/companies/fortrea/","asOf":"2026-09-08","days":1},{"id":"medpace","kind":"company","name":"Medpace","route":"/companies/medpace/","asOf":"2026-09-08","days":1},{"id":"calyx","kind":"company","name":"Calyx","route":"/companies/calyx/","asOf":"2026-09-08","days":1},{"id":"clario","kind":"company","name":"Clario","route":"/companies/clario/","asOf":"2026-09-08","days":1},{"id":"discovery-life-sciences","kind":"company","name":"Discovery Life Sciences","route":"/companies/discovery-life-sciences/","asOf":"2026-09-08","days":1},{"id":"indivumed","kind":"company","name":"Indivumed","route":"/companies/indivumed/","asOf":"2026-09-08","days":1},{"id":"hub-organoids","kind":"company","name":"HUB Organoids","route":"/companies/hub-organoids/","asOf":"2026-09-08","days":1},{"id":"labcorp","kind":"company","name":"Labcorp","route":"/companies/labcorp/","asOf":"2026-09-08","days":1},{"id":"quest-diagnostics","kind":"company","name":"Quest Diagnostics","route":"/companies/quest-diagnostics/","asOf":"2026-09-08","days":1},{"id":"neogenomics","kind":"company","name":"NeoGenomics","route":"/companies/neogenomics/","asOf":"2026-09-08","days":1},{"id":"agilent","kind":"company","name":"Agilent Technologies (Dako)","route":"/companies/agilent/","asOf":"2026-09-08","days":1},{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","route":"/companies/canon-medical/","asOf":"2026-09-08","days":1},{"id":"kaiku-health","kind":"company","name":"Kaiku Health (Elekta)","route":"/companies/kaiku-health/","asOf":"2026-09-08","days":1},{"id":"omnicell","kind":"company","name":"Omnicell","route":"/companies/omnicell/","asOf":"2026-09-08","days":1},{"id":"becton-dickinson","kind":"company","name":"BD (Becton, Dickinson and Company)","route":"/companies/becton-dickinson/","asOf":"2026-09-08","days":1},{"id":"microsoft","kind":"company","name":"Microsoft (Health & Life Sciences)","route":"/companies/microsoft/","asOf":"2026-09-08","days":1},{"id":"google-health","kind":"company","name":"Google (Health, DeepMind, Verily)","route":"/companies/google-health/","asOf":"2026-09-08","days":1},{"id":"civica-rx","kind":"company","name":"Civica Rx","route":"/companies/civica-rx/","asOf":"2026-09-08","days":1},{"id":"terumo-bct","kind":"company","name":"Terumo Blood and Cell Technologies","route":"/companies/terumo-bct/","asOf":"2026-09-08","days":1},{"id":"fresenius-kabi","kind":"company","name":"Fresenius Kabi","route":"/companies/fresenius-kabi/","asOf":"2026-09-08","days":1},{"id":"cryoport","kind":"company","name":"Cryoport","route":"/companies/cryoport/","asOf":"2026-09-08","days":1},{"id":"biolife-solutions","kind":"company","name":"BioLife Solutions","route":"/companies/biolife-solutions/","asOf":"2026-09-08","days":1},{"id":"fujifilm-diosynth","kind":"company","name":"FUJIFILM Diosynth Biotechnologies","route":"/companies/fujifilm-diosynth/","asOf":"2026-09-08","days":1},{"id":"boehringer-ingelheim-biox","kind":"company","name":"Boehringer Ingelheim BioXcellence","route":"/companies/boehringer-ingelheim-biox/","asOf":"2026-09-08","days":1},{"id":"trasis","kind":"company","name":"Trasis","route":"/companies/trasis/","asOf":"2026-09-08","days":1},{"id":"comecer","kind":"company","name":"Comecer (ATS)","route":"/companies/comecer/","asOf":"2026-09-08","days":1},{"id":"sophia-genetics","kind":"company","name":"SOPHiA GENETICS","route":"/companies/sophia-genetics/","asOf":"2026-09-08","days":1},{"id":"qiagen","kind":"company","name":"QIAGEN","route":"/companies/qiagen/","asOf":"2026-09-08","days":1},{"id":"velsera","kind":"company","name":"Velsera (Seven Bridges and Pierian)","route":"/companies/velsera/","asOf":"2026-09-08","days":1},{"id":"dnanexus","kind":"company","name":"DNAnexus","route":"/companies/dnanexus/","asOf":"2026-09-08","days":1},{"id":"standard-biotools","kind":"company","name":"Standard BioTools (SomaLogic)","route":"/companies/standard-biotools/","asOf":"2026-09-08","days":1},{"id":"streck","kind":"company","name":"Streck","route":"/companies/streck/","asOf":"2026-09-08","days":1},{"id":"sakura-finetek","kind":"company","name":"Sakura Finetek","route":"/companies/sakura-finetek/","asOf":"2026-09-08","days":1},{"id":"baxter","kind":"company","name":"Baxter International","route":"/companies/baxter/","asOf":"2026-09-08","days":1},{"id":"b-braun","kind":"company","name":"B. Braun","route":"/companies/b-braun/","asOf":"2026-09-08","days":1},{"id":"project-optimus","kind":"term","name":"Project Optimus","route":"/terms/project-optimus/","asOf":"2026-09-08","days":1},{"id":"project-orbis","kind":"term","name":"Project Orbis","route":"/terms/project-orbis/","asOf":"2026-09-08","days":1},{"id":"real-time-oncology-review","kind":"term","name":"Real-Time Oncology Review (RTOR) and Assessment Aid","route":"/terms/real-time-oncology-review/","asOf":"2026-09-08","days":1},{"id":"project-frontrunner","kind":"term","name":"Project FrontRunner","route":"/terms/project-frontrunner/","asOf":"2026-09-08","days":1},{"id":"340b-program","kind":"term","name":"340B Drug Pricing Program","route":"/terms/340b-program/","asOf":"2026-09-08","days":1},{"id":"nccn-compendium","kind":"term","name":"NCCN Compendium and drug compendia","route":"/terms/nccn-compendium/","asOf":"2026-09-08","days":1},{"id":"icer-value-assessment","kind":"term","name":"ICER and health technology assessment","route":"/terms/icer-value-assessment/","asOf":"2026-09-08","days":1},{"id":"omop-ohdsi","kind":"term","name":"OMOP common data model and OHDSI","route":"/terms/omop-ohdsi/","asOf":"2026-09-08","days":1},{"id":"mcode","kind":"term","name":"mCODE (minimal Common Oncology Data Elements)","route":"/terms/mcode/","asOf":"2026-09-08","days":1},{"id":"bicr","kind":"term","name":"Blinded independent central review (BICR)","route":"/terms/bicr/","asOf":"2026-09-08","days":1},{"id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/","asOf":"2026-09-08","days":1},{"id":"biosecure-act","kind":"term","name":"BIOSECURE Act","route":"/terms/biosecure-act/","asOf":"2026-09-08","days":1},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","asOf":"2026-09-08","days":1},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/","asOf":"2026-09-08","days":1},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/","asOf":"2026-09-08","days":1},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","asOf":"2026-09-08","days":1},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","asOf":"2026-09-08","days":1},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","asOf":"2026-09-08","days":1},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","asOf":"2026-09-08","days":1},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","asOf":"2026-09-08","days":1},{"id":"hairy-cell-leukemia","kind":"cancer","name":"Hairy cell leukaemia","route":"/cancers/hairy-cell-leukemia/","asOf":"2026-09-08","days":1},{"id":"bpdcn","kind":"cancer","name":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN)","route":"/cancers/bpdcn/","asOf":"2026-09-08","days":1},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","asOf":"2026-09-08","days":1},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","asOf":"2026-09-08","days":1},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","asOf":"2026-09-08","days":1},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/","asOf":"2026-09-08","days":1},{"id":"testicular","kind":"cancer","name":"Testicular germ cell tumours","route":"/cancers/testicular/","asOf":"2026-09-08","days":1},{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/","asOf":"2026-09-08","days":1},{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/","asOf":"2026-09-08","days":1},{"id":"appendiceal","kind":"cancer","name":"Appendiceal cancer and pseudomyxoma peritonei","route":"/cancers/appendiceal/","asOf":"2026-09-08","days":1},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/","asOf":"2026-09-08","days":1},{"id":"gestational-trophoblastic","kind":"cancer","name":"Gestational trophoblastic neoplasia","route":"/cancers/gestational-trophoblastic/","asOf":"2026-09-08","days":1},{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/","asOf":"2026-09-08","days":1},{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/","asOf":"2026-09-08","days":1},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/","asOf":"2026-09-08","days":1},{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/","asOf":"2026-09-08","days":1},{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/","asOf":"2026-09-08","days":1},{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/","asOf":"2026-09-08","days":1},{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/","asOf":"2026-09-08","days":1},{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","asOf":"2026-09-08","days":1},{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/","asOf":"2026-09-08","days":1},{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/","asOf":"2026-09-08","days":1},{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/","asOf":"2026-09-08","days":1},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/","asOf":"2026-09-08","days":1},{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/","asOf":"2026-09-08","days":1},{"id":"nilotinib","kind":"drug","name":"Nilotinib","route":"/drugs/nilotinib/","asOf":"2026-09-08","days":1},{"id":"bosutinib","kind":"drug","name":"Bosutinib","route":"/drugs/bosutinib/","asOf":"2026-09-08","days":1},{"id":"luspatercept","kind":"drug","name":"Luspatercept","route":"/drugs/luspatercept/","asOf":"2026-09-08","days":1},{"id":"imetelstat","kind":"drug","name":"Imetelstat","route":"/drugs/imetelstat/","asOf":"2026-09-08","days":1},{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/","asOf":"2026-09-08","days":1},{"id":"fedratinib","kind":"drug","name":"Fedratinib","route":"/drugs/fedratinib/","asOf":"2026-09-08","days":1},{"id":"pacritinib","kind":"drug","name":"Pacritinib","route":"/drugs/pacritinib/","asOf":"2026-09-08","days":1},{"id":"momelotinib","kind":"drug","name":"Momelotinib","route":"/drugs/momelotinib/","asOf":"2026-09-08","days":1},{"id":"hydroxyurea","kind":"drug","name":"Hydroxyurea (hydroxycarbamide)","route":"/drugs/hydroxyurea/","asOf":"2026-09-08","days":1},{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/","asOf":"2026-09-08","days":1},{"id":"rusfertide","kind":"drug","name":"Rusfertide","route":"/drugs/rusfertide/","asOf":"2026-09-08","days":1},{"id":"glasdegib","kind":"drug","name":"Glasdegib","route":"/drugs/glasdegib/","asOf":"2026-09-08","days":1},{"id":"arsenic-trioxide","kind":"drug","name":"Arsenic trioxide","route":"/drugs/arsenic-trioxide/","asOf":"2026-09-08","days":1},{"id":"tretinoin-atra","kind":"drug","name":"Tretinoin (all-trans retinoic acid, ATRA)","route":"/drugs/tretinoin-atra/","asOf":"2026-09-08","days":1},{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/","asOf":"2026-09-08","days":1},{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/","asOf":"2026-09-08","days":1},{"id":"brexucabtagene-autoleucel","kind":"drug","name":"Brexucabtagene autoleucel","route":"/drugs/brexucabtagene-autoleucel/","asOf":"2026-09-08","days":1},{"id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/","asOf":"2026-09-08","days":1},{"id":"romidepsin","kind":"drug","name":"Romidepsin","route":"/drugs/romidepsin/","asOf":"2026-09-08","days":1},{"id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/","asOf":"2026-09-08","days":1},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/","asOf":"2026-09-08","days":1},{"id":"cladribine","kind":"drug","name":"Cladribine","route":"/drugs/cladribine/","asOf":"2026-09-08","days":1},{"id":"moxetumomab-pasudotox","kind":"drug","name":"Moxetumomab pasudotox","route":"/drugs/moxetumomab-pasudotox/","asOf":"2026-09-08","days":1},{"id":"interferon-alfa","kind":"drug","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/","asOf":"2026-09-08","days":1},{"id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/","asOf":"2026-09-08","days":1},{"id":"idelalisib","kind":"drug","name":"Idelalisib","route":"/drugs/idelalisib/","asOf":"2026-09-08","days":1},{"id":"duvelisib","kind":"drug","name":"Duvelisib","route":"/drugs/duvelisib/","asOf":"2026-09-08","days":1},{"id":"copanlisib","kind":"drug","name":"Copanlisib","route":"/drugs/copanlisib/","asOf":"2026-09-08","days":1},{"id":"umbralisib","kind":"drug","name":"Umbralisib","route":"/drugs/umbralisib/","asOf":"2026-09-08","days":1},{"id":"ixazomib","kind":"drug","name":"Ixazomib","route":"/drugs/ixazomib/","asOf":"2026-09-08","days":1},{"id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/","asOf":"2026-09-08","days":1},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/","asOf":"2026-09-08","days":1},{"id":"thalidomide","kind":"drug","name":"Thalidomide","route":"/drugs/thalidomide/","asOf":"2026-09-08","days":1},{"id":"panobinostat","kind":"drug","name":"Panobinostat","route":"/drugs/panobinostat/","asOf":"2026-09-08","days":1},{"id":"asparaginase","kind":"drug","name":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)","route":"/drugs/asparaginase/","asOf":"2026-09-08","days":1},{"id":"belumosudil","kind":"drug","name":"Belumosudil","route":"/drugs/belumosudil/","asOf":"2026-09-08","days":1},{"id":"treosulfan","kind":"drug","name":"Treosulfan","route":"/drugs/treosulfan/","asOf":"2026-09-08","days":1},{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/","asOf":"2026-09-08","days":1},{"id":"cosibelimab","kind":"drug","name":"Cosibelimab","route":"/drugs/cosibelimab/","asOf":"2026-09-08","days":1},{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/","asOf":"2026-09-08","days":1},{"id":"vismodegib","kind":"drug","name":"Vismodegib","route":"/drugs/vismodegib/","asOf":"2026-09-08","days":1},{"id":"sonidegib","kind":"drug","name":"Sonidegib","route":"/drugs/sonidegib/","asOf":"2026-09-08","days":1},{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/","asOf":"2026-09-08","days":1},{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/","asOf":"2026-09-08","days":1},{"id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/","asOf":"2026-09-08","days":1},{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/","asOf":"2026-09-08","days":1},{"id":"mobocertinib","kind":"drug","name":"Mobocertinib","route":"/drugs/mobocertinib/","asOf":"2026-09-08","days":1},{"id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","asOf":"2026-09-08","days":1},{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/","asOf":"2026-09-08","days":1},{"id":"ceritinib","kind":"drug","name":"Ceritinib","route":"/drugs/ceritinib/","asOf":"2026-09-08","days":1},{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/","asOf":"2026-09-08","days":1},{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/","asOf":"2026-09-08","days":1},{"id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/","asOf":"2026-09-08","days":1},{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","asOf":"2026-09-08","days":1},{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","asOf":"2026-09-08","days":1},{"id":"temsirolimus","kind":"drug","name":"Temsirolimus","route":"/drugs/temsirolimus/","asOf":"2026-09-08","days":1},{"id":"pexidartinib","kind":"drug","name":"Pexidartinib","route":"/drugs/pexidartinib/","asOf":"2026-09-08","days":1},{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","asOf":"2026-09-08","days":1},{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/","asOf":"2026-09-08","days":1},{"id":"leuprolide","kind":"drug","name":"Leuprolide (leuprorelin) and GnRH agonists","route":"/drugs/leuprolide/","asOf":"2026-09-08","days":1},{"id":"degarelix","kind":"drug","name":"Degarelix","route":"/drugs/degarelix/","asOf":"2026-09-08","days":1},{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/","asOf":"2026-09-08","days":1},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/","asOf":"2026-09-08","days":1},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/","asOf":"2026-09-08","days":1},{"id":"vinblastine","kind":"drug","name":"Vinblastine","route":"/drugs/vinblastine/","asOf":"2026-09-08","days":1},{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/","asOf":"2026-09-08","days":1},{"id":"methotrexate","kind":"drug","name":"Methotrexate","route":"/drugs/methotrexate/","asOf":"2026-09-08","days":1},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/","asOf":"2026-09-08","days":1},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/","asOf":"2026-09-08","days":1},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/","asOf":"2026-09-08","days":1},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/","asOf":"2026-09-08","days":1},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/","asOf":"2026-09-08","days":1},{"id":"bleomycin","kind":"drug","name":"Bleomycin","route":"/drugs/bleomycin/","asOf":"2026-09-08","days":1},{"id":"dactinomycin","kind":"drug","name":"Dactinomycin (actinomycin D)","route":"/drugs/dactinomycin/","asOf":"2026-09-08","days":1},{"id":"mitomycin","kind":"drug","name":"Mitomycin C","route":"/drugs/mitomycin/","asOf":"2026-09-08","days":1},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/","asOf":"2026-09-08","days":1},{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/","asOf":"2026-09-08","days":1},{"id":"mitotane","kind":"drug","name":"Mitotane","route":"/drugs/mitotane/","asOf":"2026-09-08","days":1},{"id":"mifamurtide","kind":"drug","name":"Mifamurtide","route":"/drugs/mifamurtide/","asOf":"2026-09-08","days":1},{"id":"sodium-thiosulfate","kind":"drug","name":"Sodium thiosulfate (otoprotectant)","route":"/drugs/sodium-thiosulfate/","asOf":"2026-09-08","days":1},{"id":"pafolacianine","kind":"drug","name":"Pafolacianine","route":"/drugs/pafolacianine/","asOf":"2026-09-08","days":1},{"id":"pegulicianine","kind":"drug","name":"Pegulicianine","route":"/drugs/pegulicianine/","asOf":"2026-09-08","days":1},{"id":"aminolevulinic-acid-gleolan","kind":"drug","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/","asOf":"2026-09-08","days":1},{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/","asOf":"2026-09-08","days":1},{"id":"fluoroestradiol-f18","kind":"drug","name":"Fluoroestradiol F-18 (FES PET)","route":"/drugs/fluoroestradiol-f18/","asOf":"2026-09-08","days":1},{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/","asOf":"2026-09-08","days":1},{"id":"tilmanocept-tc99m","kind":"drug","name":"Technetium-99m tilmanocept","route":"/drugs/tilmanocept-tc99m/","asOf":"2026-09-08","days":1},{"id":"jak2","kind":"target","name":"JAK2","route":"/targets/jak2/","asOf":"2026-09-08","days":1},{"id":"cd79b","kind":"target","name":"CD79b","route":"/targets/cd79b/","asOf":"2026-09-08","days":1},{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/","asOf":"2026-09-08","days":1},{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/","asOf":"2026-09-08","days":1},{"id":"tim3","kind":"target","name":"TIM-3","route":"/targets/tim3/","asOf":"2026-09-08","days":1},{"id":"smoothened","kind":"target","name":"Smoothened (hedgehog pathway)","route":"/targets/smoothened/","asOf":"2026-09-08","days":1},{"id":"pdgfra","kind":"target","name":"PDGFRA","route":"/targets/pdgfra/","asOf":"2026-09-08","days":1},{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/","asOf":"2026-09-08","days":1},{"id":"ewsr1-fli1","kind":"target","name":"EWSR1-FLI1 fusion","route":"/targets/ewsr1-fli1/","asOf":"2026-09-08","days":1},{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/","asOf":"2026-09-08","days":1},{"id":"cldn6","kind":"target","name":"Claudin 6","route":"/targets/cldn6/","asOf":"2026-09-08","days":1},{"id":"cd73-adenosine","kind":"target","name":"CD73 / adenosine axis","route":"/targets/cd73-adenosine/","asOf":"2026-09-08","days":1},{"id":"vista","kind":"target","name":"VISTA","route":"/targets/vista/","asOf":"2026-09-08","days":1},{"id":"muc16","kind":"target","name":"MUC16 (CA-125)","route":"/targets/muc16/","asOf":"2026-09-08","days":1},{"id":"liv1","kind":"target","name":"LIV-1 (SLC39A6)","route":"/targets/liv1/","asOf":"2026-09-08","days":1},{"id":"mdm2","kind":"target","name":"MDM2","route":"/targets/mdm2/","asOf":"2026-09-08","days":1},{"id":"prmt5-mtap","kind":"target","name":"PRMT5 (MTAP-deleted cancers)","route":"/targets/prmt5-mtap/","asOf":"2026-09-08","days":1},{"id":"wrn","kind":"target","name":"WRN helicase (MSI-high cancers)","route":"/targets/wrn/","asOf":"2026-09-08","days":1},{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/","asOf":"2026-09-08","days":1},{"id":"cd7","kind":"target","name":"CD7","route":"/targets/cd7/","asOf":"2026-09-08","days":1},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","asOf":"2026-09-08","days":1},{"id":"hospice-end-of-life","kind":"technology","name":"Hospice and end-of-life care","route":"/technologies/hospice-end-of-life/","asOf":"2026-09-08","days":1},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","asOf":"2026-09-08","days":1},{"id":"palliative-radiotherapy","kind":"technology","name":"Palliative radiotherapy","route":"/technologies/palliative-radiotherapy/","asOf":"2026-09-08","days":1},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","asOf":"2026-09-08","days":1},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","asOf":"2026-09-08","days":1},{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","asOf":"2026-09-08","days":1},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/","asOf":"2026-09-08","days":1},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","asOf":"2026-09-08","days":1},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","asOf":"2026-09-08","days":1},{"id":"oncology-nursing","kind":"technology","name":"Oncology nursing and nurse-led care","route":"/technologies/oncology-nursing/","asOf":"2026-09-08","days":1},{"id":"integrative-oncology","kind":"technology","name":"Evidence-based integrative oncology","route":"/technologies/integrative-oncology/","asOf":"2026-09-08","days":1},{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/","asOf":"2026-09-08","days":1},{"id":"bone-modifying-agents","kind":"technology","name":"Bone-modifying agents (bisphosphonates, denosumab)","route":"/technologies/bone-modifying-agents/","asOf":"2026-09-08","days":1},{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/","asOf":"2026-09-08","days":1},{"id":"transfusion-support","kind":"technology","name":"Transfusion support and anaemia management","route":"/technologies/transfusion-support/","asOf":"2026-09-08","days":1},{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/","asOf":"2026-09-08","days":1},{"id":"epro-symptom-monitoring","kind":"technology","name":"Electronic patient-reported outcome (ePRO) symptom monitoring","route":"/technologies/epro-symptom-monitoring/","asOf":"2026-09-08","days":1},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/","asOf":"2026-09-08","days":1},{"id":"telehealth-oncology","kind":"technology","name":"Telehealth and hospital-at-home in oncology","route":"/technologies/telehealth-oncology/","asOf":"2026-09-08","days":1},{"id":"electrochemotherapy","kind":"technology","name":"Electrochemotherapy","route":"/technologies/electrochemotherapy/","asOf":"2026-09-08","days":1},{"id":"isolated-limb-perfusion","kind":"technology","name":"Isolated limb perfusion and infusion","route":"/technologies/isolated-limb-perfusion/","asOf":"2026-09-08","days":1},{"id":"percutaneous-hepatic-perfusion","kind":"technology","name":"Percutaneous hepatic perfusion (chemosaturation)","route":"/technologies/percutaneous-hepatic-perfusion/","asOf":"2026-09-08","days":1},{"id":"intraoperative-radiotherapy","kind":"technology","name":"Intraoperative radiotherapy (IORT)","route":"/technologies/intraoperative-radiotherapy/","asOf":"2026-09-08","days":1},{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/","asOf":"2026-09-08","days":1},{"id":"rare-cancers","kind":"term","name":"Rare cancers","route":"/terms/rare-cancers/","asOf":"2026-09-08","days":1},{"id":"cancer-health-disparities","kind":"term","name":"Cancer health disparities and equity","route":"/terms/cancer-health-disparities/","asOf":"2026-09-08","days":1},{"id":"aya-oncology","kind":"term","name":"Adolescent and young adult (AYA) oncology","route":"/terms/aya-oncology/","asOf":"2026-09-08","days":1},{"id":"cancer-in-pregnancy","kind":"term","name":"Cancer during pregnancy","route":"/terms/cancer-in-pregnancy/","asOf":"2026-09-08","days":1},{"id":"hereditary-cancer-syndromes","kind":"term","name":"Hereditary cancer syndromes","route":"/terms/hereditary-cancer-syndromes/","asOf":"2026-09-08","days":1},{"id":"li-fraumeni","kind":"term","name":"Li-Fraumeni syndrome (germline TP53)","route":"/terms/li-fraumeni/","asOf":"2026-09-08","days":1},{"id":"vhl-disease","kind":"term","name":"Von Hippel-Lindau disease","route":"/terms/vhl-disease/","asOf":"2026-09-08","days":1},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/","asOf":"2026-09-08","days":1},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","asOf":"2026-09-08","days":1},{"id":"oncology-workforce","kind":"term","name":"Oncology workforce","route":"/terms/oncology-workforce/","asOf":"2026-09-08","days":1},{"id":"who-essential-medicines","kind":"term","name":"WHO Essential Medicines List for cancer","route":"/terms/who-essential-medicines/","asOf":"2026-09-08","days":1},{"id":"plasma-ebv-dna","kind":"term","name":"Plasma EBV DNA","route":"/terms/plasma-ebv-dna/","asOf":"2026-09-08","days":1},{"id":"nice-guidance","kind":"collection","name":"NICE cancer guidance and technology appraisals (UK)","route":"/collections/nice-guidance/","asOf":"2026-09-08","days":1},{"id":"asco-guidelines","kind":"collection","name":"ASCO clinical practice guidelines","route":"/collections/asco-guidelines/","asOf":"2026-09-08","days":1},{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","route":"/collections/csco-guidelines/","asOf":"2026-09-08","days":1},{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/","asOf":"2026-09-08","days":1},{"id":"american-cancer-society","kind":"collection","name":"American Cancer Society (ACS)","route":"/collections/american-cancer-society/","asOf":"2026-09-08","days":1},{"id":"leukemia-lymphoma-society","kind":"collection","name":"Leukemia & Lymphoma Society (LLS)","route":"/collections/leukemia-lymphoma-society/","asOf":"2026-09-08","days":1},{"id":"pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","route":"/collections/pancan/","asOf":"2026-09-08","days":1},{"id":"mmrf","kind":"collection","name":"Multiple Myeloma Research Foundation (MMRF)","route":"/collections/mmrf/","asOf":"2026-09-08","days":1},{"id":"lymphoma-research-foundation","kind":"collection","name":"Lymphoma Research Foundation (LRF)","route":"/collections/lymphoma-research-foundation/","asOf":"2026-09-08","days":1},{"id":"national-brain-tumor-society","kind":"collection","name":"National Brain Tumor Society (NBTS)","route":"/collections/national-brain-tumor-society/","asOf":"2026-09-08","days":1},{"id":"alexs-lemonade-stand","kind":"collection","name":"Alex's Lemonade Stand Foundation (ALSF)","route":"/collections/alexs-lemonade-stand/","asOf":"2026-09-08","days":1},{"id":"st-baldricks","kind":"collection","name":"St. Baldrick's Foundation","route":"/collections/st-baldricks/","asOf":"2026-09-08","days":1},{"id":"colorectal-cancer-alliance","kind":"collection","name":"Colorectal Cancer Alliance","route":"/collections/colorectal-cancer-alliance/","asOf":"2026-09-08","days":1},{"id":"lungevity","kind":"collection","name":"LUNGevity Foundation (and GO2 for Lung Cancer)","route":"/collections/lungevity/","asOf":"2026-09-08","days":1},{"id":"melanoma-research-alliance","kind":"collection","name":"Melanoma Research Alliance (MRA)","route":"/collections/melanoma-research-alliance/","asOf":"2026-09-08","days":1},{"id":"ovarian-cancer-research-alliance","kind":"collection","name":"Ovarian Cancer Research Alliance (OCRA)","route":"/collections/ovarian-cancer-research-alliance/","asOf":"2026-09-08","days":1},{"id":"susan-g-komen","kind":"collection","name":"Susan G. Komen","route":"/collections/susan-g-komen/","asOf":"2026-09-08","days":1},{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","asOf":"2026-09-08","days":1},{"id":"paper-keynote-522-nejm-2022","kind":"paper","name":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","route":"/key-papers/paper-keynote-522-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-destiny-breast06-nejm-2024","kind":"paper","name":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","route":"/key-papers/paper-destiny-breast06-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/","asOf":"2026-09-08","days":1},{"id":"paper-natalee-nejm-2024","kind":"paper","name":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","route":"/key-papers/paper-natalee-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/","asOf":"2026-09-08","days":1},{"id":"paper-katherine-nejm-2019","kind":"paper","name":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","route":"/key-papers/paper-katherine-nejm-2019/","asOf":"2026-09-08","days":1},{"id":"paper-tropion-breast01-jco-2024","kind":"paper","name":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","route":"/key-papers/paper-tropion-breast01-jco-2024/","asOf":"2026-09-08","days":1},{"id":"paper-ascent-nejm-2021","kind":"paper","name":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","route":"/key-papers/paper-ascent-nejm-2021/","asOf":"2026-09-08","days":1},{"id":"paper-flaura-nejm-2018","kind":"paper","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/","asOf":"2026-09-08","days":1},{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-adaura-nejm-2020","kind":"paper","name":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","route":"/key-papers/paper-adaura-nejm-2020/","asOf":"2026-09-08","days":1},{"id":"paper-crown-nejm-2020","kind":"paper","name":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer","route":"/key-papers/paper-crown-nejm-2020/","asOf":"2026-09-08","days":1},{"id":"paper-keynote-189-nejm-2018","kind":"paper","name":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","route":"/key-papers/paper-keynote-189-nejm-2018/","asOf":"2026-09-08","days":1},{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-pacific-nejm-2017","kind":"paper","name":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","route":"/key-papers/paper-pacific-nejm-2017/","asOf":"2026-09-08","days":1},{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/","asOf":"2026-09-08","days":1},{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/","asOf":"2026-09-08","days":1},{"id":"paper-harmoni-2-lancet-2025","kind":"paper","name":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","route":"/key-papers/paper-harmoni-2-lancet-2025/","asOf":"2026-09-08","days":1},{"id":"paper-napoli-3-lancet-2023","kind":"paper","name":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","route":"/key-papers/paper-napoli-3-lancet-2023/","asOf":"2026-09-08","days":1},{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/","asOf":"2026-09-08","days":1},{"id":"paper-checkmate-649-lancet-2021","kind":"paper","name":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","route":"/key-papers/paper-checkmate-649-lancet-2021/","asOf":"2026-09-08","days":1},{"id":"paper-imbrave150-nejm-2020","kind":"paper","name":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","route":"/key-papers/paper-imbrave150-nejm-2020/","asOf":"2026-09-08","days":1},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/","asOf":"2026-09-08","days":1},{"id":"paper-breakwater-nejm-2025","kind":"paper","name":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-breakwater-nejm-2025/","asOf":"2026-09-08","days":1},{"id":"paper-codebreak-300-nejm-2023","kind":"paper","name":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","route":"/key-papers/paper-codebreak-300-nejm-2023/","asOf":"2026-09-08","days":1},{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-cercek-dmmr-rectal-nejm-2022","kind":"paper","name":"Dostarlimab alone cures mismatch-repair-deficient rectal cancer without surgery or radiotherapy","route":"/key-papers/paper-cercek-dmmr-rectal-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/","asOf":"2026-09-08","days":1},{"id":"paper-stampede-abiraterone-nejm-2017","kind":"paper","name":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","route":"/key-papers/paper-stampede-abiraterone-nejm-2017/","asOf":"2026-09-08","days":1},{"id":"paper-ev-302-nejm-2024","kind":"paper","name":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","route":"/key-papers/paper-ev-302-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-niagara-nejm-2024","kind":"paper","name":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-niagara-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-clear-nejm-2021","kind":"paper","name":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer","route":"/key-papers/paper-clear-nejm-2021/","asOf":"2026-09-08","days":1},{"id":"paper-keynote-564-nejm-2021","kind":"paper","name":"KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery","route":"/key-papers/paper-keynote-564-nejm-2021/","asOf":"2026-09-08","days":1},{"id":"paper-sunrise-1-jco-2025","kind":"paper","name":"SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-sunrise-1-jco-2025/","asOf":"2026-09-08","days":1},{"id":"paper-paola-1-nejm-2019","kind":"paper","name":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","route":"/key-papers/paper-paola-1-nejm-2019/","asOf":"2026-09-08","days":1},{"id":"paper-solo-1-nejm-2018","kind":"paper","name":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","route":"/key-papers/paper-solo-1-nejm-2018/","asOf":"2026-09-08","days":1},{"id":"paper-keynote-a18-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-keynote-a18-lancet-2024/","asOf":"2026-09-08","days":1},{"id":"paper-ruby-nejm-2023","kind":"paper","name":"RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer","route":"/key-papers/paper-ruby-nejm-2023/","asOf":"2026-09-08","days":1},{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/","asOf":"2026-09-08","days":1},{"id":"paper-nadina-nejm-2024","kind":"paper","name":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","route":"/key-papers/paper-nadina-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-relativity-047-nejm-2022","kind":"paper","name":"RELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma","route":"/key-papers/paper-relativity-047-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-keynote-942-lancet-2024","kind":"paper","name":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","route":"/key-papers/paper-keynote-942-lancet-2024/","asOf":"2026-09-08","days":1},{"id":"paper-indigo-nejm-2023","kind":"paper","name":"INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma","route":"/key-papers/paper-indigo-nejm-2023/","asOf":"2026-09-08","days":1},{"id":"paper-stupp-temozolomide-nejm-2005","kind":"paper","name":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","route":"/key-papers/paper-stupp-temozolomide-nejm-2005/","asOf":"2026-09-08","days":1},{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/","asOf":"2026-09-08","days":1},{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/","asOf":"2026-09-08","days":1},{"id":"paper-keynote-048-lancet-2019","kind":"paper","name":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","route":"/key-papers/paper-keynote-048-lancet-2019/","asOf":"2026-09-08","days":1},{"id":"paper-druker-imatinib-phase1-nejm-2001","kind":"paper","name":"First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia","route":"/key-papers/paper-druker-imatinib-phase1-nejm-2001/","asOf":"2026-09-08","days":1},{"id":"paper-iris-imatinib-nejm-2003","kind":"paper","name":"IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia","route":"/key-papers/paper-iris-imatinib-nejm-2003/","asOf":"2026-09-08","days":1},{"id":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","kind":"paper","name":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","route":"/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/","asOf":"2026-09-08","days":1},{"id":"paper-elevate-tn-acalabrutinib-lancet-2020","kind":"paper","name":"ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL","route":"/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/","asOf":"2026-09-08","days":1},{"id":"paper-amplify-acalabrutinib-venetoclax-nejm-2025","kind":"paper","name":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","route":"/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/","asOf":"2026-09-08","days":1},{"id":"paper-murano-venetoclax-rituximab-nejm-2018","kind":"paper","name":"MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL","route":"/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/","asOf":"2026-09-08","days":1},{"id":"paper-maia-daratumumab-rd-nejm-2019","kind":"paper","name":"MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant","route":"/key-papers/paper-maia-daratumumab-rd-nejm-2019/","asOf":"2026-09-08","days":1},{"id":"paper-perseus-dara-vrd-transplant-nejm-2024","kind":"paper","name":"PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma","route":"/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-cepheus-dara-vrd-natmed-2025","kind":"paper","name":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","route":"/key-papers/paper-cepheus-dara-vrd-natmed-2025/","asOf":"2026-09-08","days":1},{"id":"paper-cartitude-1-cilta-cel-lancet-2021","kind":"paper","name":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","route":"/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/","asOf":"2026-09-08","days":1},{"id":"paper-cartitude-4-cilta-cel-nejm-2023","kind":"paper","name":"CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy","route":"/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/","asOf":"2026-09-08","days":1},{"id":"paper-karmma-3-ide-cel-nejm-2023","kind":"paper","name":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","route":"/key-papers/paper-karmma-3-ide-cel-nejm-2023/","asOf":"2026-09-08","days":1},{"id":"paper-majestec-1-teclistamab-nejm-2022","kind":"paper","name":"MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma","route":"/key-papers/paper-majestec-1-teclistamab-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-magnetismm-3-elranatamab-natmed-2023","kind":"paper","name":"MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response","route":"/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/","asOf":"2026-09-08","days":1},{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-transform-liso-cel-lancet-2022","kind":"paper","name":"TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma","route":"/key-papers/paper-transform-liso-cel-lancet-2022/","asOf":"2026-09-08","days":1},{"id":"paper-polarix-polatuzumab-rchp-nejm-2022","kind":"paper","name":"POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma","route":"/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-echelon-1-brentuximab-avd-nejm-2018","kind":"paper","name":"ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma","route":"/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/","asOf":"2026-09-08","days":1},{"id":"paper-swog-s1826-nivolumab-avd-nejm-2024","kind":"paper","name":"SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults","route":"/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-epcore-nhl-1-epcoritamab-jco-2023","kind":"paper","name":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","route":"/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/","asOf":"2026-09-08","days":1},{"id":"paper-zuma-2-brexu-cel-mantle-cell-nejm-2020","kind":"paper","name":"ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors","route":"/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/","asOf":"2026-09-08","days":1},{"id":"paper-viale-a-venetoclax-azacitidine-nejm-2020","kind":"paper","name":"VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy","route":"/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/","asOf":"2026-09-08","days":1},{"id":"paper-admiral-gilteritinib-flt3-nejm-2019","kind":"paper","name":"ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia","route":"/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/","asOf":"2026-09-08","days":1},{"id":"paper-quantum-first-quizartinib-lancet-2023","kind":"paper","name":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML","route":"/key-papers/paper-quantum-first-quizartinib-lancet-2023/","asOf":"2026-09-08","days":1},{"id":"paper-agile-ivosidenib-azacitidine-nejm-2022","kind":"paper","name":"AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy","route":"/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-augment-101-revumenib-menin-nature-2023","kind":"paper","name":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","route":"/key-papers/paper-augment-101-revumenib-menin-nature-2023/","asOf":"2026-09-08","days":1},{"id":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","kind":"paper","name":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","route":"/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-aall1731-blinatumomab-children-nejm-2025","kind":"paper","name":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","route":"/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/","asOf":"2026-09-08","days":1},{"id":"paper-ino-vate-inotuzumab-all-nejm-2016","kind":"paper","name":"INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL","route":"/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/","asOf":"2026-09-08","days":1},{"id":"paper-commands-luspatercept-mds-lancet-2023","kind":"paper","name":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","route":"/key-papers/paper-commands-luspatercept-mds-lancet-2023/","asOf":"2026-09-08","days":1},{"id":"paper-imerge-imetelstat-mds-lancet-2024","kind":"paper","name":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","route":"/key-papers/paper-imerge-imetelstat-mds-lancet-2024/","asOf":"2026-09-08","days":1},{"id":"paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012","kind":"paper","name":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis","route":"/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/","asOf":"2026-09-08","days":1},{"id":"paper-momentum-momelotinib-lancet-2023","kind":"paper","name":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor","route":"/key-papers/paper-momentum-momelotinib-lancet-2023/","asOf":"2026-09-08","days":1},{"id":"paper-maude-ctl019-all-nejm-2014","kind":"paper","name":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","route":"/key-papers/paper-maude-ctl019-all-nejm-2014/","asOf":"2026-09-08","days":1},{"id":"paper-eliana-tisagenlecleucel-nejm-2018","kind":"paper","name":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","route":"/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/","asOf":"2026-09-08","days":1},{"id":"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019","kind":"paper","name":"JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/","asOf":"2026-09-08","days":1},{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/","asOf":"2026-09-08","days":1},{"id":"paper-ucart19-allogeneic-car-t-lancet-2020","kind":"paper","name":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL","route":"/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/","asOf":"2026-09-08","days":1},{"id":"paper-c-144-01-lifileucel-melanoma-jco-2021","kind":"paper","name":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","route":"/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/","asOf":"2026-09-08","days":1},{"id":"paper-rohaas-til-vs-ipilimumab-nejm-2022","kind":"paper","name":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","route":"/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-spearhead-1-afami-cel-sarcoma-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afami-cel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-afami-cel-sarcoma-lancet-2024/","asOf":"2026-09-08","days":1},{"id":"paper-hodi-ipilimumab-melanoma-nejm-2010","kind":"paper","name":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","route":"/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/","asOf":"2026-09-08","days":1},{"id":"paper-topalian-anti-pd1-nejm-2012","kind":"paper","name":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","route":"/key-papers/paper-topalian-anti-pd1-nejm-2012/","asOf":"2026-09-08","days":1},{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","kind":"paper","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/","asOf":"2026-09-08","days":1},{"id":"paper-le-mmr-deficiency-science-2017","kind":"paper","name":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","route":"/key-papers/paper-le-mmr-deficiency-science-2017/","asOf":"2026-09-08","days":1},{"id":"paper-niche-2-neoadjuvant-colon-nejm-2024","kind":"paper","name":"NICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients","route":"/key-papers/paper-niche-2-neoadjuvant-colon-nejm-2024/","asOf":"2026-09-08","days":1},{"id":"paper-cercek-dostarlimab-rectal-nejm-2022","kind":"paper","name":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency","route":"/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023","kind":"paper","name":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","route":"/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/","asOf":"2026-09-08","days":1},{"id":"paper-checkmate-067-ten-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later","route":"/key-papers/paper-checkmate-067-ten-year-nejm-2025/","asOf":"2026-09-08","days":1},{"id":"paper-asco-irae-guideline-jco-2021","kind":"paper","name":"ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors","route":"/key-papers/paper-asco-irae-guideline-jco-2021/","asOf":"2026-09-08","days":1},{"id":"paper-nlst-nejm-2011","kind":"paper","name":"NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers","route":"/key-papers/paper-nlst-nejm-2011/","asOf":"2026-09-08","days":1},{"id":"paper-nelson-nejm-2020","kind":"paper","name":"NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms","route":"/key-papers/paper-nelson-nejm-2020/","asOf":"2026-09-08","days":1},{"id":"paper-nordicc-nejm-2022","kind":"paper","name":"NordICC: inviting people to a screening colonoscopy reduced bowel cancer, but less than expected","route":"/key-papers/paper-nordicc-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-minnesota-fobt-nejm-1993","kind":"paper","name":"Minnesota trial: a yearly stool blood test cuts bowel cancer deaths by a third","route":"/key-papers/paper-minnesota-fobt-nejm-1993/","asOf":"2026-09-08","days":1},{"id":"paper-hpv-vaccine-sweden-nejm-2020","kind":"paper","name":"Swedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17","route":"/key-papers/paper-hpv-vaccine-sweden-nejm-2020/","asOf":"2026-09-08","days":1},{"id":"paper-hpv-vaccine-england-lancet-2021","kind":"paper","name":"England's HPV programme: cervical cancer down 87% in the first cohort vaccinated at 12-13","route":"/key-papers/paper-hpv-vaccine-england-lancet-2021/","asOf":"2026-09-08","days":1},{"id":"paper-hpv-self-sampling-bmj-2018","kind":"paper","name":"Self-collected HPV samples are as accurate as clinician samples and reach women who never attend screening","route":"/key-papers/paper-hpv-self-sampling-bmj-2018/","asOf":"2026-09-08","days":1},{"id":"paper-masai-lancet-oncol-2023","kind":"paper","name":"MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload","route":"/key-papers/paper-masai-lancet-oncol-2023/","asOf":"2026-09-08","days":1},{"id":"paper-pathfinder-lancet-2023","kind":"paper","name":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms","route":"/key-papers/paper-pathfinder-lancet-2023/","asOf":"2026-09-08","days":1},{"id":"paper-nhs-galleri-design-cancers-2022","kind":"paper","name":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test","route":"/key-papers/paper-nhs-galleri-design-cancers-2022/","asOf":"2026-09-08","days":1},{"id":"paper-detect-a-science-2020","kind":"paper","name":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","route":"/key-papers/paper-detect-a-science-2020/","asOf":"2026-09-08","days":1},{"id":"paper-imvigor011-nejm-2025","kind":"paper","name":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery","route":"/key-papers/paper-imvigor011-nejm-2025/","asOf":"2026-09-08","days":1},{"id":"paper-dynamic-nejm-2022","kind":"paper","name":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","route":"/key-papers/paper-dynamic-nejm-2022/","asOf":"2026-09-08","days":1},{"id":"paper-galaxy-signatera-nat-med-2023","kind":"paper","name":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","route":"/key-papers/paper-galaxy-signatera-nat-med-2023/","asOf":"2026-09-08","days":1},{"id":"paper-challenge-exercise-nejm-2025","kind":"paper","name":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","route":"/key-papers/paper-challenge-exercise-nejm-2025/","asOf":"2026-09-08","days":1},{"id":"paper-predimed-breast-jama-im-2015","kind":"paper","name":"PREDIMED: a Mediterranean diet with extra-virgin olive oil and fewer breast cancers","route":"/key-papers/paper-predimed-breast-jama-im-2015/","asOf":"2026-09-08","days":1},{"id":"paper-body-fatness-iarc-nejm-2016","kind":"paper","name":"IARC verdict: excess body fat causes 13 cancers","route":"/key-papers/paper-body-fatness-iarc-nejm-2016/","asOf":"2026-09-08","days":1},{"id":"paper-capp2-aspirin-lynch-lancet-2020","kind":"paper","name":"CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years","route":"/key-papers/paper-capp2-aspirin-lynch-lancet-2020/","asOf":"2026-09-08","days":1},{"id":"paper-ibis-i-tamoxifen-lancet-oncol-2015","kind":"paper","name":"IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years","route":"/key-papers/paper-ibis-i-tamoxifen-lancet-oncol-2015/","asOf":"2026-09-08","days":1},{"id":"paper-brca-risk-reducing-surgery-jama-2010","kind":"paper","name":"PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers","route":"/key-papers/paper-brca-risk-reducing-surgery-jama-2010/","asOf":"2026-09-08","days":1},{"id":"paper-lynch-frameshift-vaccine-ccr-2020","kind":"paper","name":"First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers","route":"/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/","asOf":"2026-09-08","days":1},{"id":"paper-doll-hill-smoking-lung-cancer-bmj-1950","kind":"paper","name":"Doll and Hill 1950: the case-control study that tied smoking to lung cancer","route":"/key-papers/paper-doll-hill-smoking-lung-cancer-bmj-1950/","asOf":"2026-09-08","days":1},{"id":"paper-doll-peto-50-year-doctors-bmj-2004","kind":"paper","name":"Fifty years of the British Doctors Study: smokers lose ten years of life, quitting gives most of it back","route":"/key-papers/paper-doll-peto-50-year-doctors-bmj-2004/","asOf":"2026-09-08","days":1},{"id":"paper-alcohol-cancer-burden-lancet-oncol-2021","kind":"paper","name":"Alcohol caused an estimated 741,000 cancers worldwide in 2020","route":"/key-papers/paper-alcohol-cancer-burden-lancet-oncol-2021/","asOf":"2026-09-08","days":1},{"id":"paper-basch-epro-survival-jama-2017","kind":"paper","name":"Basch: asking patients to report symptoms online during chemotherapy improved survival","route":"/key-papers/paper-basch-epro-survival-jama-2017/","asOf":"2026-09-08","days":1},{"id":"paper-temel-early-palliative-care-nejm-2010","kind":"paper","name":"Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer","route":"/key-papers/paper-temel-early-palliative-care-nejm-2010/","asOf":"2026-09-08","days":1},{"id":"paper-gap70-geriatric-assessment-lancet-2021","kind":"paper","name":"GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth","route":"/key-papers/paper-gap70-geriatric-assessment-lancet-2021/","asOf":"2026-09-08","days":1},{"id":"paper-drug-dosing-conundrum-nejm-2021","kind":"paper","name":"FDA's Project Optimus manifesto: cancer drugs are approved at doses that are too high","route":"/key-papers/paper-drug-dosing-conundrum-nejm-2021/","asOf":"2026-09-08","days":1},{"id":"paper-hallmarks-of-cancer-cell-2000","kind":"paper","name":"The Hallmarks of Cancer: six capabilities every tumour must acquire","route":"/key-papers/paper-hallmarks-of-cancer-cell-2000/","asOf":"2026-09-08","days":1},{"id":"paper-hallmarks-new-dimensions-cancer-discov-2022","kind":"paper","name":"Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells","route":"/key-papers/paper-hallmarks-new-dimensions-cancer-discov-2022/","asOf":"2026-09-08","days":1},{"id":"paper-tcga-pancancer-atlas-cell-2018","kind":"paper","name":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","route":"/key-papers/paper-tcga-pancancer-atlas-cell-2018/","asOf":"2026-09-08","days":1},{"id":"paper-vogelstein-cancer-genome-landscapes-science-2013","kind":"paper","name":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful","route":"/key-papers/paper-vogelstein-cancer-genome-landscapes-science-2013/","asOf":"2026-09-08","days":1},{"id":"paper-gerlinger-intratumour-heterogeneity-nejm-2012","kind":"paper","name":"Gerlinger: a single biopsy misses most of the mutations in a kidney tumour","route":"/key-papers/paper-gerlinger-intratumour-heterogeneity-nejm-2012/","asOf":"2026-09-08","days":1},{"id":"paper-tracerx-100-nejm-2017","kind":"paper","name":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse","route":"/key-papers/paper-tracerx-100-nejm-2017/","asOf":"2026-09-08","days":1},{"id":"paper-tracerx-evolution-nature-2023","kind":"paper","name":"TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse","route":"/key-papers/paper-tracerx-evolution-nature-2023/","asOf":"2026-09-08","days":1},{"id":"paper-martincorena-somatic-mutations-normal-skin-science-2015","kind":"paper","name":"Martincorena: normal sun-exposed skin is a patchwork of cancer-mutation clones","route":"/key-papers/paper-martincorena-somatic-mutations-normal-skin-science-2015/","asOf":"2026-09-08","days":1},{"id":"paper-jaiswal-chip-nejm-2014","kind":"paper","name":"Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70","route":"/key-papers/paper-jaiswal-chip-nejm-2014/","asOf":"2026-09-08","days":1},{"id":"paper-depmap-tsherniak-cell-2017","kind":"paper","name":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without","route":"/key-papers/paper-depmap-tsherniak-cell-2017/","asOf":"2026-09-08","days":1},{"id":"paper-alphafold2-jumper-nature-2021","kind":"paper","name":"AlphaFold 2: predicting protein structures to near-experimental accuracy","route":"/key-papers/paper-alphafold2-jumper-nature-2021/","asOf":"2026-09-08","days":1},{"id":"paper-ostrem-kras-g12c-nature-2013","kind":"paper","name":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable","route":"/key-papers/paper-ostrem-kras-g12c-nature-2013/","asOf":"2026-09-08","days":1},{"id":"paper-protac-concept-sakamoto-pnas-2001","kind":"paper","name":"The first PROTAC: a chimeric molecule that tags a protein for destruction","route":"/key-papers/paper-protac-concept-sakamoto-pnas-2001/","asOf":"2026-09-08","days":1},{"id":"paper-leach-allison-ctla4-blockade-science-1996","kind":"paper","name":"Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours","route":"/key-papers/paper-leach-allison-ctla4-blockade-science-1996/","asOf":"2026-09-08","days":1},{"id":"paper-iwai-pdl1-tumour-escape-pnas-2002","kind":"paper","name":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","route":"/key-papers/paper-iwai-pdl1-tumour-escape-pnas-2002/","asOf":"2026-09-08","days":1},{"id":"paper-reproducibility-project-cancer-biology-elife-2021","kind":"paper","name":"Reproducibility Project: Cancer Biology found that landmark preclinical results mostly shrank or vanished on replication","route":"/key-papers/paper-reproducibility-project-cancer-biology-elife-2021/","asOf":"2026-09-08","days":1},{"id":"paper-prasad-surrogate-endpoints-jama-im-2015","kind":"paper","name":"Prasad: most surrogate endpoints in cancer trials correlate poorly with survival","route":"/key-papers/paper-prasad-surrogate-endpoints-jama-im-2015/","asOf":"2026-09-08","days":1},{"id":"paper-unger-trial-participation-barriers-jnci-2019","kind":"paper","name":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes","route":"/key-papers/paper-unger-trial-participation-barriers-jnci-2019/","asOf":"2026-09-08","days":1},{"id":"structured-exercise-survivorship","kind":"technology","name":"Structured exercise programmes after curative treatment","route":"/technologies/structured-exercise-survivorship/","asOf":"2026-09-08","days":1},{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/","asOf":"2026-09-08","days":1},{"id":"resistance-training-cachexia","kind":"technology","name":"Resistance training and protein for cachexia and sarcopenia","route":"/technologies/resistance-training-cachexia/","asOf":"2026-09-08","days":1},{"id":"eras-perioperative-nutrition","kind":"technology","name":"Enhanced recovery (ERAS) and perioperative nutrition","route":"/technologies/eras-perioperative-nutrition/","asOf":"2026-09-08","days":1},{"id":"nutrition-screening-mnt","kind":"technology","name":"Oncology nutrition assessment and medical nutrition therapy","route":"/technologies/nutrition-screening-mnt/","asOf":"2026-09-08","days":1},{"id":"enteral-parenteral-nutrition","kind":"technology","name":"Enteral and parenteral nutrition support","route":"/technologies/enteral-parenteral-nutrition/","asOf":"2026-09-08","days":1},{"id":"immunonutrition-perioperative","kind":"technology","name":"Immunonutrition before cancer surgery","route":"/technologies/immunonutrition-perioperative/","asOf":"2026-09-08","days":1},{"id":"fasting-mimicking-diet","kind":"technology","name":"Fasting and fasting-mimicking diets around chemotherapy","route":"/technologies/fasting-mimicking-diet/","asOf":"2026-09-08","days":1},{"id":"ketogenic-diet-glioblastoma","kind":"technology","name":"Ketogenic diets in glioblastoma","route":"/technologies/ketogenic-diet-glioblastoma/","asOf":"2026-09-08","days":1},{"id":"time-restricted-eating","kind":"technology","name":"Time-restricted eating in cancer prevention and survivorship","route":"/technologies/time-restricted-eating/","asOf":"2026-09-08","days":1},{"id":"mediterranean-plant-forward-diet","kind":"technology","name":"Mediterranean and plant-forward dietary patterns","route":"/technologies/mediterranean-plant-forward-diet/","asOf":"2026-09-08","days":1},{"id":"dietary-fibre-microbiome-io","kind":"technology","name":"Dietary fibre and the gut microbiome for immunotherapy response","route":"/technologies/dietary-fibre-microbiome-io/","asOf":"2026-09-08","days":1},{"id":"fmt-checkpoint-nonresponders","kind":"technology","name":"Faecal microbiota transplantation for PD-1 non-responders","route":"/technologies/fmt-checkpoint-nonresponders/","asOf":"2026-09-08","days":1},{"id":"probiotics-antibiotic-stewardship-io","kind":"technology","name":"Probiotics, antibiotics and stewardship around immunotherapy","route":"/technologies/probiotics-antibiotic-stewardship-io/","asOf":"2026-09-08","days":1},{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","route":"/technologies/glp1-agonists-cancer-risk/","asOf":"2026-09-08","days":1},{"id":"bariatric-surgery-cancer-incidence","kind":"technology","name":"Bariatric surgery and cancer incidence","route":"/technologies/bariatric-surgery-cancer-incidence/","asOf":"2026-09-08","days":1},{"id":"alcohol-reduction-labelling","kind":"technology","name":"Alcohol reduction, pricing and cancer warning labels","route":"/technologies/alcohol-reduction-labelling/","asOf":"2026-09-08","days":1},{"id":"vitamin-d-omega3-supplementation","kind":"technology","name":"Vitamin D and omega-3 supplementation","route":"/technologies/vitamin-d-omega3-supplementation/","asOf":"2026-09-08","days":1},{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/","asOf":"2026-09-08","days":1},{"id":"coffee-intake-cancer","kind":"technology","name":"Coffee and tea intake","route":"/technologies/coffee-intake-cancer/","asOf":"2026-09-08","days":1},{"id":"red-processed-meat-reduction","kind":"technology","name":"Red and processed meat reduction","route":"/technologies/red-processed-meat-reduction/","asOf":"2026-09-08","days":1},{"id":"ultra-processed-food-ssb","kind":"technology","name":"Ultra-processed food and sugar-sweetened drinks","route":"/technologies/ultra-processed-food-ssb/","asOf":"2026-09-08","days":1},{"id":"smoking-cessation-after-diagnosis","kind":"technology","name":"Smoking cessation in cancer patients","route":"/technologies/smoking-cessation-after-diagnosis/","asOf":"2026-09-08","days":1},{"id":"sleep-circadian-interventions","kind":"technology","name":"Sleep and circadian interventions in cancer","route":"/technologies/sleep-circadian-interventions/","asOf":"2026-09-08","days":1},{"id":"cachexia-appetite-pharmacotherapy","kind":"technology","name":"Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine","route":"/technologies/cachexia-appetite-pharmacotherapy/","asOf":"2026-09-08","days":1},{"id":"dietitian-led-weight-loss-breast","kind":"technology","name":"Dietitian-led weight-loss programmes in HR-positive breast cancer","route":"/technologies/dietitian-led-weight-loss-breast/","asOf":"2026-09-08","days":1},{"id":"soy-breast-cancer","kind":"technology","name":"Soy foods and breast cancer","route":"/technologies/soy-breast-cancer/","asOf":"2026-09-08","days":1},{"id":"dietary-supplements-treatment-interactions","kind":"technology","name":"Dietary supplements during cancer treatment: interactions and harms","route":"/technologies/dietary-supplements-treatment-interactions/","asOf":"2026-09-08","days":1},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","asOf":"2026-09-08","days":1},{"id":"sarcopenia","kind":"term","name":"Sarcopenia","route":"/terms/sarcopenia/","asOf":"2026-09-08","days":1},{"id":"immunonutrition","kind":"term","name":"Immunonutrition","route":"/terms/immunonutrition/","asOf":"2026-09-08","days":1},{"id":"glycaemic-index","kind":"term","name":"Glycaemic index and glycaemic load","route":"/terms/glycaemic-index/","asOf":"2026-09-08","days":1},{"id":"warburg-effect-diet-claims","kind":"term","name":"Warburg-effect diet claims ('sugar feeds cancer')","route":"/terms/warburg-effect-diet-claims/","asOf":"2026-09-08","days":1},{"id":"unproven-diet-claims","kind":"term","name":"Unproven diet claims (alkaline, juice, 'anti-cancer' diets)","route":"/terms/unproven-diet-claims/","asOf":"2026-09-08","days":1},{"id":"ultra-processed-food","kind":"term","name":"Ultra-processed food (NOVA group 4)","route":"/terms/ultra-processed-food/","asOf":"2026-09-08","days":1},{"id":"metabolic-syndrome","kind":"term","name":"Metabolic syndrome and insulin resistance","route":"/terms/metabolic-syndrome/","asOf":"2026-09-08","days":1},{"id":"prehabilitation-term","kind":"term","name":"Prehabilitation (the pre-treatment window)","route":"/terms/prehabilitation-term/","asOf":"2026-09-08","days":1},{"id":"met-hours","kind":"term","name":"MET-hours per week","route":"/terms/met-hours/","asOf":"2026-09-08","days":1},{"id":"body-composition","kind":"term","name":"Body composition (lean mass, fat mass, visceral fat)","route":"/terms/body-composition/","asOf":"2026-09-08","days":1},{"id":"gut-microbiome-diversity","kind":"term","name":"Gut microbiome diversity and composition","route":"/terms/gut-microbiome-diversity/","asOf":"2026-09-08","days":1},{"id":"dietary-pattern-scores","kind":"term","name":"Dietary pattern scores (Mediterranean, HEI, AHEI, DASH, WCRF/AICR)","route":"/terms/dietary-pattern-scores/","asOf":"2026-09-08","days":1},{"id":"nutrition-impact-symptoms","kind":"term","name":"Nutrition impact symptoms","route":"/terms/nutrition-impact-symptoms/","asOf":"2026-09-08","days":1},{"id":"malnutrition-screening","kind":"term","name":"Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA)","route":"/terms/malnutrition-screening/","asOf":"2026-09-08","days":1},{"id":"obesity-related-cancers","kind":"term","name":"Obesity-related cancers (IARC list of 13)","route":"/terms/obesity-related-cancers/","asOf":"2026-09-08","days":1},{"id":"energy-balance","kind":"term","name":"Energy balance","route":"/terms/energy-balance/","asOf":"2026-09-08","days":1},{"id":"alcohol-attributable-cancer","kind":"term","name":"Alcohol-attributable cancer","route":"/terms/alcohol-attributable-cancer/","asOf":"2026-09-08","days":1},{"id":"challenge","kind":"trial","name":"CHALLENGE (CCTG CO.21)","route":"/trials/challenge/","asOf":"2026-09-08","days":1},{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/","asOf":"2026-09-08","days":1},{"id":"vital","kind":"trial","name":"VITAL (VITamin D and OmegA-3 TriaL)","route":"/trials/vital/","asOf":"2026-09-08","days":1},{"id":"aspree","kind":"trial","name":"ASPREE (ASPirin in Reducing Events in the Elderly)","route":"/trials/aspree/","asOf":"2026-09-08","days":1},{"id":"alascca","kind":"trial","name":"ALASCCA","route":"/trials/alascca/","asOf":"2026-09-08","days":1},{"id":"add-aspirin","kind":"trial","name":"Add-Aspirin","route":"/trials/add-aspirin/","asOf":"2026-09-08","days":1},{"id":"romana-1-2","kind":"trial","name":"ROMANA 1 and ROMANA 2","route":"/trials/romana-1-2/","asOf":"2026-09-08","days":1},{"id":"ponsegromab-phase-2","kind":"trial","name":"Ponsegromab phase 2 in cancer cachexia","route":"/trials/ponsegromab-phase-2/","asOf":"2026-09-08","days":1},{"id":"olanzapine-appetite-tmh","kind":"trial","name":"Low-dose olanzapine for cancer anorexia (Tata Memorial)","route":"/trials/olanzapine-appetite-tmh/","asOf":"2026-09-08","days":1},{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/","asOf":"2026-09-08","days":1},{"id":"mimic-01","kind":"trial","name":"MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma","route":"/trials/mimic-01/","asOf":"2026-09-08","days":1},{"id":"ergo2","kind":"trial","name":"ERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma","route":"/trials/ergo2/","asOf":"2026-09-08","days":1},{"id":"prehab-trial","kind":"trial","name":"PREHAB: multimodal prehabilitation before colorectal cancer surgery","route":"/trials/prehab-trial/","asOf":"2026-09-08","days":1},{"id":"whel","kind":"trial","name":"WHEL (Women's Healthy Eating and Living)","route":"/trials/whel/","asOf":"2026-09-08","days":1},{"id":"idea-nl-exercise-dose-finding","kind":"idea","name":"A dose-finding trial for exercise after cancer","route":"/ideas/idea-nl-exercise-dose-finding/","asOf":"2026-09-08","days":1},{"id":"idea-nl-glp1-adjuvant-hr-breast","kind":"idea","name":"GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer","route":"/ideas/idea-nl-glp1-adjuvant-hr-breast/","asOf":"2026-09-08","days":1},{"id":"idea-nl-ketogenic-gbm-definitive-trial","kind":"idea","name":"One definitive ketogenic diet trial in glioblastoma, then stop","route":"/ideas/idea-nl-ketogenic-gbm-definitive-trial/","asOf":"2026-09-08","days":1},{"id":"idea-nl-diet-covariates-io-trials","kind":"idea","name":"Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial","route":"/ideas/idea-nl-diet-covariates-io-trials/","asOf":"2026-09-08","days":1},{"id":"idea-nl-alcohol-minimum-pricing-cancer-endpoints","kind":"idea","name":"Evaluate alcohol minimum unit pricing against cancer incidence","route":"/ideas/idea-nl-alcohol-minimum-pricing-cancer-endpoints/","asOf":"2026-09-08","days":1},{"id":"idea-nl-upf-controlled-feeding-trial","kind":"idea","name":"Controlled feeding trials to separate ultra-processing from calories","route":"/ideas/idea-nl-upf-controlled-feeding-trial/","asOf":"2026-09-08","days":1},{"id":"idea-nl-antioxidant-supplement-harm-confirmation","kind":"idea","name":"Confirm or refute the harm of antioxidant supplements during chemotherapy","route":"/ideas/idea-nl-antioxidant-supplement-harm-confirmation/","asOf":"2026-09-08","days":1},{"id":"idea-nl-bariatric-cancer-registry-linkage","kind":"idea","name":"Link bariatric and GLP-1 registries to cancer registries in every country that has both","route":"/ideas/idea-nl-bariatric-cancer-registry-linkage/","asOf":"2026-09-08","days":1},{"id":"idea-nl-sleep-circadian-survivorship-rct","kind":"idea","name":"Treat insomnia in survivors and measure whether the cancer notices","route":"/ideas/idea-nl-sleep-circadian-survivorship-rct/","asOf":"2026-09-08","days":1},{"id":"idea-nl-dietitian-in-every-mdt","kind":"idea","name":"A dietitian in every gastrointestinal and head and neck tumour board","route":"/ideas/idea-nl-dietitian-in-every-mdt/","asOf":"2026-09-08","days":1},{"id":"idea-nl-ask-about-diet-prebunking","kind":"idea","name":"Ask about diet at diagnosis, and prebunk the myths before the internet does","route":"/ideas/idea-nl-ask-about-diet-prebunking/","asOf":"2026-09-08","days":1},{"id":"arc-institute","kind":"institution","name":"Arc Institute","route":"/institutions/arc-institute/","asOf":"2026-09-08","days":1},{"id":"institute-for-protein-design","kind":"institution","name":"Institute for Protein Design (University of Washington)","route":"/institutions/institute-for-protein-design/","asOf":"2026-09-08","days":1},{"id":"providence-health","kind":"institution","name":"Providence Health & Services","route":"/institutions/providence-health/","asOf":"2026-09-08","days":1},{"id":"yale-school-of-medicine","kind":"institution","name":"Yale School of Medicine / Yale Cancer Center","route":"/institutions/yale-school-of-medicine/","asOf":"2026-09-08","days":1},{"id":"google-deepmind","kind":"company","name":"Google DeepMind (and Google Research)","route":"/companies/google-deepmind/","asOf":"2026-09-08","days":1},{"id":"microsoft-research","kind":"company","name":"Microsoft (Research and Health AI)","route":"/companies/microsoft-research/","asOf":"2026-09-08","days":1},{"id":"nvidia","kind":"company","name":"NVIDIA","route":"/companies/nvidia/","asOf":"2026-09-08","days":1},{"id":"evolutionaryscale","kind":"company","name":"EvolutionaryScale","route":"/companies/evolutionaryscale/","asOf":"2026-09-08","days":1},{"id":"vevo-therapeutics","kind":"company","name":"Vevo Therapeutics","route":"/companies/vevo-therapeutics/","asOf":"2026-09-08","days":1},{"id":"bioptimus","kind":"company","name":"Bioptimus","route":"/companies/bioptimus/","asOf":"2026-09-08","days":1},{"id":"aignostics","kind":"company","name":"Aignostics","route":"/companies/aignostics/","asOf":"2026-09-08","days":1},{"id":"kaiko-ai","kind":"company","name":"kaiko.ai","route":"/companies/kaiko-ai/","asOf":"2026-09-08","days":1},{"id":"histai","kind":"company","name":"HistAI","route":"/companies/histai/","asOf":"2026-09-08","days":1},{"id":"chai-discovery","kind":"company","name":"Chai Discovery","route":"/companies/chai-discovery/","asOf":"2026-09-08","days":1},{"id":"xaira-therapeutics","kind":"company","name":"Xaira Therapeutics","route":"/companies/xaira-therapeutics/","asOf":"2026-09-08","days":1},{"id":"lila-sciences","kind":"company","name":"Lila Sciences","route":"/companies/lila-sciences/","asOf":"2026-09-08","days":1},{"id":"cradle-bio","kind":"company","name":"Cradle","route":"/companies/cradle-bio/","asOf":"2026-09-08","days":1},{"id":"profluent-bio","kind":"company","name":"Profluent","route":"/companies/profluent-bio/","asOf":"2026-09-08","days":1},{"id":"latent-labs","kind":"company","name":"Latent Labs","route":"/companies/latent-labs/","asOf":"2026-09-08","days":1},{"id":"genesis-molecular-ai","kind":"company","name":"Genesis Molecular AI (formerly Genesis Therapeutics)","route":"/companies/genesis-molecular-ai/","asOf":"2026-09-08","days":1},{"id":"iambic-therapeutics","kind":"company","name":"Iambic Therapeutics","route":"/companies/iambic-therapeutics/","asOf":"2026-09-08","days":1},{"id":"chan-zuckerberg-initiative","kind":"company","name":"Chan Zuckerberg Initiative (Biohub)","route":"/companies/chan-zuckerberg-initiative/","asOf":"2026-09-08","days":1},{"id":"tcia","kind":"collection","name":"The Cancer Imaging Archive (TCIA)","route":"/collections/tcia/","asOf":"2026-09-08","days":1},{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","route":"/collections/imaging-data-commons/","asOf":"2026-09-08","days":1},{"id":"uk-biobank","kind":"collection","name":"UK Biobank","route":"/collections/uk-biobank/","asOf":"2026-09-08","days":1},{"id":"all-of-us","kind":"collection","name":"All of Us Research Program","route":"/collections/all-of-us/","asOf":"2026-09-08","days":1},{"id":"flatiron-foundation-cgdb","kind":"collection","name":"Flatiron Health–Foundation Medicine Clinico-Genomic Database","route":"/collections/flatiron-foundation-cgdb/","asOf":"2026-09-08","days":1},{"id":"cdas-nlst-plco","kind":"collection","name":"NCI CDAS: NLST and PLCO screening trial data","route":"/collections/cdas-nlst-plco/","asOf":"2026-09-08","days":1},{"id":"pathology-benchmarks","kind":"collection","name":"Pathology AI benchmarks (CAMELYON, PANDA, TCGA slide tasks)","route":"/collections/pathology-benchmarks/","asOf":"2026-09-08","days":1},{"id":"tahoe-100m","kind":"collection","name":"Tahoe-100M","route":"/collections/tahoe-100m/","asOf":"2026-09-08","days":1},{"id":"arc-virtual-cell-atlas","kind":"collection","name":"Arc Virtual Cell Atlas","route":"/collections/arc-virtual-cell-atlas/","asOf":"2026-09-08","days":1},{"id":"virchow","kind":"technology","name":"Virchow / Virchow2 (Paige, MSK)","route":"/technologies/virchow/","asOf":"2026-09-08","days":1},{"id":"uni-conch","kind":"technology","name":"UNI and CONCH (Harvard, Mahmood Lab)","route":"/technologies/uni-conch/","asOf":"2026-09-08","days":1},{"id":"titan","kind":"technology","name":"TITAN (whole-slide multimodal model)","route":"/technologies/titan/","asOf":"2026-09-08","days":1},{"id":"prov-gigapath","kind":"technology","name":"Prov-GigaPath (Microsoft, Providence)","route":"/technologies/prov-gigapath/","asOf":"2026-09-08","days":1},{"id":"chief","kind":"technology","name":"CHIEF (Harvard, Yu Lab)","route":"/technologies/chief/","asOf":"2026-09-08","days":1},{"id":"musk","kind":"technology","name":"MUSK (Stanford, vision-language pathology)","route":"/technologies/musk/","asOf":"2026-09-08","days":1},{"id":"h-optimus","kind":"technology","name":"H-optimus (Bioptimus)","route":"/technologies/h-optimus/","asOf":"2026-09-08","days":1},{"id":"pluto","kind":"technology","name":"PLUTO (PathAI)","route":"/technologies/pluto/","asOf":"2026-09-08","days":1},{"id":"hibou","kind":"technology","name":"Hibou (HistAI)","route":"/technologies/hibou/","asOf":"2026-09-08","days":1},{"id":"kaiko-midnight","kind":"technology","name":"Midnight (kaiko.ai)","route":"/technologies/kaiko-midnight/","asOf":"2026-09-08","days":1},{"id":"atlas-aignostics","kind":"technology","name":"Atlas (Aignostics, Mayo Clinic, Charité)","route":"/technologies/atlas-aignostics/","asOf":"2026-09-08","days":1},{"id":"phikon","kind":"technology","name":"Phikon / Phikon-v2 (Owkin)","route":"/technologies/phikon/","asOf":"2026-09-08","days":1},{"id":"merlin-ct","kind":"technology","name":"Merlin (Stanford abdominal CT vision-language model)","route":"/technologies/merlin-ct/","asOf":"2026-09-08","days":1},{"id":"radfm","kind":"technology","name":"RadFM (generalist radiology foundation model)","route":"/technologies/radfm/","asOf":"2026-09-08","days":1},{"id":"ct-fm","kind":"technology","name":"CT-FM (whole-body CT foundation model)","route":"/technologies/ct-fm/","asOf":"2026-09-08","days":1},{"id":"medsam","kind":"technology","name":"MedSAM / SAM-Med3D (segment anything for medicine)","route":"/technologies/medsam/","asOf":"2026-09-08","days":1},{"id":"sybil","kind":"technology","name":"Sybil (MIT/MGH lung cancer risk from CT)","route":"/technologies/sybil/","asOf":"2026-09-08","days":1},{"id":"mirai","kind":"technology","name":"Mirai (MIT breast cancer risk from mammograms)","route":"/technologies/mirai/","asOf":"2026-09-08","days":1},{"id":"med-gemini","kind":"technology","name":"Med-Gemini and MedLM (Google)","route":"/technologies/med-gemini/","asOf":"2026-09-08","days":1},{"id":"aidoc-care","kind":"technology","name":"Aidoc CARE (clinical radiology foundation model)","route":"/technologies/aidoc-care/","asOf":"2026-09-08","days":1},{"id":"geneformer","kind":"technology","name":"Geneformer","route":"/technologies/geneformer/","asOf":"2026-09-08","days":1},{"id":"scgpt","kind":"technology","name":"scGPT","route":"/technologies/scgpt/","asOf":"2026-09-08","days":1},{"id":"universal-cell-embedding","kind":"technology","name":"Universal Cell Embedding (UCE)","route":"/technologies/universal-cell-embedding/","asOf":"2026-09-08","days":1},{"id":"scfoundation","kind":"technology","name":"scFoundation (BioMap)","route":"/technologies/scfoundation/","asOf":"2026-09-08","days":1},{"id":"nicheformer","kind":"technology","name":"Nicheformer (spatial single-cell)","route":"/technologies/nicheformer/","asOf":"2026-09-08","days":1},{"id":"cellfm","kind":"technology","name":"CellFM","route":"/technologies/cellfm/","asOf":"2026-09-08","days":1},{"id":"genept","kind":"technology","name":"GenePT","route":"/technologies/genept/","asOf":"2026-09-08","days":1},{"id":"c2s-scale","kind":"technology","name":"Cell2Sentence / C2S-Scale (Yale, Google)","route":"/technologies/c2s-scale/","asOf":"2026-09-08","days":1},{"id":"state-arc","kind":"technology","name":"State (Arc Institute perturbation model)","route":"/technologies/state-arc/","asOf":"2026-09-08","days":1},{"id":"transcriptformer","kind":"technology","name":"TranscriptFormer and rBio (CZI virtual cell models)","route":"/technologies/transcriptformer/","asOf":"2026-09-08","days":1},{"id":"gears","kind":"technology","name":"GEARS and perturbation prediction benchmarks","route":"/technologies/gears/","asOf":"2026-09-08","days":1},{"id":"alphafold3","kind":"technology","name":"AlphaFold 3","route":"/technologies/alphafold3/","asOf":"2026-09-08","days":1},{"id":"boltz","kind":"technology","name":"Boltz-1 / Boltz-2 (MIT, open)","route":"/technologies/boltz/","asOf":"2026-09-08","days":1},{"id":"chai-1","kind":"technology","name":"Chai-1 / Chai-2","route":"/technologies/chai-1/","asOf":"2026-09-08","days":1},{"id":"esm3","kind":"technology","name":"ESM3 (EvolutionaryScale)","route":"/technologies/esm3/","asOf":"2026-09-08","days":1},{"id":"evo2","kind":"technology","name":"Evo 2 (Arc Institute, NVIDIA)","route":"/technologies/evo2/","asOf":"2026-09-08","days":1},{"id":"rfdiffusion","kind":"technology","name":"RFdiffusion / RFdiffusion2 and ProteinMPNN (Baker Lab)","route":"/technologies/rfdiffusion/","asOf":"2026-09-08","days":1},{"id":"bioemu","kind":"technology","name":"BioEmu (Microsoft)","route":"/technologies/bioemu/","asOf":"2026-09-08","days":1},{"id":"nucleotide-transformer","kind":"technology","name":"Nucleotide Transformer (InstaDeep)","route":"/technologies/nucleotide-transformer/","asOf":"2026-09-08","days":1},{"id":"enformer-borzoi","kind":"technology","name":"Enformer and Borzoi (DeepMind, Calico)","route":"/technologies/enformer-borzoi/","asOf":"2026-09-08","days":1},{"id":"alphamissense","kind":"technology","name":"AlphaMissense","route":"/technologies/alphamissense/","asOf":"2026-09-08","days":1},{"id":"alphagenome","kind":"technology","name":"AlphaGenome","route":"/technologies/alphagenome/","asOf":"2026-09-08","days":1},{"id":"foresight-ehr","kind":"technology","name":"Foresight (generative EHR model)","route":"/technologies/foresight-ehr/","asOf":"2026-09-08","days":1},{"id":"tempus-multimodal","kind":"technology","name":"Tempus multimodal models","route":"/technologies/tempus-multimodal/","asOf":"2026-09-08","days":1},{"id":"bionemo","kind":"technology","name":"NVIDIA BioNeMo","route":"/technologies/bionemo/","asOf":"2026-09-08","days":1},{"id":"phenom-2","kind":"technology","name":"Phenom-2 and Recursion OS","route":"/technologies/phenom-2/","asOf":"2026-09-08","days":1},{"id":"chemistry42","kind":"technology","name":"Chemistry42 and Pharma.AI (Insilico)","route":"/technologies/chemistry42/","asOf":"2026-09-08","days":1},{"id":"virtual-cell","kind":"roadmap","name":"Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell","route":"/roadmaps/virtual-cell/","asOf":"2026-09-08","days":1},{"id":"ai-oncology-clinic","kind":"roadmap","name":"AI in the oncology clinic: from narrow cleared tools to multimodal decision support","route":"/roadmaps/ai-oncology-clinic/","asOf":"2026-09-08","days":1},{"id":"emily-whitehead","kind":"person","name":"Emily Whitehead","route":"/people/emily-whitehead/","asOf":"2026-09-09","days":0},{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/","asOf":"2026-09-09","days":0},{"id":"einar-gustafson","kind":"person","name":"Einar \"Jimmy\" Gustafson","route":"/people/einar-gustafson/","asOf":"2026-09-09","days":0},{"id":"terry-fox","kind":"person","name":"Terry Fox","route":"/people/terry-fox/","asOf":"2026-09-09","days":0},{"id":"stephen-sutton","kind":"person","name":"Stephen Sutton","route":"/people/stephen-sutton/","asOf":"2026-09-09","days":0},{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/","asOf":"2026-09-09","days":0},{"id":"katie-couric","kind":"person","name":"Katie Couric","route":"/people/katie-couric/","asOf":"2026-09-09","days":0},{"id":"chadwick-boseman","kind":"person","name":"Chadwick Boseman","route":"/people/chadwick-boseman/","asOf":"2026-09-09","days":0},{"id":"jade-goody","kind":"person","name":"Jade Goody","route":"/people/jade-goody/","asOf":"2026-09-09","days":0},{"id":"lance-armstrong","kind":"person","name":"Lance Armstrong","route":"/people/lance-armstrong/","asOf":"2026-09-09","days":0},{"id":"steve-jobs","kind":"person","name":"Steve Jobs","route":"/people/steve-jobs/","asOf":"2026-09-09","days":0},{"id":"randy-pausch","kind":"person","name":"Randy Pausch","route":"/people/randy-pausch/","asOf":"2026-09-09","days":0},{"id":"deborah-james","kind":"person","name":"Dame Deborah James","route":"/people/deborah-james/","asOf":"2026-09-09","days":0},{"id":"kris-hallenga","kind":"person","name":"Kris Hallenga","route":"/people/kris-hallenga/","asOf":"2026-09-09","days":0},{"id":"ashya-king","kind":"person","name":"Ashya King","route":"/people/ashya-king/","asOf":"2026-09-09","days":0},{"id":"kate-granger","kind":"person","name":"Kate Granger","route":"/people/kate-granger/","asOf":"2026-09-09","days":0},{"id":"betty-ford","kind":"person","name":"Betty Ford","route":"/people/betty-ford/","asOf":"2026-09-09","days":0},{"id":"audre-lorde","kind":"person","name":"Audre Lorde","route":"/people/audre-lorde/","asOf":"2026-09-09","days":0},{"id":"rose-kushner","kind":"person","name":"Rose Kushner","route":"/people/rose-kushner/","asOf":"2026-09-09","days":0},{"id":"gilda-radner","kind":"person","name":"Gilda Radner","route":"/people/gilda-radner/","asOf":"2026-09-09","days":0},{"id":"jim-valvano","kind":"person","name":"Jim Valvano","route":"/people/jim-valvano/","asOf":"2026-09-09","days":0},{"id":"alex-scott","kind":"person","name":"Alexandra \"Alex\" Scott","route":"/people/alex-scott/","asOf":"2026-09-09","days":0},{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/","asOf":"2026-09-09","days":0},{"id":"bud-romine","kind":"person","name":"Bud Romine","route":"/people/bud-romine/","asOf":"2026-09-09","days":0},{"id":"sharon-belvin","kind":"person","name":"Sharon Belvin","route":"/people/sharon-belvin/","asOf":"2026-09-09","days":0},{"id":"robert-sandler","kind":"person","name":"Robert Sandler","route":"/people/robert-sandler/","asOf":"2026-09-09","days":0},{"id":"mary-lasker","kind":"person","name":"Mary Lasker","route":"/people/mary-lasker/","asOf":"2026-09-09","days":0},{"id":"nancy-brinker","kind":"person","name":"Nancy Brinker","route":"/people/nancy-brinker/","asOf":"2026-09-09","days":0},{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","route":"/people/evelyn-lauder/","asOf":"2026-09-09","days":0},{"id":"fran-visco","kind":"person","name":"Fran Visco","route":"/people/fran-visco/","asOf":"2026-09-09","days":0},{"id":"susan-love","kind":"person","name":"Susan Love","route":"/people/susan-love/","asOf":"2026-09-09","days":0},{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","route":"/people/cicely-saunders/","asOf":"2026-09-09","days":0},{"id":"elisabeth-kubler-ross","kind":"person","name":"Elisabeth Kübler-Ross","route":"/people/elisabeth-kubler-ross/","asOf":"2026-09-09","days":0},{"id":"sidney-farber","kind":"person","name":"Sidney Farber","route":"/people/sidney-farber/","asOf":"2026-09-09","days":0},{"id":"gertrude-elion","kind":"person","name":"Gertrude Elion","route":"/people/gertrude-elion/","asOf":"2026-09-09","days":0},{"id":"jane-cooke-wright","kind":"person","name":"Jane Cooke Wright","route":"/people/jane-cooke-wright/","asOf":"2026-09-09","days":0},{"id":"emil-freireich","kind":"person","name":"Emil J Freireich","route":"/people/emil-freireich/","asOf":"2026-09-09","days":0},{"id":"emil-frei","kind":"person","name":"Emil \"Tom\" Frei III","route":"/people/emil-frei/","asOf":"2026-09-09","days":0},{"id":"donald-pinkel","kind":"person","name":"Donald Pinkel","route":"/people/donald-pinkel/","asOf":"2026-09-09","days":0},{"id":"bernard-fisher","kind":"person","name":"Bernard Fisher","route":"/people/bernard-fisher/","asOf":"2026-09-09","days":0},{"id":"jimmie-holland","kind":"person","name":"Jimmie Holland","route":"/people/jimmie-holland/","asOf":"2026-09-09","days":0},{"id":"judah-folkman","kind":"person","name":"Judah Folkman","route":"/people/judah-folkman/","asOf":"2026-09-09","days":0},{"id":"brian-druker","kind":"person","name":"Brian Druker","route":"/people/brian-druker/","asOf":"2026-09-09","days":0},{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","route":"/people/tasuku-honjo/","asOf":"2026-09-09","days":0},{"id":"harald-zur-hausen","kind":"person","name":"Harald zur Hausen","route":"/people/harald-zur-hausen/","asOf":"2026-09-09","days":0},{"id":"ian-frazer","kind":"person","name":"Ian Frazer","route":"/people/ian-frazer/","asOf":"2026-09-09","days":0},{"id":"jian-zhou","kind":"person","name":"Jian Zhou","route":"/people/jian-zhou/","asOf":"2026-09-09","days":0},{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","route":"/people/mary-claire-king/","asOf":"2026-09-09","days":0},{"id":"janet-rowley","kind":"person","name":"Janet Rowley","route":"/people/janet-rowley/","asOf":"2026-09-09","days":0},{"id":"sn-38","kind":"term","name":"SN-38","route":"/terms/sn-38/","asOf":"2026-09-09","days":0},{"id":"dxd","kind":"term","name":"DXd","route":"/terms/dxd/","asOf":"2026-09-09","days":0},{"id":"exatecan","kind":"term","name":"Exatecan (and derivatives)","route":"/terms/exatecan/","asOf":"2026-09-09","days":0},{"id":"t030","kind":"term","name":"T030 (belotecan derivative)","route":"/terms/t030/","asOf":"2026-09-09","days":0},{"id":"mmae","kind":"term","name":"MMAE","route":"/terms/mmae/","asOf":"2026-09-09","days":0},{"id":"mmaf","kind":"term","name":"MMAF","route":"/terms/mmaf/","asOf":"2026-09-09","days":0},{"id":"dm1","kind":"term","name":"DM1","route":"/terms/dm1/","asOf":"2026-09-09","days":0},{"id":"dm4","kind":"term","name":"DM4","route":"/terms/dm4/","asOf":"2026-09-09","days":0},{"id":"pbd-sg3199","kind":"term","name":"PBD dimer (SG3199 / tesirine)","route":"/terms/pbd-sg3199/","asOf":"2026-09-09","days":0},{"id":"calicheamicin","kind":"term","name":"Calicheamicin","route":"/terms/calicheamicin/","asOf":"2026-09-09","days":0},{"id":"duocarmycin","kind":"term","name":"Duocarmycin (seco-DUBA)","route":"/terms/duocarmycin/","asOf":"2026-09-09","days":0},{"id":"topoisomerase-i-payloads","kind":"term","name":"Topoisomerase-I inhibitor payloads","route":"/terms/topoisomerase-i-payloads/","asOf":"2026-09-09","days":0},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/","asOf":"2026-09-09","days":0},{"id":"pbd-dimer-payloads","kind":"term","name":"DNA crosslinker payloads (PBD dimers)","route":"/terms/pbd-dimer-payloads/","asOf":"2026-09-09","days":0},{"id":"dna-cleaver-payloads","kind":"term","name":"DNA cleaver payloads (enediynes)","route":"/terms/dna-cleaver-payloads/","asOf":"2026-09-09","days":0},{"id":"dna-alkylator-payloads","kind":"term","name":"DNA alkylator payloads","route":"/terms/dna-alkylator-payloads/","asOf":"2026-09-09","days":0},{"id":"cl2a","kind":"term","name":"CL2A","route":"/terms/cl2a/","asOf":"2026-09-09","days":0},{"id":"ggfg","kind":"term","name":"Tetrapeptide GGFG (maleimide-GGFG-aminomethyl)","route":"/terms/ggfg/","asOf":"2026-09-09","days":0},{"id":"mc-vc-pabc","kind":"term","name":"mc-Val-Cit-PABC","route":"/terms/mc-vc-pabc/","asOf":"2026-09-09","days":0},{"id":"smcc","kind":"term","name":"SMCC (thioether, non-cleavable)","route":"/terms/smcc/","asOf":"2026-09-09","days":0},{"id":"sulfo-spdb","kind":"term","name":"Sulfo-SPDB (disulfide)","route":"/terms/sulfo-spdb/","asOf":"2026-09-09","days":0},{"id":"hydrazone","kind":"term","name":"Acid-labile hydrazone (AcBut)","route":"/terms/hydrazone/","asOf":"2026-09-09","days":0},{"id":"val-ala","kind":"term","name":"Val-Ala dipeptide","route":"/terms/val-ala/","asOf":"2026-09-09","days":0},{"id":"mc-non-cleavable","kind":"term","name":"Maleimidocaproyl (mc), non-cleavable","route":"/terms/mc-non-cleavable/","asOf":"2026-09-09","days":0},{"id":"hydrophilic-next-gen","kind":"term","name":"Hydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing)","route":"/terms/hydrophilic-next-gen/","asOf":"2026-09-09","days":0},{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","asOf":"2026-09-09","days":0},{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","asOf":"2026-09-09","days":0},{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","asOf":"2026-09-09","days":0},{"id":"jama-internal-medicine","kind":"journal","name":"JAMA Internal Medicine","route":"/journals/jama-internal-medicine/","asOf":"2026-09-09","days":0},{"id":"bmj","kind":"journal","name":"BMJ","route":"/journals/bmj/","asOf":"2026-09-09","days":0},{"id":"annals-internal-medicine","kind":"journal","name":"Annals of Internal Medicine","route":"/journals/annals-internal-medicine/","asOf":"2026-09-09","days":0},{"id":"plos-medicine","kind":"journal","name":"PLOS Medicine","route":"/journals/plos-medicine/","asOf":"2026-09-09","days":0},{"id":"lancet-global-health","kind":"journal","name":"The Lancet Global Health","route":"/journals/lancet-global-health/","asOf":"2026-09-09","days":0},{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","asOf":"2026-09-09","days":0},{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","asOf":"2026-09-09","days":0},{"id":"jco-precision-oncology","kind":"journal","name":"JCO Precision Oncology","route":"/journals/jco-precision-oncology/","asOf":"2026-09-09","days":0},{"id":"jco-oncology-practice","kind":"journal","name":"JCO Oncology Practice","route":"/journals/jco-oncology-practice/","asOf":"2026-09-09","days":0},{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/","asOf":"2026-09-09","days":0},{"id":"esmo-open","kind":"journal","name":"ESMO Open","route":"/journals/esmo-open/","asOf":"2026-09-09","days":0},{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/","asOf":"2026-09-09","days":0},{"id":"jnci","kind":"journal","name":"JNCI: Journal of the National Cancer Institute","route":"/journals/jnci/","asOf":"2026-09-09","days":0},{"id":"cancer-wiley","kind":"journal","name":"Cancer","route":"/journals/cancer-wiley/","asOf":"2026-09-09","days":0},{"id":"ca-cancer-journal","kind":"journal","name":"CA: A Cancer Journal for Clinicians","route":"/journals/ca-cancer-journal/","asOf":"2026-09-09","days":0},{"id":"british-journal-of-cancer","kind":"journal","name":"British Journal of Cancer","route":"/journals/british-journal-of-cancer/","asOf":"2026-09-09","days":0},{"id":"european-journal-of-cancer","kind":"journal","name":"European Journal of Cancer","route":"/journals/european-journal-of-cancer/","asOf":"2026-09-09","days":0},{"id":"jnccn","kind":"journal","name":"Journal of the National Comprehensive Cancer Network","route":"/journals/jnccn/","asOf":"2026-09-09","days":0},{"id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","route":"/journals/journal-of-thoracic-oncology/","asOf":"2026-09-09","days":0},{"id":"gynecologic-oncology","kind":"journal","name":"Gynecologic Oncology","route":"/journals/gynecologic-oncology/","asOf":"2026-09-09","days":0},{"id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/","asOf":"2026-09-09","days":0},{"id":"european-urology-oncology","kind":"journal","name":"European Urology Oncology","route":"/journals/european-urology-oncology/","asOf":"2026-09-09","days":0},{"id":"neuro-oncology","kind":"journal","name":"Neuro-Oncology","route":"/journals/neuro-oncology/","asOf":"2026-09-09","days":0},{"id":"radiotherapy-and-oncology","kind":"journal","name":"Radiotherapy and Oncology","route":"/journals/radiotherapy-and-oncology/","asOf":"2026-09-09","days":0},{"id":"ijrobp","kind":"journal","name":"International Journal of Radiation Oncology, Biology, Physics","route":"/journals/ijrobp/","asOf":"2026-09-09","days":0},{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/","asOf":"2026-09-09","days":0},{"id":"radiology","kind":"journal","name":"Radiology","route":"/journals/radiology/","asOf":"2026-09-09","days":0},{"id":"pediatric-blood-and-cancer","kind":"journal","name":"Pediatric Blood & Cancer","route":"/journals/pediatric-blood-and-cancer/","asOf":"2026-09-09","days":0},{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/","asOf":"2026-09-09","days":0},{"id":"blood-advances","kind":"journal","name":"Blood Advances","route":"/journals/blood-advances/","asOf":"2026-09-09","days":0},{"id":"leukemia","kind":"journal","name":"Leukemia","route":"/journals/leukemia/","asOf":"2026-09-09","days":0},{"id":"lancet-haematology","kind":"journal","name":"The Lancet Haematology","route":"/journals/lancet-haematology/","asOf":"2026-09-09","days":0},{"id":"haematologica","kind":"journal","name":"Haematologica","route":"/journals/haematologica/","asOf":"2026-09-09","days":0},{"id":"nature","kind":"journal","name":"Nature","route":"/journals/nature/","asOf":"2026-09-09","days":0},{"id":"science","kind":"journal","name":"Science","route":"/journals/science/","asOf":"2026-09-09","days":0},{"id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","asOf":"2026-09-09","days":0},{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/","asOf":"2026-09-09","days":0},{"id":"cell-stem-cell","kind":"journal","name":"Cell Stem Cell","route":"/journals/cell-stem-cell/","asOf":"2026-09-09","days":0},{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","asOf":"2026-09-09","days":0},{"id":"nature-cancer","kind":"journal","name":"Nature Cancer","route":"/journals/nature-cancer/","asOf":"2026-09-09","days":0},{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/","asOf":"2026-09-09","days":0},{"id":"nature-reviews-clinical-oncology","kind":"journal","name":"Nature Reviews Clinical Oncology","route":"/journals/nature-reviews-clinical-oncology/","asOf":"2026-09-09","days":0},{"id":"nature-reviews-drug-discovery","kind":"journal","name":"Nature Reviews Drug Discovery","route":"/journals/nature-reviews-drug-discovery/","asOf":"2026-09-09","days":0},{"id":"nature-genetics","kind":"journal","name":"Nature Genetics","route":"/journals/nature-genetics/","asOf":"2026-09-09","days":0},{"id":"nature-biotechnology","kind":"journal","name":"Nature Biotechnology","route":"/journals/nature-biotechnology/","asOf":"2026-09-09","days":0},{"id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/","asOf":"2026-09-09","days":0},{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/","asOf":"2026-09-09","days":0},{"id":"cancer-discovery","kind":"journal","name":"Cancer Discovery","route":"/journals/cancer-discovery/","asOf":"2026-09-09","days":0},{"id":"cancer-research","kind":"journal","name":"Cancer Research","route":"/journals/cancer-research/","asOf":"2026-09-09","days":0},{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/","asOf":"2026-09-09","days":0},{"id":"cancer-immunology-research","kind":"journal","name":"Cancer Immunology Research","route":"/journals/cancer-immunology-research/","asOf":"2026-09-09","days":0},{"id":"molecular-cancer-therapeutics","kind":"journal","name":"Molecular Cancer Therapeutics","route":"/journals/molecular-cancer-therapeutics/","asOf":"2026-09-09","days":0},{"id":"cancer-epidemiology-biomarkers-prevention","kind":"journal","name":"Cancer Epidemiology, Biomarkers & Prevention","route":"/journals/cancer-epidemiology-biomarkers-prevention/","asOf":"2026-09-09","days":0},{"id":"jitc","kind":"journal","name":"Journal for ImmunoTherapy of Cancer","route":"/journals/jitc/","asOf":"2026-09-09","days":0},{"id":"jci","kind":"journal","name":"Journal of Clinical Investigation","route":"/journals/jci/","asOf":"2026-09-09","days":0},{"id":"genes-and-development","kind":"journal","name":"Genes & Development","route":"/journals/genes-and-development/","asOf":"2026-09-09","days":0},{"id":"pnas","kind":"journal","name":"Proceedings of the National Academy of Sciences","route":"/journals/pnas/","asOf":"2026-09-09","days":0},{"id":"elife","kind":"journal","name":"eLife","route":"/journals/elife/","asOf":"2026-09-09","days":0},{"id":"cancers-mdpi","kind":"journal","name":"Cancers","route":"/journals/cancers-mdpi/","asOf":"2026-09-09","days":0},{"id":"clinical-pharmacology-and-therapeutics","kind":"journal","name":"Clinical Pharmacology & Therapeutics","route":"/journals/clinical-pharmacology-and-therapeutics/","asOf":"2026-09-09","days":0},{"id":"lancet-digital-health","kind":"journal","name":"The Lancet Digital Health","route":"/journals/lancet-digital-health/","asOf":"2026-09-09","days":0},{"id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","route":"/journals/nejm-evidence/","asOf":"2026-09-09","days":0},{"id":"medrxiv","kind":"journal","name":"medRxiv","route":"/journals/medrxiv/","asOf":"2026-09-09","days":0},{"id":"biorxiv","kind":"journal","name":"bioRxiv","route":"/journals/biorxiv/","asOf":"2026-09-09","days":0},{"id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","asOf":"2026-09-09","days":0},{"id":"cell-membrane","kind":"term","name":"Cell membrane","route":"/terms/cell-membrane/","asOf":"2026-09-09","days":0},{"id":"nucleus","kind":"term","name":"Nucleus","route":"/terms/nucleus/","asOf":"2026-09-09","days":0},{"id":"dna-term","kind":"term","name":"DNA","route":"/terms/dna-term/","asOf":"2026-09-09","days":0},{"id":"rna","kind":"term","name":"RNA","route":"/terms/rna/","asOf":"2026-09-09","days":0},{"id":"gene","kind":"term","name":"Gene","route":"/terms/gene/","asOf":"2026-09-09","days":0},{"id":"chromosome","kind":"term","name":"Chromosome","route":"/terms/chromosome/","asOf":"2026-09-09","days":0},{"id":"protein","kind":"term","name":"Protein","route":"/terms/protein/","asOf":"2026-09-09","days":0},{"id":"enzyme","kind":"term","name":"Enzyme","route":"/terms/enzyme/","asOf":"2026-09-09","days":0},{"id":"gene-expression","kind":"term","name":"Gene expression","route":"/terms/gene-expression/","asOf":"2026-09-09","days":0},{"id":"mutation","kind":"term","name":"Mutation","route":"/terms/mutation/","asOf":"2026-09-09","days":0},{"id":"driver-mutation","kind":"term","name":"Driver mutation","route":"/terms/driver-mutation/","asOf":"2026-09-09","days":0},{"id":"amplification","kind":"term","name":"Amplification","route":"/terms/amplification/","asOf":"2026-09-09","days":0},{"id":"overexpression","kind":"term","name":"Overexpression","route":"/terms/overexpression/","asOf":"2026-09-09","days":0},{"id":"deletion","kind":"term","name":"Deletion","route":"/terms/deletion/","asOf":"2026-09-09","days":0},{"id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/","asOf":"2026-09-09","days":0},{"id":"tumour-suppressor-gene","kind":"term","name":"Tumour suppressor gene","route":"/terms/tumour-suppressor-gene/","asOf":"2026-09-09","days":0},{"id":"receptor","kind":"term","name":"Receptor","route":"/terms/receptor/","asOf":"2026-09-09","days":0},{"id":"ligand","kind":"term","name":"Ligand","route":"/terms/ligand/","asOf":"2026-09-09","days":0},{"id":"growth-factor","kind":"term","name":"Growth factor","route":"/terms/growth-factor/","asOf":"2026-09-09","days":0},{"id":"growth-signal","kind":"term","name":"Growth signal","route":"/terms/growth-signal/","asOf":"2026-09-09","days":0},{"id":"signalling-pathway","kind":"term","name":"Signalling pathway","route":"/terms/signalling-pathway/","asOf":"2026-09-09","days":0},{"id":"downstream","kind":"term","name":"Downstream and upstream","route":"/terms/downstream/","asOf":"2026-09-09","days":0},{"id":"kinase","kind":"term","name":"Kinase","route":"/terms/kinase/","asOf":"2026-09-09","days":0},{"id":"phosphorylation","kind":"term","name":"Phosphorylation","route":"/terms/phosphorylation/","asOf":"2026-09-09","days":0},{"id":"inhibitor","kind":"term","name":"Inhibitor","route":"/terms/inhibitor/","asOf":"2026-09-09","days":0},{"id":"agonist-antagonist","kind":"term","name":"Agonist and antagonist","route":"/terms/agonist-antagonist/","asOf":"2026-09-09","days":0},{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/","asOf":"2026-09-09","days":0},{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/","asOf":"2026-09-09","days":0},{"id":"epitope","kind":"term","name":"Epitope","route":"/terms/epitope/","asOf":"2026-09-09","days":0},{"id":"monoclonal","kind":"term","name":"Monoclonal","route":"/terms/monoclonal/","asOf":"2026-09-09","days":0},{"id":"cell-cycle","kind":"term","name":"Cell cycle","route":"/terms/cell-cycle/","asOf":"2026-09-09","days":0},{"id":"cell-division","kind":"term","name":"Cell division","route":"/terms/cell-division/","asOf":"2026-09-09","days":0},{"id":"proliferation","kind":"term","name":"Proliferation","route":"/terms/proliferation/","asOf":"2026-09-09","days":0},{"id":"differentiation","kind":"term","name":"Differentiation","route":"/terms/differentiation/","asOf":"2026-09-09","days":0},{"id":"stem-cell","kind":"term","name":"Stem cell","route":"/terms/stem-cell/","asOf":"2026-09-09","days":0},{"id":"apoptosis","kind":"term","name":"Apoptosis","route":"/terms/apoptosis/","asOf":"2026-09-09","days":0},{"id":"necrosis","kind":"term","name":"Necrosis","route":"/terms/necrosis/","asOf":"2026-09-09","days":0},{"id":"angiogenesis","kind":"term","name":"Angiogenesis","route":"/terms/angiogenesis/","asOf":"2026-09-09","days":0},{"id":"benign-vs-malignant","kind":"term","name":"Benign versus malignant","route":"/terms/benign-vs-malignant/","asOf":"2026-09-09","days":0},{"id":"primary-tumour","kind":"term","name":"Primary tumour","route":"/terms/primary-tumour/","asOf":"2026-09-09","days":0},{"id":"metastasis","kind":"term","name":"Metastasis","route":"/terms/metastasis/","asOf":"2026-09-09","days":0},{"id":"lesion","kind":"term","name":"Lesion","route":"/terms/lesion/","asOf":"2026-09-09","days":0},{"id":"carcinoma","kind":"term","name":"Carcinoma","route":"/terms/carcinoma/","asOf":"2026-09-09","days":0},{"id":"adenocarcinoma","kind":"term","name":"Adenocarcinoma","route":"/terms/adenocarcinoma/","asOf":"2026-09-09","days":0},{"id":"squamous-cell-carcinoma","kind":"term","name":"Squamous cell carcinoma","route":"/terms/squamous-cell-carcinoma/","asOf":"2026-09-09","days":0},{"id":"sarcoma-type","kind":"term","name":"Sarcoma (tissue type)","route":"/terms/sarcoma-type/","asOf":"2026-09-09","days":0},{"id":"lymphoma-type","kind":"term","name":"Lymphoma (tissue type)","route":"/terms/lymphoma-type/","asOf":"2026-09-09","days":0},{"id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","asOf":"2026-09-09","days":0},{"id":"bone-marrow","kind":"term","name":"Bone marrow","route":"/terms/bone-marrow/","asOf":"2026-09-09","days":0},{"id":"tumour-grade","kind":"term","name":"Grade","route":"/terms/tumour-grade/","asOf":"2026-09-09","days":0},{"id":"cancer-stage","kind":"term","name":"Stage","route":"/terms/cancer-stage/","asOf":"2026-09-09","days":0},{"id":"in-situ","kind":"term","name":"In situ","route":"/terms/in-situ/","asOf":"2026-09-09","days":0},{"id":"invasive-cancer","kind":"term","name":"Invasive","route":"/terms/invasive-cancer/","asOf":"2026-09-09","days":0},{"id":"lymph-node","kind":"term","name":"Lymph node","route":"/terms/lymph-node/","asOf":"2026-09-09","days":0},{"id":"biopsy","kind":"term","name":"Biopsy","route":"/terms/biopsy/","asOf":"2026-09-09","days":0},{"id":"histology","kind":"term","name":"Histology","route":"/terms/histology/","asOf":"2026-09-09","days":0},{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/","asOf":"2026-09-09","days":0},{"id":"tumour-marker","kind":"term","name":"Tumour marker","route":"/terms/tumour-marker/","asOf":"2026-09-09","days":0},{"id":"genomic-profiling","kind":"term","name":"Genomic profiling","route":"/terms/genomic-profiling/","asOf":"2026-09-09","days":0},{"id":"immune-system","kind":"term","name":"Immune system","route":"/terms/immune-system/","asOf":"2026-09-09","days":0},{"id":"t-cell","kind":"term","name":"T cell","route":"/terms/t-cell/","asOf":"2026-09-09","days":0},{"id":"b-cell","kind":"term","name":"B cell","route":"/terms/b-cell/","asOf":"2026-09-09","days":0},{"id":"nk-cell","kind":"term","name":"NK cell","route":"/terms/nk-cell/","asOf":"2026-09-09","days":0},{"id":"macrophage","kind":"term","name":"Macrophage","route":"/terms/macrophage/","asOf":"2026-09-09","days":0},{"id":"cytokine","kind":"term","name":"Cytokine","route":"/terms/cytokine/","asOf":"2026-09-09","days":0},{"id":"inflammation","kind":"term","name":"Inflammation","route":"/terms/inflammation/","asOf":"2026-09-09","days":0},{"id":"immune-checkpoint","kind":"term","name":"Immune checkpoint","route":"/terms/immune-checkpoint/","asOf":"2026-09-09","days":0},{"id":"immunotherapy-term","kind":"term","name":"Immunotherapy","route":"/terms/immunotherapy-term/","asOf":"2026-09-09","days":0},{"id":"chemotherapy-term","kind":"term","name":"Chemotherapy","route":"/terms/chemotherapy-term/","asOf":"2026-09-09","days":0},{"id":"targeted-therapy-term","kind":"term","name":"Targeted therapy","route":"/terms/targeted-therapy-term/","asOf":"2026-09-09","days":0},{"id":"hormone-therapy","kind":"term","name":"Hormone therapy","route":"/terms/hormone-therapy/","asOf":"2026-09-09","days":0},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","asOf":"2026-09-09","days":0},{"id":"systemic-vs-local-therapy","kind":"term","name":"Systemic versus local therapy","route":"/terms/systemic-vs-local-therapy/","asOf":"2026-09-09","days":0},{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/","asOf":"2026-09-09","days":0},{"id":"palliative-treatment","kind":"term","name":"Palliative","route":"/terms/palliative-treatment/","asOf":"2026-09-09","days":0},{"id":"remission","kind":"term","name":"Remission","route":"/terms/remission/","asOf":"2026-09-09","days":0},{"id":"complete-response","kind":"term","name":"Complete response","route":"/terms/complete-response/","asOf":"2026-09-09","days":0},{"id":"partial-response","kind":"term","name":"Partial response","route":"/terms/partial-response/","asOf":"2026-09-09","days":0},{"id":"stable-disease","kind":"term","name":"Stable disease","route":"/terms/stable-disease/","asOf":"2026-09-09","days":0},{"id":"progression","kind":"term","name":"Progression","route":"/terms/progression/","asOf":"2026-09-09","days":0},{"id":"relapse-recurrence","kind":"term","name":"Recurrence and relapse","route":"/terms/relapse-recurrence/","asOf":"2026-09-09","days":0},{"id":"refractory","kind":"term","name":"Refractory","route":"/terms/refractory/","asOf":"2026-09-09","days":0},{"id":"duration-of-response","kind":"term","name":"Duration of response","route":"/terms/duration-of-response/","asOf":"2026-09-09","days":0},{"id":"prognosis","kind":"term","name":"Prognosis","route":"/terms/prognosis/","asOf":"2026-09-09","days":0},{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/","asOf":"2026-09-09","days":0},{"id":"trial-phases","kind":"term","name":"Phase 1, 2 and 3 trials","route":"/terms/trial-phases/","asOf":"2026-09-09","days":0},{"id":"randomised-trial","kind":"term","name":"Randomised trial","route":"/terms/randomised-trial/","asOf":"2026-09-09","days":0},{"id":"placebo","kind":"term","name":"Placebo","route":"/terms/placebo/","asOf":"2026-09-09","days":0},{"id":"blinding","kind":"term","name":"Blinded trial","route":"/terms/blinding/","asOf":"2026-09-09","days":0},{"id":"endpoint","kind":"term","name":"Endpoint","route":"/terms/endpoint/","asOf":"2026-09-09","days":0},{"id":"surrogate-endpoint","kind":"term","name":"Surrogate endpoint","route":"/terms/surrogate-endpoint/","asOf":"2026-09-09","days":0},{"id":"hazard-ratio-basics","kind":"term","name":"Reading a hazard ratio","route":"/terms/hazard-ratio-basics/","asOf":"2026-09-09","days":0},{"id":"median-survival","kind":"term","name":"Median survival","route":"/terms/median-survival/","asOf":"2026-09-09","days":0},{"id":"confidence-interval","kind":"term","name":"Confidence interval","route":"/terms/confidence-interval/","asOf":"2026-09-09","days":0},{"id":"p-value","kind":"term","name":"P-value","route":"/terms/p-value/","asOf":"2026-09-09","days":0},{"id":"dose","kind":"term","name":"Dose","route":"/terms/dose/","asOf":"2026-09-09","days":0},{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/","asOf":"2026-09-09","days":0},{"id":"toxicity-grade","kind":"term","name":"Toxicity grade","route":"/terms/toxicity-grade/","asOf":"2026-09-09","days":0},{"id":"side-effect-vs-adverse-event","kind":"term","name":"Side effect versus adverse event","route":"/terms/side-effect-vs-adverse-event/","asOf":"2026-09-09","days":0},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/","asOf":"2026-09-09","days":0},{"id":"prodrug","kind":"term","name":"Prodrug","route":"/terms/prodrug/","asOf":"2026-09-09","days":0},{"id":"off-label","kind":"term","name":"Off-label","route":"/terms/off-label/","asOf":"2026-09-09","days":0},{"id":"orphan-drug","kind":"term","name":"Orphan drug","route":"/terms/orphan-drug/","asOf":"2026-09-09","days":0},{"id":"incidence-vs-prevalence","kind":"term","name":"Incidence versus prevalence","route":"/terms/incidence-vs-prevalence/","asOf":"2026-09-09","days":0},{"id":"mortality","kind":"term","name":"Mortality","route":"/terms/mortality/","asOf":"2026-09-09","days":0},{"id":"risk-factor","kind":"term","name":"Risk factor","route":"/terms/risk-factor/","asOf":"2026-09-09","days":0},{"id":"screening","kind":"term","name":"Screening","route":"/terms/screening/","asOf":"2026-09-09","days":0},{"id":"early-detection-term","kind":"term","name":"Early detection","route":"/terms/early-detection-term/","asOf":"2026-09-09","days":0},{"id":"in-vitro-in-vivo","kind":"term","name":"In vitro and in vivo","route":"/terms/in-vitro-in-vivo/","asOf":"2026-09-09","days":0},{"id":"preclinical","kind":"term","name":"Preclinical","route":"/terms/preclinical/","asOf":"2026-09-09","days":0},{"id":"model-organism","kind":"term","name":"Model organism","route":"/terms/model-organism/","asOf":"2026-09-09","days":0},{"id":"cell-line","kind":"term","name":"Cell line","route":"/terms/cell-line/","asOf":"2026-09-09","days":0},{"id":"organoid","kind":"term","name":"Organoid","route":"/terms/organoid/","asOf":"2026-09-09","days":0},{"id":"oneal-uab","kind":"institution","name":"O'Neal Comprehensive Cancer Center at UAB","route":"/institutions/oneal-uab/","asOf":"2026-09-09","days":0},{"id":"arizona-cancer-center","kind":"institution","name":"University of Arizona Cancer Center","route":"/institutions/arizona-cancer-center/","asOf":"2026-09-09","days":0},{"id":"uci-chao","kind":"institution","name":"Chao Family Comprehensive Cancer Center, UC Irvine","route":"/institutions/uci-chao/","asOf":"2026-09-09","days":0},{"id":"uc-davis-cancer","kind":"institution","name":"UC Davis Comprehensive Cancer Center","route":"/institutions/uc-davis-cancer/","asOf":"2026-09-09","days":0},{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/","asOf":"2026-09-09","days":0},{"id":"usc-norris","kind":"institution","name":"USC Norris Comprehensive Cancer Center","route":"/institutions/usc-norris/","asOf":"2026-09-09","days":0},{"id":"colorado-cancer-center","kind":"institution","name":"University of Colorado Cancer Center","route":"/institutions/colorado-cancer-center/","asOf":"2026-09-09","days":0},{"id":"georgetown-lombardi","kind":"institution","name":"Georgetown Lombardi Comprehensive Cancer Center","route":"/institutions/georgetown-lombardi/","asOf":"2026-09-09","days":0},{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/","asOf":"2026-09-09","days":0},{"id":"northwestern-lurie","kind":"institution","name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","route":"/institutions/northwestern-lurie/","asOf":"2026-09-09","days":0},{"id":"uchicago-cancer","kind":"institution","name":"University of Chicago Medicine Comprehensive Cancer Center","route":"/institutions/uchicago-cancer/","asOf":"2026-09-09","days":0},{"id":"iu-simon","kind":"institution","name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","route":"/institutions/iu-simon/","asOf":"2026-09-09","days":0},{"id":"iowa-holden","kind":"institution","name":"Holden Comprehensive Cancer Center, University of Iowa","route":"/institutions/iowa-holden/","asOf":"2026-09-09","days":0},{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","route":"/institutions/ku-cancer-center/","asOf":"2026-09-09","days":0},{"id":"kentucky-markey","kind":"institution","name":"Markey Cancer Center, University of Kentucky","route":"/institutions/kentucky-markey/","asOf":"2026-09-09","days":0},{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","route":"/institutions/maryland-greenebaum/","asOf":"2026-09-09","days":0},{"id":"karmanos","kind":"institution","name":"Barbara Ann Karmanos Cancer Institute","route":"/institutions/karmanos/","asOf":"2026-09-09","days":0},{"id":"minnesota-masonic","kind":"institution","name":"Masonic Cancer Center, University of Minnesota","route":"/institutions/minnesota-masonic/","asOf":"2026-09-09","days":0},{"id":"dartmouth-cancer-center","kind":"institution","name":"Dartmouth Cancer Center","route":"/institutions/dartmouth-cancer-center/","asOf":"2026-09-09","days":0},{"id":"rutgers-cinj","kind":"institution","name":"Rutgers Cancer Institute of New Jersey","route":"/institutions/rutgers-cinj/","asOf":"2026-09-09","days":0},{"id":"unm-cancer-center","kind":"institution","name":"University of New Mexico Comprehensive Cancer Center","route":"/institutions/unm-cancer-center/","asOf":"2026-09-09","days":0},{"id":"montefiore-einstein","kind":"institution","name":"Montefiore Einstein Comprehensive Cancer Center","route":"/institutions/montefiore-einstein/","asOf":"2026-09-09","days":0},{"id":"columbia-hicc","kind":"institution","name":"Herbert Irving Comprehensive Cancer Center, Columbia University","route":"/institutions/columbia-hicc/","asOf":"2026-09-09","days":0},{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/","asOf":"2026-09-09","days":0},{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/","asOf":"2026-09-09","days":0},{"id":"unc-lineberger","kind":"institution","name":"UNC Lineberger Comprehensive Cancer Center","route":"/institutions/unc-lineberger/","asOf":"2026-09-09","days":0},{"id":"wake-forest-cancer","kind":"institution","name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","route":"/institutions/wake-forest-cancer/","asOf":"2026-09-09","days":0},{"id":"case-ccc","kind":"institution","name":"Case Comprehensive Cancer Center","route":"/institutions/case-ccc/","asOf":"2026-09-09","days":0},{"id":"osu-james","kind":"institution","name":"The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute","route":"/institutions/osu-james/","asOf":"2026-09-09","days":0},{"id":"ohsu-knight","kind":"institution","name":"OHSU Knight Cancer Institute","route":"/institutions/ohsu-knight/","asOf":"2026-09-09","days":0},{"id":"fox-chase","kind":"institution","name":"Fox Chase Cancer Center","route":"/institutions/fox-chase/","asOf":"2026-09-09","days":0},{"id":"jefferson-kimmel","kind":"institution","name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health","route":"/institutions/jefferson-kimmel/","asOf":"2026-09-09","days":0},{"id":"upmc-hillman","kind":"institution","name":"UPMC Hillman Cancer Center","route":"/institutions/upmc-hillman/","asOf":"2026-09-09","days":0},{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","route":"/institutions/vanderbilt-ingram/","asOf":"2026-09-09","days":0},{"id":"baylor-duncan","kind":"institution","name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","route":"/institutions/baylor-duncan/","asOf":"2026-09-09","days":0},{"id":"utsw-simmons","kind":"institution","name":"Harold C. Simmons Comprehensive Cancer Center, UT Southwestern","route":"/institutions/utsw-simmons/","asOf":"2026-09-09","days":0},{"id":"huntsman","kind":"institution","name":"Huntsman Cancer Institute, University of Utah","route":"/institutions/huntsman/","asOf":"2026-09-09","days":0},{"id":"vcu-massey","kind":"institution","name":"VCU Massey Comprehensive Cancer Center","route":"/institutions/vcu-massey/","asOf":"2026-09-09","days":0},{"id":"uva-cancer-center","kind":"institution","name":"UVA Comprehensive Cancer Center","route":"/institutions/uva-cancer-center/","asOf":"2026-09-09","days":0},{"id":"uw-carbone","kind":"institution","name":"University of Wisconsin Carbone Cancer Center","route":"/institutions/uw-carbone/","asOf":"2026-09-09","days":0},{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/","asOf":"2026-09-09","days":0},{"id":"sylvester-miami","kind":"institution","name":"Sylvester Comprehensive Cancer Center, University of Miami","route":"/institutions/sylvester-miami/","asOf":"2026-09-09","days":0},{"id":"uf-health-cancer-center","kind":"institution","name":"University of Florida Health Cancer Center","route":"/institutions/uf-health-cancer-center/","asOf":"2026-09-09","days":0},{"id":"hawaii-cancer-center","kind":"institution","name":"University of Hawai'i Cancer Center","route":"/institutions/hawaii-cancer-center/","asOf":"2026-09-09","days":0},{"id":"nebraska-buffett","kind":"institution","name":"Fred & Pamela Buffett Cancer Center","route":"/institutions/nebraska-buffett/","asOf":"2026-09-09","days":0},{"id":"wilmot","kind":"institution","name":"Wilmot Cancer Institute, University of Rochester","route":"/institutions/wilmot/","asOf":"2026-09-09","days":0},{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/","asOf":"2026-09-09","days":0},{"id":"musc-hollings","kind":"institution","name":"MUSC Hollings Cancer Center","route":"/institutions/musc-hollings/","asOf":"2026-09-09","days":0},{"id":"mays-cancer-center","kind":"institution","name":"Mays Cancer Center at UT Health San Antonio","route":"/institutions/mays-cancer-center/","asOf":"2026-09-09","days":0},{"id":"salk-institute","kind":"institution","name":"Salk Institute Cancer Center","route":"/institutions/salk-institute/","asOf":"2026-09-09","days":0},{"id":"sanford-burnham-prebys","kind":"institution","name":"Sanford Burnham Prebys Medical Discovery Institute","route":"/institutions/sanford-burnham-prebys/","asOf":"2026-09-09","days":0},{"id":"cancer-center-at-illinois","kind":"institution","name":"Cancer Center at Illinois","route":"/institutions/cancer-center-at-illinois/","asOf":"2026-09-09","days":0},{"id":"purdue-cancer-research","kind":"institution","name":"Purdue Institute for Cancer Research","route":"/institutions/purdue-cancer-research/","asOf":"2026-09-09","days":0},{"id":"jackson-laboratory","kind":"institution","name":"The Jackson Laboratory Cancer Center","route":"/institutions/jackson-laboratory/","asOf":"2026-09-09","days":0},{"id":"mit-koch","kind":"institution","name":"David H. Koch Institute for Integrative Cancer Research at MIT","route":"/institutions/mit-koch/","asOf":"2026-09-09","days":0},{"id":"wistar","kind":"institution","name":"The Wistar Institute","route":"/institutions/wistar/","asOf":"2026-09-09","days":0},{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","route":"/institutions/nci-ccr/","asOf":"2026-09-09","days":0},{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","route":"/institutions/frederick-national-lab/","asOf":"2026-09-09","days":0},{"id":"mayo-clinic-florida","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center – Florida","route":"/institutions/mayo-clinic-florida/","asOf":"2026-09-09","days":0},{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center – Arizona","route":"/institutions/mayo-clinic-arizona/","asOf":"2026-09-09","days":0},{"id":"city-of-hope-orange-county","kind":"institution","name":"City of Hope Orange County","route":"/institutions/city-of-hope-orange-county/","asOf":"2026-09-09","days":0},{"id":"cedars-sinai-cancer","kind":"institution","name":"Cedars-Sinai Cancer","route":"/institutions/cedars-sinai-cancer/","asOf":"2026-09-09","days":0},{"id":"northwell-cancer-institute","kind":"institution","name":"Northwell Health Cancer Institute","route":"/institutions/northwell-cancer-institute/","asOf":"2026-09-09","days":0},{"id":"intermountain-cancer","kind":"institution","name":"Intermountain Health Cancer Center","route":"/institutions/intermountain-cancer/","asOf":"2026-09-09","days":0},{"id":"kaiser-permanente-research","kind":"institution","name":"Kaiser Permanente Division of Research","route":"/institutions/kaiser-permanente-research/","asOf":"2026-09-09","days":0},{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","route":"/institutions/chop/","asOf":"2026-09-09","days":0},{"id":"texas-childrens","kind":"institution","name":"Texas Children's Cancer and Hematology Center","route":"/institutions/texas-childrens/","asOf":"2026-09-09","days":0},{"id":"nationwide-childrens","kind":"institution","name":"Nationwide Children's Hospital","route":"/institutions/nationwide-childrens/","asOf":"2026-09-09","days":0},{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/","asOf":"2026-09-09","days":0},{"id":"cancer-care-alberta","kind":"institution","name":"Cancer Care Alberta (Alberta Health Services)","route":"/institutions/cancer-care-alberta/","asOf":"2026-09-09","days":0},{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","route":"/institutions/chum/","asOf":"2026-09-09","days":0},{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","route":"/institutions/mcgill-goodman/","asOf":"2026-09-09","days":0},{"id":"ottawa-hospital","kind":"institution","name":"The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute","route":"/institutions/ottawa-hospital/","asOf":"2026-09-09","days":0},{"id":"sunnybrook-odette","kind":"institution","name":"Sunnybrook Odette Cancer Centre","route":"/institutions/sunnybrook-odette/","asOf":"2026-09-09","days":0},{"id":"juravinski","kind":"institution","name":"Juravinski Cancer Centre / Escarpment Cancer Research Institute","route":"/institutions/juravinski/","asOf":"2026-09-09","days":0},{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/","asOf":"2026-09-09","days":0},{"id":"sickkids","kind":"institution","name":"The Hospital for Sick Children (SickKids)","route":"/institutions/sickkids/","asOf":"2026-09-09","days":0},{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","route":"/institutions/pumch/","asOf":"2026-09-09","days":0},{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/","asOf":"2026-09-09","days":0},{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/","asOf":"2026-09-09","days":0},{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","route":"/institutions/shanghai-pulmonary-hospital/","asOf":"2026-09-09","days":0},{"id":"zhongshan-hospital-fudan","kind":"institution","name":"Zhongshan Hospital, Fudan University","route":"/institutions/zhongshan-hospital-fudan/","asOf":"2026-09-09","days":0},{"id":"ruijin-hospital","kind":"institution","name":"Ruijin Hospital, Shanghai Jiao Tong University","route":"/institutions/ruijin-hospital/","asOf":"2026-09-09","days":0},{"id":"sysu-first-affiliated-hospital","kind":"institution","name":"First Affiliated Hospital of Sun Yat-sen University","route":"/institutions/sysu-first-affiliated-hospital/","asOf":"2026-09-09","days":0},{"id":"tmucih","kind":"institution","name":"Tianjin Medical University Cancer Institute and Hospital","route":"/institutions/tmucih/","asOf":"2026-09-09","days":0},{"id":"zhejiang-cancer-hospital","kind":"institution","name":"Zhejiang Cancer Hospital","route":"/institutions/zhejiang-cancer-hospital/","asOf":"2026-09-09","days":0},{"id":"hunan-cancer-hospital","kind":"institution","name":"Hunan Cancer Hospital","route":"/institutions/hunan-cancer-hospital/","asOf":"2026-09-09","days":0},{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","route":"/institutions/pla-general-hospital/","asOf":"2026-09-09","days":0},{"id":"henan-cancer-hospital","kind":"institution","name":"Henan Cancer Hospital","route":"/institutions/henan-cancer-hospital/","asOf":"2026-09-09","days":0},{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/","asOf":"2026-09-09","days":0},{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/","asOf":"2026-09-09","days":0},{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","route":"/institutions/tongji-hospital-wuhan/","asOf":"2026-09-09","days":0},{"id":"union-hospital-wuhan","kind":"institution","name":"Union Hospital, Tongji Medical College","route":"/institutions/union-hospital-wuhan/","asOf":"2026-09-09","days":0},{"id":"queen-mary-hospital-hku","kind":"institution","name":"Queen Mary Hospital / University of Hong Kong","route":"/institutions/queen-mary-hospital-hku/","asOf":"2026-09-09","days":0},{"id":"prince-of-wales-hospital-cuhk","kind":"institution","name":"Prince of Wales Hospital / Chinese University of Hong Kong","route":"/institutions/prince-of-wales-hospital-cuhk/","asOf":"2026-09-09","days":0},{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/","asOf":"2026-09-09","days":0},{"id":"chang-gung-memorial-hospital","kind":"institution","name":"Chang Gung Memorial Hospital","route":"/institutions/chang-gung-memorial-hospital/","asOf":"2026-09-09","days":0},{"id":"taipei-veterans-general-hospital","kind":"institution","name":"Taipei Veterans General Hospital","route":"/institutions/taipei-veterans-general-hospital/","asOf":"2026-09-09","days":0},{"id":"koo-foundation-sun-yat-sen-cancer-center","kind":"institution","name":"Koo Foundation Sun Yat-Sen Cancer Center","route":"/institutions/koo-foundation-sun-yat-sen-cancer-center/","asOf":"2026-09-09","days":0},{"id":"kyoto-university-hospital","kind":"institution","name":"Kyoto University Hospital","route":"/institutions/kyoto-university-hospital/","asOf":"2026-09-09","days":0},{"id":"osaka-international-cancer-institute","kind":"institution","name":"Osaka International Cancer Institute","route":"/institutions/osaka-international-cancer-institute/","asOf":"2026-09-09","days":0},{"id":"aichi-cancer-center","kind":"institution","name":"Aichi Cancer Center","route":"/institutions/aichi-cancer-center/","asOf":"2026-09-09","days":0},{"id":"shizuoka-cancer-center","kind":"institution","name":"Shizuoka Cancer Center","route":"/institutions/shizuoka-cancer-center/","asOf":"2026-09-09","days":0},{"id":"kyushu-university-hospital","kind":"institution","name":"Kyushu University Hospital","route":"/institutions/kyushu-university-hospital/","asOf":"2026-09-09","days":0},{"id":"hokkaido-university-hospital","kind":"institution","name":"Hokkaido University Hospital","route":"/institutions/hokkaido-university-hospital/","asOf":"2026-09-09","days":0},{"id":"tohoku-university-hospital","kind":"institution","name":"Tohoku University Hospital","route":"/institutions/tohoku-university-hospital/","asOf":"2026-09-09","days":0},{"id":"keio-university-hospital","kind":"institution","name":"Keio University Hospital","route":"/institutions/keio-university-hospital/","asOf":"2026-09-09","days":0},{"id":"gunma-heavy-ion-medical-center","kind":"institution","name":"Gunma University Heavy Ion Medical Center","route":"/institutions/gunma-heavy-ion-medical-center/","asOf":"2026-09-09","days":0},{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/","asOf":"2026-09-09","days":0},{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","asOf":"2026-09-09","days":0},{"id":"ncc-korea","kind":"institution","name":"National Cancer Center Korea","route":"/institutions/ncc-korea/","asOf":"2026-09-09","days":0},{"id":"seoul-st-marys-hospital","kind":"institution","name":"Seoul St. Mary's Hospital","route":"/institutions/seoul-st-marys-hospital/","asOf":"2026-09-09","days":0},{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/","asOf":"2026-09-09","days":0},{"id":"nuh-ncis","kind":"institution","name":"National University Hospital / National University Cancer Institute, Singapore","route":"/institutions/nuh-ncis/","asOf":"2026-09-09","days":0},{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/","asOf":"2026-09-09","days":0},{"id":"rgci","kind":"institution","name":"Rajiv Gandhi Cancer Institute and Research Centre","route":"/institutions/rgci/","asOf":"2026-09-09","days":0},{"id":"kidwai-memorial-institute-of-oncology","kind":"institution","name":"Kidwai Memorial Institute of Oncology","route":"/institutions/kidwai-memorial-institute-of-oncology/","asOf":"2026-09-09","days":0},{"id":"cancer-institute-adyar","kind":"institution","name":"Cancer Institute (WIA), Adyar","route":"/institutions/cancer-institute-adyar/","asOf":"2026-09-09","days":0},{"id":"tata-medical-center-kolkata","kind":"institution","name":"Tata Medical Center, Kolkata","route":"/institutions/tata-medical-center-kolkata/","asOf":"2026-09-09","days":0},{"id":"hcg","kind":"institution","name":"HealthCare Global Enterprises","route":"/institutions/hcg/","asOf":"2026-09-09","days":0},{"id":"apollo-hospitals","kind":"institution","name":"Apollo Hospitals (Apollo Cancer Centres)","route":"/institutions/apollo-hospitals/","asOf":"2026-09-09","days":0},{"id":"cmc-vellore","kind":"institution","name":"Christian Medical College, Vellore","route":"/institutions/cmc-vellore/","asOf":"2026-09-09","days":0},{"id":"pgimer-chandigarh","kind":"institution","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","route":"/institutions/pgimer-chandigarh/","asOf":"2026-09-09","days":0},{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/","asOf":"2026-09-09","days":0},{"id":"chris-obrien-lifehouse","kind":"institution","name":"Chris O'Brien Lifehouse","route":"/institutions/chris-obrien-lifehouse/","asOf":"2026-09-09","days":0},{"id":"onj-cancer-centre","kind":"institution","name":"Olivia Newton-John Cancer Wellness and Research Centre","route":"/institutions/onj-cancer-centre/","asOf":"2026-09-09","days":0},{"id":"garvan-institute","kind":"institution","name":"Garvan Institute of Medical Research / Kinghorn Cancer Centre","route":"/institutions/garvan-institute/","asOf":"2026-09-09","days":0},{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","route":"/institutions/wehi/","asOf":"2026-09-09","days":0},{"id":"qimr-berghofer","kind":"institution","name":"QIMR Berghofer Medical Research Institute","route":"/institutions/qimr-berghofer/","asOf":"2026-09-09","days":0},{"id":"sydney-childrens-hospitals-network","kind":"institution","name":"Sydney Children's Hospitals Network / Children's Cancer Institute","route":"/institutions/sydney-childrens-hospitals-network/","asOf":"2026-09-09","days":0},{"id":"royal-adelaide-hospital","kind":"institution","name":"Royal Adelaide Hospital","route":"/institutions/royal-adelaide-hospital/","asOf":"2026-09-09","days":0},{"id":"auckland-city-hospital","kind":"institution","name":"Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service","route":"/institutions/auckland-city-hospital/","asOf":"2026-09-09","days":0},{"id":"siriraj-hospital","kind":"institution","name":"Siriraj Hospital, Mahidol University","route":"/institutions/siriraj-hospital/","asOf":"2026-09-09","days":0},{"id":"chulabhorn-hospital","kind":"institution","name":"Chulabhorn Hospital / Chulabhorn Royal Academy","route":"/institutions/chulabhorn-hospital/","asOf":"2026-09-09","days":0},{"id":"ramathibodi-hospital","kind":"institution","name":"Ramathibodi Hospital, Mahidol University","route":"/institutions/ramathibodi-hospital/","asOf":"2026-09-09","days":0},{"id":"dharmais-cancer-hospital","kind":"institution","name":"Dharmais National Cancer Center","route":"/institutions/dharmais-cancer-hospital/","asOf":"2026-09-09","days":0},{"id":"ummc-kuala-lumpur","kind":"institution","name":"University of Malaya Medical Centre","route":"/institutions/ummc-kuala-lumpur/","asOf":"2026-09-09","days":0},{"id":"philippine-general-hospital","kind":"institution","name":"Philippine General Hospital","route":"/institutions/philippine-general-hospital/","asOf":"2026-09-09","days":0},{"id":"k-hospital-hanoi","kind":"institution","name":"Vietnam National Cancer Hospital (K Hospital)","route":"/institutions/k-hospital-hanoi/","asOf":"2026-09-09","days":0},{"id":"hcmc-oncology-hospital","kind":"institution","name":"Ho Chi Minh City Oncology Hospital","route":"/institutions/hcmc-oncology-hospital/","asOf":"2026-09-09","days":0},{"id":"khcc","kind":"institution","name":"King Hussein Cancer Center","route":"/institutions/khcc/","asOf":"2026-09-09","days":0},{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","route":"/institutions/kfshrc/","asOf":"2026-09-09","days":0},{"id":"tawam-hospital","kind":"institution","name":"Tawam Hospital","route":"/institutions/tawam-hospital/","asOf":"2026-09-09","days":0},{"id":"cleveland-clinic-abu-dhabi","kind":"institution","name":"Cleveland Clinic Abu Dhabi","route":"/institutions/cleveland-clinic-abu-dhabi/","asOf":"2026-09-09","days":0},{"id":"hamad-medical-corporation","kind":"institution","name":"Hamad Medical Corporation / National Center for Cancer Care and Research","route":"/institutions/hamad-medical-corporation/","asOf":"2026-09-09","days":0},{"id":"tehran-cancer-institute","kind":"institution","name":"Cancer Institute of Iran, Imam Khomeini Hospital Complex","route":"/institutions/tehran-cancer-institute/","asOf":"2026-09-09","days":0},{"id":"inca-brazil","kind":"institution","name":"Instituto Nacional de Câncer (INCA)","route":"/institutions/inca-brazil/","asOf":"2026-09-09","days":0},{"id":"ac-camargo","kind":"institution","name":"A.C. Camargo Cancer Center","route":"/institutions/ac-camargo/","asOf":"2026-09-09","days":0},{"id":"hospital-de-amor-barretos","kind":"institution","name":"Hospital de Amor (Barretos Cancer Hospital)","route":"/institutions/hospital-de-amor-barretos/","asOf":"2026-09-09","days":0},{"id":"hcpa-porto-alegre","kind":"institution","name":"Hospital de Clínicas de Porto Alegre","route":"/institutions/hcpa-porto-alegre/","asOf":"2026-09-09","days":0},{"id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","route":"/institutions/incan-mexico/","asOf":"2026-09-09","days":0},{"id":"inc-colombia","kind":"institution","name":"Instituto Nacional de Cancerología (Colombia)","route":"/institutions/inc-colombia/","asOf":"2026-09-09","days":0},{"id":"inen-peru","kind":"institution","name":"Instituto Nacional de Enfermedades Neoplásicas","route":"/institutions/inen-peru/","asOf":"2026-09-09","days":0},{"id":"instituto-alexander-fleming","kind":"institution","name":"Instituto Alexander Fleming","route":"/institutions/instituto-alexander-fleming/","asOf":"2026-09-09","days":0},{"id":"falp-chile","kind":"institution","name":"Fundación Arturo López Pérez","route":"/institutions/falp-chile/","asOf":"2026-09-09","days":0},{"id":"groote-schuur-uct","kind":"institution","name":"Groote Schuur Hospital / University of Cape Town","route":"/institutions/groote-schuur-uct/","asOf":"2026-09-09","days":0},{"id":"wits-charlotte-maxeke","kind":"institution","name":"Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand","route":"/institutions/wits-charlotte-maxeke/","asOf":"2026-09-09","days":0},{"id":"kenyatta-national-hospital","kind":"institution","name":"Kenyatta National Hospital","route":"/institutions/kenyatta-national-hospital/","asOf":"2026-09-09","days":0},{"id":"uganda-cancer-institute","kind":"institution","name":"Uganda Cancer Institute","route":"/institutions/uganda-cancer-institute/","asOf":"2026-09-09","days":0},{"id":"ocean-road-cancer-institute","kind":"institution","name":"Ocean Road Cancer Institute","route":"/institutions/ocean-road-cancer-institute/","asOf":"2026-09-09","days":0},{"id":"korle-bu-teaching-hospital","kind":"institution","name":"Korle Bu Teaching Hospital","route":"/institutions/korle-bu-teaching-hospital/","asOf":"2026-09-09","days":0},{"id":"luth-lagos","kind":"institution","name":"Lagos University Teaching Hospital","route":"/institutions/luth-lagos/","asOf":"2026-09-09","days":0},{"id":"nci-cairo","kind":"institution","name":"National Cancer Institute, Cairo University","route":"/institutions/nci-cairo/","asOf":"2026-09-09","days":0},{"id":"cche-57357","kind":"institution","name":"Children's Cancer Hospital Egypt 57357","route":"/institutions/cche-57357/","asOf":"2026-09-09","days":0},{"id":"institut-national-oncologie-rabat","kind":"institution","name":"Institut National d'Oncologie, Rabat","route":"/institutions/institut-national-oncologie-rabat/","asOf":"2026-09-09","days":0},{"id":"institut-salah-azaiez","kind":"institution","name":"Institut Salah Azaïez","route":"/institutions/institut-salah-azaiez/","asOf":"2026-09-09","days":0},{"id":"butaro-cancer-center","kind":"institution","name":"Butaro Cancer Center of Excellence","route":"/institutions/butaro-cancer-center/","asOf":"2026-09-09","days":0},{"id":"abcsg","kind":"institution","name":"Austrian Breast & Colorectal Cancer Study Group","route":"/institutions/abcsg/","asOf":"2026-09-09","days":0},{"id":"wjog","kind":"institution","name":"West Japan Oncology Group","route":"/institutions/wjog/","asOf":"2026-09-09","days":0},{"id":"kcsg","kind":"institution","name":"Korean Cancer Study Group","route":"/institutions/kcsg/","asOf":"2026-09-09","days":0},{"id":"trog","kind":"institution","name":"TROG Cancer Research","route":"/institutions/trog/","asOf":"2026-09-09","days":0},{"id":"anzup","kind":"institution","name":"ANZUP Cancer Trials Group","route":"/institutions/anzup/","asOf":"2026-09-09","days":0},{"id":"agitg","kind":"institution","name":"Australasian Gastro-Intestinal Trials Group","route":"/institutions/agitg/","asOf":"2026-09-09","days":0},{"id":"breast-cancer-trials","kind":"institution","name":"Breast Cancer Trials","route":"/institutions/breast-cancer-trials/","asOf":"2026-09-09","days":0},{"id":"geicam","kind":"institution","name":"GEICAM Spanish Breast Cancer Group","route":"/institutions/geicam/","asOf":"2026-09-09","days":0},{"id":"solti","kind":"institution","name":"SOLTI Cancer Research Group","route":"/institutions/solti/","asOf":"2026-09-09","days":0},{"id":"hovon","kind":"institution","name":"HOVON","route":"/institutions/hovon/","asOf":"2026-09-09","days":0},{"id":"gimema","kind":"institution","name":"GIMEMA","route":"/institutions/gimema/","asOf":"2026-09-09","days":0},{"id":"ielsg","kind":"institution","name":"International Extranodal Lymphoma Study Group","route":"/institutions/ielsg/","asOf":"2026-09-09","days":0},{"id":"lysa","kind":"institution","name":"LYSA – The Lymphoma Study Association","route":"/institutions/lysa/","asOf":"2026-09-09","days":0},{"id":"german-lymphoma-alliance","kind":"institution","name":"German Lymphoma Alliance","route":"/institutions/german-lymphoma-alliance/","asOf":"2026-09-09","days":0},{"id":"ghsg","kind":"institution","name":"German Hodgkin Study Group","route":"/institutions/ghsg/","asOf":"2026-09-09","days":0},{"id":"nordic-lymphoma-group","kind":"institution","name":"Nordic Lymphoma Group","route":"/institutions/nordic-lymphoma-group/","asOf":"2026-09-09","days":0},{"id":"cclg","kind":"institution","name":"Children's Cancer and Leukaemia Group","route":"/institutions/cclg/","asOf":"2026-09-09","days":0},{"id":"siop-europe","kind":"institution","name":"SIOP Europe – European Society for Paediatric Oncology","route":"/institutions/siop-europe/","asOf":"2026-09-09","days":0},{"id":"etop-ibcsg","kind":"institution","name":"ETOP IBCSG Partners Foundation","route":"/institutions/etop-ibcsg/","asOf":"2026-09-09","days":0},{"id":"ifct","kind":"institution","name":"Intergroupe Francophone de Cancérologie Thoracique","route":"/institutions/ifct/","asOf":"2026-09-09","days":0},{"id":"arcagy-gineco","kind":"institution","name":"ARCAGY-GINECO","route":"/institutions/arcagy-gineco/","asOf":"2026-09-09","days":0},{"id":"gog-foundation","kind":"institution","name":"GOG Foundation","route":"/institutions/gog-foundation/","asOf":"2026-09-09","days":0},{"id":"nsabp-foundation","kind":"institution","name":"NSABP Foundation","route":"/institutions/nsabp-foundation/","asOf":"2026-09-09","days":0},{"id":"fondation-arc","kind":"institution","name":"Fondation ARC pour la recherche sur le cancer","route":"/institutions/fondation-arc/","asOf":"2026-09-09","days":0},{"id":"ligue-contre-le-cancer","kind":"institution","name":"Ligue nationale contre le cancer","route":"/institutions/ligue-contre-le-cancer/","asOf":"2026-09-09","days":0},{"id":"deutsche-krebshilfe","kind":"institution","name":"Deutsche Krebshilfe","route":"/institutions/deutsche-krebshilfe/","asOf":"2026-09-09","days":0},{"id":"kwf","kind":"institution","name":"KWF Dutch Cancer Society","route":"/institutions/kwf/","asOf":"2026-09-09","days":0},{"id":"airc","kind":"institution","name":"Fondazione AIRC per la ricerca sul cancro","route":"/institutions/airc/","asOf":"2026-09-09","days":0},{"id":"cancer-council-australia","kind":"institution","name":"Cancer Council Australia","route":"/institutions/cancer-council-australia/","asOf":"2026-09-09","days":0},{"id":"canadian-cancer-society","kind":"institution","name":"Canadian Cancer Society","route":"/institutions/canadian-cancer-society/","asOf":"2026-09-09","days":0},{"id":"irish-cancer-society","kind":"institution","name":"Irish Cancer Society","route":"/institutions/irish-cancer-society/","asOf":"2026-09-09","days":0},{"id":"worldwide-cancer-research","kind":"institution","name":"Worldwide Cancer Research","route":"/institutions/worldwide-cancer-research/","asOf":"2026-09-09","days":0},{"id":"wellcome","kind":"institution","name":"Wellcome","route":"/institutions/wellcome/","asOf":"2026-09-09","days":0},{"id":"hhmi","kind":"institution","name":"Howard Hughes Medical Institute","route":"/institutions/hhmi/","asOf":"2026-09-09","days":0},{"id":"damon-runyon","kind":"institution","name":"Damon Runyon Cancer Research Foundation","route":"/institutions/damon-runyon/","asOf":"2026-09-09","days":0},{"id":"v-foundation","kind":"institution","name":"The V Foundation for Cancer Research","route":"/institutions/v-foundation/","asOf":"2026-09-09","days":0},{"id":"stand-up-to-cancer","kind":"institution","name":"Stand Up To Cancer","route":"/institutions/stand-up-to-cancer/","asOf":"2026-09-09","days":0},{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/","asOf":"2026-09-09","days":0},{"id":"lustgarten-foundation","kind":"institution","name":"Lustgarten Foundation","route":"/institutions/lustgarten-foundation/","asOf":"2026-09-09","days":0},{"id":"cprit","kind":"institution","name":"Cancer Prevention and Research Institute of Texas","route":"/institutions/cprit/","asOf":"2026-09-09","days":0},{"id":"mark-foundation","kind":"institution","name":"The Mark Foundation for Cancer Research","route":"/institutions/mark-foundation/","asOf":"2026-09-09","days":0},{"id":"emerson-collective","kind":"institution","name":"Emerson Collective","route":"/institutions/emerson-collective/","asOf":"2026-09-09","days":0},{"id":"cz-biohub","kind":"institution","name":"Chan Zuckerberg Biohub","route":"/institutions/cz-biohub/","asOf":"2026-09-09","days":0},{"id":"gates-foundation","kind":"institution","name":"Gates Foundation","route":"/institutions/gates-foundation/","asOf":"2026-09-09","days":0},{"id":"cancer-grand-challenges","kind":"institution","name":"Cancer Grand Challenges","route":"/institutions/cancer-grand-challenges/","asOf":"2026-09-09","days":0},{"id":"arpa-h","kind":"institution","name":"Advanced Research Projects Agency for Health","route":"/institutions/arpa-h/","asOf":"2026-09-09","days":0},{"id":"movember","kind":"institution","name":"Movember","route":"/institutions/movember/","asOf":"2026-09-09","days":0},{"id":"macmillan-cancer-support","kind":"institution","name":"Macmillan Cancer Support","route":"/institutions/macmillan-cancer-support/","asOf":"2026-09-09","days":0},{"id":"marie-curie-uk","kind":"institution","name":"Marie Curie","route":"/institutions/marie-curie-uk/","asOf":"2026-09-09","days":0},{"id":"uicc","kind":"institution","name":"Union for International Cancer Control","route":"/institutions/uicc/","asOf":"2026-09-09","days":0},{"id":"who","kind":"institution","name":"World Health Organization – Cancer Programme","route":"/institutions/who/","asOf":"2026-09-09","days":0},{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency – Rays of Hope","route":"/institutions/iaea/","asOf":"2026-09-09","days":0},{"id":"fda-oce","kind":"institution","name":"FDA Oncology Center of Excellence","route":"/institutions/fda-oce/","asOf":"2026-09-09","days":0},{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","asOf":"2026-09-09","days":0},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/","asOf":"2026-09-09","days":0},{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/","asOf":"2026-09-09","days":0},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/","asOf":"2026-09-09","days":0},{"id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/","asOf":"2026-09-09","days":0},{"id":"tga","kind":"institution","name":"Therapeutic Goods Administration","route":"/institutions/tga/","asOf":"2026-09-09","days":0},{"id":"health-canada","kind":"institution","name":"Health Canada","route":"/institutions/health-canada/","asOf":"2026-09-09","days":0},{"id":"swissmedic","kind":"institution","name":"Swissmedic","route":"/institutions/swissmedic/","asOf":"2026-09-09","days":0},{"id":"has-france","kind":"institution","name":"Haute Autorité de Santé","route":"/institutions/has-france/","asOf":"2026-09-09","days":0},{"id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/","asOf":"2026-09-09","days":0},{"id":"smc","kind":"institution","name":"Scottish Medicines Consortium","route":"/institutions/smc/","asOf":"2026-09-09","days":0},{"id":"pbac","kind":"institution","name":"Pharmaceutical Benefits Advisory Committee","route":"/institutions/pbac/","asOf":"2026-09-09","days":0},{"id":"anvisa","kind":"institution","name":"Agência Nacional de Vigilância Sanitária","route":"/institutions/anvisa/","asOf":"2026-09-09","days":0},{"id":"cofepris","kind":"institution","name":"Comisión Federal para la Protección contra Riesgos Sanitarios","route":"/institutions/cofepris/","asOf":"2026-09-09","days":0},{"id":"cdsco","kind":"institution","name":"Central Drugs Standard Control Organization","route":"/institutions/cdsco/","asOf":"2026-09-09","days":0},{"id":"ash","kind":"institution","name":"American Society of Hematology","route":"/institutions/ash/","asOf":"2026-09-09","days":0},{"id":"astro","kind":"institution","name":"American Society for Radiation Oncology","route":"/institutions/astro/","asOf":"2026-09-09","days":0},{"id":"estro","kind":"institution","name":"European Society for Radiotherapy and Oncology","route":"/institutions/estro/","asOf":"2026-09-09","days":0},{"id":"snmmi","kind":"institution","name":"Society of Nuclear Medicine and Molecular Imaging","route":"/institutions/snmmi/","asOf":"2026-09-09","days":0},{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/","asOf":"2026-09-09","days":0},{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/","asOf":"2026-09-09","days":0},{"id":"sso","kind":"institution","name":"Society of Surgical Oncology","route":"/institutions/sso/","asOf":"2026-09-09","days":0},{"id":"esso","kind":"institution","name":"European Society of Surgical Oncology","route":"/institutions/esso/","asOf":"2026-09-09","days":0},{"id":"jsmo","kind":"institution","name":"Japanese Society of Medical Oncology","route":"/institutions/jsmo/","asOf":"2026-09-09","days":0},{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/","asOf":"2026-09-09","days":0},{"id":"ispor","kind":"institution","name":"ISPOR – The Professional Society for Health Economics and Outcomes Research","route":"/institutions/ispor/","asOf":"2026-09-09","days":0},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/","asOf":"2026-09-09","days":0},{"id":"sgo","kind":"institution","name":"Society of Gynecologic Oncology","route":"/institutions/sgo/","asOf":"2026-09-09","days":0},{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/","asOf":"2026-09-09","days":0},{"id":"eha","kind":"institution","name":"European Hematology Association","route":"/institutions/eha/","asOf":"2026-09-09","days":0},{"id":"isoqol","kind":"institution","name":"International Society for Quality of Life Research","route":"/institutions/isoqol/","asOf":"2026-09-09","days":0},{"id":"mascc","kind":"institution","name":"Multinational Association of Supportive Care in Cancer","route":"/institutions/mascc/","asOf":"2026-09-09","days":0},{"id":"espen","kind":"institution","name":"European Society for Clinical Nutrition and Metabolism","route":"/institutions/espen/","asOf":"2026-09-09","days":0},{"id":"cdisc","kind":"institution","name":"Clinical Data Interchange Standards Consortium","route":"/institutions/cdisc/","asOf":"2026-09-09","days":0},{"id":"hl7","kind":"institution","name":"HL7 International","route":"/institutions/hl7/","asOf":"2026-09-09","days":0},{"id":"vivli","kind":"institution","name":"Vivli","route":"/institutions/vivli/","asOf":"2026-09-09","days":0},{"id":"yoda-project","kind":"institution","name":"Yale University Open Data Access (YODA) Project","route":"/institutions/yoda-project/","asOf":"2026-09-09","days":0},{"id":"institut-bergonie","kind":"institution","name":"Institut Bergonié","route":"/institutions/institut-bergonie/","asOf":"2026-09-09","days":0},{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/","asOf":"2026-09-09","days":0},{"id":"institut-paoli-calmettes","kind":"institution","name":"Institut Paoli-Calmettes","route":"/institutions/institut-paoli-calmettes/","asOf":"2026-09-09","days":0},{"id":"iuct-oncopole","kind":"institution","name":"IUCT Oncopole – Institut Universitaire du Cancer de Toulouse","route":"/institutions/iuct-oncopole/","asOf":"2026-09-09","days":0},{"id":"centre-oscar-lambret","kind":"institution","name":"Centre Oscar Lambret","route":"/institutions/centre-oscar-lambret/","asOf":"2026-09-09","days":0},{"id":"centre-antoine-lacassagne","kind":"institution","name":"Centre Antoine Lacassagne","route":"/institutions/centre-antoine-lacassagne/","asOf":"2026-09-09","days":0},{"id":"inca","kind":"institution","name":"Institut National du Cancer","route":"/institutions/inca/","asOf":"2026-09-09","days":0},{"id":"institut-pasteur","kind":"institution","name":"Institut Pasteur","route":"/institutions/institut-pasteur/","asOf":"2026-09-09","days":0},{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","asOf":"2026-09-09","days":0},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","asOf":"2026-09-09","days":0},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden – University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","asOf":"2026-09-09","days":0},{"id":"uct-frankfurt","kind":"institution","name":"University Cancer Center Frankfurt (UCT)","route":"/institutions/uct-frankfurt/","asOf":"2026-09-09","days":0},{"id":"ccc-freiburg","kind":"institution","name":"Comprehensive Cancer Center Freiburg (CCCF)","route":"/institutions/ccc-freiburg/","asOf":"2026-09-09","days":0},{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","route":"/institutions/ccc-tuebingen/","asOf":"2026-09-09","days":0},{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","asOf":"2026-09-09","days":0},{"id":"uct-mainz","kind":"institution","name":"University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz","route":"/institutions/uct-mainz/","asOf":"2026-09-09","days":0},{"id":"uk-duesseldorf","kind":"institution","name":"University Hospital Düsseldorf / CIO Düsseldorf","route":"/institutions/uk-duesseldorf/","asOf":"2026-09-09","days":0},{"id":"mdc-berlin","kind":"institution","name":"Max Delbrück Center for Molecular Medicine","route":"/institutions/mdc-berlin/","asOf":"2026-09-09","days":0},{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/","asOf":"2026-09-09","days":0},{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/","asOf":"2026-09-09","days":0},{"id":"guys-st-thomas","kind":"institution","name":"Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre","route":"/institutions/guys-st-thomas/","asOf":"2026-09-09","days":0},{"id":"leeds-cancer-centre","kind":"institution","name":"Leeds Cancer Centre, St James's University Hospital","route":"/institutions/leeds-cancer-centre/","asOf":"2026-09-09","days":0},{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","route":"/institutions/newcastle-cancer-centre/","asOf":"2026-09-09","days":0},{"id":"beatson-glasgow","kind":"institution","name":"Beatson West of Scotland Cancer Centre / CRUK Scotland Institute","route":"/institutions/beatson-glasgow/","asOf":"2026-09-09","days":0},{"id":"edinburgh-cancer-centre","kind":"institution","name":"Edinburgh Cancer Centre / CRUK Scotland Centre","route":"/institutions/edinburgh-cancer-centre/","asOf":"2026-09-09","days":0},{"id":"velindre-cardiff","kind":"institution","name":"Velindre Cancer Centre","route":"/institutions/velindre-cardiff/","asOf":"2026-09-09","days":0},{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer – Oxford University Hospitals and University of Oxford","route":"/institutions/oxford-cancer/","asOf":"2026-09-09","days":0},{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/","asOf":"2026-09-09","days":0},{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/","asOf":"2026-09-09","days":0},{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","route":"/institutions/cruk-manchester-institute/","asOf":"2026-09-09","days":0},{"id":"great-ormond-street","kind":"institution","name":"Great Ormond Street Hospital for Children","route":"/institutions/great-ormond-street/","asOf":"2026-09-09","days":0},{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/","asOf":"2026-09-09","days":0},{"id":"embl-ebi","kind":"institution","name":"EMBL's European Bioinformatics Institute","route":"/institutions/embl-ebi/","asOf":"2026-09-09","days":0},{"id":"birmingham-cancer-centre","kind":"institution","name":"University Hospitals Birmingham / University of Birmingham Cancer Research Centre","route":"/institutions/birmingham-cancer-centre/","asOf":"2026-09-09","days":0},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/","asOf":"2026-09-09","days":0},{"id":"umc-utrecht","kind":"institution","name":"UMC Utrecht Cancer Center","route":"/institutions/umc-utrecht/","asOf":"2026-09-09","days":0},{"id":"princess-maxima","kind":"institution","name":"Princess Máxima Center for Pediatric Oncology","route":"/institutions/princess-maxima/","asOf":"2026-09-09","days":0},{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/","asOf":"2026-09-09","days":0},{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/","asOf":"2026-09-09","days":0},{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","asOf":"2026-09-09","days":0},{"id":"uz-gent","kind":"institution","name":"Ghent University Hospital / Cancer Research Institute Ghent","route":"/institutions/uz-gent/","asOf":"2026-09-09","days":0},{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/","asOf":"2026-09-09","days":0},{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/","asOf":"2026-09-09","days":0},{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/","asOf":"2026-09-09","days":0},{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","route":"/institutions/cun-navarra/","asOf":"2026-09-09","days":0},{"id":"cnio","kind":"institution","name":"Centro Nacional de Investigaciones Oncológicas (CNIO)","route":"/institutions/cnio/","asOf":"2026-09-09","days":0},{"id":"incliva-valencia","kind":"institution","name":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia","route":"/institutions/incliva-valencia/","asOf":"2026-09-09","days":0},{"id":"hospital-del-mar","kind":"institution","name":"Hospital del Mar / Hospital del Mar Research Institute","route":"/institutions/hospital-del-mar/","asOf":"2026-09-09","days":0},{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS – FPO","route":"/institutions/candiolo/","asOf":"2026-09-09","days":0},{"id":"pascale-naples","kind":"institution","name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","route":"/institutions/pascale-naples/","asOf":"2026-09-09","days":0},{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","route":"/institutions/regina-elena-rome/","asOf":"2026-09-09","days":0},{"id":"humanitas","kind":"institution","name":"IRCCS Humanitas Research Hospital","route":"/institutions/humanitas/","asOf":"2026-09-09","days":0},{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","asOf":"2026-09-09","days":0},{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna – Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/","asOf":"2026-09-09","days":0},{"id":"irst-meldola","kind":"institution","name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)","route":"/institutions/irst-meldola/","asOf":"2026-09-09","days":0},{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","route":"/institutions/san-raffaele/","asOf":"2026-09-09","days":0},{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet – Copenhagen University Hospital","route":"/institutions/rigshospitalet/","asOf":"2026-09-09","days":0},{"id":"aarhus-university-hospital","kind":"institution","name":"Aarhus University Hospital","route":"/institutions/aarhus-university-hospital/","asOf":"2026-09-09","days":0},{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital – The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","asOf":"2026-09-09","days":0},{"id":"helsinki-hus","kind":"institution","name":"HUS Comprehensive Cancer Center, Helsinki University Hospital","route":"/institutions/helsinki-hus/","asOf":"2026-09-09","days":0},{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","route":"/institutions/uppsala-akademiska/","asOf":"2026-09-09","days":0},{"id":"lund-skane","kind":"institution","name":"Skåne University Hospital / Lund University Cancer Centre","route":"/institutions/lund-skane/","asOf":"2026-09-09","days":0},{"id":"sahlgrenska","kind":"institution","name":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research","route":"/institutions/sahlgrenska/","asOf":"2026-09-09","days":0},{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/","asOf":"2026-09-09","days":0},{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/","asOf":"2026-09-09","days":0},{"id":"hug-geneva","kind":"institution","name":"Geneva University Hospitals (HUG)","route":"/institutions/hug-geneva/","asOf":"2026-09-09","days":0},{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","asOf":"2026-09-09","days":0},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/","asOf":"2026-09-09","days":0},{"id":"ccc-vienna","kind":"institution","name":"Comprehensive Cancer Center Vienna – Medical University of Vienna / AKH","route":"/institutions/ccc-vienna/","asOf":"2026-09-09","days":0},{"id":"ipo-porto","kind":"institution","name":"Instituto Português de Oncologia do Porto Francisco Gentil","route":"/institutions/ipo-porto/","asOf":"2026-09-09","days":0},{"id":"ipo-lisboa","kind":"institution","name":"Instituto Português de Oncologia de Lisboa Francisco Gentil","route":"/institutions/ipo-lisboa/","asOf":"2026-09-09","days":0},{"id":"champalimaud","kind":"institution","name":"Champalimaud Foundation – Champalimaud Clinical Centre","route":"/institutions/champalimaud/","asOf":"2026-09-09","days":0},{"id":"nio-warsaw","kind":"institution","name":"Maria Skłodowska-Curie National Research Institute of Oncology","route":"/institutions/nio-warsaw/","asOf":"2026-09-09","days":0},{"id":"mou-brno","kind":"institution","name":"Masaryk Memorial Cancer Institute","route":"/institutions/mou-brno/","asOf":"2026-09-09","days":0},{"id":"noi-budapest","kind":"institution","name":"National Institute of Oncology, Hungary","route":"/institutions/noi-budapest/","asOf":"2026-09-09","days":0},{"id":"onkoloski-institut-ljubljana","kind":"institution","name":"Institute of Oncology Ljubljana","route":"/institutions/onkoloski-institut-ljubljana/","asOf":"2026-09-09","days":0},{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/","asOf":"2026-09-09","days":0},{"id":"hadassah","kind":"institution","name":"Hadassah Medical Center","route":"/institutions/hadassah/","asOf":"2026-09-09","days":0},{"id":"tel-aviv-sourasky","kind":"institution","name":"Tel Aviv Sourasky Medical Center","route":"/institutions/tel-aviv-sourasky/","asOf":"2026-09-09","days":0},{"id":"rambam","kind":"institution","name":"Rambam Health Care Campus","route":"/institutions/rambam/","asOf":"2026-09-09","days":0},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/","asOf":"2026-09-09","days":0},{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","route":"/institutions/shaare-zedek/","asOf":"2026-09-09","days":0},{"id":"hacettepe-cancer-institute","kind":"institution","name":"Hacettepe University Cancer Institute","route":"/institutions/hacettepe-cancer-institute/","asOf":"2026-09-09","days":0},{"id":"istanbul-oncology-institute","kind":"institution","name":"Istanbul University Institute of Oncology","route":"/institutions/istanbul-oncology-institute/","asOf":"2026-09-09","days":0},{"id":"ecco","kind":"institution","name":"European Cancer Organisation","route":"/institutions/ecco/","asOf":"2026-09-09","days":0},{"id":"eacr","kind":"institution","name":"European Association for Cancer Research","route":"/institutions/eacr/","asOf":"2026-09-09","days":0},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/","asOf":"2026-09-09","days":0}],"summary":{"approvals-vs-regional":163,"soc-cites-dead":16,"status-vs-approvals":7,"duplicate-name":58,"future-year-in-text":33,"near-duplicate-levenshtein":3,"outcome-no-source":104,"pipeline-cites-dead":1,"positive-hr-ge-1":1,"spike-scalar-divergence":13,"unsourced-numbers":264,"name-collision-across-kinds":10,"orphan":99,"regional-approval-only":3,"text-says-approved":1,"unsourced":1601}}